Clustering O 0 8.867394353728741e-05
of O 0 4.622163032763638e-06
missense O 0 5.1481518312357366e-05
mutations O 0 3.726482873389614e-06
in O 0 5.729050371883204e-07
the O 0 2.5701747290440835e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 4.048875780426897e-05
in O 0 1.8180959671099117e-07
a O 0 4.0980054905048746e-07
sporadic B-Disease 0 0.0003368620527908206
T I-Disease 1 0.9999868869781494
- I-Disease 1 0.9973329305648804
cell I-Disease 1 0.7570033669471741
leukaemia I-Disease 1 0.9383487701416016
. O 0 2.2817528588348068e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999901056289673
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.666127443262667e-07
is O 0 1.9587897526207598e-08
a O 0 7.685495972964418e-08
recessive B-Disease 0 2.945854612335097e-05
multi I-Disease 1 0.8579074740409851
- I-Disease 1 0.9910675883293152
system I-Disease 0 0.09680891782045364
disorder I-Disease 1 0.9798533916473389
caused O 0 7.693707857470145e-07
by O 0 3.1140704237486716e-08
mutations O 0 7.532518964126211e-08
in O 0 2.0183295035280935e-08
the O 0 5.5805084997473386e-08
ATM O 0 3.7754250570287695e-06
gene O 0 2.0733824612761964e-07
at O 0 1.1879650401169783e-06
11q22 O 0 1.1638289834081661e-05
- O 0 1.336996410827851e-05
q23 O 0 2.9562055715359747e-05
( O 0 3.6263372749090195e-07
ref O 0 9.555073120282032e-06
. O 0 9.881951967827263e-08
3 O 0 2.08906521947938e-06
) O 0 6.30226850262261e-07
. O 0 6.722057605657028e-06

The O 0 3.7683494156226516e-06
risk O 0 2.944700781881693e-06
of O 0 2.5358449420309626e-06
cancer B-Disease 0 0.002727892016991973
, O 0 3.7755944504169747e-07
especially O 0 1.39317603498057e-06
lymphoid B-Disease 1 0.9998302459716797
neoplasias I-Disease 1 0.9965952038764954
, O 0 7.40705843327305e-07
is O 0 7.041464300527878e-08
substantially O 0 4.393562846871646e-07
elevated O 0 1.845216320361942e-05
in O 0 3.393159886400099e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.7122637220600154e-06
and O 0 2.2517087927553803e-07
has O 0 5.1294282599201324e-08
long O 0 6.772885541295182e-08
been O 0 9.329384909051441e-08
associated O 0 2.910572618475271e-07
with O 0 1.1355732567608356e-06
chromosomal O 1 0.9999997615814209
instability O 1 1.0
. O 0 0.0015448909252882004

By O 0 6.681505055894377e-06
analysing O 0 5.9491187130333856e-05
tumour B-Disease 1 0.9999995231628418
DNA O 0 2.6871355203184066e-06
from O 0 1.121139590054554e-07
patients O 0 8.018615460514411e-08
with O 0 1.221187204691887e-07
sporadic B-Disease 0 8.468642772641033e-05
T I-Disease 1 0.9988555908203125
- I-Disease 0 0.26100653409957886
cell I-Disease 0 0.007615762297064066
prolymphocytic I-Disease 0 0.005199845880270004
leukaemia I-Disease 1 0.9562995433807373
( O 0 2.071976496154093e-06
T B-Disease 0 0.0033695336896926165
- I-Disease 0 0.00012931416858918965
PLL I-Disease 0 0.015210446901619434
) O 0 1.280605061992901e-07
, O 0 4.474257053743713e-08
a O 0 8.59532178765221e-08
rare O 0 7.198815978881612e-07
clonal B-Disease 0 8.367306145373732e-05
malignancy I-Disease 0 2.4709732315386645e-05
with O 0 3.359883038456246e-08
similarities O 0 1.6258624668807897e-07
to O 0 4.117227447864025e-08
a O 0 3.098934939771425e-07
mature B-Disease 0 0.00012045329640386626
T I-Disease 0 0.3792838454246521
- I-Disease 0 0.0003302194527350366
cell I-Disease 0 0.0001779830636223778
leukaemia I-Disease 0 0.000446672405814752
seen O 0 3.517107245443185e-07
in O 0 7.715355110349265e-08
A B-Disease 1 0.9994853734970093
- I-Disease 1 0.99530029296875
T I-Disease 1 0.9999997615814209
, O 0 1.0355130086736608e-07
we O 0 2.4423000510864767e-08
demonstrate O 0 2.1305208264266184e-08
a O 0 1.9093166159223074e-08
high O 0 8.769882953174601e-08
frequency O 0 1.341152966460868e-07
of O 0 5.4729060394720364e-08
ATM O 0 2.402303152848617e-06
mutations O 0 5.472268753692333e-07
in O 0 4.112777673981327e-07
T B-Disease 0 0.002767397090792656
- I-Disease 0 0.0003985482035204768
PLL I-Disease 0 0.004566042684018612
. O 0 3.412519799894653e-05

In O 0 1.921940565807745e-06
marked O 0 1.9476099168969085e-06
contrast O 0 2.3694988726674637e-07
to O 0 3.3824779421820494e-08
the O 0 5.8362214616636265e-08
ATM O 0 2.5561871552781668e-06
mutation O 0 1.350833969127052e-07
pattern O 0 4.6279134835458535e-07
in O 0 1.5497347760629054e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 3.081526926962397e-07
the O 0 3.2424718909851435e-08
most O 0 6.079446723816773e-09
frequent O 0 1.1195258053930957e-08
nucleotide O 0 5.882466780349205e-08
changes O 0 3.4846610930117095e-08
in O 0 1.0969784192127463e-08
this O 0 2.7928034995738926e-08
leukaemia B-Disease 0 1.4144491615297738e-05
were O 0 7.437878366545192e-07
missense O 0 3.562997517292388e-05
mutations O 0 1.4576123248843942e-05
. O 0 2.7335749109624885e-05

These O 0 2.2536044070875505e-06
clustered O 0 4.154677299084142e-06
in O 0 1.0343207179630554e-07
the O 0 9.185622928953308e-08
region O 0 1.6070599428985588e-07
corresponding O 0 1.042158714881225e-07
to O 0 2.5534912850844194e-08
the O 0 7.448824845823765e-08
kinase O 0 6.645306598329626e-07
domain O 0 7.349248676291609e-08
, O 0 9.474418583010902e-09
which O 0 7.666649537441117e-09
is O 0 4.004344411612237e-09
highly O 0 3.692235850394354e-08
conserved O 0 2.0413271784036624e-07
in O 0 5.4757041567654596e-08
ATM O 0 1.4114794794295449e-05
- O 0 1.7704463743939414e-06
related O 0 1.0098617053699854e-07
proteins O 0 2.8102606464130986e-08
in O 0 2.4980247204098305e-08
mouse O 0 2.7246352374277194e-07
, O 0 5.2469442124447596e-08
yeast O 0 2.1863713755010394e-06
and O 0 9.916510634866427e-07
Drosophila O 0 1.5476771295652725e-05
. O 0 5.122162747284165e-06

The O 0 1.6243748177657835e-05
resulting O 0 2.3206323021440767e-05
amino O 0 2.0218481949996203e-05
- O 0 9.113171472563408e-06
acid O 0 1.0054160384243005e-06
substitutions O 0 8.771561965659203e-07
are O 0 2.840730850550699e-08
predicted O 0 3.590572248413082e-07
to O 0 4.72175685217735e-08
interfere O 0 4.90665343022556e-07
with O 0 1.766495216770636e-07
ATP O 0 0.00039248415851034224
binding O 0 8.91345905529306e-07
or O 0 2.0606638884146378e-07
substrate O 0 1.6849569419719046e-06
recognition O 0 1.4795136848988477e-06
. O 0 6.063264663680457e-06

Two O 0 4.556044132186798e-06
of O 0 3.1849851893639425e-06
seventeen O 0 2.099324410664849e-05
mutated O 0 2.148722342099063e-05
T B-Disease 0 0.0008459846721962094
- I-Disease 0 3.921036477549933e-05
PLL I-Disease 0 0.00011744004586944357
samples O 0 2.0194893579628115e-07
had O 0 8.519327820977196e-08
a O 0 1.2039491537052527e-07
previously O 0 7.813106890353083e-07
reported O 0 2.438535602777847e-06
A B-Disease 1 0.9999749660491943
- I-Disease 1 0.999977707862854
T I-Disease 1 0.9999998807907104
allele O 0 0.0007780437590554357
. O 0 2.8904050850542262e-05

In O 0 1.5893159570623538e-06
contrast O 0 1.059115106727404e-06
, O 0 9.382026178172964e-08
no O 0 4.9441887028933706e-08
mutations O 0 1.3705295032195863e-07
were O 0 6.364054172536271e-08
detected O 0 9.838920789206895e-08
in O 0 1.1562646839990975e-08
the O 0 2.0022637770011897e-08
p53 O 0 6.88943089244276e-08
gene O 0 6.654578754705653e-08
, O 0 3.172523932448712e-08
suggesting O 0 8.38270537428798e-08
that O 0 1.437261154535463e-08
this O 0 9.131783684779293e-08
tumour B-Disease 1 1.0
suppressor O 0 0.021871395409107208
is O 0 6.340246727631893e-08
not O 0 2.456755510138464e-08
frequently O 0 9.237171383347231e-08
altered O 0 8.442667649433133e-07
in O 0 3.4269226034666644e-07
this O 0 9.495323638475384e-07
leukaemia B-Disease 0 0.004386615939438343
. O 0 3.0260824132710695e-05

Occasional O 0 2.5375346012879163e-05
missense O 0 2.5589341021259315e-05
mutations O 0 7.82603763127554e-07
in O 0 9.5610509731614e-08
ATM O 0 3.3381285902578384e-05
were O 0 3.693398582527152e-07
also O 0 3.969843476170354e-08
found O 0 8.104692028609861e-08
in O 0 1.14502846315645e-07
tumour B-Disease 1 0.9999996423721313
DNA O 0 1.4894092146278126e-06
from O 0 4.9838508431321316e-08
patients O 0 1.8174748817045838e-08
with O 0 4.904889649992583e-08
B B-Disease 0 0.00041018365300260484
- I-Disease 0 0.00021349229791667312
cell I-Disease 0 0.00029638715204782784
non I-Disease 0 0.003292570821940899
- I-Disease 0 0.2020609974861145
Hodgkins I-Disease 1 0.9999997615814209
lymphomas I-Disease 0 0.25908830761909485
( O 0 4.1016298268914397e-07
B B-Disease 0 2.3570570192532614e-05
- I-Disease 0 3.3425849323975854e-06
NHL I-Disease 0 2.5149107386823744e-05
) O 0 2.2123508358617983e-08
and O 0 2.720438807557457e-08
a O 0 1.1117742104715944e-07
B B-Disease 0 1.4274675777414814e-05
- I-Disease 0 6.013373422320001e-06
NHL I-Disease 0 0.00024023503647185862
cell O 0 2.7297217457089573e-05
line O 0 1.3628928172693122e-05
. O 0 8.125236490741372e-06

The O 0 1.327257564298634e-06
evidence O 0 9.709908681543311e-07
of O 0 2.2028311263966316e-07
a O 0 1.2905357493764313e-07
significant O 0 1.0130062833013653e-07
proportion O 0 1.780973377663031e-07
of O 0 2.5107817691605305e-07
loss O 0 1.157418137154309e-05
- O 0 4.105631887796335e-06
of O 0 1.088823637473979e-06
- O 0 3.6590097352018347e-06
function O 0 1.2776663993463444e-07
mutations O 0 6.261757334868889e-08
and O 0 1.5627291460873494e-08
a O 0 1.7549638187119854e-08
complete O 0 7.758741560337512e-08
absence O 0 1.6991882034744776e-07
of O 0 8.191489087039372e-08
the O 0 2.998184456259878e-08
normal O 0 2.3327359599534248e-08
copy O 0 2.8635408710897536e-08
of O 0 1.8512404054149556e-08
ATM O 0 8.565566531615332e-07
in O 0 1.5286408583392586e-08
the O 0 2.032174073463011e-08
majority O 0 5.5672515486548946e-08
of O 0 5.816168595629279e-07
mutated O 0 1.8647353499545716e-05
tumours B-Disease 1 0.9999998807907104
establishes O 0 4.19898333348101e-06
somatic O 0 5.439652341010515e-06
inactivation O 0 3.2921002457442228e-06
of O 0 1.1244762276874098e-07
this O 0 1.9517001348390295e-08
gene O 0 5.1554895463823414e-08
in O 0 3.7707650335505605e-08
the O 0 1.851722970513947e-07
pathogenesis O 0 0.00016981085354927927
of O 0 2.894768385885982e-06
sporadic B-Disease 0 0.2791397273540497
T I-Disease 1 0.9999983310699463
- I-Disease 1 0.9975589513778687
PLL I-Disease 0 0.2569867670536041
and O 0 1.220338390339748e-07
suggests O 0 9.664366729111862e-08
that O 0 9.861763849983163e-09
ATM O 0 2.360952976232511e-06
acts O 0 2.874316180623282e-07
as O 0 2.2522586107243114e-07
a O 0 1.361386352982663e-06
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.005177531857043505
. O 0 5.172387682250701e-05

As O 0 2.1585287868219893e-06
constitutional O 0 3.1281786050385563e-06
DNA O 0 9.630414297134848e-07
was O 0 1.6096875299353997e-07
not O 0 1.29989450314838e-08
available O 0 5.0842714927057386e-08
, O 0 3.81127875925813e-08
a O 0 1.6165255090072606e-07
putative O 0 6.862152531539323e-06
hereditary O 0 0.15485647320747375
predisposition O 0 0.00015392729255836457
to O 0 9.588748071109876e-06
T B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999804496765137
PLL I-Disease 1 0.9454024434089661
will O 0 1.244443126324768e-07
require O 0 6.106282768314486e-08
further O 0 1.3225769635027973e-07
investigation O 0 5.437673848973645e-07
. O 0 4.076815685039037e-07
. O 0 4.396229996928014e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0005420436500571668
kinase O 0 1.2591577615239657e-05
is O 0 1.4244858626000223e-08
involved O 0 1.5046316192979248e-08
in O 0 5.0715032173798136e-09
the O 0 1.664125726108523e-08
modulation O 0 2.683007949144667e-07
of O 0 3.0974426579177816e-08
the O 0 4.4092441697785034e-08
Ca2 O 0 6.25022437361622e-07
+ O 0 1.778126943463576e-06
homeostasis O 0 2.1419315089588054e-05
in O 0 5.141800443198008e-07
skeletal O 0 0.012171981856226921
muscle O 0 0.0006328898016363382
cells O 0 0.00010435533476993442
. O 0 1.7033826225087978e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999513626098633
DM B-Disease 1 1.0
) O 0 1.5208925105980597e-06
, O 0 6.815493946987772e-08
the O 0 4.2557562807132854e-08
most O 0 8.867117884392428e-08
prevalent O 1 0.9503581523895264
muscular B-Disease 1 1.0
disorder I-Disease 1 0.9999995231628418
in O 0 7.596549380650686e-07
adults O 0 1.214932240145572e-06
, O 0 4.686656396302169e-08
is O 0 1.1180341985550513e-08
caused O 0 7.916749922287636e-08
by O 0 7.60116023457158e-08
( O 0 2.0018214286210423e-07
CTG O 0 3.015119000338018e-05
) O 0 1.0493472046846364e-07
n O 0 3.738496161531657e-07
- O 0 2.2914690589459497e-07
repeat O 0 1.8296070436463197e-07
expansion O 0 1.2654936654143967e-07
in O 0 7.959170211790934e-09
a O 0 1.9542481410894652e-08
gene O 0 3.75630762050605e-08
encoding O 0 1.4048461594029504e-07
a O 0 1.0960921059677275e-07
protein O 0 4.2954465584443824e-07
kinase O 0 3.53464315594465e-06
( O 0 4.5178546770330286e-07
DM B-Disease 1 0.9993352293968201
protein O 0 1.1976043197137187e-06
kinase O 0 1.0478077001607744e-06
; O 0 6.10148589430537e-08
DMPK O 0 4.8602658353047445e-05
) O 0 1.4718744978381437e-07
and O 0 5.9373739702550665e-08
involves O 0 1.2383898706502805e-07
changes O 0 1.5888583959622338e-07
in O 0 1.1680887723741762e-07
cytoarchitecture O 0 8.440738383796997e-06
and O 0 1.8081791495205835e-06
ion O 0 0.0002970669593196362
homeostasis O 0 0.0040226345881819725
. O 0 2.475959263392724e-05

To O 0 8.635497010800464e-07
obtain O 0 7.610806278535165e-07
clues O 0 1.543587018204562e-06
to O 0 4.758300065077492e-08
the O 0 5.578667838790352e-08
normal O 0 1.183520339509414e-07
biological O 0 2.0042378423568152e-07
role O 0 2.156140936904194e-07
of O 0 3.5954926147496735e-07
DMPK O 0 0.0006949746748432517
in O 0 4.499117096656846e-07
cellular O 0 9.843715815804899e-06
ion O 0 6.13479787716642e-05
homeostasis O 0 0.0002742237120401114
, O 0 8.957550790000823e-08
we O 0 4.033543987702615e-08
have O 0 1.2798196280527918e-08
compared O 0 3.500288769942017e-08
the O 0 3.959997130209558e-08
resting O 0 8.118196319628623e-07
[ O 0 2.0405212808327633e-07
Ca2 O 0 1.6302811900459346e-07
+ O 0 1.6830587412641762e-07
] O 0 1.6615923925655807e-07
i O 0 8.347556246235399e-08
, O 0 1.946592220747334e-08
the O 0 3.548676019704544e-08
amplitude O 0 8.763033179093327e-07
and O 0 5.5200406023914184e-08
shape O 0 8.939022677623143e-07
of O 0 7.999259423741023e-07
depolarization O 0 7.017329153313767e-06
- O 0 1.5792744534337544e-06
induced O 0 3.4405812243676337e-07
Ca2 O 0 6.154163543214963e-07
+ O 0 6.155772211968724e-07
transients O 0 7.449384611390997e-07
, O 0 1.5464475922044585e-08
and O 0 1.0238155212505262e-08
the O 0 9.639822273754817e-09
content O 0 3.1848735204675904e-08
of O 0 1.0163989117017991e-07
ATP O 0 1.5130894098547287e-05
- O 0 5.096155177852779e-07
driven O 0 3.886961508214881e-07
ion O 0 4.976943728252081e-06
pumps O 0 2.019367229877389e-06
in O 0 2.592818475477543e-07
cultured O 0 1.4483685845334549e-05
skeletal O 0 3.3619129681028426e-05
muscle O 0 8.432512004219461e-07
cells O 0 2.7355446263754857e-07
of O 0 1.9807913531622034e-07
wild O 0 2.3488743750021968e-07
- O 0 2.783168611131259e-07
type O 0 3.075027166232758e-07
and O 0 3.410825684113661e-07
DMPK O 0 0.005627358332276344
[ O 0 6.17172281636158e-06
- O 0 1.6452595446025953e-05
/ O 0 4.055773752043024e-05
- O 0 7.835977157810703e-05
] O 0 2.4389017198700458e-05
knockout O 1 0.9999405145645142
mice O 0 0.00015345291467383504
. O 0 1.1943812751269434e-05

In O 0 1.7513963030069135e-05
vitro O 0 3.46855194948148e-05
- O 0 2.1132827896508388e-05
differentiated O 0 1.984899427043274e-05
DMPK O 0 0.000580145395360887
[ O 0 1.5233909834933002e-05
- O 0 5.519970727618784e-05
/ O 0 9.370906627736986e-05
- O 0 0.00010385520727140829
] O 0 6.30480781182996e-06
myotubes O 0 1.7236403436982073e-05
exhibit O 0 3.925135843019234e-07
a O 0 2.541837034186756e-07
higher O 0 1.3351387906368473e-06
resting O 0 5.699128905689577e-06
[ O 0 1.1815440075224615e-06
Ca2 O 0 5.919236514273507e-07
+ O 0 5.958474389444746e-07
] O 0 3.155361412154889e-07
i O 0 1.0080546530844003e-07
than O 0 3.197930453779918e-08
do O 0 4.0548489010916455e-08
wild O 0 3.1601678074366646e-07
- O 0 7.570420166302938e-07
type O 0 1.0344011798224528e-06
myotubes O 0 8.82581025507534e-06
because O 0 2.5012287352410567e-08
of O 0 2.6965716770632753e-08
an O 0 1.2348724709454473e-08
altered O 0 9.174381432330847e-08
open O 0 9.188917005076291e-08
probability O 0 6.467492141837283e-08
of O 0 1.1432706514824531e-07
voltage O 0 5.655042514263187e-06
- O 0 1.3218385674917954e-06
dependent O 0 2.1098004765462974e-07
l O 0 5.483992140398186e-07
- O 0 8.63297984210476e-08
type O 0 6.131936203246369e-08
Ca2 O 0 1.5378330431303766e-07
+ O 0 1.4665683067960344e-07
and O 0 8.44110701336831e-08
Na O 0 3.410332283237949e-06
+ O 0 6.754405603714986e-07
channels O 0 1.0366310334575246e-06
. O 0 2.3863717615313362e-06

The O 0 1.3104818208375946e-05
mutant O 0 5.985754978610203e-05
myotubes O 0 6.537973240483552e-05
exhibit O 0 4.772429065269534e-07
smaller O 0 1.9208634682854608e-07
and O 0 1.281424744092874e-07
slower O 0 9.671397265265114e-07
Ca2 O 0 3.601391824759048e-07
+ O 0 2.1675835171208746e-07
responses O 0 4.4682700206521986e-08
upon O 0 5.599081376317372e-08
triggering O 0 6.404579835361801e-07
by O 0 3.4628826028892945e-08
acetylcholine O 0 5.557776603382081e-07
or O 0 1.0779344705724725e-07
high O 0 1.1503208270369214e-06
external O 0 3.5616117202152964e-06
K O 0 9.987398698285688e-06
+ O 0 6.100012797105592e-06
. O 0 4.5025003601040225e-06

In O 0 1.9222595710743917e-06
addition O 0 8.554936812288361e-07
, O 0 9.193475136726192e-08
we O 0 4.096453309898607e-08
observed O 0 3.8087716092150004e-08
that O 0 3.8068668217761115e-09
these O 0 1.7621852421711992e-08
Ca2 O 0 7.611256478412542e-07
+ O 0 1.6527972093172139e-06
transients O 0 3.771243427763693e-06
partially O 0 2.459144923250278e-07
result O 0 5.079677123376314e-08
from O 0 8.905995940722278e-09
an O 0 3.506100298977799e-09
influx O 0 1.900672508270418e-08
of O 0 5.395800783958293e-08
extracellular O 0 1.1027058377521826e-07
Ca2 O 0 1.251820549441618e-07
+ O 0 6.983496803059097e-08
through O 0 9.030161507439516e-09
the O 0 2.4925135733155912e-08
l O 0 2.9157209269214945e-07
- O 0 6.753922576763216e-08
type O 0 6.295756094232274e-08
Ca2 O 0 2.0864997907210636e-07
+ O 0 5.022786240260757e-07
channel O 0 2.1456521608342882e-06
. O 0 2.240098638139898e-06

Neither O 0 7.645954610779881e-06
the O 0 4.709151824044966e-07
content O 0 3.4152293437728076e-07
nor O 0 2.2937953758628282e-07
the O 0 3.193182607219569e-08
activity O 0 8.267711137932565e-08
of O 0 2.0870828620900284e-07
Na O 0 5.642259566229768e-06
+ O 0 1.864883074631507e-06
/ O 0 1.4273900887928903e-06
K O 0 1.5931552752590505e-06
+ O 0 1.164319087365584e-06
ATPase O 0 4.184109457128216e-06
and O 0 2.8684368658105086e-07
sarcoplasmic O 0 7.546671440650243e-06
reticulum O 0 1.9871347376465565e-06
Ca2 O 0 2.5846318294497905e-06
+ O 0 3.945122443838045e-06
- O 0 1.5361166560978745e-06
ATPase O 0 2.5711447051435243e-06
are O 0 4.5001986137549466e-08
affected O 0 1.809355723025874e-07
by O 0 1.9853113997214678e-07
DMPK O 0 0.00045917389797978103
absence O 0 8.28862248454243e-05
. O 0 4.202776835882105e-05

In O 0 2.471031393724843e-06
conclusion O 0 5.571134806814371e-06
, O 0 2.694110037282371e-07
our O 0 1.2645756441997946e-07
data O 0 4.761496086302941e-08
suggest O 0 4.566134492733909e-08
that O 0 2.0595434691017545e-08
DMPK O 0 8.677235746290535e-05
is O 0 4.3199062105259145e-08
involved O 0 1.0073473077909512e-07
in O 0 3.499020451158685e-08
modulating O 0 1.527979861748463e-06
the O 0 8.462321687829899e-08
initial O 0 1.266736262550694e-07
events O 0 9.774240083970653e-08
of O 0 2.577739337539242e-07
excitation O 0 0.0009565048385411501
- O 0 0.04964899271726608
contraction O 0 1.5616509699611925e-05
coupling O 0 1.4950481272535399e-05
in O 0 1.5946541225275723e-06
skeletal O 1 0.969887912273407
muscle O 0 0.0012101820902898908
. O 0 5.505022727447795e-06
. O 0 1.457191046938533e-05

Constitutional O 0 0.0011680129682645202
RB1 O 1 0.941257894039154
- O 0 0.00021610676776617765
gene O 0 1.134898866439471e-06
mutations O 0 1.2058121683367062e-06
in O 0 1.1979385305949108e-07
patients O 0 1.4496924904960906e-07
with O 0 8.976158483164909e-08
isolated O 0 4.508902748057153e-06
unilateral B-Disease 0 0.00011897796503035352
retinoblastoma I-Disease 1 0.9999871253967285
. O 0 0.00047709830687381327

In O 0 4.368229383544531e-06
most O 0 3.301229014596174e-07
patients O 0 1.1929360255180654e-07
with O 0 4.118452423540475e-08
isolated O 0 5.455344194160716e-07
unilateral B-Disease 0 6.270939593377989e-06
retinoblastoma I-Disease 1 0.9999161958694458
, O 0 1.9832139059872134e-06
tumor B-Disease 0 4.482485746848397e-05
development O 0 9.980448112401064e-07
is O 0 2.5066590580991033e-08
initiated O 0 2.5559381811035564e-07
by O 0 2.6430084787421038e-08
somatic O 0 7.814746822987217e-07
inactivation O 0 1.2785942544724094e-06
of O 0 1.5492737759359443e-07
both O 0 1.5874057623932458e-07
alleles O 0 5.20799005698791e-07
of O 0 6.195537594066991e-07
the O 0 2.4860100893420167e-06
RB1 O 0 0.003450272371992469
gene O 0 2.1396595911937766e-05
. O 0 3.195601675543003e-05

However O 0 4.746122613141779e-06
, O 0 4.1425451513532607e-07
some O 0 3.6912428669211295e-08
of O 0 7.206495666878254e-08
these O 0 5.778964151659238e-08
patients O 0 7.712765892620155e-08
can O 0 7.328642936954566e-08
transmit O 0 3.8509756450366694e-06
retinoblastoma B-Disease 0 0.00024867328465916216
predisposition O 0 2.5155973162327427e-06
to O 0 1.8281244251738826e-07
their O 0 4.796141297447321e-07
offspring O 0 7.724668648734223e-06
. O 0 1.2272971616766881e-05

To O 0 5.174528041607118e-07
determine O 0 3.7201868963165907e-07
the O 0 7.172953075951227e-08
frequency O 0 6.334396402962739e-07
and O 0 4.7188940754949726e-08
nature O 0 1.1167728786176667e-07
of O 0 1.3750474181506434e-07
constitutional O 0 1.4634356375609059e-05
RB1 O 0 0.24710164964199066
- O 0 9.48331035033334e-06
gene O 0 1.3797395581605088e-07
mutations O 0 2.288542475525901e-07
in O 0 3.6935883684918736e-08
patients O 0 4.677288600873908e-08
with O 0 5.0792312578096244e-08
isolated O 0 1.4010505537953577e-06
unilateral B-Disease 0 1.0399191523902118e-05
retinoblastoma I-Disease 1 0.9980961680412292
, O 0 8.388429932892905e-07
we O 0 2.467736237576901e-07
analyzed O 0 1.8293627590537653e-07
DNA O 0 4.278602148133359e-07
from O 0 1.3859165903795656e-07
peripheral O 0 3.71732676285319e-05
blood O 0 2.7797491384262685e-06
and O 0 2.0191439489281038e-06
from O 0 2.6028224056062754e-06
tumor B-Disease 0 0.021507591009140015
tissue O 0 0.001164887798950076
. O 0 4.9995374865829945e-05

The O 0 3.7433662782859756e-06
analysis O 0 1.8636989125297987e-06
of O 0 1.4508793810819043e-06
tumors B-Disease 1 0.9999988079071045
from O 0 3.85836102623216e-07
54 O 0 2.1333282802515896e-06
( O 0 8.24896773110595e-08
71 O 0 2.8324430445536564e-07
% O 0 3.23668238877417e-08
) O 0 3.1542835898790145e-08
of O 0 1.8587682859561028e-07
76 O 0 3.207550889783306e-06
informative O 0 1.8393673144601053e-06
patients O 0 1.093077344194171e-07
showed O 0 1.7096056126320036e-07
loss O 0 1.1125703167635947e-06
of O 0 1.4444869975704933e-06
constitutional O 0 0.0008417684002779424
heterozygosity O 1 0.9955816864967346
( O 0 0.00010862933413591236
LOH O 1 0.9999125003814697
) O 0 3.0432502171606757e-06
at O 0 1.9009312381967902e-05
intragenic O 0 0.00017048302106559277
loci O 0 0.00011183571768924594
. O 0 6.707413558615372e-05

Three O 0 6.523598585772561e-06
of O 0 2.664551402631332e-06
13 O 0 2.196084096794948e-05
uninformative O 0 0.005031098611652851
patients O 0 3.3925625757547095e-06
had O 0 2.19593130168505e-06
constitutional O 0 3.955336433136836e-05
deletions O 0 0.0001032757936627604
. O 0 4.191201878711581e-05

For O 0 9.879472600005101e-06
39 O 0 1.343314943369478e-05
randomly O 0 3.487219146336429e-06
selected O 0 1.1823841305158567e-05
tumors B-Disease 1 0.9999994039535522
, O 0 4.493715096032247e-06
SSCP O 1 0.7625340223312378
, O 0 5.279916422296083e-06
hetero O 0 0.0004548372235149145
- O 0 1.432363387721125e-05
duplex O 0 6.323415163933532e-06
analysis O 0 1.4302308670721686e-07
, O 0 5.5082399086359146e-08
sequencing O 0 3.349508403971413e-07
, O 0 3.3318926284664485e-08
and O 0 4.731385061518267e-08
Southern O 0 7.308249223569874e-07
blot O 0 1.1863110103149666e-06
analysis O 0 9.487840202382358e-08
were O 0 4.5301337792125196e-08
used O 0 2.6815079934294772e-08
to O 0 6.457089796185755e-08
identify O 0 8.115633818306378e-07
mutations O 0 1.343914664175827e-05
. O 0 2.0568915715557523e-05

Mutations O 0 7.649054168723524e-06
were O 0 5.590522391685226e-07
detected O 0 2.880655074477545e-07
in O 0 2.2412274702787727e-08
21 O 0 5.22237314726226e-07
( O 0 4.6675211251567816e-08
91 O 0 2.0240106834990002e-07
% O 0 2.6301044897536485e-08
) O 0 4.718165058648083e-08
of O 0 6.507274292744114e-07
23 O 0 0.00043518480379134417
tumors B-Disease 1 1.0
with O 0 0.004694444127380848
LOH O 1 0.9999998807907104
. O 0 0.00012176542077213526

In O 0 2.248756800327101e-06
6 O 0 8.305837582156528e-06
( O 0 1.7356040871163714e-07
38 O 0 3.026646027137758e-07
% O 0 4.237967843323531e-08
) O 0 3.383213709184929e-08
of O 0 1.8968739823321812e-07
16 O 0 8.704850915819407e-05
tumors B-Disease 1 1.0
without O 0 0.0465472936630249
LOH O 1 0.9999985694885254
, O 0 9.568749703703361e-08
one O 0 2.7793273460474666e-08
mutation O 0 5.860874452423559e-08
was O 0 8.782655669392625e-08
detected O 0 7.553654057801396e-08
, O 0 4.028031597158588e-08
and O 0 2.662564391187061e-08
in O 0 3.023261641033059e-08
9 O 0 1.1698964499373687e-06
( O 0 3.8253634926377345e-08
56 O 0 9.891418528695795e-08
% O 0 1.2377540770103224e-08
) O 0 1.876938959810559e-08
of O 0 1.1621630591207577e-07
the O 0 2.0278278043406317e-06
tumors B-Disease 1 1.0
without O 1 0.7142040133476257
LOH O 1 0.9999997615814209
, O 0 1.374681630750274e-07
both O 0 8.743343471451226e-08
mutations O 0 4.67327595288225e-07
were O 0 7.164297812778386e-07
found O 0 1.9763469936151523e-06
. O 0 2.0565150407492183e-05

Thus O 0 8.822991730994545e-06
, O 0 3.497580109979026e-07
a O 0 6.104092875602873e-08
total O 0 3.5404415399398204e-08
of O 0 4.9357748110878674e-08
45 O 0 1.581584996301899e-07
mutations O 0 1.8878687058077048e-07
were O 0 1.9106178683614417e-07
identified O 0 4.240729367666063e-07
in O 0 4.5770994461236114e-07
tumors B-Disease 1 1.0
of O 0 0.00109472603071481
36 O 0 0.005960837006568909
patients O 0 1.809007881092839e-05
. O 0 3.7765552406199276e-05

Thirty O 0 0.00011963780707446858
- O 0 9.4415836429107e-06
nine O 0 4.3834134544340486e-07
of O 0 9.547419921318578e-08
the O 0 7.410167057742001e-08
mutations O 0 3.2053691256805905e-07
- O 0 3.1653979704060475e-07
including O 0 3.4576753904502766e-08
34 O 0 2.923698048107326e-07
small O 0 3.814311000382986e-08
mutations O 0 1.7964450194085657e-07
, O 0 3.92693237927233e-08
2 O 0 7.577824021609558e-07
large O 0 1.5760080884774652e-07
structural O 0 3.12683405354619e-05
alterations O 0 6.684462277917191e-06
, O 0 1.0500319547190884e-07
and O 0 2.0643460629798938e-07
hypermethylation O 0 6.790959741920233e-05
in O 0 3.3535997090439196e-07
3 O 0 6.51213777018711e-05
tumors O 1 1.0
- O 0 1.2221033102832735e-05
were O 0 1.1866940496929601e-07
not O 0 2.4205132120869166e-08
detected O 0 9.41601641102352e-08
in O 0 1.909054425652812e-08
the O 0 7.975769023005341e-08
corresponding O 0 8.71608449415362e-07
peripheral O 0 0.00012473932292778045
blood O 0 4.6377363105420955e-06
DNA O 0 1.3332452908798587e-05
. O 0 1.5604509826516733e-05

In O 0 1.922202727655531e-06
6 O 0 5.938397862337297e-06
( O 0 1.5214423854104098e-07
17 O 0 2.0272251788355788e-07
% O 0 2.0709904902105336e-08
) O 0 1.3607974302942694e-08
of O 0 1.6496015220468507e-08
the O 0 4.632638450630111e-08
36 O 0 3.2792016213534225e-07
patients O 0 5.104657319066064e-08
, O 0 2.218719075131048e-08
a O 0 2.7606242625211053e-08
mutation O 0 6.125704743453753e-08
was O 0 6.743972136291632e-08
detected O 0 5.69359279722903e-08
in O 0 1.4263918046708568e-08
constitutional O 0 2.6045057666124194e-07
DNA O 0 1.5132029318465356e-07
, O 0 1.0664410687866166e-08
and O 0 8.436403575728946e-09
1 O 0 5.381011192184815e-08
of O 0 1.1147550438295184e-08
these O 0 4.6741917003600975e-09
mutations O 0 1.7225140425125574e-08
is O 0 2.9290039282869884e-09
known O 0 8.019820363358576e-09
to O 0 6.672981278654788e-09
be O 0 2.9113214949916255e-08
associated O 0 1.6050442752657545e-07
with O 0 1.8457302530805464e-07
reduced O 0 3.632465086411685e-05
expressivity O 0 0.011449864134192467
. O 0 2.4439939807052724e-05

The O 0 1.0056749033537926e-06
presence O 0 1.6421371640262805e-07
of O 0 2.4936412046372425e-07
a O 0 1.1237172259370709e-07
constitutional O 0 1.3962833236291772e-06
mutation O 0 3.5231397532697883e-07
was O 0 1.1017512946409624e-07
not O 0 8.687551122932291e-09
associated O 0 2.5359502942023937e-08
with O 0 1.0270407635459833e-08
an O 0 1.7260921580941613e-08
early O 0 1.128349254031491e-06
age O 0 1.8098931832355447e-05
at O 0 2.106124156853184e-05
treatment O 0 1.92732441064436e-05
. O 0 1.525379775557667e-05

In O 0 2.015900008700555e-06
1 O 0 5.131452326168073e-06
patient O 0 8.553566317459627e-07
, O 0 3.5346801041669096e-07
somatic O 0 6.879409920657054e-05
mosaicism O 0 0.0007271947106346488
was O 0 1.244613372364256e-06
demonstrated O 0 3.9503115090155916e-07
by O 0 2.519019659530386e-08
molecular O 0 1.196205516862392e-07
analysis O 0 2.139985610938311e-08
of O 0 3.595358322172615e-08
DNA O 0 1.7443588262722187e-07
and O 0 7.923427602918309e-08
RNA O 0 8.977046377367515e-07
from O 0 1.800310798216742e-07
peripheral O 0 0.00022314771194942296
blood O 0 2.414779555692803e-05
. O 0 3.5009830753551796e-05

In O 0 3.3847256872832077e-06
2 O 0 1.1569203707040288e-05
patients O 0 2.9782199817418586e-07
without O 0 9.720528737489076e-08
a O 0 8.714074795079796e-08
detectable O 0 1.3313853060026304e-06
mutation O 0 1.7180522604576254e-07
in O 0 2.2908915653374606e-08
peripheral O 0 4.786933914147085e-06
blood O 0 5.329480359250738e-07
, O 0 3.9608588053852145e-07
mosaicism O 0 0.0027500372380018234
was O 0 6.704814836666628e-07
suggested O 0 1.2313545028064254e-07
because O 0 2.1040293063379067e-08
1 O 0 1.9130993678118102e-07
of O 0 7.43159631610979e-08
the O 0 1.061607264318809e-07
patients O 0 5.389700277191878e-07
showed O 0 3.225886757718399e-05
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 7.749682481517084e-06
the O 0 6.560656515830487e-07
other O 0 2.81467542606606e-08
later O 0 5.935788180977397e-07
developed O 0 2.5160004497593036e-06
bilateral B-Disease 0 9.953421249520034e-05
retinoblastoma I-Disease 1 0.8737704753875732
. O 0 3.914994886144996e-05

In O 0 1.7866632333607413e-06
conclusion O 0 3.3114874895545654e-06
, O 0 1.8298827342277946e-07
our O 0 1.1049564818677027e-07
results O 0 2.095978999250292e-07
emphasize O 0 9.909395259910525e-08
that O 0 6.781207595452088e-09
the O 0 3.507714296802078e-08
manifestation O 0 1.649436967454676e-06
and O 0 1.5533761654751288e-07
transmissibility O 0 3.2661253499099985e-05
of O 0 8.544981255909079e-07
retinoblastoma B-Disease 0 6.363835564116016e-05
depend O 0 1.3109099938901636e-07
on O 0 5.2737131994717856e-08
the O 0 1.8668526280407605e-08
nature O 0 3.434637108057359e-08
of O 0 2.076773775172569e-08
the O 0 1.871376653639345e-08
first O 0 4.5582243757280594e-08
mutation O 0 4.303031531094348e-08
, O 0 1.1637696140098797e-08
its O 0 9.040657111825112e-09
time O 0 5.6133998782570416e-08
in O 0 1.42737164310347e-08
development O 0 1.5674345377192367e-07
, O 0 1.1310837599864954e-08
and O 0 1.1870828764415364e-08
the O 0 1.3298579126796994e-08
number O 0 1.0168038855340455e-08
and O 0 7.232876964025081e-09
types O 0 2.0907839015649188e-08
of O 0 4.1450572751955406e-08
cells O 0 4.900859096323984e-08
that O 0 5.768400868078061e-09
are O 0 2.2128530119402967e-08
affected O 0 1.9757543157084e-07
. O 0 3.1165546943157096e-07
. O 0 4.121460733585991e-06

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
of I-Disease 0 0.00612847413867712
the I-Disease 0 1.43126817420125e-05
fifth I-Disease 0 3.4627417335286736e-05
component I-Disease 0 1.4354592394738575e-06
of I-Disease 0 3.720218728631153e-07
complement I-Disease 0 1.7035006294463528e-06
in O 0 6.324822834358201e-07
man O 0 2.3112017515813932e-05
. O 0 1.3079035852570087e-05

I O 0 0.0060006254352629185
. O 0 0.000231717131100595

Clinical O 0 0.0012686043046414852
, O 0 5.784406312159263e-06
immunochemical O 0 0.0018004359444603324
, O 0 2.2435235678130994e-06
and O 0 1.3270474710225244e-06
family O 0 4.4543321564560756e-07
studies O 0 2.38346501646447e-06
. O 0 1.1503643690957688e-05

The O 0 5.589591182797449e-06
first O 0 2.9184325285314117e-06
recognized O 0 2.2131880541564897e-06
human O 0 1.9910955870727776e-06
kindred O 0 0.00022628545411862433
with O 0 5.553683513426222e-05
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9094628691673279
the I-Disease 0 5.513788346434012e-05
fifth I-Disease 0 2.743090590229258e-05
component I-Disease 0 7.081883950377232e-07
of I-Disease 0 3.9365846760119894e-07
complement I-Disease 0 8.491168046020903e-06
( O 0 1.570452354826557e-06
C5 O 1 0.9999890327453613
) O 0 3.9256076433957787e-07
is O 0 3.293590680186753e-07
described O 0 5.1406759666861035e-06
. O 0 1.857965071394574e-05

The O 0 1.4967342394811567e-05
proband O 0 0.00014863850083202124
, O 0 4.59704324384802e-07
a O 0 2.124394171687527e-07
20 O 0 1.045513954522903e-06
- O 0 1.2002134326394298e-06
year O 0 1.536138682922683e-07
- O 0 1.9411104403843638e-06
old O 0 6.000031589792343e-06
black O 0 4.43585122411605e-06
female O 0 6.538821708090836e-06
with O 0 4.6822089643683285e-05
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.43526172637939453
age O 0 9.907664934871718e-05
11 O 0 4.19963998865569e-06
, O 0 1.2603773313912825e-07
lacked O 0 5.826627784699667e-06
serum O 0 4.060076207679231e-06
hemolytic O 0 0.0012780652614310384
complement O 0 8.872072498888883e-07
activity O 0 7.831444008843391e-07
, O 0 1.2164053941887687e-07
even O 0 2.125914164707865e-07
during O 0 2.2237643406697316e-06
remission O 0 1.1263656233495567e-05
. O 0 5.265680101729231e-06

C5 O 1 0.9999370574951172
was O 0 3.5697827115654945e-05
undetectable O 0 6.45554464426823e-05
in O 0 1.0642509806757516e-07
her O 0 2.5995470664952336e-08
serum O 0 3.423812984237884e-07
by O 0 7.911648225444878e-08
both O 0 5.864105219188787e-07
immunodiffusion O 0 0.0004369589441921562
and O 0 2.5968818590627052e-05
hemolytic O 1 0.9999988079071045
assays O 0 0.0012169232359156013
. O 0 6.637454498559237e-05

Other O 0 9.542774250803632e-07
complement O 0 1.442931193196273e-06
components O 0 1.2486626701502246e-06
were O 0 1.2219281586567377e-07
normal O 0 1.2678782468356076e-07
during O 0 1.0271097039549204e-07
remission O 0 3.0772451964367065e-07
of O 0 1.595006864363313e-07
lupus O 0 0.011348273605108261
, O 0 1.4111436996699922e-07
but O 0 3.108237933702185e-07
C1 O 1 0.9638630151748657
, O 0 1.6836075928949867e-06
C4 O 1 0.9996935129165649
, O 0 9.290503157899366e-07
C2 O 0 0.03880571573972702
, O 0 4.994108735445479e-07
and O 0 9.094826509681297e-07
C3 O 1 0.9998373985290527
levels O 0 1.931799852172844e-05
fell O 0 0.00016982089437078685
during O 0 8.95127232070081e-06
exacerbations O 0 0.0007373571861535311
. O 0 1.9302417058497667e-05

A O 0 5.3893571021035314e-05
younger O 0 5.1689858082681894e-05
half O 0 5.405686806625454e-06
- O 0 1.1902162441401742e-05
sister O 0 9.593417189535103e-07
, O 0 8.979189658475661e-08
who O 0 4.972200429165241e-08
had O 0 2.8199613666402e-07
no O 0 1.266128947463585e-06
underlying O 1 0.9999761581420898
disease O 1 0.9999951124191284
, O 0 3.1541990210826043e-06
was O 0 8.05309900897555e-06
also O 0 3.637711998294435e-08
found O 0 3.1630861485609785e-08
to O 0 5.482225162722898e-08
lack O 0 8.502268428856041e-06
immunochemically O 0 0.285972535610199
detectable O 1 0.9309685230255127
C5 O 1 0.9999501705169678
. O 0 8.653165423311293e-05

By O 0 2.0728872186737135e-05
hemolytic O 1 0.9999812841415405
assay O 0 0.00011725797958206385
, O 0 5.807671641377965e-07
she O 0 1.2835958784762624e-07
exhibited O 0 1.8895420339504199e-07
1 O 0 7.261978112182987e-07
- O 0 2.223977588755588e-07
2 O 0 8.305676146846963e-08
% O 0 4.813129450553788e-09
of O 0 9.412978840828146e-09
the O 0 2.9315595284629126e-08
normal O 0 3.548135225628357e-07
serum O 0 7.568319233541843e-07
C5 O 0 0.00043468683725222945
level O 0 5.318878493199009e-07
and O 0 1.989085873788099e-08
normal O 0 2.7075182984503954e-08
concentrations O 0 2.916567964916794e-08
of O 0 3.4422118488919295e-08
other O 0 3.019285443883746e-08
complement O 0 4.6415053134296613e-07
components O 0 4.223228188493522e-06
. O 0 4.871279543294804e-06

C5 O 1 0.5183321237564087
levels O 0 4.194509074295638e-06
of O 0 3.953024929614912e-07
other O 0 2.0097630226700858e-08
family O 0 8.018168351497934e-09
members O 0 8.200176537798143e-09
were O 0 1.6315466311311866e-08
either O 0 3.7301909117104515e-08
normal O 0 1.7253556450214091e-07
or O 0 3.606615450735262e-08
approximately O 0 6.468590640906768e-08
half O 0 8.708907017762613e-08
- O 0 1.7588853040706454e-07
normal O 0 7.678448099568413e-08
, O 0 2.817876953997711e-08
consistent O 0 4.138904330375226e-07
with O 0 1.0099792291384802e-07
autosomal O 0 1.8014416127698496e-05
codominant O 0 7.91918773757061e-06
inheritance O 0 1.9768397407915472e-07
of O 0 1.0383709536654351e-07
the O 0 2.2916481157153612e-07
gene O 0 3.3112885375885526e-06
determining O 0 0.00044113831245340407
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00200791098177433

Normal O 0 0.0007750043296255171
hemolytic O 1 0.9998664855957031
titers O 0 0.00048422854160889983
were O 0 1.284945938095916e-06
restored O 0 1.5756324955873424e-06
to O 0 3.1797021904367284e-08
both O 0 2.4381606067436223e-07
homozygous O 0 5.237389268586412e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999979734420776
deficient I-Disease 1 1.0
( O 0 7.543148240074515e-05
C5D B-Disease 1 1.0
) O 0 9.42374015266978e-07
sera O 0 4.509410246100742e-06
by O 0 2.0884442619717447e-08
addition O 0 6.416427567046412e-08
of O 0 2.4670444531693647e-07
highly O 0 8.4867551777279e-06
purified O 0 2.2694546714774333e-05
human O 0 2.882163789763581e-05
C5 O 1 0.999716579914093
. O 0 5.866936771781184e-05

In O 0 2.482972377038095e-06
specific O 0 4.105643711227458e-06
C5 O 1 0.9999208450317383
titrations O 0 0.0002853336918633431
, O 0 2.0241051856828562e-07
however O 0 2.0489414964686148e-07
, O 0 4.0942740753280304e-08
it O 0 7.292052739416022e-09
was O 0 7.128354440055773e-08
noted O 0 1.4156263716813555e-08
that O 0 2.7715756356627708e-09
when O 0 1.049877429437629e-08
limited O 0 1.502933599795142e-08
amounts O 0 4.2585494242075583e-08
of O 0 1.882880837911216e-07
C5 O 0 0.3682897090911865
were O 0 4.5920609181848704e-07
assayed O 0 9.96966036836966e-07
in O 0 1.2491476297782356e-08
the O 0 1.2948438765647552e-08
presence O 0 1.7693050580191994e-08
of O 0 5.911260103630411e-08
low O 0 1.1065832268286613e-06
dilutions O 0 1.7737502275849693e-05
of O 0 7.307482405849441e-07
either O 0 9.12851555767702e-06
C5D B-Disease 1 1.0
serum O 0 1.804041130526457e-05
, O 0 2.8793476758437464e-07
curving O 0 1.8849303842216614e-06
rather O 0 1.0103298819785778e-07
than O 0 4.919571239270226e-08
linear O 0 3.0282399166026153e-07
dose O 0 1.323172909906134e-06
- O 0 1.9362539660505718e-07
response O 0 2.8076836855461806e-08
plots O 0 5.675626724155336e-08
were O 0 2.4217182925667657e-08
consistently O 0 5.801505054137124e-08
obtained O 0 7.515584599104841e-08
, O 0 2.4680087307160647e-08
suggesting O 0 1.2714988883999467e-07
some O 0 7.270349300370071e-08
inhibitory O 0 2.5331667075079167e-06
effect O 0 4.4230432649783324e-06
. O 0 8.504466677550226e-06

Further O 0 7.159344022511505e-06
studies O 0 6.543198765029956e-07
suggested O 0 4.5070447640682687e-07
that O 0 3.142927340604729e-08
low O 0 1.371132384520024e-06
dilutions O 0 6.759881944162771e-05
of O 0 1.3100519936415367e-05
C5D B-Disease 1 1.0
serum O 0 1.8226181737190927e-06
contain O 0 8.266292184089252e-08
a O 0 1.92709777024902e-08
factor O 0 4.714198098554334e-08
( O 0 6.398826357667531e-09
or O 0 7.894942477548739e-09
factors O 0 3.764369083114616e-08
) O 0 2.2312679703873073e-08
interfering O 0 1.2190834297598485e-07
at O 0 1.0180830400940977e-07
some O 0 8.403449491822812e-09
step O 0 2.433208408092469e-07
in O 0 2.223289996550193e-08
the O 0 1.4202760212356225e-07
hemolytic O 0 0.0901695266366005
assay O 0 7.450170869560679e-06
of O 0 5.027597126172623e-06
C5 O 1 0.9999992847442627
, O 0 1.6146165648933675e-07
rather O 0 5.941100766904128e-08
than O 0 1.7444547140144095e-08
a O 0 5.155725446570614e-08
true O 0 1.1613635706453351e-06
C5 O 1 0.7285981178283691
inhibitor O 0 6.04893866693601e-05
or O 0 1.963304612218053e-06
inactivator O 0 7.889368134783581e-05
. O 0 1.5187999451882206e-05

Of O 0 3.724368980329018e-06
clinical O 0 8.116128810797818e-06
interest O 0 1.9130901307562453e-07
are O 0 4.4416907485356205e-08
( O 0 2.7412943026661196e-08
a O 0 2.7758201071037547e-08
) O 0 1.0761344704235398e-08
the O 0 1.3491598949144645e-08
documentation O 0 1.2863003462371125e-07
of O 0 6.845092457297142e-07
membranous O 1 0.9999998807907104
glomerulonephritis B-Disease 1 1.0
, O 1 0.9999991655349731
vasculitis B-Disease 1 1.0
, O 1 0.9994650483131409
and O 1 0.9999843835830688
arthritis B-Disease 1 1.0
in O 0 1.580871753503743e-06
an O 0 4.014410137642699e-08
individual O 0 9.362648256683315e-08
lacking O 0 0.0037375730462372303
C5 O 1 0.9999995231628418
( O 0 1.1708033298418741e-07
and O 0 3.7997882174067854e-08
its O 0 2.4350066851752672e-08
biologic O 0 1.221533693751553e-06
functions O 0 1.7614888747630175e-07
) O 0 1.1557972356968094e-08
, O 0 2.0886673723907734e-08
and O 0 4.1856552002172975e-08
( O 0 4.876791948049686e-08
b O 0 8.173897754204518e-07
) O 0 3.421945038439844e-08
a O 0 9.989934568466197e-08
remarkable O 0 5.670437985827448e-07
propensity O 0 2.104087116094888e-06
to O 0 7.113773108358146e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.6113934243076073e-07
the O 0 6.296933179328335e-07
proband O 0 4.960869046044536e-05
, O 0 3.902933087829297e-08
even O 0 2.19184990157828e-08
during O 0 4.906667072646087e-08
periods O 0 1.3136957477399847e-07
of O 0 4.238339812445702e-08
low O 0 1.3781065035800566e-06
- O 0 4.357256386811059e-07
dose O 0 5.660393753714743e-07
or O 0 6.909104399710486e-08
alternate O 0 1.0391847808932653e-06
- O 0 3.984020622738171e-06
day O 0 1.2318282642809208e-06
corticosteroid O 0 0.00027279366622678936
therapy O 0 6.167789251776412e-05
. O 0 7.478465249732835e-06

Other O 0 1.5420406498378725e-06
observations O 0 1.3448407116811723e-06
indicate O 0 3.364256997429038e-07
that O 0 4.362407679536773e-08
the O 0 4.269480200491671e-07
C5D B-Disease 1 0.9999994039535522
state O 0 1.2155229001109547e-07
is O 0 4.380592599773081e-08
compatible O 0 3.8693568171765946e-07
with O 0 1.6930616908439333e-08
normal O 0 9.986620597146612e-08
coagulation O 0 5.427979772321123e-07
function O 0 7.908208488061064e-08
and O 0 2.464104653654431e-08
the O 0 2.771598239803552e-08
capacity O 0 2.3362029821782926e-07
to O 0 3.51510109908304e-08
mount O 0 6.808316356909927e-06
a O 0 6.174772352096625e-06
neutrophilic O 1 0.9980530738830566
leukocytosis O 1 0.9718883037567139
during O 0 0.00018119854212272912
pyogenic B-Disease 1 0.5256181359291077
infection I-Disease 0 0.00028082611970603466
. O 0 3.212798219465185e-06
. O 0 1.4882569303154014e-05

Susceptibility O 0 0.0744766891002655
to O 0 0.0008651404641568661
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00013310792564880103
twins O 0 3.902936077793129e-05
: O 0 4.908408612891435e-08
the O 0 1.2279297578743353e-08
role O 0 2.6669150443581202e-08
of O 0 4.247760188036409e-08
genes O 0 8.172449383891944e-08
, O 0 2.0064314298906538e-07
HLA O 0 7.332745735766366e-05
, O 0 5.571696419792715e-07
and O 0 7.966340263010352e-07
the O 0 2.41059956351819e-06
environment O 0 5.3373518312582746e-05
. O 0 2.0736464648507535e-05

OBJECTIVE O 0 3.432023004279472e-05
To O 0 2.1820605411448923e-07
determine O 0 1.8590429817777476e-07
the O 0 5.608294983971973e-08
relative O 0 2.6378697270956764e-07
effects O 0 2.422019861114677e-06
of O 0 8.338651582562306e-07
genetic O 0 2.055508957710117e-06
and O 0 1.1717907710817599e-07
environmental O 0 9.172037351845574e-08
factors O 0 6.538925845234189e-08
in O 0 5.2426027963292654e-08
susceptibility O 0 1.1223596629861277e-05
to O 0 4.564069240586832e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9571157097816467
AS B-Disease 1 0.9999997615814209
) O 0 1.3530275282391813e-06
. O 0 4.26744691139902e-06

METHODS O 0 0.000115282426122576
Twins O 0 0.00010650967305991799
with O 0 1.8862867534608085e-07
AS B-Disease 1 0.9688397645950317
were O 0 1.5394853392081131e-07
identified O 0 4.5188201625023794e-08
from O 0 6.893016379905248e-09
the O 0 5.696601945714974e-08
Royal O 0 2.137450792361051e-05
National O 0 0.0010751857189461589
Hospital O 0 0.4277450442314148
for O 0 5.169419091544114e-05
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.00013877091987524182
. O 0 8.138990961015224e-05

Clinical O 0 0.0003056372806895524
and O 0 2.015019617829239e-06
radiographic O 0 9.937288996297866e-05
examinations O 0 2.3174479792942293e-05
were O 0 2.3991429998204694e-07
performed O 0 7.573677862637851e-08
to O 0 1.9730007849716458e-08
establish O 0 5.976058901069337e-07
diagnoses O 0 0.000586598995141685
, O 0 2.986948175021098e-06
and O 0 0.00047320840531028807
disease O 1 0.9999964237213135
severity O 1 0.8079701662063599
was O 0 2.160877011192497e-05
assessed O 0 4.404760147735942e-07
using O 0 3.484734278913493e-08
a O 0 2.5500940026290664e-08
combination O 0 2.3501650048274314e-07
of O 0 3.503087953049544e-07
validated O 0 4.186715614196146e-06
scoring O 0 1.070372400135966e-05
systems O 0 3.9250888221431524e-05
. O 0 1.4055757674213964e-05

HLA O 0 0.0033748799469321966
typing O 0 0.00010492239380255342
for O 0 4.906115009362111e-06
HLA O 0 0.0001607673184480518
- O 0 1.88964531844249e-05
B27 O 0 1.9585468180594034e-05
, O 0 7.41290250516613e-07
HLA O 0 1.9123992387903854e-05
- O 0 2.5960250695789e-06
B60 O 0 7.255550826812396e-06
, O 0 2.1418279061435896e-07
and O 0 9.171404826702201e-07
HLA O 0 0.0026272672694176435
- O 0 0.0001284138415940106
DR1 O 0 0.3459893465042114
was O 0 5.627645691674843e-07
performed O 0 1.116521630706302e-07
by O 0 6.662097007392731e-08
polymerase O 0 1.0888943506870419e-06
chain O 0 3.161165409437672e-07
reaction O 0 1.544119925256382e-07
with O 0 4.977703937925071e-08
sequence O 0 2.898296713738091e-07
- O 0 2.506568819171662e-07
specific O 0 1.9415860919025363e-08
primers O 0 3.9791078165762883e-07
, O 0 5.628838195548269e-08
and O 0 1.6551618386984046e-07
zygosity O 0 1.785877248039469e-05
was O 0 1.4294320180852083e-06
assessed O 0 1.2644408116102568e-06
using O 0 6.549373097186617e-07
microsatellite O 0 4.130304660066031e-05
markers O 0 1.6313997548422776e-05
. O 0 2.6911440727417357e-05

Genetic O 0 2.5780080250115134e-05
and O 0 7.263474230967404e-07
environmental O 0 3.274183200119296e-07
variance O 0 1.2372659341508552e-07
components O 0 6.64003664496704e-07
were O 0 1.2872563104338042e-07
assessed O 0 2.069111957325731e-07
with O 0 8.557318409430081e-09
the O 0 2.02680485728024e-08
program O 0 3.5166102918537945e-08
Mx O 0 1.9055422626479412e-06
, O 0 5.166038707926646e-09
using O 0 4.764082461861108e-09
data O 0 7.096796927896776e-09
from O 0 1.1423268997390323e-09
this O 0 8.75398142863304e-10
and O 0 2.8127582485382163e-09
previous O 0 1.2240293223442222e-08
studies O 0 1.370735347450136e-08
of O 0 5.397262015094384e-08
twins O 0 2.7072683224105276e-06
with O 0 2.8204965474287746e-07
AS B-Disease 1 0.9999765157699585
. O 0 2.5640079911681823e-05

RESULTS O 0 8.28547781566158e-05
Six O 0 8.459282071271446e-06
of O 0 1.9608830825745827e-06
8 O 0 3.7994905142113566e-05
monozygotic O 0 0.002506854245439172
( O 0 3.305697646283079e-06
MZ O 1 0.9994434714317322
) O 0 6.701349661852873e-07
twin O 0 4.46556368842721e-05
pairs O 0 2.46266813519469e-06
were O 0 9.78524622041732e-06
disease O 0 0.18070870637893677
concordant O 0 7.0522291935049e-05
, O 0 1.377855198825273e-07
compared O 0 4.962394584140384e-08
with O 0 1.3147356092702012e-08
4 O 0 2.3573052487790846e-07
of O 0 9.011737489572624e-08
15 O 0 4.2274527345398383e-07
B27 O 0 3.437826990193571e-06
- O 0 7.164147177718405e-07
positive O 0 2.157045884132458e-07
dizygotic O 0 7.733554957667366e-05
( O 0 9.74751287685649e-07
DZ O 0 0.0007451358833350241
) O 0 4.701837212905957e-07
twin O 0 5.917954240430845e-06
pairs O 0 1.7864303458736686e-07
( O 0 1.0475734768533584e-07
27 O 0 4.533725359578966e-07
% O 0 2.413809596646388e-08
) O 0 1.711366515166901e-08
and O 0 1.724025899818571e-08
4 O 0 3.266062265083747e-07
of O 0 2.1685119122594188e-07
32 O 0 1.0967045454890467e-05
DZ O 0 0.033737484365701675
twin O 0 1.3135098015482072e-05
pairs O 0 2.6691549237511936e-07
overall O 0 1.1552439218576183e-06
( O 0 1.1560401702581657e-07
12 O 0 2.0092404895422078e-07
. O 0 1.610940003615724e-08
5 O 0 1.7827372289502819e-07
% O 0 9.554068469697086e-08
) O 0 3.976399227667571e-07
. O 0 4.96996653964743e-06

Nonsignificant O 0 0.0006541093462146819
increases O 0 2.260569999634754e-06
in O 0 1.0074645473423516e-07
similarity O 0 1.5403782072098693e-07
with O 0 1.7527057138977398e-08
regard O 0 6.177035771770534e-08
to O 0 1.529483739659554e-08
age O 0 3.917569756595185e-06
at O 0 8.566457836423069e-05
disease O 0 0.003574309404939413
onset O 0 0.05063600093126297
and O 0 1.5103627504231554e-07
all O 0 4.418125953975505e-08
of O 0 1.5588062751703546e-07
the O 0 5.149745447852183e-07
disease O 0 2.386119194852654e-05
severity O 0 3.0831690764898667e-06
scores O 0 1.2162503253421164e-06
assessed O 0 4.009367842172651e-07
were O 0 7.771804888534461e-08
noted O 0 1.8856643180242827e-07
in O 0 3.0187305810613907e-07
disease O 0 0.2592025697231293
- O 0 0.017509164288640022
concordant O 1 0.6647668480873108
MZ O 1 0.9999985694885254
twins O 0 8.819739014143124e-05
compared O 0 1.7632935396250105e-06
with O 0 1.2393981023706147e-06
concordant O 0 0.007341987919062376
DZ O 1 0.9997449517250061
twins O 0 0.004001697059720755
. O 0 7.615903450641781e-05

HLA O 0 0.09181071817874908
- O 0 0.0001785538624972105
B27 O 0 3.52383685822133e-05
and O 0 3.905011283222848e-07
B60 O 0 7.96784479462076e-06
were O 0 1.5687564314248448e-07
associated O 0 9.777037490721341e-08
with O 0 2.5512228774005052e-08
the O 0 3.3121273190772627e-07
disease O 0 0.00018330190505366772
in O 0 7.320707595681597e-08
probands O 0 0.0017179379938170314
, O 0 6.58646612805569e-08
and O 0 2.8093014137198224e-08
the O 0 6.643368521963566e-08
rate O 0 2.5099294020947127e-07
of O 0 3.1799152111489093e-07
disease O 0 2.808846147672739e-05
concordance O 0 2.265082230223925e-06
was O 0 4.571960232624406e-07
significantly O 0 1.560138684908452e-07
increased O 0 3.237575185721653e-07
among O 0 1.0415162705612602e-06
DZ O 0 0.24117760360240936
twin O 0 1.0795391062856652e-05
pairs O 0 7.376900867939185e-08
in O 0 1.2569294050024382e-08
which O 0 1.1997136617480919e-08
the O 0 6.947890085484687e-08
co O 0 5.623115157504799e-06
- O 0 3.356333309056936e-06
twin O 0 4.856889972870704e-06
was O 0 2.3434840557001735e-07
positive O 0 5.085493270939878e-08
for O 0 4.460810743012189e-08
both O 0 3.0514232207679015e-07
B27 O 0 3.0347695428645238e-05
and O 0 1.0943276720354334e-05
DR1 O 0 0.14098986983299255
. O 0 3.36229131789878e-05

Additive O 0 1.716053156997077e-05
genetic O 0 3.2710327104723547e-06
effects O 0 2.8943902634637197e-06
were O 0 1.0815467277325297e-07
estimated O 0 1.5152615162605798e-08
to O 0 7.265951396107084e-09
contribute O 0 1.5617606763385083e-08
97 O 0 1.3081175609386264e-07
% O 0 8.529502437681913e-09
of O 0 2.3564055595670652e-08
the O 0 2.4333260739695106e-08
population O 0 1.9814217822045066e-08
variance O 0 7.203011591627728e-07
. O 0 4.082463874510722e-06

CONCLUSION O 0 4.55975387012586e-05
Susceptibility O 0 2.0666579075623304e-05
to O 0 2.6444612899467757e-07
AS B-Disease 1 0.9960035681724548
is O 0 3.946387394648809e-08
largely O 0 6.757053228056975e-08
genetically O 0 5.837356908955371e-08
determined O 0 6.874807922940818e-08
, O 0 3.8660289192193886e-08
and O 0 5.4644676339421494e-08
the O 0 1.0908446768098656e-07
environmental O 0 3.7351068726820813e-07
trigger O 0 2.477269845257979e-06
for O 0 3.184983654591633e-07
the O 0 3.5081002351944335e-06
disease O 0 0.04773908853530884
is O 0 9.324368477336975e-08
probably O 0 6.455907168856356e-07
ubiquitous O 0 1.0616174222377595e-05
. O 0 6.523903721245006e-06

HLA O 0 0.1455809473991394
- O 0 0.00018029389320872724
B27 O 0 1.4316339729703031e-05
accounts O 0 5.1313854498857836e-08
for O 0 2.4133170128948223e-08
a O 0 2.884343430764602e-08
minority O 0 4.6383146212747306e-08
of O 0 6.978836353255247e-08
the O 0 8.950650709493857e-08
overall O 0 7.296785611288215e-07
genetic O 0 9.742791462485911e-07
susceptibility O 0 2.896024852816481e-06
to O 0 6.030206236573576e-07
AS B-Disease 1 0.9999986886978149
. O 0 0.00012488738866522908

Cell O 0 0.00023104401770979166
cycle O 0 2.373663846810814e-05
- O 0 7.097718025761424e-06
dependent O 0 8.727529348107055e-07
colocalization O 0 1.2370750482659787e-05
of O 0 1.4893154229866923e-06
BARD1 O 0 0.002733760280534625
and O 0 9.62771423473896e-07
BRCA1 O 0 1.985391918424284e-06
proteins O 0 7.664561962883454e-08
in O 0 8.760504499605304e-08
discrete O 0 2.3491236333939014e-06
nuclear O 0 1.1236254977120552e-05
domains O 0 3.006637234648224e-05
. O 0 2.275739643664565e-05

Germ O 1 0.9979922771453857
- O 0 0.02523942105472088
line O 0 1.4182298400555737e-05
mutations O 0 9.760191232999205e-07
of O 0 3.727012085619208e-07
the O 0 5.103450462229375e-07
BRCA1 O 0 7.500743777200114e-06
gene O 0 6.831534165030462e-07
predispose O 0 2.040405888692476e-06
women O 0 1.5912480932911421e-07
to O 0 3.2440123476362714e-08
early O 0 2.3399998099193908e-05
- O 1 0.9975918531417847
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 5.862657872057753e-06
compromising O 0 7.709537385380827e-06
the O 0 2.146932303048743e-07
genes O 0 6.798136098495888e-08
presumptive O 0 2.782069714157842e-06
function O 0 5.965979994471127e-07
as O 0 3.048136818506464e-07
a O 0 7.788586344759096e-07
tumor B-Disease 0 5.161597073310986e-05
suppressor O 0 0.0006658270140178502
. O 0 4.3857453420059755e-05

Although O 0 4.677307515521534e-06
the O 0 6.937295324860315e-07
biochemical O 0 3.696594603752601e-06
properties O 0 1.5641120398868225e-06
of O 0 1.4150209608487785e-06
BRCA1 O 0 9.34335093916161e-06
polypeptides O 0 8.136829592331196e-07
are O 0 1.4231824607691124e-08
not O 0 1.9650464366804954e-08
understood O 0 1.7619223058318312e-07
, O 0 2.1126066229726348e-08
their O 0 1.2361120127479808e-08
expression O 0 1.5206011028112698e-07
pattern O 0 3.1741251405037474e-07
and O 0 1.1699818713850618e-07
subcellular O 0 8.040889042604249e-06
localization O 0 7.026142156973947e-06
suggest O 0 1.9748385682305525e-07
a O 0 1.2585178410517983e-07
role O 0 4.225824170589476e-07
in O 0 2.2892412232522474e-07
cell O 0 9.15506316232495e-05
- O 0 6.082673280616291e-05
cycle O 0 2.287349707330577e-05
regulation O 0 3.0376591894309968e-05
. O 0 1.604337739991024e-05

When O 0 7.2942434599099215e-06
resting O 0 2.5110355636570603e-05
cells O 0 7.68045367749437e-07
are O 0 3.6829373328828297e-08
induced O 0 1.6147951953371376e-07
to O 0 1.4902196809885027e-08
proliferate O 0 1.995497171947136e-07
, O 0 2.340883575868702e-08
the O 0 2.1193466537283712e-08
steady O 0 3.7467268043656077e-07
- O 0 1.0110701254006926e-07
state O 0 3.9293204245893776e-09
levels O 0 3.8954368619670277e-08
of O 0 2.3290590789315502e-08
BRCA1 O 0 1.9459095312868158e-07
increase O 0 1.3025004186317801e-08
in O 0 1.0413852891133502e-08
late O 0 9.740348332343274e-07
G1 O 0 8.465002792945597e-06
and O 0 3.053366981475847e-08
reach O 0 7.826518100273461e-08
a O 0 3.790660230151843e-08
maximum O 0 5.305969921209908e-07
during O 0 5.238065341472975e-07
S O 0 1.3005812434130348e-05
phase O 0 7.439748878823593e-05
. O 0 1.1371445907570887e-05

Moreover O 0 1.0445210136822425e-05
, O 0 8.049075859162258e-07
in O 0 9.081914953412706e-08
S O 0 2.4986618427647045e-06
phase O 0 1.4008799553266726e-05
cells O 0 5.933891884524201e-07
, O 0 6.62933103967589e-08
BRCA1 O 0 6.719114935549442e-07
polypeptides O 0 5.284936150928843e-07
are O 0 4.3862780074732655e-08
hyperphosphorylated O 0 1.0892443924603867e-06
and O 0 6.188238899085263e-08
accumulate O 0 2.1027300078912958e-07
into O 0 1.8042794636130566e-07
discrete O 0 3.2001021281757858e-06
subnuclear O 0 2.305720408912748e-05
foci O 0 5.664348282152787e-05
termed O 0 1.6725523892091587e-05
" O 0 6.354081961035263e-06
BRCA1 O 0 7.652112981304526e-05
nuclear O 0 0.00020474512712098658
dots O 0 0.00021545210620388389
. O 0 2.356283766857814e-05

" O 0 4.9023750761989504e-05
BRCA1 O 0 0.00011158294364577159
associates O 0 1.989292104553897e-05
in O 0 4.645211504339386e-07
vivo O 0 5.454066922538914e-06
with O 0 1.3310078372796852e-07
a O 0 7.434601343447866e-07
structurally O 0 1.4026485587237403e-05
related O 0 5.688566943717888e-06
protein O 0 1.7136000678874552e-05
termed O 0 3.064778502448462e-05
BARD1 O 0 0.09882637858390808
. O 0 3.350860424689017e-05

Here O 0 5.567793778027408e-06
we O 0 2.4967297918010445e-07
show O 0 3.437258300209578e-08
that O 0 6.16573370137985e-09
the O 0 2.603452387006655e-08
steady O 0 4.873137982031039e-07
- O 0 9.835093095489356e-08
state O 0 3.0254407867857935e-09
levels O 0 2.8662404005785902e-08
of O 0 9.30184427261338e-08
BARD1 O 0 0.001617959002032876
, O 0 2.5794994584771302e-08
unlike O 0 1.6698521676516975e-08
those O 0 5.490028875954067e-09
of O 0 4.591137070519835e-08
BRCA1 O 0 3.748370716039062e-07
, O 0 1.2543883265436762e-08
remain O 0 4.02663360432598e-08
relatively O 0 3.5584633906182717e-08
constant O 0 1.8388097089427902e-07
during O 0 6.875745270917832e-07
cell O 0 1.0475066119397525e-05
cycle O 0 7.988212928466965e-06
progression O 0 2.7950984076596797e-05
. O 0 6.921581643837271e-06

However O 0 1.2696312296611723e-05
, O 0 3.269860144428094e-06
immunostaining O 0 0.00011766266106860712
revealed O 0 8.018499102036003e-06
that O 0 3.790357254729315e-07
BARD1 O 0 0.0002027774607995525
resides O 0 1.881988168861426e-06
within O 0 5.313069095791434e-07
BRCA1 O 0 4.205234745313646e-06
nuclear O 0 1.0627215488057118e-05
dots O 0 2.074123358397628e-06
during O 0 3.763831273317919e-07
S O 0 1.6424800151071395e-06
phase O 0 2.4411253889411455e-06
of O 0 7.460341322484965e-08
the O 0 4.6742563597490516e-08
cell O 0 3.293421286798548e-07
cycle O 0 5.632114152831491e-08
, O 0 8.60148396952809e-09
but O 0 6.7084453547749945e-09
not O 0 1.323577070166948e-08
during O 0 1.1275710676272865e-07
the O 0 3.3316010217276926e-07
G1 O 0 0.00014392529556062073
phase O 0 5.957622852292843e-05
. O 0 1.1529959010658786e-05

Nevertheless O 0 0.00010026477684732527
, O 0 8.142060323734768e-06
BARD1 O 0 0.0004392470873426646
polypeptides O 0 3.3383928439434385e-06
are O 0 7.365822085603213e-08
found O 0 5.83803583253939e-08
exclusively O 0 8.608085977357405e-08
in O 0 2.763521855797535e-08
the O 0 3.236559109609516e-08
nuclear O 0 5.364476010072394e-07
fractions O 0 6.051845389265509e-07
of O 0 1.3519475317025353e-07
both O 0 2.643800769419613e-07
G1 O 0 5.047461672802456e-05
- O 0 8.923716450226493e-07
and O 0 1.600081844799206e-07
S O 0 1.8796685253619216e-05
- O 0 1.1513950084918179e-05
phase O 0 0.00013202133413869888
cells O 0 6.6115408117184415e-06
. O 0 2.7691364721249556e-06

Therefore O 0 9.084832527150866e-06
, O 0 5.932120643592498e-07
progression O 0 2.003873987632687e-06
to O 0 4.9758241971176176e-08
S O 0 2.958730647151242e-06
phase O 0 2.3380660422844812e-05
is O 0 2.8122874695668543e-08
accompanied O 0 3.4968721251971147e-08
by O 0 5.827586857520828e-09
the O 0 1.598464471896932e-08
aggregation O 0 1.2277685357275914e-07
of O 0 1.3856259784006397e-07
nuclear O 0 1.0001381269830745e-05
BARD1 O 0 0.00037281570257619023
polypeptides O 0 3.667281816888135e-06
into O 0 9.084736234399315e-07
BRCA1 O 0 1.4706913134432398e-05
nuclear O 0 5.052734923083335e-05
dots O 0 4.931445437250659e-05
. O 0 1.4992971046012826e-05

This O 0 2.4706096155568957e-06
cell O 0 9.275238880945835e-06
cycle O 0 4.094964879186591e-06
- O 0 1.3771041267318651e-06
dependent O 0 2.3785506186868588e-07
colocalization O 0 3.641242528829025e-06
of O 0 5.094814241601853e-07
BARD1 O 0 0.015423539094626904
and O 0 5.7324336921738e-07
BRCA1 O 0 1.5842585980863078e-06
indicates O 0 2.030795229757132e-07
a O 0 9.774576170684668e-08
role O 0 2.2427290957693913e-07
for O 0 2.809950672144623e-07
BARD1 O 0 0.00030337049975059927
in O 0 1.2640452951018233e-06
BRCA1 O 0 0.00020396885520312935
- O 0 0.000308987800963223
mediated O 0 0.0015329988673329353
tumor B-Disease 0 0.0004241426649969071
suppression O 0 0.0010904154041782022
. O 0 7.497373007936403e-05

Ethnic O 0 1.0111747542396188e-05
differences O 0 9.024574865179602e-06
in O 0 7.287904963959591e-07
the O 0 1.188400119644939e-06
HFE O 0 0.000660651654470712
codon O 0 4.7521178203169256e-05
282 O 0 3.653663952718489e-05
( O 0 1.1679071576509159e-05
Cys O 1 0.9994127750396729
/ O 0 0.01428768690675497
Tyr O 0 0.02005741558969021
) O 0 8.971082024800126e-06
polymorphism O 0 0.00010482848301762715
. O 0 3.1636001949664205e-05

Recent O 0 1.7936972653842531e-06
studies O 0 2.8011533004246303e-07
have O 0 6.128568230678866e-08
shown O 0 2.5940352088582586e-07
that O 0 1.2064310794812627e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9998822212219238
HH B-Disease 1 1.0
) O 0 4.772065267388825e-07
is O 0 2.2584654146839966e-08
likely O 0 5.1940517664661456e-08
to O 0 1.7593105638979978e-08
be O 0 5.003738579034689e-08
caused O 0 2.874683389109123e-07
by O 0 5.771143563038095e-08
homozygosity O 0 5.28104874319979e-06
for O 0 6.836129529119717e-08
a O 0 1.5711040646237961e-07
Cys282Tyr O 0 5.157228770258371e-06
mutation O 0 1.6163544103164895e-07
in O 0 2.989003178299754e-08
the O 0 1.5005969089543214e-07
HFE O 0 6.187565304571763e-05
gene O 0 9.462003731641744e-07
located O 0 1.5446339602931403e-06
4 O 0 1.718196836009156e-05
. O 0 2.3782111384207383e-05

5 O 0 0.0001249766064574942
Mb O 0 0.001988879404962063
telomeric O 0 0.00027146656066179276
to O 0 5.9245048760203645e-06
HLA O 0 0.003971724770963192
- O 0 9.849984780885279e-05
A O 0 3.881677912431769e-05
. O 0 2.4713806851650588e-05

Population O 0 3.180506666922156e-07
studies O 0 3.4837117368624604e-07
of O 0 1.3194350856338133e-07
this O 0 2.854586611533705e-08
polymorphism O 0 4.3299701246724e-07
are O 0 1.1679278877352317e-08
facilitated O 0 1.0555822882452048e-07
by O 0 7.916777455818647e-09
the O 0 1.4538536596830909e-08
fact O 0 2.404458676608101e-08
that O 0 8.534481565902752e-09
the O 0 1.6881514852684631e-07
Cys282Tyr O 0 5.601350130746141e-05
mutation O 0 2.7953778953815345e-06
creates O 0 1.2846064691984793e-06
a O 0 6.124782885308377e-07
Rsal O 0 3.303688208688982e-05
restriction O 0 2.0023685465275776e-06
site O 0 2.920982751675183e-06
. O 0 5.454145139083266e-06

We O 0 2.772407924567233e-06
have O 0 2.2296455881587462e-07
studied O 0 1.7957785303224227e-06
the O 0 2.696474723506981e-07
codon O 0 1.1220183296245523e-05
282 O 0 9.50391677179141e-06
( O 0 4.32624074164778e-06
Cys O 1 0.9997830986976624
/ O 0 0.07207632809877396
Tyr O 0 0.006545227952301502
) O 0 3.070531988669245e-07
polymorphism O 0 3.8589129758292984e-07
in O 0 8.393165273901104e-09
different O 0 1.2315701347631602e-08
ethnic O 0 1.3903527928960102e-07
groups O 0 3.4525191949796863e-07
. O 0 4.499667284108e-06

In O 0 1.728519237076398e-06
agreement O 0 1.2809413192371721e-06
with O 0 9.085605512382244e-08
previous O 0 5.159415081834595e-07
observations O 0 5.158400995242118e-07
the O 0 1.786685857041448e-07
Tyr O 0 3.0243025321397e-05
allele O 0 1.2382627119222889e-06
appeared O 0 7.338937990652994e-08
to O 0 9.129063727186804e-09
be O 0 2.580675584340497e-08
rare O 0 5.4599773591235135e-08
or O 0 2.8141764474298725e-08
absent O 0 4.6070010739640566e-07
in O 0 5.918378676028624e-08
Asiatic O 0 3.431681989241042e-06
( O 0 1.8564901438367087e-07
Indian O 0 2.148197921769679e-07
, O 0 9.785769350401097e-08
Chinese O 0 2.918049233358033e-07
) O 0 2.2698972657053673e-07
populations O 0 1.0221881439065328e-06
. O 0 8.166344741766807e-06

The O 0 3.6515775718726218e-06
highest O 0 3.041961690541939e-06
allele O 0 1.18882519473118e-06
frequency O 0 1.204978730129369e-06
( O 0 2.8486960346185697e-08
7 O 0 7.736663576451974e-08
. O 0 4.3710421948617295e-09
5 O 0 3.67433514725235e-08
% O 0 1.070592503538137e-08
) O 0 1.802522930915984e-08
was O 0 1.2988961373139318e-07
found O 0 5.9296439758327324e-08
in O 0 2.658784410414228e-07
Swedes O 0 0.00012717756908386946
. O 0 4.637912206817418e-05

Saamis O 0 0.0011632429668679833
( O 0 9.733792012411868e-07
2 O 0 1.3755893633060623e-06
% O 0 1.147814217006271e-07
) O 0 4.014188093037774e-08
and O 0 8.310335175565342e-08
Mordvinians O 0 6.423924787668511e-06
( O 0 3.4465216458556824e-08
1 O 0 1.191564749092322e-07
. O 0 6.659897522354186e-09
8 O 0 5.44944853686502e-08
% O 0 7.739243024218467e-09
) O 0 1.0533453220773481e-08
had O 0 2.7939650593111764e-08
significantly O 0 7.390998746359401e-08
lower O 0 2.735805537668057e-07
frequencies O 0 1.1762328995246207e-06
of O 0 2.2511076736009272e-07
the O 0 1.0064271691589965e-06
Tyr O 0 0.00013393702101893723
allele O 0 4.216767774778418e-05
. O 0 9.54688493948197e-06

Comparisons O 0 6.5432946030341554e-06
with O 0 5.48267962585669e-07
allele O 0 3.1232007131620776e-06
frequencies O 0 1.9101564703305485e-06
based O 0 1.4381460289314418e-07
on O 0 2.137966674808922e-07
prevalence O 0 5.024281222176796e-07
estimates O 0 6.991759704533251e-08
of O 0 2.0630746178085246e-07
HH B-Disease 1 0.9528793096542358
showed O 0 5.022546929467353e-07
some O 0 4.5159765704738675e-08
disagreements O 0 5.172086048332858e-07
with O 0 3.811249627005964e-08
the O 0 1.7402165042312845e-07
RFLP O 0 9.598564247426111e-06
data O 0 1.822811270812963e-07
, O 0 8.33840587688428e-08
particularly O 0 4.140044893574668e-07
in O 0 6.487593964266125e-07
Finns O 0 8.454240014543757e-05
. O 0 2.4210652554756962e-05

The O 0 1.7189688151120208e-05
newly O 0 7.908305269666016e-05
described O 0 1.3748898709309287e-05
HFE O 0 0.14051055908203125
marker O 0 1.3771218618785497e-05
provides O 0 3.1998379768083396e-07
a O 0 6.212695780050126e-08
new O 0 5.107890999056508e-08
approach O 0 4.8009461295350775e-08
to O 0 5.709140715737249e-09
the O 0 1.1993749104988183e-08
screening O 0 4.867907676953109e-08
of O 0 1.2259924631052854e-07
HH B-Disease 1 0.8490456938743591
as O 0 6.37907504597024e-08
well O 0 1.4482104404578422e-08
as O 0 7.255108513959385e-09
studies O 0 1.3411114885286679e-08
of O 0 2.1876191524938804e-08
the O 0 4.469957914920997e-08
relationship O 0 8.025669728795037e-08
between O 0 2.1209406497746386e-07
the O 0 6.481855052697938e-07
HFE O 0 0.014122724533081055
Tyr O 0 0.0006489193765446544
allele O 0 9.02148531167768e-06
and O 0 1.1494259979372146e-06
different O 0 2.280204171256628e-05
disorders O 1 0.9999996423721313
including O 0 0.004578154068440199
cancer B-Disease 1 0.9999969005584717

Autosomal B-Disease 1 0.9999994039535522
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999310970306396
associated O 0 2.055011236734572e-06
with O 0 2.2394119980617688e-07
a O 0 5.424352025329426e-07
missense O 0 5.984670679026749e-06
mutation O 0 8.712245289643761e-07
encoding O 0 2.8207678042235784e-06
Gly23 O 0 6.362634303513914e-05
- O 0 3.146015296806581e-05
- O 0 2.9685281333513558e-05
> O 0 2.7241434509051032e-05
Val O 0 2.8058266252628528e-05
in O 0 5.322831384546589e-07
neurophysin O 0 9.85947553999722e-05
II O 1 0.9982226490974426
. O 0 3.889248182531446e-05

Autosomal B-Disease 1 0.9999806880950928
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 8.811500447336584e-05
ADNDI B-Disease 1 0.9999953508377075
) O 0 5.20054527441971e-07
is O 0 8.232243686734364e-08
an O 0 5.859186558154761e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9979748129844666
by O 0 5.220345701673068e-05
progressive O 1 0.9999998807907104
degeneration O 1 1.0
of O 0 0.005472730845212936
the O 0 2.161656266252976e-05
magnocellular O 0 0.06970100849866867
neurons O 0 7.66829998610774e-06
of O 0 1.533338604531309e-06
the O 0 2.575090547907166e-06
hypothalamus O 0 1.2636905921681318e-05
leading O 0 3.157115315843839e-06
to O 0 5.528533364440591e-08
decreased O 0 4.322230324760312e-07
ability O 0 5.9403298280358285e-08
to O 0 3.292371530960736e-08
produce O 0 3.786614115597331e-07
the O 0 6.677089459117269e-07
hormone O 0 1.5069950677570887e-05
arginine O 0 2.9374417863436975e-05
vasopressin O 0 3.301577817182988e-05
( O 0 2.4250107344414573e-06
AVP O 0 0.00042327019036747515
) O 0 3.4331092138017993e-06
. O 0 2.5467301384196617e-05

Affected O 0 2.0966612282791175e-05
individuals O 0 3.4798267734004185e-07
are O 0 7.134271129416447e-08
not O 0 1.0523537241624581e-07
symptomatic O 0 1.5808651369297877e-05
at O 0 2.3049249193718424e-06
birth O 0 4.61899787751463e-07
, O 0 1.528664910210864e-07
but O 0 3.507236385758006e-07
usually O 0 4.657188583223615e-06
develop O 0 0.0374082587659359
diabetes B-Disease 1 0.9999431371688843
insipidus I-Disease 0 0.0038242731243371964
at O 0 4.885953330813209e-06
1 O 0 4.773703949467745e-06
- O 0 4.328349859861191e-06
6 O 0 9.233969649358187e-06
yr O 0 0.000260449800407514
of O 0 1.6441568959635333e-06
age O 0 2.0996287275920622e-05
. O 0 1.9911141862394288e-05

The O 0 4.156135673838435e-06
genetic O 0 3.2185666896111798e-06
locus O 0 3.367034878465347e-06
of O 0 8.686998285156733e-07
the O 0 4.079910468135495e-06
disease O 0 0.024138525128364563
is O 0 2.2265835752932617e-07
the O 0 1.3323074199433904e-06
AVP O 0 0.0209577027708292
- O 0 0.0002348109701415524
neurophysin O 0 0.0007696673274040222
II O 1 0.9999997615814209
( O 0 3.8056782614148688e-06
NPII O 0 0.015641145408153534
) O 0 1.0032420760808236e-07
gene O 0 1.4348992749546596e-07
, O 0 3.2878595845886593e-08
and O 0 6.310098399353592e-08
mutations O 0 2.505471741187648e-07
that O 0 2.4158270051088948e-08
cause O 0 4.134361461183289e-06
ADNDI B-Disease 1 0.9990410208702087
have O 0 1.3895125050567003e-07
been O 0 7.555657077773503e-08
found O 0 1.5704141986816467e-08
in O 0 8.296457743028895e-09
both O 0 1.2935405635516872e-08
the O 0 3.618977828523384e-08
signal O 0 3.9817953734200273e-07
peptide O 0 1.8891293507294904e-07
of O 0 1.5625985838596534e-07
the O 0 4.814674525732698e-07
prepro O 0 0.00017413307796232402
- O 0 0.00071313651278615
AVP O 0 0.0031122600194066763
- O 0 0.00012097634316887707
NPII O 0 0.0017752679996192455
precursor O 0 2.055340701190289e-05
and O 0 1.140284211942344e-06
within O 0 3.716166247613728e-06
NPII O 0 0.0009484585607424378
itself O 0 1.4420589650399052e-05
. O 0 1.959260589501355e-05

An O 0 5.0916505642817356e-06
affected O 0 7.2081852522387635e-06
girl O 0 7.197701961558778e-06
who O 0 1.915507255034754e-07
presented O 0 1.0201848681390402e-06
at O 0 6.551459819092997e-07
9 O 0 4.7550341264468443e-07
months O 0 4.5669967363437536e-08
of O 0 4.250985696785392e-08
age O 0 3.272060382641939e-07
and O 0 4.993489355342717e-08
her O 0 2.1815440121031315e-08
similarly O 0 2.1473580602560105e-07
affected O 0 2.506442058347602e-07
younger O 0 3.7619827253365656e-06
brother O 0 2.894782255680184e-06
and O 0 1.2315834396758873e-07
father O 0 1.8480869812265155e-07
were O 0 9.358310393281499e-08
all O 0 1.9476503965165648e-08
found O 0 1.4554517591136573e-08
to O 0 1.4178015206312011e-08
have O 0 3.137040494038956e-08
a O 0 9.992031380079425e-08
novel O 0 6.072600626794156e-07
missense O 0 1.0729232599260285e-05
mutation O 0 1.5211682011795347e-06
( O 0 3.9405435359185503e-07
G1758 O 0 1.1594951502047479e-05
- O 0 1.9250321201980114e-05
- O 0 1.9966399122495204e-05
> O 0 1.3293248230183963e-05
T O 0 6.479187504737638e-06
) O 0 7.737637730542701e-08
encoding O 0 2.650819226346357e-07
the O 0 6.01263394628404e-08
amino O 0 1.7367349869346072e-07
acid O 0 1.9332888712142449e-07
substitution O 0 9.470967938796093e-07
Gly23 O 0 6.611963908653706e-05
- O 0 3.34255637426395e-05
- O 0 2.8294887670199387e-05
> O 0 4.2566447518765926e-05
Val O 0 6.47736233077012e-05
within O 0 6.197941274876939e-06
NPII O 0 0.001813213573768735
. O 0 3.769995964830741e-05

The O 0 5.064636752649676e-06
mutation O 0 5.177739240025403e-06
was O 0 1.4544674513672362e-06
confirmed O 0 5.526582071979647e-07
by O 0 8.488526503924732e-08
restriction O 0 7.91138916156342e-07
endonuclease O 0 1.8848419131245464e-05
analysis O 0 8.55694725032663e-06
. O 0 3.2059368095360696e-05

A O 0 0.0008605471812188625
T1 O 1 0.8847013115882874
- O 0 9.248319111065939e-05
weighted O 0 5.473236797115533e-06
magnetic O 0 8.98190319276182e-06
resonance O 0 1.1440539310569875e-05
imaging O 0 1.3978520655655302e-05
of O 0 8.187893740796426e-07
the O 0 3.62948981091904e-06
fathers O 0 7.999442459549755e-05
pituitary O 0 0.000823154638055712
gland O 0 8.63320310600102e-05
demonstrates O 0 2.0240427147655282e-06
an O 0 8.049851203395519e-07
attenuated O 0 0.00025777972768992186
posterior O 0 0.026866775006055832
pituitary O 1 0.999707043170929
bright O 1 0.9999185800552368
spot O 1 0.9298759698867798
. O 0 0.0001641560229472816

This O 0 5.612007498712046e-07
mutation O 0 2.036012801909237e-06
may O 0 3.1600743000126386e-07
be O 0 8.754223301821185e-08
valuable O 0 7.150482019824267e-07
for O 0 7.654452360839059e-08
developing O 0 2.98203360671323e-07
models O 0 4.710908285687765e-07
of O 0 5.200703867558332e-07
dominantly B-Disease 1 0.8535465598106384
inherited I-Disease 1 0.998992383480072
neurodegeneration I-Disease 1 1.0
, O 0 7.292250074897311e-07
as O 0 4.122373908899135e-08
the O 0 1.4280087334839209e-08
early O 0 6.11722867915887e-08
age O 0 6.370831329149951e-08
of O 0 6.844401667649436e-08
onset O 0 0.13374623656272888
of O 0 1.038851678458741e-05
symptoms O 0 0.004606554284691811
suggests O 0 2.7183881456949166e-07
that O 0 4.2194470140088924e-09
this O 0 3.2948574979485556e-09
mutation O 0 3.649832436281031e-08
may O 0 3.3352243633544276e-08
be O 0 3.37784911152994e-08
particularly O 0 9.154909008657341e-08
deleterious O 0 2.6580084977467777e-06
to O 0 7.321671802174023e-08
the O 0 8.470733519061469e-07
magnocellular O 0 0.000327636138536036
neuron O 0 4.310767326387577e-05
. O 0 1.4609748859584215e-06
. O 0 6.7411169766273815e-06

Frequent O 0 2.057289930235129e-05
inactivation O 0 0.00017817766638472676
of O 0 4.060281935380772e-05
PTEN O 1 0.9999256134033203
/ O 1 0.9995802044868469
MMAC1 O 1 0.9999532699584961
in O 0 2.146971019101329e-05
primary O 1 0.9999905824661255
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00047701899893581867

Sporadic B-Disease 1 0.9999979734420776
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.1947161510761362e-05
the O 0 4.155888007062458e-07
most O 0 6.31844443432783e-08
common O 0 3.7073095882078633e-07
male B-Disease 0 6.984694778111589e-07
cancer I-Disease 0 9.085048304768861e-07
in O 0 1.532181670427235e-08
the O 0 4.561425015481291e-08
Western O 0 2.4109810965455836e-06
world O 0 1.1126699064334389e-06
, O 0 1.1441962932678962e-08
yet O 0 1.487899403684878e-08
many O 0 2.154026734757508e-09
of O 0 1.0895341517880297e-08
the O 0 1.8647316579745166e-08
major O 0 2.2336787708354677e-07
genetic O 0 3.294570944945008e-07
events O 0 9.608949369521724e-08
involved O 0 1.3083295868909772e-07
in O 0 3.911637591613726e-08
the O 0 9.854998239688939e-08
progression O 0 1.1070212167396676e-05
of O 0 8.415946695095045e-07
this O 0 1.246212661953905e-07
often O 0 2.1465812096721493e-06
fatal O 1 0.9988369345664978
cancer B-Disease 0 0.005134474486112595
remain O 0 2.2944086595089175e-06
to O 0 3.724247790160007e-07
be O 0 2.215388349213754e-06
elucidated O 0 0.00050403515342623
. O 0 2.015308928093873e-05

Numerous O 0 2.115823735948652e-05
cytogenetic O 0 0.0012536150170490146
and O 0 3.928797923435923e-06
allelotype O 0 0.00017122946155723184
studies O 0 6.693161935800163e-07
have O 0 1.5975584233274276e-07
reported O 0 2.92577908567182e-07
frequent O 0 2.2399545684947952e-07
loss O 0 2.610852561701904e-06
of O 0 5.334816705726553e-06
heterozygosity O 1 0.6692314743995667
on O 0 3.822243888862431e-05
chromosomal O 0 0.0007275204989127815
arm O 0 0.0005783602246083319
10q O 0 0.0006722935358993709
in O 0 8.967566827777773e-06
sporadic B-Disease 1 0.9999988079071045
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0012422966537997127

Deletion O 0 8.846161654219031e-05
mapping O 0 1.1056548828491941e-05
studies O 0 9.69931988947792e-07
have O 0 2.8915050620526017e-07
unambiguously O 0 2.5148872282443335e-06
identified O 0 9.238225402441458e-07
a O 0 2.3091020295851195e-07
region O 0 4.812617362404126e-07
of O 0 1.4312448683995171e-06
chromosome O 0 3.646308869065251e-06
10q23 O 0 1.9581307242333423e-06
to O 0 1.7290776810341413e-08
be O 0 2.159198153606212e-08
the O 0 2.518664210526822e-08
minimal O 0 6.402100893865281e-07
area O 0 3.686627678689547e-07
of O 0 1.3659848718816647e-06
loss O 0 0.0002539255656301975
. O 0 5.281762787490152e-05

A O 0 1.6097217667265795e-05
new O 0 2.2246190383157227e-06
tumor B-Disease 0 7.653219654457644e-06
suppressor O 0 1.6950956705841236e-05
gene O 0 1.1660981726890896e-06
, O 0 1.047866703629552e-06
PTEN O 0 0.04581829905509949
/ O 0 0.09041102230548859
MMAC1 O 1 0.9999188184738159
, O 0 1.1726185675797751e-06
was O 0 2.9625650768139167e-06
isolated O 0 4.3105893610118073e-07
recently O 0 3.247646986892505e-07
at O 0 3.4694318173933425e-07
this O 0 1.3240417651161351e-08
region O 0 8.012087704400983e-08
of O 0 2.2395529697405436e-07
chromosome O 0 2.6427571810927475e-06
10q23 O 0 3.585194235711242e-06
and O 0 3.290312378112503e-08
found O 0 1.4564403016947836e-08
to O 0 5.729747787341921e-09
be O 0 1.39731488602024e-08
inactivated O 0 5.584138875747158e-07
by O 0 2.353005790212137e-08
mutation O 0 3.81247531322515e-07
in O 0 3.4402893334117834e-07
three O 0 0.0016962578520178795
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9233813285827637
lines O 0 8.111222268780693e-05
. O 0 2.2303664081846364e-05

We O 0 2.3214714019559324e-05
screened O 0 2.456134279782418e-05
80 O 0 4.241732312948443e-05
prostate B-Disease 1 0.999849796295166
tumors I-Disease 1 0.9999997615814209
by O 0 5.275061880638532e-07
microsatellite O 0 2.4468274204991758e-05
analysis O 0 7.482772161893081e-07
and O 0 3.0955587249081873e-07
found O 0 3.0778556947552715e-07
chromosome O 0 1.3198181250118068e-06
10q23 O 0 1.711830691419891e-06
to O 0 7.813927993538528e-08
be O 0 1.4747787702162896e-07
deleted O 0 4.863690037382185e-07
in O 0 1.5323635693675897e-07
23 O 0 4.376151991891675e-06
cases O 0 2.859739424820873e-06
. O 0 1.5563860870315693e-05

We O 0 1.7937588836502982e-06
then O 0 5.81213726036367e-07
proceeded O 0 9.94375682239479e-07
with O 0 2.043044311506037e-08
sequence O 0 5.764641741734522e-08
analysis O 0 2.3490864364816844e-08
of O 0 4.264645525609012e-08
the O 0 1.299459881920484e-07
entire O 0 4.588109277392505e-06
PTEN O 0 0.011819775216281414
/ O 0 0.0011340549681335688
MMAC1 O 0 0.056278105825185776
coding O 0 2.425356797175482e-05
region O 0 7.020643693067541e-07
and O 0 2.2630129592471349e-07
tested O 0 7.409248610201757e-07
for O 0 9.375336418315783e-08
homozygous O 0 6.590676093765069e-07
deletion O 0 3.8352121123352845e-07
with O 0 4.249834617553461e-08
new O 0 4.486913951495808e-07
intragenic O 0 1.7985199519898742e-05
markers O 0 3.048258463422826e-07
in O 0 2.610169502759163e-08
these O 0 2.817876953997711e-08
23 O 0 6.18269439200958e-07
cases O 0 8.90217961568851e-08
with O 0 9.230601705212393e-08
10q23 O 0 1.7258807929465547e-05
loss O 0 1.7212867533089593e-05
of O 0 2.3352113203145564e-05
heterozygosity O 0 0.18885532021522522
. O 0 0.00010066042887046933

The O 0 1.2647736866711057e-06
identification O 0 5.587158966591232e-07
of O 0 3.1668290034758684e-07
the O 0 3.4135427995352075e-07
second O 0 1.935168029376655e-06
mutational O 0 1.4972924873291049e-05
event O 0 8.39710594391363e-07
in O 0 1.0603222477811869e-07
10 O 0 3.508209829305997e-07
( O 0 9.734760197943615e-08
43 O 0 4.099580905858602e-07
% O 0 1.6379735257032735e-07
) O 0 1.1053829211959965e-06
tumors B-Disease 1 1.0
establishes O 0 0.00011011654714820907
PTEN O 1 0.9895519614219666
/ O 0 0.0019610857125371695
MMAC1 O 0 0.002969419816508889
as O 0 1.9441658594132605e-07
a O 0 5.536637104341935e-08
main O 0 1.363960393518937e-07
inactivation O 0 1.275385329790879e-06
target O 0 1.881753490806659e-07
of O 0 2.2355797568707203e-07
10q O 0 1.2868483281636145e-05
loss O 0 9.067287464858964e-06
in O 0 2.086081167362863e-06
sporadic B-Disease 1 0.9999946355819702
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.3370048438664526e-05
. O 0 2.877339102269616e-05

Risk O 0 6.360335828503594e-05
reversals O 0 3.8376645534299314e-05
in O 0 4.5371723444986856e-07
predictive O 0 1.1622937563515734e-05
testing O 0 2.697421223274432e-05
for O 0 9.992783452617005e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0006323607522062957

The O 0 4.3027953324781265e-06
first O 0 1.2505646509453072e-06
predictive O 0 3.060760263906559e-06
testing O 0 3.308169880256173e-06
for O 0 5.315807356964797e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.4000876262798556e-06
HD B-Disease 1 0.9905248284339905
) O 0 4.5404881632293836e-08
was O 0 1.2744050081892055e-07
based O 0 2.4257680308892304e-08
on O 0 4.1899202329886975e-08
analysis O 0 6.485564796321341e-08
of O 0 1.3085292493997258e-07
linked O 0 2.9527941478590947e-06
polymorphic O 0 2.764571490843082e-06
DNA O 0 4.5982093865859497e-07
markers O 0 1.6621120835225156e-07
to O 0 1.5121347729518675e-08
estimate O 0 5.997411989255852e-08
the O 0 2.475027827131271e-08
likelihood O 0 2.1950697259853769e-07
of O 0 3.24375918125952e-07
inheriting O 0 1.869270363386022e-06
the O 0 2.336833517802006e-07
mutation O 0 5.272994485494564e-07
for O 0 6.031310704202042e-07
HD B-Disease 0 0.09770030528306961
. O 0 1.8255706891068257e-05

Limits O 0 1.8002987189902342e-06
to O 0 1.0631919167281012e-07
accuracy O 0 1.29441139051778e-06
included O 0 1.832739968676833e-07
recombination O 0 2.5922497570718406e-07
between O 0 6.574266819825425e-08
the O 0 2.8523334805186096e-08
DNA O 0 1.4294072059328755e-07
markers O 0 1.4054974428745481e-07
and O 0 5.136771363822845e-08
the O 0 1.1903983221372982e-07
mutation O 0 5.058532224211376e-07
, O 0 9.803441258782186e-08
pedigree O 0 8.209427164729277e-07
structure O 0 7.404956704704091e-06
, O 0 6.467394086939748e-08
and O 0 2.423414180441341e-08
whether O 0 1.0188870191996102e-08
DNA O 0 2.084969530358194e-08
samples O 0 6.642415950608438e-09
were O 0 2.653560571275193e-08
available O 0 4.174453138716672e-08
from O 0 5.6096531864113786e-08
family O 0 9.583764182252708e-08
members O 0 7.573452762699162e-07
. O 0 7.998938599484973e-06

With O 0 5.603514523500053e-07
direct O 0 2.0669780553816963e-07
tests O 0 7.421228076509578e-08
for O 0 8.699888809360345e-09
the O 0 2.5534621528322532e-08
HD B-Disease 0 4.938100028084591e-05
mutation O 0 9.073638551626573e-08
, O 0 9.40639210966765e-09
we O 0 9.573255077555132e-09
have O 0 5.3546957978767296e-09
assessed O 0 8.713542598570712e-08
the O 0 5.777925693450925e-09
accuracy O 0 9.881838280989541e-08
of O 0 4.568948241967519e-08
results O 0 1.2635051405140985e-07
obtained O 0 9.643503773304474e-08
by O 0 1.20080327903338e-08
linkage O 0 9.978090531603812e-08
approaches O 0 9.250676669125824e-08
when O 0 2.2335502336545687e-08
requested O 0 1.7963314391522545e-08
to O 0 5.7286655419375165e-09
do O 0 7.502577226148333e-09
so O 0 9.832932690301277e-09
by O 0 8.680213881007148e-09
the O 0 7.037597526959871e-08
test O 0 1.1239524155826075e-06
individuals O 0 5.890274792363925e-07
. O 0 7.824949534551706e-06

For O 0 1.6540997194169904e-06
six O 0 6.594756314370898e-07
such O 0 1.983547015527165e-08
individuals O 0 1.5472414460759865e-08
, O 0 2.7025754079090802e-08
there O 0 3.2479871237001134e-08
was O 0 2.1357291757340136e-07
significant O 0 2.4184345193134504e-07
disparity O 0 2.7913872600038303e-06
between O 0 2.9926889055786887e-07
the O 0 3.9538693386020896e-07
tests O 0 1.690630824668915e-06
. O 0 4.46397871201043e-06

Three O 0 5.856879397470038e-06
went O 0 2.0066047454747604e-06
from O 0 8.877186274958149e-08
a O 0 1.057238492307988e-07
decreased O 0 4.118138861031184e-07
risk O 0 7.708530347372289e-08
to O 0 8.926557271138336e-09
an O 0 6.538399155431307e-09
increased O 0 5.3091785190417795e-08
risk O 0 3.015251763827109e-07
, O 0 2.7358202814298238e-08
while O 0 2.478187965948564e-08
in O 0 8.157837072531038e-09
another O 0 1.3909543739032415e-08
three O 0 9.782143983727565e-09
the O 0 4.7774705080882995e-08
risk O 0 3.596672684125224e-07
was O 0 1.8062695517073735e-06
decreased O 0 1.3774121725873556e-05
. O 0 1.1478220585559029e-05

Knowledge O 0 1.5054996765684336e-05
of O 0 8.674952596265939e-07
the O 0 1.237965818745579e-07
potential O 0 2.466174180426606e-07
reasons O 0 1.1243454167697564e-07
for O 0 1.7952524800080027e-08
these O 0 9.413265722457709e-09
changes O 0 4.548801157966409e-08
in O 0 1.2475285693369642e-08
results O 0 1.0693214846924093e-07
and O 0 1.6413473247212096e-08
impact O 0 1.1868411320392624e-07
of O 0 3.298934103668216e-08
these O 0 1.3773003182393495e-08
risk O 0 8.698996367684231e-08
reversals O 0 4.517954153016035e-07
on O 0 9.487080632197831e-08
both O 0 2.9052195316126017e-08
patients O 0 3.248278090950407e-08
and O 0 2.24257448167009e-08
the O 0 6.864038226694902e-08
counseling O 0 2.3072331600815232e-07
team O 0 1.0639282521651694e-07
can O 0 1.2953973005380703e-08
assist O 0 1.256026394003129e-07
in O 0 1.1962770329887462e-08
the O 0 1.805165261714592e-08
development O 0 6.53850165122094e-08
of O 0 2.1609531941635396e-08
strategies O 0 1.444638257908082e-07
for O 0 7.46153361319557e-09
the O 0 1.838053442781984e-08
prevention O 0 3.647014636953827e-07
and O 0 9.679379076033001e-09
, O 0 9.037984582960235e-09
where O 0 1.8669060963816264e-08
necessary O 0 2.446011535539583e-07
, O 0 8.872193291153962e-08
management O 0 4.742444161820458e-07
of O 0 6.778740413437845e-08
a O 0 9.930321454021396e-08
risk O 0 1.5965181887622748e-07
reversal O 0 2.584365859092941e-07
in O 0 3.097466105828062e-08
any O 0 4.102646400383492e-08
predictive O 0 5.315805537975393e-07
testing O 0 4.0723199390413356e-07
program O 0 1.1612988970455262e-07
. O 0 2.4433396106360306e-07
. O 0 3.4685656373767415e-06

A O 0 2.8549069611472078e-05
novel O 0 8.634388905193191e-06
common O 0 2.571274762885878e-06
missense O 0 2.171416417695582e-05
mutation O 0 1.4533790135828895e-06
G301C O 0 5.565675564866979e-06
in O 0 1.0829008090240677e-07
the O 0 1.8710595384163753e-07
N O 0 9.330876309832092e-06
- O 0 5.052937922300771e-06
acetylgalactosamine O 0 1.8238495613331906e-05
- O 0 1.0804165867739357e-05
6 O 0 2.618721737235319e-05
- O 0 9.997051165555604e-06
sulfate O 0 1.783135849109385e-05
sulfatase O 0 0.00013231486082077026
gene O 0 6.551596811732452e-07
in O 0 6.364090836541436e-07
mucopolysaccharidosis B-Disease 0 0.00036941259168088436
IVA I-Disease 1 0.5168488025665283
. O 0 7.016462768660858e-05

Mucopolysaccharidosis B-Disease 0 0.3781396448612213
IVA I-Disease 1 0.9999912977218628
( O 0 0.00015644334780517966
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
) O 0 1.7477553910794086e-06
is O 0 1.5809909825748036e-07
an O 0 2.7025038207284524e-07
autosomal B-Disease 1 0.9860379099845886
recessive I-Disease 1 0.9999990463256836
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9985148310661316
by O 0 9.404272532265168e-06
a O 0 0.00011977615940850228
genetic B-Disease 1 0.9999996423721313
defect I-Disease 1 0.9999382495880127
in O 0 2.0171805772406515e-06
N O 0 0.00011033075134037063
- O 0 0.0001404023205395788
acetylgalactosamine O 0 4.1526862332830206e-05
- O 0 1.077297201845795e-05
6 O 0 2.028104972850997e-05
- O 0 1.7682577890809625e-05
sulfate O 0 4.0387643821304664e-05
sulfatase O 0 0.040093861520290375
( O 0 1.4519949900204665e-06
GALNS O 0 0.0005744443624280393
) O 0 2.3207019239634974e-06
. O 0 1.3528298040910158e-05

In O 0 1.017245040202397e-06
previous O 0 5.467271080306091e-07
studies O 0 1.2080792544111318e-07
, O 0 3.807304338465656e-08
we O 0 2.7551433134931358e-08
have O 0 5.879760234250853e-09
found O 0 1.1591287041312626e-08
two O 0 1.943876171139891e-08
common O 0 5.423111915092704e-08
mutations O 0 1.8941082657875086e-07
in O 0 5.305696504365187e-08
Caucasians O 0 7.657308742636815e-06
and O 0 3.751514441319159e-07
Japanese O 0 7.035435373836663e-06
, O 0 1.5514012829953572e-06
respectively O 0 1.917980807775166e-05
. O 0 1.2257310118002351e-05

To O 0 4.425861789059127e-06
characterize O 0 1.3966873666504398e-05
the O 0 1.6112369394249981e-06
mutational O 0 5.110488200443797e-05
spectrum O 0 9.999187568610068e-06
in O 0 8.694119912888709e-08
various O 0 2.4006963528222514e-08
ethnic O 0 1.564981033652657e-08
groups O 0 8.502603066062875e-09
, O 0 1.2262376003491227e-08
mutations O 0 2.6332115155014435e-08
in O 0 1.1137625044455035e-08
the O 0 5.4592277365372865e-08
GALNS O 0 7.393870873784181e-06
gene O 0 7.886578146099055e-08
in O 0 8.97629561791291e-08
Colombian O 0 7.365620604105061e-06
MPS B-Disease 1 0.9999994039535522
IVA I-Disease 1 1.0
patients O 0 2.5152135094685946e-06
were O 0 6.689294878015062e-07
investigated O 0 9.281627171731088e-06
, O 0 9.297871628177745e-08
and O 0 1.077309619290645e-07
genetic O 0 4.0153756231120497e-07
backgrounds O 0 6.783978392377321e-07
were O 0 2.2357629347879993e-07
extensively O 0 7.66732597412556e-08
analyzed O 0 3.61437670903797e-08
to O 0 4.789337815225281e-09
identify O 0 5.0853767419312135e-08
racial O 0 1.7297875842814392e-07
origin O 0 5.7306795753220285e-08
, O 0 6.297689481016278e-08
based O 0 5.57699735281858e-08
on O 0 1.39444793489929e-07
mitochondrial O 0 3.392787846223655e-07
DNA O 0 5.606406148217502e-07
( O 0 1.5385253959721013e-07
mtDNA O 0 7.25814231827826e-07
) O 0 9.223647339240415e-07
lineages O 0 2.4039596610236913e-05
. O 0 3.1729057809570804e-05

Three O 0 6.83356211084174e-06
novel O 0 4.42934151578811e-06
missense O 0 4.52560416306369e-05
mutations O 0 4.690985861088848e-06
never O 0 1.1422041552577866e-06
identified O 0 4.7628446964154136e-07
previously O 0 2.3529210579908977e-07
in O 0 2.643925967049654e-08
other O 0 8.968232378947505e-09
populations O 0 1.609778799149808e-08
and O 0 1.5316324208924925e-08
found O 0 1.3331797887872199e-08
in O 0 2.0918808019132484e-08
16 O 0 1.7182522071834683e-07
out O 0 1.824494333391158e-08
of O 0 8.311064192412232e-08
19 O 0 2.956603793791146e-06
Colombian O 0 1.3053851944277994e-05
MPS B-Disease 1 0.9994996786117554
IVA I-Disease 1 0.999998927116394
unrelated O 0 3.830061814369401e-06
alleles O 0 9.501610520601389e-07
account O 0 1.2678709992997028e-07
for O 0 2.4495690809089865e-07
84 O 0 1.1125077435281128e-05
. O 0 1.7481424947618507e-05

2 O 0 1.233415059687104e-05
% O 0 2.705611450437573e-07
of O 0 3.1868523819866823e-07
the O 0 1.5581078116611025e-07
alleles O 0 5.520587365026586e-07
in O 0 9.145903590024318e-08
this O 0 1.0671780614757154e-07
study O 0 7.242473998303467e-07
. O 0 4.112532678846037e-06

The O 0 1.8977740182890557e-05
G301C O 0 7.482895307475701e-05
and O 0 1.3082501482131192e-06
S162F O 0 1.1039659511880018e-05
mutations O 0 7.846177823012113e-07
account O 0 1.4175614637679246e-07
for O 0 4.066940562097443e-07
68 O 0 1.3913391740061343e-05
. O 0 1.2742006219923496e-05

4 O 0 2.3074513592291623e-05
% O 0 1.4306648381534615e-06
and O 0 2.3618515569978626e-06
10 O 0 1.1794110832852311e-05
. O 0 2.2320602511172183e-05

5 O 0 4.557069587463047e-06
% O 0 1.2991004894047364e-07
of O 0 1.483944913616142e-07
mutations O 0 3.6529846170196834e-07
, O 0 8.406915696923534e-08
respectively O 0 4.951370442540792e-07
, O 0 5.177928485977645e-08
whereas O 0 7.388433687083307e-08
the O 0 4.0325286221332135e-08
remaining O 0 9.743563396114041e-07
F69V O 0 9.517710714135319e-05
is O 0 2.035044310844114e-08
limited O 0 4.6378371365563e-08
to O 0 3.177774487994611e-08
a O 0 2.0124640798258042e-07
single O 0 1.0308165201422526e-06
allele O 0 4.745442856801674e-05
. O 0 1.3297482837515417e-05

The O 0 6.1426626416505314e-06
skewed O 0 4.647245987143833e-06
prevalence O 0 2.2317972252494656e-06
of O 0 3.029447270819219e-07
G301C O 0 3.882303644786589e-06
in O 0 2.697991519085008e-08
only O 0 2.2557358647645742e-08
Colombian O 0 2.716778624289873e-07
patients O 0 4.2230482222294086e-08
and O 0 5.227286337117221e-08
haplotype O 0 9.536315133118478e-07
analysis O 0 5.555509119403723e-08
by O 0 1.6367454946930593e-08
restriction O 0 5.2291408536575545e-08
fragment O 0 2.7578832373365003e-07
length O 0 1.003959937406762e-07
polymorphisms O 0 1.7370646787639998e-07
in O 0 1.8088806896798815e-08
the O 0 9.661693667339932e-08
GALNS O 0 1.7257012586924247e-05
gene O 0 1.135501435101105e-07
suggest O 0 7.973593341148444e-08
that O 0 2.9012104718617593e-08
G301C O 0 2.8354641017358517e-06
originated O 0 2.6358048899055575e-07
from O 0 1.266778468789198e-07
a O 0 2.9452101557581045e-07
common O 0 2.4932896849350072e-06
ancestor O 0 3.483884211163968e-05
. O 0 2.3466032871510834e-05

Investigation O 0 2.0189407223369926e-05
of O 0 1.008067897600995e-06
the O 0 2.971320327560534e-07
genetic O 0 3.0332518008435727e-07
background O 0 1.234681121786707e-07
by O 0 2.8350635616902764e-08
means O 0 1.595244327745604e-07
of O 0 1.2472256116780045e-07
mtDNA O 0 1.195936363274086e-07
lineages O 0 5.25932861705769e-08
indicate O 0 2.7935175950233315e-08
that O 0 7.261337753305952e-09
all O 0 2.085665684603555e-08
our O 0 3.630108125207698e-08
patients O 0 1.1607857786088971e-08
are O 0 9.254326194252371e-09
probably O 0 1.587899447486052e-07
of O 0 2.6168723366026825e-07
native O 0 7.711455509706866e-07
American O 0 9.702627721708268e-06
descent O 0 0.0005965379532426596

Low O 0 1.9217524823034182e-05
frequency O 0 7.019196345936507e-06
of O 0 1.3972396573080914e-06
BRCA1 O 0 1.4295724213297945e-05
germline O 0 2.8629008738789707e-05
mutations O 0 5.224425194683135e-07
in O 0 8.271717888419516e-08
45 O 0 1.5643909136997536e-06
German O 1 0.9999998807907104
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.1805304641020484e-05
. O 0 6.140745972516015e-05

In O 0 6.370989353854384e-07
this O 0 1.1147426448587794e-07
study O 0 1.196356151922373e-07
we O 0 1.319695570600743e-07
investigated O 0 1.641772087168647e-06
45 O 0 1.227992697749869e-06
German O 1 0.9999960660934448
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.4061225190052937e-07
for O 0 4.431485933764634e-07
germline O 0 2.5432473194086924e-05
mutations O 0 4.379857898584305e-07
in O 0 1.31453177232288e-07
the O 0 5.731236001338402e-07
BRCA1 O 0 1.3650779692397919e-05
gene O 0 9.28595727600623e-06
. O 0 1.731614611344412e-05

We O 0 3.2633645332680317e-06
identified O 0 2.6329134925617836e-06
four O 0 1.4019834679857013e-06
germline O 0 5.617301576421596e-05
mutations O 0 3.975401341449469e-06
in O 0 2.8679309593826474e-07
three O 0 5.113407041790197e-06
breast B-Disease 1 0.9914802312850952
cancer I-Disease 0 0.02055070549249649
families O 0 3.6937784386736894e-08
and O 0 3.9979630628295126e-07
in O 0 8.199114631679549e-07
one O 0 0.016027718782424927
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.6950580124539556e-06
. O 0 6.71314523970068e-08
among O 0 1.8834800386002826e-08
these O 0 7.503378363082902e-09
were O 0 5.7252059093571006e-08
one O 0 5.681811288127392e-08
frameshift O 0 5.652955678669969e-06
mutation O 0 6.090742772357771e-07
, O 0 1.5909249384549184e-07
one O 0 1.3976539037230395e-07
nonsense O 0 3.358866024427698e-06
mutation O 0 1.0946710062853526e-06
, O 0 1.4973633710724243e-07
one O 0 9.426744895790762e-08
novel O 0 2.3142344218740618e-07
splice O 0 2.175230065404321e-06
site O 0 4.788755632034736e-07
mutation O 0 6.718179292874993e-07
, O 0 4.015045931282657e-07
and O 0 7.556960213150887e-07
one O 0 1.984700929824612e-06
missense O 0 0.00015606507076881826
mutation O 0 5.590187356574461e-05
. O 0 3.647004996309988e-05

The O 0 5.405140200309688e-06
missense O 0 7.829142123227939e-05
mutation O 0 6.181866865517804e-06
was O 0 2.632260702739586e-06
also O 0 7.900489151779766e-08
found O 0 8.514990668118116e-08
in O 0 1.771358881796914e-07
2 O 0 2.28224689635681e-05
. O 0 1.500750568084186e-05

8 O 0 1.0112597010447644e-05
% O 0 2.273911974270959e-07
of O 0 1.5707578882029338e-07
the O 0 6.670158825272665e-08
general O 0 2.1973673369757307e-07
population O 0 6.355900250554214e-09
, O 0 1.3769746232128455e-08
suggesting O 0 4.165338651773709e-08
that O 0 6.701373234108132e-09
it O 0 1.7307735689087167e-08
is O 0 6.028262333757084e-08
not O 0 3.674220181437704e-07
disease O 0 0.00041860510827973485
associated O 0 1.7057169316103682e-05
. O 0 4.9155194574268535e-05

The O 0 7.925686077214777e-06
average O 0 2.361675797146745e-06
age O 0 2.22403787120129e-06
of O 0 2.108506350850803e-06
disease O 0 0.215420201420784
onset O 0 0.1780400276184082
in O 0 8.977939103260724e-08
those O 0 4.2211798501057274e-08
families O 0 2.9548337110441025e-08
harbouring O 0 2.290591328346636e-05
causative O 0 3.301167453173548e-06
mutations O 0 2.1599969386443263e-06
was O 0 2.7670432700688252e-06
between O 0 3.2523876143386588e-06
32 O 0 4.242610521032475e-05
. O 0 1.936294574989006e-05

3 O 0 8.567715849494562e-05
and O 0 1.1609257853706367e-05
37 O 0 5.9291880461387336e-05
. O 0 3.1726092856843024e-05

4 O 0 2.5655024728621356e-05
years O 0 1.3514903685063473e-06
, O 0 2.0164561931323988e-07
whereas O 0 3.810152691130497e-07
the O 0 1.8125076906017057e-07
family O 0 1.0372090031296466e-07
harbouring O 0 9.609646440367214e-06
the O 0 4.1260250327468384e-07
missense O 0 1.2905242328997701e-05
mutation O 0 1.4448548881773604e-06
had O 0 2.5251225110878295e-07
an O 0 4.1921264681832326e-08
average O 0 1.2028897344862344e-07
age O 0 4.4830986212218704e-07
of O 0 6.80316873058473e-07
onset O 0 0.037782538682222366
of O 0 2.2920468836673535e-05
51 O 0 5.698089807992801e-05
. O 0 1.60090366989607e-05

2 O 0 0.00012080159649485722
years O 0 1.8324570191907696e-05
. O 0 2.2447271476266906e-05

These O 0 1.1012676850441494e-06
findings O 0 6.897608386680076e-07
show O 0 1.299171117352671e-07
that O 0 4.629140804013332e-08
BRCA1 O 0 5.1532565521483775e-06
is O 0 1.5909158435079007e-07
implicated O 0 3.0113544653431745e-06
in O 0 2.9770207632395795e-08
a O 0 3.7684927178816e-08
small O 0 2.3755349687348826e-08
fraction O 0 1.9881818502653914e-07
of O 0 0.00015612223069183528
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0599845978731537e-07
suggesting O 0 1.260930275748251e-07
the O 0 4.4855703151824855e-08
involvement O 0 2.2482970507553546e-07
of O 0 1.2293222084736044e-07
another O 0 2.3704618001829658e-07
susceptibility O 0 2.3549062007077737e-06
gene O 0 3.028825631190557e-06
( O 0 3.174035782649298e-06
s O 0 0.00016056158347055316
) O 0 6.539793685078621e-05

Paternal O 0 0.00045735648018307984
transmission O 1 0.9999980926513672
of O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999926090240479

We O 0 7.113561423466308e-06
report O 0 5.084746703687415e-07
a O 0 1.7656026329859742e-07
rare O 0 2.2533241406108573e-07
case O 0 4.351849156591925e-07
of O 0 1.7732836568029597e-06
paternally O 1 0.9998552799224854
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999997615814209
DM B-Disease 1 1.0
) O 0 4.693143637268804e-05
. O 0 2.278678039147053e-05

The O 0 9.28304416447645e-06
proband O 0 0.00016644236166030169
is O 0 1.5904743122518994e-07
a O 0 1.2310984232044575e-07
23 O 0 8.82781364452967e-07
year O 0 1.3146633648375428e-07
old O 0 9.076284186448902e-06
, O 0 2.5217048460035585e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.9673184752464294
who O 0 0.04041097313165665
suffers O 1 0.9999998807907104
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999833106994629

He O 0 3.465691770543344e-05
presented O 0 3.8311849493766204e-05
with O 0 4.420019467943348e-05
respiratory O 1 0.9999997615814209
and O 0 0.0010470907436683774
feeding O 0 0.00042144107283093035
difficulties O 0 0.017040442675352097
at O 0 0.00021615023433696479
birth O 0 7.719248060311656e-06
. O 0 1.647099452384282e-05

His O 0 1.9901706764358096e-05
two O 0 2.1805761207360774e-05
sibs O 1 0.9900957345962524
suffer O 0 0.00017629102512728423
from O 0 5.1282677304698154e-06
childhood O 0 0.09859924763441086
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.02593119442462921

Their O 0 2.1084338186483365e-06
late O 0 1.547179817862343e-05
father O 0 1.4939571428840281e-06
had O 0 2.6752303483590367e-07
the O 0 8.902943449129452e-08
adult O 0 2.2146775791043183e-07
type O 0 8.538586371287238e-07
of O 0 9.668488019087818e-06
DM B-Disease 1 1.0
, O 0 3.3225085189769743e-06
with O 0 6.947167321413872e-07
onset O 1 0.8101001381874084
around O 0 1.8232022966913064e-06
30 O 0 1.1773237247325596e-06
years O 0 1.2007984651063452e-06
. O 0 5.499323833646486e-06

Only O 0 2.7635883270704653e-06
six O 0 1.0392491276434157e-06
other O 0 2.7806315472389542e-08
cases O 0 3.3113909836401945e-08
of O 0 6.242129302336252e-08
paternal O 0 1.5776697637193138e-06
transmission O 1 0.9998923540115356
of O 1 0.9999905824661255
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 1 0.7879606485366821
been O 0 1.224935294885654e-05
reported O 0 3.505692120597814e-06
recently O 0 6.3183997554006055e-06
. O 0 1.4115992598817684e-05

We O 0 3.661103846752667e-06
review O 0 1.8879347862821305e-06
the O 0 3.3356513995386194e-07
sex O 0 5.133970262249932e-07
related O 0 3.098888043950865e-07
effects O 0 3.6340304632176412e-06
on O 0 3.59433465746406e-06
transmission O 1 0.9978302121162415
of O 1 0.9848328232765198
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9927281141281128

Decreased O 0 5.6197615776909515e-05
fertility O 0 3.771912361116847e-06
of O 0 2.598970354483754e-07
males O 0 1.960324453875728e-07
with O 0 6.698794408066533e-08
adult O 0 5.035687536292244e-06
onset O 1 0.9999960660934448
DM B-Disease 1 1.0
and O 0 7.6675096352119e-06
contraction O 0 1.2926633417009725e-06
of O 0 6.52472280648908e-08
the O 0 3.2402155625277373e-08
repeat O 0 1.1926492504699127e-07
upon O 0 7.350103459202728e-08
male O 0 1.6766443877713755e-07
transmission O 0 6.496571813841001e-07
contribute O 0 1.64203939334584e-08
to O 0 5.477571285439353e-09
the O 0 2.0250698895551977e-08
almost O 0 3.584081653684734e-08
absent O 0 9.663039435281462e-08
occurrence O 0 4.552663668278001e-08
of O 0 5.2465740196794286e-08
paternal O 0 8.833017659526377e-07
transmission O 1 0.9444335699081421
of O 1 0.9980596899986267
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.999570906162262

Also O 0 2.8421184197213734e-06
the O 0 1.039471158037486e-06
fathers O 0 1.6201831840589875e-06
of O 0 4.633142225429765e-07
the O 0 8.811672387309955e-07
reported O 0 9.06454624782782e-06
congenitally O 0 0.12744688987731934
affected O 0 3.0778985546930926e-06
children O 0 2.0605027373221674e-07
showed O 0 7.484227353415918e-07
, O 0 1.5628565108727344e-07
on O 0 4.776254058924678e-07
average O 0 3.4190620112894976e-07
, O 0 2.6493157179174887e-07
shorter O 0 1.3880590813641902e-05
CTG O 0 0.0014407273847609758
repeat O 0 1.2628966942429543e-05
lengths O 0 1.7730635590851307e-05
and O 0 1.10559106758501e-07
hence O 0 4.49899715704305e-07
less O 0 9.604420938558178e-07
severe O 0 0.03598489239811897
clinical O 0 0.3794505000114441
symptoms O 0 3.8695663533871993e-05
than O 0 1.425739526439429e-07
the O 0 9.068811124279819e-08
mothers O 0 8.19805379137506e-08
of O 0 1.505216431496592e-07
children O 0 7.679985287722957e-07
with O 0 5.450308890431188e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9197450876235962

We O 0 6.450057298934553e-06
conclude O 0 7.91604816186009e-06
that O 0 1.2540347427147935e-07
paternal O 0 1.4347571095640888e-06
transmission O 1 0.9167240262031555
of O 1 0.9998377561569214
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.07975989580154419
rare O 0 2.476015652064234e-06
and O 0 1.0636827596499643e-07
preferentially O 0 1.1218775597399144e-07
occurs O 0 1.9572585330251968e-08
with O 0 1.6206911368499277e-08
onset O 0 8.629556759842671e-06
of O 0 8.666098437970504e-06
DM B-Disease 1 1.0
past O 0 6.529814982059179e-07
30 O 0 1.347946323448923e-07
years O 0 2.4954532662491147e-08
in O 0 8.8072429349495e-09
the O 0 4.584363821891202e-08
father O 0 6.011980531184236e-07
. O 0 6.510526304737141e-07
. O 0 1.0202276826021262e-05

The O 0 2.1386824300861917e-05
RB1 O 0 0.0006708812434226274
gene O 0 2.5538040517858462e-06
mutation O 0 2.823962404363556e-06
in O 0 2.0994579585931206e-07
a O 0 9.04605656160129e-07
child O 0 2.0259127268218435e-05
with O 0 2.0028512153658085e-05
ectopic B-Disease 1 0.9999959468841553
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999998807907104
. O 0 0.013412987813353539

The O 0 1.1219337466172874e-05
RB1 O 0 0.0006994181894697249
gene O 0 3.4958500236825785e-06
mutation O 0 3.8291345845209435e-06
was O 0 4.232852461427683e-06
investigated O 0 6.066538389859488e-06
in O 0 1.0661465665862124e-07
a O 0 5.97055645812361e-07
child O 0 4.2048936848004814e-06
with O 0 3.1718177524453495e-06
ectopic B-Disease 1 0.9761896133422852
intracranial I-Disease 1 0.9999083280563354
retinoblastoma I-Disease 0 0.32188791036605835
using O 0 2.6946338493871735e-07
DNA O 0 1.9890295277491532e-07
obtained O 0 5.323293450487654e-08
from O 0 1.5986595158778982e-08
both O 0 7.6519853564605e-08
the O 0 4.2103087594114186e-07
pineal B-Disease 0 0.0008728053071536124
and I-Disease 0 1.0689890586945694e-05
retinal I-Disease 1 0.9999899864196777
tumours I-Disease 1 1.0
of O 0 0.09802551567554474
the O 0 9.583125938661397e-05
patient O 0 3.109091267106123e-05
. O 0 1.9527280528564006e-05

A O 0 2.8205924536450766e-05
nonsense O 0 3.3814460039138794e-05
mutation O 0 3.0253729619289516e-06
in O 0 2.760530435352848e-07
exon O 0 1.9949502529925667e-06
17 O 0 8.61126125073497e-07
( O 0 1.0521168292143557e-07
codon O 0 1.2084992704330944e-06
556 O 0 4.141257079481875e-07
) O 0 2.068756010942252e-08
of O 0 5.1551452884268656e-08
the O 0 1.6691681992142549e-07
RB1 O 0 0.0002166466583730653
gene O 0 3.7831921417819103e-07
was O 0 2.7358782972441986e-07
found O 0 2.057509718156325e-08
to O 0 9.980255732955357e-09
be O 0 3.000678816533764e-08
present O 0 1.0882179424243077e-07
homozygously O 0 1.6309173588524573e-05
in O 0 7.313506245054668e-08
both O 0 1.3594166148322984e-07
the O 0 4.98552424232912e-07
retinal B-Disease 0 0.0007614708738401532
and I-Disease 0 6.915497579029761e-06
the I-Disease 0 0.00018393428763374686
pineal I-Disease 1 0.9999059438705444
tumours I-Disease 1 1.0
. O 0 0.00019901302584912628

The O 0 2.259996563225286e-06
same O 0 2.353006323119189e-07
mutation O 0 4.2051644300045155e-07
was O 0 2.3470313692541822e-07
present O 0 9.926760924372502e-08
heterozygously O 0 2.8211443350301124e-06
in O 0 2.0030849867680445e-08
the O 0 2.1223319990326672e-08
DNA O 0 4.9095508103391694e-08
from O 0 6.09722539124391e-09
the O 0 1.8768457010764905e-08
constitutional O 0 3.1525340205007524e-07
cells O 0 5.377994938271513e-08
of O 0 4.5384187075114824e-08
the O 0 5.5078615446291224e-08
patient O 0 9.230513597913159e-08
, O 0 1.4869177888954255e-08
proving O 0 1.0548094309115186e-07
it O 0 3.865503472866294e-09
to O 0 3.957352667782743e-09
be O 0 3.542373505638352e-08
of O 0 3.843029219297023e-07
germline O 0 7.795647979946807e-05
origin O 0 4.123359758523293e-06
. O 0 2.5699049729155377e-05

The O 0 1.311459300268325e-06
initial O 0 1.5009877643024083e-06
mutation O 0 1.4039316056368989e-06
was O 0 5.318472631188342e-07
shown O 0 3.916452939733972e-08
to O 0 2.1050849952075623e-08
have O 0 2.8905832394343633e-08
occurred O 0 6.175752673698298e-07
in O 0 4.3724288190105653e-08
the O 0 1.6956252579802822e-07
paternally O 0 5.925081040913938e-06
derived O 0 3.235335952922469e-06
RB1 O 0 0.0006628920091316104
allele O 0 0.00013275931996759027
. O 0 3.774434662773274e-05

The O 0 1.9693272861331934e-06
mutation O 0 8.847796948430187e-07
is O 0 3.4380978064518786e-08
in O 0 1.0023905261391519e-08
an O 0 6.623451120901791e-09
area O 0 2.791386854994471e-08
of O 0 3.595770081687988e-08
the O 0 4.54806361460669e-08
gene O 0 3.005284199275593e-08
that O 0 7.399204360325484e-09
encodes O 0 6.561864296372732e-08
the O 0 5.065599850695435e-08
protein O 0 5.349681373445492e-07
- O 0 9.577876198818558e-07
binding O 0 2.8440496180337504e-07
region O 0 3.220137330117723e-07
known O 0 1.3351981920095568e-07
as O 0 4.8289290788261496e-08
the O 0 9.581899718114073e-08
pocket O 0 1.7853699318948202e-05
region O 0 3.986217791407398e-07
and O 0 5.558074178679817e-08
has O 0 9.618205787376155e-09
been O 0 8.703041842750281e-09
detected O 0 1.7349711001202195e-08
in O 0 5.460620400299376e-09
other O 0 8.135478068993507e-09
cases O 0 3.056233666143271e-08
of O 0 3.483542343474255e-07
retinoblastoma B-Disease 0 0.0037665050476789474
. O 0 2.824468765538768e-06
. O 0 1.308361333940411e-05

Low O 0 1.4228454347176012e-05
levels O 0 1.0809068271555589e-06
of O 0 2.3042008479023934e-07
beta O 0 3.0159585548972245e-06
hexosaminidase O 0 4.193964741716627e-06
A O 0 1.8473680540864734e-07
in O 0 3.004728199584861e-08
healthy O 0 3.802398964580789e-07
individuals O 0 1.0674565231738598e-08
with O 0 6.37766390809702e-08
apparent O 0 0.00016053786384873092
deficiency O 1 0.9967089891433716
of O 0 2.6593181246425956e-05
this O 0 5.947738372924505e-07
enzyme O 0 5.6374674386461265e-06
. O 0 3.0693304324813653e-06

Appreciable O 0 0.000231705853366293
beta O 0 8.383439853787422e-05
hexosaminidase O 0 0.00019803346367552876
A O 0 9.129986210609786e-06
( O 0 9.186198326460726e-07
hex O 0 9.391124876856338e-06
A O 0 7.158737957979611e-07
) O 0 5.4175906427644804e-08
activity O 0 1.7035804944498523e-07
has O 0 2.480542882210557e-08
been O 0 3.9645993155090764e-08
detected O 0 1.7731149171140714e-07
in O 0 2.0576770509705966e-07
cultured O 0 0.027982087805867195
skin O 1 0.9989739656448364
fibroblasts O 0 0.20251378417015076
and O 0 0.0003454350808169693
melanoma B-Disease 1 0.9999998807907104
tissue O 0 0.00019342311134096235
from O 0 2.9280650437613076e-07
healthy O 0 4.967156655766303e-06
individuals O 0 4.618539861667159e-08
previously O 0 5.507703804141784e-07
reported O 0 2.515827191018616e-07
as O 0 1.7787836270599655e-07
having O 0 6.894497801113175e-06
deficiency B-Disease 0 0.2948661744594574
of I-Disease 0 2.0321049305493943e-05
hex I-Disease 0 0.00023505580611526966
A I-Disease 0 7.910876433925296e-07
activity O 0 1.1632951668616442e-07
indistinguishable O 0 4.380642693035952e-08
from O 0 2.4575275148208675e-09
that O 0 2.572158042113415e-09
of O 0 4.008526488519237e-08
patients O 0 1.8963567072205478e-07
with O 0 1.2015949323540553e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.022003555670380592
TSD B-Disease 1 0.9999812841415405
) O 0 4.672612703870982e-06
. O 0 1.4552107131748926e-05

Identification O 0 1.2626511306734756e-05
and O 0 2.8623724119825056e-06
quantitation O 0 0.00043696918874047697
of O 0 2.554760067141615e-05
hex O 0 0.00033996859565377235
A O 0 4.340357918408699e-06
, O 0 2.3075391197835415e-07
amounting O 0 6.261494149839564e-07
to O 0 1.1071906413917532e-07
3 O 0 5.331627562554786e-06
. O 0 6.974031293793814e-06

5 O 0 2.1524649127968587e-05
% O 0 3.3471594633738277e-06
- O 0 2.0367418983369134e-05
6 O 0 4.2698946344899014e-05
. O 0 1.4133961485640611e-05

9 O 0 1.1954308320127893e-05
% O 0 2.0939070566328155e-07
of O 0 1.6901634580790414e-07
total O 0 8.757061920050546e-08
beta O 0 3.698999648804602e-07
hexosaminidase O 0 9.268458711630956e-07
activity O 0 5.817106440986208e-08
, O 0 1.4824491856302302e-08
has O 0 3.6370300104948683e-09
been O 0 8.963666253691827e-09
obtained O 0 5.1939725409511084e-08
by O 0 1.388819583780787e-07
cellulose O 0 1.0575189662631601e-05
acetate O 0 3.2162990919459844e-06
gel O 0 1.1118002475996036e-05
electrophoresis O 0 6.2900103330321144e-06
, O 0 7.702848847657151e-07
DEAE O 0 0.00025421602185815573
- O 0 1.9811626771115698e-05
cellulose O 0 1.614315260667354e-05
ion O 0 3.422263762331568e-05
- O 0 7.2657294367672876e-06
exchange O 0 1.917402187245898e-06
chromatography O 0 3.2150885090231895e-05
, O 0 3.605416054597299e-07
radial O 0 2.5566343538230285e-05
immunodiffusion O 0 5.950509148533456e-05
, O 0 5.539277481148019e-07
and O 0 1.1703461950673955e-06
radioimmunoassay O 0 0.00018255134637001902
. O 0 1.4075596482143737e-05

Previous O 0 2.887220398406498e-05
family O 0 5.702700036636088e-07
studies O 0 2.292161980221863e-07
suggested O 0 1.6225537535774492e-07
that O 0 9.09184194597401e-09
these O 0 1.3474266147284197e-08
individuals O 0 7.412412017515635e-09
may O 0 3.933266867761631e-08
be O 0 4.5270155624166364e-08
compound O 0 2.672820471616433e-07
heterozygotes O 0 5.034449372942618e-07
for O 0 2.4322401870335852e-08
the O 0 3.659410197087709e-08
common O 0 1.5008458831289317e-07
mutant O 0 2.0674681309174048e-06
TSD B-Disease 0 6.673147436231375e-05
gene O 0 1.80889685452712e-07
and O 0 5.763432753269626e-08
a O 0 1.300011547300528e-07
rare O 0 4.747448940634058e-07
( O 0 2.5482421506239916e-07
allelic O 0 1.5557094229734503e-05
) O 0 3.6062689900973055e-07
mutant O 0 9.757671250554267e-06
gene O 0 7.424706836900441e-06
. O 0 1.563765727041755e-05

Thus O 0 1.109681761590764e-05
, O 0 5.041521831117279e-07
the O 0 2.2151233736167342e-07
postulated O 0 1.5105024431250058e-06
rate O 0 1.3751773053627403e-07
mutant O 0 3.010286775406712e-07
gene O 0 1.9674391893431675e-08
appears O 0 2.3371182322762252e-08
to O 0 4.06072908631927e-09
code O 0 1.0060470678752154e-08
for O 0 6.043710421010928e-09
the O 0 1.4882626686585354e-08
expression O 0 3.972358086912209e-08
of O 0 3.3885608985428917e-08
low O 0 2.4972132450784557e-07
amounts O 0 1.5143059783895296e-07
of O 0 6.149634259600134e-07
hex O 0 4.7717810957692564e-05
A O 0 1.0521924195927568e-05
. O 0 1.0163646948058158e-05

Heterozygotes O 0 0.000491408456582576
for O 0 1.5636735497537302e-06
the O 0 6.294459922173701e-07
rare O 0 6.138495791674359e-07
mutant O 0 1.4321788057714002e-06
may O 0 9.703764902724288e-08
be O 0 4.311929302502904e-08
indistinguishable O 0 1.869703822876545e-07
from O 0 2.2271946065188786e-08
heterozygotes O 0 9.311249300480995e-07
for O 0 1.0867245237022871e-07
the O 0 4.044777313083614e-07
common O 0 8.856814929458778e-06
TSD B-Disease 0 0.03165273740887642
mutant O 0 0.0001818992750486359
. O 0 3.0624061764683574e-05

However O 0 3.2911366361076944e-06
, O 0 4.665563153594121e-07
direct O 0 3.1669497957409476e-07
visualization O 0 4.277160314813955e-06
and O 0 3.9656589478909154e-07
quantitation O 0 0.000123029196402058
of O 0 4.818073193746386e-06
hex O 0 7.18625306035392e-05
A O 0 5.242043243924854e-07
by O 0 2.3230123602502317e-08
the O 0 3.215956567714784e-08
methods O 0 3.699101966958551e-07
described O 0 1.4426171901504858e-07
may O 0 1.2218197298352607e-07
prevent O 0 5.822701041324763e-07
false O 0 1.4736527873537852e-06
- O 0 4.768166945723351e-06
positive O 0 2.307380668753467e-07
prenatal O 0 1.6536328075744677e-06
diagnosis O 0 1.7975039554585237e-06
of O 0 2.41545512835728e-06
TSD B-Disease 1 0.9998733997344971
in O 0 1.3406942116489518e-06
fetuses O 0 5.845116902492009e-06
having O 0 7.182221111179388e-07
the O 0 4.6496168693010986e-07
incomplete O 0 7.357133199548116e-06
hex B-Disease 0 0.012046637944877148
A I-Disease 0 0.0013538458151742816
deficiency I-Disease 1 0.9332517385482788
of O 0 7.44649832995492e-06
the O 0 1.3568316035161843e-06
type O 0 0.00017726597434375435
described O 0 6.187401027091255e-07
in O 0 7.746335484171141e-08
the O 0 4.358606986443192e-07
four O 0 5.516578767128522e-06
healthy O 0 3.772707350435667e-05
individuals O 0 1.1155961146869231e-05

The O 0 1.8925291442428716e-05
tumor B-Disease 0 5.054069697507657e-05
suppressor O 0 8.34714446682483e-05
gene O 0 7.935252142488025e-06
Smad4 O 0 0.0007417532033286989
/ O 0 0.00021153291163500398
Dpc4 O 0 0.0001772800023900345
is O 0 4.1618125834474995e-08
required O 0 5.485551568540359e-08
for O 0 5.325182073079304e-08
gastrulation O 0 7.413655566779198e-06
and O 0 7.697481407831219e-08
later O 0 1.7301785248946544e-07
for O 0 4.008151677226124e-08
anterior O 0 2.1043761080363765e-06
development O 0 4.5927922087685147e-07
of O 0 5.288227953315072e-07
the O 0 1.120305341828498e-06
mouse O 0 5.262823378870962e-06
embryo O 0 4.1443568079557735e-06
. O 0 6.391476290446008e-06

Mutations O 0 2.509156911401078e-05
in O 0 9.032884236148675e-07
the O 0 2.1763028144050622e-06
SMAD4 O 1 0.9051220417022705
/ O 0 0.003882757155224681
DPC4 O 0 0.00234576896764338
tumor B-Disease 0 5.930666247877525e-06
suppressor O 0 6.0898523770447355e-06
gene O 0 1.4521693003644032e-07
, O 0 4.7547707993089716e-08
a O 0 1.0225826230225721e-07
key O 0 1.158548229795997e-06
signal O 0 2.093554712701007e-06
transducer O 0 3.8334642340487335e-06
in O 0 8.920995497874173e-08
most O 0 9.917525289893092e-08
TGFbeta O 0 0.00010451805428601801
- O 0 5.998990218358813e-06
related O 0 2.3512184554874693e-07
pathways O 0 2.6186623358626093e-07
, O 0 1.2649767455741312e-08
are O 0 4.401746966919973e-09
involved O 0 1.9704623710481428e-08
in O 0 1.2074545807649883e-08
50 O 0 6.712761546623369e-08
% O 0 1.1989421011548984e-07
of O 0 1.7435122572351247e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 0.0004520468646660447

Homozygous O 0 0.0005521222483366728
Smad4 O 0 0.002103258855640888
mutant O 0 0.00022258753597270697
mice O 0 5.2950414101360366e-05
die O 0 1.6979334759525955e-05
before O 0 4.7082498895179015e-06
day O 0 3.912723059329437e-06
7 O 0 2.2928554244572297e-05
. O 0 2.4814555217744783e-05

5 O 0 5.694764695363119e-05
of O 0 2.1874036974622868e-05
embryogenesis O 0 0.0005756381433457136
. O 0 5.1151444495189935e-05

Mutant O 0 2.437999501125887e-05
embryos O 0 1.2376347058307147e-06
have O 0 7.335160034926957e-08
reduced O 0 2.576289261924103e-07
size O 0 8.010040630779258e-08
, O 0 2.9296813863766147e-08
fail O 0 1.5401813868720637e-07
to O 0 5.717850370956512e-08
gastrulate O 0 1.3668547580891754e-05
or O 0 1.7481059444435232e-07
express O 0 1.3773744456102577e-07
a O 0 1.7543739261327573e-07
mesodermal O 0 7.423545866913628e-06
marker O 0 2.530033043512958e-06
, O 0 3.4328203923905676e-07
and O 0 4.570055125441286e-07
show O 0 1.6119562360472628e-06
abnormal O 0 2.2090753191150725e-05
visceral O 0 0.0022935003507882357
endoderm O 1 0.9954456090927124
development O 0 0.0003804889274761081
. O 0 5.3410894906846806e-05

Growth B-Disease 1 0.9999998807907104
retardation I-Disease 1 1.0
of O 0 1.3811609278491233e-05
the O 0 3.7389063436421566e-06
Smad4 O 0 0.2426362782716751
- O 0 0.00011162072041770443
deficient O 0 1.0782639492390445e-06
embryos O 0 4.714692636298423e-08
results O 0 5.483135012696039e-08
from O 0 7.133111878943055e-09
reduced O 0 4.0891788444241683e-07
cell O 0 5.991718694531301e-07
proliferation O 0 4.221208200760884e-07
rather O 0 5.850644058114085e-08
than O 0 6.922505946249657e-08
increased O 0 7.182049444054428e-07
apoptosis O 0 1.611704647075385e-05
. O 0 4.760419869853649e-06

Aggregation O 0 2.6567780878394842e-05
of O 0 3.2994364573823987e-06
mutant O 0 1.720477666822262e-05
Smad4 O 0 0.00011639297008514404
ES O 0 4.129789158469066e-05
cells O 0 5.999460199745954e-07
with O 0 1.1179024284047046e-07
wild O 0 1.0998130619555013e-06
- O 0 3.5647071854327805e-06
type O 0 1.0693439435272012e-05
tetraploid O 0 0.11216100305318832
morulae O 0 0.0020106760784983635
rescues O 0 2.9299410016392358e-05
the O 0 6.3380616666108835e-06
gastrulation B-Disease 0 0.0015913108363747597
defect I-Disease 0 0.0003230210568290204
. O 0 5.7467881561024114e-05

These O 0 1.0507066008358379e-06
results O 0 1.4954581502024666e-06
indicate O 0 2.625601780437137e-07
that O 0 2.186142289417603e-08
Smad4 O 0 8.802820957498625e-06
is O 0 1.9922296701224695e-08
initially O 0 5.329948038479415e-08
required O 0 1.3971630075104713e-08
for O 0 7.757761544269215e-09
the O 0 1.1489834861322379e-08
differentiation O 0 6.83516532262729e-08
of O 0 2.5555912941399583e-08
the O 0 6.240069438945284e-08
visceral O 0 7.400346476060804e-06
endoderm O 0 0.00012559712922666222
and O 0 1.2510497526818654e-07
that O 0 1.9476949830732337e-08
the O 0 2.4527855657652253e-07
gastrulation B-Disease 0 9.113758278544992e-05
defect I-Disease 0 1.8751624111246201e-06
in O 0 4.0156429292892426e-08
the O 0 2.0422230306849087e-07
epiblast O 0 0.00012976452126167715
is O 0 5.902326094542332e-08
secondary O 0 1.2107624343116186e-06
and O 0 2.979092244004278e-07
non O 0 3.152282806695439e-05
- O 0 4.3111293052788824e-05
cell O 0 2.460032919771038e-05
autonomous O 0 2.888483777496731e-06
. O 0 8.46732837089803e-06

Rescued O 0 0.00016308404156006873
embryos O 0 5.8692030506790616e-06
show O 0 5.0371427278150804e-06
severe O 0 0.008518976159393787
anterior O 0 0.37736421823501587
truncations O 1 0.9999430179595947
, O 0 2.7076685000793077e-06
indicating O 0 2.105596649926156e-06
a O 0 2.754826198270166e-07
second O 0 4.0824028246788657e-07
important O 0 1.0828161123299651e-07
role O 0 2.7744974318011373e-07
for O 0 1.3422827294107265e-07
Smad4 O 0 5.4624946642434224e-05
in O 0 3.597475028982444e-07
anterior O 0 7.884615479269996e-05
patterning O 0 0.0008947959286160767
during O 0 5.4320589697454125e-05
embryogenesis O 0 0.0002972703950945288
. O 0 4.355872079031542e-05

Prevalence O 0 7.300086872419342e-05
of O 0 5.498107839230215e-06
p16 O 0 2.241330366814509e-05
and O 0 2.1707414816773962e-06
CDK4 O 0 0.006159880664199591
germline O 0 0.0002331947471247986
mutations O 0 2.2650626760878367e-06
in O 0 3.2149145567927917e-07
48 O 0 7.109313446562737e-05
melanoma B-Disease 1 1.0
- O 1 0.990725576877594
prone O 0 0.005317486356943846
families O 0 4.3435647967271507e-07
in O 0 1.0533151453273604e-06
France O 0 0.00032006780384108424
. O 0 5.7696146541275084e-05

The O 0 1.841134871938266e-05
French O 0 0.0018011291977018118
Familial B-Disease 1 0.9987404942512512
Melanoma I-Disease 1 0.9999997615814209
Study O 0 1.7535507140564732e-05
Group O 0 1.7157013644464314e-05
. O 0 4.114693365409039e-05

Germline O 0 0.002744764555245638
mutations O 0 1.3259190382086672e-05
in O 0 3.9885335922917875e-07
the O 0 6.07209642566886e-07
p16 O 0 7.690488928346895e-06
and O 0 4.142450222843763e-07
CDK4 O 0 0.002239625435322523
genes O 0 1.9232994930007408e-07
have O 0 2.1615305101363447e-08
been O 0 5.379615686251782e-08
reported O 0 6.551909592644733e-08
in O 0 1.277570849111953e-08
a O 0 4.114738416660657e-08
subset O 0 5.875648412256851e-07
of O 0 1.4662734884041129e-06
melanoma B-Disease 1 0.9983466863632202
pedigrees O 0 1.688629367890826e-06
, O 0 1.0860614452212758e-07
but O 0 4.094672334531424e-08
their O 0 3.054963215731732e-08
prevalence O 0 9.017348361339828e-07
is O 0 1.936175841876775e-08
not O 0 1.9312961896389425e-08
well O 0 2.5046475116141664e-07
known O 0 1.1395309229556005e-06
. O 0 7.1085291892813984e-06

We O 0 4.653237283491762e-06
searched O 0 2.3007303298072657e-06
for O 0 5.165490080116797e-08
such O 0 1.0333860700484365e-07
germline O 0 1.201447048515547e-05
mutations O 0 5.093793902233301e-07
in O 0 1.1676900157908676e-07
48 O 0 3.0362175493792165e-06
French O 1 0.9801970720291138
melanoma B-Disease 1 1.0
- O 1 0.999220609664917
prone O 0 0.0038098872173577547
families O 0 4.355016613999396e-08
selected O 0 9.558898739214783e-08
according O 0 9.89983206522993e-09
to O 0 6.562612675509172e-09
two O 0 2.1127879890059376e-08
major O 0 1.7435107224628155e-07
criteria O 0 1.1194472904207942e-07
families O 0 5.304459094190861e-09
with O 0 1.2961856477033962e-08
at O 0 2.0169197512132087e-07
least O 0 3.393722280975453e-08
three O 0 2.0426936586659394e-08
affected O 0 1.9093748804266397e-08
members O 0 1.3801403575541826e-08
( O 0 2.064097337495241e-08
n O 0 1.587521012424986e-07
= O 0 4.0144183799384336e-07
20 O 0 1.5852485546474782e-07
) O 0 1.109765346285485e-08
or O 0 6.663670948370282e-09
families O 0 2.5151296600967044e-09
with O 0 3.660357794643687e-09
two O 0 1.4599447872853943e-08
affected O 0 3.6606525810611856e-08
members O 0 8.20969159320839e-09
, O 0 8.782014226937918e-09
one O 0 5.236024946952966e-09
of O 0 1.590305309662199e-08
them O 0 7.2606729517588064e-09
affected O 0 1.8177278349185144e-08
before O 0 4.80529784852024e-08
the O 0 1.1854154102763914e-08
age O 0 2.8007145047581616e-08
of O 0 2.3219758560344417e-08
50 O 0 4.6914141904608186e-08
( O 0 1.7101591254231607e-08
n O 0 1.2267433646684367e-07
= O 0 2.5387799951204215e-07
28 O 0 3.0720607924195065e-07
) O 0 2.1866261690206557e-08
, O 0 1.6295841120950172e-08
and O 0 2.1294523477877192e-08
one O 0 2.985128588761654e-08
additional O 0 1.6822532700189186e-07
minor O 0 5.412186055764323e-06
criterion O 0 4.240721318637952e-05
. O 0 1.4474792806140613e-05

Sixteen O 0 5.662512194248848e-05
different O 0 2.1797943645651685e-06
p16 O 0 3.100164758507162e-05
germline O 0 5.682624032488093e-05
mutations O 0 1.0824697938005556e-06
were O 0 1.4081363985951612e-07
found O 0 3.412428739579809e-08
in O 0 3.9829643583289e-08
21 O 0 8.363140295841731e-07
families O 0 2.990987724160732e-08
, O 0 4.8780666617176394e-08
while O 0 5.374590017481751e-08
one O 0 9.398056732834448e-08
germline O 0 6.626007689192193e-06
mutation O 0 5.118799890624359e-07
, O 0 2.9938590273559385e-07
Arg24His O 0 0.0002637477882672101
, O 0 4.0995925587594684e-07
was O 0 9.905046454150579e-07
detected O 0 5.222652248448867e-07
in O 0 1.314197106694337e-07
the O 0 2.1970563466311432e-06
CDK4 O 0 0.0036219744943082333
gene O 0 3.429644129937515e-05
. O 0 4.0880659071262926e-05

The O 0 2.1761470634373836e-06
frequency O 0 4.7219641601259355e-06
of O 0 7.578228746751847e-07
p16 O 0 1.899252083603642e-06
gene O 0 4.885627191697495e-08
mutation O 0 4.016800048134428e-08
in O 0 6.279623043781157e-09
our O 0 8.499668524564186e-09
sample O 0 5.0464641354608375e-09
( O 0 5.996288354737089e-09
44 O 0 5.468940855735127e-08
% O 0 1.660517767732017e-08
) O 0 1.6777152112013027e-08
is O 0 6.7475975917830056e-09
among O 0 1.3788564068306641e-08
the O 0 2.1329848109985505e-08
highest O 0 1.859603315779168e-07
rates O 0 5.35257456135696e-08
yet O 0 4.239180739773474e-08
reported O 0 3.3334561777564886e-08
and O 0 1.8881561203443198e-08
the O 0 1.2468368026929966e-07
CDK4 O 0 6.185966049088165e-05
mutation O 0 2.5377994461450726e-07
is O 0 1.1478618944238406e-08
the O 0 1.4917867829922216e-08
second O 0 6.031448407384232e-08
mutation O 0 6.112143324799035e-08
detected O 0 5.633778954461377e-08
in O 0 1.496420409807797e-08
this O 0 1.8478466756732814e-08
gene O 0 5.779536991212808e-07
worldwide O 0 1.3390522326517384e-06
. O 0 8.13720816950081e-06

In O 0 4.035097845189739e-06
summary O 0 4.895731035503559e-05
, O 0 3.036600446648663e-07
our O 0 2.1823684903665708e-07
results O 0 2.7172399086339283e-07
show O 0 4.757719196391008e-08
frequent O 0 4.000048292596148e-08
involvement O 0 1.4834340333891305e-07
of O 0 1.4400769998701435e-07
the O 0 2.0252831234301993e-07
p16 O 0 2.260819883304066e-06
gene O 0 3.356405500198889e-07
in O 0 1.6768426291946525e-07
familial B-Disease 0 0.00020151554781477898
melanoma I-Disease 1 0.9998776912689209
and O 0 6.199674658091681e-07
confirm O 0 5.241453209237079e-07
the O 0 1.3028213174948178e-07
role O 0 3.0345594836944656e-07
of O 0 3.324846318264463e-07
the O 0 5.673975351783156e-07
CDK4 O 0 0.3542901575565338
gene O 0 1.3255017847768613e-06
as O 0 5.388713475440454e-07
a O 0 5.315791895554867e-06
melanoma B-Disease 1 0.999964714050293
- O 0 0.0018901501316577196
predisposing O 0 1.3830880561727099e-05
gene O 0 1.7921925064001698e-06
. O 0 2.049912154689082e-06
. O 0 2.0226927517796867e-05

Progression O 0 0.00030541152227669954
of O 0 2.1410003682831302e-05
somatic O 0 0.0019376607378944755
CTG O 0 0.002610699040815234
repeat O 0 5.293301455822075e-06
length O 0 3.8109411093500967e-07
heterogeneity O 0 1.3675569334736792e-06
in O 0 2.9706225035397438e-08
the O 0 4.6382879759221396e-08
blood O 0 3.083537762904598e-07
cells O 0 1.742262247717008e-05
of O 1 0.6803634762763977
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.39570924639701843
. O 0 9.627723193261772e-05

The O 0 1.4714591998199467e-06
genetic O 0 7.849403118598275e-07
basis O 0 2.12482063943753e-06
of O 0 0.019629638642072678
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999887943267822
DM B-Disease 1 1.0
) O 0 3.7651167872354563e-07
is O 0 8.270389706410697e-09
the O 0 9.324187644210724e-09
expansion O 0 9.754740659673189e-08
of O 0 5.5483400984712716e-08
an O 0 4.6396419151051305e-08
unstable O 0 5.492363925441168e-06
CTG O 0 0.00015269624418579042
repeat O 0 7.984381227288395e-07
in O 0 3.032681306081031e-08
the O 0 7.560803538808614e-08
34 O 0 4.862446871811699e-07
UTR O 0 1.685123424977064e-05
of O 0 7.783492605994979e-07
the O 0 3.58600118488539e-06
DM B-Disease 1 0.999998927116394
protein O 0 5.636176865664311e-06
kinase O 0 3.932017534680199e-06
gene O 0 3.0099423042884155e-07
on O 0 1.1797492334153503e-06
chromosome O 0 6.762772500223946e-06
19 O 0 1.9686629457282834e-05
. O 0 2.634140764712356e-05

One O 0 2.1499208742170595e-06
of O 0 6.050910315025249e-07
the O 0 2.7371103783480066e-07
principal O 0 1.4598690540879034e-06
features O 0 3.5084775618088315e-07
of O 0 3.622476185682899e-07
the O 0 2.34955382438784e-06
DM B-Disease 1 1.0
mutation O 0 2.669786454134737e-06
is O 0 3.3593575921031515e-08
an O 0 1.3306215684849576e-08
extraordinarily O 0 2.867124067051918e-07
high O 0 5.387531700762338e-07
level O 0 2.0484874312387547e-06
of O 0 4.160710318501515e-07
somatic O 0 0.00017897009092848748
mosaicism O 0 7.032170105958357e-05
, O 0 2.323242576096618e-08
due O 0 4.583306179029023e-08
to O 0 7.013702063574101e-09
an O 0 4.7869721520044095e-09
extremely O 0 6.47958060540077e-08
high O 0 3.049991619263892e-07
degree O 0 6.794428486500692e-07
of O 0 1.8850315086638147e-07
somatic O 0 1.1750437806767877e-05
instability O 0 7.442320111294976e-07
both O 0 6.303891098013992e-08
within O 0 7.949616076530219e-08
and O 0 3.5913078733074144e-08
between O 0 1.85055071710849e-07
different O 0 2.724229943851242e-07
tissues O 0 9.933994988386985e-06
. O 0 6.314460279099876e-06

This O 0 1.5547279872407671e-06
instability O 0 6.11249788562418e-06
appears O 0 3.038135503174999e-07
to O 0 1.5211863768627154e-08
be O 0 1.5640203798739094e-08
biased O 0 9.116573806977613e-08
towards O 0 5.541571113099053e-08
further O 0 2.8037984378670444e-08
expansion O 0 7.089344933319808e-08
and O 0 7.273051050304957e-09
continuous O 0 4.827612443136786e-08
throughout O 0 5.796193303098107e-09
the O 0 5.211345133204759e-09
life O 0 5.570987671177363e-09
of O 0 6.145749686936597e-09
an O 0 2.093679896120193e-09
individual O 0 3.974356843627902e-09
, O 0 7.458446305008692e-09
features O 0 2.0715159365636282e-08
that O 0 1.7709788080466637e-09
could O 0 1.0761918467494525e-08
be O 0 1.1544136313546005e-08
associated O 0 2.6987327927940896e-08
with O 0 8.862683920085601e-09
the O 0 9.442364756750976e-08
progressive O 0 9.423930168850347e-05
nature O 0 6.891053203617048e-07
of O 0 2.42179817178112e-06
the O 0 2.309271803824231e-05
disease O 1 0.7866456508636475
. O 0 2.8085729354643263e-05

Although O 0 4.682462076743832e-06
increasing O 0 1.8119836795449373e-06
measured O 0 1.960103418241488e-06
allele O 0 1.313108782596828e-06
size O 0 2.436140960071498e-07
between O 0 1.638132829384631e-07
patients O 0 1.3641933094277192e-07
clearly O 0 1.4980088280935888e-07
correlates O 0 1.6950657766301447e-07
with O 0 6.005490771343602e-09
an O 0 3.3224289985867017e-09
increased O 0 2.8835072996002964e-08
severity O 0 2.484516926415381e-06
of O 0 1.0405611874375609e-06
symptoms O 0 0.00012666502152569592
and O 0 6.050517242783826e-08
an O 0 4.526184316233639e-09
earlier O 0 2.927050424261779e-08
age O 0 2.982300273401961e-08
of O 0 2.3780646785098725e-08
onset O 0 8.444434570265003e-06
, O 0 1.4697936201457651e-08
this O 0 2.4649164931389578e-09
correlation O 0 1.2191037512820913e-08
is O 0 1.4375948209632838e-09
not O 0 2.959434697302754e-09
precise O 0 1.6598565366621187e-07
and O 0 5.332957897508095e-08
measured O 0 2.512691139600065e-07
allele O 0 4.819258947463823e-07
length O 0 3.642982093765568e-08
cannot O 0 1.3575180979330526e-08
be O 0 4.364094863262835e-09
used O 0 4.6370205453172275e-09
as O 0 5.520121693081137e-09
an O 0 3.738479747994461e-09
accurate O 0 1.8657941325272986e-07
predictor O 0 6.867114734632196e-06
of O 0 3.1758631280354166e-07
age O 0 5.106890512251994e-06
of O 0 1.2670816431636922e-05
onset O 1 0.9999078512191772
. O 0 5.8821191487368196e-05

In O 0 1.4021386505191913e-06
order O 0 8.398403679166222e-07
to O 0 1.1098207863824427e-07
further O 0 3.112251079073758e-07
characterize O 0 1.1057139772674418e-06
the O 0 4.474171930723969e-07
dynamics O 0 1.7146610844065435e-05
of O 0 2.1837935491930693e-05
DM B-Disease 1 1.0
CTG O 1 0.9844356775283813
repeat O 0 9.230527211911976e-06
somatic O 0 1.211266135214828e-05
instability O 0 9.932222155839554e-07
, O 0 3.8573745086978306e-08
we O 0 2.0161287750397605e-08
have O 0 8.593318057137367e-09
studied O 0 3.051510475415853e-07
repeat O 0 2.4355787786589644e-07
length O 0 4.74561083763092e-08
changes O 0 4.3386254588995143e-08
over O 0 2.5330692210445704e-08
time O 0 7.44780166428427e-08
in O 0 2.3280917105239496e-07
111 O 0 0.00290288426913321
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.6124858979746932e-06
with O 0 1.0049312493265461e-07
varying O 0 1.3637928759635543e-06
clinical O 0 2.0055691493325867e-05
severity O 0 1.2960768799530342e-05
and O 0 9.24800929169578e-07
CTG O 0 0.00014873234613332897
repeat O 0 4.3259584003862983e-07
size O 0 4.140742859704005e-08
over O 0 1.7860207535136396e-08
time O 0 1.030545426772278e-08
intervals O 0 3.935840808821922e-08
of O 0 1.7149575981534326e-08
1 O 0 5.706388037651777e-07
- O 0 5.81103449803777e-07
7 O 0 9.734237664815737e-07
years O 0 1.0505723366804887e-06
. O 0 4.80112066725269e-06

We O 0 1.5732886140540359e-06
have O 0 6.09113754990176e-08
found O 0 1.851748976378076e-08
a O 0 1.5798418573353956e-08
direct O 0 1.9611858803614268e-08
progression O 0 4.96861730425735e-07
of O 0 7.300503312990259e-08
the O 0 5.468336183866995e-08
size O 0 6.140550112831988e-08
heterogeneity O 0 4.1135737660624727e-07
over O 0 6.507211480766273e-08
time O 0 5.3078217376878456e-08
related O 0 2.8326962109304077e-08
to O 0 1.2989179509759197e-08
initial O 0 2.742108335951343e-07
CTG O 0 2.7143436454935e-05
repeat O 0 4.304242509078904e-07
size O 0 5.878585795926483e-08
and O 0 2.0637548558966046e-08
the O 0 2.0723419424939493e-08
time O 0 3.9755871483748706e-08
interval O 0 1.8391307321508066e-07
and O 0 1.4980654938767657e-08
always O 0 5.7947588061324495e-08
biased O 0 3.31286344135151e-07
towards O 0 4.314899513246928e-07
further O 0 5.195092285248393e-07
expansion O 0 1.1017572433047462e-05
. O 0 1.3903204489906784e-05

Attempts O 0 8.738391443330329e-06
to O 0 3.297833757187618e-07
mathematically O 0 5.968175628368044e-06
model O 0 7.636463692506368e-07
the O 0 1.294265388196436e-07
dynamics O 0 4.163756784691941e-06
have O 0 5.9459868140265826e-08
proved O 0 3.868769908876857e-06
only O 0 9.672794476500712e-08
partially O 0 6.507336252070672e-07
successful O 0 2.4343643190150033e-07
suggesting O 0 1.0116218618350103e-07
that O 0 8.347886826243212e-09
individual O 0 5.884169596015454e-09
specific O 0 1.7911242267132366e-08
genetic O 0 2.0414167067883682e-07
and O 0 2.3536976812010835e-07
/ O 0 0.00043826422188431025
or O 0 2.548133011259779e-07
environmental O 0 2.1105149983213778e-07
factors O 0 6.136404806511564e-08
also O 0 1.8172771731883586e-08
play O 0 1.2573458718634356e-07
a O 0 4.473949744010497e-08
role O 0 1.5629339600309322e-07
in O 0 1.3526724274015578e-07
somatic O 0 2.366252738283947e-05
mosaicism O 0 0.00017225558985956013
. O 0 2.8009981178911403e-06
. O 0 1.0964024113491178e-05

Aspartylglucosaminuria B-Disease 1 0.9995445609092712
among O 0 2.7100788429379463e-05
Palestinian O 0 0.00014229188673198223
Arabs O 0 0.00014597429253626615
. O 0 3.582509816624224e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9696313738822937
AGU B-Disease 1 1.0
) O 0 4.664785137720173e-06
is O 0 2.9303140536285355e-07
a O 0 4.662467176785867e-07
rare O 0 1.4732783711224329e-05
disorder B-Disease 1 0.9999834299087524
of I-Disease 0 0.42400622367858887
glycoprotein I-Disease 1 0.9999943971633911
metabolism I-Disease 1 0.9993730187416077
caused O 0 9.205577953252941e-06
by O 0 2.920615997936693e-07
the O 0 8.479384632664733e-06
deficiency B-Disease 1 0.9996122717857361
of I-Disease 0 0.00013980102085042745
the I-Disease 0 2.9749809982604347e-05
lysosomal I-Disease 1 0.9331291317939758
enzyme I-Disease 0 2.327485526620876e-05
aspartylglucosaminidase I-Disease 0 0.0002846164570655674
( O 0 1.6053658100645407e-06
AGA O 0 0.00020924146519973874
) O 0 2.158956931452849e-06
. O 0 1.5521856767009012e-05

AGU B-Disease 1 1.0
is O 0 2.1154826754354872e-05
inherited O 0 0.0003573536523617804
as O 0 2.318180349902832e-06
an O 0 5.595483116849209e-07
autosomal O 0 0.48749423027038574
recessive O 1 0.9680583477020264
trait O 0 0.00018563699268270284
and O 0 7.736633165222884e-07
occurs O 0 1.8518801425670972e-07
with O 0 1.8840191629010405e-08
a O 0 5.5973945478626774e-08
high O 0 1.0249233355352771e-06
frequency O 0 1.132779402723827e-06
in O 0 1.8483966357507597e-08
Finland O 0 2.1160674634757015e-07
because O 0 2.0930540856056723e-08
of O 0 8.388879280118999e-08
a O 0 2.8247254135749245e-07
founder O 0 7.062931217660662e-06
effect O 0 1.1257159712840803e-05
. O 0 1.1813956007244997e-05

While O 0 8.30441240395885e-06
very O 0 1.0022816923083155e-06
few O 0 4.985538453183835e-07
patients O 0 3.605096310366207e-07
with O 0 2.4437034085167397e-07
AGU B-Disease 1 1.0
have O 0 1.5741815673209203e-07
been O 0 6.044103884050855e-08
reported O 0 4.498962624666092e-08
from O 0 2.0870464467748207e-08
non O 0 2.0068057438038522e-06
- O 0 2.9891598387621343e-06
Finnish O 0 7.91521688370267e-06
origin O 0 3.10844825435197e-07
, O 0 3.637982786131033e-07
we O 0 1.968016931641614e-06
diagnosed O 0 0.037420932203531265
the O 0 1.1562258350750199e-06
disorder O 0 0.045530978590250015
in O 0 1.5594559954479337e-07
8 O 0 3.1060324090503855e-06
patients O 0 5.318320361880069e-08
originating O 0 3.361575195981459e-08
from O 0 1.5546190113013836e-08
3 O 0 9.346997558168368e-07
unrelated O 0 1.2639330293495732e-07
families O 0 4.811632869916593e-09
, O 0 7.629946452425429e-09
all O 0 9.578479343019808e-09
Palestinian O 0 5.110873644298408e-07
Arabs O 0 3.0387732863346173e-07
from O 0 2.4576459978220555e-08
the O 0 4.684011400968302e-08
region O 0 2.3943064775266976e-07
of O 0 1.0911355730058858e-06
Jerusalem O 0 7.11317770765163e-05
. O 0 2.2015630747773685e-05

The O 0 8.384907232539263e-06
clinical O 0 0.00039000852848403156
diagnosis O 1 0.7681877613067627
of O 1 0.9914026856422424
AGU B-Disease 1 1.0
is O 0 6.154237325972645e-06
often O 0 7.11287171384356e-08
difficult O 0 3.9084875425032806e-07
, O 0 2.6740613279230274e-08
in O 0 6.890137793647e-09
particular O 0 1.160374107911366e-08
early O 0 1.019303326188492e-07
in O 0 5.020657223298031e-09
the O 0 2.036605373234579e-08
course O 0 1.2369851276616828e-07
of O 0 7.7338604853594e-08
the O 0 3.680086990698328e-07
disease O 0 0.004561623092740774
, O 0 1.1504059926892296e-07
and O 0 9.954595014960432e-08
most O 0 2.4006507004514788e-08
of O 0 1.4013831162174029e-07
the O 0 2.1515481307687878e-07
patients O 0 3.056158561776101e-07
are O 0 1.5047943691115506e-07
diagnosed O 0 6.629218842135742e-05
after O 0 4.736631353807752e-07
the O 0 9.741205531099695e-08
age O 0 3.01027540672294e-07
of O 0 2.735805537668057e-07
5 O 0 3.125682724203216e-06
years O 0 1.3268551128930994e-06
. O 0 5.318926014297176e-06

However O 0 6.118925284681609e-06
, O 0 6.089145472287782e-07
since O 0 3.0716216770088067e-07
these O 0 5.389875923356158e-08
patients O 0 4.651798946042618e-08
excrete O 0 3.787191928950051e-07
early O 0 1.0273605255406437e-07
large O 0 2.178142821662732e-08
amounts O 0 6.331485735699971e-08
of O 0 8.871921863828902e-08
aspartylglucosamine O 0 3.418267169763567e-06
in O 0 4.421717036962036e-08
urine O 0 1.3551644428844156e-07
, O 0 4.2453301318801095e-08
biochemical O 0 6.39849929484626e-07
screening O 0 3.5047824553657847e-07
is O 0 4.468150649472591e-08
easy O 0 2.824097578013607e-07
by O 0 1.752051446146652e-07
urine O 0 2.9174889277783222e-06
chromatography O 0 7.24892015568912e-05
. O 0 2.4941887204477098e-06
. O 0 1.322993830399355e-05

Detection O 0 2.6025145416497253e-05
of O 0 1.883568188532081e-06
heterozygous O 0 1.2903515198559035e-06
carriers O 0 2.947803920960723e-07
of O 0 5.46561352621211e-07
the O 0 2.8009768357151188e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0037214080803096294
ATM O 0 0.01085036713629961
) O 0 1.5414597953622433e-07
gene O 0 1.0980463827081621e-07
by O 0 1.1749901318580669e-07
G2 O 0 0.00034843097091652453
phase O 0 0.00014259493036661297
chromosomal O 0 3.801541606662795e-05
radiosensitivity O 0 5.2335348300402984e-05
of O 0 7.0518658503715415e-06
peripheral O 0 0.0053879874758422375
blood O 0 8.405629341723397e-05
lymphocytes O 0 0.0001877714676083997
. O 0 5.143985617905855e-05

In O 0 0.00046024314360693097
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999995231628418
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.642758083013177e-07
patients O 0 4.477424297988364e-08
, O 0 4.831930411342e-09
mutations O 0 9.11559627780889e-09
in O 0 2.3272506144422778e-09
a O 0 4.7405515068987825e-09
single O 0 6.647840944395966e-09
gene O 0 1.7513089645149194e-08
, O 0 1.7118301443019845e-08
ATM O 0 2.934446229119203e-06
, O 0 4.032997935610183e-08
result O 0 1.4278322169047897e-07
in O 0 1.3878317872695334e-07
an O 0 2.337934529350605e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 0.00014947123418096453
embraces O 0 2.3245129341376014e-05
a O 0 2.497048967597948e-07
variety O 0 2.1975895947434765e-07
of O 0 3.236590089272795e-07
clinical O 0 1.3161479728296399e-05
features O 0 8.43592260935111e-07
and O 0 2.676475787666277e-07
manifests O 0 7.381283921858994e-07
extreme O 0 7.42907695894246e-06
radiosensitivity O 0 0.00013866773224435747
and O 0 2.5407999260096403e-07
a O 0 1.6009214220957801e-07
strong O 0 1.1284547554168967e-06
pre O 0 0.00014785172243136913
- O 0 1.4486336112895515e-05
disposition O 0 2.3532502382295206e-05
to O 0 1.5370633263955824e-06
malignancy B-Disease 0 0.05334877967834473
. O 0 5.9981204685755074e-05

Heterozygotes O 0 9.751202014740556e-05
for O 0 5.147957722329011e-07
the O 0 1.9811523088719696e-07
ATM O 0 2.966251486213878e-06
gene O 0 4.9506340360494505e-08
have O 0 5.845286921157822e-09
no O 0 1.7530201290583136e-08
clinical O 0 1.8709721416598768e-07
expression O 0 5.159385096931146e-08
of O 0 1.0121234481630381e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 5.622287062578835e-07
may O 0 5.357145482776104e-07
be O 0 4.537215829714114e-07
cancer B-Disease 0 3.7338548281695694e-05
prone O 0 9.749883247422986e-07
with O 0 1.7655228390367483e-08
a O 0 8.18327450247125e-08
moderate O 0 9.496759048488457e-06
increase O 0 1.4653464575076214e-07
in O 0 8.783190708072652e-08
in O 0 2.0944243317444489e-07
vitro O 0 5.225130735198036e-06
radiosensitivity O 0 3.7722184060839936e-05
. O 0 7.946377081680112e-06

We O 0 6.966102318983758e-06
performed O 0 3.055563183806953e-06
a O 0 1.5644582163076848e-06
blind O 0 9.053124813362956e-06
chromosomal O 0 4.2559609028103296e-06
analysis O 0 7.463899009962915e-07
on O 0 1.311339246967691e-06
G2 O 0 0.0002848444855771959
- O 0 1.8642695067683235e-06
phase O 0 3.1434212814929197e-06
lymphocytes O 0 3.5043643720200635e-07
from O 0 2.6073729841868953e-08
7 O 0 1.1915880122614908e-06
unrelated O 0 2.2013348370819585e-06
A B-Disease 1 0.9999847412109375
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 1.461931105950498e-06
, O 0 1.4456513497407286e-07
13 O 0 1.0429754411234171e-06
obligate O 0 1.3665803635376506e-06
A B-Disease 1 0.9999284744262695
- I-Disease 1 0.9999914169311523
T I-Disease 1 1.0
heterozygotes O 0 0.000273075740551576
( O 0 1.1967223656483839e-07
parents O 0 1.8652261957186056e-08
of O 0 3.756866462367725e-08
the O 0 3.302661255588646e-08
patients O 0 2.25400711428847e-08
) O 0 1.4365786782377654e-08
, O 0 2.0337017403448954e-08
and O 0 3.8389075029954256e-08
14 O 0 5.697975780094566e-07
normal O 0 1.7547972674947232e-07
controls O 0 2.0208436524171702e-07
following O 0 9.024517311218005e-08
X O 0 1.632255134609295e-06
- O 0 2.3119841330299096e-07
irradiation O 0 1.263390743133641e-07
with O 0 1.819986295004128e-08
1 O 0 1.0479305956323515e-06
Gy O 0 7.929479579615872e-06
in O 0 7.861463480196562e-09
order O 0 1.663586246536397e-08
to O 0 7.799140000486204e-09
evaluate O 0 1.1543976086159091e-07
this O 0 9.377478349392732e-09
cytogenetic O 0 2.2080837425164646e-06
method O 0 2.272648202961136e-07
as O 0 3.041927598701477e-08
a O 0 2.797585807456926e-08
tool O 0 2.504747840248456e-07
for O 0 1.9722220301332527e-08
detection O 0 4.2872738958976697e-07
of O 0 3.9356686443170474e-07
ATM O 0 4.429521504789591e-05
carriers O 0 5.120487458043499e-06
. O 0 1.8199109035776928e-05

Both O 0 8.133606752380729e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 1 0.6303530931472778
and O 0 3.843102604150772e-06
heterozygotes O 0 2.7520778530742973e-05
showed O 0 5.872875590284821e-07
significantly O 0 1.9288910380055313e-07
increased O 0 4.936057251825332e-08
levels O 0 8.087473446494187e-08
of O 0 7.513234123734946e-08
radiation O 0 0.00027403997955843806
- O 0 3.999970795121044e-05
induced O 0 8.16604915598873e-06
chromatid O 0 1.8882241420214996e-05
damage O 0 4.3710403474506165e-07
relative O 0 1.3273951537939865e-07
to O 0 1.5398692099211075e-08
that O 0 6.684114595145729e-09
of O 0 1.2802949811430153e-07
normal O 0 1.9083665847574593e-06
controls O 0 1.1213357538508717e-05
. O 0 9.34585477807559e-06

These O 0 1.1302653319944511e-06
results O 0 1.3926527344665374e-06
show O 0 1.0225513591421986e-07
that O 0 2.6042123124625505e-08
the O 0 2.598848709567392e-07
G2 O 0 0.0007233983487822115
- O 0 1.1138909940200392e-05
phase O 0 7.355576963163912e-05
chromosomal O 0 1.7969015971175395e-05
radiosensitivity O 0 1.3853585187462159e-05
assay O 0 9.201840498462843e-07
can O 0 1.7153404030523234e-08
be O 0 1.011409178630629e-08
used O 0 6.513181993739181e-09
for O 0 9.586246463300085e-09
the O 0 1.1836666757858438e-08
detection O 0 3.82306666324439e-07
of O 0 1.879498654488998e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.14333374798297882
. O 0 6.687799759674817e-05

In O 0 7.094739885360468e-06
combination O 0 2.2475804144050926e-05
with O 0 4.448206709639635e-07
molecular O 0 1.7111033230321482e-05
genetic O 0 7.333620715144207e-07
analyses O 0 2.157323564233593e-07
, O 0 1.9521097627261952e-08
this O 0 6.8965539945509136e-09
test O 0 1.1661254006867239e-07
may O 0 2.2526316811877223e-08
be O 0 6.151590348224545e-09
of O 0 5.852158757591042e-09
value O 0 7.75819053444593e-09
in O 0 2.4511095375601144e-09
studies O 0 5.2576814013605144e-09
of O 0 2.935269094450632e-08
familial B-Disease 0 6.424485832212667e-07
and I-Disease 0 4.833361231249e-07
sporadic I-Disease 0 0.00024981802562251687
cancers I-Disease 1 0.9993925094604492
aimed O 0 4.9470458179712296e-05
at O 0 1.326083406638645e-06
determination O 0 2.839082355876599e-07
of O 0 7.016728886810597e-08
the O 0 5.4940120008950544e-08
potential O 0 1.4574052897842193e-07
involvement O 0 1.916190655038008e-07
of O 0 1.954684734073453e-07
ATM O 0 1.7868229406303726e-05
mutations O 0 5.600271606454044e-07
in O 0 8.480613189476571e-08
tumor B-Disease 0 3.611736246966757e-05
risk O 0 2.7769724511017557e-06
or O 0 1.6448360611320822e-06
development O 0 6.911581749591278e-06
. O 0 1.0131316230399534e-06
. O 0 6.264089734031586e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 4.3737818486988544e-06
identification O 0 2.5259581093450834e-07
and O 0 4.3013741901631874e-08
detection O 0 1.3636837365993415e-06
of O 0 6.523118258883187e-07
founder O 0 4.099429861526005e-05
- O 0 2.036131263594143e-06
effect O 0 1.8357310693772888e-07
mutations O 0 5.021464133392328e-08
in O 0 8.484653868379155e-09
the O 0 3.728796471591522e-08
ATM O 0 1.6798305750853615e-06
gene O 0 6.83164600445707e-08
in O 0 4.5416140181941955e-08
ethnic O 0 4.6674236386934354e-07
populations O 0 2.1056287096143933e-06
. O 0 1.1798993000411429e-05

To O 0 6.660699227722944e-07
facilitate O 0 6.73465876843693e-07
the O 0 7.670572443885249e-08
evaluation O 0 2.2594741722059553e-07
of O 0 2.7840604843731853e-07
ATM O 0 0.00010950073919957504
heterozygotes O 0 8.289663128380198e-06
for O 0 1.5839610512102809e-07
susceptibility O 0 1.7953950646187877e-06
to O 0 5.448970341603854e-08
other O 0 4.5647581714547414e-07
diseases O 1 0.998449444770813
, O 0 7.745818209059507e-08
such O 0 3.4523505831884904e-08
as O 0 1.7736083464114927e-06
breast B-Disease 0 0.16699868440628052
cancer I-Disease 0 0.0001607120066182688
, O 0 1.0778234127428732e-07
we O 0 5.509458844699111e-08
have O 0 1.536035476590314e-08
attempted O 0 1.491955288202007e-07
to O 0 1.7322530965202532e-08
define O 0 1.19748051474744e-07
the O 0 3.6157903338107644e-08
most O 0 9.56801571305732e-09
common O 0 2.195255710546462e-08
mutations O 0 2.6238462069727575e-08
and O 0 9.954629121011749e-09
their O 0 1.1285366419144793e-08
frequencies O 0 1.4485000292552286e-06
in O 0 7.377758493021247e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9825992584228516
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.9866504885612812e-07
homozygotes O 0 2.014950268858229e-06
from O 0 1.827025997158671e-08
10 O 0 1.0246598947105667e-07
ethnic O 0 1.646633194241076e-07
populations O 0 8.627726515442191e-07
. O 0 6.474573638115544e-06

Both O 0 3.0330456866067834e-06
genomic O 0 4.247312517691171e-06
mutations O 0 1.529990754534083e-06
and O 0 6.888826931117364e-08
their O 0 3.793850211764038e-08
effects O 0 1.361713543701626e-06
on O 0 4.885222324446659e-07
cDNA O 0 1.7667105112195713e-06
were O 0 1.4008181778990547e-06
characterized O 0 1.5006847206677776e-05
. O 0 2.4638831746415235e-05

Protein O 0 9.371845226269215e-05
- O 0 1.6966141629382037e-05
truncation O 0 6.90797651259345e-06
testing O 0 6.696150194329675e-07
of O 0 9.778156595530163e-08
the O 0 1.229357451393298e-07
entire O 0 6.320131546999619e-07
ATM O 0 1.8232440197607502e-06
cDNA O 0 4.772879833581101e-07
detected O 0 2.2782143105359864e-07
92 O 0 1.4587278656108538e-06
( O 0 1.0842814646139232e-07
66 O 0 8.082706699497066e-07
% O 0 1.592303249253746e-07
) O 0 1.000627847247415e-07
truncating O 0 3.2160539831238566e-06
mutations O 0 5.308526169756078e-07
in O 0 1.2189579479127133e-07
140 O 0 1.069023255695356e-06
mutant O 0 9.729311386763584e-06
alleles O 0 1.2783450074493885e-05
screened O 0 1.9502547729643993e-05
. O 0 2.215161657659337e-05

The O 0 1.1087508937634993e-05
haplotyping O 0 0.0005273082060739398
of O 0 2.055381628451869e-06
patients O 0 5.31069815679075e-07
with O 0 7.406465130088691e-08
identical O 0 9.998434506997e-07
mutations O 0 2.767288833638304e-07
indicates O 0 7.209493446680426e-08
that O 0 5.3681841194475055e-09
almost O 0 1.747998368273329e-08
all O 0 5.022649851582628e-09
of O 0 6.219712744837125e-09
these O 0 2.003305521469656e-09
represent O 0 9.551387236683695e-09
common O 0 6.030619914554336e-08
ancestry O 0 2.1339207734172305e-08
and O 0 2.6277827913645524e-08
that O 0 8.34584934494842e-09
very O 0 5.262198499167425e-08
few O 0 1.535593696644355e-07
spontaneously O 0 5.462757712848543e-07
recurring O 0 8.266124496003613e-07
ATM O 0 1.080058154911967e-05
mutations O 0 1.7036272765835747e-06
exist O 0 3.208670705134864e-06
. O 0 9.413829502591398e-06

Assays O 0 5.1864946726709604e-05
requiring O 0 4.2628380469977856e-06
minimal O 0 1.4821290506006335e-06
amounts O 0 2.668152205842489e-07
of O 0 1.1917363451630081e-07
genomic O 0 1.220960115233538e-07
DNA O 0 1.3949295407655882e-07
were O 0 4.2061749638833135e-08
designed O 0 1.1932863230867952e-07
to O 0 1.410725936068502e-08
allow O 0 4.3796820392572045e-08
rapid O 0 5.15239321430272e-07
screening O 0 1.7410482655577653e-07
for O 0 4.6965269007159804e-08
common O 0 2.967055934277596e-07
ethnic O 0 8.835587550493074e-07
mutations O 0 1.1111388630524743e-05
. O 0 8.923928362492006e-06

These O 0 1.1562181043700548e-06
rapid O 0 3.760562549359747e-06
assays O 0 2.5504502900730586e-06
detected O 0 3.365495615526015e-07
mutations O 0 2.612698040138639e-07
in O 0 2.7074149144823423e-08
76 O 0 2.0949238432876882e-07
% O 0 2.548081212694342e-08
of O 0 1.8102066690062202e-07
Costa O 0 1.6418518953287276e-06
Rican O 0 8.330806053891138e-07
patients O 0 2.3695434947512695e-08
( O 0 1.6040811345874317e-08
3 O 0 1.3607640880763938e-07
) O 0 1.4605881837326251e-08
, O 0 7.892503539608242e-09
50 O 0 2.2319490255995333e-08
% O 0 8.519486449642955e-09
of O 0 5.135527203492529e-08
Norwegian O 0 1.6581840327489772e-06
patients O 0 2.7786223100179086e-08
( O 0 1.3917186514333935e-08
1 O 0 1.1158616075590544e-07
) O 0 9.713168047653653e-09
, O 0 9.59813917233987e-09
25 O 0 3.591246056089403e-08
% O 0 8.204963819480326e-09
of O 0 6.916975792137237e-08
Polish O 0 2.423285332042724e-05
patients O 0 2.269366916607396e-07
( O 0 3.932314029952977e-08
4 O 0 4.6889766736057936e-07
) O 0 1.4479811127898756e-08
, O 0 1.053532194816853e-08
and O 0 1.3112845920204563e-08
14 O 0 9.309352577702157e-08
% O 0 8.535947060295257e-09
of O 0 6.499831073369933e-08
Italian O 0 8.697213161212858e-06
patients O 0 4.7630582145075095e-08
( O 0 1.7806872421033404e-08
1 O 0 4.178372705609945e-07
) O 0 2.178533264896032e-08
, O 0 1.549828709812573e-08
as O 0 2.569148804809629e-08
well O 0 2.9153222058653228e-08
as O 0 2.4065464288014482e-08
in O 0 1.7560587650677917e-08
patients O 0 2.0397076028189076e-08
of O 0 1.8579086713543802e-07
Amish O 0 9.848015906754881e-06
/ O 0 3.864499740302563e-05
Mennonite O 0 3.630224455264397e-05
and O 0 9.34141041852854e-07
Irish O 0 1.0060337444883771e-05
English O 0 3.117329833912663e-05
backgrounds O 0 6.301172106759623e-05
. O 0 3.646128243417479e-05

Additional O 0 3.0415151286433684e-06
mutations O 0 1.9974022507085465e-06
were O 0 3.181990280154423e-07
observed O 0 2.998922639108059e-07
in O 0 3.359959777071708e-08
Japanese O 0 4.686120291808038e-07
, O 0 1.0978244802117842e-07
Utah O 0 6.664219540652994e-07
Mormon O 0 4.87796910420002e-07
, O 0 1.201018022811695e-07
and O 0 3.0623846214439254e-07
African O 0 8.07425476523349e-06
American O 0 2.3519614842371084e-06
patients O 0 4.013766101707006e-06
. O 0 8.982579856819939e-06

These O 0 1.4806074659645674e-06
assays O 0 3.973278580815531e-06
should O 0 2.896169064570131e-07
facilitate O 0 5.608593482975266e-07
screening O 0 2.53550126672053e-07
for O 0 2.429938774639595e-07
A B-Disease 1 0.999994158744812
- I-Disease 1 0.9999967813491821
T I-Disease 1 1.0
heterozygotes O 0 1.5864412489463575e-05
in O 0 6.074441927239604e-08
the O 0 3.308537444013382e-08
populations O 0 4.95795760002693e-08
studied O 0 5.686814574801247e-07
. O 0 3.486929074369982e-07
. O 0 2.8233323519089026e-06

The O 0 4.030023410450667e-05
von B-Disease 1 0.9737589359283447
Hippel I-Disease 1 0.9999617338180542
- I-Disease 1 0.9989280104637146
Lindau I-Disease 1 0.91497802734375
tumor I-Disease 0 9.086822683457285e-05
suppressor O 0 3.05008034047205e-05
gene O 0 3.089389508659224e-07
is O 0 3.332254649990318e-08
required O 0 8.639271698029916e-08
for O 0 8.573856291604898e-08
cell O 0 1.3335721860130434e-06
cycle O 0 3.705793005792657e-07
exit O 0 4.0411723034594615e-07
upon O 0 4.3806511484945077e-07
serum O 0 2.845704102583113e-06
withdrawal O 0 7.660003575438168e-06
. O 0 1.808871456887573e-05

The O 0 4.820624326384859e-06
inactivation O 0 3.3468397305114195e-05
of O 0 2.153733703380567e-06
the O 0 2.629649088703445e-06
von B-Disease 1 0.9322673678398132
Hippel I-Disease 1 0.9999971389770508
- I-Disease 1 0.9999977350234985
Lindau I-Disease 1 0.9999988079071045
( I-Disease 0 4.001656998298131e-05
VHL I-Disease 1 0.9997571110725403
) I-Disease 0 1.296437403652817e-06
tumor I-Disease 0 2.7755460905609652e-05
suppressor O 0 0.0001311713276663795
gene O 0 3.215790002286667e-06
predisposes O 0 1.2501253877417184e-05
affected O 0 4.780852123076329e-07
individuals O 0 2.233925222583366e-08
to O 0 2.2925526366179838e-08
the O 0 1.1051457704525092e-06
human O 1 0.9991647005081177
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.000707130937371403
is O 0 2.1868457622531423e-07
associated O 0 1.7072528635253548e-07
with O 0 1.7602813784378668e-07
sporadic B-Disease 1 0.7262298464775085
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.9459460377693176
RCC B-Disease 1 1.0
) O 0 3.262529207859188e-05
and O 0 7.036577153485268e-05
brain B-Disease 1 0.9999388456344604
hemangioblastomas I-Disease 1 0.8853395581245422
. O 0 0.0001913916930789128

VHL O 1 0.6932718753814697
- O 0 0.0002608842041809112
negative O 0 1.0809937521116808e-05
786 O 0 8.724370854906738e-05
- O 0 2.1261514120851643e-05
0 O 0 6.876249699416803e-06
RCC B-Disease 0 0.2813156545162201
cells O 0 1.1529688208611333e-06
are O 0 1.289608064780623e-07
tumorigenic O 0 2.9707087378483266e-05
in O 0 5.62527418423997e-07
nude O 0 6.268512152018957e-06
mice O 0 2.775929317522241e-07
which O 0 2.371908536247247e-08
is O 0 1.5253352358968186e-08
suppressed O 0 2.604565452202223e-07
by O 0 1.8889487307660602e-08
the O 0 1.1481743911190279e-07
reintroduction O 0 2.284459014845197e-06
of O 0 3.8870234675414395e-06
VHL B-Disease 1 0.9925404191017151
. O 0 0.00013366311031859368

Remarkably O 0 0.0007993901381269097
, O 0 5.313474389367911e-07
this O 0 7.533539303494763e-08
occurs O 0 1.395419104710527e-07
without O 0 1.2993940856631525e-07
affecting O 0 1.380205389978073e-07
the O 0 1.4195143727135928e-08
growth O 0 5.209887632418031e-08
rate O 0 4.683439414066015e-08
and O 0 3.1331893524111365e-08
cell O 0 4.884779514213733e-07
cycle O 0 1.249919137080724e-07
profile O 0 4.6592493418984304e-08
of O 0 3.2173616659747495e-08
these O 0 1.1158909352104729e-08
cells O 0 1.6550102088785934e-07
in O 0 6.747085734559732e-08
culture O 0 1.1824074590549571e-06
. O 0 4.011175406049006e-06

The O 0 1.6937203326961026e-05
786 O 0 7.041705248411745e-05
- O 0 1.0569865480647422e-05
0 O 0 2.2909039216756355e-06
cell O 0 5.149994194653118e-06
line O 0 1.7094666873163078e-06
, O 0 8.003488716212814e-08
like O 0 4.559633026701704e-08
many O 0 3.0945962237183267e-08
cancer B-Disease 0 7.561985171378183e-07
cells O 0 1.4954268579003838e-07
, O 0 2.089065631594167e-08
fails O 0 5.701808802882624e-08
to O 0 1.9669025519419847e-08
exit O 0 4.887370437245409e-07
the O 0 2.690038058972277e-07
cell O 0 2.3311561108130263e-06
cycle O 0 6.349855539156124e-07
upon O 0 5.014114208279352e-07
serum O 0 3.905140602000756e-06
withdrawal O 0 1.450219042453682e-05
. O 0 2.3959719328559004e-05

Here O 0 5.532901923288591e-06
, O 0 1.5779181694597355e-07
it O 0 1.2218786871187604e-08
is O 0 5.426274984898782e-09
shown O 0 4.963073507724403e-09
that O 0 1.7375401117902811e-09
reintroduction O 0 6.369057103938758e-08
of O 0 4.943076348240538e-08
the O 0 1.1163639612732368e-07
wild O 0 6.978362989684683e-07
- O 0 3.1351435154647334e-06
type O 0 6.154636594146723e-06
VHL B-Disease 0 0.3210827112197876
gene O 0 1.3279210406835773e-06
restores O 0 1.9428828181844437e-06
the O 0 1.93653647784231e-07
ability O 0 1.9715079702109506e-07
of O 0 1.686537189016235e-06
VHL O 1 0.9999743700027466
- O 0 0.3371258080005646
negative O 0 2.2313430235954e-05
RCC B-Disease 1 0.9999997615814209
cancer I-Disease 0 6.807511454098858e-06
cells O 0 5.0480934987717774e-08
to O 0 1.2345051203510593e-08
exit O 0 1.198181820427635e-07
the O 0 3.86504837024404e-08
cell O 0 5.55330530005449e-07
cycle O 0 1.9771111681166076e-07
and O 0 7.219868791707995e-08
enter O 0 9.90393118627253e-07
G0 O 0 0.08227821439504623
/ O 0 2.2776133846491575e-05
quiescence O 0 1.6534386304556392e-05
in O 0 3.87200714158098e-07
low O 0 1.1151120816066395e-05
serum O 0 1.5872537915129215e-05
. O 0 7.508122052968247e-06

Both O 0 0.00010473435395397246
VHL O 1 0.9993728995323181
- O 0 0.000893603079020977
positive O 0 6.240990387595957e-06
and O 0 4.597666247718735e-06
VHL O 1 0.996519923210144
- O 0 5.480385880218819e-05
negative O 0 1.891685201371729e-06
RCC B-Disease 0 0.4353007376194
cells O 0 4.6933476482990955e-07
exit O 0 5.06131186739367e-07
the O 0 9.672443468389247e-08
cell O 0 9.404329261997191e-07
cycle O 0 4.195094334136229e-07
by O 0 7.361622067492135e-08
contact O 0 1.6766521184763405e-06
inhibition O 0 3.229174035368487e-05
. O 0 1.2322617294557858e-05

The O 0 3.2968047889880836e-05
cyclin O 0 0.00018341081158723682
- O 0 1.2282843272259925e-05
dependent O 0 1.4308654954220401e-06
kinase O 0 9.47897024161648e-06
inhibitor O 0 6.424157618312165e-06
, O 0 2.2044282843580731e-07
p27 O 0 6.245551503525348e-06
, O 0 7.690907466439967e-08
accumulates O 0 2.572660662281123e-07
upon O 0 4.387014485018881e-08
serum O 0 6.61869279383609e-08
withdrawal O 0 8.490064828947652e-08
, O 0 2.2794154119765153e-08
only O 0 1.0158559327066996e-08
in O 0 3.219711386392987e-09
the O 0 5.707943007138283e-09
presence O 0 3.149991201212288e-08
of O 0 2.260909752749285e-07
VHL B-Disease 1 0.9990060925483704
, O 0 1.5450110879555723e-07
as O 0 2.4221108674282732e-08
a O 0 1.3765859563363847e-08
result O 0 2.2062868865191376e-08
of O 0 3.514746182986528e-08
the O 0 4.5784918967228805e-08
stabilization O 0 6.070770837141026e-07
of O 0 3.6573382544702326e-07
the O 0 9.522265713712841e-07
protein O 0 7.170543995016487e-06
. O 0 5.0851381274696905e-06

We O 0 3.660866468635504e-06
propose O 0 1.0033777471107896e-06
that O 0 1.9415640650777277e-08
the O 0 6.199650925964306e-08
loss O 0 3.809378483765613e-07
of O 0 6.29322300937929e-07
wild O 0 1.967951220649411e-06
- O 0 1.2737328688672278e-05
type O 0 3.55581178155262e-05
VHL B-Disease 1 0.9990270137786865
gene O 0 1.1767490377678769e-06
results O 0 9.720063189888606e-07
in O 0 2.9394708889185495e-08
a O 0 4.803785813578543e-08
specific O 0 9.718341686948406e-08
cellular O 0 6.548626060975948e-06
defect O 0 5.441455641630455e-07
in O 0 5.982354167599624e-08
serum O 0 9.739047754919739e-07
- O 0 1.1714649872374139e-06
dependent O 0 5.452525897453597e-08
growth O 0 5.648293921467484e-08
control O 0 1.9201490886189276e-07
, O 0 3.334219300654695e-08
which O 0 1.706203889284552e-08
may O 0 1.601162580300297e-07
initiate O 0 1.5422508568008197e-06
tumor B-Disease 0 1.4257371731218882e-05
formation O 0 4.252558937878348e-05
. O 0 5.224997585173696e-05

This O 0 1.0536688250795123e-06
is O 0 1.832781890698243e-07
corrected O 0 1.1915686854990781e-06
by O 0 1.659738657622256e-08
the O 0 2.0343611240036807e-08
reintroduction O 0 4.990242814528756e-07
of O 0 1.4037854612070078e-07
wild O 0 1.372469455418468e-06
- O 0 1.8902546798926778e-05
type O 0 0.0029732761904597282
VHL B-Disease 1 1.0
, O 0 0.0001476035249652341
implicating O 1 0.9984502792358398
VHL B-Disease 1 0.9999029636383057
as O 0 4.3326303966750856e-07
the O 0 1.0434794006641823e-07
first O 0 1.4284287885857339e-07
tumor B-Disease 0 1.1182260095665697e-06
suppressor O 0 3.815490345004946e-06
involved O 0 1.2123219050863554e-07
in O 0 1.780442815402239e-08
the O 0 4.085046256818714e-08
regulation O 0 2.8717570899061684e-07
of O 0 1.1845671110677358e-07
cell O 0 1.0526764526730403e-06
cycle O 0 2.5767096190065786e-07
exit O 0 1.9764476633099548e-07
, O 0 2.3314459696166523e-08
which O 0 1.2004941041254824e-08
is O 0 1.0865499611156793e-08
consistent O 0 7.507217958391266e-08
with O 0 1.2393416071176944e-08
its O 0 6.544976827171922e-08
gatekeeper O 0 2.613909373394563e-06
function O 0 2.0311090054292436e-07
in O 0 6.382470729704437e-08
the O 0 4.84408531065128e-07
kidney O 0 0.0011081764241680503
. O 0 2.7274559215584304e-06
. O 0 1.9776742192334495e-05

Piebaldism B-Disease 1 1.0
with O 0 0.00981700886040926
deafness B-Disease 1 1.0
: O 0 1.8401901797915343e-06
molecular O 0 4.6731834117963444e-06
evidence O 0 5.771440214630275e-07
for O 0 1.7496103055236745e-07
an O 0 2.0717497761779669e-07
expanded O 0 7.037752220639959e-05
syndrome O 1 0.999996542930603
. O 0 0.00021613150602206588

In O 0 1.5102763200047775e-06
a O 0 1.3131100331520429e-06
South O 0 5.809638423670549e-06
African O 0 9.677823982201517e-06
girl O 0 2.5030478809640044e-06
of O 0 1.1500202390379854e-06
Xhosa O 0 7.086960977176204e-05
stock O 0 1.8039489759757998e-06
with O 0 2.2644701402896317e-07
severe O 0 0.39237841963768005
piebaldism B-Disease 1 0.979850709438324
and O 0 0.0012841833522543311
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.0004267644544597715
identified O 0 1.048436388373375e-06
a O 0 1.6271792446787003e-07
novel O 0 4.6287303234748833e-07
missense O 0 5.207336926105199e-06
substitution O 0 2.9972809443279402e-06
at O 0 2.5491492579021724e-06
a O 0 2.4700625544937793e-07
highly O 0 8.345994615410746e-07
conserved O 0 6.6416703248251e-07
residue O 0 7.58802059408481e-07
in O 0 4.7282910031754e-08
the O 0 1.0181957321719892e-07
intracellular O 0 9.639895779400831e-07
kinase O 0 5.035669232711371e-07
domain O 0 4.491726102173743e-08
of O 0 3.5841161150074186e-08
the O 0 2.0074764961464098e-07
KIT O 0 9.54731585807167e-05
proto O 0 0.006808410864323378
- O 0 0.0002390430454397574
oncogene O 0 0.00030942767625674605
, O 0 4.68171219836222e-06
R796G O 0 0.00024857016978785396
. O 0 4.386117507237941e-05

Though O 0 1.726041955407709e-05
auditory B-Disease 0 0.21255607903003693
anomalies I-Disease 0 0.00032964698038995266
have O 0 1.4479527976618556e-07
been O 0 1.7145920594430208e-07
observed O 0 2.911327783294837e-07
in O 0 7.809637025957272e-08
mice O 0 1.0746698535513133e-06
with O 0 9.430863201487227e-08
dominant O 1 0.9672427177429199
white O 0 3.248964640079066e-05
spotting O 0 0.03949643671512604
( O 0 3.1449867492483463e-06
W O 0 0.005927423946559429
) O 0 4.5911804136267165e-08
due O 0 1.133528968466635e-07
to O 0 3.935871006888192e-08
KIT O 0 0.00028808688512071967
mutations O 0 9.467146446695551e-05
, O 0 2.3498505470342934e-05
deafness B-Disease 1 1.0
is O 0 1.0297107166934438e-07
not O 0 3.389763136851798e-08
typical O 0 3.288550090019271e-07
in O 0 2.0584464266448776e-07
human O 0 3.851177552860463e-06
piebaldism B-Disease 0 0.00019391189562156796
. O 0 1.7759981346898712e-05

Thus O 0 1.0973406460834667e-05
, O 0 6.353163257699634e-07
the O 0 3.377720645403315e-07
occurrence O 0 2.9660138807230396e-06
of O 0 0.0002699873293749988
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 7.545181688328739e-06
this O 0 1.63876109127159e-07
patient O 0 5.428590270639688e-07
extends O 0 4.640367308184068e-07
considerably O 0 4.797577730641933e-07
the O 0 7.023463410860131e-08
phenotypic O 0 2.836897465385846e-06
range O 0 6.138636194918945e-07
of O 0 2.541335391015309e-07
piebaldism B-Disease 0 7.072806056385161e-06
due O 0 2.750730629941245e-07
to O 0 5.8364442168112873e-08
KIT O 0 5.288962256599916e-06
gene O 0 2.3978438434824056e-07
mutation O 0 3.975542313128244e-07
in O 0 8.462160394628881e-08
humans O 0 7.35592948331032e-07
and O 0 1.8710220217599272e-07
tightens O 0 7.544934987890883e-07
the O 0 9.146216939370788e-08
clinical O 0 9.055136729330115e-07
similarity O 0 2.4466552872581815e-07
between O 0 9.033728360918758e-07
piebaldism B-Disease 0 3.829355046036653e-05
and O 0 8.488640190762453e-08
the O 0 6.39388773038263e-08
various O 0 3.3112396380374776e-08
forms O 0 5.834691023665073e-07
of O 0 7.338131399592385e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 7.710302270425018e-06
. O 0 1.619108661543578e-05

Cycloheximide O 0 0.00043306619045324624
facilitates O 0 5.218801106821047e-06
the O 0 1.5249548823703662e-07
identification O 0 8.983557364672379e-08
of O 0 2.7185359385839547e-07
aberrant O 0 1.5685859580116812e-06
transcripts O 0 1.4169208952807821e-06
resulting O 0 4.320342839037039e-07
from O 0 6.880593161895376e-08
a O 0 1.936085993747838e-07
novel O 0 4.2544414213807613e-07
splice O 0 1.25403003039537e-05
- O 0 3.4287443213543156e-06
site O 0 1.9832505415706692e-07
mutation O 0 2.682255626496044e-07
in O 0 1.2633690005259268e-07
COL17A1 O 0 0.11972270905971527
in O 0 1.546737422586375e-07
a O 0 3.5846019841301313e-07
patient O 0 6.748642249476688e-07
with O 0 1.9247413547418546e-06
generalized O 1 0.9990550875663757
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999959468841553
. O 0 0.0005445259157568216

Patients O 0 5.390169462771155e-05
with O 0 6.533554369525518e-06
generalized O 1 0.9426634311676025
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999983310699463
often O 0 9.295882250626164e-07
show O 0 2.995372767600202e-07
decreased O 0 4.1237433379137656e-07
expression O 0 1.0208169953784818e-07
of O 0 1.4156078975702258e-07
type O 0 6.822954219387611e-06
XVII O 1 0.9998788833618164
collagen O 0 2.9508704756153747e-05
, O 0 1.6369273225791403e-07
a O 0 2.2976047375777853e-07
transmembrane O 0 4.23077835876029e-06
hemidesmosomal O 0 3.6862236356682843e-06
protein O 0 1.3389318098688818e-07
encoded O 0 1.7745122704582172e-07
by O 0 1.4313920360109478e-07
COL17A1 O 0 0.00014538226241711527
. O 0 1.3633295566251036e-05

This O 0 2.5328622541564982e-06
report O 0 1.1407616966607748e-06
documents O 0 1.3041282045378466e-06
a O 0 5.786022825304826e-07
novel O 0 1.2684723742495407e-06
splice O 0 1.5691284716012888e-05
- O 0 6.477470378740691e-06
site O 0 8.304818948090542e-07
mutation O 0 8.387646062146814e-07
in O 0 2.4380653940170305e-07
COL17A1 O 0 0.09787386655807495
in O 0 2.1987131049172604e-07
a O 0 2.6660487151275447e-07
patient O 0 3.254002649555332e-07
with O 0 6.961751637390989e-07
generalized O 1 0.9929929971694946
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 3.3593755688343663e-06
and O 0 3.3480617389614054e-07
applies O 0 2.678017949619971e-07
a O 0 3.5864683667341524e-08
new O 0 2.6431749233779556e-08
methodology O 0 6.89903032480288e-08
to O 0 6.588851242383953e-09
define O 0 7.617357056233232e-08
and O 0 4.724603996919541e-08
characterize O 0 3.9613010471839516e-07
the O 0 1.155955331455516e-07
resulting O 0 4.5007223548054753e-07
mRNA O 0 2.0170343759673415e-06
splice O 0 1.0674446457414888e-05
variants O 0 1.1438706678745802e-05
. O 0 1.1680932402668986e-05

Mutational O 0 0.0005073068896308541
analysis O 0 1.2106759641028475e-05
of O 0 1.3208355085225776e-05
COL17A1 O 1 0.9881932139396667
identified O 0 1.6708192561054602e-05
a O 0 4.201078354526544e-06
maternally O 0 3.062382893403992e-05
inherited O 0 4.86833268951159e-05
G O 0 0.0021809495519846678
- O 0 0.00019196410721633583
to O 0 8.307591770062572e-07
- O 0 0.03926674649119377
T O 0 0.0029543775599449873
transversion O 0 4.20671422034502e-05
at O 0 5.764338766311994e-07
the O 0 3.686282923354156e-08
- O 0 7.497887821728e-08
1 O 0 9.635818543074492e-08
position O 0 2.027060759246524e-07
of O 0 4.776828177455172e-07
exon O 0 7.6180776886758395e-06
32 O 0 7.70718452258734e-06
. O 0 9.753308404469863e-06

This O 0 3.3317198813165305e-06
acceptor O 0 1.1342809557390865e-05
splice O 0 4.180711039225571e-05
- O 0 4.5639940253749955e-06
site O 0 3.716910441653454e-07
mutation O 0 1.5982212175913446e-07
led O 0 1.9598908806983673e-07
to O 0 2.1428325780448176e-08
the O 0 7.454708850218594e-08
formation O 0 1.1545961342562805e-06
of O 0 5.854193432242027e-07
aberrant O 0 2.3421150672220392e-06
transcripts O 0 2.0676573058153735e-06
present O 0 1.8836981041658873e-07
at O 0 2.88765750156017e-06
extremely O 0 5.631271960737649e-06
low O 0 0.00010372178803663701
levels O 0 8.460062235826626e-05
. O 0 1.7823962480179034e-05

Based O 0 5.548161425394937e-06
on O 0 9.82912752078846e-07
our O 0 1.873788022521694e-07
recent O 0 6.079460490582278e-08
finding O 0 2.3265644699677068e-07
that O 0 5.28892414308757e-08
cycloheximide O 0 7.824016392987687e-06
stabilized O 0 1.2835525922128e-05
mutant O 0 8.086853995337151e-06
COL17A1 O 0 7.445640221703798e-05
transcripts O 0 2.7515386591403512e-06
in O 0 1.1936813848478778e-07
keratinocytes O 0 2.91963215204305e-06
homozygous O 0 1.5094771015355946e-06
for O 0 8.750651403488519e-08
a O 0 2.9161574843783455e-07
frameshift O 0 1.5048667592054699e-05
mutation O 0 7.97174379840726e-07
, O 0 9.779965637335408e-08
the O 0 1.1337269256728177e-07
effects O 0 1.5502359929087106e-06
of O 0 4.872910039921408e-07
the O 0 4.794458732249041e-07
splice O 0 6.420127192541258e-06
- O 0 5.728891778744583e-07
site O 0 5.6749879462358876e-08
mutation O 0 3.645324397894001e-08
on O 0 6.226100879302976e-08
splicing O 0 4.7425527327504824e-07
of O 0 3.1612799489266763e-07
COL17A1 O 0 6.48162531433627e-05
transcripts O 0 1.9316516954859253e-06
were O 0 1.016278758925182e-07
determined O 0 2.1279952022723592e-07
using O 0 1.6250314160970447e-07
reverse O 0 2.928301682914025e-06
transcriptase O 0 5.312882876751246e-06
polymerase O 0 2.7900618988496717e-06
chain O 0 2.725264209857414e-07
reaction O 0 8.386511751723447e-08
of O 0 1.3620184802221047e-07
total O 0 8.030967535432865e-08
RNA O 0 2.982690432418167e-07
from O 0 4.453346846844397e-08
keratinocytes O 0 1.4174927400745219e-06
incubated O 0 1.264724119209859e-06
for O 0 1.0660998128741994e-07
2 O 0 3.2613452276564203e-06
. O 0 4.297366103855893e-06

5 O 0 2.620545456011314e-05
h O 0 7.873432878113817e-06
in O 0 1.0040825060286807e-07
the O 0 3.689208938340016e-08
presence O 0 8.581758237369286e-08
or O 0 5.4421050776909397e-08
absence O 0 5.736310981774295e-07
of O 0 4.1075134049606277e-07
10 O 0 2.5125500542344525e-06
microg O 0 5.991511352476664e-05
cycloheximide O 0 4.624075518222526e-05
per O 0 4.020083451905521e-06
ml O 0 7.793328404659405e-05
. O 0 1.241566405951744e-05

Using O 0 1.3904113984608557e-06
this O 0 4.8875381963853215e-08
approach O 0 2.524149920191121e-07
, O 0 4.551534615870878e-08
an O 0 3.492792544079748e-08
abnormally O 0 1.3124164297551033e-06
spliced O 0 3.836104951915331e-06
transcript O 0 3.446171376708662e-06
was O 0 2.883928971186833e-07
identified O 0 7.572103299935407e-08
that O 0 8.027135400823227e-09
contains O 0 1.88298443504209e-08
an O 0 1.1497990115572065e-08
extra O 0 2.984631350955169e-07
264 O 0 3.5992803759654635e-07
bases O 0 9.091568387020743e-08
upstream O 0 2.3308574270686222e-07
from O 0 4.3373926672529706e-08
exon O 0 1.017884528664581e-06
32 O 0 5.06216110807145e-07
, O 0 5.729630458972679e-08
resulting O 0 2.0791941324205254e-07
in O 0 6.005986108448269e-08
a O 0 3.531371248755022e-07
premature O 0 6.320056854747236e-06
termination O 0 1.486602832301287e-05
codon O 0 3.0809194868197665e-05
27 O 0 1.8390448531135917e-05
bp O 0 1.214696021634154e-05
downstream O 0 2.368293280596845e-06
from O 0 1.999863599166929e-07
the O 0 5.707874493054987e-07
cryptic O 0 1.6843989214976318e-05
splice O 0 2.9900244044256397e-05
site O 0 8.065803740464617e-06
. O 0 1.72664786077803e-05

Three O 0 6.364695309457602e-06
other O 0 2.086038364268461e-07
splice O 0 4.839177108806325e-06
variants O 0 8.836506140141864e-07
, O 0 5.057229657268181e-08
including O 0 2.7245462774772022e-08
one O 0 6.643721128796187e-09
derived O 0 1.1973132707510104e-08
from O 0 1.4808496651141922e-08
the O 0 3.480675303535463e-08
skipping O 0 2.927062610069697e-07
of O 0 1.1224918949892526e-07
exon O 0 1.0700514394557104e-06
32 O 0 5.154231530468678e-07
, O 0 9.907996911806549e-08
were O 0 2.385361028700572e-07
also O 0 2.6898842975242587e-07
identified O 0 4.088163677806733e-06
. O 0 1.6483567378600128e-05

These O 0 1.1990156281171949e-06
results O 0 1.0282401490258053e-06
indicate O 0 2.8463017542890157e-07
the O 0 1.0761903013190022e-07
usefulness O 0 1.781623495844542e-06
of O 0 5.403750833465892e-07
cycloheximide O 0 1.740711013553664e-05
treatment O 0 4.876778234574886e-07
in O 0 4.833121636238502e-08
evaluating O 0 4.0392109212916694e-07
the O 0 6.276871999943978e-08
abnormal O 0 1.3903435558404453e-07
processing O 0 8.793583816668615e-08
of O 0 5.1653223920311575e-08
mRNA O 0 1.3874891635623499e-07
due O 0 6.371633531898624e-08
to O 0 3.130907089143875e-08
splice O 0 1.3401994465311873e-06
- O 0 2.5363235067743517e-07
site O 0 4.3294910767599504e-08
mutations O 0 6.984934941556276e-08
, O 0 3.114623225997093e-08
because O 0 7.971875248813376e-08
( O 0 2.0550862700474681e-07
i O 0 6.433547810047457e-07
) O 0 1.3083932515201013e-07
aberrant O 0 1.2462274980862276e-06
splicing O 0 9.426796054867737e-07
often O 0 1.0965060681655814e-07
generates O 0 2.612700598092488e-07
a O 0 1.43295324050996e-07
premature O 0 1.5806698456799495e-06
termination O 0 1.9326100755279185e-06
codon O 0 4.1756466089282185e-06
, O 0 2.792804139062355e-07
( O 0 1.345840985322866e-07
ii O 0 4.774593617185019e-05
) O 0 1.5652190654691367e-07
transcripts O 0 1.4114615396465524e-06
with O 0 1.200543948698396e-07
premature O 0 3.5708692394109676e-06
termination O 0 4.076223376614507e-06
codons O 0 3.3448873182351235e-06
can O 0 3.8777933752953686e-08
occur O 0 1.306000854128797e-07
at O 0 4.5673232307308353e-07
low O 0 8.504893003191683e-07
or O 0 6.953364817263719e-08
undetectable O 0 3.9920158201312006e-07
levels O 0 2.5513783086239528e-08
due O 0 2.943212784600746e-08
to O 0 1.3816285004963902e-08
nonsense O 0 8.222425549320178e-07
- O 0 2.2482025485714985e-07
mediated O 0 4.390751939808979e-07
mRNA O 0 5.130407032538642e-08
decay O 0 1.5967846422881848e-07
, O 0 1.0863883126432938e-08
and O 0 1.6452840867486884e-08
( O 0 1.1143914235844932e-08
iii O 0 2.5329927666462027e-06
) O 0 1.141569505591633e-08
the O 0 7.632144694014187e-09
levels O 0 1.9565865372328517e-08
of O 0 1.5797061436728654e-08
these O 0 9.01424357380165e-09
transcripts O 0 1.1775242114708817e-07
can O 0 4.0393084432821524e-09
be O 0 8.638114223913362e-09
increased O 0 5.015807147401574e-08
by O 0 1.8005820834332553e-07
cycloheximide O 0 6.46508124191314e-05
. O 0 1.1034532690246124e-05

A O 0 2.284500442328863e-05
deletion O 0 1.4997533980931621e-05
mutation O 0 2.9743898721790174e-06
in O 0 4.068589305461501e-07
COL17A1 O 0 0.0011177692795172334
in O 0 3.4489028166717617e-07
five O 0 5.352819698600797e-07
Austrian O 0 5.012559086026158e-06
families O 0 2.0560155178372952e-07
with O 0 1.1400309176679002e-06
generalized O 1 0.9172126650810242
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999674558639526
represents O 0 3.2573229873378295e-06
propagation O 0 6.778811894037062e-06
of O 0 4.982192649549688e-07
an O 0 1.6686621506778465e-07
ancestral O 0 4.1044340832741e-06
allele O 0 4.4669013732345775e-05
. O 0 3.0585619242629036e-05

Patients O 0 4.263559094397351e-05
with O 0 4.607739811035572e-06
generalized O 1 0.9407472014427185
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999997615814209
, O 0 1.2661531627600198e-06
a O 0 2.4051428226812277e-07
usually O 0 1.599004946228888e-07
nonlethal O 0 1.171776148112258e-05
form O 0 1.4040507494428311e-06
of O 0 1.756013989506755e-05
junctional B-Disease 1 0.9999940395355225
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999493360519409
, O 0 1.1754635806937586e-06
have O 0 4.0186813521359e-07
generalized O 0 1.7240645320271142e-05
blistering B-Disease 0 0.03429644927382469
, O 0 0.0011946344748139381
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 0.012542740441858768
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.0010360853048041463
and O 0 0.10222995281219482
dental B-Disease 1 0.9999996423721313
abnormalities I-Disease 1 0.9999998807907104
. O 0 0.0014267624355852604

Skin B-Disease 1 0.9999984502792358
fragility I-Disease 1 0.7919526696205139
in O 0 6.544840402966656e-07
most O 0 4.8785040007715e-08
cases O 0 1.3835641077264427e-08
is O 0 3.837617335022969e-09
due O 0 2.905873408565185e-08
to O 0 7.521605560611988e-09
mutations O 0 3.354670852218078e-08
in O 0 8.310268029276813e-09
the O 0 2.0610915640872918e-08
gene O 0 5.5829787015682086e-08
encoding O 0 5.807970637761173e-07
type O 0 7.245497272378998e-06
XVII O 1 0.9999446868896484
collagen O 0 0.004830599296838045
( O 0 3.163398787364713e-06
COL17A1 O 0 0.009247301146388054
) O 0 3.492357791401446e-06
. O 0 1.9481358322082087e-05

Recently O 0 2.8297907192609273e-05
, O 0 9.962816420738818e-07
we O 0 5.390378419178887e-07
reported O 0 6.116458735050401e-07
five O 0 1.9561525732569862e-07
Austrian O 0 2.7675127967086155e-06
families O 0 1.5467506386812602e-07
with O 0 6.272288146647043e-07
generalized O 1 0.7927971482276917
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
who O 0 2.2118481410871027e-06
share O 0 1.4048061984794913e-06
the O 0 1.041178620653227e-06
same O 0 1.850119701884978e-06
COL17A1 O 0 0.0011218885192647576
mutation O 0 2.139530988642946e-05
. O 0 2.424378544674255e-05

Affected O 0 1.2336608961049933e-05
individuals O 0 1.9133054252051807e-07
in O 0 4.3332665455864117e-08
three O 0 4.772934403263207e-08
families O 0 4.743291981412767e-09
are O 0 6.4665650612028e-09
homozygous O 0 9.733924599686361e-08
for O 0 3.831577899404692e-08
4003delTC O 0 1.8312005067855353e-06
, O 0 5.739714836749954e-08
whereas O 0 8.166310294654977e-08
those O 0 2.2251905207326672e-08
in O 0 2.2661893694930768e-08
two O 0 5.1044434457026e-08
others O 0 7.288802095217761e-08
are O 0 1.0025056695894818e-07
compound O 0 5.408151537267258e-06
heterozygotes O 0 7.411970000248402e-05
. O 0 2.801751543302089e-05

To O 0 5.597692620540329e-07
determine O 0 7.130570338631514e-07
if O 0 1.0592732024861107e-07
the O 0 7.253215272839952e-08
occurrence O 0 2.469037951868813e-07
of O 0 2.372313900877998e-07
4003delTC O 0 4.830338639294496e-06
in O 0 5.26083354657203e-08
these O 0 4.89546856385914e-08
unrelated O 0 2.613198830658803e-07
families O 0 1.9588904720535538e-08
signifies O 0 1.0471419642499313e-07
propagation O 0 7.005929205661232e-07
of O 0 8.361578807125625e-08
an O 0 4.019696930868122e-08
ancestral O 0 6.070446261219331e-07
allele O 0 3.2978916806314373e-06
or O 0 3.6602554587261693e-07
a O 0 4.1408463857806055e-07
mutational O 0 1.887102916953154e-05
hot O 0 3.576877134037204e-05
spot O 0 3.4271175536559895e-05
, O 0 1.8342576879604167e-07
haplotypes O 0 7.207223688965314e-07
were O 0 5.104657319066064e-08
determined O 0 1.2694609097252396e-07
for O 0 5.0913360638560334e-08
polymorphisms O 0 4.822624077860382e-07
both O 0 1.2334864152308e-07
within O 0 4.3306476982252207e-07
and O 0 1.5551104297628626e-06
flanking O 0 0.00046618792111985385
COL17A1 O 1 0.9830535054206848
. O 0 8.953484211815521e-05

Five O 0 4.936216282658279e-05
intragenic O 0 0.00024643720826134086
polymorphisms O 0 5.70603560845484e-06
were O 0 4.972513920620258e-07
chosen O 0 8.280192673737474e-07
based O 0 3.4227093692607014e-07
on O 0 8.119062613332062e-07
their O 0 1.3081216820864938e-06
informativeness O 0 0.00030070694629102945
. O 0 3.62961545761209e-05

One O 0 1.2089670917703188e-06
of O 0 2.400202561148035e-07
these O 0 3.23315312300565e-08
, O 0 2.56554972821732e-08
not O 0 1.6704987615412392e-08
previously O 0 1.0499118019424714e-07
reported O 0 7.835269855149818e-08
, O 0 4.662742725258795e-08
was O 0 9.706667469799868e-07
2988 O 0 4.542117949313251e-06
A O 0 8.020938935260347e-07
or O 0 1.5260415864304377e-07
C O 0 1.5039155186968856e-05
that O 0 1.669785198998852e-08
introduces O 0 9.382474530639229e-08
a O 0 2.454348191349709e-08
new O 0 3.085590449813935e-08
restriction O 0 6.501456084606616e-08
site O 0 9.962192137891179e-08
for O 0 1.5473437997570727e-07
Eco0109 O 0 2.537275940994732e-05
I O 0 4.496331530390307e-05
. O 0 1.9185406927135773e-05

All O 0 1.6324373746101628e-06
the O 0 5.475307034430443e-07
4003delTC O 0 5.277856871543918e-06
alleles O 0 6.410592732208897e-07
showed O 0 1.1303789904104633e-07
the O 0 3.182736207918424e-08
same O 0 4.2645318387712905e-08
haplotype O 0 9.071109730030003e-07
for O 0 3.8429295301511956e-08
these O 0 5.030149097251524e-08
five O 0 4.612144550719677e-07
polymorphic O 0 7.059772997308755e-06
markers O 0 8.005464223970193e-06
. O 0 1.4580085007764865e-05

Fourteen O 0 0.0001295596593990922
microsatellite O 0 0.0001104360053432174
polymorphisms O 0 6.038416813680669e-06
were O 0 3.952731049139402e-07
selected O 0 3.272344599736243e-07
based O 0 6.96068980232667e-08
on O 0 7.217830955141835e-08
their O 0 2.644556573727641e-08
high O 0 3.7080556012369925e-06
heterozygosity O 0 1.4359275155584328e-05
and O 0 6.185984346984696e-08
their O 0 4.518113172480298e-08
location O 0 2.9605382678710157e-07
within O 0 5.772287750005489e-07
10q23 O 0 1.8316532077733427e-05
- O 0 1.8503265891922638e-05
q25 O 0 4.603471825248562e-05
near O 0 3.088747325818986e-05
COL17A1 O 0 0.006374872289597988
. O 0 9.736242645885795e-05

Three O 0 1.1723351235559676e-05
families O 0 8.871666636878217e-07
shared O 0 3.122009275102755e-06
microsatellite O 0 0.00016332355153281242
polymorphisms O 0 3.89441083825659e-05
covering O 0 2.6594905648380518e-05
at O 0 3.7760873965453357e-06
most O 0 1.6294885085699207e-07
19 O 0 1.917129793582717e-06
cM O 0 4.538606390269706e-06
, O 0 9.00235690437512e-08
whereas O 0 2.0986111337606417e-07
the O 0 8.292885667060546e-08
others O 0 5.4369486690575286e-08
shared O 0 6.579710998266819e-08
smaller O 0 4.629158212310358e-08
regions O 0 5.0287582098462735e-08
consistent O 0 3.0903763104106474e-07
with O 0 3.678093563053153e-08
cross O 0 3.6632656019719434e-07
- O 0 1.0729044106483343e-06
over O 0 4.744316584037733e-08
events O 0 1.7750176439790266e-08
during O 0 1.888819056716784e-08
passage O 0 1.2703492480170553e-08
of O 0 1.3601487047765204e-08
this O 0 7.547299674115493e-09
mutation O 0 4.849142243301685e-08
through O 0 3.969934425640531e-08
several O 0 1.8999627116045303e-07
generations O 0 3.984727300121449e-06
. O 0 6.618283805437386e-06

These O 0 7.33889578441449e-07
results O 0 1.559957354402286e-06
indicate O 0 2.0366738340271695e-07
that O 0 3.370216461462405e-08
4003delTC O 0 2.5613924208300887e-06
occurs O 0 9.0414879139189e-08
on O 0 1.0361946323200755e-07
a O 0 4.941021103377352e-08
single O 0 8.652959593291598e-08
ancestral O 0 7.723938324488699e-07
allele O 0 2.6679588245315244e-06
. O 0 9.98181803879561e-07
. O 0 1.0745022336777765e-05

The O 0 1.7736994777806103e-05
haptoglobin O 0 0.0002865342830773443
- O 0 1.3160250091459602e-05
gene O 0 7.222704994092055e-07
deletion O 0 1.925224296428496e-06
responsible O 0 2.0493239389907103e-06
for O 0 1.5759044345031725e-06
anhaptoglobinemia B-Disease 0 0.002072068629786372
. O 0 6.589391705347225e-05

We O 0 1.8893902051786426e-06
have O 0 1.2658038883728295e-07
found O 0 7.482458386220969e-08
an O 0 5.93276645588503e-08
allelic O 0 5.2428358685574494e-06
deletion O 0 1.6091410088847624e-06
of O 0 5.674771159647207e-07
the O 0 1.998846528294962e-06
haptoglobin O 0 0.014727035537362099
( O 0 9.09725542896922e-07
Hp O 0 2.176115958718583e-05
) O 0 6.771245608661047e-08
gene O 0 4.405629283610324e-08
from O 0 1.092826806825542e-08
an O 0 1.575658892249976e-08
individual O 0 6.497884896816686e-08
with O 0 6.13365614299255e-07
anhaptoglobinemia B-Disease 0 0.0012822657590731978
. O 0 2.771541585389059e-05

The O 0 1.6381423847633414e-05
Hp O 0 7.418786844937131e-05
gene O 0 8.68418169375218e-07
cluster O 0 3.40930432685127e-06
consists O 0 1.0340864946556394e-06
of O 0 3.230928200537164e-07
coding O 0 1.667371861913125e-06
regions O 0 1.2707315022453258e-07
of O 0 2.2332186233597895e-07
the O 0 3.5144080356985796e-07
alpha O 0 5.238907306193141e-06
chain O 0 3.073394339025981e-07
and O 0 7.712015559491192e-08
beta O 0 5.249306695986888e-07
chain O 0 6.568576083054722e-08
of O 0 3.769937606534768e-08
the O 0 1.0981720777181181e-07
haptoglobin O 0 5.573717771767406e-06
gene O 0 2.055786296750739e-07
( O 0 8.894100744782918e-08
Hp O 0 5.7354254749952815e-06
) O 0 3.928850489387514e-08
and O 0 3.2557029072677324e-08
of O 0 1.5426716970523557e-07
the O 0 1.281110826312215e-07
alpha O 0 2.45921319219633e-06
chain O 0 2.2282149814145669e-07
and O 0 4.536834907753473e-08
beta O 0 6.710124011988228e-07
chain O 0 2.0219289353917702e-07
of O 0 8.367083381699558e-08
the O 0 1.8670347401439358e-07
haptoglobin O 0 2.3240609152708203e-05
- O 0 1.5778202850924572e-06
related O 0 1.7118506434599112e-07
gene O 0 2.812374191307754e-07
( O 0 1.460040124356965e-07
Hpr O 0 1.1032798283849843e-05
) O 0 8.375818083550257e-08
, O 0 4.74250718696112e-08
in O 0 3.791151925724989e-08
tandem O 0 1.4466693301073974e-06
from O 0 4.230037475849713e-08
the O 0 1.9143986662584211e-07
5 O 0 3.7723225432273466e-06
side O 0 1.9333407180965878e-05
. O 0 1.3209539247327484e-05

Southern O 0 0.00011136110697407275
blot O 0 4.6972898417152464e-05
and O 0 9.258845921067405e-07
PCR O 0 4.708573214884382e-06
analyses O 0 6.031793873262359e-07
have O 0 2.3950892824586845e-08
indicated O 0 8.457578104525965e-08
that O 0 7.373788690756555e-09
the O 0 2.6212251924562224e-08
individual O 0 1.636233548651944e-08
with O 0 2.572723545313238e-08
anhaptoglobinemia B-Disease 0 7.87061799201183e-06
was O 0 3.0907418135939224e-07
homozygous O 0 5.346758769064763e-08
for O 0 5.947152104113229e-09
the O 0 1.4763908318116137e-08
gene O 0 2.8063450230320086e-08
deletion O 0 6.669547758519911e-08
and O 0 1.1916949205215133e-08
that O 0 6.139423192053073e-09
the O 0 2.8945555285986302e-08
gene O 0 1.1615569661671543e-07
deletion O 0 7.479119403797085e-07
was O 0 6.137980221865291e-07
included O 0 1.9570146037040104e-07
at O 0 1.0137750905414578e-06
least O 0 5.2404637074232596e-08
from O 0 1.6051217244239524e-08
the O 0 1.697285227919565e-07
promoter O 0 2.010040043387562e-05
region O 0 1.1657400591502665e-06
of O 0 2.0124327875237213e-06
Hp O 0 4.686332613346167e-05
to O 0 6.075021588003438e-07
Hpr O 0 3.406478572287597e-05
alpha O 0 4.6207214836613275e-06
but O 0 5.8475531972135286e-08
not O 0 1.7755931835949923e-08
to O 0 5.748874798428005e-08
Hpr O 0 7.161877874750644e-06
beta O 0 7.383428055618424e-06
( O 0 8.545486593902751e-07
Hpdel O 0 7.151756290113553e-05
) O 0 2.2615661237068707e-06
. O 0 1.4081571862334386e-05

In O 0 1.0419464615551988e-06
addition O 0 4.3450853581816773e-07
, O 0 6.138230901342467e-08
we O 0 2.9061505202321314e-08
found O 0 2.0326082150745606e-08
seven O 0 9.037315606974516e-08
individuals O 0 1.0453036658475412e-08
with O 0 2.078358818380366e-08
hypohaptoglobinemia B-Disease 0 7.862417987780645e-06
in O 0 3.954215443968678e-08
three O 0 3.104327106484561e-08
families O 0 1.6488646004120255e-09
, O 0 6.294253118710458e-09
and O 0 1.3873350468429635e-08
the O 0 1.9455045574545693e-08
genotypes O 0 5.446751174531528e-07
of O 0 1.0562146712800313e-07
six O 0 1.2527127069006383e-07
of O 0 7.653007116914523e-08
the O 0 6.381910822028658e-08
seven O 0 1.6202560004785482e-07
individuals O 0 5.978724626487519e-09
were O 0 2.8931978590662766e-08
found O 0 2.13090682876782e-08
to O 0 3.099026102404423e-08
be O 0 6.868096988910111e-07
Hp2 O 0 0.004549864213913679
/ O 0 0.05534571409225464
Hpdel O 0 0.15874235332012177
. O 0 7.153530168579891e-05

The O 0 7.384160198853351e-06
phenotypes O 0 2.9124463253538124e-05
and O 0 5.07361619384028e-07
genotypes O 0 1.075574618880637e-05
in O 0 7.043358607461414e-08
one O 0 2.039182334101497e-08
of O 0 2.5144306192714794e-08
these O 0 7.399317603073996e-09
three O 0 1.5398986974446416e-08
families O 0 6.532714813545226e-09
showed O 0 4.735032632652292e-08
the O 0 2.3180373176501234e-08
father O 0 6.632758697833196e-08
to O 0 1.5753222726289096e-08
be O 0 1.537715661470429e-07
hypohaptoglobinemic B-Disease 0 5.999292989145033e-05
( O 0 6.30351792096917e-07
Hp2 O 0 6.81205274304375e-05
) O 0 1.3527265707580227e-07
and O 0 3.4821570693566173e-07
Hp2 O 0 0.0014025830896571279
/ O 0 0.00029907634598203003
Hpdel O 0 0.002914506709203124
, O 0 1.8416861280456942e-07
the O 0 7.212312880255922e-08
mother O 0 3.043308893779795e-08
to O 0 7.788688805021593e-09
be O 0 5.8919216172625966e-08
Hp2 O 0 6.578954071301268e-06
- O 0 8.576486720812682e-07
1 O 0 8.136053679663746e-07
and O 0 2.2908594132786675e-07
Hp1 O 0 0.0001879050541901961
/ O 0 1.893576336442493e-05
Hp2 O 0 5.40121145604644e-05
, O 0 4.924142871232107e-08
one O 0 7.15323578148741e-09
of O 0 1.8670519352781412e-08
the O 0 2.366914664264641e-08
two O 0 1.3471258775155093e-08
children O 0 6.5802603366194035e-09
to O 0 6.686676989886564e-09
be O 0 1.2174417918231484e-07
hypohaptoglobinemic B-Disease 0 2.1202449715929106e-05
( O 0 5.162456204743648e-07
Hp2 O 0 3.23069907608442e-05
) O 0 1.363078752092406e-07
and O 0 3.010246700796415e-07
Hp2 O 0 0.0006516991415992379
/ O 0 0.00019454416178632528
Hpdel O 0 0.01980496384203434
, O 0 1.2587628361870884e-07
and O 0 3.94585271124015e-08
the O 0 4.684029164536696e-08
other O 0 9.961086178122969e-09
child O 0 1.7638162930211365e-08
to O 0 5.416223913812246e-09
be O 0 4.1914873349924164e-08
Hp1 O 0 6.2421868278761394e-06
and O 0 6.943219545973989e-07
Hp1 O 0 0.02338167279958725
/ O 0 0.0011338817421346903
Hpdel O 0 0.003978373948484659
, O 0 3.371274601704499e-07
showing O 0 3.8684416381329356e-07
an O 0 6.178095901532288e-08
anomalous O 0 3.600733180064708e-06
inheritance O 0 8.419181654062413e-07
of O 0 3.3419444207538618e-06
Hp O 0 0.004606492817401886
phenotypes O 0 6.586897507077083e-05
in O 0 2.8457969847295317e-07
the O 0 6.70034637550998e-07
child O 0 2.21772825170774e-06
with O 0 1.019249339151429e-06
Hp1 O 0 0.004977204371243715
. O 0 7.036349416011944e-05

The O 0 2.158039205824025e-05
Hp2 O 0 0.18419107794761658
/ O 0 0.00967280101031065
Hpdel O 0 0.004514806903898716
individuals O 0 1.2424924022980122e-07
had O 0 2.3687894668000808e-07
an O 0 4.596113356569731e-08
extremely O 0 3.5671689602168044e-07
low O 0 2.2193935365066864e-06
level O 0 9.684239557827823e-06
of O 0 8.113660214803531e-07
Hp O 0 1.8541681129136123e-05
( O 0 2.58755612492223e-08
mean O 0 8.128997563972007e-08
+ O 0 1.589525169265471e-07
/ O 0 2.0137082401561202e-07
- O 0 1.64416803727363e-07
SD O 0 2.586434220575029e-06
= O 0 3.1465447136724833e-07
0 O 0 2.6555863996691187e-07
. O 0 5.2532531213955735e-08
049 O 0 3.61749880539719e-06
+ O 0 7.773455763526727e-07
/ O 0 9.261557920581254e-07
- O 0 5.640133053930185e-07
0 O 0 3.611269505654491e-07
. O 0 1.175015924559375e-07
043 O 0 9.272444003727287e-06
mg O 0 2.4672572180861607e-05
/ O 0 2.8486635983426822e-06
ml O 0 1.4774071814827039e-06
; O 0 2.4934788456221213e-08
n O 0 1.494624086717522e-07
= O 0 2.0941686784681224e-07
6 O 0 2.9268142043292755e-07
) O 0 1.188224629800061e-08
, O 0 1.1101697339199745e-08
compared O 0 1.195907373130467e-08
with O 0 3.1904536790250404e-09
the O 0 1.2113205549724171e-08
level O 0 2.8542606855808117e-07
( O 0 4.4883750049962146e-09
1 O 0 3.857948271956957e-08
. O 0 8.008600893560924e-09
64 O 0 5.823800464099804e-08
+ O 0 1.2504376911692816e-07
/ O 0 2.428020593470137e-07
- O 0 5.814510828372477e-08
1 O 0 9.441806270160669e-08
. O 0 3.0179151622178324e-08
07 O 0 3.2750278933235677e-06
mg O 0 2.00784852495417e-05
/ O 0 2.316120799150667e-06
ml O 0 1.708971240077517e-06
) O 0 1.592621323709409e-08
obtained O 0 8.041973131867053e-08
from O 0 4.4688327704989206e-08
52 O 0 8.640398050374642e-07
healthy O 0 1.170578343590023e-06
volunteers O 0 3.249124631565792e-07
having O 0 8.14582051589241e-07
phenotype O 0 1.340665858151624e-05
Hp2 O 0 4.215143053443171e-05
, O 0 1.9144991370012576e-07
whereas O 0 4.996614393348864e-07
the O 0 1.2153732598108036e-07
serum O 0 8.101815183181316e-07
Hp O 0 2.6787331535160774e-06
level O 0 6.997202035563532e-07
of O 0 2.8486907055480515e-08
an O 0 5.535304214987491e-09
individual O 0 6.027616183956752e-09
with O 0 2.9330696094120867e-08
Hp1 O 0 0.00010748906061053276
/ O 0 1.8472268493496813e-05
Hpdel O 0 3.9113976527005434e-05
was O 0 3.006734687005519e-06
0 O 0 4.493852429732215e-06
. O 0 6.7368755480856635e-06

50 O 0 2.563907764852047e-05
mg O 0 0.012079084292054176
/ O 0 0.00025283507420681417
ml O 0 8.971277566161007e-05
, O 0 1.1074165939817249e-07
which O 0 1.6510684375248275e-08
was O 0 7.67923964417605e-08
approximately O 0 2.477942295797675e-08
half O 0 1.247404757265258e-08
the O 0 7.296991899607974e-09
level O 0 1.4736203013399063e-07
of O 0 8.740692436504105e-08
Hp O 0 2.006172508117743e-06
in O 0 3.041173357587468e-08
control O 0 7.801402261975454e-07
sera O 0 4.471041847864399e-06
from O 0 2.921099806485472e-08
the O 0 1.1574876168651826e-07
Hp1 O 0 1.3218865205999464e-05
phenotype O 0 1.0185020755670848e-06
( O 0 2.6791411755766603e-08
1 O 0 1.6345234143955167e-07
. O 0 3.007680859923312e-08
26 O 0 3.418537062316318e-07
+ O 0 3.067991372063261e-07
/ O 0 3.3023277978827537e-07
- O 0 1.412763594998978e-07
0 O 0 1.4510133894418686e-07
. O 0 3.520267455314752e-08
33 O 0 5.164731646800647e-07
mg O 0 9.9314374892856e-06
/ O 0 1.1830887842734228e-06
ml O 0 7.699147204220935e-07
; O 0 1.892547807358369e-08
n O 0 1.0392268734449317e-07
= O 0 2.121158928503064e-07
9 O 0 2.3820557260023634e-07
) O 0 1.277280947675763e-08
, O 0 1.961792150950714e-08
showing O 0 1.099068995813468e-07
a O 0 1.4492168531887728e-07
gene O 0 7.232127927636611e-07
- O 0 3.501649189274758e-06
dosage O 0 3.136109444312751e-05
effect O 0 1.477340265410021e-05
. O 0 1.2673535820795223e-05

The O 0 1.7881293388199992e-06
other O 0 2.0263766487005341e-07
allele O 0 3.4990289350389503e-06
( O 0 2.8218687475600746e-07
Hp2 O 0 1.462588716094615e-05
) O 0 4.468014580538693e-08
of O 0 9.160568481547671e-08
individuals O 0 4.5251852043293184e-08
with O 0 1.8404887214273913e-07
Hp2 O 1 0.9499417543411255
/ O 0 0.4064750075340271
Hpdel O 0 0.15032126009464264
was O 0 4.817544549950981e-07
found O 0 1.4023853189826241e-08
to O 0 3.8957246317750105e-09
have O 0 6.6357799255456484e-09
, O 0 9.057986360971881e-09
in O 0 5.724220208946917e-09
all O 0 1.8489149766764967e-08
exons O 0 4.756258533689106e-07
, O 0 1.5978731227050957e-08
no O 0 2.3944405569409355e-08
mutation O 0 4.906442541141587e-08
, O 0 2.319673875206263e-08
by O 0 4.092720473636291e-08
DNA O 0 1.4874985936330631e-06
sequencing O 0 4.725095095636789e-06
. O 0 9.419495654583443e-06

On O 0 3.314928335385048e-06
the O 0 1.0775520564720864e-07
basis O 0 9.046456028727334e-08
of O 0 3.111185264970118e-08
the O 0 1.9103401527331698e-08
present O 0 2.1739674949117216e-08
study O 0 3.5372689666246515e-08
, O 0 1.2892104273021232e-08
the O 0 1.4745840992702597e-08
mechanism O 0 3.8569115190512093e-07
of O 0 2.755966761469608e-07
anhaptoglobinemia B-Disease 0 4.0814051317283884e-05
and O 0 9.144856960574543e-08
the O 0 9.474349838001217e-08
mechanism O 0 1.413390464222175e-06
of O 0 1.3805384924125974e-07
anomalous O 0 3.165317821185454e-06
inheritance O 0 4.131647699523455e-07
of O 0 5.493246248988726e-07
Hp O 0 7.061166252242401e-05
phenotypes O 0 1.3234896869107615e-05
were O 0 5.699557164007274e-07
well O 0 8.458350180262642e-07
explained O 0 6.571241556230234e-06
. O 0 1.076234366337303e-05

However O 0 4.780287326866528e-06
, O 0 6.085395511945535e-07
the O 0 2.99760728239562e-07
mechanism O 0 3.7357413020799868e-06
of O 0 1.6252064369837171e-06
hypohaptoglobinemia B-Disease 0 0.00013551872689276934
remains O 0 1.6021591363823973e-05
unknown O 0 0.00013878878962714225

ATM O 0 0.00027014411170966923
mutations O 0 1.768799302226398e-05
and O 0 2.3379241156362696e-06
phenotypes O 0 0.0002413973124930635
in O 0 2.8015698262606747e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.4964425645302981e-06
in O 0 1.1568750579726839e-07
the O 0 9.725258109938295e-08
British O 0 4.823644985663122e-07
Isles O 0 8.418065817750175e-07
: O 0 1.9065002021534383e-08
expression O 0 2.959108869049487e-08
of O 0 7.506272936552705e-08
mutant O 0 6.462732358158974e-07
ATM O 0 4.772889042214956e-06
and O 0 5.460310958937953e-08
the O 0 6.085876691486192e-08
risk O 0 4.848790808864578e-07
of O 0 6.127854248916265e-06
leukemia B-Disease 1 1.0
, O 1 0.9999978542327881
lymphoma B-Disease 1 1.0
, O 1 1.0
and O 1 1.0
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 0.006073928438127041

We O 0 6.962562110857107e-06
report O 0 5.447753892440232e-07
the O 0 1.3147662514256808e-07
spectrum O 0 9.89845489129948e-07
of O 0 1.707997228095337e-07
59 O 0 9.363163826492382e-07
ATM O 0 3.392789039935451e-06
mutations O 0 4.900359158455103e-07
observed O 0 9.57372208176821e-07
in O 0 2.4884388949431013e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.628697863357957e-07
patients O 0 4.482192039745314e-08
in O 0 1.9576205545490666e-08
the O 0 1.2322401232722768e-07
British O 0 4.897139660897665e-06
Isles O 0 8.852751489030197e-05
. O 0 2.463314558553975e-05

Of O 0 1.173858890979318e-05
51 O 0 1.712217999738641e-05
ATM O 0 3.843953527393751e-05
mutations O 0 1.4051491916688974e-06
identified O 0 3.1482377949032525e-07
in O 0 3.9518781136393955e-08
families O 0 1.1329104765422926e-08
native O 0 2.1108546022219343e-08
to O 0 1.5183340806856904e-08
the O 0 9.465716033218996e-08
British O 0 1.2965796258868068e-06
Isles O 0 3.2974860459944466e-06
, O 0 9.692980285080921e-08
11 O 0 3.8203114627322066e-07
were O 0 1.4955266181004845e-07
founder O 0 1.084535256268282e-06
mutations O 0 1.2950901862041064e-07
, O 0 3.079898647229129e-08
and O 0 2.5814090420794855e-08
2 O 0 6.030838903825497e-07
of O 0 9.474855744429078e-08
these O 0 3.398295334022805e-08
11 O 0 6.226872528714011e-07
conferred O 0 5.820246542498353e-07
a O 0 9.446092974485509e-08
milder O 0 5.564476396102691e-06
clinical O 0 3.5360187666810816e-06
phenotype O 0 5.828556481901614e-07
with O 0 1.0714300557879142e-08
respect O 0 3.834955819570496e-08
to O 0 5.697470939480809e-08
both O 0 2.4287139694934012e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 0.0006985068321228027
cellular O 0 0.014539308845996857
features O 0 2.0434170437511057e-05
. O 0 1.2833738765039016e-05

We O 0 5.1503770919225644e-06
report O 0 4.998015583623783e-07
, O 0 8.504618875804226e-08
in O 0 3.9405428253758146e-08
two O 0 8.111047833381235e-08
A B-Disease 1 0.9997262358665466
- I-Disease 1 0.9991229176521301
T I-Disease 1 0.9999997615814209
families O 0 4.057309510585583e-08
, O 0 3.061694897610323e-08
an O 0 1.355481860088048e-08
ATM O 0 1.7554561964061577e-06
mutation O 0 3.726958652805479e-07
( O 0 1.8598657902657578e-07
7271T O 0 4.528277713689022e-06
- O 0 4.48640139438794e-06
- O 0 2.6672007606975967e-06
> O 0 2.5704778181534493e-06
G O 0 6.194490197231062e-06
) O 0 9.964811198415191e-09
that O 0 1.998089249610757e-09
may O 0 1.3720301339503749e-08
be O 0 1.2207046928836007e-08
associated O 0 1.510892211342707e-08
with O 0 4.995297064880333e-09
an O 0 4.696291355799076e-09
increased O 0 7.731691908929861e-08
risk O 0 1.142250994234928e-06
of O 0 4.363547122920863e-05
breast B-Disease 1 0.9978183507919312
cancer I-Disease 0 0.00010798136645462364
in O 0 7.20762258765717e-08
both O 0 2.5911793954946916e-07
homozygotes O 0 5.693131242878735e-06
and O 0 1.7593332302112685e-07
heterozygotes O 0 2.1512557850655867e-06
( O 0 1.9635141512708287e-08
relative O 0 9.573916059935073e-08
risk O 0 4.033113043533376e-08
12 O 0 6.225839399576216e-08
. O 0 1.40224356570684e-08
7 O 0 1.5591689361826866e-07
; O 0 3.2690749662833696e-08
P O 0 4.74754415336065e-06
= O 0 9.028896670315589e-07
. O 0 9.725517458036848e-08
0025 O 0 1.685660390648991e-05
) O 0 2.4381391128258656e-08
, O 0 1.30800978936918e-08
although O 0 1.8965007342330864e-08
there O 0 1.9656123839695283e-08
is O 0 1.0873191236271396e-08
a O 0 5.605492958693503e-08
less O 0 1.1339025149936788e-06
severe O 1 0.9991267323493958
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 5.706519914383534e-06
in O 0 5.635098165868158e-09
terms O 0 9.418726243382025e-09
of O 0 1.2668455617870222e-08
the O 0 1.5506183004276863e-08
degree O 0 9.29371935853851e-07
of O 0 5.899360076000448e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.00042756478069350123

This O 0 1.2036797443215619e-06
mutation O 0 2.975870756927179e-06
( O 0 5.187057467992418e-07
7271T O 0 9.786775990505703e-06
- O 0 5.004372269468149e-06
- O 0 2.0684385617641965e-06
> O 0 2.4594360183982644e-06
G O 0 1.2706148481811397e-05
) O 0 2.617453453979124e-08
also O 0 7.754610287236119e-09
allows O 0 4.353145843793982e-09
expression O 0 1.0112625403735365e-08
of O 0 1.6717418560574515e-08
full O 0 7.197058948804624e-08
- O 0 1.4733730324678618e-07
length O 0 1.837212160182844e-08
ATM O 0 3.285045693246502e-07
protein O 0 5.123757063074663e-08
at O 0 9.912305642956198e-08
a O 0 1.641823210718485e-08
level O 0 2.7098337795905536e-07
comparable O 0 1.456267426647173e-07
with O 0 4.756510296743954e-09
that O 0 5.3467257288275505e-09
in O 0 2.6014717491307238e-08
unaffected O 0 1.0067554967463366e-06
individuals O 0 2.9236562681944633e-07
. O 0 5.79551624468877e-06

In O 0 1.3755460486208904e-06
addition O 0 4.392565529087733e-07
, O 0 7.566588777763172e-08
we O 0 3.770204060060678e-08
have O 0 1.439420227455912e-08
studied O 0 4.4468833948485553e-07
18 O 0 1.95268148672767e-06
A B-Disease 1 0.9999892711639404
- I-Disease 1 0.9999961853027344
T I-Disease 1 1.0
patients O 0 3.3977389080064313e-07
, O 0 2.0620275265059718e-08
in O 0 1.012540273848117e-08
15 O 0 9.938658251940069e-08
families O 0 4.432092026718237e-09
, O 0 1.7689643527774024e-08
who O 0 3.236126744354806e-08
developed O 0 1.1860761333082337e-05
leukemia B-Disease 1 0.9999997615814209
, O 0 0.00199632509611547
lymphoma B-Disease 1 1.0
, O 0 8.459795935777947e-05
preleukemic O 1 0.7992992997169495
T O 0 0.3344356417655945
- O 0 1.77340170921525e-05
cell O 0 3.526206000969978e-06
proliferation O 0 3.0555747798644006e-06
, O 0 2.1109316605816275e-07
or O 0 1.3816760656482074e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 0.006231244187802076
mostly O 0 1.2769029353876249e-06
in O 0 6.154351694931393e-07
childhood O 0 1.7329859474557452e-05
. O 0 1.1315226402075496e-05

A O 0 2.0457935534068383e-05
wide O 0 4.589587661030237e-06
variety O 0 4.580383006214106e-07
of O 0 4.326123530518089e-07
ATM O 0 1.1867671673826408e-05
mutation O 0 2.564297858498321e-07
types O 0 1.478555873291043e-07
, O 0 4.230650674230674e-08
including O 0 6.904664928697457e-08
missense O 0 3.1561130526824854e-06
mutations O 0 6.99847703344858e-07
and O 0 1.5275603004738514e-07
in O 0 2.2255093767853396e-07
- O 0 3.0282621082733385e-05
frame O 0 0.00013199994282331318
deletions O 0 2.8092106276744744e-06
, O 0 2.275940573781554e-07
were O 0 1.0404313570688828e-06
seen O 0 1.3471870943249087e-06
in O 0 1.2150094619300944e-07
these O 0 3.6613306519939215e-07
patients O 0 1.9550795968825696e-06
. O 0 1.0864300747925881e-05

We O 0 1.6234203030762728e-06
also O 0 6.045603129223309e-08
show O 0 3.126974235101443e-08
that O 0 2.3120312331315063e-09
25 O 0 2.3891214340210354e-08
% O 0 8.135570439549156e-09
of O 0 4.034282596876437e-08
all O 0 1.2748328970246803e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 6.648793373642548e-07
carried O 0 1.9594926925492473e-07
in O 0 7.941053326021574e-08
- O 0 2.598754690552596e-06
frame O 0 3.822195139946416e-06
deletions O 0 3.599544697863166e-07
or O 0 8.2136423884549e-08
missense O 0 2.440594698782661e-06
mutations O 0 2.112931554165698e-07
, O 0 3.2945703054565456e-08
many O 0 5.928917357067576e-09
of O 0 2.587407976761824e-08
which O 0 1.6621019227613942e-08
were O 0 7.070453733604154e-08
also O 0 1.8953002722810197e-08
associated O 0 3.9941934204534846e-08
with O 0 2.2102588204120366e-08
expression O 0 9.806041134652332e-08
of O 0 5.669323854817776e-07
mutant O 0 8.685849024914205e-06
ATM O 0 5.9102207160321996e-05
protein O 0 1.1830112271127291e-05
. O 0 9.601786587154493e-06

The O 0 1.315630925091682e-05
DMPK O 0 0.0005333968438208103
gene O 0 3.4822542147594504e-06
of O 0 1.691776924417354e-05
severely O 1 0.9999995231628418
affected O 1 0.9999998807907104
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9920541048049927
is O 0 1.6716085156076588e-06
hypermethylated O 0 4.9533478886587545e-05
proximal O 0 1.2416362551448401e-05
to O 0 7.509910204817061e-08
the O 0 3.674987567592325e-07
largely O 0 1.4234002492230502e-06
expanded O 0 4.028261628263863e-06
CTG O 0 0.00039895783993415534
repeat O 0 7.304982136702165e-05
. O 0 2.5573730454198085e-05

Using O 0 1.0230922271148302e-05
methylation O 0 2.884176683437545e-05
- O 0 2.022384069277905e-05
sensitive O 0 2.0141415006946772e-06
restriction O 0 1.7064682822365285e-07
enzymes O 0 3.333472875510779e-07
, O 0 2.5744316900500053e-08
we O 0 2.6577849254749708e-08
characterized O 0 6.672856756040346e-08
the O 0 2.938764787074888e-08
methylation O 0 1.9264477657543466e-07
pattern O 0 2.1210497891388513e-07
on O 0 6.788469875118608e-08
the O 0 3.778093926598558e-08
5 O 0 1.5101524297733704e-07
side O 0 1.593899980889546e-07
of O 0 1.352449174873982e-07
the O 0 1.6428326432560425e-07
CTG O 0 3.0249399060267024e-05
repeat O 0 3.5533469144866103e-07
in O 0 1.9544904361623594e-08
the O 0 5.8439965755496814e-08
DMPK O 0 5.4394445214711595e-06
gene O 0 4.468866521278869e-08
of O 0 5.367296296299173e-08
normal O 0 3.0199828415788943e-07
individuals O 0 1.4761289079956441e-08
and O 0 7.365442655782317e-08
of O 0 1.1919494227186078e-06
patients O 0 1.923192940012086e-06
affected O 0 6.550100351887522e-06
with O 1 0.9990046620368958
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.796435678144917e-05
showing O 0 2.0751504052896053e-06
expansions O 0 1.9262176920165075e-06
of O 0 4.189521121134021e-07
the O 0 8.282008820970077e-07
repetitive O 0 1.968244214367587e-05
sequence O 0 4.086818535142811e-06
. O 0 1.163753495347919e-05

The O 0 9.629223313822877e-06
gene O 0 4.6356135499081574e-06
segment O 0 2.3206443984236103e-06
analyzed O 0 7.604740517308528e-07
corresponds O 0 4.246844866884203e-07
to O 0 6.3092322477587e-08
the O 0 2.446501525810163e-07
genomic O 0 4.145771981711732e-06
SacI O 0 0.00014182903396431357
- O 0 1.1569017260626424e-05
HindIII O 0 2.5659574021119624e-05
fragment O 0 2.2432711830333574e-06
carrying O 0 1.7412720580978203e-06
exons O 0 8.260432878159918e-06
11 O 0 9.20115508051822e-06
- O 0 1.203705232910579e-05
15 O 0 1.0254423614242114e-05
. O 0 2.182615025958512e-05

There O 0 5.033824436395662e-06
is O 0 7.949514611027553e-07
constitutive O 0 1.0390121133241337e-05
methylation O 0 2.650556325534126e-06
in O 0 3.1883266160548374e-07
intron O 0 6.99553356753313e-06
12 O 0 2.086506810883293e-06
at O 0 8.759148499848379e-07
restriction O 0 6.616294712102899e-08
sites O 0 9.094829067635146e-08
of O 0 1.3162905077024334e-07
SacII O 0 2.239270725112874e-05
and O 0 3.53577235046032e-07
HhaI O 0 2.3112084818421863e-05
, O 0 9.397034972380425e-08
localized O 0 4.5828429051653075e-07
1 O 0 5.052982601227995e-07
, O 0 6.508763306101173e-08
159 O 0 2.2129043486529554e-07
- O 0 2.3136296078973828e-07
1 O 0 2.9821870839441544e-07
, O 0 1.145776735711479e-07
232 O 0 9.137862093666627e-07
bp O 0 1.0148246474273037e-06
upstream O 0 1.3765603057436238e-07
of O 0 1.2161942208877008e-07
the O 0 2.746293148447876e-07
CTG O 0 0.00048721092753112316
repeat O 0 2.820189365593251e-06
, O 0 7.742288232748251e-08
whereas O 0 7.159339077134064e-08
most O 0 1.4729002906221922e-08
, O 0 4.025241473470942e-09
if O 0 2.3756561162713297e-09
not O 0 1.7321201140063636e-09
all O 0 3.297699446846991e-09
, O 0 6.1192335643056595e-09
of O 0 7.424623582608092e-09
the O 0 9.29102483837596e-09
other O 0 2.662603693082133e-09
sites O 0 1.990433240450784e-08
of O 0 6.61653416500485e-08
SacII O 0 1.6248766769422218e-05
, O 0 2.791888391584507e-07
HhaI O 0 3.383607690921053e-05
, O 0 1.207996263019595e-07
and O 0 9.923732591232692e-08
HpaII O 0 1.2607330063474365e-05
in O 0 1.477272437711008e-08
this O 0 3.946302395974044e-09
region O 0 3.934700032459659e-08
are O 0 4.1360859626138335e-08
unmethylated O 0 3.3805770272010705e-06
, O 0 4.9880537034141526e-08
in O 0 1.5746463688515178e-08
normal O 0 1.5202589054297277e-07
individuals O 0 7.595431839035882e-09
and O 0 2.2711569513944596e-08
most O 0 1.9235686821161835e-08
of O 0 1.1830588420025379e-07
the O 0 7.062029112603341e-07
patients O 0 2.0196926016069483e-06
. O 0 8.680333849042654e-06

In O 0 8.771737043389294e-07
a O 0 1.513787424300972e-07
number O 0 4.347389648273747e-08
of O 0 2.2712072222930146e-07
young O 0 5.0802016630768776e-05
and O 0 6.86096109348e-06
severely O 1 0.9908983111381531
affected O 0 1.5983248431439279e-06
patients O 0 1.0129753036380862e-07
, O 0 2.8617936465025196e-08
however O 0 5.372550404558751e-08
, O 0 1.8806872503773775e-08
complete O 0 5.233910371771344e-08
methylation O 0 1.1989386905497668e-07
of O 0 2.4654584152017378e-08
these O 0 7.52826423422448e-09
restriction O 0 2.0707693337840283e-08
sites O 0 3.2636549462949915e-08
was O 0 1.1929951426736807e-07
found O 0 4.5403496073959104e-08
in O 0 5.987422468933801e-08
the O 0 5.153611937203095e-07
mutated O 0 1.2719520782411564e-05
allele O 0 7.737324631307274e-05
. O 0 3.937682049581781e-05

In O 0 2.07297262022621e-06
most O 0 1.7649645656092616e-07
of O 0 1.1223806239968326e-07
these O 0 2.2781113884207116e-08
patients O 0 2.5095244993167398e-08
, O 0 1.5116965457195874e-08
the O 0 2.4637566653495924e-08
onset O 0 0.0019138504285365343
of O 0 2.800696347549092e-05
the O 0 0.03542675822973251
disease O 1 1.0
was O 1 0.9994891881942749
congenital O 1 1.0
. O 0 0.003991377539932728

Preliminary O 0 4.173648630967364e-05
in O 0 1.9651122329378268e-06
vivo O 0 3.723457484738901e-05
footprinting O 0 7.575189374620095e-05
data O 0 6.655315019088448e-07
gave O 0 2.720011309520487e-07
evidence O 0 1.531720670300274e-07
for O 0 6.61364509824125e-08
protein O 0 5.489198429131648e-07
- O 0 9.4644309456271e-07
DNA O 0 2.46561910444143e-07
contact O 0 1.53753248355315e-07
in O 0 3.145968108242414e-08
normal O 0 1.6564723637202405e-07
genes O 0 5.6008119031503156e-08
at O 0 2.1885482226480235e-07
an O 0 2.1748052247971827e-08
Sp1 O 0 3.0044470804568846e-06
consensus O 0 9.323654239778989e-07
binding O 0 3.3477357419542386e-07
site O 0 1.6927072010730626e-07
upstream O 0 1.4211634891125868e-07
of O 0 9.010259560682243e-08
the O 0 2.1726705767832755e-07
CTG O 0 0.00012710496957879514
repeat O 0 1.4008902553541702e-06
and O 0 6.313011624570208e-08
for O 0 2.4745604676468247e-08
a O 0 1.8395406087279298e-08
significant O 0 1.631895152343077e-08
reduction O 0 7.139662017152659e-08
of O 0 2.044513891519273e-08
this O 0 4.584554069708702e-09
interaction O 0 2.4435022893953828e-08
in O 0 4.1889518520576985e-09
cells O 0 2.0691190982802254e-08
with O 0 6.810241703902875e-09
a O 0 7.184865324916245e-08
hypermethylated O 0 7.912635737739038e-06
DMPK O 0 4.568781514535658e-05
gene O 0 6.884307026666647e-07
. O 0 4.979760319656634e-07
. O 0 6.698501692881109e-06

The O 0 0.00023418448108714074
hemochromatosis B-Disease 1 1.0
gene O 0 4.4255662032810505e-06
product O 0 6.036455033608945e-07
complexes O 0 5.468303925226792e-07
with O 0 4.962839028621602e-08
the O 0 2.7581936024034803e-07
transferrin O 0 3.8771381696278695e-06
receptor O 0 7.223408147183363e-07
and O 0 7.004226176832162e-08
lowers O 0 2.4425335709565843e-07
its O 0 1.0764177993394242e-08
affinity O 0 2.545196053915788e-08
for O 0 5.704919558979782e-08
ligand O 0 1.2072678146068938e-06
binding O 0 2.781284365482861e-06
. O 0 6.152600235509453e-06

We O 0 1.1861246093758382e-05
recently O 0 3.117576397926314e-06
reported O 0 5.474743147715344e-07
the O 0 8.938333451169456e-08
positional O 0 3.0703056381753413e-06
cloning O 0 2.7360482590665924e-07
of O 0 7.83906699552972e-08
a O 0 5.790118606796568e-08
candidate O 0 2.482645413692808e-07
gene O 0 2.2433396225096658e-06
for O 0 2.8591954105650075e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.999977707862854
HFE O 1 0.9999988079071045
. O 0 0.0005779091152362525

The O 0 2.4524213131371653e-06
gene O 0 5.848573323419259e-07
product O 0 1.4037385653864476e-07
, O 0 9.949280155296947e-08
a O 0 1.1835836488671703e-07
member O 0 2.4231141537711665e-07
of O 0 3.651107363111805e-07
the O 0 7.476152177332551e-07
major O 0 1.3008319001528434e-05
histocompatibility O 1 0.9930740594863892
complex O 0 1.278543822991196e-05
class O 0 1.4238524954635068e-06
I O 0 1.8387185264145955e-05
- O 0 4.6458508222713135e-06
like O 0 7.011457370253993e-08
family O 0 1.602842480963318e-08
, O 0 2.4080614835497727e-08
was O 0 1.0904889080620705e-07
found O 0 1.1539601274535016e-08
to O 0 8.011167729193858e-09
have O 0 3.381039448413503e-08
a O 0 2.1626651403039432e-07
mutation O 0 1.0963195791191538e-06
, O 0 9.99496364784136e-07
Cys O 0 0.2138797640800476
- O 0 0.00012652149598579854
282 O 0 1.4060236026125494e-05
- O 0 0.0001041106297634542
- O 0 0.00011094857472926378
> O 0 3.853790258290246e-05
Tyr O 0 0.0013497022446244955
( O 0 1.7309889699390624e-07
C282Y O 0 2.014166511798976e-06
) O 0 2.3510049018682366e-08
, O 0 1.1822812950867956e-08
in O 0 1.4161826378256137e-08
85 O 0 1.2697103102254914e-07
% O 0 5.108086043037474e-08
of O 0 5.752103788836394e-07
patient O 0 2.4804328404570697e-06
chromosomes O 0 6.4016144278866705e-06
. O 0 1.304275338043226e-05

This O 0 8.412335432694817e-07
mutation O 0 2.0172190033918014e-06
eliminates O 0 3.2858740723895608e-06
the O 0 1.43138393582376e-07
ability O 0 1.7456835621487699e-07
of O 0 4.4075460436943104e-07
HFE O 0 0.00011709585669450462
to O 0 1.0123901006409142e-07
associate O 0 1.7402062439941801e-06
with O 0 2.0838352554619632e-07
beta2 O 0 0.0002552976366132498
- O 0 0.0009202132932841778
microglobulin O 0 0.002279222011566162
( O 0 6.131714371804264e-07
beta2m O 0 3.4267282899236307e-05
) O 0 1.5647280804387265e-07
and O 0 1.4601070574826736e-07
prevents O 0 2.2706505831138202e-07
cell O 0 6.917700829944806e-06
- O 0 3.4951133329741424e-06
surface O 0 3.5392642985243583e-06
expression O 0 1.0839421520358883e-05
. O 0 1.0832373845914844e-05

A O 0 1.3569968359661289e-05
second O 0 2.4904215933929663e-06
mutation O 0 4.0673438661542605e-07
that O 0 1.2931705484220402e-08
has O 0 8.792405914448409e-09
no O 0 1.4885465304814716e-08
effect O 0 1.192377538927758e-07
on O 0 4.727529017145571e-07
beta2m O 0 6.15606113569811e-05
association O 0 3.552055716227187e-07
, O 0 2.2867078541821684e-07
H63D O 0 0.0015053034294396639
, O 0 1.3613328064820962e-07
was O 0 2.0028717528930429e-07
found O 0 1.8178699434656664e-08
in O 0 2.1501405100821103e-08
eight O 0 1.0405538120039637e-07
out O 0 2.1341527656204562e-08
of O 0 1.1310551428778126e-07
nine O 0 1.382402956551232e-06
patients O 0 7.253326828049467e-08
heterozygous O 0 1.7047182154783513e-07
for O 0 5.8682122272557535e-08
the O 0 6.05890193128289e-07
C282Y O 0 4.603274282999337e-05
mutant O 0 8.382160740438849e-05
. O 0 3.910357190761715e-05

In O 0 1.336369336968346e-06
this O 0 1.2491243239765026e-07
report O 0 7.981505945053868e-08
, O 0 3.823095440225188e-08
we O 0 4.680456555661294e-08
demonstrate O 0 1.9041274867959146e-07
in O 0 1.1294092416846979e-07
cultured O 0 4.769549377670046e-06
293 O 0 2.6708305540523725e-06
cells O 0 1.658131850490463e-06
overexpressing O 0 1.7507900338387117e-05
wild O 0 9.816873216550448e-07
- O 0 1.5940504454192705e-06
type O 0 5.041598569732741e-07
or O 0 1.4040237772405817e-07
mutant O 0 6.703382950945524e-07
HFE O 0 7.112163984857034e-06
proteins O 0 6.608233071858649e-09
that O 0 1.8535643020456405e-09
both O 0 8.906862802859905e-09
the O 0 3.521120461869032e-08
wild O 0 2.4772035089881683e-07
- O 0 7.84643191309442e-07
type O 0 1.5977076373019372e-06
and O 0 1.7478488416600158e-06
H63D O 1 0.9892545938491821
HFE O 0 0.0367569625377655
proteins O 0 1.1466337213050792e-07
form O 0 2.2838592883545061e-07
stable O 0 1.6589781353104627e-06
complexes O 0 1.3600558190773882e-07
with O 0 2.7509109656875808e-08
the O 0 9.182924998185626e-08
transferrin O 0 2.323647322555189e-06
receptor O 0 1.3017995570407948e-06
( O 0 1.5312006951262447e-07
TfR O 0 1.848338797572069e-05
) O 0 7.086843538672838e-07
. O 0 7.528865808126284e-06

The O 0 1.1770310266001616e-05
C282Y O 0 7.202169217634946e-05
mutation O 0 3.887008915626211e-06
nearly O 0 1.1543396567503805e-06
completely O 0 9.294233791479201e-07
prevents O 0 1.1079806938596448e-07
the O 0 9.112609689054807e-08
association O 0 8.264683515335491e-08
of O 0 8.77754686712251e-08
the O 0 2.4837061118887505e-07
mutant O 0 4.152293058723444e-06
HFE O 0 0.00010101072257384658
protein O 0 1.7616664536035387e-06
with O 0 1.8731199702415324e-07
the O 0 1.7766963082976872e-06
TfR O 0 0.0008655821438878775
. O 0 2.402634891041089e-05

Studies O 0 1.8898148482549004e-05
on O 0 5.719792170566507e-06
cell O 0 3.736145299626514e-05
- O 0 7.759533218631987e-06
associated O 0 8.84390772171173e-07
transferrin O 0 6.549587851623073e-06
at O 0 8.667245197102602e-07
37 O 0 2.5051301122402947e-07
degrees O 0 5.738307322644687e-07
C O 0 2.299909738212591e-06
suggest O 0 4.078179927091696e-08
that O 0 8.544564167323188e-09
the O 0 9.376105225555875e-08
overexpressed O 0 3.6275935144658433e-06
wild O 0 5.533152602765767e-07
- O 0 1.7904243350130855e-06
type O 0 1.4113121551417862e-06
HFE O 0 6.791044143028557e-05
protein O 0 2.0062229566519818e-07
decreases O 0 4.1247101734143143e-08
the O 0 1.1549884604278304e-08
affinity O 0 3.239257750919933e-08
of O 0 1.2054805154093629e-07
the O 0 3.571165052562719e-07
TfR O 0 2.1972089598421007e-05
for O 0 1.012926759358379e-06
transferrin O 0 9.97779643512331e-05
. O 0 2.444450910843443e-05

The O 0 3.842077057925053e-05
overexpressed O 0 0.00047964887926355004
H63D O 0 0.0007265491294674575
protein O 0 1.3001023262404487e-06
does O 0 1.826771622859269e-08
not O 0 6.04195848907807e-09
have O 0 2.7242901268209607e-09
this O 0 2.0494206331989062e-09
effect O 0 3.3425671119857725e-08
, O 0 7.725041051287462e-09
providing O 0 1.8676255209015835e-08
the O 0 6.428184651241509e-09
first O 0 1.072855404515849e-08
direct O 0 1.3688437938697007e-08
evidence O 0 4.510123119416676e-08
for O 0 1.7328247281511722e-08
a O 0 5.598932162342862e-08
functional O 0 9.696351526145008e-07
consequence O 0 2.0018530904053478e-06
of O 0 9.426427709513518e-07
the O 0 2.146405222447356e-06
H63D O 0 0.0016089949058368802
mutation O 0 4.537760833045468e-05
. O 0 2.003248482651543e-05

Addition O 0 4.79455457025324e-06
of O 0 1.8690243450691923e-06
soluble O 0 2.5637024009483866e-05
wild O 0 2.0692198177130194e-06
- O 0 6.135227977210889e-06
type O 0 1.9617638827185147e-05
HFE O 1 0.9999738931655884
/ O 1 0.7366383671760559
beta2m O 0 0.0003239095094613731
heterodimers O 0 4.062873631482944e-05
to O 0 1.3584886460193957e-07
cultured O 0 2.03111017071933e-06
cells O 0 2.632707492011832e-07
also O 0 2.37306689854222e-08
decreased O 0 8.058848521841355e-08
the O 0 1.529127935384622e-08
apparent O 0 7.526774936650327e-08
affinity O 0 7.39649905767692e-08
of O 0 1.2307920371767977e-07
the O 0 1.0562327901197932e-07
TfR O 0 2.9253676530061057e-06
for O 0 2.2840286106884378e-08
its O 0 1.265469062872171e-08
ligand O 0 1.4615724808209052e-07
under O 0 6.671965735449703e-08
steady O 0 6.252960815800179e-07
- O 0 1.6179582473796472e-07
state O 0 4.881870907524899e-09
conditions O 0 7.822219316722112e-08
, O 0 1.2546323979734098e-08
both O 0 1.3309896296220813e-08
in O 0 1.2948093264242289e-08
293 O 0 1.316665958484009e-07
cells O 0 7.665483536811735e-08
and O 0 8.48158379085362e-08
in O 0 2.2719069647791912e-07
HeLa O 0 4.015442027593963e-05
cells O 0 9.306542779086158e-06
. O 0 1.0999599908245727e-05

Furthermore O 0 1.6473290088470094e-05
, O 0 9.047143407769909e-07
at O 0 1.2234712585268426e-06
4 O 0 8.917854756873567e-07
degrees O 0 9.601645842849393e-07
C O 0 1.1228725270484574e-05
, O 0 1.2386200864966668e-07
the O 0 8.844028087651168e-08
added O 0 6.430149710467958e-07
soluble O 0 8.444769150628417e-07
complex O 0 6.569953825419361e-07
of O 0 4.96637142077816e-07
HFE O 0 0.05210351571440697
/ O 0 0.00014845690748188645
beta2m O 0 5.560837598750368e-05
inhibited O 0 1.601231247150281e-06
binding O 0 3.0559692731912946e-07
of O 0 3.350559438786149e-07
transferrin O 0 5.273690931062447e-06
to O 0 3.170485740611184e-07
HeLa O 0 4.674892625189386e-05
cell O 0 9.635718924982939e-06
TfR O 0 1.0689227565308101e-05
in O 0 5.417880188929303e-08
a O 0 1.2419913275607541e-07
concentration O 0 5.304272235662211e-06
- O 0 2.8433655643311795e-06
dependent O 0 5.944035592619912e-07
manner O 0 1.2146624612796586e-05
. O 0 8.362514563486911e-06

Scatchard O 0 0.0002581196022219956
plots O 0 6.624832622037502e-06
of O 0 7.366327281488338e-07
these O 0 6.65394424004262e-08
data O 0 1.3572389434557408e-07
indicate O 0 6.941956343098354e-08
that O 0 4.1380346260666556e-08
the O 0 2.832875338754093e-07
added O 0 2.4805133307381766e-06
heterodimer O 0 4.730997261503944e-06
substantially O 0 3.674584831969696e-07
reduced O 0 1.404157643491999e-07
the O 0 4.1307487208541716e-08
affinity O 0 1.1156062384998222e-07
of O 0 5.990084446239052e-07
TfR O 0 3.039711191377137e-05
for O 0 1.6636423652016674e-06
transferrin O 0 9.312274778494611e-05
. O 0 2.0885232515865937e-05

These O 0 1.316879775004054e-06
results O 0 1.9808076103799976e-06
establish O 0 4.951795631313871e-07
a O 0 9.836706738042267e-08
molecular O 0 1.2619735798580223e-06
link O 0 8.532058473065263e-07
between O 0 1.0079218100145226e-06
HFE O 1 0.5121830105781555
and O 0 1.9853398214308982e-07
a O 0 1.4416296778563265e-07
key O 0 1.2333799759289832e-06
protein O 0 2.3897942469375266e-07
involved O 0 8.214833258080034e-08
in O 0 2.876317140021456e-08
iron O 0 9.458872227696702e-05
transport O 0 8.409716429014225e-06
, O 0 1.0816705042770991e-07
the O 0 1.2516547087670915e-07
TfR O 0 4.3651369196595624e-05
, O 0 8.767892722971737e-08
and O 0 6.943849228946419e-08
raise O 0 7.897807563495007e-08
the O 0 3.168955586829725e-08
possibility O 0 1.5457553104170074e-07
that O 0 6.0835758652899585e-09
alterations O 0 1.3026375711433502e-07
in O 0 6.997560753063681e-09
this O 0 6.197875102031958e-09
regulatory O 0 1.1291722756823219e-07
mechanism O 0 1.0351965329391533e-06
may O 0 5.3729294791082793e-08
play O 0 9.806208822737972e-08
a O 0 1.788406933656006e-08
role O 0 5.201804853527392e-08
in O 0 1.625269518967798e-08
the O 0 1.3835634149472753e-07
pathogenesis O 1 0.9810894131660461
of O 1 0.629484236240387
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.15509188175201416
. O 0 0.00017875400953926146

Genomic O 0 1.8020413335761987e-05
organization O 0 2.043500217041583e-06
of O 0 1.3992238336868468e-06
the O 0 3.14098224407644e-06
UBE3A O 0 0.020527541637420654
/ O 0 0.06240187957882881
E6 O 1 0.6214425563812256
- O 0 6.594119622604921e-05
AP O 0 2.185914672736544e-05
gene O 0 6.011200639477465e-07
and O 0 3.556001217930316e-07
related O 0 3.5981447581434622e-06
pseudogenes O 0 3.7962960050208494e-05
. O 0 1.580635944264941e-05

The O 0 3.5560355172492564e-05
UBE3A O 0 0.0006642332300543785
gene O 0 4.632953277905472e-06
encodes O 0 4.0494192035112064e-06
the O 0 1.951657623067149e-06
E6 O 0 0.0006751527544111013
- O 0 0.00015582612832076848
AP O 0 0.0010320551227778196
ubiquitin O 0 0.0003252593451179564
- O 0 8.723971404833719e-05
protein O 0 4.127301963308128e-06
ligase O 0 3.150681322949822e-06
and O 0 1.417326274122388e-07
has O 0 3.492439404340075e-08
recently O 0 4.2007869183180446e-08
been O 0 1.0294844976499462e-08
shown O 0 4.6961208255424935e-09
to O 0 4.185285895630386e-09
be O 0 3.735124565196202e-08
mutated O 0 6.201133601280162e-06
in O 0 5.90401905355975e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0007914059679023921
who O 0 6.346018039948831e-07
lack O 0 1.3070993190922309e-05
15q11 O 0 0.00020718439191114157
- O 0 6.619269697694108e-05
q13 O 0 2.1791895051137544e-05
deletions O 0 5.40313521923963e-06
or O 0 1.1974341305176495e-06
chromosome O 0 1.0531692169024609e-05
15 O 0 1.2122714906581677e-05
paternal O 0 6.674497126368806e-05
uniparental B-Disease 0 0.4705616533756256
disomy I-Disease 0 0.16041316092014313
. O 0 0.00045929080806672573

Previous O 0 4.914160672342405e-05
UBE3A O 0 0.00046355905942618847
cDNA O 0 7.686530807404779e-06
analysis O 0 1.025801452669839e-06
has O 0 6.542293817801692e-08
shown O 0 1.0511601544749283e-07
a O 0 1.1888904793977417e-07
coding O 0 7.137196575968119e-07
region O 0 2.809961472394207e-07
of O 0 3.2855592735359096e-07
approximately O 0 5.287870408210438e-07
2 O 0 4.931507191940909e-06
. O 0 4.487787919060793e-06

6 O 0 0.0001625820732442662
kb O 0 0.00045916734961792827
and O 0 7.899312208792253e-07
a O 0 6.20034882103937e-07
3 O 0 2.892980091928621e-06
- O 0 2.333785459995852e-06
untranslated O 0 1.1852494935737923e-05
region O 0 4.0485284102942387e-07
( O 0 6.91196433422192e-08
UTR O 0 2.024773129960522e-05
) O 0 3.9930508677343823e-08
of O 0 1.9863985301071807e-07
< O 0 2.492212843208108e-06
50 O 0 4.5536884840657876e-07
bp O 0 1.2073091966158245e-06
, O 0 6.594360257849985e-08
whereas O 0 1.513588330226412e-07
Northern O 0 2.810320438584313e-07
analysis O 0 1.6119670931402652e-07
has O 0 3.4129367776358777e-08
indicated O 0 1.55935637735638e-07
mRNA O 0 2.6055940338665096e-07
sizes O 0 2.948782480416412e-07
of O 0 3.045512926291849e-07
5 O 0 5.067047368356725e-06
- O 0 7.460905635525705e-06
8 O 0 1.689258533588145e-05
kb O 0 0.0005154666141606867
. O 0 3.1454270356334746e-05

We O 0 3.812554950854974e-06
have O 0 2.1232436608897842e-07
analyzed O 0 4.373229955945135e-07
additional O 0 1.5292553712242807e-07
cDNA O 0 6.953656566111022e-07
clones O 0 3.976550999595929e-07
and O 0 4.703411704554128e-08
provide O 0 5.470557695730349e-08
evidence O 0 6.759244541854059e-08
for O 0 1.1656868359466444e-08
an O 0 1.377147995640371e-08
additional O 0 1.7174036770484236e-07
0 O 0 5.552369657380041e-06
. O 0 1.1943721801799256e-05

5 O 0 2.9212947993073612e-05
kb O 0 7.200025720521808e-05
of O 0 1.6326927152476856e-06
5 O 0 4.0190943764173426e-06
- O 0 2.9796053695463343e-06
UTR O 0 3.509155794745311e-05
and O 0 2.530281051349448e-07
> O 0 1.6638805391266942e-06
2 O 0 1.2624899454749539e-06
kb O 0 6.371612471411936e-06
of O 0 6.994026193751779e-07
3 O 0 9.394161679665558e-06
- O 0 2.3112017515813932e-05
UTR O 0 0.0008463092381134629
. O 0 2.601864434836898e-05

We O 0 1.9047282648898545e-06
have O 0 6.394277818344563e-08
established O 0 1.564977338830431e-07
the O 0 3.372968748749372e-08
genomic O 0 1.2309529040521738e-07
organization O 0 5.9575885558160735e-08
of O 0 1.6070522690370126e-07
UBE3A O 0 2.1401940102805384e-05
and O 0 1.2985913144802907e-07
the O 0 8.611501556288204e-08
sequence O 0 1.3293117717694258e-07
of O 0 5.405167939898092e-07
intron O 0 3.9774600736564025e-05
- O 0 0.0004362979670986533
exon O 0 3.68986620742362e-05
borders O 0 4.288821855880087e-06
. O 0 2.5081064450205304e-05

We O 0 7.090303824952571e-06
have O 0 4.451843835795444e-07
also O 0 2.597778347990243e-07
mapped O 0 7.478049042219936e-07
two O 0 1.2326715648214304e-07
highly O 0 6.600041615456576e-07
homologous O 0 1.4061666888665059e-06
processed O 0 7.002236088737845e-07
pseudogenes O 0 2.704158760025166e-06
, O 0 3.713069816058123e-07
UBE3AP1 O 0 0.0001737590500852093
and O 0 8.586634976381902e-07
UBE3AP2 O 0 0.000559405074454844
, O 0 7.022311621085464e-08
to O 0 1.8508236721004323e-08
chromosomes O 0 4.771214179299932e-08
2 O 0 1.2047060238273843e-07
and O 0 1.7791593975857722e-08
21 O 0 2.3051285324982018e-07
, O 0 2.7295865123733165e-08
respectively O 0 1.792149930679443e-07
, O 0 1.907158342362436e-08
and O 0 1.4907740819580795e-08
determined O 0 9.653368238105031e-08
their O 0 3.3496576179459225e-08
genomic O 0 9.098105806515377e-07
organization O 0 2.9908733267802745e-06
. O 0 1.2062436326232273e-05

These O 0 8.512041631547618e-07
results O 0 7.255443392750749e-07
will O 0 3.7152513954197275e-08
form O 0 1.9076894730574168e-08
the O 0 1.1555855827793948e-08
basis O 0 1.5678223164172778e-08
for O 0 3.008103988122457e-09
studies O 0 6.569901955799651e-09
of O 0 2.0861667948679496e-08
mutation O 0 1.8222220887764706e-07
and O 0 3.2601587918179575e-07
imprinting O 0 1.1747020835173316e-05
of O 0 2.0485289496718906e-05
UBE3A O 1 0.8176430463790894
. O 0 0.0002508785401005298

Mutation O 0 0.00011009649460902438
spectrum O 0 0.00012311109458096325
and O 0 5.882472123630578e-06
genotype O 0 0.00027363296248950064
- O 0 0.00019670618348754942
phenotype O 0 1.1353588888596278e-05
analyses O 0 8.036695930968563e-07
in O 0 5.564246521316818e-07
Cowden B-Disease 1 0.9998644590377808
disease I-Disease 1 0.9980928301811218
and O 0 6.138842582004145e-05
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.4610817490611225e-05
two O 0 5.2051243983441964e-05
hamartoma B-Disease 1 0.9999637603759766
syndromes I-Disease 1 0.5722623467445374
with O 0 6.532071711262688e-05
germline O 1 0.9999221563339233
PTEN O 1 0.9984390139579773
mutation O 0 0.00028388414648361504
. O 0 6.795235094614327e-05

The O 0 2.547058102209121e-05
tumour B-Disease 1 0.9999982118606567
suppressor O 0 0.0007724851602688432
gene O 0 7.1594326982449275e-06
PTEN O 0 0.00019592877652030438
, O 0 3.7870185565225256e-07
which O 0 1.0745596767947063e-07
maps O 0 6.740460776200052e-07
to O 0 6.619329724344425e-07
10q23 O 0 0.0001995806087506935
. O 0 5.408654033089988e-05

3 O 0 2.7175065042683855e-05
and O 0 7.755410820209363e-07
encodes O 0 7.50770425383962e-07
a O 0 1.5898814353931812e-07
403 O 0 2.5239933165721595e-07
amino O 0 4.213265185626369e-07
acid O 0 5.255839141682372e-07
dual O 0 5.439071173896082e-06
specificity O 0 1.8533924958319403e-05
phosphatase O 0 0.003550669876858592
( O 0 5.559255669140839e-07
protein O 0 1.6996027625282295e-06
tyrosine O 0 2.534515033403295e-06
phosphatase O 0 6.477606348198606e-06
; O 0 5.0986635358185595e-08
PTPase O 0 7.871609341236763e-06
) O 0 3.5839860856867745e-08
, O 0 2.400069121222259e-08
was O 0 1.1180517134334877e-07
shown O 0 3.146826443867212e-08
recently O 0 6.311711331363767e-08
to O 0 1.2911987923303059e-08
play O 0 2.4366985940105224e-07
a O 0 1.048864959329876e-07
broad O 0 1.4467190112554817e-06
role O 0 2.0407853753567906e-06
in O 0 4.481833286718029e-07
human O 0 5.353500910132425e-06
malignancy B-Disease 0 0.001001129043288529
. O 0 2.4353830667678267e-05

Somatic O 0 0.0032740733586251736
PTEN O 0 0.0010003338102251291
deletions O 0 7.703158189542592e-06
and O 0 2.440743003262469e-07
mutations O 0 3.8634055954389623e-07
were O 0 1.7341778857371537e-07
observed O 0 1.2692441941908328e-07
in O 0 5.0802583473341656e-08
sporadic B-Disease 0 0.0011927582090720534
breast I-Disease 1 0.9999977350234985
, I-Disease 0 0.4048334062099457
brain I-Disease 1 1.0
, I-Disease 1 0.9108046889305115
prostate I-Disease 1 1.0
and I-Disease 1 0.9993689656257629
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9999946355819702
cell O 1 0.7984744906425476
lines O 0 2.5906876999215456e-06
and O 0 1.4899291045367136e-07
in O 0 3.708002083158135e-08
several O 0 7.169916926841324e-08
primary O 0 1.5846539099584334e-05
tumours B-Disease 1 1.0
such O 0 4.793279231307679e-07
as O 0 5.8752455515787005e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9991499185562134

In O 0 1.79379821929615e-06
addition O 0 1.4690868965772097e-06
, O 0 6.041569236003852e-07
PTEN O 0 0.0004943732055835426
was O 0 1.8027210444415687e-06
identified O 0 2.385916104685748e-07
as O 0 4.455385749224661e-08
the O 0 8.678877350121184e-08
susceptibility O 0 1.387390057061566e-06
gene O 0 6.831215273450653e-07
for O 0 5.530240514417528e-07
two O 0 2.360296275583096e-05
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999978542327881
( O 0 4.888703188044019e-06
CD B-Disease 0 0.00015154368884395808
; O 0 1.1637672514552833e-06
MIM O 0 0.00021708154235966504
158350 O 0 1.561780482006725e-05
) O 0 2.3006877825082483e-07
and O 0 7.738397016510135e-07
Bannayan B-Disease 0 0.00331538962200284
- I-Disease 0 0.08269453793764114
Zonana I-Disease 1 0.9993982315063477
( I-Disease 0 2.487340452717035e-06
BZS I-Disease 0 0.0012548357481136918
) I-Disease 0 1.7457381318308762e-06
or I-Disease 0 3.479724455246469e-06
Ruvalcaba I-Disease 0 0.000698438729159534
- I-Disease 0 0.0002846256538759917
Riley I-Disease 0 0.003620917908847332
- I-Disease 1 0.9979528188705444
Smith I-Disease 1 0.9996359348297119
syndrome I-Disease 1 1.0
( O 0 0.0006108882953412831
MIM O 1 0.9992716908454895
153480 O 0 0.0008205307531170547
) O 0 8.208407962229103e-06
. O 0 3.497095894999802e-05

Constitutive O 0 0.00011977604299318045
DNA O 0 6.166374987515155e-06
from O 0 2.602172060051089e-07
37 O 0 2.07545303965162e-06
CD B-Disease 0 3.4452118597982917e-06
families O 0 7.793581602300037e-08
and O 0 1.1141474942633067e-07
seven O 0 1.0088872386404546e-06
BZS B-Disease 0 9.993565618060529e-05
families O 0 1.2673778826410853e-07
was O 0 1.1354920843587024e-06
screened O 0 8.711380701242888e-07
for O 0 1.0505443697184091e-06
germline O 0 0.0008886072319000959
PTEN O 0 0.0030139831360429525
mutations O 0 0.000181560346391052
. O 0 6.983440107433125e-05

PTEN O 0 0.0011495738290250301
mutations O 0 9.16249609872466e-06
were O 0 9.764547712620697e-07
identified O 0 4.491212166612968e-07
in O 0 6.110884953614004e-08
30 O 0 2.3665157300456485e-07
of O 0 1.1465571958524379e-07
37 O 0 1.1504030226205941e-06
( O 0 5.786784385009014e-08
81 O 0 2.4868489845175645e-07
% O 0 2.922844188901763e-08
) O 0 5.5240533924916235e-08
CD B-Disease 0 1.6894717873583431e-06
families O 0 4.9611546870664824e-08
, O 0 4.5828517869495045e-08
including O 0 1.3997615155858512e-07
missense O 0 4.951151822751854e-06
and O 0 1.3577179913681903e-07
nonsense O 0 2.333458269276889e-06
point O 0 5.300229872773343e-07
mutations O 0 2.4541895982110873e-07
, O 0 6.668085461569717e-08
deletions O 0 7.080249702084984e-07
, O 0 1.6968061800071155e-07
insertions O 0 2.178090426241397e-06
, O 0 5.071221380603674e-07
a O 0 1.0183019867326948e-06
deletion O 0 1.9837565560010262e-05
/ O 0 0.00027531772502698004
insertion O 0 9.740080713527277e-06
and O 0 4.102876573597314e-06
splice O 0 8.3049206295982e-05
site O 0 8.270932994491886e-06
mutations O 0 3.4652326576178893e-05
. O 0 3.185667083016597e-05

These O 0 4.6081041205070505e-07
mutations O 0 1.2409509508870542e-06
were O 0 1.7126556883795274e-07
scattered O 0 1.900058776982405e-07
over O 0 8.986128818833095e-08
the O 0 6.541769437262701e-08
entire O 0 2.3104237811821804e-07
length O 0 6.400757257551959e-08
of O 0 1.6000331015675329e-07
PTEN O 0 0.00023212288215290755
, O 0 6.867206536753656e-08
with O 0 1.2253210890378341e-08
the O 0 3.082184818481437e-08
exception O 0 3.163333417433023e-08
of O 0 3.4990669917078776e-08
the O 0 4.499125694223949e-08
first O 0 1.1122471477165163e-07
, O 0 8.52394421713143e-08
fourth O 0 1.2066358294759993e-06
and O 0 3.725388353359449e-07
last O 0 5.736131242883857e-06
exons O 0 8.39958738652058e-05
. O 0 2.12355353141902e-05

A O 0 2.3167318431660533e-05
hot O 0 2.7472060537547804e-05
spot O 0 1.29261206893716e-05
for O 0 5.322821152731194e-07
PTEN O 0 3.19309183396399e-05
mutation O 0 5.407338790064387e-07
in O 0 6.100636795736136e-08
CD B-Disease 0 2.501897597539937e-06
was O 0 2.736128976721375e-07
identified O 0 1.399339879526451e-07
in O 0 2.9008395685536925e-08
exon O 0 4.0735938000580063e-07
5 O 0 1.195895293903959e-07
that O 0 4.8994359680420985e-09
contains O 0 1.8414572977576427e-08
the O 0 6.696865284538944e-08
PTPase O 0 8.847823664837051e-06
core O 0 3.966463737015147e-06
motif O 0 5.034228252043249e-07
, O 0 2.0522966437397372e-08
with O 0 7.720592165583184e-09
13 O 0 6.84897258906858e-08
of O 0 2.7242085920420323e-08
30 O 0 1.390405941492645e-07
( O 0 1.861217313603447e-08
43 O 0 9.005362500147385e-08
% O 0 1.6264666058418698e-08
) O 0 2.9683286939530262e-08
CD B-Disease 0 1.2016405435133493e-06
mutations O 0 2.513155834549252e-07
identified O 0 2.1867957400445448e-07
in O 0 9.464921646440416e-08
this O 0 2.8041870336892316e-07
exon O 0 2.663579653017223e-05
. O 0 1.4428389476961456e-05

Seven O 0 7.0709511419408955e-06
of O 0 6.326825428004668e-07
30 O 0 8.982261761047994e-07
( O 0 1.3087563388580747e-07
23 O 0 2.4734521275604493e-07
% O 0 1.4206086973445053e-08
) O 0 2.1595853993972014e-08
were O 0 4.2280209555656256e-08
within O 0 4.496560634947855e-08
the O 0 5.854751705669514e-08
core O 0 1.8589381625133683e-06
motif O 0 1.83501697392785e-07
, O 0 9.737282091748511e-09
the O 0 9.839967951563722e-09
majority O 0 1.3163012901884485e-08
( O 0 1.7839575150446763e-08
five O 0 2.836296886243872e-08
of O 0 2.9453468997076016e-08
seven O 0 5.544267267509895e-08
) O 0 4.463191149994827e-09
of O 0 6.572784982949997e-09
which O 0 3.671391191062412e-09
were O 0 8.175786092579074e-08
missense O 0 3.742734406841919e-06
mutations O 0 9.260117508347321e-07
, O 0 1.7017764264437574e-07
possibly O 0 2.2896392692928202e-06
pointing O 0 7.833774020582496e-07
to O 0 4.300036948734487e-08
the O 0 1.0853822374201627e-07
functional O 0 5.530652629204269e-07
significance O 0 1.9039458720726543e-07
of O 0 2.113058741315399e-07
this O 0 1.067768522489132e-07
region O 0 2.5400781851203647e-06
. O 0 1.503106796008069e-05

Germline O 0 0.012137670069932938
PTEN O 0 0.0006563090137206018
mutations O 0 4.72482906843652e-06
were O 0 5.047381250733451e-07
identified O 0 2.532770508878457e-07
in O 0 2.425828071750402e-08
four O 0 7.549952840690821e-08
of O 0 1.878325406323711e-07
seven O 0 1.1673454309857334e-06
( O 0 1.2957882233877172e-07
57 O 0 5.565403853324824e-07
% O 0 1.4377496881934348e-07
) O 0 9.228152180185134e-07
BZS B-Disease 0 0.0003290184249635786
families O 0 2.6024947601399617e-06
studied O 0 6.079628656152636e-05
. O 0 4.84058000438381e-05

Interestingly O 0 3.6153931432636455e-05
, O 0 5.393504807216232e-07
none O 0 4.504096864366147e-07
of O 0 9.101042053316633e-08
these O 0 3.2755973933262794e-08
mutations O 0 2.9535922863033193e-07
was O 0 3.444432081778359e-07
observed O 0 1.502458530922013e-07
in O 0 6.098355953554346e-08
the O 0 3.7908705508016283e-07
PTPase O 0 0.00013780947483610362
core O 0 0.0002080472477246076
motif O 0 4.2949122871505097e-05
. O 0 1.3898471479478758e-05

It O 0 7.764461429360381e-07
is O 0 8.18717751371878e-08
also O 0 2.4825876465683905e-08
worthy O 0 1.4300931638899783e-07
of O 0 4.3572434549332684e-08
note O 0 4.57171154266689e-08
that O 0 5.03149966135652e-09
a O 0 2.4048301128232197e-08
single O 0 3.569400419678459e-08
nonsense O 0 2.6034777533823217e-07
point O 0 1.618251559420969e-07
mutation O 0 7.400393542411621e-08
, O 0 5.25729255684837e-08
R233X O 0 2.182785920012975e-06
, O 0 9.533845002351882e-08
was O 0 1.9421905506078474e-07
observed O 0 7.783850719533802e-08
in O 0 1.8054718609050724e-08
the O 0 6.381642947417276e-08
germline O 0 4.633231583284214e-06
DNA O 0 2.1435852204376715e-07
from O 0 3.087780697796916e-08
two O 0 6.955553999432595e-08
unrelated O 0 6.604366831197694e-07
CD B-Disease 0 8.228794285969343e-06
families O 0 8.418613361982352e-08
and O 0 4.6682202992087696e-07
one O 0 2.129947461071424e-06
BZS B-Disease 0 0.0022901217453181744
family O 0 1.5150213585002348e-05
. O 0 2.8466583898989484e-05

Genotype O 0 0.0006637884071096778
- O 0 0.00012413501099217683
phenotype O 0 4.416830051923171e-06
studies O 0 1.2322753661919705e-07
were O 0 6.160821897083224e-08
not O 0 1.6377635247977196e-08
performed O 0 3.353506272674167e-08
on O 0 5.147737169863831e-08
this O 0 8.3398656869349e-09
small O 0 5.121539103924988e-08
group O 0 2.840894239852787e-07
of O 0 2.8962485885131173e-06
BZS B-Disease 0 0.014380970038473606
families O 0 6.203031716722762e-06
. O 0 3.2293126423610374e-05

However O 0 1.049631646310445e-05
, O 0 3.715822458616458e-06
genotype O 0 3.671519152703695e-05
- O 0 1.4387675946636591e-05
phenotype O 0 5.803745807497762e-06
analysis O 0 7.910136901045917e-07
inthe O 0 1.0960458894260228e-05
group O 0 2.69032284450077e-07
of O 0 3.056455852856743e-07
CD B-Disease 0 1.778253681550268e-05
families O 0 4.885450621827658e-08
revealed O 0 3.628699971613969e-07
two O 0 3.747019405864194e-08
possible O 0 1.385035375278676e-07
associations O 0 8.14701905937909e-08
worthy O 0 4.2372488451292156e-07
of O 0 2.3333151943916164e-07
follow O 0 3.1296568181460316e-07
- O 0 1.4240343944038614e-06
up O 0 1.6259089363757084e-07
in O 0 6.356775372751144e-08
independent O 0 4.76837158203125e-07
analyses O 0 3.43181932294101e-06
. O 0 1.2308323675824795e-05

The O 0 4.185993020655587e-06
first O 0 1.3164165011403384e-06
was O 0 2.1286457467795117e-06
an O 0 8.56086472822426e-08
association O 0 1.4637764422786859e-07
noted O 0 5.912940181929116e-08
in O 0 1.7419941045204723e-08
the O 0 6.014480646854281e-08
group O 0 1.1059516680234083e-07
of O 0 3.6046080253981927e-07
CD B-Disease 0 0.00016604842676315457
families O 0 3.4228432355121186e-07
with O 0 5.025061182095669e-05
breast B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999849796295166
. O 0 0.0003419398854020983

A O 0 1.7905347704072483e-05
correlation O 0 5.480397703649942e-06
was O 0 1.438080403204367e-06
observed O 0 2.5140309389826143e-07
between O 0 6.419548981284606e-08
the O 0 5.292910287835184e-08
presence O 0 2.184923602044364e-07
/ O 0 4.502028332353802e-06
absence O 0 1.1190378472747398e-06
of O 0 4.78428205497039e-07
a O 0 3.6766877542504517e-07
PTEN O 0 4.556528801913373e-05
mutation O 0 2.8887816938549804e-07
and O 0 5.7907811878976645e-08
the O 0 5.187190765809646e-08
type O 0 1.570799895489472e-06
of O 0 3.232359631510917e-06
breast O 0 0.3634399175643921
involvement O 0 0.0020998669788241386
( O 0 5.26452549820533e-06
unaffected O 0 9.630001295590773e-05
versus O 1 0.8581276535987854
benign O 1 0.9957383871078491
versus O 1 0.9930881857872009
malignant O 1 0.9996080994606018
) O 0 1.4114673831500113e-05
. O 0 3.210722570656799e-05

Specifically O 0 5.2849836720270105e-06
and O 0 3.5432725553619093e-07
more O 0 3.667235759508003e-08
directly O 0 3.316688079735286e-08
, O 0 2.8835954068995306e-08
an O 0 2.2186767978382704e-08
association O 0 2.0860760230334563e-07
was O 0 4.783524900631164e-07
also O 0 2.0293349223265977e-08
observed O 0 4.949302478962636e-08
between O 0 2.242968122345701e-08
the O 0 1.2007758343202113e-08
presence O 0 2.7004835700950025e-08
of O 0 1.5583543699904112e-07
a O 0 1.4195300082064932e-06
PTEN O 1 0.6868206858634949
mutation O 0 0.002389882691204548
and O 1 0.7251577973365784
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.02370958961546421

Secondly O 0 0.00017877071513794363
, O 0 1.206250431096123e-06
there O 0 1.5887036397543852e-07
appeared O 0 1.413157093566042e-07
to O 0 1.4224442068666576e-08
be O 0 4.208229142932396e-08
an O 0 4.65254430537243e-08
interdependent O 0 0.00015549779345747083
association O 0 1.6728175467051187e-07
between O 0 2.2406659638818383e-07
mutations O 0 2.2702566582211148e-07
upstream O 0 1.8214505814739823e-07
and O 0 3.032947404335573e-08
within O 0 7.212243247067818e-08
the O 0 6.765280602394341e-08
PTPase O 0 1.4789289707550779e-05
core O 0 7.029640983091667e-06
motif O 0 5.070921247352089e-07
, O 0 3.008438298479632e-08
the O 0 4.892509153364699e-08
core O 0 9.779924994290923e-07
motif O 0 1.2861433162925096e-07
containing O 0 2.8594474343890397e-08
the O 0 1.0194876054470114e-08
majority O 0 1.1463522575638763e-08
of O 0 5.596924523842972e-08
missense O 0 2.019502062466927e-06
mutations O 0 3.167176600982202e-07
, O 0 5.009687953361208e-08
and O 0 3.4588097719279176e-08
the O 0 7.449733629982802e-08
involvement O 0 3.141304034670611e-07
of O 0 1.5814070764008648e-07
all O 0 4.435519329604176e-08
major O 0 5.308794470693101e-07
organ O 0 0.005951751954853535
systems O 0 0.18781134486198425
( O 0 1.3545471801990061e-06
central O 0 1.638401772652287e-05
nervous O 0 9.344770660391077e-05
system O 0 0.0027573942206799984
, O 0 0.00026224684552289546
thyroid O 1 1.0
, O 1 0.9743427634239197
breast O 1 1.0
, O 1 0.9999487400054932
skin O 1 1.0
and O 1 0.9999998807907104
gastrointestinal O 1 1.0
tract O 1 0.9999943971633911
) O 0 0.00016377720749005675
. O 0 0.00025022707995958626

However O 0 3.85802968594362e-06
, O 0 2.992548786551197e-07
these O 0 2.2300257640495147e-08
observations O 0 4.767239047964722e-08
would O 0 7.856142403284139e-09
need O 0 1.5561143484887907e-08
to O 0 6.509691896638969e-09
be O 0 1.2356807133073744e-08
confirmed O 0 4.772579487166695e-08
by O 0 7.617223296563225e-09
studying O 0 2.902040741048495e-08
a O 0 6.7616663379510555e-09
larger O 0 1.4457458341610163e-08
number O 0 1.4557599570252933e-08
of O 0 1.1333798966006725e-07
CD B-Disease 0 7.2051811912388075e-06
families O 0 5.679080459231045e-07
. O 0 5.705594958271831e-06

Molecular O 1 0.9999297857284546
defects O 1 0.999966025352478
leading O 0 3.925721102859825e-05
to O 0 1.3911856910908682e-07
human O 0 7.895206977082125e-07
complement B-Disease 0 1.5637358956155367e-05
component I-Disease 1 0.999998927116394
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.635448114711835e-07
an O 0 1.8911403998345122e-08
African O 0 1.0884946277656127e-06
- O 0 7.437757290063018e-07
American O 0 2.481561125478038e-07
family O 0 5.126914857100928e-07
. O 0 3.793307541855029e-06

Complement B-Disease 0 0.0010429163230583072
component I-Disease 1 0.9999804496765137
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.852903890016023e-05
C6D B-Disease 1 0.9997875094413757
) O 0 7.672247193113435e-07
was O 0 3.443162086114171e-06
diagnosed O 0 7.498833838326391e-06
in O 0 4.264889597038746e-08
a O 0 9.743230577896611e-08
16 O 0 1.5650027762603713e-06
- O 0 6.82600557411206e-07
year O 0 6.812089736740745e-08
- O 0 4.383020950626815e-07
old O 0 2.1822299913765164e-06
African O 0 1.4244393241824582e-05
- O 0 4.230629201629199e-06
American O 0 4.874839305557543e-07
male O 0 1.0661059604899492e-05
with O 0 0.00013129318540450186
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.012448633089661598

The O 0 9.240303370461334e-06
patients O 0 3.2481593734701164e-06
father O 0 1.4922184163879137e-06
and O 0 3.2277745276587666e-07
two O 0 4.3709027863769734e-07
brothers O 0 7.3880069066945e-06
also O 0 1.8335197182750562e-07
had O 0 7.204914709291188e-07
C6D B-Disease 1 0.5918204188346863
, O 0 1.3057655223747133e-07
but O 0 4.1364568659219e-08
gave O 0 1.8987617522725486e-07
no O 0 6.152003351189705e-08
history O 0 2.483502612449229e-07
of O 0 2.72908710030606e-06
meningitis B-Disease 1 1.0
or O 0 1.716026963549666e-05
other O 0 2.3084819531504763e-06
neisserial B-Disease 1 0.5915563106536865
infection I-Disease 0 0.06878602504730225
. O 0 4.2866013245657086e-05

By O 0 5.377191882871557e-06
using O 0 4.2044448491651565e-06
exon O 0 1.6580654119024985e-05
- O 0 1.8348558796787984e-06
specific O 0 1.5773254347095644e-07
polymerase O 0 1.8887504893427831e-06
chain O 0 3.7226715221549966e-07
reaction O 0 1.271867375862712e-07
( O 0 1.1712433689581303e-07
PCR O 0 1.981671175599331e-06
) O 0 1.591700424796727e-07
/ O 0 1.3436535937216831e-06
single O 0 3.3524517562000256e-07
- O 0 2.330927145521855e-06
strand O 0 4.403886748605146e-07
conformation O 0 2.3420966499543283e-07
polymorphism O 0 1.582731812277416e-07
as O 0 6.583662948145275e-09
a O 0 7.311773853047043e-09
screening O 0 1.6484786868886658e-08
step O 0 3.784829871733564e-08
and O 0 1.3003556453838883e-08
nucleotide O 0 2.8353071002129582e-08
sequencing O 0 2.4617603955334744e-08
of O 0 9.40926270232012e-09
target O 0 1.1703501456850063e-07
exons O 0 6.547924158439855e-07
, O 0 1.9701765552326833e-08
we O 0 1.4829129035831556e-08
determined O 0 4.5218463640139817e-08
that O 0 6.337463442918079e-09
the O 0 6.960039655723449e-08
proband O 0 1.195854929392226e-05
was O 0 6.115321866673185e-07
a O 0 1.5575179190818744e-07
compound O 0 6.053091965441126e-07
heterozygote O 0 2.8057700092176674e-06
for O 0 1.9700607367667544e-07
two O 0 2.238872639281908e-06
C6 O 1 0.6752544641494751
gene O 0 1.1996871762676165e-05
mutations O 0 2.7337391657056287e-05
. O 0 2.5071738491533324e-05

The O 0 6.514739652629942e-06
first O 0 2.198567472078139e-06
, O 0 4.920120773022063e-07
1195delC O 0 6.9054672167112585e-06
located O 0 2.3009312144495198e-07
in O 0 3.5944328402592873e-08
exon O 0 1.0038112350230222e-06
7 O 0 1.0595342700980837e-06
, O 0 6.961486320733457e-08
is O 0 1.1842335112532965e-08
a O 0 1.233733026850814e-08
novel O 0 4.138753340043877e-08
mutation O 0 7.175470528864025e-08
, O 0 2.0975461367811477e-08
while O 0 4.943708020732629e-08
the O 0 4.696383726354725e-08
second O 0 2.4260046416202385e-07
, O 0 8.818677343924719e-08
1936delG O 0 1.590048100297281e-06
in O 0 5.55754411379894e-08
exon O 0 9.873583621811122e-07
12 O 0 6.788080781916506e-07
, O 0 5.354361931608764e-08
has O 0 2.7584031059291192e-08
been O 0 3.531889092300844e-08
described O 0 5.779802236816067e-08
before O 0 1.2153338957432425e-07
to O 0 4.4357729933608425e-08
cause O 0 2.3434556624124525e-06
C6D B-Disease 1 0.8131382465362549
in O 0 2.2765223661735945e-07
an O 0 8.060939649112697e-08
unrelated O 0 1.936266471602721e-06
African O 0 8.03969396656612e-06
- O 0 6.5782446654338855e-06
American O 0 5.730295811190445e-07
individual O 0 1.240583060280187e-06
. O 0 8.80248535395367e-06

Both O 0 5.894815330975689e-06
mutations O 0 1.0847218618437182e-05
result O 0 2.447649876557989e-06
in O 0 7.078305657159945e-07
premature O 0 9.389378647028934e-06
termination O 0 1.0220116564596538e-05
codons O 0 2.696780939004384e-05
and O 0 5.453203812066931e-06
C6 O 1 0.7639216780662537
null O 0 0.00018933482351712883
alleles O 0 6.790947372792289e-05
. O 0 3.113758793915622e-05

Allele O 0 0.0002010873577091843
- O 0 9.549743481329642e-06
specific O 0 1.7373777438933757e-07
PCR O 0 1.7331838080281159e-06
indicated O 0 3.961516483741434e-07
that O 0 2.7879762498628224e-08
the O 0 1.8049661321128951e-07
probands O 0 3.0339533623191528e-05
two O 0 3.3089068551817036e-07
brothers O 0 2.0595807654899545e-06
also O 0 8.47526067104809e-08
inherited O 0 9.497479140918585e-07
the O 0 1.770833506498093e-07
1195delC O 0 1.10946689346747e-06
mutation O 0 7.154316250534976e-08
from O 0 1.7898537763016975e-08
their O 0 2.1094942681543216e-08
heterozygous O 0 2.928034348315123e-07
mother O 0 3.725021713307797e-08
and O 0 4.999235869718177e-08
the O 0 1.0806146377717596e-07
1936delG O 0 1.0121648301719688e-06
mutation O 0 1.319026239343657e-07
from O 0 2.6598742763894734e-08
their O 0 7.31915861251764e-08
homozygous O 0 2.2577519303013105e-06
father O 0 3.1546712762065e-06
. O 0 2.9903371796535794e-06
. O 0 2.644954656716436e-05

PAX6 O 0 0.21863789856433868
mutations O 0 0.0008838193607516587
reviewed O 0 0.00025371069204993546
. O 0 0.0001124521077144891

Mutations O 0 2.9825914680259302e-05
in O 0 1.2334363646004931e-06
PAX6 O 0 0.010784831829369068
are O 0 1.7816070396747818e-07
responsible O 0 8.388877859033528e-07
for O 0 1.8978022353621782e-07
human O 0 4.812048700841842e-06
aniridia B-Disease 1 1.0
and O 0 1.0836710089279222e-06
have O 0 1.1163938751224123e-07
also O 0 4.157694633022402e-08
been O 0 4.978159751090061e-08
found O 0 3.1142903367253894e-08
in O 0 4.645317730478382e-08
patients O 0 1.2534692928056757e-07
with O 0 1.1049190788980923e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 0.022383352741599083
with O 1 0.9999978542327881
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.9102372527122498
with O 0 0.09167646616697311
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 1.563765727041755e-05
and O 0 2.798424247885123e-06
with O 0 9.687214514997322e-06
isolated B-Disease 1 0.8620129227638245
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.01131097599864006

No O 0 7.739150532870553e-06
locus O 0 7.237306363094831e-06
other O 0 1.5688820553805272e-07
than O 0 1.786580412499461e-07
chromosome O 0 1.8285165879206033e-06
11p13 O 0 3.819819085038034e-06
has O 0 8.952546437512865e-08
been O 0 1.5775178496824083e-07
implicated O 0 3.32546619574714e-06
in O 0 2.695160787880013e-07
aniridia B-Disease 1 1.0
, O 0 1.5516351368205505e-06
and O 0 1.323632318417367e-06
PAX6 O 1 0.9997351765632629
is O 0 7.9189547363967e-08
clearly O 0 8.976261511861594e-08
the O 0 4.146488663536729e-08
major O 0 1.960524542710118e-07
, O 0 1.5385483109753295e-08
if O 0 5.6393560932122e-09
not O 0 5.41529443509603e-09
only O 0 1.2276299976576865e-08
, O 0 5.9108089089932037e-08
gene O 0 4.441801593202399e-07
responsible O 0 3.514040372465388e-06
. O 0 1.8712624296313152e-05

Twenty O 0 0.00011831272422568873
- O 0 1.5906374756013975e-05
eight O 0 7.383079605460807e-07
percent O 0 2.3187143938230292e-07
of O 0 3.1035816050462017e-07
identified O 0 1.3177001392250531e-06
PAX6 O 0 0.00010772857058327645
mutations O 0 1.775029772943526e-06
are O 0 2.1928875071353104e-07
C O 0 0.0002513288345653564
- O 0 0.00011224533955100924
T O 0 1.535110641270876e-05
changes O 0 8.082683393695334e-07
at O 0 1.2539298950287048e-06
CpG O 0 2.513376784918364e-06
dinucleotides O 0 3.5465084238239797e-06
, O 0 6.285593201482698e-08
20 O 0 6.814181574554823e-08
% O 0 7.378178068506713e-09
are O 0 7.588365491528748e-09
splicing O 0 5.996045615574985e-07
errors O 0 1.3938964684712118e-06
, O 0 2.247567465474276e-08
and O 0 1.0342414036301761e-08
more O 0 3.686576377504025e-09
than O 0 6.5392598003199964e-09
30 O 0 2.8260259909984597e-08
% O 0 9.581036408690125e-09
are O 0 3.3622036710312386e-08
deletion O 0 8.668137638778717e-07
or O 0 3.7376653949650063e-07
insertion O 0 4.3993754843540955e-06
events O 0 5.187074748391751e-06
. O 0 2.0320818293839693e-05

There O 0 4.260265541233821e-06
is O 0 2.798592504404951e-07
a O 0 3.2553586493122566e-07
noticeably O 0 3.7194388369243825e-06
elevated O 0 5.464219157147454e-06
level O 0 5.62676063964318e-07
of O 0 7.667852486292759e-08
mutation O 0 7.823129521966621e-08
in O 0 9.20575438101423e-09
the O 0 2.673413845855066e-08
paired O 0 1.283424495568397e-07
domain O 0 4.462410529981753e-08
compared O 0 2.0963582869626407e-08
with O 0 5.235086142363343e-09
the O 0 2.059009140964463e-08
rest O 0 7.3464448746563e-08
of O 0 7.133468926667774e-08
the O 0 2.07292771392531e-07
gene O 0 1.3396181657299167e-06
. O 0 5.263751972961472e-06

Increased O 0 3.6692690628115088e-06
mutation O 0 1.9434592104516923e-06
in O 0 1.0704356867563547e-07
the O 0 1.73281236470757e-07
homeodomain O 0 6.795440185669577e-06
is O 0 5.5510181340423514e-08
accounted O 0 1.3971035173199198e-07
for O 0 3.522235658692807e-08
by O 0 4.2749071837988595e-08
the O 0 3.4676025961744017e-07
hypermutable O 0 9.140111797023565e-05
CpG O 0 6.753220077371225e-05
dinucleotide O 0 5.979142588330433e-05
in O 0 1.622669628886797e-06
codon O 0 4.625588553608395e-05
240 O 0 3.965491850976832e-05
. O 0 3.352075145812705e-05

Very O 0 6.8358826865733135e-06
nearly O 0 7.73945259879838e-07
all O 0 4.001093856231819e-08
mutations O 0 7.392070244804927e-08
appear O 0 5.915658718436134e-08
to O 0 1.5659455954164514e-08
cause O 0 1.3210328120294434e-07
loss O 0 5.671606118085037e-07
of O 0 1.1111975339872515e-07
function O 0 7.83718334673722e-08
of O 0 4.7957477988802566e-08
the O 0 4.050643909181417e-08
mutant O 0 4.5280731342245417e-07
allele O 0 3.906665142494603e-07
, O 0 2.7358568743807155e-08
and O 0 1.0866370026008099e-08
more O 0 4.489813409946919e-09
than O 0 8.107579496652306e-09
80 O 0 2.408309462964553e-08
% O 0 6.6362741968362116e-09
of O 0 5.505970790409265e-08
exonic O 0 2.1941102659184253e-06
substitutions O 0 5.968620371277211e-07
result O 0 3.2016478712648677e-07
in O 0 1.8287225600488455e-07
nonsense O 0 1.0914780432358384e-05
codons O 0 3.5199682315578684e-05
. O 0 2.0177340047666803e-05

In O 0 1.7841774706539582e-06
a O 0 3.569690818494564e-07
gene O 0 1.3138900101239415e-07
with O 0 2.1094299640367353e-08
such O 0 4.045239521133226e-08
extraordinarily O 0 2.414669779682299e-06
high O 0 1.6729178469176986e-06
sequence O 0 8.711698740171414e-08
conservation O 0 1.2457024745060608e-08
throughout O 0 5.157444249448417e-09
evolution O 0 5.295141747296839e-08
, O 0 3.0714437659895566e-09
there O 0 3.2644191794162225e-09
are O 0 3.199204012815926e-09
presumed O 0 3.4991614938917337e-07
undiscovered O 0 3.223752173653338e-06
missense O 0 3.2785212624730775e-06
mutations O 0 7.602876621604082e-07
, O 0 5.2694399954589244e-08
these O 0 1.6176521455690818e-08
are O 0 1.1663296106689813e-08
hypothesized O 0 9.969110692509275e-08
to O 0 5.995465013342027e-09
exist O 0 4.800470065902118e-08
in O 0 2.10217194762663e-08
as O 0 9.304879000637811e-08
- O 0 9.591880143489107e-07
yet O 0 2.3510122559855517e-07
unidentified O 0 2.365115278735175e-06
phenotypes O 0 6.791773557779379e-06
. O 0 1.3235603546490893e-06
. O 0 9.504006811766885e-06

Genetic O 0 2.247439078928437e-05
heterogeneity O 0 3.5769389796769246e-05
and O 0 1.0773974281619303e-06
penetrance O 0 2.066301203740295e-05
analysis O 0 1.9423980290866893e-07
of O 0 3.527392777868954e-07
the O 0 6.465790534093685e-07
BRCA1 O 0 3.740943793673068e-05
and O 0 5.356177098292392e-06
BRCA2 O 0 0.0011299961479380727
genes O 0 1.1697643458319362e-05
in O 0 1.5695324691478163e-05
breast B-Disease 1 0.999977707862854
cancer I-Disease 1 0.8746293187141418
families O 0 5.719197815778898e-06
. O 0 5.0484813982620835e-05

The O 0 0.05956323444843292
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0061131492257118225
Consortium O 0 0.00021814886713400483
. O 0 3.635868415585719e-05

The O 0 3.4578117720229784e-06
contribution O 0 3.2396956157754175e-06
of O 0 2.3504096589022083e-06
BRCA1 O 0 5.3315990953706205e-05
and O 0 3.2233554065896897e-06
BRCA2 O 0 0.003731725737452507
to O 0 1.745964982546866e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.994642972946167
assessed O 0 7.106292287062388e-06
by O 0 4.7822837245803385e-08
linkage O 0 5.562272917813971e-07
and O 0 7.733653717423294e-08
mutation O 0 1.877304640629518e-07
analysis O 0 7.4484837853106e-08
in O 0 5.4971248886204194e-08
237 O 0 3.518076709951856e-07
families O 0 1.0700270003383139e-08
, O 0 1.8914722232921122e-08
each O 0 4.898240035799972e-09
with O 0 1.3171577606385654e-08
at O 0 5.374138822844543e-07
least O 0 8.302001930360348e-08
four O 0 1.2548339611839765e-07
cases O 0 7.749837038772966e-08
of O 0 1.6800213415990584e-06
breast B-Disease 1 0.9948312640190125
cancer I-Disease 0 0.05865732952952385
, O 0 1.9631794145880122e-07
collected O 0 8.893201908222181e-08
by O 0 1.0309094733429447e-07
the O 0 8.94341337698279e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.021172674372792244
Consortium O 0 0.0003449636569712311
. O 0 2.7077510821982287e-05

Families O 0 1.7135292864622897e-06
were O 0 9.971885219783871e-07
included O 0 2.7386246870264586e-07
without O 0 1.5704658551385364e-07
regard O 0 1.1122705245725228e-07
to O 0 1.3038177648638793e-08
the O 0 2.990896419419187e-08
occurrence O 0 7.871877869547461e-07
of O 0 1.1184201866853982e-05
ovarian B-Disease 1 1.0
or I-Disease 0 0.03989362344145775
other I-Disease 0 6.325410504359752e-05
cancers I-Disease 1 0.9999951124191284
. O 0 9.172820136882365e-05

Overall O 0 0.015424523502588272
, O 0 0.0002623391046654433
disease O 1 0.9960711002349854
was O 0 1.1963283213844988e-05
linked O 0 1.4326760719995946e-06
to O 0 3.05797165367494e-08
BRCA1 O 0 6.277392685660743e-07
in O 0 1.9738100931476765e-08
an O 0 8.81606698754922e-09
estimated O 0 2.4709288837243548e-08
52 O 0 8.354293612455876e-08
% O 0 1.7579756317331885e-08
of O 0 8.013188335098675e-08
families O 0 2.20793303640221e-08
, O 0 3.601631703986641e-08
to O 0 2.8804896246015232e-08
BRCA2 O 0 1.1119221881017438e-06
in O 0 4.192774483158246e-08
32 O 0 2.2725289738900756e-07
% O 0 1.5769275663046756e-08
of O 0 5.611247999581792e-08
families O 0 1.659979353973995e-08
, O 0 2.2101323438050713e-08
and O 0 1.4333626729978732e-08
to O 0 9.28128329746869e-09
neither O 0 4.3682110373310934e-08
gene O 0 2.3358524003924686e-08
in O 0 1.3234257245642311e-08
16 O 0 1.8651020639026683e-07
% O 0 1.9827336217304037e-08
( O 0 1.9434979847687828e-08
95 O 0 1.1238115149581063e-07
% O 0 3.0045100629649824e-08
confidence O 0 1.583892981216195e-06
interval O 0 3.5176208257325925e-06
[ O 0 2.6610825898387702e-06
CI O 0 1.7930125977727585e-05
] O 0 1.042628355207853e-06
6 O 0 7.604414236084267e-07
% O 0 4.000338549303706e-08
- O 0 2.53275089789895e-07
28 O 0 1.816879091620649e-07
% O 0 4.56202506882164e-08
) O 0 6.108565742124483e-08
, O 0 1.0340169609435179e-07
suggesting O 0 7.978946996445302e-07
other O 0 2.1644416392518906e-07
predisposition O 0 7.329940672207158e-06
genes O 0 5.1780652938759886e-06
. O 0 1.2397146747389343e-05

The O 0 2.2294784685072955e-06
majority O 0 5.666324227604491e-07
( O 0 2.818961206685344e-07
81 O 0 8.367145483134664e-07
% O 0 6.840773636440645e-08
) O 0 4.678448561890036e-08
of O 0 3.8205627106435713e-07
the O 0 4.398834425956011e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.845434773415036e-07
were O 0 2.7523708467924735e-07
due O 0 3.9046091160344076e-07
to O 0 3.5458814551248e-08
BRCA1 O 0 2.5220542738679796e-06
, O 0 3.7419557230577993e-08
with O 0 1.1469340144287798e-08
most O 0 2.358923900658283e-08
others O 0 4.013621435206005e-08
( O 0 2.989328251601364e-08
14 O 0 1.6170945116300572e-07
% O 0 2.556824796329238e-08
) O 0 4.417476873186388e-08
due O 0 5.734713681704307e-07
to O 0 1.1644511914710165e-06
BRCA2 O 0 0.00025465775979682803
. O 0 4.767818973050453e-05

Conversely O 0 2.3800375856808387e-05
, O 0 5.035198569203203e-07
the O 0 7.049204953091248e-08
majority O 0 5.270676339819147e-08
of O 0 1.301888516991312e-07
families O 0 1.5397695563024172e-08
with O 0 9.344575602199257e-08
male B-Disease 0 0.0035922639071941376
and I-Disease 0 0.3767799139022827
female I-Disease 1 0.9999924898147583
breast I-Disease 1 0.9999979734420776
cancer I-Disease 1 0.8735211491584778
were O 0 1.8358517763772397e-06
due O 0 4.126058229303453e-06
to O 0 1.3736227799654444e-07
BRCA2 O 0 1.578758929099422e-05
( O 0 2.653001729413518e-07
76 O 0 1.6427525224571582e-06
% O 0 2.0992756333271245e-07
) O 0 6.639073717451538e-07
. O 0 7.904302037786692e-06

The O 0 3.823288807325298e-06
largest O 0 1.8709682763073943e-06
proportion O 0 3.7160668853175594e-07
( O 0 8.101507376068184e-08
67 O 0 3.011961098309257e-07
% O 0 2.7464965413059872e-08
) O 0 2.4469770210089337e-08
of O 0 2.9189722638989224e-08
families O 0 6.72785827049438e-09
due O 0 5.5811689492202277e-08
to O 0 8.761301018012091e-09
other O 0 4.551272247965699e-09
genes O 0 1.900005663912907e-08
was O 0 5.580253059633833e-08
found O 0 6.028662458135159e-09
in O 0 5.9760791870644425e-09
families O 0 3.80962683621533e-09
with O 0 1.636058755138947e-08
four O 0 5.135958645041683e-07
or O 0 2.446566895741853e-07
five O 0 5.179914523978368e-07
cases O 0 1.4475897103238822e-07
of O 0 1.0991231647494715e-05
female O 1 0.9948036074638367
breast B-Disease 1 0.9999725818634033
cancer I-Disease 1 0.5993720293045044
only O 0 1.2543709090095945e-05
. O 0 3.389990160940215e-05

These O 0 1.3971970247439458e-06
estimates O 0 5.579528874477546e-07
were O 0 2.2753567918698536e-07
not O 0 4.3360362411704045e-08
substantially O 0 4.2936855493280746e-07
affected O 0 4.762567584748467e-08
either O 0 5.397890134872796e-08
by O 0 3.0496423164549924e-08
changing O 0 1.054224156860073e-07
the O 0 3.7698946186992544e-08
assumed O 0 2.841994444224838e-07
penetrance O 0 1.9993879050161922e-06
model O 0 3.158667141178739e-07
for O 0 6.659429629962688e-08
BRCA1 O 0 8.962743436313758e-07
or O 0 2.9273072854607562e-08
by O 0 2.2826393220043428e-08
including O 0 1.0876431844053513e-07
or O 0 3.5496583450367325e-07
excluding O 0 3.364944859640673e-06
BRCA1 O 0 9.697419045551214e-06
mutation O 0 2.8791605473088566e-06
data O 0 5.418456112238346e-06
. O 0 1.4833684872428421e-05

Among O 0 6.2221038206189405e-06
those O 0 2.6637917471816763e-07
families O 0 9.32860260149937e-08
with O 0 3.2208129141508834e-07
disease O 0 5.649297600029968e-05
due O 0 1.3504557045962429e-06
to O 0 5.031473193639613e-08
BRCA1 O 0 1.2109506997148856e-06
that O 0 1.2462537668511686e-08
were O 0 5.400196911864441e-08
tested O 0 7.321378348024155e-08
by O 0 6.3882414913507546e-09
one O 0 8.330136580525505e-09
of O 0 1.8177695793042403e-08
the O 0 1.564247043006617e-08
standard O 0 7.435892968032931e-08
screening O 0 1.3409912291706405e-08
methods O 0 3.478564991610256e-08
, O 0 7.971080684399112e-09
mutations O 0 2.57582186691252e-08
were O 0 2.1801961125333946e-08
detected O 0 4.5385313285351e-08
in O 0 1.5008566833785153e-08
the O 0 4.626836513921262e-08
coding O 0 2.127920168959463e-07
sequence O 0 2.6620924131748325e-08
or O 0 1.1884263351191748e-08
splice O 0 1.3910663199112605e-07
sites O 0 1.537474680901596e-08
in O 0 5.9442601951786855e-09
an O 0 4.158573041479485e-09
estimated O 0 1.4403950920893749e-08
63 O 0 9.232485354004893e-08
% O 0 2.4686677591034822e-08
( O 0 2.2939959265499965e-08
95 O 0 3.8010864500392927e-07
% O 0 1.071173016953253e-07
CI O 0 2.07418834179407e-05
51 O 0 1.1382719549146714e-06
% O 0 1.4561825878445234e-07
- O 0 1.1795534646807937e-06
77 O 0 7.873829872551141e-07
% O 0 3.6128781744082517e-07
) O 0 1.3878863001082209e-06
. O 0 1.4718334568897262e-05

The O 0 4.209713097225176e-06
estimated O 0 7.857282184886571e-07
sensitivity O 0 1.3051123914920026e-06
was O 0 3.9004518725960224e-07
identical O 0 8.985408328499034e-08
for O 0 7.342169539015231e-09
direct O 0 3.106880086534147e-08
sequencing O 0 1.268007707722063e-07
and O 0 6.035878641341696e-08
other O 0 8.471171497603791e-08
techniques O 0 1.154661822511116e-05
. O 0 8.537066605640575e-06

The O 0 6.659596238023369e-06
penetrance O 0 0.00014564659795723855
of O 0 7.600414392072707e-06
BRCA2 O 0 8.075427467701957e-05
was O 0 2.849266820703633e-06
estimated O 0 1.61764674544429e-07
by O 0 4.497306704820403e-08
maximizing O 0 1.1579375041037565e-06
the O 0 1.1683617628932552e-07
LOD O 0 3.215949982404709e-05
score O 0 2.06672689273546e-06
in O 0 4.0041177840066666e-07
BRCA2 O 0 6.858841516077518e-05
- O 0 1.1382925549696665e-05
mutation O 0 3.200051708063256e-07
families O 0 1.8348378816313016e-08
, O 0 4.029706701658142e-08
over O 0 5.911710942996251e-08
all O 0 4.872515191323146e-08
possible O 0 5.942573579886812e-07
penetrance O 0 2.4269946152344346e-05
functions O 0 7.700719834247138e-06
. O 0 7.140341040212661e-06

The O 0 3.915257821063278e-06
estimated O 0 6.390303042280721e-07
cumulative O 0 1.3657790987053886e-06
risk O 0 1.450457261853444e-06
of O 0 2.867033117581741e-06
breast B-Disease 0 0.0007613940397277474
cancer I-Disease 0 5.229592716204934e-06
reached O 0 1.3113717614032794e-06
28 O 0 7.074013979035954e-07
% O 0 3.24902167392338e-08
( O 0 3.099032142017677e-08
95 O 0 2.2574796787466767e-07
% O 0 4.010117038433236e-08
CI O 0 3.8885732465132605e-06
9 O 0 4.2034324110318266e-07
% O 0 2.5810201975673408e-08
- O 0 1.1970718105658307e-07
44 O 0 3.002980619726259e-08
% O 0 9.666334399582865e-09
) O 0 5.136494340973741e-09
by O 0 4.515733120769028e-09
age O 0 2.983808045087244e-08
50 O 0 2.1505835334778567e-08
years O 0 1.0812327033704605e-08
and O 0 6.759861115313015e-09
84 O 0 4.7858883078788494e-08
% O 0 7.006708990786592e-09
( O 0 1.0913645986931897e-08
95 O 0 1.2329054754900426e-07
% O 0 5.2241961867594e-08
CI O 0 6.834201030869735e-06
43 O 0 2.656283015767258e-07
% O 0 6.701644394979667e-08
- O 0 1.6345032349818212e-07
95 O 0 9.621584950991746e-08
% O 0 2.1681328732370275e-08
) O 0 1.628459322944309e-08
by O 0 2.3820504679861187e-08
age O 0 4.424539383762749e-07
70 O 0 8.144080538841081e-07
years O 0 1.3814935755362967e-06
. O 0 6.780434887332376e-06

The O 0 2.6957961381413043e-05
corresponding O 1 0.6764967441558838
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.00010313142411177978
were O 0 5.01346266901237e-06
0 O 0 2.4552140530431643e-05
. O 0 1.228649853146635e-05

4 O 0 1.073022485797992e-05
% O 0 4.4622234440794273e-07
( O 0 1.215689735545311e-07
95 O 0 4.7569301386829466e-07
% O 0 9.296930869595599e-08
CI O 0 4.06309754907852e-06
0 O 0 1.7223470649696537e-07
% O 0 1.1765000529351255e-08
- O 0 2.456305558951044e-08
1 O 0 3.8281736891576656e-08
% O 0 5.393421265154075e-09
) O 0 2.3435628992984903e-09
by O 0 3.1042426407168477e-09
age O 0 1.9631022141197718e-08
50 O 0 9.421654567631776e-09
years O 0 6.581616140977076e-09
and O 0 9.677145307307455e-09
27 O 0 8.233154602521608e-08
% O 0 7.947823732479264e-09
( O 0 1.1076294548217902e-08
95 O 0 9.413250978695942e-08
% O 0 2.7572564675892863e-08
CI O 0 2.246880967504694e-06
0 O 0 1.8459942907611548e-07
% O 0 2.3478770927454207e-08
- O 0 9.82712364816507e-08
47 O 0 5.285031434709708e-08
% O 0 1.1297879076721529e-08
) O 0 1.6900997934499173e-08
by O 0 2.7079469333557427e-08
age O 0 2.959711196126591e-07
70 O 0 5.354407903723768e-07
years O 0 1.0309414619769086e-06
. O 0 4.218084086460294e-06

The O 0 8.546654498786665e-06
lifetime O 0 2.9835304303560406e-05
risk O 0 5.397081622504629e-05
of O 0 0.031875088810920715
breast B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.7555813789367676
appears O 0 4.2441240566404304e-07
similar O 0 3.483279087390656e-08
to O 0 9.454778293616073e-09
the O 0 4.892388005828252e-08
risk O 0 1.650741552339241e-07
in O 0 3.4831259654311e-08
BRCA1 O 0 5.135997298566508e-07
carriers O 0 4.380642693035952e-08
, O 0 1.8030627657594778e-08
but O 0 1.4569015327481338e-08
there O 0 1.897568324693566e-08
was O 0 6.386550666093171e-08
some O 0 9.554921298615682e-09
suggestion O 0 1.5795832553067157e-07
of O 0 1.437276750948513e-07
a O 0 2.8492539172475517e-07
lower O 0 3.7953593619022286e-06
risk O 0 1.5597340734530007e-06
in O 0 2.6268213559887954e-07
BRCA2 O 0 6.385907454387052e-06
carriers O 0 2.7887057285624905e-07
< O 0 1.981695731956279e-06
50 O 0 1.7351705139390106e-07
years O 0 7.84325493441429e-08
of O 0 2.350032701770033e-07
age O 0 2.8580298021552153e-06
. O 0 7.768670911900699e-06

Eye B-Disease 1 0.9995442032814026
movement I-Disease 0 0.002214314416050911
abnormalities I-Disease 0 0.3917231261730194
correlate O 0 3.879742052959045e-06
with O 0 1.8983706695507863e-07
genotype O 0 2.9248181817820296e-05
in O 0 8.241416367127385e-07
autosomal O 1 0.9932165741920471
dominant O 1 0.9999998807907104
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999988079071045
. O 0 0.00017663328617345542

We O 0 1.0727492735895794e-05
compared O 0 8.595815415901598e-06
horizontal O 0 0.0004707050684373826
eye O 0 0.00413630111142993
movements O 0 1.3253261386125814e-05
( O 0 1.7388326796208275e-06
visually O 0 3.862060566461878e-06
guided O 0 9.054531801666599e-06
saccades O 0 0.00011983032163698226
, O 0 7.278680413946859e-07
antisaccades O 0 3.08878552459646e-05
, O 0 1.9037116771869478e-07
and O 0 1.1639299657417723e-07
smooth O 0 3.1973595469025895e-06
pursuit O 0 3.651312908914406e-06
) O 0 5.500460531493445e-08
in O 0 2.116171771149311e-08
control O 0 2.4162537215488555e-07
subjects O 0 1.3928930684414809e-06
( O 0 9.158384273177944e-08
n O 0 2.080699630369054e-07
= O 0 5.164396839063556e-07
14 O 0 2.786312904845545e-07
) O 0 1.680703398676542e-08
and O 0 1.8277054536497417e-08
patients O 0 1.867091192764292e-08
with O 0 8.596169998043024e-09
three O 0 2.0738839978662327e-08
forms O 0 6.215848458168693e-08
of O 0 5.993010177007818e-07
autosomal O 0 0.005335840862244368
dominant O 1 0.9984291195869446
cerebellar B-Disease 1 0.9999998807907104
ataxias I-Disease 1 0.9515879154205322
type I-Disease 0 0.0018931031227111816
I I-Disease 0 0.0010418706806376576
spinocerebellar B-Disease 0 0.0028889761306345463
ataxias I-Disease 0 2.1017865947214887e-05
1 I-Disease 0 1.4188573231876944e-06
and I-Disease 0 9.877862794382963e-08
2 I-Disease 0 1.109508161789563e-06
( O 0 8.447517529930337e-08
SCA1 B-Disease 0 5.013692316424567e-06
, O 0 6.140105313079403e-08
n O 0 2.2707763491780497e-07
= O 0 4.4088577055845235e-07
11 O 0 2.3957019834597304e-07
; O 0 4.445284673693095e-08
SCA2 B-Disease 0 6.357470283546718e-06
, O 0 1.0314779075315528e-07
n O 0 2.6540521957940655e-07
= O 0 3.2393847959610866e-07
10 O 0 1.0211635981249856e-07
) O 0 3.0415328922117624e-08
and O 0 3.034475639651646e-07
SCA3 B-Disease 1 0.9999998807907104
/ O 0 0.000296239391900599
Machado B-Disease 0 4.1495590267004445e-05
- I-Disease 0 1.5732850442873314e-05
Joseph I-Disease 0 0.003334497567266226
disease I-Disease 0 0.42024290561676025
( O 0 1.7713127817842178e-06
MJD B-Disease 1 1.0
) O 0 2.899065236761089e-07
( O 0 7.549578384669076e-08
n O 0 6.157251277727482e-07
= O 0 2.03467538995028e-06
16 O 0 2.4815992674120935e-06
) O 0 9.376424259244232e-07
. O 0 7.739697139186319e-06

In O 0 1.0160787496715784e-05
SCA1 B-Disease 0 0.0006416594260372221
, O 0 1.7734002994984621e-06
saccade O 0 2.5285657102358527e-05
amplitude O 0 6.147421117930207e-06
was O 0 5.989073201817519e-07
significantly O 0 1.941447891340431e-07
increased O 0 1.7995709811202687e-07
, O 0 9.921555488290323e-08
resulting O 0 6.584581910829002e-07
in O 0 6.006427497595723e-07
hypermetria B-Disease 0 5.2833194786217064e-05
. O 0 1.3433995263767429e-05

The O 0 9.28330064198235e-06
smooth O 0 2.312813558091875e-05
pursuit O 0 4.196661393507384e-05
gain O 0 5.646421413985081e-05
was O 0 5.1285027439007536e-05
decreased O 0 4.448605250217952e-05
. O 0 2.3720820536254905e-05

In O 0 8.015272214834113e-06
SCA2 B-Disease 0 0.0009519848972558975
, O 0 1.926792947415379e-06
saccade O 0 3.467678834567778e-05
velocity O 0 2.803774805215653e-05
was O 0 1.2077885003236588e-05
markedly O 0 6.437722186092287e-05
decreased O 0 3.859174103126861e-05
. O 0 1.783151128620375e-05

The O 0 2.4098433186736656e-06
percentage O 0 2.260112978547113e-06
of O 0 5.643608460559335e-07
errors O 0 2.610680166981183e-05
in O 0 2.482927072833263e-07
antisaccades O 0 8.187940693460405e-05
was O 0 8.939304052546504e-07
greatly O 0 2.0988652238429495e-07
increased O 0 1.0953542783909143e-07
and O 0 7.143026437006483e-08
was O 0 2.1665707095053222e-07
significantly O 0 8.367163673028699e-08
correlated O 0 1.4291687477907544e-07
with O 0 2.7271250147009596e-08
age O 0 2.0088942619622685e-05
at O 0 0.0004730446671601385
disease O 0 0.10773328691720963
onset O 0 0.3851739764213562
. O 0 2.8403783289832063e-05

In O 0 1.0877795375563437e-06
addition O 0 7.039328693281277e-07
, O 0 9.759560981592585e-08
a O 0 8.758365765970666e-08
correlation O 0 1.8331664364268363e-07
between O 0 9.314182847219854e-08
smooth O 0 1.0560348755461746e-06
pursuit O 0 1.107621073970222e-06
gain O 0 5.56424140540912e-07
and O 0 4.21569268382882e-08
the O 0 2.434598123102205e-08
number O 0 1.3906572782218518e-08
of O 0 1.8955250880026142e-07
trinucleotide O 0 6.99478987371549e-05
repeats O 0 3.476606480035116e-06
was O 0 1.2702688536592177e-06
found O 0 1.1487684332678327e-06
. O 0 1.086740849132184e-05

In O 0 2.774090535240248e-05
SCA3 B-Disease 1 1.0
, O 0 1.0279303751303814e-05
gaze B-Disease 0 0.03645775094628334
- I-Disease 0 0.08167509734630585
evoked I-Disease 0 0.00045964904711581767
nystagmus I-Disease 1 0.9878178238868713
was O 0 1.792778903109138e-06
often O 0 4.247808504942441e-08
present O 0 5.4725823872558976e-08
as O 0 1.0954609308555519e-07
was O 0 9.815066732699051e-07
saccade O 0 1.2946883543918375e-05
hypometria O 0 1.4572883628716227e-05
and O 0 4.7004073167045135e-07
smooth O 0 1.0122882486029994e-05
pursuit O 0 2.0435007172636688e-05
gain O 0 5.1271243137307465e-05
was O 0 4.7487345000263304e-05
markedly O 0 4.402847116580233e-05
decreased O 0 2.2359930881066248e-05
. O 0 1.0511704203963745e-05

Three O 0 5.9149638218514156e-06
major O 0 2.6167076612182427e-06
criteria O 0 1.3636498579217005e-06
, O 0 2.684323305857106e-07
saccade O 0 7.1978192863753065e-06
amplitude O 0 2.604843984954641e-06
, O 0 1.4574038686987478e-07
saccade O 0 1.971798610611586e-06
velocity O 0 1.3933249647379853e-06
, O 0 1.0661383953447512e-07
and O 0 4.83227395875474e-08
presence O 0 2.048402194532173e-07
of O 0 1.169967845271458e-06
gaze B-Disease 0 0.008338868618011475
- I-Disease 0 0.03384437784552574
evoked I-Disease 0 8.294591680169106e-05
nystagmus I-Disease 0 0.0008312904392369092
, O 0 9.416519475280438e-08
permitted O 0 5.19016971622932e-08
the O 0 3.128078063241446e-08
correct O 0 1.8378138122443488e-07
assignment O 0 2.1584082787740044e-07
of O 0 5.581041051527791e-08
90 O 0 1.407769758543509e-07
% O 0 2.8415492181466107e-08
of O 0 1.0279642026489455e-07
the O 0 2.0989193671994144e-07
SCA1 B-Disease 0 4.290261858841404e-05
, O 0 7.821920888773093e-08
90 O 0 1.0275055473130124e-07
% O 0 1.2785703162876416e-08
of O 0 5.158745608468962e-08
the O 0 1.734713919177011e-07
SCA2 B-Disease 0 0.0003050108498428017
, O 0 9.78952101604591e-08
and O 0 4.068437320370322e-08
93 O 0 2.2391002119093173e-07
% O 0 1.7783825967399025e-08
of O 0 8.814204477403109e-08
the O 0 1.2162824702954822e-07
patients O 0 1.0027925156919082e-07
with O 0 9.411851209506494e-08
SCA3 B-Disease 1 1.0
to O 0 3.4575037943795905e-08
their O 0 3.9637907178757814e-08
genetically O 0 2.3934549631121627e-07
confirmed O 0 9.124907052182607e-08
patient O 0 6.926072160240437e-08
group O 0 2.9781961785602107e-08
and O 0 4.059135960687854e-08
, O 0 3.859155484065013e-08
therefore O 0 7.77718796030058e-08
, O 0 6.483400483148216e-08
may O 0 1.4327359565413644e-07
help O 0 2.515724304430478e-07
orient O 0 1.5499681467190385e-05
diagnoses O 0 2.0221057184244273e-06
of O 0 4.3676197947206674e-07
SCA1 B-Disease 0 0.0016555562615394592
, O 0 5.337619199963228e-07
SCA2 B-Disease 0 0.016826003789901733
, O 0 4.49445991534958e-07
and O 0 1.088037947738485e-06
SCA3 B-Disease 1 1.0
at O 0 5.364642674976494e-06
early O 0 6.033772592672904e-07
clinical O 0 2.182898242608644e-06
stages O 0 2.3255272481037537e-06
of O 0 1.081807226910314e-06
the O 0 6.521471277665114e-06
diseases O 1 0.860102117061615
. O 0 2.9639977583428845e-06
. O 0 1.6464933651150204e-05

Genetic O 0 8.693788004165981e-06
basis O 0 1.7696715985948686e-06
and O 0 4.943137810187181e-07
molecular O 0 1.7041089449776337e-05
mechanism O 0 0.0005889684543944895
for O 0 8.595326653448865e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.999291181564331

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999997615814209
causes O 0 8.561558206565678e-05
more O 0 1.9345708324181032e-07
than O 0 6.391887552581466e-08
300 O 0 1.3486405237017607e-07
, O 0 2.9030813308850156e-08
000 O 0 2.3799347559361195e-07
sudden O 0 3.7310911693566595e-07
deaths O 0 6.117100070923698e-08
each O 0 9.094964781297676e-09
year O 0 1.1626048568302849e-08
in O 0 1.5402159547761585e-08
the O 0 2.0323082594586594e-07
USA O 0 4.116146101296181e-06
alone O 0 3.912115062121302e-06
. O 0 8.188485480786767e-06

In O 0 2.2863312096887967e-06
approximately O 0 1.7473571460868698e-06
5 O 0 1.040980123434565e-06
- O 0 4.982952646059857e-07
12 O 0 1.58997380594883e-07
% O 0 1.4866681219416478e-08
of O 0 1.863910270571978e-08
these O 0 9.945595458304979e-09
cases O 0 1.016666217878992e-08
, O 0 3.6920366763837364e-09
there O 0 4.505460893255986e-09
are O 0 3.060794284692747e-09
no O 0 5.166356942254424e-08
demonstrable O 0 3.7457844882737845e-05
cardiac O 0 0.25390738248825073
or O 0 6.231254246813478e-06
non O 1 0.9959775805473328
- O 1 0.9928883910179138
cardiac O 0 0.48317569494247437
causes O 0 7.093497060850495e-07
to O 0 2.4184824809481142e-08
account O 0 1.0249351589664002e-08
for O 0 1.0663759653084526e-08
the O 0 2.7102721844585176e-08
episode O 0 1.371941777961183e-07
, O 0 2.823913725080729e-08
which O 0 7.88744713986489e-09
is O 0 5.2650470649950876e-09
therefore O 0 4.218950167000912e-08
classified O 0 1.4940169990040886e-07
as O 0 6.323905950011977e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999798536300659
IVF B-Disease 1 1.0
) O 0 4.300182263250463e-05
. O 0 7.703201845288277e-05

A O 0 1.3178835615690332e-05
distinct O 0 2.1612786440528e-06
group O 0 8.275866321127978e-07
of O 0 1.771150346030481e-05
IVF B-Disease 1 1.0
patients O 0 1.6934691302594729e-06
has O 0 2.5430317407426628e-08
been O 0 1.3394548581402432e-08
found O 0 2.295469814228568e-09
to O 0 1.7949263186878284e-09
present O 0 1.535543248110116e-08
with O 0 2.1213688583543444e-08
a O 0 4.6945385179242294e-07
characteristic O 0 0.0007620828691869974
electrocardiographic O 0 0.49344080686569214
pattern O 0 0.0006522138719446957
. O 0 2.4793076590867713e-05

Because O 0 1.1808804174506804e-06
of O 0 5.543600423152384e-07
the O 0 1.1033327496079437e-07
small O 0 2.1148119699887502e-08
size O 0 3.086473299163117e-08
of O 0 6.279458375502145e-08
most O 0 2.6218851090220596e-08
pedigrees O 0 2.3951105276864837e-07
and O 0 4.34757190248547e-08
the O 0 5.988907503251539e-08
high O 0 3.3863241242215736e-06
incidence O 0 2.0802722247026395e-06
of O 0 1.7284205000578368e-07
sudden B-Disease 0 8.858310138748493e-06
death I-Disease 0 1.712178891466465e-05
, O 0 8.700838094455321e-08
however O 0 7.304905125238292e-08
, O 0 2.164154189188139e-08
molecular O 0 1.5978677936345775e-07
genetic O 0 2.464278558989008e-08
studies O 0 2.1260149196677958e-08
of O 0 1.623435963438169e-07
IVF B-Disease 1 0.9998741149902344
have O 0 3.735010523087112e-08
not O 0 2.4638037388058365e-08
yet O 0 2.806953602885187e-07
been O 0 4.797248607246729e-07
done O 0 1.3594091115010087e-06
. O 0 5.548304216063116e-06

Because O 0 3.964429197367281e-05
IVF B-Disease 1 0.9999960660934448
causes O 0 0.00019795908883679658
cardiac O 1 0.9994729161262512
rhythm O 1 0.999954342842102
disturbance O 1 0.9997757077217102
, O 0 5.467073265208455e-07
we O 0 1.8305267701634875e-07
investigated O 0 4.880058099843154e-07
whether O 0 4.2255862808815436e-08
malfunction O 0 2.149367219317355e-06
of O 0 1.0688443552453464e-07
ion O 0 1.2286614946788177e-05
channels O 0 8.565320968045853e-07
could O 0 1.6297931892950146e-07
cause O 0 1.097122776627657e-06
the O 0 3.6204386333338334e-07
disorder O 0 2.358790698053781e-05
by O 0 3.6339670828056114e-08
studying O 0 2.3495216794344742e-07
mutations O 0 1.4519143576308124e-07
in O 0 2.373297647295658e-08
the O 0 1.523589929774971e-07
cardiac O 0 8.339188752870541e-06
sodium O 0 1.5092659850779455e-05
channel O 0 7.038683634164045e-06
gene O 0 2.924979980889475e-06
SCN5A O 0 0.00030795528437010944
. O 0 2.7251751816947944e-05

We O 0 2.8988322355871787e-06
have O 0 1.591817238022486e-07
now O 0 1.0392606242248803e-07
identified O 0 2.393783518073178e-07
a O 0 1.1049205994595468e-07
missense O 0 3.5184898479201365e-06
mutation O 0 6.258115377022477e-07
, O 0 1.87090961389913e-07
a O 0 2.444975848447939e-07
splice O 0 4.8607080316287465e-06
- O 0 1.6292038935716846e-06
donor O 0 4.164710887266665e-08
mutation O 0 2.537879311148572e-07
, O 0 8.272159846001159e-08
and O 0 1.1289471757436331e-07
a O 0 3.4014024663520104e-07
frameshift O 0 9.843086445471272e-06
mutation O 0 4.2131523514399305e-07
in O 0 7.376127086899942e-08
the O 0 1.0047031651083671e-07
coding O 0 7.947642188810278e-07
region O 0 2.3166235507687816e-07
of O 0 5.743842734773352e-07
SCN5A O 0 0.007809554226696491
in O 0 3.557174750312697e-07
three O 0 2.733489509409992e-06
IVF B-Disease 1 0.9828589558601379
families O 0 1.7991006870943238e-06
. O 0 1.1359545169398189e-05

We O 0 1.7882606471175677e-06
show O 0 1.5032955502647383e-07
that O 0 1.1170728342335678e-08
sodium O 0 1.4411884308174194e-07
channels O 0 5.581892636996599e-08
with O 0 9.182904214810605e-09
the O 0 3.513170909741348e-08
missense O 0 1.5497452068302664e-06
mutation O 0 4.956444854542497e-07
recover O 0 6.289611178544874e-07
from O 0 4.7045418227753544e-08
inactivation O 0 6.310709068202414e-06
more O 0 4.216198945528049e-08
rapidly O 0 1.4705990736274543e-07
than O 0 1.3200272874769325e-08
normal O 0 2.452345349013285e-08
and O 0 4.109081963576955e-09
that O 0 2.329782367027633e-09
the O 0 2.9608591134433482e-08
frameshift O 0 1.3881498261980596e-06
mutation O 0 8.047067723282453e-08
causes O 0 2.570840074156422e-08
the O 0 1.840333574421038e-08
sodium O 0 1.4030655393071356e-07
channel O 0 5.6339406029337624e-08
to O 0 7.25636795095852e-09
be O 0 4.060661495941531e-08
non O 0 1.7449126517021796e-06
- O 0 4.862019977736054e-06
functional O 0 1.553151014377363e-05
. O 0 8.325839189637918e-06

Our O 0 8.936694939620793e-06
results O 0 2.2104079562268453e-06
indicate O 0 3.5608948678600427e-07
that O 0 3.282351812572415e-08
mutations O 0 2.5488645860605175e-07
in O 0 6.499185900565863e-08
cardiac O 0 4.664842890633736e-06
ion O 0 0.00015012355288490653
- O 0 0.0008780612261034548
channel O 0 6.293612955232675e-07
genes O 0 1.215064582282821e-08
contribute O 0 9.006440926384585e-09
to O 0 4.0535637069183394e-09
the O 0 1.6091343368884736e-08
risk O 0 8.559281639008987e-08
of O 0 5.677033527717867e-07
developing O 0 0.00020276005670893937
IVF B-Disease 1 0.9999825954437256
. O 0 1.1336343277434935e-06
. O 0 6.790581664972706e-06

Molecular O 0 0.00010036856838269159
heterogeneity O 0 3.710353485075757e-05
in O 0 1.1500027312649763e-06
mucopolysaccharidosis B-Disease 0 0.0002093570219585672
IVA I-Disease 0 0.04620381444692612
in O 0 2.54837345892156e-07
Australia O 0 2.638058447246294e-07
and O 0 4.1999701494432884e-08
Northern O 0 4.526471286681044e-07
Ireland O 0 1.1458831750132958e-06
: O 0 1.1711205161191174e-07
nine O 0 2.7720381012841244e-07
novel O 0 1.3806069887323247e-07
mutations O 0 2.4969347123260377e-07
including O 0 2.1162973951049935e-07
T312S O 0 9.505565685685724e-06
, O 0 1.7523456108392566e-07
a O 0 1.2060463916441222e-07
common O 0 2.524229216760432e-07
allele O 0 2.248705186502775e-06
that O 0 6.337599245398451e-08
confers O 0 2.866973090931424e-06
a O 0 2.2799254111305345e-06
mild O 0 0.0247909314930439
phenotype O 0 0.0017330693081021309
. O 0 4.7993406042223796e-05

Mucopolysaccharidosis B-Disease 1 0.5255364775657654
IVA I-Disease 1 0.9999911785125732
( O 0 0.00026944628916680813
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 2.5210345029336167e-06
is O 0 2.633822475672787e-07
an O 0 5.12161761889729e-07
autosomal B-Disease 1 0.9997590184211731
recessive I-Disease 1 0.9999997615814209
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999085664749146
by O 0 3.48297726304736e-05
a O 0 0.0003234796749893576
genetic B-Disease 1 0.9999997615814209
defect I-Disease 1 0.9998946189880371
in O 0 1.5038132232803036e-06
N O 0 0.00011425314733060077
- O 0 0.000252496829489246
acetylgalactosamine O 0 0.00011074330541305244
- O 0 2.5458266463829204e-05
6 O 0 2.7511699954629876e-05
- O 0 2.4173161364160478e-05
sulfate O 0 9.704579133540392e-05
sulfatase O 0 0.37964314222335815
( O 0 1.7811835277825594e-06
GALNS O 0 0.0006315801874734461
) O 0 2.811024842230836e-06
. O 0 1.844487815105822e-05

Previous O 0 1.6312314983224496e-05
studies O 0 1.2625080216821516e-06
of O 0 3.874422986882564e-07
patients O 0 9.28814074541151e-08
from O 0 2.0650503529395792e-08
a O 0 1.0567062957989037e-07
British O 0 2.461606754877721e-06
- O 0 1.561241333547514e-05
Irish O 0 1.6576259440626018e-06
population O 0 1.0691986851441015e-08
showed O 0 4.2914908959801323e-08
that O 0 5.87218451642002e-09
the O 0 5.9251444639585316e-08
I113F O 0 2.208151272498071e-06
mutation O 0 1.435048346820622e-07
is O 0 1.5769515471220075e-08
the O 0 2.0401159872562857e-08
most O 0 1.1712719683032446e-08
common O 0 5.3550870404706075e-08
single O 0 6.153329223934634e-08
mutation O 0 4.1088807734013244e-07
among O 0 1.0222017863270594e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 5.4672003898303956e-05
and O 0 2.082622586385696e-06
produces O 0 7.388704034383409e-06
a O 0 1.345831151411403e-06
severe O 1 0.6087177395820618
clinical O 0 0.02006378024816513
phenotype O 0 0.0008878657245077193
. O 0 2.3668530047871172e-05

We O 0 3.6921273931511678e-06
studied O 0 4.5510369091061875e-06
mutations O 0 4.470205396955862e-07
in O 0 4.9763372089728364e-08
the O 0 1.819969526195564e-07
GALNS O 0 9.504740773991216e-06
gene O 0 8.002038498489128e-08
from O 0 1.9739793799544714e-08
23 O 0 3.967391535297793e-07
additional O 0 6.984168408052938e-07
MPS B-Disease 1 0.9999958276748657
IVA I-Disease 1 1.0
patients O 0 5.364226467463595e-07
( O 0 5.3112547249156705e-08
15 O 0 7.350482178480888e-08
from O 0 6.206925196039492e-09
Australia O 0 1.8893629771810083e-08
, O 0 5.44464562324265e-09
8 O 0 4.7525407609327885e-08
from O 0 3.6760507970967637e-09
Northern O 0 6.395790563828996e-08
Ireland O 0 2.6377941253485915e-07
) O 0 1.8525083689269195e-08
, O 0 8.195235601249351e-09
with O 0 4.027453481825205e-09
various O 0 4.6059774660989206e-08
clinical O 0 3.2976917282212526e-05
phenotypes O 0 0.0052599613554775715
( O 0 8.778230835559953e-07
severe O 0 0.0028220436070114374
, O 0 3.9989697597775375e-07
16 O 0 2.0831864731007954e-06
cases O 0 7.45738262253326e-08
; O 0 2.8494188342165216e-08
intermediate O 0 6.407734872482251e-06
, O 0 3.558951888749107e-08
4 O 0 4.0738501638770686e-07
cases O 0 2.3050310105077187e-08
; O 0 2.8497831650042826e-08
mild O 0 5.174960278964136e-06
, O 0 1.255901906915824e-07
3 O 0 1.9741391952265985e-06
cases O 0 2.985556477597129e-07
) O 0 4.3999489207635634e-07
. O 0 4.6066547838563565e-06

We O 0 4.81158076581778e-06
found O 0 4.401035766932182e-07
two O 0 1.1768550933766164e-07
common O 0 6.929044360504122e-08
mutations O 0 1.1786622877707487e-07
that O 0 4.658322616535315e-09
together O 0 1.75243837219341e-08
accounted O 0 5.5146944788475594e-08
for O 0 1.670301408296382e-08
32 O 0 1.021255187083625e-07
% O 0 1.1166511271198942e-08
of O 0 4.2634418662146345e-08
the O 0 7.302271853859565e-08
44 O 0 2.958641687200725e-07
unrelated O 0 3.017849508069048e-07
alleles O 0 2.95553377327451e-07
in O 0 5.7459807578652544e-08
these O 0 1.6308503347772785e-07
patients O 0 1.9075223463005386e-06
. O 0 6.223979198693996e-06

One O 0 5.59551153855864e-06
is O 0 3.6188541230330884e-07
the O 0 2.7859675810759654e-07
T312S O 0 9.012438567879144e-06
mutation O 0 1.260773046851682e-06
, O 0 7.404007362765697e-08
a O 0 7.516918287819863e-08
novel O 0 1.6531362234672997e-07
mutation O 0 2.459747747707297e-07
found O 0 8.459465306032143e-08
exclusively O 0 4.6615468818345107e-07
in O 0 6.859665973024676e-07
milder O 0 0.014522634446620941
patients O 0 4.061792424181476e-05
. O 0 3.75867348338943e-05

The O 0 2.1173684672248783e-06
other O 0 1.2398847104577726e-07
is O 0 4.668580899647168e-08
the O 0 8.970510378958352e-08
previously O 0 2.802542837798683e-07
described O 0 4.2795082322300004e-07
I113F O 0 4.066206656716531e-06
that O 0 8.026312059428165e-08
produces O 0 1.3793675179840648e-06
a O 0 1.6968689351415378e-06
severe O 1 0.9205337762832642
phenotype O 1 0.8417287468910217
. O 0 6.723199476255104e-05

The O 0 2.050751390925143e-05
I113F O 0 8.323775546159595e-05
and O 0 1.1615342145887553e-06
T312S O 0 8.669578164699487e-06
mutations O 0 3.0870421596773667e-07
accounted O 0 9.425468761037337e-08
for O 0 2.6654099372080964e-08
8 O 0 5.319872684594884e-07
( O 0 1.9171588760968916e-08
18 O 0 1.0647261206031544e-07
% O 0 9.232482334198266e-09
) O 0 1.0175275733104172e-08
and O 0 2.585355929340949e-08
6 O 0 7.783299906805041e-07
( O 0 3.3023901835349534e-08
14 O 0 1.1976186442552716e-07
% O 0 1.150801676175206e-08
) O 0 7.802428036995934e-09
of O 0 3.825589800499074e-08
44 O 0 3.2349547041121696e-07
unrelated O 0 6.519560997730878e-07
alleles O 0 2.1115749859745847e-06
, O 0 7.25209417851147e-07
respectively O 0 1.3654646863869857e-05
. O 0 2.1806032236781903e-05

The O 0 5.117085038364166e-06
relatively O 0 3.190746383552323e-06
high O 0 8.603425158071332e-06
residual O 0 1.7811882571550086e-05
GALNS O 0 0.0004978274228051305
activity O 0 8.466379881610919e-07
seen O 0 2.2852624681490852e-07
when O 0 3.1530689170722326e-08
the O 0 7.510454480552653e-08
T312S O 0 9.75208649833803e-07
mutant O 0 2.8039542598889966e-07
cDNA O 0 3.109227861841646e-07
is O 0 2.841175295031917e-08
overexpressed O 0 5.932499789196299e-07
in O 0 2.7934374813298746e-08
mutant O 0 5.516866394827957e-07
cells O 0 1.4916138013632008e-07
provides O 0 2.7463864071819444e-08
an O 0 3.631741130050159e-09
explanation O 0 5.4941274640896154e-08
for O 0 2.5327405950292814e-08
the O 0 2.1696060059639422e-07
mild O 1 0.71631920337677
phenotype O 0 0.002640926744788885
in O 0 9.690300117881634e-08
patients O 0 7.270072188703125e-08
with O 0 2.715270497333222e-08
this O 0 7.992199613227058e-08
mutation O 0 2.0115674033149844e-06
. O 0 6.167257197375875e-06

The O 0 1.0363048659201013e-06
distribution O 0 1.923009875781645e-07
and O 0 5.020190485538478e-08
relative O 0 1.678364043300462e-07
frequencies O 0 3.6704204831039533e-07
of O 0 6.0905442467174e-08
the O 0 4.1543337658822566e-08
I113F O 0 2.3968316327227512e-06
and O 0 1.0594389010520899e-07
T312S O 0 1.571420170876081e-06
mutations O 0 1.5361328564722498e-07
in O 0 2.1702719621430333e-08
Australia O 0 8.6131109355847e-08
corresponded O 0 2.2835886070993183e-08
to O 0 5.220448517917475e-09
those O 0 6.027891963356069e-09
observed O 0 3.920765578868668e-08
in O 0 1.1025539592424138e-08
Northern O 0 2.026631733542672e-07
Ireland O 0 5.410186076915124e-07
and O 0 4.9704365068237166e-08
are O 0 4.294518518577206e-09
unique O 0 6.209613268026715e-09
to O 0 1.8411403512885727e-09
these O 0 2.666344034452095e-09
two O 0 6.940735097771267e-09
populations O 0 6.510747940779993e-09
, O 0 6.971515809084394e-09
suggesting O 0 1.7375176852851837e-08
that O 0 1.9319510435877874e-09
both O 0 1.2081318168100097e-08
mutations O 0 5.561955163102539e-08
were O 0 1.835464580324242e-08
probably O 0 3.257634517694896e-08
introduced O 0 3.1510968057091304e-08
to O 0 4.804883158016082e-09
Australia O 0 3.3843107871689426e-08
by O 0 9.024324398865247e-09
Irish O 0 2.7599250529419805e-07
migrants O 0 5.6979601481543796e-08
during O 0 1.4167748929594381e-07
the O 0 2.023707708076472e-07
19th O 0 4.463595359993633e-06
century O 0 1.1720544534910005e-05
. O 0 1.5354884453699924e-05

Haplotype O 0 0.00011015414929715917
analysis O 0 2.4053290417214157e-06
using O 0 1.2249633982719388e-06
6 O 0 1.2217538824188523e-05
RFLPs O 0 3.163905057590455e-05
provides O 0 1.7205003643994132e-07
additional O 0 4.553697152687164e-08
data O 0 2.4288652866744087e-08
that O 0 2.9790583333522136e-09
the O 0 1.8680102797929976e-08
I113F O 0 4.5600245357491076e-07
mutation O 0 8.39404918906439e-08
originated O 0 6.793962370466033e-08
from O 0 2.426281575651501e-08
a O 0 1.265760403157401e-07
common O 0 8.124980581669661e-07
ancestor O 0 1.4346736861625686e-05
. O 0 1.6463913198094815e-05

The O 0 1.3273005379232927e-06
other O 0 8.00886397200884e-08
9 O 0 6.449378702200192e-07
novel O 0 8.1007506480546e-08
mutations O 0 1.1469978744571563e-07
identified O 0 5.080781662059053e-08
in O 0 1.0856199494924113e-08
these O 0 1.7054425427431852e-08
23 O 0 1.0657953453119262e-06
patients O 0 5.745519970901114e-08
were O 0 3.966188089066236e-08
each O 0 6.822241438442234e-09
limited O 0 1.859496379097436e-08
to O 0 1.4490420419122074e-08
a O 0 1.439794203861311e-07
single O 0 4.933497166348388e-07
family O 0 7.942982165332069e-07
. O 0 6.500378731288947e-06

These O 0 8.287705668408307e-07
data O 0 5.078844083072909e-07
provide O 0 7.553121150749575e-08
further O 0 5.729499008566563e-08
evidence O 0 7.462462292551209e-08
for O 0 3.011349036796673e-08
extensive O 0 2.483836567535036e-07
allelic O 0 8.30605949886376e-06
heterogeneity O 0 1.0779014701256528e-05
in O 0 6.632682243434829e-07
MPS B-Disease 1 0.999958872795105
IVA I-Disease 1 1.0
in O 0 2.54480823969061e-07
British O 0 3.856996045215055e-06
- O 0 1.7338950783596374e-05
Irish O 0 1.7136731003120076e-06
patients O 0 1.0421487672829244e-07
and O 0 3.728832353999678e-08
provide O 0 5.039694883635093e-08
evidence O 0 1.2439957686183334e-07
for O 0 1.6477178732543507e-08
their O 0 1.8626522546583146e-08
transmission O 0 1.3258659237180836e-06
to O 0 9.364091724251011e-09
Australia O 0 3.0516030591343224e-08
by O 0 7.095199983098155e-09
British O 0 3.5405534504207026e-07
- O 0 5.503775923898502e-07
Irish O 0 5.657354904542444e-07
migrants O 0 2.3555345762815705e-07
. O 0 4.815188958673389e-07
. O 0 6.137299806141527e-06

Identification O 0 4.627411271940218e-06
of O 0 4.340067789598834e-06
constitutional O 0 9.899608267005533e-05
WT1 O 1 0.8051460981369019
mutations O 0 1.5903357052593492e-05
, O 0 4.2934192379107117e-07
in O 0 1.0902247993271885e-07
patients O 0 1.462082792613728e-07
with O 0 1.9627020719781285e-07
isolated O 0 6.02706968493294e-05
diffuse B-Disease 1 0.9999998807907104
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.862855919578578e-06
and O 0 1.3172549984119541e-07
analysis O 0 1.0897674940224533e-07
of O 0 3.786505544667307e-07
genotype O 0 5.337479160516523e-05
/ O 0 4.740426811622456e-05
phenotype O 0 1.731665406623506e-06
correlations O 0 3.854006820347422e-07
by O 0 1.132746163534648e-08
use O 0 2.1447501552529502e-08
of O 0 1.5135046282921394e-07
a O 0 3.6639920608649845e-07
computerized O 0 4.667798293667147e-06
mutation O 0 2.1525386273424374e-06
database O 0 2.6769530450110324e-06
. O 0 1.1493731108203065e-05

Constitutional O 0 2.813682658597827e-05
mutations O 0 2.501225026207976e-06
of O 0 6.92353523845668e-07
the O 0 9.146214665634034e-07
WT1 O 0 0.0002400111116003245
gene O 0 7.777185828672373e-07
, O 0 2.41073877305098e-07
encoding O 0 3.637570443970617e-06
a O 0 1.1084960078733275e-06
zinc O 0 0.0011994242668151855
- O 0 0.12314026057720184
finger O 0 1.4974981240811758e-05
transcription O 0 2.2006504423188744e-06
factor O 0 8.804137792139954e-07
involved O 0 3.468753391189239e-07
in O 0 1.9217979740915325e-07
renal O 1 0.9999988079071045
and O 0 4.251330392435193e-05
gonadal O 1 0.9999998807907104
development O 0 0.028343725949525833
, O 0 1.0237027225912243e-07
are O 0 5.1296118463994844e-09
found O 0 7.904766619049042e-09
in O 0 1.2063956056351799e-08
most O 0 3.9402500817686814e-08
patients O 0 6.405215202676118e-08
with O 0 3.0293000463643693e-07
Denys B-Disease 1 0.999993085861206
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9975563287734985
DDS B-Disease 1 1.0
) O 0 3.3020301088981796e-06
, O 0 3.711434430897498e-07
or O 0 3.8108244098111754e-06
diffuse B-Disease 1 0.9999860525131226
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.13102181255817413
DMS B-Disease 1 0.9999995231628418
) O 0 2.7575964622883475e-07
associated O 0 1.8330405282540596e-07
with O 0 3.605629217418027e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.011887366883456707
/ O 1 0.9999783039093018
or O 0 0.00046354797086678445
Wilms B-Disease 1 0.9999979734420776
tumor I-Disease 0 0.007293537259101868
( O 0 6.950474016775843e-06
WT B-Disease 1 0.9999997615814209
) O 0 1.2203611731820274e-05
. O 0 5.2887433412251994e-05

Most O 0 2.454990635669674e-06
mutations O 0 1.2003486517642159e-05
in O 0 2.6871584850596264e-06
DDS B-Disease 1 1.0
patients O 0 7.42146403354127e-06
lie O 0 3.5433913581073284e-06
in O 0 2.035809671951938e-07
exon O 0 1.7060808659152826e-06
8 O 0 1.449489332117082e-06
or O 0 1.3471546367327392e-07
exon O 0 8.885298825589416e-07
9 O 0 8.820113066576596e-07
, O 0 1.7820011066760344e-07
encoding O 0 3.701060677485657e-06
zinc O 0 2.4090270017040893e-05
finger O 0 9.436650543648284e-06
2 O 0 4.835117215407081e-05
or O 0 1.2970162970304955e-06
zinc O 0 1.6438323655165732e-05
finger O 0 2.0123616195633076e-06
3 O 0 2.061231270999997e-06
, O 0 2.999431458761137e-08
respectively O 0 1.0544513173726955e-07
, O 0 1.1299926327978937e-08
with O 0 6.847806766074882e-09
a O 0 2.9745118368396106e-08
hot O 0 6.64511674131063e-07
spot O 0 2.0808158751606243e-06
( O 0 1.311600215103681e-07
R394W O 0 2.065956550723058e-06
) O 0 4.7772331868145557e-08
in O 0 1.0069496880760198e-07
exon O 0 5.955939741397742e-06
9 O 0 1.1544118933670688e-05
. O 0 8.609926226199605e-06

We O 0 5.519357273442438e-06
analyzed O 0 1.6976896404230502e-06
a O 0 1.5848947043650696e-07
series O 0 2.1206776068538602e-07
of O 0 1.0729007726695272e-07
24 O 0 1.3850211644239607e-06
patients O 0 5.633403432625528e-08
, O 0 2.932280906975393e-08
10 O 0 9.292783431646967e-08
with O 0 4.779219864303741e-08
isolated B-Disease 0 7.348003691731719e-06
DMS I-Disease 1 0.9999890327453613
( O 0 4.5217743718239944e-06
IDMS B-Disease 1 0.7620855569839478
) O 0 1.6672845504217548e-07
, O 0 1.0933880645325189e-07
10 O 0 2.9060075235065597e-07
with O 0 1.9216439284264197e-07
DDS B-Disease 1 1.0
, O 0 2.6456370960659115e-07
and O 0 1.250443659728262e-07
4 O 0 4.327573606133228e-06
with O 0 4.2241680375809665e-07
urogenital B-Disease 1 0.9999104738235474
abnormalities I-Disease 1 0.9999717473983765
and O 0 6.988476525293663e-05
/ O 1 0.9998785257339478
or O 0 0.005624901503324509
WT B-Disease 1 1.0
. O 0 0.00018154337885789573

We O 0 2.7285352189210244e-05
report O 0 1.5439414710272104e-05
WT1 O 0 0.0006271480233408511
heterozygous O 0 7.464528607670218e-06
mutations O 0 2.4725563889660407e-06
in O 0 1.9524826200267853e-07
16 O 0 1.9709600564965513e-06
patients O 0 1.1192977922291902e-07
, O 0 3.3377190788996813e-08
4 O 0 4.6994838953651197e-07
of O 0 1.944685124044554e-07
whom O 0 6.328962172119645e-07
presented O 0 3.609882469390868e-06
with O 0 3.868016847263789e-06
IDMS B-Disease 1 0.9818379282951355
. O 0 0.00013615054194815457

One O 0 1.7669566659606062e-05
male O 0 1.2057387721142732e-05
and O 0 9.326660119768349e-07
two O 0 1.1064787486247951e-06
female O 0 2.0255361960153095e-05
IDMS B-Disease 1 0.9993181228637695
patients O 0 6.796049092372414e-06
with O 0 7.44006001696107e-06
WT1 O 1 0.999995231628418
mutations O 0 0.30059850215911865
underwent O 0 0.3687554597854614
normal O 0 0.00012090255040675402
puberty O 0 0.04941631853580475
. O 0 3.1563886295771226e-05

Two O 0 5.441208486445248e-06
mutations O 0 8.021849680517334e-06
associated O 0 1.0981947298205341e-06
with O 0 4.358561227491009e-07
IDMS B-Disease 1 0.9851155877113342
are O 0 6.794506646201626e-08
different O 0 3.956689909045963e-08
from O 0 2.6491910887216363e-08
those O 0 4.4964487244669726e-08
described O 0 7.966872317410889e-07
in O 0 1.932720579134184e-06
DDS B-Disease 1 1.0
patients O 0 9.922064054990187e-05
. O 0 6.229423161130399e-05

No O 0 1.5010540664661676e-05
WT1 O 0 0.0009032259695231915
mutations O 0 4.094848009117413e-06
were O 0 5.371064162318362e-07
detected O 0 5.017453190703236e-07
in O 0 5.5642900065322465e-08
the O 0 2.0519763666015933e-07
six O 0 2.1654193460562965e-06
other O 0 3.0985006560513284e-07
IDMS B-Disease 1 0.999981164932251
patients O 0 2.272679239467834e-06
, O 0 1.7264106588754657e-07
suggesting O 0 8.638066901767161e-07
genetic O 0 1.137211938839755e-06
heterogeneity O 0 1.2445370884961449e-05
of O 0 1.2052512829541229e-05
this O 0 8.561934919271152e-06
disease O 1 0.9991623163223267
. O 0 6.692827446386218e-05

We O 0 1.695582250249572e-05
analyzed O 0 3.0083867386565544e-05
genotype O 0 0.00011426743003539741
/ O 0 6.486634083557874e-05
phenotype O 0 2.575725011411123e-05
correlations O 0 5.61289198230952e-06
, O 0 1.279451424807121e-07
on O 0 6.395838880735027e-08
the O 0 1.717278230728425e-08
basis O 0 2.391510278698661e-08
of O 0 1.750480649320707e-08
the O 0 2.761851547461447e-08
constitution O 0 4.896253003039419e-08
of O 0 6.143349651210883e-08
a O 0 1.5220257409964688e-07
WT1 O 0 1.8769907910609618e-05
mutation O 0 2.0367497199913487e-07
database O 0 6.681491271365303e-08
of O 0 1.3005497123685927e-07
84 O 0 2.9993684620421845e-06
germ O 1 0.5908659100532532
- O 0 0.3139188289642334
line O 0 6.562659109476954e-05
mutations O 0 1.3514038528228411e-06
, O 0 3.866552589215644e-08
to O 0 1.0418044205096066e-08
compare O 0 2.998356052330564e-08
the O 0 1.442699293363603e-08
distribution O 0 1.8434251458643303e-08
and O 0 1.0927601046262225e-08
type O 0 1.2935683457726554e-07
of O 0 1.2817841366086213e-07
mutations O 0 2.420384248580376e-07
, O 0 1.336866883860921e-08
according O 0 5.307353223571454e-09
to O 0 7.158681203378592e-09
the O 0 9.423095548299898e-08
different O 0 7.968939144120668e-07
symptoms O 0 0.0014516818337142467
. O 0 2.2331376385409385e-05

This O 0 8.509825875080423e-07
demonstrated O 0 3.5976338494947413e-06
( O 0 1.6128622348787758e-07
1 O 0 8.919870424506371e-07
) O 0 5.8248780021585844e-08
the O 0 7.469881779798015e-08
association O 0 8.070522738989894e-08
between O 0 5.2169674802371446e-08
mutations O 0 7.867752316315091e-08
in O 0 2.7043080663702312e-08
exons O 0 5.702069074686733e-07
8 O 0 3.478383234778448e-07
and O 0 7.606163876516803e-08
9 O 0 9.495586255070521e-07
and O 0 3.9407990470863297e-07
DMS B-Disease 0 0.0018060506554320455
; O 0 2.5051681973309314e-07
( O 0 1.215080089878029e-07
2 O 0 2.1198031845415244e-06
) O 0 8.080103697238883e-08
among O 0 1.0648296466797547e-07
patients O 0 6.892427961702197e-08
with O 0 1.4112002588717587e-07
DMS B-Disease 1 0.9479310512542725
, O 0 1.3481442806551058e-07
a O 0 6.23087643703002e-08
higher O 0 9.541703605009388e-08
frequency O 0 1.7408092389814556e-07
of O 0 4.290279775887029e-08
exon O 0 1.9814093832337676e-07
8 O 0 1.3337296422832878e-07
mutations O 0 6.767371729665683e-08
among O 0 3.221248690010725e-08
46 O 0 4.934842650072824e-07
, O 0 3.4693158568188665e-07
XY O 0 0.0023784800432622433
patients O 0 3.57935476813509e-07
with O 0 1.2660719050927582e-07
female O 0 1.6801126321297488e-06
phenotype O 0 3.1598588066117372e-06
than O 0 6.107796934884391e-08
among O 0 8.23978396624625e-08
46 O 0 7.108381510079198e-07
, O 0 5.498063160302991e-07
XY O 1 0.673925518989563
patients O 0 4.1845856912914314e-07
with O 0 6.894110526900477e-08
sexual O 0 1.3440045449897298e-06
ambiguity O 0 2.636921635712497e-06
or O 0 8.591090363552212e-07
male O 0 6.108129468884727e-07
phenotype O 0 7.857881314521364e-07
; O 0 4.900298478105469e-08
and O 0 1.5044355450299918e-07
( O 0 7.564914739077722e-08
3 O 0 4.848790808864578e-07
) O 0 9.281955648532403e-09
statistically O 0 1.1348396000698813e-08
significant O 0 9.45739309088367e-09
evidence O 0 1.9763039205145105e-08
that O 0 3.2670974814408282e-09
mutations O 0 4.158392385988918e-08
in O 0 3.752913002585956e-08
exons O 0 8.690105914865853e-07
8 O 0 7.633267387063825e-07
and O 0 1.0062873201377442e-07
9 O 0 8.425173518844531e-07
preferentially O 0 4.137613416332897e-07
affect O 0 2.052802443586188e-07
amino O 0 1.529076172346322e-07
acids O 0 2.8295101373032594e-08
with O 0 9.58306500820072e-09
different O 0 2.722307357316822e-08
functions O 0 2.3935484705361887e-07
. O 0 2.3366909829292126e-07
. O 0 1.3931787634646753e-06

The O 0 1.6229641914833337e-05
185delAG O 0 0.00010424969514133409
BRCA1 O 0 1.4382997505890671e-05
mutation O 0 9.13050996587117e-07
originated O 0 1.0976235387261113e-07
before O 0 9.517002297343424e-08
the O 0 9.827813229890126e-09
dispersion O 0 2.0640507614189119e-07
of O 0 3.962565742199331e-08
Jews O 0 1.2661153903081868e-07
in O 0 1.727864251677147e-08
the O 0 2.9206152163396837e-08
diaspora O 0 4.673248810149744e-08
and O 0 5.062663177568538e-08
is O 0 1.887432432567948e-08
not O 0 2.148381916811104e-08
limited O 0 2.8627277970372234e-07
to O 0 9.041407906806853e-07
Ashkenazim O 0 0.002199207665398717
. O 0 7.904504309408367e-05

The O 0 9.830554517975543e-06
185delAG O 0 6.264027615543455e-05
mutation O 0 4.929292117594741e-06
in O 0 3.6484686916082865e-07
BRCA1 O 0 4.172060471319128e-06
is O 0 8.064430545573487e-08
detected O 0 2.473089182331023e-07
in O 0 6.300669497250055e-08
Ashkenazi O 0 2.841224159055855e-06
Jews O 0 8.278124141725129e-07
both O 0 1.6205032693505927e-07
in O 0 2.623004036195198e-07
familial B-Disease 1 0.8069324493408203
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.043942924588918686
in O 0 6.968672892071481e-07
the O 0 4.050057782478689e-07
general O 0 1.0518114095248166e-06
population O 0 1.6630063726097433e-07
. O 0 5.198876351641957e-06

All O 0 1.1385530342522543e-05
tested O 0 1.1059532880608458e-05
Ashkenazi O 0 9.91659726423677e-06
mutation O 0 5.46147646218742e-07
carriers O 0 1.6111233946958237e-07
share O 0 9.083162666456701e-08
the O 0 9.152045521432228e-08
same O 0 2.3366150969650334e-07
allelic O 0 1.902441908896435e-05
pattern O 0 8.89089369593421e-06
at O 0 4.364839696791023e-06
the O 0 1.7104729295169818e-06
BRCA1 O 0 2.9292366889421828e-05
locus O 0 5.426043571787886e-05
. O 0 2.3545855583506636e-05

Our O 0 9.016135663841851e-06
previous O 0 2.4266232685477007e-06
study O 0 3.640332693066739e-07
showed O 0 1.3957759392724256e-07
that O 0 1.2145710215349936e-08
this O 0 1.2414140826422226e-08
Ashkenazi O 0 9.153736755251884e-07
mutation O 0 1.2779162261722377e-07
also O 0 2.925180986323994e-08
occurs O 0 3.053192543234218e-08
in O 0 1.0982576625906404e-08
Iraqi O 0 5.963670446362812e-07
Jews O 0 2.634498343923042e-07
with O 0 6.514675021662697e-08
a O 0 3.256681679886242e-07
similar O 0 1.5706621070421534e-06
allelic O 0 0.0004375846474431455
pattern O 0 0.0008360552601516247
. O 0 9.068592044059187e-05

We O 0 2.621356088639004e-06
extended O 0 4.95224924179638e-07
our O 0 5.627925858675553e-08
analysis O 0 1.7936711671495686e-08
to O 0 7.368839760601986e-09
other O 0 1.3864250192341387e-08
non O 0 4.0914335386332823e-07
- O 0 5.412657628767192e-07
Ashkenazi O 0 1.0374568546467344e-06
subsets O 0 3.7985427070452715e-07
354 O 0 3.27063474969691e-07
of O 0 5.7629929273161906e-08
Moroccan O 0 2.1583928173640743e-06
origin O 0 1.5166487798978778e-07
, O 0 2.060147181737193e-07
200 O 0 5.654928258991276e-07
Yemenites O 0 2.4508066417183727e-05
and O 0 5.209664095673361e-07
150 O 0 1.342203859167057e-06
Iranian O 0 9.339449206891004e-06
Jews O 0 3.1740379199618474e-05
. O 0 2.685821891645901e-05

Heteroduplex O 0 0.0007358262082561851
analysis O 0 4.401074875204358e-06
complemented O 0 3.3186863674927736e-06
by O 0 7.1137129964427e-08
direct O 0 1.3093918482809386e-07
DNA O 0 5.203407340559352e-07
sequencing O 0 4.168975920038065e-07
of O 0 3.730753235231532e-07
abnormally O 0 5.252794835541863e-06
migrating O 0 6.435683417294058e-07
bands O 0 3.534292773110792e-06
were O 0 3.151354803776485e-06
employed O 0 1.912581683427561e-05
. O 0 1.4863477190374397e-05

Four O 0 4.525221356743714e-06
of O 0 1.2103733979529352e-06
Moroccan O 0 1.4605091564590111e-05
origin O 0 1.4075160947868426e-07
( O 0 3.151205163476334e-08
1 O 0 5.310880268893925e-08
. O 0 3.79357301127925e-09
1 O 0 2.810979005118952e-08
% O 0 5.165585292843389e-09
) O 0 6.287149911798906e-09
and O 0 1.3118699015990387e-08
none O 0 7.812199953605159e-08
of O 0 5.150712922841194e-08
the O 0 1.1768091212616127e-07
Yemenites O 0 2.130389111698605e-05
or O 0 1.3496416784164467e-07
Iranians O 0 6.785122650398989e-07
was O 0 4.892085030405724e-07
a O 0 9.289132663070632e-08
carrier O 0 1.6751067732911906e-07
of O 0 3.994251187577902e-07
the O 0 1.1619285942288116e-06
185delAG O 0 4.126985732000321e-05
mutation O 0 1.6262489225482568e-05
. O 0 2.1127871150383726e-05

BRCA1 O 0 0.00031206669518724084
allelic O 0 0.0002251441910630092
patterns O 0 2.2625756628258387e-06
were O 0 2.1773416847281624e-07
determined O 0 1.3507670360013435e-07
for O 0 1.9487094604642152e-08
four O 0 3.06806704486462e-08
of O 0 1.567068963481688e-08
these O 0 2.439263457887364e-09
individuals O 0 1.2473089228137724e-09
and O 0 2.951159983055618e-09
for O 0 5.131754576837011e-09
12 O 0 5.924126966760923e-08
additional O 0 2.544225097267372e-08
non O 0 5.224241022006026e-07
- O 0 3.6490951060841326e-07
Ashkenazi O 0 5.44115948741819e-07
185delAG O 0 7.208392389657092e-07
mutation O 0 1.5585490587000095e-07
carriers O 0 2.860381016489555e-07
who O 0 8.027335525184753e-07
had O 0 0.002322195563465357
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.8874063491821289

Six O 0 0.00012261528172530234
non O 0 0.00045160370063968003
- O 0 0.00013409035454969853
Ashkenazi O 0 1.8059552530758083e-05
individuals O 0 4.6641304152217344e-08
shared O 0 1.2811828753456211e-07
the O 0 8.307988963451862e-08
common O 0 5.271038503451564e-07
Ashkenazi O 0 2.844373375410214e-05
haplotype O 0 8.370852810912766e-06
, O 0 2.672417735993804e-07
four O 0 5.169018777451129e-07
had O 0 2.41217634311397e-07
a O 0 2.409771298061969e-07
closely O 0 2.831665142366546e-07
related O 0 4.7072705910977675e-07
pattern O 0 6.062218290026067e-06
, O 0 2.48819645776166e-07
and O 0 1.219743950287011e-07
the O 0 7.362773857266802e-08
rest O 0 2.407791157565953e-07
( O 0 6.242319727789436e-08
n O 0 2.374735998955657e-07
= O 0 4.232055346164998e-07
6 O 0 4.362049992323591e-07
) O 0 1.7441918132021783e-08
displayed O 0 1.4863059050185257e-07
a O 0 2.5923534963112616e-07
distinct O 0 2.9242160053399857e-06
BRCA1 O 0 7.858194294385612e-05
allelic O 0 0.000298418162856251
pattern O 0 9.666757250670344e-05
. O 0 5.31503428646829e-05

We O 0 7.977920176927e-06
conclude O 0 8.626117050880566e-06
that O 0 9.924564636776267e-08
the O 0 4.547673313481937e-07
185delAG O 0 1.2259601135156117e-05
BRCA1 O 0 3.4688800951698795e-06
mutation O 0 3.187827815054334e-07
occurs O 0 5.065338370968675e-08
in O 0 2.115328356921964e-08
some O 0 2.9281395086400153e-08
non O 0 1.8890748378908029e-06
- O 0 2.835120540112257e-06
Ashkenazi O 0 3.0386274829652393e-06
populations O 0 6.25639628992758e-08
at O 0 2.1282144757606147e-07
rates O 0 4.73448160676071e-08
comparable O 0 4.758036808993893e-08
with O 0 6.366735139096136e-09
that O 0 1.220816514546641e-08
of O 0 4.6257954977591e-07
Ashkenazim O 0 0.001112132566049695
. O 0 3.211904549971223e-05

The O 0 2.0819989003939554e-06
majority O 0 3.231224070532335e-07
of O 0 3.505494134969922e-07
Jewish O 0 9.024325322570803e-07
185delAG O 0 3.5580333133111708e-06
mutation O 0 2.6177062295573705e-07
carriers O 0 1.1452599579797607e-07
have O 0 5.145538040096653e-08
a O 0 1.7942637953183294e-07
common O 0 8.647529057270731e-07
allelic O 0 9.488350042374805e-05
pattern O 0 8.590012839704286e-06
, O 0 1.7956605802282866e-07
supporting O 0 2.704205712689145e-07
the O 0 2.1592420296201453e-07
founder O 0 2.2793515199737158e-06
effect O 0 3.0308717668958707e-07
notion O 0 2.329033321757379e-07
, O 0 1.9734939016302633e-08
but O 0 1.0915310433290415e-08
dating O 0 3.2386953563445786e-08
the O 0 8.691960040607682e-09
mutations O 0 2.0741451223216245e-08
origin O 0 1.1709928138259329e-08
to O 0 5.742504249894864e-09
an O 0 7.335800411567561e-09
earlier O 0 4.9975675153746124e-08
date O 0 2.1979249709147552e-07
than O 0 5.266756986088694e-08
currently O 0 2.5856377305899514e-07
estimated O 0 9.188765943690669e-07
. O 0 5.03108412885922e-06

However O 0 3.5034663596889004e-06
, O 0 4.067363192916673e-07
the O 0 1.1271775690602226e-07
different O 0 6.049732093060811e-08
allelic O 0 7.847967935958877e-06
pattern O 0 2.7313317332300358e-06
at O 0 1.8269965949002653e-06
the O 0 1.720574118735385e-07
BRCA1 O 0 1.9075293948844774e-06
locus O 0 5.184451197237649e-07
even O 0 2.9748466801038376e-08
in O 0 5.377191580890894e-09
some O 0 5.266673763770768e-09
Jewish O 0 9.011754542598283e-08
mutation O 0 1.6151093973348907e-07
carriers O 0 8.292933273423841e-08
, O 0 3.813336491020891e-08
might O 0 4.812424592159914e-08
suggest O 0 8.03173421104475e-08
that O 0 1.548729322564668e-08
the O 0 9.203826323300746e-08
mutation O 0 7.214389370346908e-07
arose O 0 2.050422608590452e-06
independently O 0 1.1922676321773906e-06
. O 0 1.705134081930737e-06
. O 0 2.2553875169251114e-05

Crystal O 0 0.017301812767982483
structure O 0 0.00012490132940001786
of O 0 2.76276477961801e-05
the O 0 0.0001258046249859035
hemochromatosis B-Disease 1 1.0
protein O 0 0.0020284238271415234
HFE O 1 0.9367775917053223
and O 0 2.1605788447232044e-07
characterization O 0 3.994757946657046e-07
of O 0 1.517188366051414e-07
its O 0 6.357321069572208e-08
interaction O 0 2.5968469685722084e-07
with O 0 1.719658797583179e-07
transferrin O 0 2.37285130424425e-05
receptor O 0 9.825567758525722e-06
. O 0 4.168186478636926e-06

HFE O 1 0.7518060803413391
is O 0 4.196593181404751e-06
an O 0 1.24609664453601e-06
MHC O 0 0.18960821628570557
- O 0 0.03405363857746124
related O 0 2.4316177587024868e-06
protein O 0 3.742102592241281e-07
that O 0 7.702177562407542e-09
is O 0 7.032388449346172e-09
mutated O 0 8.589340438902582e-08
in O 0 3.837516970861543e-08
the O 0 1.2841275065511581e-06
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9998958110809326

HFE O 0 0.002406618557870388
binds O 0 5.598655661742669e-06
to O 0 5.965035825283849e-07
transferrin O 0 3.4869583032559603e-05
receptor O 0 1.3738544112129603e-05
( O 0 6.990312613197602e-07
TfR O 0 3.12418706016615e-05
) O 0 1.1297862556602922e-07
and O 0 5.5078196226077125e-08
reduces O 0 1.0129888750043392e-07
its O 0 1.7839235866290437e-08
affinity O 0 1.200523342959059e-07
for O 0 1.061277288272322e-07
iron O 0 0.0008150719222612679
- O 0 6.37936100247316e-05
loaded O 0 3.864856807922479e-06
transferrin O 0 2.3494067136198282e-05
, O 0 1.365638468087127e-06
implicating O 0 0.00054223119514063
HFE O 1 0.9985570311546326
in O 0 1.9726865502889268e-05
iron O 1 0.9999873638153076
metabolism O 1 0.9994908571243286
. O 0 4.703412196249701e-05

The O 0 4.839984467253089e-05
2 O 0 0.0003123280475847423
. O 0 7.416819425998256e-05

6 O 0 0.00033718161284923553
A O 0 4.94863124913536e-05
crystal O 0 0.0005168515490368009
structure O 0 5.551110007218085e-05
of O 0 8.288240678666625e-06
HFE O 1 0.9751046895980835
reveals O 0 2.2617041395278648e-06
the O 0 2.304822999121825e-07
locations O 0 3.1006527478893986e-07
of O 0 9.857139957603067e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 0.09987463057041168
and O 0 1.1083586286986247e-05
a O 0 6.078398655517958e-06
patch O 0 0.00012850986968260258
of O 0 1.4545905287377536e-05
histidines O 0 0.0008417255012318492
that O 0 1.741705091262702e-08
could O 0 3.56969351855696e-08
be O 0 3.190667996477714e-08
involved O 0 1.5746816472983483e-07
in O 0 1.847054420522909e-07
pH O 0 0.00041393356514163315
- O 0 6.676750490441918e-05
dependent O 0 2.064516593236476e-06
interactions O 0 4.444688784133177e-06
. O 0 1.1706035365932621e-05

We O 0 5.25566611031536e-06
also O 0 4.3515049696907226e-07
demonstrate O 0 6.793941906835244e-07
that O 0 1.5554249443994195e-07
soluble O 0 1.255680308531737e-05
TfR O 0 6.881876470288262e-05
and O 0 1.475278281759529e-06
HFE O 0 0.0013911466812714934
bind O 0 1.2760483514284715e-06
tightly O 0 1.0238594541078783e-06
at O 0 5.56124405193259e-07
the O 0 9.205266593426131e-08
basic O 0 3.735196116849693e-07
pH O 0 1.4996227264418849e-06
of O 0 7.814509928039115e-08
the O 0 3.919165436627736e-08
cell O 0 3.3239840036003443e-07
surface O 0 2.2910538177711715e-07
, O 0 2.0505986242369545e-08
but O 0 1.5243058371083862e-08
not O 0 1.610706412691343e-08
at O 0 3.337381997425837e-07
the O 0 1.6115737366817484e-07
acidic O 0 6.967995886952849e-06
pH O 0 3.556354567990638e-05
of O 0 4.665768756240141e-06
intracellular O 0 1.9718721887329593e-05
vesicles O 0 2.8855549317086115e-05
. O 0 1.0491532520973124e-05

TfR O 0 0.004719081800431013
HFE O 0 0.002056511351838708
stoichiometry O 0 3.525874126353301e-05
( O 0 1.2271345894987462e-06
2 O 0 4.496990641200682e-06
1 O 0 3.6790136164199794e-06
) O 0 1.0412765050205053e-07
differs O 0 1.9111627125312225e-07
from O 0 6.15361130940073e-08
TfR O 0 8.163900929503143e-06
transferrin O 0 2.5162908059428446e-06
stoichiometry O 0 8.728361535759177e-07
( O 0 5.0913360638560334e-08
2 O 0 3.3516460007376736e-07
2 O 0 4.972997658114764e-07
) O 0 2.625488271235099e-08
, O 0 2.0662007216287748e-08
implying O 0 6.235822525013646e-08
a O 0 3.834626483012471e-08
different O 0 2.7294927207321962e-08
mode O 0 7.415652589770616e-07
of O 0 5.508575995349929e-08
binding O 0 2.3164159301813925e-07
for O 0 1.8266118217979965e-07
HFE O 0 0.00011942421406274661
and O 0 2.8890352155030996e-07
transferrin O 0 2.9920518045400968e-06
to O 0 1.0371932290809127e-07
TfR O 0 7.781498425174505e-06
, O 0 3.1720457371875455e-08
consistent O 0 6.313541689451085e-08
with O 0 8.990205024872466e-09
our O 0 4.006638221198955e-08
demonstration O 0 3.2115192993842356e-07
that O 0 3.931376824084509e-08
HFE O 0 0.0001247868058271706
, O 0 5.507283162842214e-07
transferrin O 0 9.78684147412423e-06
, O 0 3.495752594062651e-07
and O 0 4.1304028286504035e-07
TfR O 0 3.232846938772127e-05
form O 0 8.325849876200664e-07
a O 0 1.0994500598826562e-06
ternary O 0 4.045703462907113e-05
complex O 0 6.153466529212892e-05
. O 0 2.8011798349325545e-05

Identification O 0 5.78321487409994e-06
of O 0 2.189392716900329e-06
three O 0 5.915883889429097e-07
novel O 0 3.4526146919233724e-07
mutations O 0 1.5057203484047932e-07
and O 0 5.47704139819416e-08
a O 0 5.567400407358036e-08
high O 0 5.797776907456864e-07
frequency O 0 8.834323352857609e-07
of O 0 1.3171657542443427e-07
the O 0 1.5053757351779495e-07
Arg778Leu O 0 3.3425116271246225e-05
mutation O 0 4.950818492943654e-07
in O 0 9.720324811723913e-08
Korean O 0 1.156826601800276e-05
patients O 0 8.713690817785391e-07
with O 0 1.1757663287426112e-06
Wilson B-Disease 0 0.00653920229524374
disease I-Disease 1 0.995311975479126
. O 0 4.4678683480015025e-05

Four O 0 2.359848440391943e-05
mutations O 0 1.0362512512074318e-05
- O 0 1.2820601114071906e-05
- O 0 7.323763384192716e-06
R778L O 0 7.697944056417327e-06
, O 0 3.639700594249007e-07
A874V O 0 1.0062917681352701e-05
, O 0 4.214663533730345e-07
L1083F O 0 5.964983756712172e-06
, O 0 1.0859081811531723e-07
and O 0 1.6226961463416956e-07
2304delC O 0 3.5113134799757972e-06
- O 0 1.1402048585296143e-06
- O 0 4.522342180734995e-07
in O 0 3.43299291216681e-08
the O 0 1.3035857193699485e-07
copper O 0 2.646034408826381e-05
- O 0 1.0687484973459505e-05
transporting O 0 1.151319452219468e-06
enzyme O 0 3.9685531305622135e-07
, O 0 1.0462135691113872e-07
P O 0 4.835735308006406e-05
- O 0 6.729472261213232e-06
type O 0 3.6419301068235654e-06
ATPase O 0 2.558614687586669e-05
( O 0 9.87174146871439e-08
ATP7B O 0 2.0359764675959013e-05
) O 0 2.3310812835575234e-08
, O 0 1.223277834583314e-08
were O 0 3.7219535897747846e-08
identified O 0 1.6610125896932004e-07
in O 0 9.202422290854884e-08
Korean O 0 9.125059477810282e-06
Patients O 0 4.578169864544179e-06
with O 0 3.4199822493974352e-06
Wilson B-Disease 0 0.458053320646286
disease I-Disease 1 0.999929666519165
. O 0 0.00013549985305871814

Arg778Leu O 0 0.04520391672849655
, O 0 1.0317824035155354e-06
the O 0 3.164305439895543e-07
most O 0 5.5896489215001566e-08
frequently O 0 5.03718666777786e-08
reported O 0 4.17777492600635e-08
mutation O 0 2.490346595607207e-08
of O 0 1.9908469539586804e-08
this O 0 1.1629929907996939e-08
enzyme O 0 1.3580753943642776e-07
, O 0 3.018795879938807e-08
was O 0 1.0135299532976205e-07
found O 0 1.20580905260681e-08
in O 0 1.7436130761439017e-08
six O 0 1.7700114085528185e-07
of O 0 4.3175256791982974e-07
eight O 0 2.782929414024693e-06
unrelated O 0 6.694112926197704e-07
patients O 0 2.6849010126284156e-08
studied O 0 2.541310948345199e-07
, O 0 2.1960220308869793e-08
an O 0 1.0588566468072713e-08
allele O 0 5.665167464030674e-07
frequency O 0 1.4340033658299944e-06
of O 0 1.1629351774899988e-06
37 O 0 1.83838728844421e-05
. O 0 2.301783206348773e-05

5 O 0 1.0495235983398743e-05
% O 0 4.143935541378596e-07
, O 0 1.856821256751573e-07
which O 0 3.6620914301011e-08
is O 0 1.4494539790632643e-08
considerably O 0 5.740306363577474e-08
higher O 0 3.730760056441795e-08
than O 0 5.109642486900157e-09
those O 0 3.57093110636697e-09
in O 0 7.088301057223134e-09
other O 0 1.825939044408642e-08
Asian O 0 4.3043411324106273e-07
populations O 0 3.1520471566182096e-07
. O 0 2.3553620849270374e-06

The O 0 4.6600139285146724e-06
novel O 0 1.7733800632413477e-06
single O 0 5.080975711280189e-07
nucleotide O 0 1.0403468877484556e-06
deletion O 0 9.85783344731317e-07
, O 0 1.4258212388540414e-07
2304delC O 0 6.754411970177898e-06
, O 0 2.398870719844126e-07
was O 0 8.457922717752808e-07
found O 0 8.302144749450235e-08
in O 0 1.4454224128712667e-07
one O 0 4.5734603304481425e-07
patient O 0 6.236379249457968e-06
. O 0 2.417302312096581e-05

Since O 0 4.765920948557323e-06
a O 0 5.551398771785898e-07
mutation O 0 5.049562332715141e-07
at O 0 1.0423121921121492e-06
cDNA O 0 2.0195827801217092e-06
nucleotide O 0 2.786897312034853e-06
2302 O 0 0.00010893316357396543
( O 0 2.6275981213075283e-07
2302insC O 0 4.819295554625569e-06
) O 0 9.078606666435007e-08
had O 0 1.0087278212722595e-07
been O 0 9.151557378572761e-08
previously O 0 1.439853178908379e-07
described O 0 1.0656931692665239e-07
, O 0 3.990933805653185e-08
this O 0 1.2814047600784306e-08
region O 0 8.51401651402739e-08
of O 0 1.2190345444196282e-07
the O 0 2.1519257131785707e-07
ATP7B O 0 0.005267946049571037
gene O 0 3.148225857785292e-07
may O 0 1.2982360431124107e-07
be O 0 9.061652406217036e-08
susceptible O 0 1.6104164615171612e-06
to O 0 1.1670287847209693e-07
gene O 0 6.373441920004552e-06
rearrangements O 1 0.6593002676963806
causing O 1 0.9995032548904419
Wilson B-Disease 1 0.9995312690734863
disease I-Disease 1 0.9999887943267822
. O 0 0.00025836803251877427

Disruption O 0 0.00018822155834641308
of O 0 6.036695140210213e-06
splicing O 0 9.824039807426743e-06
regulated O 0 8.133927735798352e-07
by O 0 1.1700532098757321e-07
a O 0 3.857323349620856e-07
CUG O 0 0.00017003784887492657
- O 0 1.4403643035620917e-05
binding O 0 3.91885487260879e-06
protein O 0 3.959491368732415e-05
in O 0 1.2741933460347354e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0006380285485647619

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999932050704956
DM B-Disease 1 1.0
) O 0 1.202444309456041e-05
is O 0 1.7786376815820404e-07
caused O 0 4.5667832182516577e-07
by O 0 7.033142424006655e-08
a O 0 2.0880862905414688e-07
CTG O 0 2.292328827024903e-05
expansion O 0 4.098181420886249e-07
in O 0 1.7230135540557967e-08
the O 0 3.397465775378805e-08
3 O 0 3.4691970540734474e-07
untranslated O 0 2.2633462322119158e-06
region O 0 2.0187459881526593e-07
of O 0 5.440225550046307e-07
the O 0 3.414106913623982e-06
DM B-Disease 1 1.0
gene O 0 2.095313902827911e-05
. O 0 1.9320319552207366e-05

One O 0 3.979729171987856e-06
model O 0 9.114189197134692e-06
of O 0 2.440388561808504e-05
DM B-Disease 1 1.0
pathogenesis O 1 0.9997926354408264
suggests O 0 3.174866947119881e-07
that O 0 1.1713233938337453e-08
RNAs O 0 1.7305647759258136e-07
from O 0 1.938189519989919e-08
the O 0 2.4851177116147483e-08
expanded O 0 8.299563347691219e-08
allele O 0 3.1618466778127186e-07
create O 0 5.71116913761216e-08
a O 0 4.093313776820651e-08
gain O 0 3.6104361811339913e-07
- O 0 5.920946932747029e-07
of O 0 1.4587179464342626e-07
- O 0 5.025321456741949e-07
function O 0 3.0347585777690256e-08
mutation O 0 1.4800109582324694e-08
by O 0 4.951075105452674e-09
the O 0 7.409796332069618e-09
inappropriate O 0 2.3609809218783084e-08
binding O 0 2.254359365849723e-08
of O 0 3.174611862277743e-08
proteins O 0 1.1286227064033483e-08
to O 0 2.4113019136962066e-08
the O 0 4.841882628170424e-07
CUG O 0 0.0009047252242453396
repeats O 0 4.197033558739349e-05
. O 0 1.7910488168126903e-05

Data O 0 1.2707202586170752e-05
presented O 0 3.337189582452993e-06
here O 0 1.6126546142913867e-07
indicate O 0 4.16290006910458e-08
that O 0 6.766375459932306e-09
the O 0 4.416415322339162e-08
conserved O 0 7.126926675482537e-07
heterogeneous O 0 5.1451979743433185e-06
nuclear O 0 4.875148442806676e-05
ribonucleoprotein O 0 0.0003431059594731778
, O 0 1.1444132042015553e-06
CUG O 0 0.0001506458065705374
- O 0 2.492281964805443e-06
binding O 0 4.415931584844657e-07
protein O 0 5.005638286093017e-07
( O 0 1.0361768687516815e-07
CUG O 0 8.695185533724725e-05
- O 0 6.590401881112484e-06
BP O 0 8.09315770311514e-06
) O 0 4.7542176417891824e-08
, O 0 3.0793170679999093e-08
may O 0 9.848326953942887e-08
mediate O 0 1.7770215663404088e-06
the O 0 2.572493826846767e-07
trans O 0 3.4703889468801208e-06
- O 0 1.5484317827940686e-06
dominant O 0 1.535353590043087e-06
effect O 0 1.4420615457311214e-07
of O 0 9.075456119944647e-08
the O 0 2.1406229677722877e-07
RNA O 0 2.985282435474801e-06
. O 0 1.9727503968169913e-06

CUG O 1 0.999640703201294
- O 1 0.9776260256767273
BP O 0 0.00033458368852734566
was O 0 1.4679468449685373e-06
found O 0 5.6104347834207147e-08
to O 0 1.842543007057884e-08
bind O 0 4.339130299513272e-08
to O 0 5.418004533908061e-08
the O 0 2.546225914556999e-07
human O 0 3.6038181860931218e-06
cardiac O 0 0.169803649187088
troponin O 1 0.5933176279067993
T O 0 0.006520324386656284
( O 0 7.258300911416882e-07
cTNT O 0 8.126244210870937e-06
) O 0 1.3179032976040617e-07
pre O 0 2.693344413273735e-06
- O 0 1.1887503887919593e-06
messenger O 0 8.193525786737155e-07
RNA O 0 5.815087433802546e-07
and O 0 4.430048861081559e-08
regulate O 0 4.502791384197735e-08
its O 0 2.506730645279731e-08
alternative O 0 7.098146284079121e-07
splicing O 0 7.786130481690634e-06
. O 0 3.6541309782478493e-06

Splicing O 0 4.270969657227397e-05
of O 0 6.320340162346838e-06
cTNT O 0 0.0003353421052452177
was O 0 2.4501452571712434e-05
disrupted O 0 0.00040002225432544947
in O 0 1.6862215488799848e-05
DM B-Disease 1 1.0
striated O 1 0.9992295503616333
muscle O 0 0.0015185920055955648
and O 0 5.84383997193072e-07
in O 0 7.324813822151555e-08
normal O 0 1.1844802116911524e-07
cells O 0 8.34986551012662e-08
expressing O 0 4.076095905247712e-08
transcripts O 0 2.041552988885087e-07
that O 0 1.579784658645167e-08
contain O 0 1.079374101209396e-06
CUG O 0 0.0004772450483869761
repeats O 0 6.832584767835215e-05
. O 0 2.318526640010532e-05

Altered O 0 9.638871233619284e-06
expression O 0 7.831301331862051e-07
of O 0 6.352073000925884e-07
genes O 0 3.662846381757845e-07
regulated O 0 3.6052060181646084e-07
posttranscriptionally O 0 3.2487266707903473e-06
by O 0 5.367541007217369e-07
CUG O 1 0.8230293393135071
- O 0 0.002804890740662813
BP O 0 2.9252172680571675e-05
therefore O 0 5.811543815070763e-07
may O 0 1.7246021855044091e-07
contribute O 0 2.6214857484774257e-07
to O 0 7.770728416289785e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9999409914016724
. O 0 2.5852602902887156e-06
. O 0 7.180041393439751e-06

Identification O 0 8.86680390976835e-06
of O 0 1.9715766939043533e-06
a O 0 1.1758538676076569e-06
novel O 0 1.3910718053011806e-06
nonsense O 0 5.142288955539698e-06
mutation O 0 5.410573180597567e-07
and O 0 9.138579315504103e-08
a O 0 1.5345982262715552e-07
missense O 0 1.664289811742492e-06
substitution O 0 6.098321705394483e-07
in O 0 7.601377660648723e-08
the O 0 1.9375839599433675e-07
vasopressin O 0 6.317784936982207e-06
- O 0 3.3369030916219344e-06
neurophysin O 0 3.802355195148266e-06
II O 0 0.0004393944691400975
gene O 0 3.343434329394768e-08
in O 0 8.293831399441842e-09
two O 0 1.9905053605384637e-08
Spanish O 0 1.933863586600637e-06
kindreds O 0 1.6685820810380392e-05
with O 0 1.3641740679304348e-06
familial B-Disease 1 0.9704481363296509
neurohypophyseal I-Disease 1 0.9999997615814209
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999955892562866
. O 0 0.0008467008010484278

Familial B-Disease 1 0.9995676875114441
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.24026760458946228
FNDI B-Disease 1 1.0
) O 0 2.694862814678345e-06
is O 0 1.6328750973571005e-07
an O 0 2.799000924369466e-07
autosomal B-Disease 1 0.9999995231628418
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999730587005615
by O 0 0.0004914997844025493
deficiency O 1 0.9999991655349731
in O 0 7.6038945735490415e-06
the O 0 9.577981836628169e-05
antidiuretic O 0 0.059717509895563126
hormone O 0 3.6855060898233205e-05
arginine O 0 2.888035487558227e-05
vasopressin O 0 1.879159390227869e-05
( O 0 5.734746082453057e-07
AVP O 0 2.7822959964396432e-05
) O 0 9.442202042464487e-08
encoded O 0 8.60943245584167e-08
by O 0 4.83343534085634e-08
the O 0 4.419630670327024e-07
AVP O 0 0.00019925966626033187
- O 0 2.374807263549883e-05
neurophysin O 0 0.00020293527632020414
II O 1 0.9999988079071045
( O 0 1.9505112504702993e-05
AVP O 0 0.004971829708665609
- O 0 5.9329322539269924e-05
NPII O 0 0.00039108283817768097
) O 0 4.432149580679834e-07
gene O 0 9.569440635459614e-07
on O 0 3.2009750157158123e-06
chromosome O 0 2.6643821911420673e-05
20p13 O 0 0.00021760955860372633
. O 0 5.039213283453137e-05

In O 0 1.2078746749466518e-06
this O 0 1.1770571717306666e-07
study O 0 1.0519804760633633e-07
, O 0 6.144322384216139e-08
we O 0 7.823980041621326e-08
analyzed O 0 1.299053451475629e-07
two O 0 3.076810273228148e-08
families O 0 1.552091788425969e-08
with O 0 7.296188186955987e-08
FNDI B-Disease 1 0.9999711513519287
using O 0 2.4195350079025957e-07
direct O 0 3.0019384666957194e-07
automated O 0 1.596300421624619e-06
fluorescent O 0 8.153584758474608e-07
, O 0 3.684679938942281e-08
solid O 0 4.887561431132781e-07
phase O 0 4.883107521891361e-06
, O 0 3.823765837296378e-08
single O 0 5.2603819966634546e-08
- O 0 8.84860114069852e-08
stranded O 0 5.498855415453363e-08
DNA O 0 5.522989354744823e-08
sequencing O 0 9.635892439519012e-08
of O 0 1.25453240684692e-07
PCR O 0 1.1063805686717387e-05
- O 0 5.93264376220759e-05
amplified O 0 5.810689981444739e-05
AVP O 0 0.0017392970621585846
- O 0 9.084310295293108e-05
NPII O 0 0.0012380894040688872
DNA O 0 3.7079586036270484e-05
. O 0 1.9800370864686556e-05

In O 0 1.1937921726712375e-06
one O 0 9.628855224264043e-08
of O 0 1.0082066381755794e-07
the O 0 8.854105004729718e-08
families O 0 2.1913148628982526e-08
, O 0 4.0270254686447515e-08
affected O 0 5.4032465612863234e-08
individuals O 0 1.1244114084263401e-08
presented O 0 1.7870557655896846e-07
a O 0 6.721588619029717e-08
novel O 0 1.876946669199242e-07
nonsense O 0 6.562921726072091e-07
mutation O 0 1.571682588519252e-07
in O 0 5.178857165333284e-08
exon O 0 4.724072368844645e-07
3 O 0 1.9905439785361523e-07
of O 0 4.3891567713671975e-08
the O 0 3.713820007078539e-08
gene O 0 3.737490672506283e-08
, O 0 2.8291594844631618e-08
consisting O 0 1.0063583744113203e-07
in O 0 2.8851632194459853e-08
a O 0 6.377286609904331e-08
G O 0 2.0858165044046473e-06
to O 0 1.0076912815293326e-07
T O 0 1.402258021698799e-05
transition O 0 2.497928107914049e-06
at O 0 1.2760897334374022e-06
nucleotide O 0 5.778142622148152e-07
2101 O 0 5.3607200243277475e-06
, O 0 4.889579940936528e-08
which O 0 1.7606465618769107e-08
produces O 0 3.299393469546885e-08
a O 0 2.023629797065496e-08
stop O 0 7.18449584269365e-08
signal O 0 5.530283146981674e-07
in O 0 6.859954737592489e-08
codon O 0 1.9540786979632685e-06
82 O 0 3.2318387184204767e-06
( O 0 9.912114364851732e-07
Glu O 0 0.000808181066531688
) O 0 6.726192509631801e-07
of O 0 4.896560312772635e-06
NPII O 0 0.049022987484931946
. O 0 7.265993190230802e-05

The O 0 2.2309557607513852e-05
premature O 0 4.2645595385693014e-05
termination O 0 1.122523462981917e-05
eliminates O 0 4.2908432078547776e-06
part O 0 2.23019227973964e-07
of O 0 1.541474574651147e-07
the O 0 2.470378035468457e-07
C O 0 5.818774297949858e-05
- O 0 1.7343925264867721e-06
terminal O 0 4.4692507117360947e-07
domain O 0 9.558133484688369e-08
of O 0 7.3290628677114e-08
NPII O 0 0.00029103580163791776
, O 0 8.261626049943516e-08
including O 0 6.381703343549816e-08
a O 0 6.981152722573825e-08
cysteine O 0 2.604292319574597e-07
residue O 0 2.241937977487396e-07
in O 0 1.3212868132939093e-08
position O 0 2.0050141813499067e-07
85 O 0 1.452487907727118e-07
, O 0 2.160631851211292e-08
which O 0 6.979445466015477e-09
could O 0 9.307804305080936e-09
be O 0 1.6920091994165887e-08
involved O 0 6.492879833785992e-08
in O 0 2.010280830688771e-08
the O 0 1.0986560994297179e-07
correct O 0 2.6349557629146148e-06
folding O 0 3.325374564155936e-05
of O 0 2.275008228025399e-06
the O 0 1.3013952411711216e-05
prohormone O 0 0.4642983675003052
. O 0 7.384807395283133e-05

In O 0 1.848074134613853e-06
the O 0 4.862136506744719e-07
second O 0 1.2465055760912946e-06
family O 0 5.008388725968871e-08
, O 0 5.116237389302114e-08
a O 0 1.0852062359845149e-07
G279A O 0 1.7187059029311058e-06
substitution O 0 7.140165507735219e-07
at O 0 5.439421215669427e-07
position O 0 6.130673568804923e-07
- O 0 1.6273344272121903e-07
1 O 0 6.676663133475813e-08
of O 0 1.3454362068898718e-08
the O 0 1.4887652000084017e-08
signal O 0 2.1927326088189147e-07
peptide O 0 1.0201843991808346e-07
was O 0 5.004349290516075e-08
observed O 0 4.8358423043737275e-08
in O 0 2.0564385749821668e-08
all O 0 7.361846598996635e-08
affected O 0 3.0138374995658523e-07
individuals O 0 4.389990237996244e-07
. O 0 5.465339654620038e-06

This O 0 3.6005098991154227e-06
missense O 0 4.6446304622804746e-05
mutation O 0 5.323600362316938e-06
, O 0 6.622328783123521e-07
which O 0 4.954658265887701e-07
replaces O 0 0.006420021876692772
Ala O 0 0.0007339270669035614
with O 0 1.0151759397558635e-06
Thr O 0 0.0019459520699456334
, O 0 2.686723235001409e-07
is O 0 6.493473847513087e-08
frequent O 0 1.3682740984677366e-07
among O 0 2.1145594928384526e-06
FNDI B-Disease 1 1.0
patients O 0 1.526209234725684e-05
and O 0 5.694699893865618e-07
is O 0 5.512149314768067e-08
thought O 0 7.112410571608052e-08
to O 0 1.552864681286792e-08
reduce O 0 5.425222227017912e-08
the O 0 4.023155852905802e-08
efficiency O 0 3.2818891781971615e-07
of O 0 1.3428372369617136e-07
cleavage O 0 7.968786803758121e-07
by O 0 1.4648560409113998e-07
signal O 0 5.715271981898695e-06
peptidases O 0 4.2768671846715733e-05
. O 0 3.1891522667137906e-06
. O 0 1.9965942556154914e-05

Genetic O 0 2.4660104827489704e-05
heterogeneity O 0 6.959951133467257e-05
of O 0 2.2047923266654834e-05
Saethre B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.0848808642549557e-06
due O 0 2.0499649053817848e-06
to O 0 1.5873285974521423e-07
TWIST O 0 0.00012071476521668956
and O 0 3.7313618577172747e-06
FGFR O 0 0.32290157675743103
mutations O 0 2.46828803938115e-05
. O 0 1.7265952919842675e-05

Thirty O 0 0.0014737274032086134
- O 0 0.0008138681878335774
two O 0 7.799156378496264e-07
unrelated O 0 1.401225631525449e-06
patients O 0 8.724968125761734e-08
with O 0 1.634362156721636e-08
features O 0 2.8742968538608693e-07
of O 0 3.774057176997303e-06
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.3072362839448033e-06
a O 0 1.5256952110576094e-06
common O 0 3.549739994923584e-05
autosomal B-Disease 1 0.9789828062057495
dominant I-Disease 1 0.9999746084213257
condition I-Disease 0 0.027575312182307243
of O 0 0.3420168459415436
craniosynostosis B-Disease 1 1.0
and O 1 0.9993626475334167
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9590920805931091
, O 0 8.769462169766484e-07
were O 0 4.5673974113924487e-07
screened O 0 2.5594408725737594e-07
for O 0 2.5655788604694862e-08
mutations O 0 1.5406044440169353e-07
in O 0 5.275735404097759e-08
TWIST O 0 7.233548967633396e-05
, O 0 1.7442920352550573e-06
FGFR2 O 1 0.7670313715934753
, O 0 1.5411599179060431e-06
and O 0 6.962044153624447e-06
FGFR3 O 0 0.461131751537323
. O 0 5.5986161896726117e-05

Nine O 0 5.1836661441484466e-05
novel O 0 3.277055839134846e-06
and O 0 6.266685090849933e-07
three O 0 4.841988925363694e-07
recurrent O 0 5.352480002329685e-06
TWIST O 0 4.1739589505596086e-05
mutations O 0 1.218127408719738e-06
were O 0 1.910140525751558e-07
found O 0 5.8355759335881885e-08
in O 0 8.493238823348292e-08
12 O 0 4.668172095989576e-06
families O 0 9.036795631800487e-07
. O 0 1.532170790596865e-05

Seven O 0 1.365046773571521e-05
families O 0 1.1767001950602207e-07
were O 0 1.1052937054500944e-07
found O 0 1.596581356011484e-08
to O 0 8.532431650110084e-09
have O 0 1.3021153932868401e-08
the O 0 7.421426317932855e-08
FGFR3 O 0 0.00016251295164693147
P250R O 0 6.768159892089898e-06
mutation O 0 3.0792972438575816e-07
, O 0 2.5679828041802466e-08
and O 0 4.067382164407718e-08
one O 0 2.2624492501677196e-08
individual O 0 1.8104064025692423e-08
was O 0 1.1725409621021754e-07
found O 0 1.237541713550172e-08
to O 0 1.7872032742616284e-08
have O 0 6.947161068637797e-08
an O 0 2.618647272356611e-07
FGFR2 O 0 0.0005032679182477295
VV269 O 0 0.0002247834054287523
- O 0 9.025853069033474e-05
270 O 0 2.3122247512219474e-05
deletion O 0 6.951832619961351e-05
. O 0 4.302959860069677e-05

To O 0 8.276726362055342e-07
date O 0 2.3140100893215276e-06
, O 0 1.0392903249112351e-07
our O 0 6.282273545821226e-08
detection O 0 3.385008540135459e-07
rate O 0 9.638152675961464e-08
for O 0 3.855800301266754e-08
TWIST O 0 6.82246627548011e-06
or O 0 3.379438169304194e-07
FGFR O 0 4.993494803784415e-05
mutations O 0 1.7378665972955787e-07
is O 0 1.29339010612739e-08
68 O 0 1.1927949117307435e-07
% O 0 1.2508117208653857e-08
in O 0 2.4769592599227508e-08
our O 0 3.85962692917019e-07
Saethre B-Disease 1 0.9314644932746887
- I-Disease 1 0.9999496936798096
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 4.600802185450448e-06
, O 0 2.863503425487579e-07
including O 0 4.160654611951031e-07
our O 0 7.987442813828238e-07
five O 0 6.840355126769282e-07
patients O 0 1.1409060363121171e-07
elsewhere O 0 2.243499181986408e-07
reported O 0 2.7485569376040075e-07
with O 0 3.4474228982617205e-07
TWIST O 0 0.0019877504091709852
mutations O 0 0.00010396220750408247
. O 0 3.048126382054761e-05

More O 0 1.1647132396319648e-06
than O 0 1.6180956663447432e-07
35 O 0 2.9624021635754616e-07
different O 0 3.4650561531179846e-08
TWIST O 0 2.0003894860565197e-06
mutations O 0 1.0392962934702155e-07
are O 0 7.496970155784766e-09
now O 0 2.0619095764118356e-08
known O 0 2.545448296586983e-08
in O 0 2.172761170982085e-08
the O 0 1.3173793433907122e-07
literature O 0 1.966930994967697e-06
. O 0 4.595193786371965e-06

The O 0 1.0924903108389117e-05
most O 0 8.98952862371516e-07
common O 0 1.258709062312846e-06
phenotypic O 0 1.6345094991265796e-05
features O 0 8.678659355609852e-07
, O 0 5.6560772065950005e-08
present O 0 3.031871997905e-08
in O 0 9.72132330190334e-09
more O 0 3.7798431051783155e-09
than O 0 6.010475672724169e-09
a O 0 1.601009103069373e-08
third O 0 6.176600209073513e-08
of O 0 4.9886821784639324e-08
our O 0 8.015542363182249e-08
patients O 0 1.3069025861511818e-08
with O 0 1.6313908446363712e-08
TWIST O 0 6.407685759768356e-06
mutations O 0 5.448345632430573e-07
, O 0 1.1012470935156671e-07
are O 0 1.0905866787425111e-07
coronal B-Disease 0 0.0017589208437129855
synostosis I-Disease 0 0.0001738207065500319
, O 0 1.921473312904709e-06
brachycephaly B-Disease 0 0.0001094416729756631
, O 0 1.4906709111528471e-06
low B-Disease 0 0.1607162058353424
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 0.05372241139411926
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.9999322891235352
, O 0 4.557780266623013e-05
ptosis B-Disease 1 0.9998512268066406
, O 0 9.349751053377986e-06
hypertelorism B-Disease 1 0.9844228625297546
, O 0 4.705673291027779e-06
broad B-Disease 0 0.01083172857761383
great I-Disease 1 0.9360556602478027
toes I-Disease 1 0.8042983412742615
, O 0 3.089565097980085e-06
and O 0 6.5110434661619365e-06
clinodactyly B-Disease 0 0.0024604916106909513
. O 0 4.0460894524585456e-05

Significant O 0 4.856119630858302e-05
intra O 0 0.015015946701169014
- O 0 0.0002963077859021723
and O 0 9.976375849873875e-07
interfamilial O 0 0.0001286272017750889
phenotypic O 0 3.556781666702591e-05
variability O 0 6.116964868851937e-06
is O 0 3.087886568664544e-08
present O 0 1.6414160697308944e-08
for O 0 1.6553631354554454e-08
either O 0 2.2268001487191214e-07
TWIST O 0 2.462872907926794e-05
mutations O 0 3.0342985155584756e-06
or O 0 1.6053504623414483e-06
FGFR O 0 0.0008035888313315809
mutations O 0 4.100411388208158e-05
. O 0 1.717043596727308e-05

The O 0 6.0883139667566866e-06
overlap O 0 1.57214424234553e-06
in O 0 1.3418603828085907e-07
clinical O 0 1.8639407244336326e-06
features O 0 1.4734320075149299e-07
and O 0 1.673368998922342e-08
the O 0 1.8418612413029223e-08
presence O 0 2.1053500276480008e-08
, O 0 1.5360969385369572e-08
in O 0 4.350381832551875e-09
the O 0 5.0950736962818155e-09
same O 0 3.4100198220698985e-09
genes O 0 6.183304979145987e-09
, O 0 4.145695786661463e-09
of O 0 1.1374204689218459e-08
mutations O 0 4.436627776271962e-08
for O 0 1.1200234517616536e-08
more O 0 5.9548814768106695e-09
than O 0 2.946290855732059e-08
one O 0 4.031013745020573e-08
craniosynostotic B-Disease 0 3.5360053516342305e-06
condition I-Disease 0 4.4392098175194405e-07
- O 0 2.301508317259504e-07
such O 0 1.1096848773206602e-08
as O 0 1.4732478348378208e-07
Saethre B-Disease 0 8.85697445482947e-05
- I-Disease 0 8.167092346411664e-06
Chotzen I-Disease 0 0.00010566900891717523
, I-Disease 0 3.826794738870376e-07
Crouzon I-Disease 0 0.00029559078393504024
, I-Disease 0 4.605213348440884e-07
and I-Disease 0 9.379375569551485e-07
Pfeiffer I-Disease 0 0.10294131189584732
syndromes I-Disease 0 0.0007959039066918194
- O 0 4.13213047067984e-06
support O 0 1.259992643554142e-07
the O 0 1.2270476190678892e-07
hypothesis O 0 2.3369182144961087e-07
that O 0 1.3123704789563817e-08
TWIST O 0 3.2450450362375705e-06
and O 0 1.91921188275046e-07
FGFRs O 0 1.5704174074926414e-05
are O 0 1.8392388057009157e-08
components O 0 1.7425033149720548e-07
of O 0 6.61071908325539e-08
the O 0 5.158253557624448e-08
same O 0 4.37573284273185e-08
molecular O 0 5.099743134451273e-07
pathway O 0 2.4777634166639473e-07
involved O 0 3.757024202855064e-08
in O 0 9.340064721641284e-09
the O 0 4.1223817248692285e-08
modulation O 0 2.2109745259513147e-05
of O 0 0.00029933193582110107
craniofacial O 1 1.0
and O 1 0.9997648596763611
limb O 1 1.0
development O 0 0.19749034941196442
in O 0 1.0173799864787725e-06
humans O 0 1.9557603536668466e-06
. O 0 4.861881279794034e-07
. O 0 4.509565314947395e-06

Mutation O 0 1.4048279808775987e-05
analysis O 0 3.3725555113051087e-06
of O 0 9.298283657699358e-06
UBE3A O 1 0.999998927116394
in O 1 0.9999533891677856
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9998751878738403
. O 0 0.0009336259681731462

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9968428611755371
AS B-Disease 1 1.0
) O 0 1.1971874300797936e-06
is O 0 5.576550776709155e-08
caused O 0 1.8051554206977016e-07
by O 0 8.538295759308312e-08
chromosome O 0 1.994870444832486e-06
15q11 O 0 1.0003574971051421e-05
- O 0 5.790621344203828e-06
q13 O 0 4.423228801897494e-06
deletions O 0 5.422397180154803e-07
of O 0 1.3582865676653455e-07
maternal O 0 3.024663897122082e-07
origin O 0 1.1282896394959607e-07
, O 0 1.2122951886794908e-07
by O 0 1.341369113561086e-07
paternal O 0 8.59291321830824e-06
uniparental B-Disease 1 0.9993842840194702
disomy I-Disease 1 0.9999760389328003
( O 0 0.005819942802190781
UPD B-Disease 1 1.0
) O 0 3.151901637465926e-06
15 O 0 4.045304194733035e-06
, O 0 3.10690438709571e-07
by O 0 3.0391325367418176e-07
imprinting O 0 0.0016749565256759524
defects O 1 0.7436054348945618
, O 0 3.730123410150554e-07
and O 0 1.230163064747103e-07
by O 0 5.0536232976128304e-08
mutations O 0 2.489411770056904e-07
in O 0 5.166455707694695e-08
the O 0 7.319276278394682e-07
UBE3A O 0 0.0009503265609964728
gene O 0 1.9523724404280074e-05
. O 0 2.3058302758727223e-05

UBE3A O 0 0.014310107566416264
encodes O 0 0.00011870055459439754
a O 0 2.453184970363509e-05
ubiquitin O 0 0.0002538568223826587
- O 0 0.00024977204157039523
protein O 0 1.140568929258734e-05
ligase O 0 5.114470241096569e-06
and O 0 6.744794518454e-07
shows O 0 1.440836967958603e-06
brain O 0 0.004725917242467403
- O 0 1.1140067726955749e-05
specific O 0 1.0271984365317621e-06
imprinting O 0 5.677992885466665e-05
. O 0 1.9564729882404208e-05

Here O 0 1.9973997041233815e-05
we O 0 3.579092663130723e-06
describe O 0 1.2019283531117253e-05
UBE3A O 0 0.0005851042224094272
coding O 0 4.5859269448556006e-05
- O 0 9.863478226179723e-06
region O 0 3.2995168908200867e-07
mutations O 0 2.969850072531699e-07
detected O 0 1.6667455327024072e-07
by O 0 3.5783646268328084e-08
SSCP O 0 1.887262988020666e-05
analysis O 0 1.6252965906460304e-07
in O 0 4.093993055676037e-08
13 O 0 2.6916086426354013e-06
AS B-Disease 1 0.9993454813957214
individuals O 0 1.4804689385528036e-07
or O 0 4.508123652158247e-07
families O 0 2.724430032685632e-07
. O 0 5.56120312467101e-06

Two O 0 8.017305844987277e-06
identical O 0 1.2319820598349907e-05
de O 0 5.069178223493509e-05
novo O 0 2.2477219317806885e-05
5 O 0 1.2210060958750546e-05
- O 0 8.330398486577906e-06
bp O 0 5.185951522435062e-06
duplications O 0 9.193357072945219e-06
in O 0 2.5523235080981976e-07
exon O 0 4.870150405622553e-06
16 O 0 2.494707359801396e-06
were O 0 1.0879040246436489e-06
found O 0 2.4214564291469287e-06
. O 0 1.6491019778186455e-05

Among O 0 1.3219545280662715e-06
the O 0 1.5624631544142176e-07
other O 0 1.4812253645857254e-08
11 O 0 1.1452130621592005e-07
unique O 0 1.933249471619547e-08
mutations O 0 2.6362769744991965e-08
, O 0 2.2427713020078954e-08
8 O 0 2.856793344108155e-07
were O 0 6.821776565857363e-08
small O 0 4.97927103992879e-08
deletions O 0 5.571786800828704e-07
or O 0 1.4483050847502454e-07
insertions O 0 7.572832032565202e-07
predicted O 0 7.339560852415161e-07
to O 0 1.0581665321751643e-07
cause O 0 2.2239212285057874e-06
frameshifts O 0 0.00018357789667788893
, O 0 1.9968067022091418e-07
1 O 0 9.398160614182416e-07
was O 0 1.428050211416121e-07
a O 0 1.3759637873533848e-08
mutation O 0 2.6067116465355866e-08
to O 0 4.800724262565836e-09
a O 0 2.5597428177093207e-08
stop O 0 1.2449618225218728e-07
codon O 0 6.671176606687368e-07
, O 0 5.8439074024363435e-08
1 O 0 3.896737723607657e-07
was O 0 2.1756396506589226e-07
a O 0 6.457791812408686e-08
missense O 0 7.783849014231237e-07
mutation O 0 1.008108512223771e-07
, O 0 2.3488311740038625e-08
and O 0 4.511680629093462e-08
1 O 0 8.210507758121821e-07
was O 0 2.653971193922189e-07
predicted O 0 2.1957376361569914e-07
to O 0 2.656001107936845e-08
cause O 0 1.3314624425220245e-07
insertion O 0 5.863540764039499e-07
of O 0 9.366629001306137e-07
an O 0 4.641527198145923e-07
isoleucine O 0 0.00030540948500856757
in O 0 1.461625487308993e-07
the O 0 3.989598837961239e-07
hect O 0 7.425867806887254e-06
domain O 0 2.2644400132776354e-07
of O 0 1.4256850988658698e-07
the O 0 1.9254302685567382e-07
UBE3A O 0 3.490378730930388e-05
protein O 0 2.824938292178558e-07
, O 0 3.8916194711191565e-08
which O 0 1.3584634750429814e-08
functions O 0 8.972580900490357e-08
in O 0 9.005345447121726e-08
E2 O 0 2.2337277187034488e-05
binding O 0 7.717046628386015e-07
and O 0 7.261583050421905e-07
ubiquitin O 0 2.2581787561648525e-05
transfer O 0 1.62686610565288e-05
. O 0 2.4820921680657193e-05

Eight O 0 9.926740858645644e-06
of O 0 7.365357532762573e-07
the O 0 1.8987039140938577e-07
cases O 0 6.029113563954525e-08
were O 0 8.018340480475672e-08
familial O 0 1.1472269534351653e-06
, O 0 1.33449546524389e-07
and O 0 1.4017091132245696e-07
five O 0 4.345251340964751e-07
were O 0 3.9138549823292124e-07
sporadic O 0 1.972799509530887e-05
. O 0 2.374784708081279e-05

In O 0 3.0462845188594656e-06
two O 0 7.817042160240817e-07
familial O 0 9.171612873615231e-06
cases O 0 3.66230125337097e-07
and O 0 7.177018090942511e-08
one O 0 4.8131131080708656e-08
sporadic O 0 1.425361801921099e-06
case O 0 1.2688861943388474e-06
, O 0 2.404943018063932e-07
mosaicism O 0 2.1980074961902574e-05
for O 0 3.19672381010605e-07
UBE3A O 0 0.00013783248141407967
mutations O 0 9.249615118278598e-07
was O 0 3.4437883300597605e-07
detected O 0 2.53456818199993e-07
in O 0 2.6040384071279732e-08
the O 0 4.6225760996776444e-08
mother O 0 3.2592506471473826e-08
of O 0 1.7924371320532373e-07
three O 0 6.373803103087994e-07
AS B-Disease 1 0.9999991655349731
sons O 0 0.0007193064084276557
, O 0 1.0911900716337186e-07
in O 0 1.800186488765121e-08
the O 0 3.604222342801222e-08
maternal O 0 2.635217128954537e-07
grandfather O 0 3.6417074511518877e-07
of O 0 4.2036725744765135e-07
two O 0 7.790867471157981e-07
AS B-Disease 1 0.9999996423721313
first O 0 3.5337061490281485e-06
cousins O 0 2.5581528007023735e-06
, O 0 1.1273033351244521e-07
and O 0 1.0439730857569884e-07
in O 0 3.7883616244016594e-08
the O 0 1.0453299381651959e-07
mother O 0 5.3415600831385746e-08
of O 0 4.3324237708475266e-07
an O 0 5.038436370341515e-07
AS B-Disease 1 0.9999997615814209
daughter O 0 0.002133831614628434
. O 0 0.00023634506214875728

The O 0 1.4084696431382326e-06
frequencies O 0 1.3721029290536535e-06
with O 0 2.4831324552110345e-08
which O 0 1.009824668329884e-08
we O 0 1.55290020842358e-08
detected O 0 3.761821432135548e-08
mutations O 0 2.7252792023091388e-08
were O 0 4.728570246470554e-08
5 O 0 2.2357117757110245e-07
( O 0 2.041906732586085e-08
14 O 0 9.232274322812373e-08
% O 0 7.902987597674382e-09
) O 0 4.24356283446059e-09
of O 0 1.5948465659221256e-08
35 O 0 9.955886071111308e-08
in O 0 1.124924065010191e-08
sporadic O 0 2.25597958092294e-07
cases O 0 1.7096144944162006e-08
and O 0 2.6647084538922172e-08
8 O 0 5.215703708927322e-07
( O 0 1.8457614103795095e-08
80 O 0 3.369933310182205e-08
% O 0 5.325443641623906e-09
) O 0 8.402551543440495e-09
of O 0 4.683466414689974e-08
10 O 0 2.763317183962499e-07
in O 0 7.679063429577582e-08
familial O 0 2.2256526790442877e-06
cases O 0 4.463130096610257e-07
. O 0 1.2920594372189953e-06
. O 0 1.5796247680555098e-05

The O 0 0.0001644524309085682
hemochromatosis B-Disease 1 0.9999997615814209
845 O 0 0.000552319863345474
G O 0 0.00044041938963346183
- O 0 5.4021747928345576e-05
- O 0 6.817470875830622e-06
> O 0 2.0443599169084337e-06
A O 0 3.109227861841646e-07
and O 0 4.595639779836347e-08
187 O 0 1.2957350747910823e-07
C O 0 2.231901589766494e-06
- O 0 1.2009130614387686e-06
- O 0 1.155314294010168e-06
> O 0 9.681594974608743e-07
G O 0 2.521380793041317e-06
mutations O 0 2.9278052693371137e-07
: O 0 4.286975041623009e-08
prevalence O 0 5.173392878532468e-07
in O 0 5.128958591171795e-08
non O 0 2.99852740681672e-06
- O 0 4.4381108637026045e-06
Caucasian O 0 4.462795459403424e-06
populations O 0 2.5441922844038345e-06
. O 0 1.296232676395448e-05

Hemochromatosis B-Disease 1 0.9999971389770508
, O 0 3.326954538351856e-05
the O 0 0.0002356336044613272
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999998807907104
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 3.416231265873648e-05
leads O 0 5.459114981931634e-05
, O 0 2.581473950158397e-07
if O 0 4.1856833377096336e-07
untreated O 0 7.39878523745574e-05
, O 0 1.7308865096765658e-07
to O 0 6.247619808164018e-07
progressive O 1 0.9999979734420776
iron B-Disease 1 1.0
overload I-Disease 1 0.9999978542327881
and O 0 0.0005859650555066764
premature B-Disease 0 0.11374881863594055
death I-Disease 0 0.001062641735188663
. O 0 3.258689685026184e-05

The O 0 9.136817243415862e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.664727799128741e-05
, O 0 4.349523351265816e-06
HFE O 1 0.9998557567596436
, O 0 2.6425457235745853e-06
recently O 0 1.6445975461465423e-06
has O 0 5.2800338323777396e-08
been O 0 4.7903725430842314e-08
identified O 0 1.3177186986013112e-07
, O 0 3.5557356170556886e-08
and O 0 2.13620925393343e-08
characterization O 0 7.9365712224444e-08
of O 0 6.284286513391635e-08
this O 0 1.063578913829133e-08
gene O 0 5.646225531563687e-08
has O 0 8.154383834835244e-09
shown O 0 9.817097357256444e-09
that O 0 3.339156506854124e-09
it O 0 5.14333731160832e-09
contains O 0 1.1262573096360029e-08
two O 0 6.028904042665317e-09
mutations O 0 2.6126599550480023e-08
that O 0 5.548908443842038e-09
result O 0 1.1986094250460155e-07
in O 0 1.664177347038276e-07
amino O 0 9.296768439526204e-07
acid O 0 7.391624876618152e-07
substitutions O 0 4.271204943506746e-06
- O 0 3.459434765318292e-06
cDNA O 0 2.9098116556269815e-06
nucleotides O 0 2.012411641771905e-06
845 O 0 5.650611456076149e-06
G O 0 1.147024431702448e-05
- O 0 5.6843100537662394e-06
- O 0 3.8648017834930215e-06
> O 0 2.443095581838861e-06
A O 0 1.0242979442409705e-06
( O 0 9.937445355490127e-08
C282Y O 0 2.011632432186161e-06
) O 0 2.4579835056215416e-08
and O 0 3.8152279557834845e-08
187 O 0 2.0016764779029472e-07
C O 0 2.229176516266307e-06
- O 0 1.2544920764412382e-06
- O 0 1.157365545623179e-06
> O 0 4.2827850847970694e-06
G O 0 2.7334444894222543e-05
( O 0 8.25023960260296e-07
H63D O 0 0.0006593490252271295
) O 0 1.7952853568203864e-06
. O 0 9.449547178519424e-06

Although O 0 0.034963201731443405
hemochromatosis B-Disease 1 1.0
is O 0 1.309408389715827e-06
common O 0 4.823345989279915e-07
in O 0 1.2424911233210878e-07
Caucasians O 0 2.174269638999249e-06
, O 0 1.2784013847522147e-07
affecting O 0 3.746409049654176e-07
> O 0 7.474883432223578e-07
= O 0 5.387254304878297e-07
1 O 0 5.456738563225372e-07
/ O 0 2.8072400937162456e-07
300 O 0 2.6797442487236367e-08
individuals O 0 1.5171377487632753e-09
of O 0 1.0120498217247587e-08
northern O 0 4.172447276573621e-08
European O 0 1.2264088411484408e-07
origin O 0 2.6696124422187495e-08
, O 0 1.1547792055921491e-08
it O 0 3.185212316125785e-09
has O 0 1.506023306063753e-09
not O 0 2.2056589887853306e-09
been O 0 6.993837953217508e-09
recognized O 0 8.72007355212645e-09
in O 0 1.1960670676103291e-08
other O 0 3.0034787101840266e-08
populations O 0 4.949841354573437e-07
. O 0 6.3953661992854904e-06

The O 0 2.172120730392635e-06
present O 0 2.0154276114681124e-07
study O 0 5.278835857325248e-08
used O 0 2.372645901971282e-08
PCR O 0 7.636012355760613e-07
and O 0 1.0282544593565035e-07
restriction O 0 2.561613996476808e-07
- O 0 6.086747248446045e-07
enzyme O 0 8.823943886682173e-08
digestion O 0 5.1126281874758206e-08
to O 0 6.163381804924484e-09
analyze O 0 7.195233564516457e-08
the O 0 1.965942431070289e-08
frequency O 0 2.3817875671738875e-07
of O 0 8.789810834741729e-08
the O 0 2.8315196232142625e-07
845 O 0 3.6307012578618014e-06
G O 0 9.668516213423572e-06
- O 0 6.430139819713077e-06
- O 0 1.5453234709639219e-06
> O 0 7.686058438594046e-07
A O 0 2.1616567380533525e-07
and O 0 3.86534324547938e-08
187 O 0 4.755913707299442e-08
C O 0 9.691885907159303e-07
- O 0 3.579826000077446e-07
- O 0 2.6622933546605054e-07
> O 0 8.910909059522965e-07
G O 0 1.765465867720195e-06
mutations O 0 1.8865637230192078e-07
in O 0 7.324702977484776e-08
HLA O 0 4.031685875816038e-06
- O 0 2.8559489351209777e-07
typed O 0 1.009495775861069e-07
samples O 0 7.389923784018038e-09
from O 0 9.333547268397524e-09
non O 0 6.047293368283135e-07
- O 0 6.676051498288871e-07
Caucasian O 0 4.796845587407006e-07
populations O 0 7.451041739159336e-08
, O 0 9.28227876784149e-08
comprising O 0 9.058539376383123e-07
Australian O 0 1.201955910801189e-05
Aboriginal O 0 1.4663055480923504e-06
, O 0 6.711506728152017e-08
Chinese O 0 1.3457960790219659e-07
, O 0 1.781428693448106e-07
and O 0 9.62568492468563e-07
Pacific O 0 3.8861155189806595e-05
Islanders O 0 0.00045177998254075646
. O 0 3.271199966548011e-05

Results O 0 2.6351986889494583e-05
showed O 0 1.979247826966457e-06
that O 0 7.704502991146e-08
the O 0 2.991735641444393e-07
845 O 0 5.9012500059907325e-06
G O 0 5.865493949386291e-05
- O 0 6.61782396491617e-05
- O 0 1.0350897355237976e-05
> O 0 2.067115246973117e-06
A O 0 2.0210055140523764e-07
mutation O 0 9.514334919913381e-08
was O 0 3.539192405810354e-08
present O 0 8.335683254756532e-09
in O 0 2.450960101541e-09
these O 0 2.5119417657037957e-09
populations O 0 6.059719837026023e-09
( O 0 4.555319232935062e-09
allele O 0 4.1811468065589e-08
frequency O 0 6.912465266850631e-08
0 O 0 3.1735588379433466e-08
. O 0 3.237773382736009e-09
32 O 0 2.72568456693989e-08
% O 0 4.842752865386046e-09
) O 0 8.342078139378373e-09
, O 0 1.2770374091530812e-08
and O 0 1.5957562382595825e-08
, O 0 1.7919306927183243e-08
furthermore O 0 6.695958632008114e-08
, O 0 1.3320512692871489e-08
it O 0 5.808233893844772e-09
was O 0 1.962413733735957e-07
always O 0 8.805735518535585e-08
seen O 0 2.2300476132386393e-07
in O 0 5.744621844883113e-08
conjunction O 0 3.632997334079846e-07
with O 0 3.2819770012793015e-07
HLA O 0 0.00014805996033828706
haplotypes O 0 3.324229510326404e-06
common O 0 3.2294616403305554e-07
in O 0 9.696364600131346e-08
Caucasians O 0 2.898862703659688e-06
, O 0 6.908879868205986e-08
suggesting O 0 1.5835183830859023e-07
that O 0 6.227288196214431e-08
845 O 0 3.800216518357047e-06
G O 0 2.6331688786740415e-05
- O 0 6.451273657148704e-05
- O 0 5.1738381444010884e-05
> O 0 2.6318114123569103e-06
A O 0 4.1914873349924164e-07
may O 0 4.5365407430608684e-08
have O 0 1.06484341344526e-08
been O 0 1.0656012960907901e-08
introduced O 0 2.5013957127839603e-08
into O 0 5.0310005050846485e-09
these O 0 4.735743353023736e-09
populations O 0 1.3195968762147459e-08
by O 0 7.512603872328327e-08
Caucasian O 0 7.4489771577646025e-06
admixture O 0 6.258599751163274e-05
. O 0 3.123877104371786e-05

187 O 0 1.5810399418114685e-05
C O 0 6.196877075126395e-05
- O 0 1.6725236491765827e-05
- O 0 4.959469151799567e-06
> O 0 6.3867905737424735e-06
G O 0 1.10785349534126e-05
was O 0 2.5393538294338214e-07
present O 0 2.9218741204317666e-08
at O 0 8.571648635324891e-08
an O 0 5.849122963752507e-09
allele O 0 1.1793684961958206e-07
frequency O 0 3.939934742902551e-07
of O 0 3.072723302466329e-07
2 O 0 1.179235550807789e-05
. O 0 7.438732609443832e-06

68 O 0 1.0708604349929374e-05
% O 0 2.282269946363158e-07
in O 0 6.085470261041337e-08
the O 0 4.6438742629106855e-08
two O 0 2.4307931667522098e-08
populations O 0 3.4949383831417435e-08
analyzed O 0 4.108194957552769e-07
( O 0 1.2222730561006756e-07
Australian O 0 6.489985480584437e-06
Aboriginal O 0 1.997842218770529e-06
and O 0 4.0407675783171726e-07
Chinese O 0 9.920768206939101e-07
) O 0 1.5633423799954471e-06
. O 0 1.2471341506170575e-05

In O 0 3.212571527910768e-06
the O 0 1.9149570107401814e-06
Australian O 0 8.367333066416904e-06
Aboriginal O 0 8.582590567129955e-07
samples O 0 9.586999283328623e-08
, O 0 1.284542321400295e-07
187 O 0 4.5120074787519115e-07
C O 0 1.0070233656733762e-05
- O 0 5.0276739784749225e-06
- O 0 4.5804758883605246e-06
> O 0 4.297214218240697e-06
G O 0 1.9033890566788614e-05
was O 0 1.7805980689900025e-07
found O 0 7.418309522222444e-09
to O 0 3.6480629628243832e-09
be O 0 1.7844747901563096e-08
associated O 0 1.1200452831872099e-07
with O 0 2.243306624905017e-07
HLA O 0 0.006862767040729523
haplotypes O 0 5.725397386413533e-06
common O 0 5.641994107463688e-07
in O 0 9.175851545251135e-08
Caucasians O 0 3.74203477804258e-06
, O 0 7.495800247170337e-08
suggesting O 0 9.08004409438945e-08
that O 0 9.936607980876033e-09
it O 0 1.773582525288475e-08
was O 0 1.5306152079119784e-07
introduced O 0 1.5731251323813922e-07
by O 0 6.664868124062195e-08
recent O 0 8.087641276688373e-07
admixture O 0 3.3081618312280625e-05
. O 0 2.211982246080879e-05

In O 0 1.5122493550734362e-06
the O 0 5.331407351150119e-07
Chinese O 0 1.6930705726281303e-07
samples O 0 2.906616280995422e-08
analyzed O 0 9.623017405147039e-08
, O 0 2.060631842937255e-08
187 O 0 8.777631421708065e-08
C O 0 1.5670474340367946e-06
- O 0 8.528999160262174e-07
- O 0 6.168830282149429e-07
> O 0 1.2542731155917863e-06
G O 0 5.155286544322735e-06
was O 0 2.6577399125926604e-07
present O 0 4.224756011694808e-08
in O 0 2.2873113181276494e-08
association O 0 3.4489413991423135e-08
with O 0 9.400401346226772e-09
a O 0 4.021621791139296e-08
wide O 0 2.425937566385983e-07
variety O 0 8.958678421322475e-08
of O 0 4.01150202833378e-07
HLA O 0 0.00013484020018950105
haplotypes O 0 1.3553444659919478e-06
, O 0 2.697153078656811e-08
showing O 0 2.6676021391836002e-08
this O 0 2.8640418925363065e-09
mutation O 0 1.075547562123802e-08
to O 0 3.514603497123403e-09
be O 0 1.2146636585441684e-08
widespread O 0 3.889408262125471e-08
and O 0 2.975822965822772e-08
likely O 0 9.613771112526592e-08
to O 0 3.008966231732302e-08
predate O 0 7.047416374916793e-07
the O 0 9.400942957427105e-08
more O 0 3.6597938901650195e-08
genetically O 0 2.134820960009165e-07
restricted O 0 1.7407212737907685e-07
845 O 0 2.556279696364072e-06
G O 0 2.170298648707103e-05
- O 0 4.231083585182205e-05
- O 0 1.2829638762923423e-05
> O 0 7.978955181897618e-06
A O 0 3.968828877987107e-06
mutation O 0 7.72572911955649e-06
. O 0 6.4780879256431945e-06

Genotype O 0 0.0017519203247502446
- O 0 0.00026286914362572134
phenotype O 0 3.954842031816952e-05
correlations O 0 2.629512528073974e-05
in O 0 6.6380880525684915e-06
attenuated B-Disease 1 0.9722317457199097
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999996423721313
. O 0 0.0035764824133366346

Germ O 1 0.9992573857307434
- O 0 0.013268129900097847
line O 0 8.929743671615142e-06
mutations O 0 8.387501679862908e-07
of O 0 3.8108137800918485e-07
the O 0 4.631105525731982e-07
tumor B-Disease 0 9.972084626497235e-06
suppressor O 0 5.9459027397679165e-05
APC O 0 1.0793188266688958e-05
are O 0 2.3049020114740415e-07
implicated O 0 1.5044191059132572e-05
in O 0 1.6887904621398775e-06
attenuated B-Disease 1 0.9922130703926086
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.99998939037323
AAPC B-Disease 1 1.0
) O 0 4.121905021747807e-06
, O 0 4.0499108422409336e-07
a O 0 3.6373444345372263e-07
variant O 0 2.5342409571749158e-05
of O 0 0.00010321376612409949
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.8340349197387695
FAP B-Disease 0 0.3482632040977478
) O 0 1.8021873984253034e-05
. O 0 4.83475778310094e-05

AAPC B-Disease 1 0.9999997615814209
is O 0 2.455161620673607e-06
recognized O 0 9.460262049287849e-07
by O 0 8.7930132508518e-08
the O 0 7.279271585503011e-08
occurrence O 0 2.8482105562943616e-07
of O 0 3.033196946944372e-07
< O 0 8.381285624636803e-06
100 O 0 2.0261111330910353e-06
colonic B-Disease 0 0.00034006405621767044
adenomas I-Disease 0 9.153736027656123e-05
and O 0 1.6601636332325143e-07
a O 0 1.3184086355977342e-07
later O 0 8.969147415882617e-07
onset O 1 0.9373390674591064
of O 1 0.9999843835830688
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.516690518765245e-06
age O 0 3.090926611548639e-06
> O 0 2.724842943280237e-06
40 O 0 2.336954025849991e-07
years O 0 1.0404743733261057e-07
) O 0 2.3100623991467728e-07
. O 0 3.221032329747686e-06

The O 0 2.139226353392587e-06
aim O 0 3.10605014419707e-06
of O 0 1.7960064724320546e-07
this O 0 3.5771087425473524e-08
study O 0 4.148062870967806e-08
was O 0 8.834114595401843e-08
to O 0 2.619925787428201e-08
assess O 0 2.069405354632181e-06
genotype O 0 2.9747854568995535e-05
- O 0 0.00015087798237800598
phenotype O 0 4.172876288066618e-05
correlations O 0 5.23817834618967e-05
in O 0 9.067494829650968e-06
AAPC B-Disease 1 0.9999997615814209
families O 0 1.124554910347797e-05
. O 0 2.6886147679761052e-05

By O 0 9.70416294876486e-06
protein O 0 1.0317507076251786e-05
- O 0 8.661727406433783e-06
truncation O 0 7.59067916078493e-06
test O 0 3.645481228886638e-06
( O 0 6.336740625556558e-07
PTT O 0 1.7659289369476028e-05
) O 0 7.633938281514929e-08
assay O 0 6.220758450581343e-07
, O 0 3.665005010589084e-08
the O 0 3.310784890686591e-08
entire O 0 2.2350639028445585e-07
coding O 0 1.9995718503196258e-07
region O 0 5.822545645628452e-08
of O 0 5.238245037730849e-08
the O 0 7.045279204476174e-08
APC B-Disease 0 1.1978223710684688e-06
gene O 0 2.495001751867676e-07
was O 0 5.13684994984942e-07
screened O 0 4.2940294520121824e-07
in O 0 4.5352344102411735e-08
affected O 0 1.5533036901160813e-07
individuals O 0 3.8102754729152366e-08
from O 0 5.559059559345769e-07
11 O 0 0.006387479603290558
AAPC B-Disease 1 1.0
kindreds O 0 0.10877213627099991
, O 0 7.980514169503294e-07
and O 0 2.7969036864305963e-07
their O 0 3.5519812513484794e-07
phenotypic O 0 7.353620458161458e-05
differences O 0 2.6561801860225387e-05
were O 0 1.5397718016174622e-05
examined O 0 0.00010584832489257678
. O 0 4.558210639515892e-05

Five O 0 5.0970789743587375e-05
novel O 0 1.2159975995018613e-05
germ O 0 0.004487004596740007
- O 0 0.0001464642264181748
line O 0 1.8251181245432235e-05
APC B-Disease 0 7.517379344790243e-06
mutations O 0 9.72727775661042e-07
were O 0 5.959452096249152e-07
identified O 0 1.1134054602734977e-06
in O 0 7.654641080989677e-07
seven O 0 2.8895232389913872e-05
kindreds O 0 0.0018335696076974273
. O 0 8.49570642458275e-05

Mutations O 0 1.4784889572183602e-05
were O 0 1.6543773426747066e-06
located O 0 4.386554053326108e-07
in O 0 2.8697028753299492e-08
three O 0 2.5631138100834505e-08
different O 0 6.3888991874705425e-09
regions O 0 1.3127210429786373e-08
of O 0 4.697037425671624e-08
the O 0 6.881025882421454e-08
APC B-Disease 0 3.328120214973751e-07
gene O 0 5.5719045377600196e-08
( O 0 2.6328649482820765e-08
1 O 0 3.638135694927769e-07
) O 0 2.6680243792043257e-08
at O 0 1.1667917476643197e-07
the O 0 3.7132817709562005e-08
5 O 0 1.8084965347497928e-07
end O 0 3.379035149464471e-07
spanning O 0 5.741438826589729e-07
exons O 0 4.1094136804531445e-07
4 O 0 1.5336311776081857e-07
and O 0 1.340346855727148e-08
5 O 0 1.1400359056779052e-07
, O 0 3.721265073863833e-08
( O 0 1.614926858906074e-08
2 O 0 1.9428685504863097e-07
) O 0 1.305978081234116e-08
within O 0 5.33330393182041e-08
exon O 0 1.7379825578700547e-07
9 O 0 2.5933303504643845e-07
, O 0 2.9294914938304828e-08
and O 0 5.0519080474487055e-08
( O 0 4.4904840734716345e-08
3 O 0 3.131116557142377e-07
) O 0 3.1169051339929865e-08
at O 0 1.390244079857439e-07
the O 0 7.102175203499428e-08
3 O 0 9.363074013890582e-07
distal O 0 2.4356118046853226e-06
end O 0 1.3630790363095002e-06
of O 0 7.106050361471716e-07
the O 0 1.3325818599696504e-06
gene O 0 5.920325293118367e-06
. O 0 1.5700685253250413e-05

Variability O 0 6.474959081970155e-05
in O 0 2.823780107519269e-07
the O 0 1.6933887536652037e-07
number O 0 4.521561720594036e-07
of O 0 0.007429247256368399
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0048717292957007885
most O 0 7.728168327503226e-08
apparent O 0 3.45077808105998e-07
in O 0 2.8789626682623748e-08
individuals O 0 8.811578133816056e-09
with O 0 1.1547241385301277e-08
mutations O 0 1.0296871266746166e-07
in O 0 2.4149610311496872e-08
region O 0 1.0218377610726748e-07
1 O 0 3.4794788916769903e-06
, O 0 1.1110661546354095e-07
and O 0 5.046678666076332e-07
upper O 1 0.9721245765686035
- O 1 0.9999796152114868
gastrointestinal O 1 0.9972902536392212
manifestations O 1 0.9879563450813293
were O 0 6.480170213762904e-06
more O 0 3.4973132301274745e-07
severe O 0 0.00010356464190408587
in O 0 4.6043220436331467e-07
them O 0 9.403755143466697e-07
. O 0 7.845977052056696e-06

In O 0 1.3521580513042863e-06
individuals O 0 9.65587219070585e-08
with O 0 3.4816846294916104e-08
mutations O 0 1.1876790040332708e-07
in O 0 1.3584660507603985e-08
either O 0 4.942152287412682e-08
region O 0 1.0659046267846861e-07
2 O 0 5.430443934528739e-07
or O 0 2.2634591090309186e-08
region O 0 3.899718592492718e-08
3 O 0 2.446394091748516e-07
, O 0 9.915535947868648e-09
the O 0 1.2924234127353884e-08
average O 0 1.6075144770866245e-08
number O 0 1.4193980213406121e-08
of O 0 1.4960130556573858e-07
adenomas B-Disease 0 2.294049772899598e-05
tended O 0 1.282009094438763e-07
to O 0 1.4350916899275035e-08
be O 0 2.8100140880837898e-08
lower O 0 1.0427173435800796e-07
than O 0 5.671673797280619e-09
those O 0 1.5085590554519968e-09
in O 0 2.405305954411574e-09
individuals O 0 1.0042980891356024e-09
with O 0 2.2280475242553166e-09
mutations O 0 1.3117899655412657e-08
in O 0 2.4130579756587167e-09
region O 0 2.0486712770662052e-08
1 O 0 2.689440350422956e-07
, O 0 1.295824780811472e-08
although O 0 2.4631647832507042e-08
age O 0 2.616762628804281e-07
at O 0 7.543632705164782e-07
diagnosis O 0 2.3169868654804304e-06
was O 0 1.260734620700532e-06
similar O 0 1.1496474598970963e-06
. O 0 1.168076505564386e-05

In O 0 1.8963555703521706e-05
all O 0 3.247825225116685e-05
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 0.0009803593857213855
, O 0 8.273522666968347e-07
a O 0 3.035297595488373e-07
predominance O 0 5.041962594987126e-06
of O 0 8.988004992716014e-06
right O 1 0.9858330488204956
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.999998927116394
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999290704727173
sparing O 0 7.416543667204678e-05
was O 0 1.1230202289880253e-05
observed O 0 1.387241263728356e-05
. O 0 3.2105879654409364e-05

No O 0 8.47242190502584e-05
desmoid B-Disease 1 0.998891294002533
tumors I-Disease 1 1.0
were O 0 2.000685071834596e-06
found O 0 1.909606766048455e-07
in O 0 1.3289023570450809e-07
these O 0 4.588550268636027e-07
kindreds O 0 0.00023575361410621554
. O 0 5.311396307661198e-05

Our O 0 6.446951829275349e-06
data O 0 8.524494319317455e-07
suggest O 0 2.1754613044322468e-07
that O 0 3.733109110726218e-08
, O 0 2.401416168140713e-07
in O 0 3.6923876223227126e-07
AAPC B-Disease 1 1.0
families O 0 1.0418546025903197e-07
, O 0 4.613345438997385e-08
the O 0 3.5133048470470385e-08
location O 0 8.566761522388333e-08
of O 0 1.4823423555299087e-07
the O 0 4.013155034954252e-07
APC B-Disease 0 1.6764899555710144e-05
mutation O 0 4.894599896942964e-06
may O 0 2.2600265765504446e-06
partially O 0 1.0463633770996239e-05
predict O 0 1.71891576883354e-06
specific O 0 8.428476121480344e-07
phenotypic O 0 8.179888391168788e-05
expression O 0 2.08136516448576e-05
. O 0 2.448148552502971e-05

This O 0 1.3590694152298965e-06
should O 0 3.8523677403645706e-07
help O 0 1.2269001103959454e-07
in O 0 3.758113464868984e-08
the O 0 5.61865896031577e-08
design O 0 4.624437224265421e-07
of O 0 4.601714351792907e-07
tailored O 0 4.493029791774461e-06
clinical O 0 0.0001389954995829612
- O 0 5.2803523431066424e-05
management O 0 4.803117462870432e-06
protocols O 0 3.2843358894751873e-06
in O 0 8.946619445282522e-09
this O 0 3.856048369499376e-09
subset O 0 1.558452424887946e-07
of O 0 2.0534444900022208e-07
FAP B-Disease 0 8.548920959583484e-06
patients O 0 6.591361056962342e-07
. O 0 1.1885167623404413e-06
. O 0 1.8081438611261547e-05

Wilms B-Disease 1 0.9997898936271667
' I-Disease 0 3.1885792850516737e-05
tumor I-Disease 0 9.041347766469698e-06
1 O 0 3.4307001897104783e-06
and O 0 1.0581368314888095e-06
Dax O 0 0.055927760899066925
- O 0 5.805716682516504e-06
1 O 0 9.595009942131583e-07
modulate O 0 5.253824610917945e-07
the O 0 8.615904789621709e-08
orphan O 0 2.367307985196021e-07
nuclear O 0 1.3878426443625358e-06
receptor O 0 1.8047026060230564e-06
SF O 0 0.00011855156481033191
- O 0 6.623680519624031e-07
1 O 0 3.093286693456321e-07
in O 0 3.626101374720747e-08
sex O 0 1.4786685653689347e-07
- O 0 1.23674325891443e-07
specific O 0 5.873385688914823e-08
gene O 0 4.158484898653114e-07
expression O 0 2.13039425034367e-06
. O 0 8.308420547109563e-06

Products O 0 1.957339009095449e-05
of O 0 6.935761575732613e-06
steroidogenic O 0 0.00020957553351763636
factor O 0 2.149477950297296e-06
1 O 0 3.3682745197438635e-06
( O 0 2.3309864616294362e-07
SF O 0 0.0001779582817107439
- O 0 9.917022225636174e-07
1 O 0 6.7966834649269e-07
) O 0 5.32717372436764e-08
and O 0 1.7378897609887645e-07
Wilms B-Disease 0 0.0001902617805171758
tumor I-Disease 0 4.027182058052858e-06
1 O 0 4.360179900686489e-06
( O 0 2.3023909534458653e-07
WT1 O 0 2.77702074527042e-05
) O 0 2.2345814087998406e-08
genes O 0 1.0900373048627898e-08
are O 0 4.0057268613225006e-09
essential O 0 7.345688146642715e-08
for O 0 6.595165302769601e-08
mammalian O 0 5.14825615027803e-06
gonadogenesis O 0 6.261462203838164e-06
prior O 0 8.353575253750023e-07
to O 0 1.9216751923067932e-07
sexual O 0 3.3185533538926393e-06
differentiation O 0 4.336045094532892e-05
. O 0 1.6543330275453627e-05

In O 0 2.7662015327223344e-06
males O 0 4.518045898294076e-06
, O 0 1.7445132698412635e-06
SF O 1 0.8683391809463501
- O 0 2.920108090620488e-05
1 O 0 3.6468234156927792e-06
participates O 0 2.987590050906874e-07
in O 0 2.38662529739031e-08
sexual O 0 9.234845776973089e-08
development O 0 5.8368673450104325e-08
by O 0 1.807528882125098e-08
regulating O 0 1.331259227299597e-07
expression O 0 9.338019424376398e-08
of O 0 1.6849314476985455e-07
the O 0 9.58090936364897e-07
polypeptide O 0 5.965224772808142e-05
hormone O 0 1.6272446373477578e-05
Mullerian O 0 0.000153786750161089
inhibiting O 0 1.009373227134347e-05
substance O 0 1.4636520063504577e-05
( O 0 2.3868863081588643e-06
MIS O 0 0.0043571083806455135
) O 0 4.801812337973388e-06
. O 0 2.696397677937057e-05

Here O 0 4.094043561053695e-06
, O 0 3.823274425940326e-07
we O 0 2.3692366823979683e-07
show O 0 2.5786735591282195e-07
that O 0 1.6004756275833643e-07
WT1 O 0 0.0006455095717683434
- O 0 0.00020964848226867616
KTS O 0 0.0027973386459052563
isoforms O 0 1.8182005078415386e-05
associate O 0 3.6762426134373527e-06
and O 0 4.3100547486574214e-07
synergize O 0 1.8197461031377316e-05
with O 0 3.071129413001472e-07
SF O 1 0.9588276743888855
- O 0 7.999557055882178e-06
1 O 0 1.3824386542182765e-06
to O 0 1.1451726322775357e-07
promote O 0 3.1770036912348587e-06
MIS O 0 0.0004613641067408025
expression O 0 8.205010999517981e-06
. O 0 1.4302748240879737e-05

In O 0 3.017212975464645e-06
contrast O 0 9.534992386761587e-06
, O 0 3.732031018444104e-06
WT1 O 0 0.002322445623576641
missense O 0 3.145529262837954e-05
mutations O 0 3.70100065083534e-06
, O 0 2.1464654764713487e-07
associated O 0 2.8024464882037137e-07
with O 0 2.3026413487059472e-07
male B-Disease 0 4.888033799943514e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 8.153622729878407e-06
Denys B-Disease 1 0.9999980926513672
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 9.959994713426568e-06
fail O 0 1.166095353255514e-05
to O 0 4.699411988440261e-07
synergize O 0 4.8473240894963965e-05
with O 0 2.051095179922413e-06
SF O 1 0.9999908208847046
- O 0 0.005133626516908407
1 O 0 4.682110738940537e-05
. O 0 9.244603461411316e-06

Additionally O 0 2.5394958356628194e-05
, O 0 6.206720399859478e-07
the O 0 3.511446777793026e-07
X O 0 6.94145928719081e-05
- O 0 6.122735067037866e-05
linked O 0 2.691505869734101e-06
, O 0 1.0702233765869096e-07
candidate O 0 4.880295136899804e-07
dosage O 0 3.378062683623284e-05
- O 0 1.5228361917252187e-05
sensitive O 0 1.7516149455332197e-06
sex O 0 3.29989745750936e-07
- O 0 4.883023621005123e-07
reversal O 0 4.068290593295387e-07
gene O 0 2.5783836576920294e-07
, O 0 5.402787337516202e-07
Dax O 1 0.7370147109031677
- O 0 2.158265488105826e-05
1 O 0 5.752033757744357e-06
, O 0 4.2914177811326226e-07
antagonizes O 0 4.899653049506014e-06
synergy O 0 3.6831452234764583e-06
between O 0 9.721406968310475e-07
SF O 0 0.0020320776384323835
- O 0 1.603159603291715e-06
1 O 0 6.273867256822996e-07
and O 0 9.876788453766494e-08
WT1 O 0 0.00022990092111285776
, O 0 3.979281970600823e-08
most O 0 1.4735578091062962e-08
likely O 0 2.7364047028299865e-08
through O 0 6.977715294453901e-09
a O 0 1.9921650107335154e-08
direct O 0 5.771441280444378e-08
interaction O 0 3.5578941037783807e-07
with O 0 3.097738385804405e-07
SF O 1 0.9974808096885681
- O 0 9.855133248493075e-05
1 O 0 2.2303218429442495e-05
. O 0 6.649942861258751e-06

We O 0 5.72672934140428e-06
propose O 0 4.46125477537862e-06
that O 0 3.3989056191785494e-07
WT1 O 0 0.0002018288359977305
and O 0 4.125491614104249e-06
Dax O 1 0.9966779947280884
- O 0 3.4034517739200965e-05
1 O 0 1.7245674825971946e-06
functionally O 0 5.998990673106164e-07
oppose O 0 1.0607855216449025e-07
each O 0 1.4048455732051934e-08
other O 0 1.717219433317041e-08
in O 0 3.1258053923011175e-08
testis O 0 9.881562164082425e-07
development O 0 8.937345796766749e-08
by O 0 4.095391048508645e-08
modulating O 0 4.431512934388593e-06
SF O 0 0.00178885692730546
- O 0 6.9809516389796045e-06
1 O 0 4.293359779694583e-06
- O 0 4.528044428298017e-06
mediated O 0 1.87990881386213e-05
transactivation O 0 3.0350474844453856e-05
. O 0 1.1155694892295287e-06
. O 0 7.665988960070536e-06

A O 0 7.266901229741052e-05
mouse O 0 1.5338653611252084e-05
model O 0 6.216006568138255e-06
for O 0 1.2614065781235695e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999998807907104
- O 1 0.9999990463256836
centre O 1 0.992933988571167
mutations O 0 7.535225449828431e-05
. O 0 2.1290810764185153e-05

Imprinting O 0 0.00015427774633280933
in O 0 1.4008861626280122e-06
the O 0 1.636429260543082e-06
15q11 O 0 6.795397348469123e-05
- O 0 2.4543805920984596e-05
q13 O 0 2.123401645803824e-05
region O 0 7.2762583158692e-07
involves O 0 4.746674733269174e-07
an O 0 5.2337409073288654e-08
imprinting O 0 6.465077603934333e-06
centre O 0 0.0027352869510650635
( O 0 1.1280598073426518e-06
IC O 0 0.23020537197589874
) O 0 2.695148282327864e-07
, O 0 5.088763188609846e-08
mapping O 0 7.23747604070013e-08
in O 0 1.1363513685580529e-08
part O 0 2.344511784713177e-08
to O 0 1.3986054092640643e-08
the O 0 9.102743092626042e-08
promoter O 0 7.399055448331637e-06
and O 0 3.7464837987499777e-07
first O 0 8.867589258443331e-07
exon O 0 5.372055966290645e-06
of O 0 4.569524207909126e-06
SNRPN O 0 0.03815675899386406
. O 0 8.383543172385544e-05

Deletion O 0 4.1020699427463114e-05
of O 0 2.325913101230981e-06
this O 0 5.401962539508531e-07
IC O 0 0.0015230493154376745
abolishes O 0 1.8250833818456158e-05
local O 0 9.038002417582902e-07
paternally O 0 1.5652326510462444e-06
derived O 0 5.1869434969376016e-08
gene O 0 8.459933553695009e-08
expression O 0 1.422891244828861e-07
and O 0 8.41612504132172e-08
results O 0 1.3883827705285512e-06
in O 0 9.932403372658882e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 0.00023713867994956672
. O 0 5.994025923428126e-05

We O 0 2.8715537609969033e-06
have O 0 1.3929434317105915e-07
created O 0 2.3711740482212917e-07
two O 0 7.017036551815181e-08
deletion O 0 8.724832696316298e-07
mutations O 0 6.49844253075571e-07
in O 0 1.2261199344720808e-07
mice O 0 7.682255613872258e-07
to O 0 1.8341947338740283e-07
understand O 0 4.455644011613913e-05
PWS B-Disease 1 1.0
and O 0 5.521415914699901e-06
the O 0 6.896108857290528e-07
mechanism O 0 5.356038855097722e-06
of O 0 5.068678206043842e-07
this O 0 2.184586094244878e-07
IC O 0 0.0007442139904014766
. O 0 1.8771912436932325e-05

Mice O 0 0.0006280329544097185
harbouring O 0 0.002882257802411914
an O 0 1.2145707160016173e-06
intragenic O 0 0.00011145800090162084
deletion O 0 6.30986096439301e-06
in O 0 3.024773320703389e-07
Snrpn O 0 0.00023130943009164184
are O 0 3.229282867778238e-07
phenotypically O 0 4.788843580172397e-05
normal O 0 5.886686835765431e-07
, O 0 3.060597109083574e-08
suggesting O 0 3.786808377981288e-08
that O 0 3.8840610727675084e-09
mutations O 0 4.349786664192834e-08
of O 0 5.794073842935177e-08
SNRPN O 0 1.6001464246073738e-05
are O 0 7.457550132983215e-09
not O 0 9.489719232647076e-09
sufficient O 0 3.2212736300607503e-07
to O 0 4.035326242046722e-07
induce O 0 7.145226118154824e-05
PWS B-Disease 1 1.0
. O 0 0.00029979945975355804

Mice O 0 5.839998266310431e-05
with O 0 3.4784562785716844e-07
a O 0 3.547079643340112e-07
larger O 0 3.6201797115609224e-07
deletion O 0 2.458312792441575e-06
involving O 0 1.2256585932846065e-06
both O 0 2.397205776105693e-07
Snrpn O 0 5.253746348898858e-05
and O 0 2.239704741668902e-07
the O 0 7.817757818884274e-07
putative O 0 0.00013806937204208225
PWS O 1 1.0
- O 1 0.9993457198143005
IC O 1 0.9491778612136841
lack O 0 6.478835530288052e-06
expression O 0 5.200703867558332e-07
of O 0 2.3363344325844082e-07
the O 0 1.9908173953808728e-07
imprinted O 0 1.1997019555565203e-06
genes O 0 4.802677722182125e-07
Zfp127 O 0 6.230973667697981e-05
( O 0 4.6914013296373014e-07
mouse O 0 1.8487422721591429e-06
homologue O 0 6.03394391873735e-06
of O 0 4.768803592014592e-07
ZNF127 O 0 0.0016717026010155678
) O 0 6.814518656028667e-07
, O 0 1.192765694213449e-06
Ndn O 0 0.004199449438601732
and O 0 1.3422613847069442e-06
Ipw O 0 0.000760990718845278
, O 0 5.476341016219521e-07
and O 0 3.3050059755623806e-07
manifest O 0 1.988031272048829e-06
several O 0 4.0676272305972816e-07
phenotypes O 0 3.032461245311424e-05
common O 0 1.4904187082720455e-05
to O 0 2.0396475520101376e-05
PWS B-Disease 1 1.0
infants O 1 0.9999949932098389
. O 0 0.0003154453297611326

These O 0 1.0089257784784422e-06
data O 0 4.703030072050751e-07
demonstrate O 0 1.9384249583254132e-07
that O 0 9.40520727965577e-09
both O 0 1.842282770780912e-08
the O 0 3.1387219934231325e-08
position O 0 3.0030696507310495e-07
of O 0 1.0037340558710639e-07
the O 0 1.1754283235632101e-07
IC O 0 0.00012015744141535833
and O 0 5.7150703725028507e-08
its O 0 2.3165434015481878e-08
role O 0 5.032250882663902e-08
in O 0 5.471473496498902e-09
the O 0 1.6379415157530275e-08
coordinate O 0 3.7089638027509864e-08
expression O 0 2.1318541598702723e-08
of O 0 2.8755930969737165e-08
genes O 0 1.7888060810378192e-08
is O 0 4.176179402293201e-09
conserved O 0 7.396329237963073e-08
between O 0 8.240899518341394e-08
mouse O 0 1.8123243705758796e-07
and O 0 3.361421363479167e-08
human O 0 3.348948851567002e-08
, O 0 6.289188725361328e-09
and O 0 8.681340091243328e-09
indicate O 0 1.536079352604247e-08
that O 0 8.510180116161337e-09
the O 0 9.51418925865255e-08
mouse O 0 2.6412706688461185e-07
is O 0 7.745549090998338e-09
a O 0 8.527680783743108e-09
suitable O 0 9.237135856210443e-08
model O 0 9.148729418484436e-08
system O 0 1.0657542048875257e-07
in O 0 6.6616632210525495e-09
which O 0 5.8639355593470555e-09
to O 0 5.0364827863802475e-09
investigate O 0 4.991765933937131e-08
the O 0 1.1523765053311763e-08
molecular O 0 3.024975399057439e-07
mechanisms O 0 5.861746217306063e-07
of O 0 6.387634243765206e-08
imprinting O 0 4.024093129828543e-07
in O 0 1.1192632598522323e-08
this O 0 7.392532364036697e-09
region O 0 4.14898053691104e-08
of O 0 8.663396755537178e-08
the O 0 1.199195907020112e-07
genome O 0 3.080416490774951e-07
. O 0 3.2022768436945626e-07
. O 0 5.182254426472355e-06

Mutations O 0 7.292580903595081e-06
of O 0 6.217330792424036e-07
the O 0 2.7999354301755375e-07
ATM O 0 6.674245469184825e-06
gene O 0 3.4732056519715115e-07
detected O 0 5.194096388549951e-07
in O 0 5.370536655391334e-07
Japanese O 1 0.9982001781463623
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.004036830738186836
: O 0 9.278773660525985e-08
possible O 0 2.1469280397923285e-07
preponderance O 0 9.502235229774669e-07
of O 0 7.9314865786273e-08
the O 0 5.3499004337709266e-08
two O 0 1.0719516296830989e-07
founder O 0 2.6928562419925584e-06
mutations O 0 1.3453511655825423e-06
4612del165 O 0 1.728862480376847e-05
and O 0 3.6578164781531086e-06
7883del5 O 0 0.00025572587037459016
. O 0 4.2696869059000164e-05

The O 0 2.0323801436461508e-05
ATM O 0 0.09257066994905472
( O 0 1.4565880519512575e-05
A O 1 0.9999994039535522
- O 1 0.9999982118606567
T O 1 1.0
, O 0 3.9689885511506873e-07
mutated O 0 2.934340841420635e-07
) O 0 3.453918395734945e-08
gene O 0 8.878558332980901e-08
on O 0 4.202967147648451e-07
human O 0 1.274528131034458e-06
chromosome O 0 1.5208231161523145e-05
11q22 O 0 0.00012283085379749537
. O 0 4.8141650040633976e-05

3 O 0 2.497932655387558e-05
has O 0 4.0062107586891216e-07
recently O 0 3.128600667423598e-07
been O 0 3.8454299300383354e-08
identified O 0 4.512429185865585e-08
as O 0 1.0144192152949927e-08
the O 0 1.964147067212707e-08
gene O 0 5.502789690581267e-08
responsible O 0 1.4466843367699767e-07
for O 0 3.136166526473971e-08
the O 0 3.91408661926107e-07
human O 0 0.0075214579701423645
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4577582078345586e-05
. O 0 1.4814769201620948e-05

In O 0 1.2771660067301127e-06
order O 0 4.491323579713935e-07
to O 0 4.597691827257222e-08
define O 0 1.6873579511411663e-07
the O 0 5.4522761416819776e-08
types O 0 3.591123629576032e-07
of O 0 5.14517842020723e-06
disease O 1 0.9891552329063416
- O 0 0.0021366572473198175
causing O 0 5.69195890420815e-06
ATM O 0 0.00014568619371857494
mutations O 0 7.012159244368377e-07
in O 0 9.087857932854604e-08
Japanese O 0 3.303893026895821e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.323511800270353e-07
as O 0 3.130554659946938e-08
well O 0 1.1852142378643293e-08
as O 0 3.9173251309421175e-09
to O 0 2.4199116044343327e-09
look O 0 2.3798024884058577e-08
for O 0 9.713279069956116e-09
possible O 0 2.3950374838932476e-07
mutational O 0 4.726992301584687e-06
hotspots O 0 1.3020752476222697e-06
, O 0 5.201328434623065e-08
reverse O 0 2.46872474463089e-07
- O 0 3.060673634536215e-07
transcribed O 0 7.440078064746558e-08
RNA O 0 3.5922052887826794e-08
derived O 0 1.523317472162944e-08
from O 0 1.4744209408945608e-08
ten O 0 1.8190324624356435e-07
patients O 0 3.265391868012557e-08
belonging O 0 6.84126888472747e-08
to O 0 4.737923475772732e-08
eight O 0 2.2418939806811977e-06
unrelated O 0 3.680768259073375e-06
Japanese O 0 3.682951501104981e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 1.397673941028188e-07
was O 0 2.790168878163968e-07
analyzed O 0 6.204039948443096e-08
for O 0 1.4852822971533897e-08
mutations O 0 1.1151659151664717e-07
by O 0 2.493341000331384e-08
the O 0 5.431423844015626e-08
restriction O 0 2.86943276250895e-07
endonuclease O 0 4.192421329207718e-06
fingerprinting O 0 3.744344667211408e-06
method O 0 5.491955107572721e-06
. O 0 1.1913756679859944e-05

As O 0 4.234903826727532e-06
has O 0 2.2309239966489258e-07
been O 0 7.924394651581679e-08
reported O 0 4.8145913922326145e-08
by O 0 1.1702001145863505e-08
others O 0 2.0969421754557516e-08
, O 0 2.0125519029079442e-08
mutations O 0 3.8149224224071077e-08
that O 0 5.66535973689497e-09
lead O 0 1.61383454155839e-07
to O 0 1.0822214591144075e-07
exon O 0 9.344820682599675e-06
skipping O 0 3.0897567739884835e-06
or O 0 1.327868659473097e-07
premature O 0 1.0203424380961224e-06
protein O 0 3.805642165843892e-07
truncation O 0 5.795670858788071e-06
were O 0 2.483059517999209e-07
also O 0 1.1999497928627534e-07
predominant O 0 1.625651179892884e-06
in O 0 1.3204811466493993e-07
our O 0 1.1142021776322508e-06
mutants O 0 2.9304719646461308e-05
. O 0 1.2181633792351931e-05

Six O 0 4.461476237338502e-06
different O 0 1.1682781320132563e-07
mutations O 0 2.3069823384958e-07
were O 0 5.452838180985964e-08
identified O 0 6.526565243802906e-08
on O 0 5.0738282908469046e-08
12 O 0 1.6791132395610475e-07
of O 0 6.323953982700914e-08
the O 0 1.5193876379271387e-07
16 O 0 3.548565246092039e-06
alleles O 0 6.708014552714303e-06
examined O 0 1.9586796042858623e-05
. O 0 1.680854256846942e-05

Four O 0 1.3226986084191594e-05
were O 0 2.272470965181128e-06
deletions O 0 1.4399811334442347e-05
involving O 0 5.252779828879284e-06
a O 0 4.668224562465184e-07
loss O 0 2.44534953708353e-06
of O 0 8.937905704442528e-07
a O 0 4.442818521965819e-07
single O 0 3.520462996675633e-07
exon O 0 4.33426885138033e-06
exon O 0 2.390649569861125e-06
7 O 0 1.7938205019163433e-06
, O 0 2.0888113283490384e-07
exon O 0 4.08269352192292e-06
16 O 0 1.3575021284850664e-06
, O 0 3.6916554790877854e-07
exon O 0 4.902634827885777e-06
33 O 0 2.5136644126178e-06
or O 0 8.627569627606135e-07
exon O 0 1.7867478163680062e-05
35 O 0 9.207281436829362e-06
. O 0 1.4870410268486012e-05

The O 0 1.590715442034707e-06
others O 0 7.308082103918423e-07
were O 0 6.191827992552135e-07
minute O 0 5.553830760618439e-06
deletions O 0 2.5251299575757002e-06
, O 0 2.966388308323076e-07
4649delA O 0 4.9896234486368485e-06
in O 0 2.701833921037178e-07
exon O 0 2.527259766793577e-06
33 O 0 1.4584065866074525e-06
and O 0 7.743542482785415e-07
7883del5 O 0 2.1019408450229093e-05
in O 0 1.6200904155994067e-06
exon O 0 3.312265471322462e-05
55 O 0 1.8742593965725973e-05
. O 0 2.352323463128414e-05

The O 0 3.7803824852744583e-06
mutations O 0 6.128748736955458e-06
4612del165 O 0 1.679754859651439e-05
and O 0 4.277476364222821e-07
7883del5 O 0 7.091453426255612e-06
were O 0 1.1762907803358758e-07
found O 0 2.1409613637501934e-08
in O 0 9.882136886574244e-09
more O 0 8.088735903299948e-09
than O 0 1.3046261848614904e-08
two O 0 1.3771925821970399e-08
unrelated O 0 6.466246560421496e-08
families O 0 2.8606570445788293e-09
; O 0 8.192610145840717e-09
44 O 0 3.505821055682645e-08
% O 0 2.8194360623956527e-08
( O 0 2.515562691485229e-08
7 O 0 3.139423085940507e-07
of O 0 7.014200065214027e-08
16 O 0 2.4817103394525475e-07
) O 0 7.500345233779626e-09
of O 0 2.1483860024318346e-08
the O 0 2.881621519179589e-08
mutant O 0 3.574749882773176e-07
alleles O 0 1.5887235349509865e-07
had O 0 4.6039222212357345e-08
one O 0 3.1498469610369284e-08
of O 0 6.548260955696605e-08
the O 0 1.1682603684448623e-07
two O 0 4.3848726249962056e-07
mutations O 0 1.0033365470007993e-05
. O 0 1.6724246961530298e-05

The O 0 5.638118182105245e-06
4612del165 O 0 1.8032946172752418e-05
mutations O 0 7.540165825048462e-07
in O 0 4.732811120788938e-08
three O 0 2.546934396718825e-08
different O 0 8.972937060036656e-09
families O 0 2.3709709751074115e-09
were O 0 1.4761740274593649e-08
all O 0 9.68560254221984e-09
ascribed O 0 7.421935777074395e-08
to O 0 1.604622745787765e-08
the O 0 4.643466411380359e-08
same O 0 1.565544636150662e-07
T O 0 6.336410297080874e-05
- O 0 1.1143223673570901e-05
- O 0 2.5546712549839867e-06
> O 0 8.176766641554423e-07
A O 0 1.1343682615461148e-07
substitution O 0 1.9389094063626544e-07
at O 0 2.837374495356926e-07
the O 0 5.2639954617461626e-08
splice O 0 5.57071871298831e-07
donor O 0 4.790509322560865e-08
site O 0 2.9050821126475057e-07
in O 0 2.059858275060833e-07
intron O 0 1.5721452655270696e-05
33 O 0 3.400995774427429e-05
. O 0 3.9173217373900115e-05

Microsatellite O 0 0.001547380699776113
genotyping O 0 0.0003382500435691327
around O 0 1.9331039311509812e-06
the O 0 6.880218279547989e-07
ATM O 0 3.0978477298049256e-05
locus O 0 2.7911851248063613e-06
also O 0 7.777470045766677e-08
indicated O 0 1.1895959062258044e-07
that O 0 8.993463751494346e-09
a O 0 6.458678569742915e-08
common O 0 2.1950424411443237e-07
haplotype O 0 4.661578714149073e-06
was O 0 4.0332636785933573e-07
shared O 0 6.028744792274665e-08
by O 0 1.266828686397048e-08
the O 0 2.4373905560537423e-08
mutant O 0 4.0793244693304587e-07
alleles O 0 2.2733289029019943e-07
in O 0 6.483350745156713e-08
both O 0 4.6694626121279725e-07
mutations O 0 1.1430189260863699e-05
. O 0 1.086170959752053e-05

This O 0 4.359712875157129e-07
suggests O 0 2.0937135047915945e-07
that O 0 9.936987233061245e-09
these O 0 1.2261581083805595e-08
two O 0 3.1776046682807646e-08
founder O 0 7.92819434991543e-07
mutations O 0 1.79919169340792e-07
may O 0 5.3228262686388916e-08
be O 0 4.041229217932596e-08
predominant O 0 9.3807170742366e-07
among O 0 1.0312515996702132e-07
Japanese O 0 1.7010395367833553e-06
ATM O 0 1.6930163837969303e-05
mutant O 0 1.1462862858024891e-05
alleles O 0 1.7073216440621763e-05
. O 0 1.7313106582150795e-05

W474C O 0 0.0006546129588969052
amino O 0 3.585418380680494e-05
acid O 0 4.657215413317317e-06
substitution O 0 1.8495711628929712e-06
affects O 0 2.1303343089584814e-07
early O 0 1.2815421257528214e-07
processing O 0 8.104120041707574e-08
of O 0 2.993567349562909e-08
the O 0 2.64440007669009e-08
alpha O 0 3.238269812300132e-07
- O 0 3.669558523711203e-08
subunit O 0 4.3151462847390576e-08
of O 0 2.7057525997520315e-08
beta O 0 8.767622716732149e-07
- O 0 5.314710733728134e-07
hexosaminidase O 0 2.413451966276625e-06
A O 0 4.0232794162875507e-07
and O 0 8.542058793636897e-08
is O 0 4.163710087823347e-08
associated O 0 1.1272550182184204e-07
with O 0 2.606324471798871e-07
subacute O 1 0.9946700930595398
G B-Disease 1 0.9991139769554138
( I-Disease 0 9.090404091693927e-06
M2 I-Disease 0 0.0017514334758743644
) I-Disease 0 3.831925369013334e-06
gangliosidosis I-Disease 0 0.00032455960172228515
. O 0 3.668828139780089e-05

Mutations O 0 1.9163060642313212e-05
in O 0 5.724025982090097e-07
the O 0 1.3433037793220137e-06
HEXA O 0 0.00021465776080731302
gene O 0 2.9598041351164284e-07
, O 0 6.231755378394155e-08
encoding O 0 8.574428278507185e-08
the O 0 6.922915218865455e-08
alpha O 0 3.665795702545438e-07
- O 0 5.415751758164333e-08
subunit O 0 8.09912847898886e-08
of O 0 3.848555607532944e-08
beta O 0 7.261451742124336e-07
- O 0 7.219455255835783e-07
hexosaminidase O 0 3.390896608834737e-06
A O 0 1.1782560704887146e-06
( O 0 1.4926696678685403e-07
Hex O 0 6.78827018418815e-06
A O 0 4.397905968289706e-07
) O 0 3.117333235991282e-08
, O 0 2.6673120601117262e-08
that O 0 1.7903250437711904e-08
abolish O 0 1.2049534916513949e-06
Hex O 0 5.743493602494709e-06
A O 0 5.906103979214095e-07
enzyme O 0 8.48396837227483e-07
activity O 0 1.5734026419522706e-06
cause O 0 0.0034952526912093163
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.01945308968424797
TSD B-Disease 1 0.9999998807907104
) O 0 6.24242034064082e-07
, O 0 1.2399213744629378e-07
the O 0 4.0372930243393057e-07
fatal O 0 0.003097986336797476
infantile B-Disease 0 1.677820910117589e-05
form I-Disease 0 5.664379045811074e-07
of I-Disease 0 5.535134278034093e-06
G I-Disease 0 0.271965354681015
( I-Disease 0 5.833394425280858e-07
M2 I-Disease 0 7.778240978950635e-05
) I-Disease 0 2.1687331752673344e-07
gangliosidosis I-Disease 0 4.931535386276664e-06
, I-Disease 0 1.489862313519552e-07
Type I-Disease 0 4.285498107492458e-06
1 I-Disease 0 2.2201316824066453e-05
. O 0 7.361414191109361e-06

Less O 0 0.0006178321782499552
severe O 1 0.9999566078186035
, O 0 0.00030518477433361113
subacute O 1 1.0
( O 0 4.909480776404962e-05
juvenile O 1 0.9699731469154358
- O 0 0.00018241858924739063
onset O 1 0.9991945624351501
) O 0 3.5790858419204596e-06
and O 0 3.328922684886493e-05
chronic O 1 0.9999996423721313
( O 0 2.175707049900666e-05
adult O 0 0.00048082286957651377
- O 0 6.216444307938218e-05
onset O 0 0.06526369601488113
) O 0 5.1138961509877845e-08
variants O 0 3.578945211302198e-07
are O 0 1.2461420340059703e-08
characterized O 0 5.177721362770171e-08
by O 0 9.647143528468405e-09
a O 0 3.0526219774174024e-08
broad O 0 5.048739240010036e-07
spectrum O 0 4.632259333448019e-06
of O 0 1.298294165508196e-07
clinical O 0 2.4715523068152834e-06
manifestations O 0 5.046133537689457e-06
and O 0 3.7034219246834255e-08
are O 0 9.483313689884199e-09
associated O 0 3.5512488949507315e-08
with O 0 1.686943740253355e-08
residual O 0 1.143028953265457e-06
levels O 0 1.1102332564405515e-06
of O 0 9.870890380625497e-07
Hex O 0 2.971737558254972e-05
A O 0 1.4505873195957975e-06
enzyme O 0 1.3568161421062541e-06
activity O 0 1.788403892533097e-06
. O 0 3.903610377165023e-06

We O 0 1.7296968508162536e-05
identified O 0 7.011957677605096e-06
a O 0 2.428674406473874e-06
1422 O 0 0.0003042978059966117
G O 0 0.0002489608305040747
- O 0 0.00010198057861998677
- O 0 2.2417878426495008e-05
> O 0 1.3364967344386969e-05
C O 0 8.031713514355943e-05
( O 0 1.5254785523666214e-07
amino O 0 2.4931037501119135e-07
acid O 0 1.0148337281634667e-07
W474C O 0 5.346656735127908e-07
) O 0 4.764691308167812e-09
substitution O 0 4.317541879572673e-08
in O 0 4.596900193831743e-09
the O 0 1.0628731672568392e-08
first O 0 3.405744664064514e-08
position O 0 1.74615308878856e-07
of O 0 1.2635183566089836e-07
exon O 0 7.010026479292719e-07
13 O 0 3.3207206229235453e-07
of O 0 4.0797056044539204e-07
HEXA O 0 0.0007750253425911069
of O 0 1.5465384421986528e-06
a O 0 7.337615102187556e-07
non O 0 9.98764608084457e-06
- O 0 1.0287511940987315e-05
Jewish O 0 3.2474226827616803e-06
proband O 0 0.0006896191043779254
who O 0 1.0789973430291866e-06
manifested O 0 1.6048717952799052e-05
a O 0 2.8813992685172707e-06
subacute O 0 0.017469342797994614
variant O 0 7.660494156880304e-05
of O 0 3.340710827615112e-05
G B-Disease 1 0.9912822246551514
( I-Disease 0 8.77397269505309e-06
M2 I-Disease 0 0.0011993559310212731
) I-Disease 0 5.417897682491457e-06
gangliosidosis I-Disease 0 0.0002926322922576219
. O 0 4.962998355040327e-05

On O 0 1.140359108831035e-05
the O 0 1.4169506812322652e-06
second O 0 2.647597966642934e-06
maternally O 0 6.5454291870992165e-06
inherited O 0 4.869212716585025e-06
allele O 0 7.180199190770509e-06
, O 0 2.508498653241986e-07
we O 0 2.455130641010328e-07
identified O 0 4.6725006086489884e-07
the O 0 5.391664217313519e-07
common O 0 0.4332432448863983
infantile O 1 1.0
disease O 1 0.9999959468841553
- O 1 0.7163442969322205
causing O 0 0.0005724619841203094
4 O 0 0.3343237340450287
- O 0 5.066099402029067e-05
bp O 0 1.0834074828380835e-06
insertion O 0 2.300470498539653e-07
, O 0 1.6133421354425082e-07
+ O 0 3.53007499143132e-06
TATC O 0 0.000153719141962938
1278 O 0 7.457528408849612e-05
, O 0 4.6459823010991386e-07
in O 0 4.142694933761959e-07
exon O 0 1.0183158337895293e-05
11 O 0 1.3432035302685108e-05
. O 0 1.470469851483358e-05

Pulse O 0 0.003939908463507891
- O 0 0.0001712201483314857
chase O 0 1.1478319720481522e-05
analysis O 0 1.0671053587429924e-06
using O 0 8.481225677314796e-07
proband O 0 7.766048656776547e-05
fibroblasts O 0 7.1149252107716165e-06
revealed O 0 9.033935270963411e-07
that O 0 4.10794740446363e-08
the O 0 1.1942027811073785e-07
W474C O 0 2.9904797429480823e-06
- O 0 3.023593819762027e-07
containing O 0 9.323301242147863e-08
alpha O 0 8.1140160546056e-07
- O 0 1.4212162113835802e-07
subunit O 0 2.302250550201279e-07
precursor O 0 2.542082029322046e-07
was O 0 6.920446082858689e-08
normally O 0 1.662105120203705e-08
synthesized O 0 6.047840628298218e-08
, O 0 7.777540389497517e-09
but O 0 5.7797659991365435e-09
not O 0 5.344604314672097e-09
phosphorylated O 0 2.3351783795533265e-07
or O 0 1.9770768133753336e-08
secreted O 0 3.930184888645272e-08
, O 0 2.301420032324586e-08
and O 0 6.641771932436313e-08
the O 0 3.524618534811452e-07
mature O 0 5.447761395771522e-06
lysosomal O 0 1.2959322702954523e-05
alpha O 0 5.110725396662019e-06
- O 0 7.857140076339419e-07
subunit O 0 1.3119421282681287e-06
was O 0 5.281948460833519e-07
not O 0 1.7316742173534294e-07
detected O 0 4.588524916471215e-06
. O 0 1.2151282135164365e-05

When O 0 6.462809778895462e-06
the O 0 1.6903759387787431e-06
W474C O 0 1.5923464161460288e-05
- O 0 1.141937332249654e-06
containing O 0 2.846975064585422e-07
alpha O 0 3.7603042528644437e-06
- O 0 4.870582870353246e-07
subunit O 0 1.5798860886206967e-06
was O 0 6.555916343131685e-07
transiently O 0 4.1116818465525284e-06
co O 0 2.011390733969165e-06
- O 0 4.173585637090582e-07
expressed O 0 2.870135418220343e-08
with O 0 9.956204749528297e-09
the O 0 4.6688835908526016e-08
beta O 0 2.9458647077262867e-07
- O 0 5.720260887187578e-08
subunit O 0 6.732302182399508e-08
to O 0 3.92869115017902e-09
produce O 0 1.170807877315383e-07
Hex O 0 9.468310054217e-06
A O 0 1.2654602414841065e-06
( O 0 2.1987300158343714e-07
alphabeta O 0 1.0350937373004854e-05
) O 0 8.775020177154147e-08
in O 0 6.857207068833304e-08
COS O 0 7.93285380495945e-06
- O 0 1.2551705594887608e-06
7 O 0 4.95228221097932e-07
cells O 0 7.118639899772461e-08
, O 0 9.765291686392175e-09
the O 0 2.427901968360402e-08
mature O 0 1.9407130480431078e-07
alpha O 0 4.714602539479529e-07
- O 0 4.6509651241422034e-08
subunit O 0 1.0798358829333665e-07
was O 0 3.512701951535746e-08
present O 0 6.628216198123482e-09
, O 0 4.560396060782068e-09
but O 0 4.336952130756799e-09
its O 0 4.3829726514843514e-09
level O 0 4.566887525925267e-07
was O 0 1.1102272878815711e-07
much O 0 1.2409358873810561e-08
lower O 0 4.2292064961202414e-08
than O 0 5.597818653058084e-09
that O 0 9.762139985269869e-10
from O 0 3.3349556449735474e-09
normal O 0 4.289478283681092e-08
alpha O 0 5.787689474345825e-07
- O 0 8.106222537662688e-08
subunit O 0 2.466562136760331e-07
transfections O 0 4.871307623943721e-07
, O 0 9.986920623816786e-09
although O 0 1.0632523306242092e-08
higher O 0 5.621028265068162e-08
than O 0 7.144331348740707e-09
in O 0 4.780730922249177e-09
those O 0 6.244150974055174e-09
cells O 0 6.41493471675858e-08
transfected O 0 2.891907513458136e-07
with O 0 5.47843859166619e-09
an O 0 1.1573988878410546e-08
alpha O 0 5.561594207392773e-07
- O 0 3.778368125040288e-07
subunit O 0 8.061244329837791e-07
associated O 0 3.6026941074851493e-07
with O 0 1.1222944067412755e-06
infantile O 1 0.624729335308075
TSD B-Disease 1 0.9980408549308777
. O 0 8.970696217147633e-05

Furthermore O 0 1.438852723367745e-05
, O 0 5.473975193126535e-07
the O 0 2.5077594045797014e-07
precursor O 0 1.3060125638730824e-06
level O 0 5.975923045298259e-07
of O 0 1.2794441772712162e-07
the O 0 1.5706335432241758e-07
W474C O 0 2.4340558866242645e-06
alpha O 0 1.7439377870687167e-06
- O 0 2.3669197446452017e-07
subunit O 0 3.0623351676695165e-07
was O 0 3.465677522740407e-08
found O 0 4.3935517446414e-09
to O 0 5.288699256311702e-09
accumulate O 0 4.9425484149878685e-08
in O 0 1.2133670068692481e-08
comparison O 0 2.6435278854819444e-08
to O 0 1.3261849396428715e-08
the O 0 3.548425553390189e-08
normal O 0 1.669215947686098e-07
alpha O 0 1.2005693861283362e-06
- O 0 3.332941957978619e-07
subunit O 0 1.555456151436374e-06
precursor O 0 1.6400256299675675e-06
levels O 0 3.1232423225446837e-06
. O 0 4.16671628045151e-06

We O 0 6.7493642745830584e-06
conclude O 0 7.139700755942613e-06
that O 0 1.2207948429932003e-07
the O 0 6.18373178440379e-07
1422 O 0 0.00011776659812312573
G O 0 0.00011758593609556556
- O 0 4.7777088184375316e-05
- O 0 9.463471542403568e-06
> O 0 5.446639079309534e-06
C O 0 1.3688297258340754e-05
mutation O 0 1.4383613233803771e-07
is O 0 7.060855011786771e-09
the O 0 1.1225770535361335e-08
cause O 0 7.636603527316765e-08
of O 0 6.943656671865028e-07
Hex B-Disease 0 0.04890919104218483
A I-Disease 1 0.6436759829521179
enzyme I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
in O 0 3.4995821351913037e-07
the O 0 1.895652985695051e-06
proband O 0 0.0001370558311464265
. O 0 1.3776118066743948e-05

The O 0 4.945249656884698e-06
resulting O 0 7.981610906426795e-06
W474C O 0 2.5819421352935024e-05
substitution O 0 3.523839041008614e-06
clearly O 0 9.31467752707249e-07
interferes O 0 3.2402346050730557e-07
with O 0 6.78223202044137e-08
alpha O 0 2.187869085901184e-06
- O 0 2.6247479922858474e-07
subunit O 0 3.5122906183460145e-07
processing O 0 1.0464411559496511e-07
, O 0 7.678444546854735e-09
but O 0 4.312980195209093e-09
because O 0 3.2304761088397527e-09
the O 0 1.0998213895163644e-08
base O 0 5.9302092125790296e-08
substitution O 0 2.84805594219506e-07
falls O 0 6.673504913123907e-07
at O 0 1.831806883956233e-07
the O 0 1.9429903019840822e-08
first O 0 2.649221286787906e-08
position O 0 1.0383907778077628e-07
of O 0 1.330431729229531e-07
exon O 0 6.818627298343927e-07
13 O 0 2.9307665272426675e-07
, O 0 6.762572013485624e-08
aberrant O 0 7.973607125677518e-07
splicing O 0 1.2760557410729234e-06
may O 0 1.4874247256102535e-07
also O 0 5.667502733786023e-08
contribute O 0 1.1773333596920565e-07
to O 0 8.360925818351461e-08
Hex B-Disease 0 0.005771891679614782
A I-Disease 0 0.0004970637382939458
deficiency I-Disease 0 0.2022046446800232
in O 0 9.98324907186543e-08
this O 0 9.584641702531371e-08
proband O 0 7.424012437695637e-06
. O 0 4.6951743115641875e-07
. O 0 5.816734301333781e-06

Two O 0 6.84121096128365e-06
frequent O 0 5.082922598376172e-06
missense O 0 0.00018652768631000072
mutations O 0 0.00014873064355924726
in O 0 8.522564166923985e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.5232632756233215

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.778875518240966e-05
an O 0 0.0012980877654626966
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.998783528804779
by O 0 5.825128027936444e-06
early O 1 0.9997768998146057
childhood O 1 0.9999998807907104
deafness B-Disease 1 1.0
and O 1 0.9999974966049194
goiter B-Disease 1 1.0
. O 1 0.9840908646583557

A O 0 1.5089075532159768e-05
century O 0 3.45885405295121e-06
after O 0 1.8135796153728734e-07
its O 0 1.4308087159520255e-08
recognition O 0 5.121050605794153e-08
as O 0 1.5478352111131244e-07
a O 0 4.7222161470017454e-07
syndrome O 0 5.227339715929702e-05
by O 0 1.147935719814086e-07
Vaughan O 0 0.0005131959915161133
Pendred O 1 0.6192663311958313
, O 0 2.667531475708529e-07
the O 0 2.3722550679394772e-07
disease O 0 4.666391760110855e-06
gene O 0 4.7216309440045734e-07
( O 0 8.654740213387413e-07
PDS O 0 0.08954384177923203
) O 0 4.957191777066328e-07
was O 0 1.7883783129946096e-06
mapped O 0 8.424522661698575e-07
to O 0 2.9810922796968953e-07
chromosome O 0 1.5148277270782273e-05
7q22 O 0 0.00018800972611643374
- O 0 0.0005839462974108756
q31 O 0 0.0006261897506192327
. O 0 8.804957178654149e-05

1 O 0 3.515784555929713e-05
and O 0 8.997874374472303e-07
, O 0 2.4611250637462945e-07
recently O 0 2.2530447552071564e-07
, O 0 2.4540064202938083e-08
found O 0 9.099475839491333e-09
to O 0 1.2316546893487157e-08
encode O 0 1.7173053379337944e-07
a O 0 5.285077122607618e-07
putative O 0 2.33991722780047e-05
sulfate O 0 0.0004702341975644231
transporter O 0 0.0023535797372460365
. O 0 6.234231113921851e-05

We O 0 2.374172709096456e-06
performed O 0 2.3605133492310415e-07
mutation O 0 1.1293025892200603e-07
analysis O 0 7.275884428281643e-08
of O 0 5.608316300254046e-08
the O 0 2.241820311610354e-07
PDS B-Disease 0 0.0005608732462860644
gene O 0 4.458514126781665e-07
in O 0 4.86331401816642e-08
patients O 0 4.734075176315855e-08
from O 0 6.032311006265445e-08
14 O 0 2.323742819498875e-06
Pendred B-Disease 0 2.840576235030312e-05
families O 0 1.1712965708454703e-08
originating O 0 2.5902373579356208e-08
from O 0 6.82873801949313e-09
seven O 0 3.8953995584734e-08
countries O 0 6.1828804298613704e-09
and O 0 3.614349353142643e-08
identified O 0 2.0583620141678693e-07
all O 0 2.0931504707277782e-07
mutations O 0 3.514650416036602e-06
. O 0 8.114132469927426e-06

The O 0 1.990389364436851e-06
mutations O 0 1.1001382063113851e-06
include O 0 1.7076290248496662e-07
three O 0 7.722805150933709e-08
single O 0 4.975653666861035e-08
base O 0 3.5310006296640495e-07
deletions O 0 1.4528426390825189e-06
, O 0 2.1207584666171897e-07
one O 0 2.2394164034267305e-07
splice O 0 3.4649917779461248e-06
site O 0 5.51159700989956e-07
mutation O 0 7.021815804364451e-07
and O 0 6.285281983764435e-07
10 O 0 8.302092282974627e-06
missense O 0 0.00016420360771007836
mutations O 0 0.00010782157187350094
. O 0 9.219649655278772e-05

One O 0 6.932970791240223e-06
missense O 0 5.331319334800355e-05
mutation O 0 4.05657738156151e-06
( O 0 7.072267180774361e-07
L236P O 0 1.759609585860744e-05
) O 0 1.0845668185766044e-07
was O 0 2.184267344773616e-07
found O 0 1.558169415716293e-08
in O 0 1.1545061795459333e-08
a O 0 2.5073331855196557e-08
homozygous O 0 1.6144240078119765e-07
state O 0 1.9627389491461145e-08
in O 0 2.6208754277945445e-08
two O 0 1.4228844236185978e-07
consanguineous O 0 6.673430561932037e-06
families O 0 4.769058037368268e-08
and O 0 6.715860934036755e-08
in O 0 4.376149931317741e-08
a O 0 4.846497958510554e-08
heterozygous O 0 9.884214335897923e-08
state O 0 1.3962758949048748e-08
in O 0 2.0911308240556536e-08
five O 0 8.786609129174394e-08
additional O 0 2.519702775316546e-07
non O 0 1.3780165318166837e-05
- O 0 4.8842317482922226e-05
consanguineous O 0 8.193800749722868e-05
families O 0 2.247551947220927e-06
. O 0 2.185810444643721e-05

Another O 0 3.043238029931672e-05
missense O 0 0.00010281150025548413
mutation O 0 1.0612125151965301e-05
( O 0 1.2926916497235652e-06
T416P O 0 2.3705193598289043e-05
) O 0 2.399774530204013e-07
was O 0 3.0244765980569355e-07
found O 0 2.1459246823951617e-08
in O 0 1.3278758537182966e-08
a O 0 3.6991508522987715e-08
homozygous O 0 2.5630509981056093e-07
state O 0 1.7062170343251637e-08
in O 0 3.108818447117301e-08
one O 0 4.02983779679289e-08
family O 0 1.875528887751443e-08
and O 0 2.3567876539232202e-08
in O 0 1.891923240293636e-08
a O 0 5.8616343778794544e-08
heterozygous O 0 1.1711775016465253e-07
state O 0 2.281368338685752e-08
in O 0 5.850018780506616e-08
four O 0 5.591903118329355e-07
families O 0 4.648215963243274e-07
. O 0 1.0095792276842985e-05

Pendred B-Disease 0 0.0294270608574152
patients O 0 5.725659320887644e-06
in O 0 3.030366144685104e-07
three O 0 4.332147227614769e-07
non O 0 1.2876623259217013e-05
- O 0 1.1286289009149186e-05
consanguineous O 0 6.175767794047715e-06
families O 0 1.5003015718662027e-08
were O 0 2.8231060156258536e-08
shown O 0 1.8442412041963507e-08
to O 0 9.743636120163046e-09
be O 0 8.09028151138591e-08
compound O 0 9.834827778831823e-07
heterozygotes O 0 6.145416136860149e-06
for O 0 5.683496056008153e-07
L236P O 0 2.975704410346225e-05
and O 0 4.7058306336111855e-06
T416P O 0 0.0002302027278346941
. O 0 2.5355295292683877e-05

In O 0 1.0411011999167386e-06
total O 0 3.821141945081763e-07
, O 0 9.118730304180644e-08
one O 0 1.7721184519814415e-08
or O 0 6.596597046382158e-09
both O 0 5.250105239440472e-09
of O 0 9.109861309752887e-09
these O 0 3.5086424876595856e-09
mutations O 0 2.8214264702342007e-08
were O 0 1.619467404623265e-08
found O 0 1.1413256117975834e-08
in O 0 1.5308380341139127e-08
nine O 0 1.84902134492404e-07
of O 0 1.1141113276380565e-07
the O 0 1.8707615367929975e-07
14 O 0 2.455505864418228e-06
families O 0 3.8739017327316105e-07
analyzed O 0 5.293670255923644e-06
. O 0 1.1382122465875e-05

The O 0 6.47101558115537e-07
identification O 0 2.709544162371458e-07
of O 0 2.2965664925322926e-07
two O 0 1.5596388891481183e-07
frequent O 0 2.977788255975611e-07
PDS B-Disease 0 0.0004860424669459462
mutations O 0 1.046166175910912e-06
will O 0 1.0338354883288048e-07
facilitate O 0 2.716284086545784e-07
the O 0 1.0728884802801986e-07
molecular O 0 2.0555347873596475e-05
diagnosis O 0 0.02052147686481476
of O 1 0.5924168229103088
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.6234498620033264

Insertional O 0 0.0002403088001301512
mutation O 0 3.0302642244350864e-06
by O 0 2.693030864975299e-07
transposable O 0 2.0146613678662106e-05
element O 0 2.985179889947176e-06
, O 0 5.23597236679052e-07
L1 O 0 0.00011926226579817012
, O 0 1.9080684410255344e-07
in O 0 9.548767820888315e-08
the O 0 5.566783443100576e-07
DMD B-Disease 1 0.9999992847442627
gene O 0 1.1000920494552702e-06
results O 0 1.3941370298198308e-06
in O 0 4.6550565002689837e-07
X B-Disease 1 0.9992755055427551
- I-Disease 1 0.9999865293502808
linked I-Disease 1 0.998364269733429
dilated I-Disease 1 0.9985176920890808
cardiomyopathy I-Disease 1 1.0
. O 0 0.009060507640242577

X B-Disease 1 0.9987431168556213
- I-Disease 1 0.9999793767929077
linked I-Disease 1 0.9975637197494507
dilated I-Disease 1 0.9998644590377808
cardiomyopathy I-Disease 1 1.0
( O 0 0.48243406414985657
XLDCM B-Disease 1 0.9999998807907104
) O 0 1.1899481933141942e-06
is O 0 5.2397236771639655e-08
a O 0 7.968227322407984e-08
clinical O 0 1.5460207123396685e-06
phenotype O 0 3.858195213979343e-06
of O 0 1.1556779782040394e-06
dystrophinopathy B-Disease 0 0.0011794604361057281
which O 0 4.9076312791385135e-08
is O 0 1.628782442253396e-08
characterized O 0 6.559812248951857e-08
by O 0 2.590242331734771e-08
preferential O 0 2.2663377876597224e-06
myocardial B-Disease 1 0.8284410834312439
involvement I-Disease 0 3.70596649190702e-06
without O 0 2.4921862973315e-07
any O 0 7.053724004890682e-08
overt O 0 5.584085442933429e-07
clinical O 0 8.430627531197388e-06
signs O 0 2.1279158318066038e-05
of O 1 0.973013162612915
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.999701201915741

To O 0 5.239159577286046e-07
date O 0 1.7402029470758862e-06
, O 0 9.323834859742419e-08
several O 0 5.5738922810633085e-08
mutations O 0 1.4471507370217296e-07
in O 0 6.456067325188997e-08
the O 0 6.051682248653378e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9027180075645447
, O 0 0.0262899212539196
DMD O 1 1.0
, O 0 1.559316160637536e-06
have O 0 3.117166613719746e-08
been O 0 6.75769769031831e-08
identified O 0 8.762425807162799e-08
in O 0 3.210893950722493e-08
patients O 0 5.6772833545437607e-08
with O 0 1.0706234832014161e-07
XLDCM B-Disease 1 0.999860405921936
, O 0 2.1432580865621276e-07
but O 0 4.4824574274571205e-08
a O 0 3.888013466735174e-08
pathogenic O 0 4.5406093818201043e-07
correlation O 0 6.545276676206413e-08
of O 0 3.222225686272395e-08
these O 0 1.803719840154372e-08
cardiospecific O 0 1.8575576632429147e-06
mutations O 0 3.7310164202608576e-07
in O 0 2.6021101007245306e-07
DMD O 1 0.9999997615814209
with O 0 2.580680984465289e-07
the O 0 9.679952199803665e-07
XLDCM B-Disease 1 0.9940727353096008
phenotype O 0 1.0277244655299e-05
has O 0 3.481638088942418e-08
remained O 0 2.7852610173795256e-07
to O 0 5.3396352228674004e-08
be O 0 7.31754539629037e-07
elucidated O 0 0.00012845963647123426
. O 0 1.9359531506779604e-05

We O 0 1.4054658095119521e-05
report O 0 7.541790978393692e-07
here O 0 1.3565272638516035e-07
the O 0 1.7554759423887845e-08
identification O 0 2.341709581799023e-08
of O 0 7.421624559356133e-08
a O 0 1.3357025352433993e-07
unique O 0 3.9627479964110535e-07
de O 0 1.4474268937192392e-05
novo O 0 9.553898053127341e-06
L1 O 0 4.055672980030067e-05
insertion O 0 2.373486950091319e-06
in O 0 2.351115284682237e-07
the O 0 3.4577880114738946e-07
muscle O 0 5.219463218963938e-06
exon O 0 7.862005986680742e-06
1 O 0 1.9271108158136485e-06
in O 0 2.963492704566306e-07
DMD O 1 0.9999998807907104
in O 0 2.718222162911843e-07
three O 0 5.350109972823702e-07
XLDCM B-Disease 0 0.012870675884187222
patients O 0 2.0612930029528798e-07
from O 0 1.0051632415297718e-07
two O 0 3.6232017919246573e-07
unrelated O 0 2.116538780683186e-06
Japanese O 0 8.94401910045417e-06
families O 0 2.8381316496961517e-06
. O 0 2.1522617316804826e-05

The O 0 3.873214609484421e-06
insertion O 0 5.0333255785517395e-06
was O 0 1.6934901623244514e-06
a O 0 2.000985546146694e-07
5 O 0 1.0217300996373524e-06
- O 0 6.468874289566884e-07
truncated O 0 3.4256615322192374e-07
form O 0 1.1418519818562345e-07
of O 0 2.519712154480658e-07
human O 0 3.8210183106457407e-07
L1 O 0 1.8003356672124937e-05
inversely O 0 2.9206623821664834e-06
integrated O 0 2.413550873825443e-06
in O 0 2.7083240539127473e-08
the O 0 5.6297942307992344e-08
5 O 0 9.385138355355593e-07
- O 0 1.1408388900235877e-06
untranslated O 0 6.2243470893008634e-06
region O 0 1.9633760928172705e-07
in O 0 3.206744381145654e-08
the O 0 1.0888491175364834e-07
muscle O 0 1.1172517133672955e-06
exon O 0 1.091806893782632e-06
1 O 0 3.2507517744306824e-07
, O 0 1.4680649584875027e-08
which O 0 5.859038587630039e-09
affected O 0 2.1296269636650322e-08
the O 0 1.0801795014003801e-08
transcription O 0 5.667988745017283e-08
or O 0 1.2648271763282537e-08
the O 0 2.040337676589843e-08
stability O 0 4.86922147047153e-07
of O 0 1.513047180878857e-07
the O 0 7.087087539048298e-08
muscle O 0 2.6138494035876647e-07
form O 0 2.9798874834341404e-07
of O 0 1.0724052117438987e-06
dystrophin O 0 1.1268759408267215e-05
transcripts O 0 3.785513058573997e-07
but O 0 5.619899212661039e-09
not O 0 2.8127955520318437e-09
that O 0 2.722337244520645e-09
of O 0 4.6310834278529e-08
the O 0 3.4734375731204636e-07
brain O 0 0.00461796997115016
or O 0 2.0090901671210304e-06
Purkinje O 0 0.144324392080307
cell O 0 4.070098293595947e-05
form O 0 7.553466048193513e-07
, O 0 1.0711219289305518e-07
probably O 0 1.4525181768476614e-07
due O 0 1.2494936640905507e-07
to O 0 1.4321083874335727e-08
its O 0 1.7710844346652266e-08
unique O 0 5.504427491587194e-08
site O 0 1.6270955427444278e-07
of O 0 3.776048060899484e-07
integration O 0 3.321907206554897e-05
. O 0 2.016527832893189e-05

We O 0 2.9176142106734915e-06
speculate O 0 1.2614694924195646e-06
that O 0 9.108157783543902e-09
this O 0 4.3646357639204325e-09
insertion O 0 3.6837874972661666e-08
of O 0 3.526053404812046e-08
an O 0 2.1016870022094736e-08
L1 O 0 9.468672033108305e-06
sequence O 0 6.592951535822067e-07
in O 0 8.197316105906793e-07
DMD O 1 1.0
is O 0 1.873671919838671e-07
responsible O 0 1.7570245347542368e-07
for O 0 9.32443633416824e-09
some O 0 4.864257441283826e-09
of O 0 1.276759675761241e-08
the O 0 1.6654530199389228e-08
population O 0 2.881339833393781e-09
of O 0 3.505172330164896e-08
Japanese O 0 1.0469966582604684e-06
patients O 0 1.905886222175468e-07
with O 0 2.539704837545287e-07
XLDCM B-Disease 0 0.015636732801795006
. O 0 2.6178784082731e-06
. O 0 1.2823620636481792e-05

Severe O 1 0.9535820484161377
early O 1 0.6045375466346741
- O 1 0.9999963045120239
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.2268209606409073
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.999993085861206
red O 1 0.9999995231628418
hair O 1 0.9999891519546509
pigmentation O 1 0.9999040365219116
caused O 0 1.4650261618953664e-05
by O 0 4.672375837344589e-07
POMC O 0 0.3505692481994629
mutations O 0 3.946857759729028e-06
in O 0 4.3001600147363206e-07
humans O 0 8.266469194495585e-06
. O 0 9.376564776175655e-06

Sequential O 0 0.0001387907686876133
cleavage O 0 1.8625458324095234e-05
of O 0 1.3879591733712004e-06
the O 0 3.976876996603096e-07
precursor O 0 2.0152963315922534e-06
protein O 0 3.3949532962651574e-07
pre O 0 4.676085154642351e-06
- O 0 5.248163233773084e-06
pro O 0 0.0017171072540804744
- O 0 0.0007417525048367679
opiomelanocortin O 0 0.0005399567889980972
( O 0 1.5611642538715387e-06
POMC O 0 0.0002620361337903887
) O 0 2.2214464934222633e-07
generates O 0 3.418840037738846e-07
the O 0 4.0741727502791036e-07
melanocortin O 0 8.393486496061087e-05
peptides O 0 3.2067068787000608e-06
adrenocorticotrophin O 0 5.910750405746512e-05
( O 0 1.2673382343564299e-06
ACTH O 0 8.004250412341207e-05
) O 0 1.3037575854468741e-06
, O 0 3.6190861010254594e-06
melanocyte O 1 0.7278276085853577
- O 1 0.5253521203994751
stimulating O 0 0.001750409253872931
hormones O 0 5.744052032241598e-06
( O 0 2.9650195187969075e-07
MSH O 0 5.877834337297827e-05
) O 0 5.14035853882433e-08
alpha O 0 4.963256401424587e-07
, O 0 1.0801731953336002e-08
beta O 0 1.0626971658211914e-07
and O 0 1.6439479111340916e-08
gamma O 0 3.1259102684089157e-07
as O 0 1.2861820941623137e-08
well O 0 9.161944980462522e-09
as O 0 1.1777124164780162e-08
the O 0 3.103344425881005e-08
opioid O 0 1.1948025075980695e-06
- O 0 5.24570396009949e-07
receptor O 0 4.895286451755965e-07
ligand O 0 1.9493361378408736e-06
beta O 0 1.3524299902201165e-05
- O 0 1.9043023712583818e-05
endorphin O 0 0.00014675389684271067
. O 0 1.9486004021018744e-05

While O 0 9.510598829365335e-06
a O 0 9.117805461755779e-07
few O 0 2.5653545776549436e-07
cases O 0 1.3204861204485496e-07
of O 0 5.437082677417493e-07
isolated O 0 0.00010626853327266872
ACTH B-Disease 1 0.9999874830245972
deficiency I-Disease 1 0.9999892711639404
have O 0 5.758152497037372e-07
been O 0 1.1066370007029036e-06
reported O 0 1.3862222658644896e-06
( O 0 1.3404999208432855e-06
OMIM O 0 0.005685445852577686
201400 O 0 6.607243267353624e-05
) O 0 3.663880363546923e-07
, O 0 1.7925670192653342e-07
an O 0 2.5437165618313884e-07
inherited O 1 0.9937612414360046
POMC O 1 1.0
defect O 1 0.998702883720398
has O 0 8.333094001500285e-07
not O 0 1.0431470798266673e-07
been O 0 1.2837855933867104e-07
described O 0 2.3332972887146752e-07
so O 0 1.2553498152101383e-07
far O 0 1.0597283335300745e-06
. O 0 1.114869701268617e-05

Recent O 0 8.782587428868283e-06
studies O 0 2.2734791400580434e-06
in O 0 2.130350793549951e-07
animal O 0 4.6699523181814584e-07
models O 0 1.0014523468271364e-06
elucidated O 0 8.908588824851904e-06
a O 0 7.860897710543213e-08
central O 0 1.8134966239813366e-07
role O 0 1.1828591794937893e-07
of O 0 3.233776340039185e-07
alpha O 0 3.0454273655777797e-05
- O 0 1.2863722986367065e-05
MSH O 0 0.004364255350083113
in O 0 5.1367521791689796e-08
the O 0 6.661640128413637e-08
regulation O 0 1.4020621108556952e-07
of O 0 4.0651329413776693e-08
food O 0 1.1973773084150707e-08
intake O 0 3.089877864681512e-08
by O 0 3.10444381312891e-09
activation O 0 6.210847658394414e-08
of O 0 6.588351197933662e-08
the O 0 1.9041237919736886e-07
brain O 0 8.079546205408406e-06
melanocortin O 0 7.591518078697845e-05
- O 0 1.1734485951819806e-06
4 O 0 8.111285296763526e-07
- O 0 4.0720479432820866e-07
receptor O 0 7.889840389907476e-07
( O 0 1.0965228369741453e-07
MC4 O 0 4.54445653303992e-05
- O 0 1.7106767700170167e-06
R O 0 2.154255298592034e-06
; O 0 9.333300710068215e-08
refs O 0 2.700870027183555e-06
3 O 0 3.804542814123124e-07
- O 0 1.4039862605841336e-07
5 O 0 9.816726276312693e-08
) O 0 9.817209267737326e-09
and O 0 1.8852196248531072e-08
the O 0 7.05397908973282e-08
linkage O 0 1.9930998860218097e-06
of O 0 1.5690003465351765e-06
human O 0 8.545423952455167e-06
obesity B-Disease 1 0.899850606918335
to O 0 2.982294589060075e-08
chromosome O 0 2.7155405746270844e-07
2 O 0 5.020229423280398e-07
in O 0 2.3893582223877274e-08
close O 0 1.6673132563482795e-07
proximity O 0 1.194782726088306e-07
to O 0 4.131875286361719e-08
the O 0 2.8924097250637715e-07
POMC O 0 0.00036431296030059457
locus O 0 2.1515163552976446e-06
, O 0 8.058279377110011e-08
led O 0 1.225075010324872e-07
to O 0 1.745759270477265e-08
the O 0 2.6240915218522787e-08
proposal O 0 4.5938520543131744e-08
of O 0 6.302315824768812e-08
an O 0 5.0222780600961414e-08
association O 0 3.261788492636697e-07
of O 0 9.400443559570704e-06
POMC O 1 0.9999996423721313
with O 0 0.0016506818355992436
human O 1 0.9902352690696716
obesity B-Disease 1 1.0
. O 0 5.4384709073929116e-05

The O 0 2.5262283998017665e-06
dual O 0 5.739972948504146e-06
role O 0 1.9778290152316913e-06
of O 0 3.6782171264349017e-06
alpha O 0 0.0026274470146745443
- O 0 0.01929844357073307
MSH O 1 0.9984918832778931
in O 0 3.9748940139361366e-07
regulating O 0 1.9404460545047186e-06
food O 0 2.1818753737079533e-07
intake O 0 1.1930751497857273e-06
and O 0 4.833287334804481e-07
influencing O 0 4.704771708929911e-05
hair O 0 0.0038522903341799974
pigmentation O 0 0.010161485522985458
predicts O 0 1.245342332367727e-06
that O 0 1.1213231232432008e-08
the O 0 6.535969987453427e-08
phenotype O 0 1.9024263337996672e-06
associated O 0 1.1720132420123264e-07
with O 0 4.4693102552173514e-08
a O 0 2.9052370109639014e-07
defect O 0 5.149493063072441e-06
in O 0 6.489685802080203e-07
POMC O 1 0.7823097705841064
function O 0 8.916553611015843e-07
would O 0 9.439212789175144e-08
include O 0 1.7629101876082132e-06
obesity B-Disease 1 0.9999997615814209
, O 0 4.775848765348201e-07
alteration O 0 3.8191112253116444e-05
in O 0 2.9873726816731505e-06
pigmentation O 1 0.999982476234436
and O 0 0.06302476674318314
ACTH B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999995231628418
. O 0 0.00013655996008310467

The O 0 3.559014203347033e-06
observation O 0 8.841429917083587e-06
of O 0 1.0461183137522312e-06
these O 0 5.373667022467998e-07
symptoms O 0 8.18055123090744e-05
in O 0 2.3533206672254892e-07
two O 0 5.02832676829712e-07
probands O 0 2.351240073039662e-05
prompted O 0 3.883811814375804e-07
us O 0 3.923009828099566e-08
to O 0 7.539386892574385e-09
search O 0 6.072982472460353e-08
for O 0 2.767546725124248e-08
mutations O 0 1.81724828962615e-07
within O 0 1.984255248999034e-07
their O 0 4.3458231857584906e-07
POMC O 0 0.0006143483915366232
genes O 0 8.020992936508264e-06
. O 0 1.7337843019049615e-05

Patient O 0 1.8332120816921815e-05
1 O 0 7.537307283200789e-06
was O 0 9.648845207266277e-07
found O 0 2.8112417282954993e-08
to O 0 1.2608480481901552e-08
be O 0 3.1870854400040116e-08
a O 0 7.829144976767566e-08
compound O 0 6.032162218616577e-07
heterozygote O 0 2.149145984731149e-06
for O 0 3.780573365474993e-08
two O 0 2.796166853613613e-08
mutations O 0 6.999818680242242e-08
in O 0 4.422745902843417e-08
exon O 0 7.40663381293416e-07
3 O 0 6.498566449408827e-07
( O 0 1.192467351529558e-07
G7013T O 0 1.6813563661344233e-06
, O 0 7.489398257121138e-08
C7133delta O 0 8.364629138668533e-06
) O 0 4.0347675422935936e-08
which O 0 1.8147694902381772e-08
interfere O 0 4.118420804388734e-08
with O 0 9.108175547112296e-09
appropriate O 0 1.119993982001688e-07
synthesis O 0 4.2631614860511036e-07
of O 0 3.5736181303036574e-07
ACTH O 0 6.215543544385582e-05
and O 0 2.540836476327968e-06
alpha O 0 0.0004943590611219406
- O 0 0.00027790904277935624
MSH O 0 0.04620707407593727
. O 0 1.7174284948850982e-05

Patient O 0 1.780079401214607e-05
2 O 0 8.747421816224232e-06
was O 0 1.9342730865901103e-06
homozygous O 0 6.402283929674013e-07
for O 0 2.9750001573347618e-08
a O 0 4.560328648040013e-08
mutation O 0 9.182591753642555e-08
in O 0 4.9568416926604186e-08
exon O 0 6.693098271171039e-07
2 O 0 1.2096326145183411e-06
( O 0 1.2368884938496194e-07
C3804A O 0 2.6367001737526152e-06
) O 0 1.5028024336061208e-07
which O 0 2.791483382225124e-07
abolishes O 0 4.0130758861778304e-05
POMC O 0 0.000755864370148629
translation O 0 5.03843002661597e-05
. O 0 3.578903852030635e-05

These O 0 1.5031537259346806e-06
findings O 0 1.0900880624831188e-06
represent O 0 2.261226654809434e-07
the O 0 1.0283211082651178e-07
first O 0 1.0184501775256649e-07
examples O 0 7.54140287995142e-08
of O 0 1.2365511281586805e-07
a O 0 8.452842621409218e-07
genetic B-Disease 1 0.999968409538269
defect I-Disease 1 0.9987419247627258
within O 0 2.7408871119405376e-06
the O 0 1.131200178861036e-06
POMC O 0 0.0005783683736808598
gene O 0 1.8591458683658857e-07
and O 0 4.222863125846743e-08
define O 0 1.2709641339370137e-07
a O 0 1.670574363288324e-07
new O 0 6.382753781508654e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999443292617798
resulting O 0 4.884052941633854e-06
in O 0 2.2652952225143963e-07
early O 0 0.008812608197331429
- O 1 0.9999829530715942
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9930843114852905
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9999986886978149
red O 1 0.9999997615814209
hair O 1 0.9999877214431763
pigmentation O 1 0.9991753697395325
. O 0 4.939297014061594e-06
. O 0 1.5843441360630095e-05

A O 0 5.15390420332551e-05
European O 0 3.5744735214393586e-05
multicenter O 0 0.0012098754523321986
study O 0 2.0522556951618753e-06
of O 0 7.615772483404726e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.3452062148644472e-06
classification O 0 8.9271890146847e-07
of O 0 3.263748737936112e-07
105 O 0 5.171903580958315e-07
mutations O 0 1.1284133449862566e-07
and O 0 2.426938827682079e-08
a O 0 4.4398870358008935e-08
general O 0 9.47173006693447e-08
system O 0 8.585065103261513e-08
for O 0 3.989936914194914e-08
genotype O 0 1.1227290315218852e-06
- O 0 7.597607805109874e-07
based O 0 1.7631947457630304e-07
prediction O 0 6.118551937106531e-06
of O 0 1.467058973503299e-05
metabolic O 1 0.9999898672103882
phenotype O 0 0.00427313381806016
. O 0 5.827648055856116e-05

Phenylketonuria B-Disease 1 0.9999401569366455
( O 0 7.389696111204103e-05
PKU B-Disease 1 0.9997273087501526
) O 0 2.17906676880375e-06
and O 0 7.712368642387446e-06
mild B-Disease 1 0.9999998807907104
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9918496608734131
MHP B-Disease 1 1.0
) O 0 5.4070737860456575e-06
are O 0 1.6052923683673725e-06
allelic B-Disease 1 0.9999804496765137
disorders I-Disease 1 0.9999626874923706
caused O 0 1.1763485190385836e-06
by O 0 4.7343281295297857e-08
mutations O 0 5.621392773491607e-08
in O 0 1.766903956479382e-08
the O 0 5.599786589982614e-08
gene O 0 2.0755983598519379e-07
encoding O 0 2.2771398562326794e-06
phenylalanine O 0 2.5965993700083345e-05
hydroxylase O 0 0.00033066992182284594
( O 0 8.20998138806317e-06
PAH O 1 0.9998911619186401
) O 0 6.054447112546768e-06
. O 0 2.4328623112523928e-05

Previous O 0 1.1086694030382205e-05
studies O 0 6.802272878303484e-07
have O 0 5.1578108895000696e-08
suggested O 0 2.2074283378969994e-07
that O 0 1.522878889659296e-08
the O 0 5.999528696065681e-08
highly O 0 1.2747566415782785e-06
variable O 0 1.6460347978863865e-05
metabolic O 1 0.9877519607543945
phenotypes O 0 0.0017307805828750134
of O 1 0.7834165096282959
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
correlate O 0 2.154459070879966e-05
with O 0 2.143588790204376e-05
PAH O 1 0.9999998807907104
genotypes O 0 0.13021022081375122
. O 0 3.681690577650443e-05

We O 0 5.2147465794405434e-06
identified O 0 2.2373635601979913e-06
both O 0 2.29913936777848e-07
causative O 0 2.231099188065855e-06
mutations O 0 9.279434607378789e-07
in O 0 2.0182974935778475e-07
686 O 0 9.287878128816374e-06
patients O 0 1.2243800995292986e-07
from O 0 7.74906894207561e-08
seven O 0 2.2451911263488e-06
European O 0 1.4815758731856477e-05
centers O 0 8.242750482168049e-06
. O 0 7.589014330733335e-06

On O 0 3.717722620422137e-06
the O 0 1.9767568915085576e-07
basis O 0 3.0591735367124784e-07
of O 0 1.3047834102053457e-07
the O 0 1.3863595427210385e-07
phenotypic O 0 4.417723175720312e-06
characteristics O 0 2.091248006763635e-06
of O 0 2.3956158656801563e-06
297 O 0 1.3922574908065144e-05
functionally O 0 2.390072950220201e-05
hemizygous O 0 2.3312439225264825e-05
patients O 0 1.609946878033952e-07
, O 0 8.31117503707901e-08
105 O 0 2.4274788756883936e-07
of O 0 3.732639086706513e-08
the O 0 2.72983644578062e-08
mutations O 0 4.365878680800961e-08
were O 0 3.5087378336129404e-08
assigned O 0 3.410080040566754e-08
to O 0 1.0139587836022201e-08
one O 0 2.1258609095298198e-08
of O 0 1.1637701646804999e-07
four O 0 6.742595246578276e-07
arbitrary O 0 1.5690900454501389e-06
phenotype O 0 1.401622921548551e-05
categories O 0 6.199022209329996e-06
. O 0 1.338871970801847e-05

We O 0 5.155547114554793e-06
proposed O 0 2.2925059965928085e-06
and O 0 2.7914941824747075e-07
tested O 0 9.004080538943526e-07
a O 0 6.34270236332668e-08
simple O 0 7.508062793704084e-08
model O 0 1.0315703491414752e-07
for O 0 1.6755661746969963e-08
correlation O 0 9.678644374844225e-08
between O 0 1.4205956233581674e-07
genotype O 0 1.844721737143118e-06
and O 0 3.9352033809336717e-07
phenotypic O 0 2.505498196114786e-05
outcome O 0 4.1950606828322634e-05
. O 0 2.1380339603638276e-05

The O 0 8.800260729913134e-06
observed O 0 9.877136108116247e-06
phenotype O 0 1.2659282219829038e-05
matched O 0 1.0658116025297204e-06
the O 0 1.8520337619065685e-07
predicted O 0 2.0651723389164545e-06
phenotype O 0 1.0989920156134758e-06
in O 0 1.712924380115055e-08
79 O 0 9.944309198317569e-08
% O 0 9.424529601176346e-09
of O 0 3.5246483065520806e-08
the O 0 5.3074373340677994e-08
cases O 0 4.051509350233573e-08
, O 0 1.581439690312436e-08
and O 0 1.0968738806127476e-08
in O 0 5.248963486081948e-09
only O 0 7.704087146009897e-09
5 O 0 6.302640542799054e-08
of O 0 5.288399052005843e-08
184 O 0 1.9122218475331465e-07
patients O 0 2.9608138163439435e-08
was O 0 1.1218156004133562e-07
the O 0 6.302568777982742e-08
observed O 0 1.6018330484257604e-07
phenotype O 0 3.1136968914324825e-07
more O 0 7.269209234550544e-09
than O 0 9.370506148798086e-09
one O 0 4.926780761138616e-09
category O 0 2.0487142649017187e-08
away O 0 2.0388439381235912e-08
from O 0 6.97754209966206e-09
that O 0 1.3200072146446473e-08
expected O 0 1.1915857385247364e-06
. O 0 5.262788363324944e-06

Among O 0 8.418085599259939e-06
the O 0 1.4536714161295095e-06
seven O 0 8.84952726210031e-07
contributing O 0 3.006339284183923e-07
centers O 0 1.382355350187936e-07
, O 0 3.911056012384506e-08
the O 0 2.7937838709135576e-08
proportion O 0 5.2324732990882694e-08
of O 0 1.1408233291376746e-07
patients O 0 4.35229274842186e-08
for O 0 2.111909758184538e-08
whom O 0 7.687797420885545e-08
the O 0 9.923807908762683e-08
observed O 0 1.5241755590977846e-07
phenotype O 0 4.978150514034496e-07
did O 0 2.7646816391779794e-08
not O 0 2.3170914076331428e-08
match O 0 7.598615070492087e-07
the O 0 9.335970929669202e-08
predicted O 0 9.04697969872359e-07
phenotype O 0 6.332958832899749e-07
was O 0 2.2303134983303607e-07
4 O 0 2.2388974230125314e-07
% O 0 2.5242428591809585e-08
- O 0 2.191566181863891e-07
23 O 0 3.6131501701675006e-07
% O 0 6.955713161005406e-08
( O 0 8.776007831556853e-08
P O 0 1.5481451555388048e-05
< O 0 2.6465049813850783e-06
. O 0 1.9057061706462264e-07
0001 O 0 0.00025733132497407496
) O 0 9.266782541317298e-08
, O 0 3.862837161250354e-08
suggesting O 0 1.544411531995138e-07
that O 0 1.1181707115781592e-08
differences O 0 1.321267149023697e-07
in O 0 2.1666281213583716e-08
methods O 0 7.125078127501183e-08
used O 0 1.793154780216355e-08
for O 0 1.977306851586036e-08
mutation O 0 1.3430779688405892e-07
detection O 0 1.408332650498778e-06
or O 0 3.790732989727985e-07
phenotype O 0 1.311346932197921e-05
classification O 0 1.0042411986432853e-06
may O 0 7.524248246681964e-08
account O 0 1.259723081403763e-08
for O 0 6.6953300681404926e-09
a O 0 1.1980831438052064e-08
considerable O 0 6.026882459764238e-08
proportion O 0 9.692074343092827e-08
of O 0 7.050871317915153e-07
genotype O 0 0.00010048165859188884
- O 0 0.00023958360543474555
phenotype O 0 5.4524713050341234e-05
inconsistencies O 0 4.014105797978118e-05
. O 0 2.412650610494893e-05

Our O 0 3.931492756237276e-06
data O 0 7.898408398432366e-07
indicate O 0 2.3290731121505814e-07
that O 0 8.349244495775565e-08
the O 0 1.6543963283766061e-06
PAH O 1 0.9999916553497314
- O 0 1.5255819562298711e-05
mutation O 0 5.197560426495329e-07
genotype O 0 1.9101892121398123e-06
is O 0 3.1437128455991115e-08
the O 0 6.027848797884872e-08
main O 0 8.517221203874215e-07
determinant O 0 6.653875971096568e-06
of O 0 2.803274583129678e-06
metabolic O 1 0.9993771910667419
phenotype O 0 8.934924699133262e-05
in O 0 2.9382246680143e-07
most O 0 6.670806556030584e-07
patients O 0 1.029986196954269e-05
with O 0 0.19468571245670319
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.03942597284913063

In O 0 1.0071991027871263e-06
the O 0 2.1767480973267084e-07
present O 0 6.421728926397918e-08
study O 0 2.9634069420581e-08
, O 0 1.3103096385691515e-08
the O 0 1.9572210518958855e-08
classification O 0 1.4618332500049291e-07
of O 0 3.8085178744040604e-07
105 O 0 1.6091998986667022e-05
PAH O 1 0.9999879598617554
mutations O 0 4.3931856907875044e-07
may O 0 5.097652433505573e-08
allow O 0 2.270169474627437e-08
the O 0 3.398359993411759e-08
prediction O 0 2.227858004744121e-07
of O 0 5.5148838384866394e-08
the O 0 7.923306100110494e-08
biochemical O 0 1.6912692899495596e-06
phenotype O 0 2.175781901314622e-06
in O 0 9.491532892980103e-08
> O 0 1.6023892612793134e-06
10 O 0 2.64721194298545e-07
, O 0 5.1613831431041035e-08
000 O 0 2.905749738602026e-07
genotypes O 0 1.2640863360502408e-06
, O 0 2.125848830303312e-08
which O 0 4.286122567975781e-09
may O 0 1.3415617949874559e-08
be O 0 1.0443470088716822e-08
useful O 0 5.073547626466279e-08
for O 0 1.5688334187302644e-08
the O 0 8.939084494841154e-08
management O 0 1.4121172853265307e-06
of O 0 2.7715750547940843e-06
hyperphenylalaninemia B-Disease 1 0.9999998807907104
in O 0 6.775826022931142e-06
newborns O 0 3.0705181416124105e-05
. O 0 2.0573113943100907e-05

Somatic O 0 0.0004455725138541311
instability O 0 4.424666622071527e-05
of O 0 5.069126018497627e-06
the O 0 4.10027905672905e-06
CTG O 0 0.029148494824767113
repeat O 0 1.975551640498452e-05
in O 0 4.947537490807008e-07
mice O 0 5.037541541241808e-06
transgenic O 0 3.3918247481778963e-06
for O 0 4.43840548314256e-07
the O 0 0.0009640859789215028
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0014698319137096405
is O 0 1.1692077350744512e-07
age O 0 5.97824723058693e-08
dependent O 0 1.2321974551809944e-08
but O 0 4.69103600408971e-09
not O 0 3.6811376169509913e-09
correlated O 0 2.6349297854721954e-08
to O 0 4.832179101299516e-09
the O 0 2.6891344262480743e-08
relative O 0 7.617864525855111e-07
intertissue O 0 1.1555629498616327e-05
transcription O 0 1.2789638503818423e-06
levels O 0 1.3727784562433953e-06
and O 0 1.667047627051943e-06
proliferative O 1 0.5847404599189758
capacities O 0 0.0008956762030720711
. O 0 2.613086689962074e-05

A O 0 0.00011558422556845471
( O 0 1.2828256330976728e-05
CTG O 0 0.0014852031599730253
) O 0 1.4286565601651091e-06
nexpansion O 0 1.4909362107573543e-05
in O 0 9.970385406177229e-08
the O 0 9.789315669195275e-08
3 O 0 9.559753380017355e-07
- O 0 1.965575165741029e-06
untranslated O 0 9.648104423831683e-06
region O 0 3.0363224823304336e-07
( O 0 1.284885513541667e-07
UTR O 0 4.1999926907010376e-05
) O 0 8.38763227761774e-08
of O 0 2.1366582814152935e-07
the O 0 1.1640414641078678e-06
DM O 1 0.9999996423721313
protein O 0 1.305976411458687e-06
kinase O 0 1.2085740763723152e-06
gene O 0 1.5250944329636695e-07
( O 0 6.473206326518266e-08
DMPK O 0 4.57184505648911e-05
) O 0 8.408679974536426e-08
is O 0 5.791875423710735e-08
responsible O 0 8.617825528745016e-07
for O 0 2.522564273021999e-06
causing O 1 0.9999997615814209
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999961853027344
DM B-Disease 1 1.0
) O 0 2.4240942366304807e-05
. O 0 2.4868850232451223e-05

Major O 0 6.944967753952369e-05
instability O 0 0.00010776494309538975
, O 0 6.97645305081096e-07
with O 0 5.418541704216295e-08
very O 0 6.887788117637683e-08
large O 0 4.8258815610324746e-08
expansions O 0 3.0440347131843737e-07
between O 0 4.7614413745122874e-08
generations O 0 5.296727678683055e-08
and O 0 1.3471850301982613e-08
high O 0 9.66748245900817e-08
levels O 0 5.778523615163067e-08
of O 0 8.55890576190177e-08
somatic O 0 1.9421440811129287e-05
mosaicism O 0 0.00012741622049361467
, O 0 8.129726580818897e-08
is O 0 2.380397035040005e-08
observed O 0 2.488293660007912e-07
in O 0 2.0337411399395933e-07
patients O 0 1.4494989954982884e-06
. O 0 8.654889825265855e-06

There O 0 1.96822520592832e-06
is O 0 1.8435417814544053e-07
a O 0 6.781895933727355e-08
good O 0 1.2142680816396023e-07
correlation O 0 1.6752841247580363e-07
between O 0 8.062492184990333e-08
repeat O 0 3.513607396143925e-07
size O 0 1.469492900696423e-07
( O 0 3.786787061699215e-08
at O 0 1.3285387012729188e-07
least O 0 2.8971072651984286e-08
in O 0 1.768805724111644e-08
leucocytes O 0 1.9681388039316516e-06
) O 0 3.632241529771818e-08
, O 0 2.8316373246184412e-08
clinical O 0 1.1387714948796201e-06
severity O 0 3.00270835396077e-06
and O 0 2.338182270023026e-07
age O 0 3.0200742457964225e-06
of O 0 7.1946551543078385e-06
onset O 1 0.9993077516555786
. O 0 0.0001101172820199281

The O 0 3.0364632038981654e-05
trinucleotide O 0 0.004009596537798643
repeat O 0 6.285952258622274e-05
instability O 0 4.7828652895987034e-05
mechanisms O 0 0.0010751252993941307
involved O 0 2.1379760255513247e-06
in O 0 1.0313957545804442e-06
DM B-Disease 1 1.0
and O 0 2.4629034669487737e-05
other O 0 1.1936454029637389e-06
human O 0 0.002723321784287691
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.3646342128813558e-07
unknown O 0 8.606133633293211e-06
. O 0 1.2806206541426945e-05

We O 0 6.455023594753584e-06
studied O 0 8.898163287085481e-06
somatic O 0 2.9713095500483178e-05
instability O 0 6.551718342961976e-06
by O 0 5.574476062975009e-07
measuring O 0 4.2646694055292755e-05
the O 0 1.6849696748977294e-06
CTG O 0 0.004025991074740887
repeat O 0 6.922162356204353e-06
length O 0 4.985448072147847e-07
at O 0 3.339225713716587e-07
several O 0 2.542255650439529e-08
ages O 0 1.4425718575239443e-07
in O 0 7.091181419838222e-09
various O 0 1.9850835641932463e-08
tissues O 0 2.0610531237252872e-07
of O 0 3.804060213496996e-07
transgenic O 0 1.5120259604373132e-06
mice O 0 2.403812686679885e-07
carrying O 0 1.9746013890653558e-07
a O 0 3.3109557762145414e-07
( O 0 5.777332603429386e-07
CTG O 0 0.00044533939217217267
) O 0 7.161701773839013e-07
55expansion O 0 1.8890996216214262e-05
surrounded O 0 1.7162376479973318e-06
by O 0 8.547583263407432e-08
45 O 0 4.937394351145485e-07
kb O 0 1.4950895092624705e-05
of O 0 8.499022783325927e-07
the O 0 1.6576843790971907e-06
human O 0 2.165993646485731e-05
DM B-Disease 1 1.0
region O 0 2.371878053963883e-06
, O 0 1.1687796330761557e-07
using O 0 1.451878404168383e-07
small O 0 4.888759121968178e-07
- O 0 1.195674849441275e-05
pool O 0 1.2159141078882385e-05
PCR O 0 4.901519059785642e-05
. O 0 1.2130926734243985e-05

These O 0 3.276690222264733e-06
mice O 0 2.0402035261213314e-06
have O 0 3.215428989733482e-08
been O 0 3.421853733698299e-08
shown O 0 2.3328782461362607e-08
to O 0 1.948579431143571e-08
reproduce O 0 3.33293542098545e-07
the O 0 7.101511556584228e-08
intergenerational O 0 1.527101403553388e-06
and O 0 1.261395681240174e-07
somatic O 0 4.433186859387206e-06
instability O 0 1.488875341237872e-06
of O 0 4.246545017849712e-07
the O 0 3.2036669495028036e-07
55 O 0 2.3603022327733925e-06
CTG O 0 0.00020547283929772675
repeat O 0 1.234368369296135e-06
suggesting O 0 1.1840137403851259e-07
that O 0 6.7205090381605714e-09
surrounding O 0 6.938143570778266e-08
sequences O 0 4.9416716052519405e-08
and O 0 4.065513081741301e-08
the O 0 8.34540756500246e-08
chromatin O 0 2.7047803996538278e-06
environment O 0 8.985414297058014e-07
are O 0 3.1948516721058695e-08
involved O 0 1.0438775177590287e-07
in O 0 1.1634105590019317e-07
instability O 0 1.9575369151425548e-05
mechanisms O 0 0.08767592906951904
. O 0 3.992505298811011e-05

As O 0 3.331049583721324e-06
observed O 0 9.341979989585525e-07
in O 0 3.522564639979464e-08
some O 0 2.0399799183223877e-08
of O 0 6.376836836352595e-08
the O 0 9.523685662315984e-08
tissues O 0 4.054075361636933e-06
of O 0 5.293723370414227e-05
DM B-Disease 1 1.0
patients O 0 1.1463212103990372e-05
, O 0 8.107289062309064e-08
there O 0 2.6960266907849473e-08
is O 0 6.708624322726564e-09
a O 0 1.2043815722506679e-08
tendency O 0 3.9498136317206445e-08
for O 0 3.394240266629822e-08
repeat O 0 4.2564383306853415e-07
length O 0 8.213140745283454e-08
and O 0 7.863326345614041e-08
somatic O 0 5.910143499932019e-06
mosaicism O 0 6.26913970336318e-06
to O 0 1.5354700622083328e-08
increase O 0 1.3313552926774719e-08
with O 0 7.567018123211255e-09
the O 0 2.366138396325823e-08
age O 0 1.4036542950179864e-07
of O 0 1.992796541117059e-07
the O 0 6.6631264417083e-07
mouse O 0 6.60602017887868e-06
. O 0 6.462513738370035e-06

Furthermore O 0 1.5231948964355979e-05
, O 0 4.309158612159081e-07
we O 0 1.3101950457894418e-07
observed O 0 5.7419704546646244e-08
no O 0 1.7066238200413864e-08
correlation O 0 6.797021256943481e-08
between O 0 5.99533080958281e-08
the O 0 6.933274931952838e-08
somatic O 0 4.623780569090741e-06
mutation O 0 3.944017805679323e-07
rate O 0 4.879778998656548e-07
and O 0 2.6740698899629933e-07
tissue O 0 1.6237165255006403e-05
proliferation O 0 5.7236040447605774e-05
capacity O 0 7.173229823820293e-05
. O 0 1.1359545169398189e-05

The O 0 7.300771358131897e-06
somatic O 0 8.273697312688455e-05
mutation O 0 1.6898827652767068e-06
rates O 0 2.41811619616783e-07
in O 0 1.590296250242318e-08
different O 0 2.134653520613483e-08
tissues O 0 1.9915387383662164e-07
were O 0 6.27231173666587e-08
also O 0 1.9604080137014535e-08
not O 0 1.0099171277033747e-08
correlated O 0 4.3112219572094546e-08
to O 0 6.049753586978568e-09
the O 0 4.054980706769129e-08
relative O 0 2.1685523279302288e-06
inter O 1 0.9994051456451416
- O 0 1.7969632608583197e-05
tissue O 0 4.916541342936398e-07
difference O 0 1.7580870803612925e-07
in O 0 1.0360182933766282e-08
transcriptional O 0 9.936800893228792e-08
levels O 0 4.669560382808413e-08
of O 0 1.2336812460489455e-08
the O 0 2.492428130551616e-08
three O 0 2.4795259179200002e-08
genes O 0 6.530898843948307e-08
( O 0 8.914464189047067e-08
DMAHP O 0 7.301458390429616e-05
, O 0 6.406369834621728e-07
DMPK O 0 0.0001532921742182225
and O 0 3.887510047206888e-07
59 O 0 1.6732369658711832e-06
) O 0 9.095123942870487e-08
surrounding O 0 2.913449748120911e-07
the O 0 2.6601819058669207e-07
repeat O 0 3.996089617430698e-06
. O 0 1.134090666710108e-06
. O 0 1.0482182005944196e-05

A O 0 3.244893014198169e-05
novel O 0 1.2509662155935075e-05
missense O 0 7.313764217542484e-05
mutation O 0 2.3539180347142974e-06
in O 0 1.3276280697027687e-07
patients O 0 1.90354839446627e-07
from O 0 7.171202298650314e-08
a O 0 1.1159760333612212e-06
retinoblastoma B-Disease 1 0.7695210576057434
pedigree O 0 1.1398817150620744e-05
showing O 0 1.1259844541200437e-06
only O 0 2.058962706996681e-07
mild O 0 1.9175382476532832e-05
expression O 0 3.6602554587261693e-07
of O 0 4.668776796279417e-07
the O 0 9.015723776428786e-07
tumor B-Disease 0 7.738955901004374e-05
phenotype O 0 0.00010213395580649376
. O 0 3.0020872145541944e-05

We O 0 2.236019781776122e-06
have O 0 1.4631498856942926e-07
used O 0 1.603723944754165e-07
single O 0 3.886149784193549e-07
strand O 0 9.49217223933374e-07
conformation O 0 2.484151480075525e-07
polymorphism O 0 1.9227034897539852e-07
analysis O 0 3.004327098210524e-08
to O 0 8.283018715360413e-09
study O 0 2.379834107557599e-08
the O 0 2.7532363944260396e-08
27 O 0 3.7445764178301033e-07
exons O 0 7.2928344252432e-07
of O 0 6.064589541665555e-08
the O 0 7.278382696540575e-08
RB1 O 0 1.5283780157915317e-05
gene O 0 6.36520738339641e-08
in O 0 1.2744409971787718e-08
individuals O 0 8.012985830418984e-09
from O 0 1.5376915740716868e-08
a O 0 7.577073546372048e-08
family O 0 3.054159591897587e-08
showing O 0 4.1675329498502833e-07
mild O 0 7.306884072022513e-05
expression O 0 9.330343573310529e-07
of O 0 1.995007323785103e-06
the O 0 4.0103109313349705e-06
retinoblastoma B-Disease 1 0.9489319920539856
phenotype O 0 0.0005470538744702935
. O 0 3.1846404453972355e-05

In O 0 2.7818707621918293e-06
this O 0 3.5023097666453396e-07
family O 0 1.6988981599297404e-07
affected O 0 1.6628003152163728e-07
individuals O 0 3.327332720459708e-08
developed O 0 2.789854306683992e-06
unilateral B-Disease 0 0.000251370103796944
tumors I-Disease 1 1.0
and O 0 1.3030469744990114e-05
, O 0 2.44258018256005e-07
as O 0 3.445272866997584e-08
a O 0 2.1399040761593824e-08
result O 0 4.787504437331336e-08
of O 0 1.1303153968356128e-07
linkage O 0 6.010536139910982e-07
analysis O 0 7.999535256431045e-08
, O 0 2.1364497726494847e-08
unaffected O 0 1.8611220298225817e-07
mutation O 0 5.7594984781417224e-08
carriers O 0 7.419996705948506e-08
were O 0 1.103223254972363e-07
also O 0 6.866237356462079e-08
identified O 0 2.3233140211686987e-07
within O 0 2.672109360446484e-07
the O 0 5.719666091863473e-07
pedigree O 0 1.0129178917850368e-05
. O 0 1.8029850252787583e-05

A O 0 1.3427962585410569e-05
single O 0 1.2526211321528535e-06
band O 0 2.1564917460636934e-06
shift O 0 1.053230789693771e-06
using O 0 4.960814408150327e-07
SSCP O 0 0.00024055178801063448
was O 0 7.857349828555016e-07
identified O 0 1.414220918150022e-07
in O 0 2.4682911714535294e-08
exon O 0 3.771164642785152e-07
21 O 0 1.5902847394499986e-07
which O 0 5.5012652211416935e-09
resulted O 0 8.974549814411148e-08
in O 0 2.1369062963572105e-08
a O 0 9.484059404485379e-08
missense O 0 2.183256356147467e-06
mutation O 0 5.370951612349018e-07
converting O 0 2.10330063055153e-06
a O 0 1.0754326922324253e-06
cys O 0 0.000432453554822132
- O 0 5.426292045740411e-05
- O 0 3.0271417926996946e-05
> O 0 1.555973540234845e-05
arg O 0 1.2236217116878834e-05
at O 0 6.10379117915727e-07
nucleotide O 0 3.5632521644402004e-07
position O 0 6.7765546418741e-07
28 O 0 1.3773812952422304e-06
in O 0 1.4223972755189607e-07
the O 0 9.865423180599464e-07
exon O 0 2.4393297280767e-05
. O 0 1.0563850082689896e-05

The O 0 5.304883870849153e-06
mutation O 0 5.115708972880384e-06
destroyed O 0 1.329832048213575e-05
an O 0 5.49521701032063e-07
NdeI O 0 5.213843542151153e-05
restriction O 0 3.459329036559211e-06
enzyme O 0 5.307292212819448e-06
site O 0 4.648061349143973e-06
. O 0 1.704767237242777e-05

Analysis O 0 2.8318320346443215e-06
of O 0 8.908597806112084e-07
all O 0 2.421954548026406e-07
family O 0 2.7878911623702152e-08
members O 0 3.157727235247876e-08
demonstrated O 0 1.277612824424068e-07
that O 0 8.852952149140947e-09
the O 0 1.0594974497735166e-07
missense O 0 2.0673714971053414e-05
mutation O 0 1.2602077731571626e-05
co O 0 0.0005890170577913523
- O 0 0.42076539993286133
segregated O 0 6.143974587757839e-06
with O 0 1.6745300968068477e-07
patients O 0 2.2682600047119195e-06
with O 0 2.7232345019001514e-05
tumors B-Disease 1 1.0
or O 1 0.9909493327140808
who O 0 4.725739472632995e-06
, O 0 1.307690951080076e-07
as O 0 1.9384927441024047e-08
a O 0 1.2478094113532734e-08
result O 0 2.9493046227457853e-08
of O 0 1.1295686164203289e-07
linkage O 0 7.452383670170093e-07
analysis O 0 8.836609310947097e-08
had O 0 6.189312529158997e-08
been O 0 5.597010144242631e-08
predicted O 0 2.118207760304358e-07
to O 0 3.7227774640768985e-08
carry O 0 1.308317223447375e-07
the O 0 6.009498179082584e-07
predisposing O 0 3.197586192982271e-05
mutation O 0 2.6435298423166387e-05
. O 0 1.654542938922532e-05

These O 0 9.006115533338743e-07
observations O 0 1.2402281299728202e-06
point O 0 6.105886996010668e-07
to O 0 5.1007837953420676e-08
another O 0 1.5859107804772066e-07
region O 0 1.675979319770704e-07
of O 0 2.3655951508771977e-07
the O 0 2.9538429657804954e-07
RB1 O 0 4.882377834292129e-05
gene O 0 9.381972887467782e-08
where O 0 4.59166251687293e-08
mutations O 0 5.960271209914936e-08
only O 0 1.0393473637293482e-08
modify O 0 3.7830833576890655e-08
the O 0 5.535314873128527e-09
function O 0 1.246101710705716e-08
of O 0 1.6081523668276532e-08
the O 0 2.0480655393839697e-08
gene O 0 3.099309964227359e-08
and O 0 3.4228065715069533e-08
raise O 0 6.875620783830527e-08
important O 0 6.526627061020918e-08
questions O 0 1.0620649248949121e-07
for O 0 3.022344685632561e-08
genetic O 0 4.916494731332932e-07
counseling O 0 3.999423654477141e-07
in O 0 2.063640636151831e-08
families O 0 9.690277025242722e-09
with O 0 2.3859337616727316e-08
these O 0 7.207320606994472e-08
distinctive O 0 8.055656508076936e-06
phenotypes O 0 5.09247365698684e-05
. O 0 2.7259918624622514e-06
. O 0 1.8146840375266038e-05

Maternal B-Disease 0 0.0005222701583988965
disomy I-Disease 0 0.2206607162952423
and O 1 0.81667160987854
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9999731779098511
with O 0 5.305303602654021e-06
gamete O 0 0.00012709744623862207
complementation O 0 0.0001364118797937408
in O 0 2.6159209909337733e-08
a O 0 2.478187965948564e-08
case O 0 4.699815292497078e-08
of O 0 7.541331825677844e-08
familial O 0 5.621665195576497e-07
translocation O 0 1.0645122756614e-06
( O 0 4.523424834701473e-08
3 O 0 2.85879650618881e-07
; O 0 1.9601200662577867e-08
15 O 0 2.4687577138138295e-07
) O 0 7.239726329544283e-08
( O 0 6.232207283574098e-08
p25 O 0 3.0608421184297185e-06
; O 0 1.0228907854070712e-07
q11 O 0 4.189875198790105e-06
. O 0 1.810343093211486e-07
2 O 0 3.5148580082022818e-06
) O 0 1.1065378657804104e-06
. O 0 1.0801240023283754e-05

Maternal B-Disease 0 0.003813776420429349
uniparental I-Disease 1 0.9998223185539246
disomy I-Disease 1 0.999843955039978
( I-Disease 0 0.00037234416231513023
UPD I-Disease 1 1.0
) I-Disease 0 2.1455866772157606e-06
for I-Disease 0 3.9757696868036874e-07
chromosome I-Disease 0 2.1840060071554035e-06
15 I-Disease 0 6.60986131606478e-07
is O 0 2.2400309163117527e-08
responsible O 0 8.087874903139891e-08
for O 0 5.450225160075206e-09
an O 0 2.181222313879516e-09
estimated O 0 7.940853308241458e-09
30 O 0 2.7213886255594844e-08
% O 0 7.200351870295663e-09
of O 0 3.972305151478395e-08
cases O 0 1.741385489140157e-07
of O 0 8.178585267160088e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999997615814209
PWS B-Disease 1 1.0
) O 0 3.5744975320994854e-05
. O 0 1.815009454730898e-05

We O 0 6.693826890113996e-06
report O 0 5.579901198871084e-07
on O 0 1.991926410482847e-07
an O 0 2.408635602080267e-08
unusual O 0 1.4934100533992023e-07
case O 0 3.8949616509853513e-07
of O 0 3.5166075917913986e-07
maternal B-Disease 0 2.8730303256452316e-06
disomy I-Disease 0 0.00014536950038746
15 I-Disease 0 5.698008862964343e-06
in O 0 6.56700990475656e-07
PWS B-Disease 1 1.0
that O 0 4.926454266751534e-08
is O 0 1.8594361606005805e-08
most O 0 8.440701471101875e-09
consistent O 0 7.911391719517269e-08
with O 0 1.7409512054200604e-08
adjacent O 0 2.595604087218817e-07
- O 0 4.7327299057542405e-07
1 O 0 4.51353542985089e-07
segregation O 0 3.321543999845744e-07
of O 0 3.746369259260973e-08
a O 0 4.9720483730197884e-08
paternal O 0 2.3092562173587794e-07
t O 0 9.441911288377014e-07
( O 0 4.406654596778026e-08
3 O 0 2.2050799941553123e-07
; O 0 3.52136204639919e-08
15 O 0 1.768432156268318e-07
) O 0 3.271563642215369e-08
( O 0 4.9806672564045584e-08
p25 O 0 2.003682993745315e-06
; O 0 4.501855599414739e-08
q11 O 0 8.000922093742702e-07
. O 0 2.053635839160961e-08
2 O 0 2.992277927660325e-07
) O 0 2.2005670174962688e-08
with O 0 2.8678480035182474e-08
simultaneous O 0 6.802791858717683e-07
maternal O 0 4.979450295650167e-06
meiotic O 0 0.00022918461763765663
nondisjunction O 0 0.0002787008124869317
for O 0 2.941949787782505e-06
chromosome O 0 1.311712185270153e-05
15 O 0 1.515191797807347e-05
. O 0 1.6631454855087213e-05

The O 0 9.811157724470831e-06
patient O 0 4.1890803004207555e-06
( O 0 3.3047570013877703e-07
J O 0 1.4173564522934612e-05
. O 0 7.796302270435262e-08
B O 0 7.20778075447015e-07
. O 0 2.327380599354001e-08
) O 0 6.977342703606837e-09
, O 0 1.2301731189268139e-08
a O 0 6.375790917445556e-08
17 O 0 8.831106015350088e-07
- O 0 1.0931352107945713e-06
year O 0 1.3987992986130848e-07
- O 0 2.9697812351514585e-06
old O 0 5.3771818784298375e-06
white O 0 7.66910886795813e-07
male O 0 1.0770625067380024e-06
with O 0 1.1556680874491576e-06
PWS B-Disease 1 1.0
, O 0 2.5693677798699355e-06
was O 0 6.561989494002773e-07
found O 0 1.1738797489613262e-08
to O 0 6.735870528018495e-09
have O 0 1.3825538047740338e-08
47 O 0 2.3327410758611222e-07
chromosomes O 0 1.6185401818802347e-07
with O 0 4.2597839922109415e-08
a O 0 3.3701624602144875e-07
supernumerary O 0 3.488654692773707e-05
, O 0 2.3023119410936488e-07
paternal O 0 1.8166069821745623e-06
der O 0 0.04739772155880928
( O 0 5.200803343541338e-07
15 O 0 1.2481233397920732e-06
) O 0 5.89255115812648e-08
consisting O 0 2.011577748817217e-07
of O 0 2.1895711199704238e-07
the O 0 8.283810188913776e-07
short O 0 4.2364913497294765e-06
arm O 0 0.00023123777646105736
and O 0 1.3698150951313437e-06
the O 0 6.236789431568468e-06
proximal O 1 0.9991258978843689
long O 0 5.592533489107154e-05
arm O 0 0.0024849537294358015
of O 0 0.00014161402941681445
chromosome O 0 0.00010503220255486667
15 O 0 2.4635071895318106e-05
, O 0 1.4846684734948212e-06
and O 0 1.0151537935598753e-05
distal O 1 0.9967216849327087
chromosome O 1 0.9763889908790588
arm O 1 0.9972475171089172
3p O 1 0.9999812841415405
. O 0 0.0007164074340835214

The O 0 6.52847165838466e-06
t O 0 8.985527529148385e-06
( O 0 1.4504917089652736e-07
3 O 0 2.6532447350291477e-07
; O 0 1.425399087651158e-08
15 O 0 9.627257924194055e-08
) O 0 8.529176476201883e-09
was O 0 4.532086705921756e-08
present O 0 9.743227558089984e-09
in O 0 3.0512172788377256e-09
the O 0 8.205386592408104e-09
balanced O 0 6.36947063981097e-08
state O 0 7.259524092972924e-09
in O 0 8.568522780194598e-09
the O 0 5.3936499710971475e-08
patients O 0 9.026737757267256e-08
father O 0 3.749028678612376e-07
and O 0 9.036588721755834e-07
a O 0 3.314634568596375e-06
sister O 0 2.9940190870547667e-05
. O 0 4.198566603008658e-05

Fluorescent O 0 0.00011604629980865866
in O 0 9.920389629769488e-07
situ O 0 7.925519639684353e-06
hybridization O 0 6.770998766114644e-07
analysis O 0 2.5399737069164985e-07
demonstrated O 0 4.484047906316846e-07
that O 0 5.236147515574885e-08
the O 0 1.0178243883274263e-06
PWS B-Disease 1 1.0
critical O 0 1.8833290596376173e-05
region O 0 1.125950007008214e-06
resided O 0 4.894590688309108e-07
on O 0 1.1057154836180416e-07
the O 0 4.247914020538701e-08
derivative O 0 2.7313996042721556e-07
chromosome O 0 1.2962145490291732e-07
3 O 0 1.5977413170276122e-07
and O 0 1.2352352918298948e-08
that O 0 2.4054023217701115e-09
there O 0 7.438784255242581e-09
was O 0 5.016103798993754e-08
no O 0 1.5386127927285997e-08
deletion O 0 1.3731984438436484e-07
of O 0 1.852106237265616e-07
the O 0 2.97424503514776e-06
PWS B-Disease 1 1.0
region O 0 1.1555178389244247e-05
on O 0 1.5633931980119087e-06
the O 0 1.575614447801854e-07
normal O 0 5.136330401001032e-07
pair O 0 5.686104032065487e-07
of O 0 8.619321079095243e-07
15s O 0 0.00018316002388019115
present O 0 6.400787810889597e-07
in O 0 1.2579039321281016e-06
J O 0 0.0005024717538617551
. O 0 3.64123989129439e-05

B O 0 0.004782595206052065
. O 0 0.0002586359332781285

Methylation O 0 2.7443544240668416e-05
analysis O 0 3.9256105992535595e-06
at O 0 4.864153197559062e-06
exon O 0 2.6524048735154793e-06
alpha O 0 2.2698850443703122e-06
of O 0 2.4536140585951216e-07
the O 0 1.462782819316999e-07
small O 0 1.644084903773546e-07
nuclear O 0 1.6259651602013037e-05
ribonucleoprotein O 0 0.00032811128767207265
- O 0 8.57567192724673e-06
associated O 0 1.5420611134686624e-06
polypeptide O 0 1.4509176253341138e-05
N O 0 1.4316135093395133e-05
( O 0 2.2522456788465206e-07
SNRPN O 0 4.9262096581514925e-05
) O 0 9.528136502012785e-08
gene O 0 1.5497435867928289e-07
showed O 0 1.2890511413843342e-07
a O 0 1.2614077604666818e-07
pattern O 0 1.1656800324999494e-06
characteristic O 0 3.140221451758407e-06
of O 0 9.350875984637241e-07
only O 0 1.6903794630707125e-07
the O 0 1.2853793407430203e-07
maternal O 0 5.661495379172266e-07
chromosome O 0 6.679184707536479e-07
15 O 0 1.1520465932335355e-06
in O 0 7.543488322880876e-07
J O 0 0.0008866214193403721
. O 0 5.2052932005608454e-05

B O 0 0.004446323495358229
. O 0 0.00032117587397806346

Maternal B-Disease 0 0.0003001598233822733
disomy I-Disease 0 0.0017997381510213017
was O 0 6.966533874219749e-06
confirmed O 0 1.0096582627738826e-06
by O 0 1.1330869398307186e-07
polymerase O 0 2.6180432541877963e-06
chain O 0 3.1086142371350434e-07
reaction O 0 1.6288576887291129e-07
analysis O 0 1.3877009052976064e-07
of O 0 3.5272313425593893e-07
microsatellite O 0 1.5468995115952566e-05
repeats O 0 2.643924517542473e-06
at O 0 9.873244835034711e-07
the O 0 2.2096945428984327e-07
gamma O 0 6.607582236028975e-06
- O 0 4.750084826810053e-06
aminobutyric O 0 9.150121513812337e-06
acid O 0 1.1287646657365258e-06
receptor O 0 1.2359963648123085e-06
beta3 O 0 3.763522499866667e-06
subunit O 0 3.1380839118355652e-06
( O 0 2.7597883445196203e-07
GABRB3 O 0 4.664320294978097e-05
) O 0 9.448270361644973e-07
locus O 0 3.112541526206769e-05
. O 0 1.835027796914801e-05

A O 0 8.773812442086637e-05
niece O 0 7.903840742073953e-05
( O 0 6.728194534844079e-07
B O 0 1.979466787815909e-06
. O 0 2.541712795789408e-08
B O 0 3.0165634257173224e-07
. O 0 7.634764820352302e-09
) O 0 3.589197161701918e-09
with O 0 4.870654102262506e-09
45 O 0 4.528405739279151e-08
chromosomes O 0 4.8104976002605326e-08
and O 0 1.1651644094001767e-08
the O 0 9.715372506491349e-09
derivative O 0 4.943462883488792e-08
3 O 0 6.778507355420516e-08
but O 0 6.859623979948992e-09
without O 0 1.8988753680559967e-08
the O 0 3.185541785910573e-08
der O 0 2.7271014914731495e-05
( O 0 4.827446531407986e-08
15 O 0 2.5417133997507335e-07
) O 0 3.438825757484665e-08
demonstrated O 0 2.8407507102201635e-07
a O 0 1.5909340334019362e-07
phenotype O 0 1.4924277138561592e-06
consistent O 0 2.4799334141789586e-07
with O 0 1.7534615537329046e-08
that O 0 1.3449847457991382e-08
reported O 0 1.213786475773304e-07
for O 0 1.4630424516326457e-07
haploinsufficiency O 0 1.0053172445623204e-05
of O 0 1.2252343140062294e-06
distal O 0 0.00011208725481992587
3 O 0 0.00011689303210005164
p O 0 0.0002854556078091264
. O 0 2.8713931897073053e-05

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999904632568359
associated O 0 1.1458130757091567e-05
with O 0 5.637519393530965e-07
unbalanced O 0 2.8176971682114527e-05
segregation O 0 2.026428091994603e-06
of O 0 4.7078455622795445e-07
non O 0 5.497392703546211e-05
- O 0 8.933196659199893e-05
Robertsonian O 0 0.0007569073350168765
translocations O 0 2.7452470021671616e-05
has O 0 8.32867925737446e-08
been O 0 6.499681859395423e-08
reported O 0 7.354267950177018e-08
previously O 0 7.932227674700698e-08
but O 0 1.0017025431352522e-08
has O 0 5.466049390889793e-09
not O 0 3.607370846481217e-09
, O 0 5.065258879000112e-09
to O 0 3.7044582956724526e-09
our O 0 2.8817094488431394e-08
knowledge O 0 1.6466064778342115e-07
, O 0 3.0467063538708317e-08
been O 0 2.2582844039220618e-08
observed O 0 5.119429502542516e-08
in O 0 1.2217156175609034e-08
a O 0 1.134056688556484e-07
case O 0 1.0668926506696153e-06
of O 0 1.6044066796894185e-05
PWS B-Disease 1 1.0
. O 0 0.0005317270406521857

Furthermore O 0 5.445014903671108e-05
, O 0 7.81055177867529e-07
our O 0 3.162290056479833e-07
findings O 0 1.9340838264270133e-07
are O 0 1.9895944447512193e-08
best O 0 9.245103171906521e-08
interpreted O 0 9.022124913826701e-08
as O 0 4.5411464810740654e-08
true O 0 5.16250054261036e-07
gamete O 0 1.278514537261799e-05
complementation O 0 4.848808021051809e-05
resulting O 0 2.9833868211426307e-06
in O 0 8.152426289598225e-07
maternal B-Disease 0 9.877863340079784e-05
UPD I-Disease 1 1.0
15 I-Disease 0 0.002618414117023349
and O 0 0.0014630863443017006
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9635998606681824
- I-Disease 1 0.9999868869781494
Jampel I-Disease 1 0.9999929666519165
syndrome I-Disease 1 0.9992269277572632
type I-Disease 0 0.0001154401688836515
2 I-Disease 0 7.670202467124909e-05
and O 0 2.21422442336916e-06
Stuve B-Disease 1 0.9999420642852783
- I-Disease 1 0.9999970197677612
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999995231628418
: O 0 3.5233651374255714e-07
a O 0 9.312317672538484e-08
case O 0 1.4551123683759215e-07
for O 0 3.3794599119119084e-08
" O 0 6.339448646031087e-07
lumping O 0 2.5257370452891337e-06
" O 0 2.8119070520915557e-06
. O 0 1.0543530152062885e-05

Recent O 0 4.140730197832454e-06
studies O 0 1.9613694348663557e-06
demonstrated O 0 1.4948620901122922e-06
the O 0 1.6428232640919305e-07
existence O 0 2.613483047753107e-07
of O 0 1.9033649323318969e-07
a O 0 1.7946025820947398e-07
genetically O 0 7.953541398819652e-07
distinct O 0 1.7951313679986924e-07
, O 0 4.4940826171568915e-08
usually O 0 3.451745200777623e-08
lethal O 0 4.23317743525331e-07
form O 0 1.3243666785456298e-07
of O 0 3.372287551428599e-07
the O 0 4.211987345570378e-07
Schwartz B-Disease 0 7.88741308497265e-05
- I-Disease 0 0.4764634966850281
Jampel I-Disease 1 0.9999816417694092
syndrome I-Disease 1 0.9999972581863403
( O 0 9.632723049435299e-06
SJS B-Disease 1 0.9997929930686951
) O 0 1.1400874200262479e-06
of O 0 2.335848330403678e-05
myotonia B-Disease 1 0.9999998807907104
and O 1 0.9164503216743469
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 5.367313860915601e-06
which O 0 1.7981385269649763e-07
we O 0 2.1306880171323428e-07
called O 0 6.38353640169953e-07
SJS B-Disease 0 0.00016823643818497658
type I-Disease 0 1.0051245226350147e-05
2 I-Disease 0 3.675972766359337e-05
. O 0 1.4860557712381706e-05

This O 0 5.434228569356492e-06
disorder O 1 0.9988021850585938
is O 0 1.6999871377265663e-07
reminiscent O 0 7.520677627326222e-06
of O 0 9.095937230085838e-07
another O 0 9.117205763686798e-07
rare O 0 5.171967245587439e-07
condition O 0 1.2761177003994817e-06
, O 0 1.846504886771072e-07
the O 0 6.49039748168434e-07
Stuve B-Disease 1 0.9997771382331848
- I-Disease 1 0.9999978542327881
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.005776200443506241
SWS B-Disease 1 0.9999921321868896
) O 0 6.252352591218369e-07
, O 0 1.5385489859909285e-07
which O 0 9.838357328817438e-08
comprises O 0 6.562696626133402e-07
campomelia B-Disease 0 1.1237916623940691e-05
at O 0 1.5196210370049812e-06
birth O 0 7.681698548367422e-07
with O 0 2.954213869088562e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.4417875111103058
contractures B-Disease 1 0.9999997615814209
, O 0 4.451433596841525e-06
and O 0 7.872688456700416e-07
early B-Disease 0 1.203414831252303e-05
death I-Disease 0 1.7439944713260047e-05
. O 0 9.554198186378926e-06

To O 0 1.0913863661698997e-06
test O 0 2.0849713564530248e-06
for O 0 1.2913287150695396e-07
possible O 0 1.1000678341588355e-06
nosologic O 0 1.990821874642279e-05
identity O 0 2.923831914358743e-07
between O 0 7.281367402356409e-07
these O 0 4.7263526425922464e-07
disorders O 0 0.4145859181880951
, O 0 7.765892462430202e-08
we O 0 5.765917521216579e-08
reviewed O 0 1.0659534410706328e-07
the O 0 1.1694927692929014e-08
literature O 0 2.592149961344603e-08
and O 0 9.920094967696969e-09
obtained O 0 2.86822547934662e-08
a O 0 1.3292797085284747e-08
follow O 0 3.37356063084826e-08
- O 0 1.229052628559657e-07
up O 0 1.5374013173641288e-08
of O 0 2.148361488707451e-08
the O 0 1.765799062525275e-08
only O 0 1.638304070183949e-08
two O 0 1.8160575265824264e-08
surviving O 0 6.58003727949108e-07
patients O 0 4.4808757593273185e-08
, O 0 1.889352141404288e-08
one O 0 1.6569646987818487e-08
with O 0 6.256862405962238e-08
SJS B-Disease 0 0.0003304729762021452
type I-Disease 0 5.883257017558208e-06
2 I-Disease 0 5.870916083949851e-06
at O 0 2.7474641228764085e-07
age O 0 4.0999395878316136e-08
10 O 0 1.873076449498967e-08
years O 0 7.453795802803143e-09
and O 0 8.907661275259215e-09
another O 0 3.390448810591806e-08
with O 0 5.052505258618112e-08
SWS B-Disease 0 7.133087638067082e-05
at O 0 7.775687436151202e-07
age O 0 2.267889129825562e-07
7 O 0 2.26897600441589e-06
years O 0 1.1769958518925705e-06
. O 0 5.0022681534755975e-06

Patients O 0 4.034699668409303e-05
reported O 0 2.442855929984944e-06
as O 0 2.3484552968966455e-07
having O 0 5.983809501231008e-07
either O 0 2.5593681129976176e-06
neonatal O 1 0.999984860420227
SJS B-Disease 1 0.9999995231628418
or O 0 0.0008797821938060224
SWS B-Disease 1 0.9969256520271301
presented O 0 1.400842165821814e-06
a O 0 8.140619200958099e-08
combination O 0 6.39196116480889e-07
of O 0 5.513936685019871e-07
a O 0 1.0130330565516488e-06
severe O 0 0.1760622262954712
, O 0 5.854265964444494e-06
prenatal O 0 0.09955374896526337
- O 1 0.9757441282272339
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.09407201409339905
with O 1 0.9917614459991455
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.9999879598617554
feeding O 1 0.9846477508544922
difficulties O 1 0.5980819463729858
, O 0 8.212535931306775e-07
tendency O 0 3.403190191875183e-07
to O 0 1.4958190774905233e-07
hyperthermia B-Disease 1 0.9896233677864075
, O 0 2.741248295023979e-07
and O 0 1.337527919531567e-07
frequent O 0 1.3424043743270886e-07
death O 0 9.041847874868836e-07
in O 0 1.0308151132676358e-07
infancy O 0 8.839802831062116e-06
) O 0 5.208635300846254e-08
with O 0 4.1346819301679716e-08
a O 0 2.225174284831155e-07
distinct O 0 5.1423580771370325e-06
campomelic B-Disease 1 0.9865158796310425
- I-Disease 1 0.999982476234436
metaphyseal I-Disease 1 0.99998939037323
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.001616586814634502

The O 0 4.0284071474161465e-06
similarity O 0 1.2830454352297238e-06
of O 0 1.1540457762748701e-06
the O 0 4.792218533111736e-07
clinical O 0 2.3180004063760862e-05
and O 0 3.116043671980151e-07
radiographic O 0 0.00025289488257840276
findings O 0 1.6160012137333979e-06
is O 0 3.9863238043835736e-08
so O 0 1.2029856222284252e-08
extensive O 0 4.5632003065065874e-08
that O 0 1.2730464682420006e-08
these O 0 2.3559927342375886e-07
disorders O 1 0.757963240146637
appear O 0 1.7385411865689093e-07
to O 0 2.8385372274897236e-08
be O 0 4.5403496073959104e-08
a O 0 1.0456052024210294e-07
single O 0 3.289237042736204e-07
entity O 0 6.350537660182454e-06
. O 0 1.3600727470475249e-05

The O 0 4.1050407162401825e-06
follow O 0 2.032241809502011e-06
- O 0 3.725278475030791e-06
up O 0 7.720979056102806e-08
observation O 0 1.6355009790913755e-07
of O 0 3.3244589303649263e-08
an O 0 7.938733226353634e-09
identical O 0 2.508845398097037e-07
and O 0 6.949772313191716e-08
unique O 0 2.899714957038668e-07
pattern O 0 3.9635036955587566e-05
of O 0 0.22888615727424622
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 2.0711861452582525e-06
the O 0 5.833327918480791e-07
two O 0 1.3031370826865896e-07
patients O 0 5.999974916903739e-08
( O 0 2.2800199062089632e-08
one O 0 1.9828281239142598e-08
with O 0 4.553462673584363e-08
SJS B-Disease 0 0.00015603606880176812
type I-Disease 0 4.587041530612623e-06
2 I-Disease 0 9.45331521506887e-06
, O 0 5.821035031772226e-08
one O 0 1.8505202703522627e-08
with O 0 5.001305680707446e-08
SWS B-Disease 0 0.00020369306730572134
) O 0 7.815285130163829e-08
surviving O 0 9.06761499663844e-07
beyond O 0 7.545517632934207e-07
infancy O 0 1.8085274859913625e-06
adds O 0 1.6662353630181315e-07
to O 0 1.1366396712730875e-08
the O 0 2.794647180337506e-08
evidence O 0 9.515495946743613e-08
in O 0 2.6325485791289793e-08
favor O 0 3.4572738627502986e-07
of O 0 1.1320106523271534e-06
identity O 0 5.550505647988757e-06
. O 0 2.5976967663154937e-05

The O 0 5.015839633415453e-06
hypothesis O 0 4.821722995984601e-06
that O 0 3.225484874747053e-07
SWS B-Disease 0 0.0003317884402349591
and O 0 2.0666363980126334e-06
SJS B-Disease 0 0.07110944390296936
type I-Disease 0 1.7948872482520528e-05
2 I-Disease 0 1.1631287634372711e-05
are O 0 2.865491310899415e-08
the O 0 5.8716157269600444e-08
same O 0 1.4554302651959006e-07
disorder O 0 1.9485891243675724e-05
should O 0 2.1694772200930856e-08
be O 0 3.208971577350894e-08
testable O 0 3.621146618115745e-07
by O 0 1.5003873699015458e-08
molecular O 0 3.7434875821418245e-07
methods O 0 1.186949134535098e-06
. O 0 7.859852644287457e-07
. O 0 5.936540219408926e-06

A O 0 9.517411672277376e-05
mouse O 0 1.8689101125346497e-05
model O 0 3.5060734262515325e-06
of O 0 2.5165666102111572e-06
severe O 1 0.9999990463256836
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999792575836182
defects O 1 0.9999983310699463
in O 0 1.871501444838941e-05
hemostasis O 1 0.998903751373291
and O 0 0.00022979268396738917
thrombosis B-Disease 1 0.999995231628418
. O 0 0.001385279349051416

von B-Disease 0 0.17000502347946167
Willebrand I-Disease 1 0.9972004890441895
factor I-Disease 0 0.00021491601364687085
( I-Disease 0 1.6956015315372497e-05
vWf I-Disease 1 0.6483849883079529
) I-Disease 0 0.0003640530921984464
deficiency I-Disease 1 1.0
causes O 1 0.9999834299087524
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.05989817529916763
humans O 0 0.0003457446291577071
. O 0 1.1949316103709862e-05

We O 0 5.109092398924986e-06
generated O 0 1.3300414138939232e-06
a O 0 3.152585179577727e-07
mouse O 0 5.934095383963722e-07
model O 0 1.407982068712954e-07
for O 0 2.995417958118196e-08
this O 0 1.819378958600737e-08
disease O 0 1.1741757788286122e-07
by O 0 8.515051774793392e-09
using O 0 5.578061035294013e-08
gene O 0 3.464330120550585e-07
targeting O 0 2.545568349887617e-06
. O 0 8.599127795605455e-06

vWf B-Disease 1 0.7579344511032104
- I-Disease 1 0.9999767541885376
deficient I-Disease 1 0.9700971841812134
mice O 0 2.284086622239556e-05
appeared O 0 8.930936132856004e-07
normal O 0 3.681392968246655e-07
at O 0 2.0323450655723718e-07
birth O 0 3.2231906033075575e-08
; O 0 7.796417733629823e-09
they O 0 9.878762696757803e-09
were O 0 1.0060301036673991e-07
viable O 0 3.2907976219576085e-06
and O 0 1.1162549071741523e-06
fertile O 0 8.177439303835854e-05
. O 0 2.3848109776736237e-05

Neither O 0 0.00030615285504609346
vWf O 0 0.0014497365336865187
nor O 0 0.00019439916650298983
vWf O 0 0.0007406569202430546
propolypeptide O 0 0.0005847582942806184
( O 0 4.307726612751139e-06
von B-Disease 0 0.0009954908164218068
Willebrand I-Disease 0 0.007954766973853111
antigen O 0 1.8338416339247487e-05
II O 1 0.992366373538971
) O 0 9.437700754233447e-08
were O 0 7.390082856773006e-08
detectable O 0 4.805527282769617e-07
in O 0 1.9368886938764263e-08
plasma O 0 8.352054123861308e-07
, O 0 3.735801357152013e-08
platelets O 0 2.5554166427355085e-07
, O 0 1.7762298298862333e-08
or O 0 2.0140227263709676e-08
endothelial O 0 1.115965915232664e-07
cells O 0 1.9312446752906e-08
of O 0 3.4966923578849674e-08
the O 0 1.4267352810293232e-07
homozygous O 0 4.330938281782437e-06
mutant O 0 4.20093783759512e-05
mice O 0 6.176476017571986e-05
. O 0 2.4245680833701044e-05

The O 0 2.5728279069880955e-05
mutant O 0 0.001284099998883903
mice O 0 0.0008931306656450033
exhibited O 0 5.77811042603571e-05
defects O 0 0.09858492016792297
in O 0 9.434998560209351e-07
hemostasis O 0 0.009105716831982136
with O 0 5.2913202353011e-07
a O 0 2.6761542812892003e-06
highly O 0 0.015247348695993423
prolonged O 1 0.9999170303344727
bleeding O 1 0.9999511241912842
time O 0 4.777798494615126e-06
and O 0 9.74663862507441e-07
spontaneous O 0 4.405013532959856e-05
bleeding O 0 0.00013113254681229591
events O 0 2.0805030942483427e-07
in O 0 2.868373094599974e-08
approximately O 0 3.321385122490028e-08
10 O 0 7.30910016955022e-08
% O 0 4.831591482457043e-08
of O 0 7.387121740975999e-07
neonates O 0 3.8315323763526976e-05
. O 0 3.779646795010194e-05

As O 0 4.890363015874755e-06
in O 0 2.8785541417164495e-07
the O 0 7.095878231666575e-07
human O 0 1.7273509911319707e-06
disease O 0 2.379762690907228e-06
, O 0 1.5382548568254606e-08
the O 0 1.6584698059318725e-08
factor O 0 1.4103163437084731e-07
VIII O 0 0.09321793913841248
level O 0 7.655519766558427e-06
in O 0 2.0489878238549863e-08
these O 0 2.2380193698268158e-08
mice O 0 2.353152268597114e-07
was O 0 3.363230050013044e-08
reduced O 0 3.3075405525551105e-08
strongly O 0 6.968750465574658e-09
as O 0 3.5393594721710997e-09
a O 0 4.456309987688201e-09
result O 0 8.117481797853543e-09
of O 0 1.1388379128618453e-08
the O 0 1.230593227319332e-08
lack O 0 9.538828749100503e-08
of O 0 1.0689014118270279e-07
protection O 0 2.0446179860300617e-07
provided O 0 1.9137050344397721e-07
by O 0 4.3103875668748515e-07
vWf O 0 6.299496453721076e-05
. O 0 2.210829006799031e-05

Defective O 1 0.9991648197174072
thrombosis B-Disease 1 0.9994321465492249
in O 0 6.858030701550888e-06
mutant O 0 0.000266816234216094
mice O 0 2.3292262994800694e-05
was O 0 1.0119014177689678e-06
also O 0 4.7727521490514846e-08
evident O 0 2.8494577009041677e-07
in O 0 1.8174366900325367e-08
an O 0 8.022039033050987e-09
in O 0 3.39990329223383e-08
vivo O 0 1.4694090850753128e-06
model O 0 2.0188319922453957e-06
of O 0 8.421891834586859e-05
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.07977928221225739

In O 0 1.1198417269042693e-06
this O 0 9.787672894390198e-08
model O 0 6.421919351851102e-07
, O 0 2.5882133058985346e-07
the O 0 9.142760859504051e-07
exteriorized O 0 0.00010886639211094007
mesentery O 0 0.0001982197427423671
was O 0 6.54224004392745e-06
superfused O 0 4.8636833525961265e-05
with O 0 6.797254172852263e-07
ferric O 0 0.0016600847011432052
chloride O 0 1.931902988872025e-05
and O 0 6.462553869823751e-07
the O 0 2.2216711670353106e-07
accumulation O 0 9.85783344731317e-07
of O 0 1.2474130244299886e-06
fluorescently O 0 1.4167050721880514e-05
labeled O 0 1.3448046729536145e-06
platelets O 0 2.5040030777745415e-06
was O 0 7.265053341143357e-07
observed O 0 4.5861483499720634e-07
by O 0 3.2329867849512084e-07
intravital O 0 5.073607826489024e-05
microscopy O 0 0.0001565763377584517
. O 0 2.855184538930189e-05

We O 0 6.107789886300452e-06
conclude O 0 9.51241236180067e-06
that O 0 7.742731611415365e-08
these O 0 2.0215993856709247e-07
mice O 0 1.9412307210586732e-06
very O 0 3.087439495175204e-07
closely O 0 2.407006604698836e-06
mimic O 0 0.06545151770114899
severe O 1 0.9999954700469971
human O 1 0.9998310804367065
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0001796310389181599
will O 0 1.0940326689024005e-07
be O 0 1.2636529156395682e-08
very O 0 7.707732230244346e-09
useful O 0 3.5569566847470924e-08
for O 0 1.1514669218115614e-08
investigating O 0 9.12078235160152e-08
the O 0 1.3872398341163716e-08
role O 0 9.392984878786592e-08
of O 0 2.241736893893176e-07
vWf O 0 1.1860953236464411e-05
in O 0 3.8688182257828885e-07
normal O 0 1.1403852113289759e-05
physiology O 0 0.000323026004480198
and O 0 8.91420654625108e-07
in O 0 7.382432158919983e-07
disease O 0 0.00014394917525351048
models O 0 4.0261602407554165e-06
. O 0 1.2715003094854183e-06
. O 0 6.1994778661755845e-06

Oral O 0 0.003923602867871523
contraceptives O 0 0.0007117126951925457
and O 0 9.044796911439335e-07
the O 0 4.259280785845476e-07
risk O 0 1.2898561180918477e-05
of O 0 0.4609658420085907
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9995834231376648

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 1 0.977681040763855
Study O 0 1.1386409823899157e-05
Group O 0 1.4624031791754533e-05
. O 0 1.4481447578873485e-05

BACKGROUND O 0 0.00014355317398440093
Women O 0 5.200899522606051e-06
with O 0 1.2309975261359796e-07
mutations O 0 3.054515218536835e-07
in O 0 3.40848700375318e-08
either O 0 1.4434897366299992e-07
the O 0 1.9568577158679545e-07
BRCA1 O 0 2.1235443909972673e-06
or O 0 1.0561360852534563e-07
the O 0 8.348877855723913e-08
BRCA2 O 0 1.4418155842577107e-06
gene O 0 1.1464915417036536e-07
have O 0 2.8670712026723777e-08
a O 0 1.6319208384629746e-07
high O 0 3.7117670217412524e-06
lifetime O 0 3.738332452485338e-06
risk O 0 0.00010766870400402695
of O 1 0.9996581077575684
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.7459520101547241

Oral O 0 0.021070417016744614
contraceptives O 1 0.8099584579467773
protect O 0 0.00010345331247663125
against O 1 0.9999991655349731
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.947652645474591e-07
general O 0 1.2402540505718207e-06
, O 0 1.8955136127374317e-08
but O 0 5.971237282409447e-09
it O 0 2.6321456125799614e-09
is O 0 1.921224734857674e-09
not O 0 2.2242008235195954e-09
known O 0 8.168518306206352e-09
whether O 0 1.2494717260835841e-08
they O 0 1.8568771409377405e-08
also O 0 3.610167098599959e-08
protect O 0 1.742687771866258e-07
against O 0 1.3592220057034865e-05
hereditary B-Disease 1 0.9999786615371704
forms I-Disease 1 0.6974612474441528
of I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.3006514012813568

METHODS O 0 4.986576459486969e-05
We O 0 4.397227712615859e-06
enrolled O 0 5.5097498261602595e-06
207 O 0 6.337910690490389e-06
women O 0 1.8829181271939888e-06
with O 0 3.360740493008052e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.0807031685544644e-05
161 O 0 6.534181693496066e-07
of O 0 1.4655505253813317e-07
their O 0 6.760198800748185e-08
sisters O 0 2.057060100923991e-06
as O 0 9.933371103443278e-08
controls O 0 4.822274490834388e-07
in O 0 4.9155659098687465e-08
a O 0 1.4730652253547305e-07
case O 0 9.390805644216016e-07
- O 0 3.5685950479091844e-06
control O 0 2.5814244963839883e-06
study O 0 1.7273180219490314e-06
. O 0 9.509491974313278e-06

All O 0 3.1364234018838033e-06
the O 0 7.004265967225365e-07
patients O 0 2.1507152325739298e-07
carried O 0 2.2251889220115117e-07
a O 0 1.7270710372940812e-07
pathogenic O 0 3.186100229868316e-06
mutation O 0 3.92662599324467e-07
in O 0 5.286362281253787e-08
either O 0 3.531532968281681e-07
BRCA1 O 0 9.986636541725602e-06
( O 0 2.312120983560817e-07
179 O 0 7.747775043753791e-07
women O 0 3.6755272958544083e-07
) O 0 8.568117948470899e-08
or O 0 2.0604085193554056e-07
BRCA2 O 0 2.057333040283993e-05
( O 0 8.7304510998365e-07
28 O 0 3.085888238274492e-05
women O 0 4.105925654585008e-06
) O 0 1.5776200825712294e-06
. O 0 1.3780677363683935e-05

The O 0 8.726025043870322e-06
control O 0 2.462438351358287e-05
women O 0 8.487229479214875e-07
were O 0 4.2748905570988427e-07
enrolled O 0 2.1492266455425124e-07
regardless O 0 9.189162142320129e-08
of O 0 3.776724710746748e-08
whether O 0 1.9747965041005955e-08
or O 0 1.827025997158671e-08
not O 0 9.684309354440757e-09
they O 0 1.6407526004513784e-08
had O 0 2.2507404651150864e-07
either O 0 1.469170911150286e-06
mutation O 0 1.7325166481896304e-05
. O 0 1.825654362619389e-05

Lifetime O 0 4.008998803328723e-05
histories O 0 6.45826867184951e-06
of O 0 2.66636379819829e-06
oral O 0 3.4304324799450114e-05
- O 0 6.158276391943218e-06
contraceptive O 0 9.060535148819326e-07
use O 0 2.3531494974804446e-08
were O 0 4.588020630080791e-08
obtained O 0 8.02891548801199e-08
by O 0 2.615851180109985e-08
interview O 0 1.4225193467609643e-07
or O 0 1.652867531731772e-08
by O 0 8.713888277611659e-09
written O 0 9.40994482334645e-09
questionnaire O 0 1.3071144167042803e-08
and O 0 1.593560305934716e-08
were O 0 9.48919733900766e-08
compared O 0 2.8222427772561787e-07
between O 0 5.174957209419517e-07
patients O 0 2.3866692799856537e-07
and O 0 1.767263597685087e-07
control O 0 5.089007390779443e-05
women O 0 1.107118350773817e-06
, O 0 9.199438721907427e-08
after O 0 1.50509578134006e-07
adjustment O 0 1.8456492512086697e-07
for O 0 1.3339479743024185e-08
year O 0 2.9220471375879242e-08
of O 0 6.251899264952954e-08
birth O 0 2.950672808310628e-07
and O 0 6.054708023839339e-07
parity O 0 6.362009298754856e-05
. O 0 1.1736226952052675e-05

RESULTS O 0 0.00014615661348216236
The O 0 8.469961358059663e-06
adjusted O 0 9.040795703185722e-06
odds O 0 7.355091838689987e-06
ratio O 0 5.294674792821752e-06
for O 0 6.880892760818824e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.6341288617004466e-07
with O 0 9.748767126893654e-09
any O 0 1.417206707543528e-08
past O 0 1.7637590943309078e-08
use O 0 1.1572487856881253e-08
of O 0 9.90179955806525e-08
oral O 0 6.560821020684671e-06
contraceptives O 0 8.927205271902494e-06
was O 0 2.5269944217143347e-06
0 O 0 8.934854122344404e-06
. O 0 9.718462933960836e-06

5 O 0 1.679505112406332e-05
( O 0 5.552118977902865e-07
95 O 0 1.3733689456785214e-06
percent O 0 2.569713046796096e-07
confidence O 0 1.0481405752216233e-06
interval O 0 5.199423753765586e-07
, O 0 1.658080783784044e-08
0 O 0 4.349288929006434e-08
. O 0 2.5198834130435444e-09
3 O 0 1.1858632298356042e-08
to O 0 2.0152435276088454e-09
0 O 0 4.110682993996306e-08
. O 0 1.3361632689168346e-08
8 O 0 5.774236910838226e-07
) O 0 3.6648660284299694e-07
. O 0 3.153955276502529e-06

The O 0 5.192227035877295e-06
risk O 0 5.141514066053787e-06
decreased O 0 8.122672170429723e-07
with O 0 2.487645289761531e-08
increasing O 0 5.897026156276297e-08
duration O 0 1.2779479163782526e-07
of O 0 2.3874267895962475e-08
use O 0 3.591712172124062e-08
( O 0 2.896510586936074e-08
P O 0 1.496602294537297e-06
for O 0 1.1615631123618186e-08
trend O 0 5.867115504543108e-08
, O 0 8.876556378822897e-09
< O 0 1.0176054843213933e-07
0 O 0 5.727117269316295e-08
. O 0 4.99287722277586e-09
001 O 0 2.2495861173865705e-07
) O 0 3.02650282613115e-09
; O 0 1.7524676154678787e-09
use O 0 3.978118279235332e-09
for O 0 8.271809015525378e-09
six O 0 4.131496922354927e-08
or O 0 4.6319468260946906e-09
more O 0 1.5612804382669765e-09
years O 0 9.723994054411378e-09
was O 0 2.5069601505833816e-08
associated O 0 7.423334391631897e-09
with O 0 3.0467743883377807e-09
a O 0 2.133859844377639e-08
60 O 0 1.0981281661770481e-07
percent O 0 9.081897900387048e-08
reduction O 0 5.282129222905496e-07
in O 0 2.8687622943834867e-07
risk O 0 7.974055733939167e-06
. O 0 1.094967683457071e-05

Oral O 0 0.002057743491604924
- O 0 0.00044042340596206486
contraceptive O 0 2.808749741234351e-05
use O 0 6.476275302702561e-07
protected O 0 5.021061951993033e-05
against O 1 0.9999898672103882
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 7.390032124021673e-07
for O 0 5.1225747199623584e-08
carriers O 0 4.0797669242920165e-08
of O 0 6.136463781558632e-08
the O 0 1.0154320762012503e-07
BRCA1 O 0 1.2551012105177506e-06
mutation O 0 2.305510946598588e-07
( O 0 2.1263717897568313e-08
odds O 0 3.568836461909086e-07
ratio O 0 1.0220638557711936e-07
, O 0 1.42291094462621e-08
0 O 0 3.7718582035495274e-08
. O 0 3.334713838398784e-09
5 O 0 3.013020588582549e-08
; O 0 4.201369918632736e-09
95 O 0 7.772234766889596e-08
percent O 0 4.3669196259088494e-08
confidence O 0 1.889682437195006e-07
interval O 0 2.1503664981992188e-07
, O 0 1.302945129566524e-08
0 O 0 2.3415980265895087e-08
. O 0 2.4112960517186366e-09
3 O 0 7.77202391333276e-09
to O 0 1.2247434177936611e-09
0 O 0 2.933036213903506e-08
. O 0 5.324915175464184e-09
9 O 0 1.0686038365292916e-07
) O 0 8.245455873634455e-09
and O 0 8.47355963173868e-09
for O 0 8.420038888345971e-09
carriers O 0 2.0073496642680766e-08
of O 0 4.391015551163946e-08
the O 0 1.7588249079381058e-07
BRCA2 O 0 4.3284694584144745e-06
mutation O 0 3.093310283475148e-07
( O 0 4.2347924278374194e-08
odds O 0 2.584173444120097e-07
ratio O 0 1.1163150759330165e-07
, O 0 2.129017850904802e-08
0 O 0 6.407707786593164e-08
. O 0 4.451637281022158e-09
4 O 0 5.8042722628215415e-08
; O 0 8.313216781630217e-09
95 O 0 1.3701662737730658e-07
percent O 0 3.4700832429734874e-08
confidence O 0 2.9538853141275467e-07
interval O 0 1.9869818856932397e-07
, O 0 1.5655752250154364e-08
0 O 0 3.9508531557430615e-08
. O 0 3.842487661387395e-09
2 O 0 1.8334246121298747e-08
to O 0 2.0926060884107756e-09
1 O 0 4.68005509901559e-08
. O 0 1.6145142112122812e-08
1 O 0 4.819737000616442e-07
) O 0 2.0361437691462925e-07
. O 0 2.060366341538611e-06

CONCLUSIONS O 0 0.0006718016811646521
Oral O 0 0.03369523212313652
- O 0 0.0010326746851205826
contraceptive O 0 1.5908863133518025e-05
use O 0 2.475703695381526e-07
may O 0 1.5264272690274083e-07
reduce O 0 1.4518479929392925e-07
the O 0 5.1766249953288934e-08
risk O 0 1.1081027651016484e-06
of O 0 0.11988943815231323
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.9257145140727516e-06
women O 0 1.9568894060739694e-07
with O 0 2.4355362171490924e-08
pathogenic O 0 2.257495680169086e-06
mutations O 0 1.748777975763005e-07
in O 0 5.05901454062041e-08
the O 0 3.3293014212176786e-07
BRCA1 O 0 3.1869531085249037e-05
or O 0 1.3010179827688262e-05
BRCA2 O 0 0.0007284025195986032
gene O 0 0.00027413901989348233

A O 0 4.190142863080837e-05
Japanese O 0 1.609666651347652e-05
family O 0 1.2237501323397737e-06
with O 0 1.3833234788762638e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.817170401518524e-07
a O 0 5.878910656065273e-07
codon O 0 4.14219539379701e-06
291 O 0 1.4492267155219452e-06
deletion O 0 1.718538783279655e-06
: O 0 1.9298201436868112e-07
a O 0 1.582614146400374e-07
clinical O 0 4.110317604499869e-06
, O 0 2.8865702006442007e-07
biochemical O 0 0.00014725305663887411
, O 0 2.6892478217632743e-06
pathological O 0 0.01075569074600935
, O 0 1.4950317108741729e-06
and O 0 2.336223815291305e-06
genetic O 0 2.930463415395934e-05
report O 0 3.853352609439753e-06
. O 0 2.3858710846980102e-05

We O 0 4.864751645072829e-06
report O 0 6.735403985658195e-07
a O 0 2.121834796753319e-07
Japanese O 0 1.3455243106363923e-06
family O 0 1.9240995641212066e-07
with O 0 4.286969669919927e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9997305274009705
ALD B-Disease 1 1.0
) O 0 7.419232019856281e-07
with O 0 5.2498677405310445e-08
a O 0 8.400199646985129e-08
three O 0 8.160377973354116e-08
base O 0 3.9997820522330585e-07
pair O 0 8.158087894116761e-07
deletion O 0 1.7450856830691919e-06
( O 0 1.7948660513411596e-07
delGAG O 0 6.9426369009306654e-06
291 O 0 8.699234967934899e-07
) O 0 4.916766371820813e-08
in O 0 1.0777946357620749e-07
the O 0 3.697454985740478e-06
ALD B-Disease 1 1.0
gene O 0 0.00013074798334855586
. O 0 5.2974959544371814e-05

A O 0 9.251676601707004e-06
variety O 0 1.1144052223244216e-06
of O 0 8.287839818876819e-07
phenotypes O 0 8.072991477092728e-06
were O 0 3.1306328196478717e-07
observed O 0 3.2297634788847063e-07
within O 0 1.8434538162637182e-07
this O 0 1.3032699541781767e-07
family O 0 9.446774811294745e-07
. O 0 9.158642569673248e-06

While O 0 8.410590453422628e-06
the O 0 1.691059651420801e-06
proband O 0 0.00021304569963831455
( O 0 3.2027443808146927e-07
patient O 0 1.3478614846462733e-07
1 O 0 1.4941979316063225e-06
) O 0 7.33227878413345e-08
was O 0 4.341684984865424e-07
classified O 0 1.1116596709825899e-07
as O 0 4.0527460498651635e-08
having O 0 1.1352437212508448e-07
a O 0 9.357614061400454e-08
rare O 0 1.6860501261817262e-07
intermediate O 0 1.2328977391007356e-05
type O 0 2.1601472326437943e-06
of O 0 2.1363698579079937e-06
adult O 0 1.6086076357169077e-05
cerebral O 0 0.03601762279868126
and O 0 2.363552766837529e-06
cerebello O 1 0.9991828799247742
- O 1 0.9390677809715271
brain O 0 0.00172458216547966
stem O 0 1.2245942571098567e-06
forms O 0 4.3083946366095915e-07
, O 0 6.642341787710393e-08
his O 0 1.4513592816456367e-07
younger O 0 1.1832685231638607e-05
brother O 0 1.9933979274355806e-05
( O 0 1.642133895529696e-07
patient O 0 1.1745196104584466e-07
2 O 0 2.6917318791674916e-06
) O 0 6.218647286004853e-08
and O 0 1.8100926979514043e-07
nephew O 0 0.0002611567033454776
( O 0 4.897597705166845e-07
patient O 0 7.514566959798685e-07
3 O 0 9.476783816353418e-06
) O 0 3.164389852372551e-07
had O 0 1.1986841172983986e-06
a O 0 8.668660484545399e-06
childhood O 0 0.24971559643745422
ALD B-Disease 1 1.0
type O 1 0.9999427795410156
. O 0 0.0018464148743078113

Another O 0 7.788559014443308e-05
nephew O 0 0.0034207948483526707
( O 0 1.5122205923034926e-06
patient O 0 9.970021892513614e-07
4 O 0 3.8321263673424255e-06
) O 0 5.5000512588776473e-08
of O 0 9.016413571316662e-08
patient O 0 2.7822611059491464e-07
1 O 0 4.447720584721537e-06
was O 0 8.855774922267301e-07
classified O 0 1.61441334967094e-07
as O 0 8.84323512195806e-08
having O 0 3.4004941085186147e-07
an O 0 1.6301630978432513e-07
adolescent O 0 2.02813207579311e-05
form O 0 1.8334376363782212e-05
. O 0 6.475644477177411e-05

The O 0 1.2610601515916642e-05
tau O 0 2.165526893804781e-05
level O 0 2.5623305646149674e-06
in O 0 6.997869661518052e-08
the O 0 7.980364102877502e-08
cerebrospinal O 0 6.677314104308607e-06
fluid O 0 2.560794382588938e-05
( O 0 2.6651005100575276e-06
CSF O 1 0.9997109770774841
) O 0 1.1759654938714448e-07
in O 0 2.0181754933901175e-08
patient O 0 4.1713967391387996e-08
1 O 0 8.03948637440044e-07
was O 0 2.2069208682751196e-07
as O 0 1.4326575481504733e-08
high O 0 1.3700277179395925e-07
as O 0 5.9559952525489734e-09
that O 0 2.2655355369494146e-09
of O 0 3.233942535985079e-08
patients O 0 1.0488789570217705e-07
with O 0 2.0980398858228e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999866485595703
( O 0 1.5266499531207955e-06
AD B-Disease 0 9.619455522624776e-05
) O 0 1.4658330655947793e-06
. O 0 5.73984152651974e-06

His O 0 4.743022145703435e-05
brain O 0 0.00017734475841280073
magnetic O 0 3.290648601250723e-05
resonance O 0 7.130428275559098e-05
image O 0 2.435362148389686e-05
( O 0 2.8244849090697244e-06
MRI O 0 0.01676284149289131
) O 0 1.260221324628219e-06
showed O 0 6.911186119396007e-06
abnormalities B-Disease 1 0.5816663503646851
in I-Disease 0 3.528536751673528e-07
the I-Disease 0 1.5415171219501644e-06
bilateral I-Disease 0 0.3023313283920288
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999935626983643
and O 0 0.0019132376182824373
brain O 1 0.9981269240379333
stem O 0 6.625198693654966e-06
, O 0 2.9267994250403717e-08
but O 0 8.034272802603937e-09
not O 0 4.762247485246007e-09
in O 0 1.2599104870503197e-08
the O 0 3.4968596196449653e-07
cerebral O 1 0.9984949827194214
white O 0 3.4343731840635883e-06
matter O 0 1.2218609981573536e-06
, O 0 5.186963036862835e-08
where O 0 3.605384435445558e-08
marked O 0 1.4069860299059656e-07
reductions O 0 4.466651546408684e-07
of O 0 4.281778274162207e-07
the O 0 6.623093327107199e-07
cerebral O 0 0.0002081734564853832
blood O 0 1.982651127718782e-07
flow O 0 2.157661072033079e-07
and O 0 3.733995868060447e-07
oxygen O 0 2.236346063000383e-06
metabolism O 0 3.073348125326447e-05
were O 0 9.507549947329608e-08
clearly O 0 1.680079293464587e-07
demonstrated O 0 5.716192390536889e-07
by O 0 7.61744445298973e-08
positron O 0 1.7768436464393744e-06
emission O 0 1.6836717122714617e-06
tomography O 0 5.860365945409285e-06
( O 0 5.780656238130177e-07
PET O 0 2.255395429529017e-06
) O 0 9.263438869311358e-07
. O 0 8.21834782982478e-06

In O 0 1.2949682286489406e-06
patients O 0 4.0371199361288745e-07
2 O 0 1.3380591781242401e-06
and O 0 1.0376879089335489e-07
3 O 0 7.454693786712596e-07
, O 0 2.9488546715583652e-08
the O 0 3.031952644505509e-08
autopsy O 0 1.6861773133314273e-07
findings O 0 1.7259645801459556e-07
showed O 0 5.761288548455923e-07
massive O 0 0.00018970384553540498
demyelination B-Disease 1 1.0
of I-Disease 1 0.7984970211982727
the I-Disease 1 0.5483945608139038
cerebral I-Disease 1 0.9999998807907104
white I-Disease 0 1.0993412615789566e-05
matter I-Disease 0 6.477171154983807e-07
with O 0 3.003874127216477e-08
sparing O 0 2.017818303556851e-07
of O 0 8.158759357002054e-08
the O 0 4.889533329333062e-07
U O 1 0.9849193096160889
- O 1 0.9037914276123047
fibers O 0 3.378658584551886e-05
, O 0 1.5952548437780933e-07
compatible O 0 2.304243480466539e-06
with O 0 1.820385442385941e-08
the O 0 6.776205907499389e-08
findings O 0 2.906794804857782e-07
of O 0 1.7962273659577477e-06
childhood O 0 0.033812765032052994
ALD B-Disease 1 1.0
. O 0 0.0007487215916626155

Oleic O 0 0.006094713229686022
and O 0 4.3215055484324694e-05
erucic O 0 0.36637553572654724
acids O 0 1.5972360415617004e-05
( O 0 9.708047628009808e-07
Lorenzos O 0 4.471342981560156e-05
Oil O 0 2.4060013856797013e-06
) O 0 4.771186823404605e-08
were O 0 4.259702635067697e-08
administered O 0 3.254517011441749e-08
to O 0 7.75730235602623e-09
patients O 0 1.0122700011550023e-08
1 O 0 1.2102493940346903e-07
and O 0 2.738556048598184e-08
4 O 0 2.11409258099593e-07
, O 0 9.122606670075584e-09
but O 0 4.046811774571779e-09
sufficient O 0 6.328636459329573e-08
effectiveness O 0 2.971963795062038e-07
was O 0 2.0092731745080528e-07
not O 0 6.691413290127457e-08
obtained O 0 1.4760495332666324e-06
. O 0 6.585997198271798e-06

The O 0 7.608442501805257e-06
findings O 0 4.373919637146173e-06
in O 0 9.067358774927925e-08
this O 0 2.600697790455797e-08
family O 0 1.595902432427465e-08
suggest O 0 2.1079337386709085e-08
that O 0 7.90429943720028e-09
delGAG291 O 0 4.570443081775011e-07
is O 0 1.1764910823330865e-08
part O 0 1.1014651413177035e-08
of O 0 3.967156558815077e-08
the O 0 7.146064717744594e-08
cause O 0 9.567788765707519e-07
of O 0 7.596414889121661e-06
Japanese O 0 0.2222791314125061
ALD B-Disease 1 1.0
with O 0 5.477184458868578e-06
phenotypic O 0 0.00035719378502108157
variations O 0 6.079808736103587e-05
. O 0 2.3368533220491372e-05

Moreover O 0 1.0642794222803786e-05
, O 0 4.3277330519231327e-07
although O 0 1.1543271227765217e-07
the O 0 4.805783504480132e-08
scale O 0 3.2163191576728423e-07
of O 0 4.983479584552697e-08
the O 0 2.4756275252002524e-08
study O 0 1.2835353224716073e-08
is O 0 4.580035461998477e-09
limited O 0 3.051882302429476e-08
, O 0 1.73370739986467e-08
there O 0 2.2892930218176843e-08
is O 0 7.830859516388955e-09
a O 0 2.8262308049420426e-08
possibility O 0 7.514595381508116e-07
that O 0 5.091394328360366e-08
PET O 0 7.173856033659831e-07
can O 0 1.0381511117429909e-07
detect O 0 5.610741027339827e-06
an O 0 4.238065116624057e-07
insidious B-Disease 0 0.0281368400901556
lesion I-Disease 0 0.002030284609645605
which O 0 1.8529949841195048e-07
is O 0 7.242985589073214e-08
undetectable O 0 1.120773390539398e-06
by O 0 4.8378531403159286e-08
computed O 0 1.0301444035576424e-06
tomogram O 0 1.7106480299844407e-05
( O 0 4.266928215201915e-07
CT O 0 0.10371232032775879
) O 0 1.6943999980867375e-07
or O 0 1.1355165696613767e-07
MRI O 0 6.867756383144297e-06
analysis O 0 1.462782819316999e-07
, O 0 3.652520774721779e-08
and O 0 1.880629874051465e-08
that O 0 3.0992610700053547e-09
the O 0 1.6043594897041658e-08
higher O 0 9.772916342853932e-08
level O 0 2.9955671720927057e-07
of O 0 7.270280377724703e-08
tau O 0 2.7977199579254375e-07
reflects O 0 9.439713899439539e-09
the O 0 8.05970579165205e-09
process O 0 3.737383380553183e-08
of O 0 2.7519979539647466e-07
neuronal B-Disease 0 0.0012632699217647314
degeneration I-Disease 1 0.9999994039535522
in O 0 6.05374516453594e-05
ALD B-Disease 1 1.0
. O 0 0.0006668783025816083

Lorenzos O 0 0.0006573588470928371
Oil O 0 6.676129487459548e-06
should O 0 1.6228818822128233e-07
be O 0 2.7879176300871222e-08
given O 0 1.8091464326630557e-08
in O 0 8.304833265526668e-09
the O 0 3.335688703032247e-08
early O 0 3.889201138917997e-07
stage O 0 2.4081730316538597e-06
. O 0 8.594040536991088e-07
. O 0 6.633329576288816e-06

Nonsense O 0 0.00014515483053401113
mutation O 0 5.258819783193758e-06
in O 0 2.743172728969512e-07
exon O 0 2.3709733341092942e-06
4 O 0 9.71429926721612e-07
of O 0 2.2892082540693082e-07
human O 0 3.1285705404116015e-07
complement O 0 1.6272629181912635e-06
C9 O 1 0.8487609028816223
gene O 0 3.8570220795008936e-07
is O 0 3.897785205708715e-08
the O 0 5.543304837374308e-08
major O 0 3.0298778597170894e-07
cause O 0 7.825664738447813e-07
of O 0 2.6082791464432376e-06
Japanese O 0 0.00015941059973556548
complement B-Disease 1 0.7048019170761108
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999985694885254
. O 0 0.00011226331844227389

Deficiency B-Disease 1 0.9998764991760254
of I-Disease 0 3.434891550568864e-05
the I-Disease 0 7.718349479546305e-06
ninth I-Disease 0 3.585008016671054e-05
component I-Disease 0 6.804427243878308e-07
of I-Disease 0 2.70423640813533e-07
human I-Disease 0 1.080054161661792e-07
complement I-Disease 0 7.173274525484885e-07
( O 0 4.1482417145743966e-07
C9 O 1 0.9999746084213257
) O 0 7.29767748453014e-08
is O 0 1.6636054311902626e-08
the O 0 3.648510116249781e-08
most O 0 4.407486997592969e-08
common O 0 2.1215293600107543e-05
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.9426862485925085e-07
Japan O 0 2.8399787765920337e-07
but O 0 2.6495550642380294e-08
is O 0 5.451036511061602e-09
rare O 0 1.1592127258097662e-08
in O 0 7.2878121315511635e-09
other O 0 1.1247482056830904e-08
countries O 0 4.796296693143631e-08
. O 0 3.070987759201671e-06

We O 0 2.6439975044922903e-06
studied O 0 1.5849944929868798e-06
the O 0 3.0157227826066446e-08
molecular O 0 3.006838085184427e-07
basis O 0 2.1948289941065013e-07
of O 0 2.1676053165720077e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9997825026512146
in O 0 2.061086519233868e-07
four O 0 8.861637184054416e-07
Japanese O 0 3.414277307456359e-05
C9 B-Disease 1 1.0
- I-Disease 1 0.9911317229270935
deficient I-Disease 0 0.004928895737975836
patients O 0 1.266352342099708e-06
who O 0 4.67190375275095e-07
had O 0 1.642511233512778e-05
suffered O 1 0.9999860525131226
from O 1 0.9798751473426819
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.019138384610414505

Direct O 0 6.397354354703566e-06
sequencing O 0 1.0540332368691452e-05
of O 0 3.005665121236234e-06
amplified O 0 3.483814361970872e-05
C9 O 0 0.001045521697960794
cDNA O 0 3.898286649928195e-06
and O 0 3.4679464988585096e-07
DNA O 0 8.765883308115008e-07
revealed O 0 8.605695143160119e-07
a O 0 2.2236977770262456e-07
nonsense O 0 2.357872517677606e-06
substitution O 0 3.093914301643963e-06
( O 0 1.4923864455340663e-06
CGA O 0 6.787263555452228e-05
- O 0 5.2612271247198805e-05
- O 0 4.1527615394443274e-05
> O 0 1.9916345991077833e-05
TGA O 0 3.533909693942405e-05
) O 0 2.679757642454206e-07
at O 0 8.527982799932943e-07
codon O 0 9.55095060817257e-07
95 O 0 3.316204413295054e-07
in O 0 4.7026130545191336e-08
exon O 0 3.604415610425349e-07
4 O 0 2.559147844749532e-07
in O 0 2.1107982917101253e-08
the O 0 1.1483113127042088e-07
four O 0 2.789492555166362e-06
C9 B-Disease 1 0.999921441078186
- I-Disease 0 0.0008289561956189573
deficient I-Disease 0 7.251789793372154e-05
individuals O 0 1.8690850538405357e-06
. O 0 1.6806041458039545e-05

An O 0 7.64776996220462e-06
allele O 0 4.0461007301928475e-05
- O 0 1.1358743904565927e-05
specific O 0 7.827941885807377e-07
polymerase O 0 6.006850526318885e-06
chain O 0 6.029137011864805e-07
reaction O 0 2.436164265873231e-07
system O 0 3.269621231538622e-07
designed O 0 2.3786617475707317e-07
to O 0 1.7563500875894533e-08
detect O 0 2.445073903345474e-07
exclusively O 0 4.8301913579962275e-08
only O 0 7.926991507645198e-09
one O 0 3.254794878060352e-09
of O 0 5.329060748238135e-09
the O 0 1.1700372226641775e-08
normal O 0 3.884603927417629e-08
and O 0 1.4543695137092527e-08
mutant O 0 1.310626203121501e-07
alleles O 0 4.526255636960741e-08
indicated O 0 2.317144520702641e-08
that O 0 3.154655203729817e-09
all O 0 6.017392362167584e-09
the O 0 1.2576512276041285e-08
four O 0 2.4975006951422074e-08
patients O 0 6.550657349890798e-09
were O 0 9.477310491945445e-09
homozygous O 0 1.0266612093801086e-07
for O 0 1.2647910274665719e-08
the O 0 3.828684924656045e-08
mutation O 0 1.034908834185444e-07
in O 0 5.099033018041155e-08
exon O 0 5.293960612107185e-07
4 O 0 4.3714115349757776e-07
and O 0 3.155126293563626e-08
that O 0 6.866942126038111e-09
the O 0 2.8316698319486022e-08
parents O 0 1.2805374538515935e-08
of O 0 1.0890693147302954e-07
patient O 0 3.6216576404513035e-07
2 O 0 4.921955223835539e-06
were O 0 3.700989964272594e-06
heterozygous O 0 1.7336273231194355e-05
. O 0 1.6854673958732747e-05

The O 0 6.757292339898413e-06
common O 0 2.0639536160160787e-06
mutation O 0 9.93184357866994e-07
at O 0 7.414726042043185e-07
codon O 0 8.451254416286247e-07
95 O 0 4.897551093563379e-07
in O 0 6.10210264540001e-08
exon O 0 8.882299198376131e-07
4 O 0 3.8216521147660387e-07
might O 0 7.107582433718562e-08
be O 0 3.0944548257139104e-08
responsible O 0 2.1203945266279334e-07
for O 0 6.09113754990176e-08
most O 0 2.997744559252169e-07
Japanese O 0 0.00013829825911670923
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.999968409538269
. O 0 4.3378336158639286e-06
. O 0 1.7212047168868594e-05

BRCA1 O 0 4.2357423808425665e-05
required O 0 1.2628139529624605e-06
for O 0 7.131671964089037e-07
transcription O 0 8.084548426268157e-06
- O 0 1.582971162861213e-05
coupled O 0 7.327452294703107e-06
repair O 0 1.1590993381105363e-05
of O 0 8.016205356398132e-06
oxidative O 0 0.0762363001704216
DNA O 0 6.623664376093075e-05
damage O 0 0.00022873119451105595
. O 0 3.942945841117762e-05

The O 0 0.00020642540766857564
breast B-Disease 1 0.9999918937683105
and I-Disease 1 0.9987900853157043
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.7679167985916138
gene O 0 2.6540228645899333e-05
BRCA1 O 0 7.05108541296795e-05
encodes O 0 3.0674607387481956e-06
a O 0 1.5710127172496868e-06
zinc O 0 4.041580905322917e-05
finger O 0 4.2048777686432e-06
protein O 0 8.542829732505197e-07
of O 0 4.2637756791918946e-07
unknown O 0 1.8801906662702095e-06
function O 0 3.002934590767836e-06
. O 0 4.862613423028961e-06

Association O 0 1.769583650457207e-05
of O 0 3.986274350609165e-06
the O 0 1.838528987718746e-06
BRCA1 O 0 2.975436700580758e-06
protein O 0 3.5602460002337466e-07
with O 0 4.018431809527101e-08
the O 0 1.2046622543948615e-07
DNA O 0 1.259028408640006e-06
repair O 0 2.869834588636877e-06
protein O 0 2.085973846988054e-06
Rad51 O 0 4.241178248776123e-05
and O 0 7.702886506422146e-08
changes O 0 6.112901473898091e-08
in O 0 9.991017790866863e-09
the O 0 1.2009659045020271e-08
phosphorylation O 0 2.702389778619363e-08
and O 0 2.068827065215828e-08
cellular O 0 4.922462721879128e-07
localization O 0 5.697220331057906e-07
of O 0 4.485767135520291e-08
the O 0 7.055741946260241e-08
protein O 0 9.45323037626622e-08
after O 0 1.0134797179262023e-07
exposure O 0 1.2495662815581454e-07
to O 0 3.5693666688985104e-08
DNA O 0 2.5537237888784148e-06
- O 0 7.426661341014551e-06
damaging O 0 1.365593561786227e-05
agents O 0 7.217747821641751e-08
are O 0 1.7663580820226343e-08
consistent O 0 3.4431909057275334e-07
with O 0 1.6407964764653116e-08
a O 0 6.266918717301451e-08
role O 0 2.2262226195834955e-07
for O 0 2.3071166310728586e-07
BRCA1 O 0 4.025688213005196e-06
in O 0 3.17294791329914e-07
DNA O 0 5.375915407057619e-06
repair O 0 3.484954504529014e-05
. O 0 2.4896613467717543e-05

Here O 0 8.012612852326129e-06
, O 0 1.9132488660034142e-07
it O 0 1.8835448756249207e-08
is O 0 1.2993143450046318e-08
shown O 0 3.088298683451285e-08
that O 0 2.8957870767953864e-08
mouse O 0 1.0710101605582167e-06
embryonic O 0 1.7071240563382162e-06
stem O 0 9.376514071846032e-07
cells O 0 9.831236411628197e-07
deficient B-Disease 0 1.6983211708065937e-06
in I-Disease 0 9.378555887451512e-08
BRCA1 I-Disease 0 2.399997129032272e-06
are O 0 6.050217393749335e-08
defective O 0 4.02380737796193e-06
in O 0 6.096379223663462e-08
the O 0 3.8046330530505656e-08
ability O 0 2.2157882639817217e-08
to O 0 1.1162486046600861e-08
carry O 0 8.709056942279858e-08
out O 0 8.361404013612628e-08
transcription O 0 2.088654809995205e-06
- O 0 3.442580918999738e-06
coupled O 0 3.533234348651604e-06
repair O 0 4.121079655305948e-06
of O 0 9.379170364809397e-07
oxidative O 0 9.115184366237372e-05
DNA O 0 8.07468495622743e-06
damage O 0 6.376428791554645e-05
, O 0 3.108065982360131e-07
and O 0 4.345905892932933e-07
are O 0 1.4592883701425308e-07
hypersensitive O 0 6.1092459873179905e-06
to O 0 1.309984014596921e-07
ionizing O 0 0.0001480022183386609
radiation O 0 0.00011601024016272277
and O 0 1.0665507943485864e-06
hydrogen O 0 9.085020792554133e-06
peroxide O 0 0.0005569338682107627
. O 0 4.921223080600612e-05

These O 0 1.010794221656397e-06
results O 0 1.5109043260963517e-06
suggest O 0 2.816921380599524e-07
that O 0 5.9328456814000674e-08
BRCA1 O 0 3.530418553054915e-06
participates O 0 5.553532673729933e-07
, O 0 4.1327425037707144e-08
directly O 0 3.8587430140069046e-08
or O 0 5.233291489048497e-08
indirectly O 0 1.2876429877906048e-07
, O 0 2.5517142177022833e-08
in O 0 4.181226742616673e-08
transcription O 0 1.1938890338569763e-06
- O 0 1.9244992017775076e-06
coupled O 0 3.548538415998337e-06
repair O 0 4.682756753027206e-06
of O 0 2.2822400751465466e-06
oxidative O 0 0.0006080008461140096
DNA O 0 6.260506324906601e-06
damage O 0 1.482746210967889e-05
. O 0 1.9004007754119812e-06
. O 0 8.841901944833808e-06

Truncation O 0 0.00036548703792504966
mutations O 0 1.4965429727453738e-05
in O 0 4.19462224954259e-07
the O 0 6.667143566119194e-07
transactivation O 0 3.263304097345099e-05
region O 0 9.695731932879426e-07
of O 0 1.983072024813737e-06
PAX6 O 0 0.018146125599741936
result O 0 1.744002588566218e-06
in O 0 2.9305402904356015e-07
dominant O 0 0.0006150244735181332
- O 0 1.2822703865822405e-05
negative O 0 2.337056912438129e-06
mutants O 0 5.1969509513583034e-05
. O 0 1.3505803508451208e-05

PAX6 O 0 0.11496005207300186
is O 0 8.329336083079397e-07
a O 0 2.9029357051513216e-07
transcription O 0 3.325598072478897e-07
factor O 0 1.2715594266410335e-07
with O 0 2.984024405350283e-08
two O 0 6.83146339497398e-08
DNA O 0 3.984944498824916e-07
- O 0 5.491486376740795e-07
binding O 0 3.5790100127996993e-07
domains O 0 1.1026107813449926e-06
( O 0 1.6870617969289015e-07
paired O 0 6.84496228586795e-07
box O 0 6.115117798799474e-07
and O 0 3.493499605156103e-07
homeobox O 0 7.636116606590804e-06
) O 0 9.968654524072917e-08
and O 0 2.554254194819805e-07
a O 0 1.3756260841546464e-06
proline O 0 4.146378341829404e-05
- O 0 8.596449333708733e-05
serine O 0 8.363348752027377e-05
- O 0 9.463536844123155e-05
threonine O 0 0.00015592436830047518
( O 0 1.832975840443396e-06
PST O 1 0.9989690780639648
) O 0 1.3399375120570767e-06
- O 0 1.0838335583684966e-05
rich O 0 5.968403456790838e-06
transactivation O 0 0.00022113959130365402
domain O 0 2.1883402951061726e-05
. O 0 2.184637196478434e-05

PAX6 O 1 0.9999809265136719
regulates O 0 0.0017724513309076428
eye O 1 0.8397022485733032
development O 0 2.437437251501251e-05
in O 0 3.703563606904936e-07
animals O 0 1.1178171632764133e-07
ranging O 0 9.824534572544508e-07
from O 0 5.838748862174725e-08
jellyfish O 0 4.7280114046088784e-08
to O 0 2.1991068521742818e-08
Drosophila O 0 5.362180672818795e-07
to O 0 9.47850722354815e-08
humans O 0 4.339492534199962e-06
. O 0 1.1677980182867032e-05

Heterozygous O 0 3.717528670676984e-05
mutations O 0 4.698686552728759e-06
in O 0 2.125143794273754e-07
the O 0 1.6703785377103486e-07
human O 0 4.09436864856616e-07
PAX6 O 0 8.550046186428517e-05
gene O 0 1.9381624838388234e-07
result O 0 1.6515983247700206e-07
in O 0 3.111856017312675e-08
various O 0 1.0574522946171783e-07
phenotypes O 0 3.3568260278116213e-06
, O 0 1.0202719380458802e-07
including O 0 5.668161406902072e-07
aniridia B-Disease 1 1.0
, O 0 0.00011798251944128424
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999997615814209
, O 0 3.855182967527071e-06
autosomal B-Disease 1 0.9688030481338501
dominant I-Disease 1 0.9999994039535522
keratitis I-Disease 1 1.0
, O 0 1.8181588529841974e-05
and O 0 4.07623520004563e-05
familial B-Disease 1 0.9999426603317261
foveal I-Disease 1 0.9999998807907104
dysplasia I-Disease 1 1.0
. O 0 0.15645760297775269

It O 0 1.4489158957076143e-06
is O 0 1.6384672107960796e-07
believed O 0 3.21052112894904e-07
that O 0 1.712355945926447e-08
the O 0 6.210515834936814e-08
mutated O 0 5.032941885474429e-07
allele O 0 2.189162842114456e-06
of O 0 1.0864764590223785e-06
PAX6 O 0 0.0013070286950096488
produces O 0 3.616018489083217e-07
an O 0 3.063540887637828e-08
inactive O 0 4.5667616177524906e-07
protein O 0 1.0804678822751157e-06
and O 0 1.567947379044199e-06
aniridia B-Disease 1 1.0
is O 0 3.975898437147407e-07
caused O 0 7.776266102155205e-07
due O 0 6.436284820665605e-07
to O 0 2.4763079409240163e-07
genetic O 0 6.47371507511707e-06
haploinsufficiency O 0 0.00013691525964532048
. O 0 1.7794123778003268e-05

However O 0 3.1497982035944005e-06
, O 0 3.080815815792448e-07
several O 0 1.0303158148872171e-07
truncation O 0 3.4450968087185174e-06
mutations O 0 5.996909067107481e-07
have O 0 3.197095210794032e-08
been O 0 3.4923264280450894e-08
found O 0 7.531697043816621e-09
to O 0 7.46224593228817e-09
occur O 0 3.0109870152728035e-08
in O 0 1.5069694825342594e-08
the O 0 1.0680454920475313e-07
C O 0 0.0005070772604085505
- O 0 5.89399496675469e-06
terminal O 0 2.2519113827002e-06
half O 0 1.5426509492044715e-07
of O 0 3.371017385234154e-07
PAX6 O 0 0.036963704973459244
in O 0 9.31604873244396e-08
patients O 0 1.3007320376345888e-07
with O 0 1.3854938174517883e-07
Aniridia B-Disease 1 1.0
resulting O 0 1.9694380171131343e-06
in O 0 3.7273174768870376e-08
mutant O 0 1.6415077652709442e-07
proteins O 0 6.008263664369906e-09
that O 0 2.6853812506999475e-09
retain O 0 1.0102585434879074e-07
the O 0 6.527137230705193e-08
DNA O 0 3.138997897167428e-07
- O 0 1.9886407187641453e-07
binding O 0 3.967965866991108e-08
domains O 0 5.515725476357147e-08
but O 0 6.6839866974532924e-09
have O 0 1.0790283333506068e-08
lost O 0 3.922146447621344e-07
most O 0 2.0512949561179994e-08
of O 0 1.0885418078032671e-07
the O 0 7.37872937861539e-07
transactivation O 0 5.357990812626667e-05
domain O 0 1.0096581718244124e-05
. O 0 1.3697923350264318e-05

It O 0 3.8797693946435174e-07
is O 0 2.265480603114156e-08
not O 0 1.1507642838637366e-08
clear O 0 6.693940690638556e-08
whether O 0 2.8084013337092983e-08
such O 0 3.686317739948208e-08
mutants O 0 1.2190269444545265e-05
really O 0 1.7431162859793403e-06
behave O 0 4.674252238601184e-07
as O 0 1.0116836079987479e-07
loss O 0 7.874813832131622e-07
- O 0 6.618187171625323e-07
of O 0 2.3686651218213228e-07
- O 0 1.5386589211630053e-06
function O 0 2.263159757376343e-07
mutants O 0 9.212570830641198e-07
as O 0 5.469462749374543e-08
predicted O 0 7.17733200872317e-07
by O 0 4.6132660713738005e-07
haploinsufficiency O 0 9.991278784582391e-05
. O 0 2.2886502847541124e-05

Contrary O 0 5.279487595544197e-06
to O 0 1.1770156760348982e-07
this O 0 1.9142794016602238e-08
theory O 0 2.1024293062055222e-07
, O 0 2.056701298158714e-08
our O 0 2.901022178036783e-08
data O 0 3.5393071584621794e-08
showed O 0 1.5773155226384006e-08
that O 0 4.45788250758028e-09
these O 0 9.019850644165217e-09
mutants O 0 5.899815391785523e-07
are O 0 2.3701852924773448e-08
dominant O 0 3.966653366660466e-06
- O 0 5.676535579368647e-07
negative O 0 1.0641170433700609e-07
in O 0 5.779394385285741e-08
transient O 0 1.2491165080064093e-06
transfection O 0 2.229276560683502e-06
assays O 0 4.135148117256904e-07
when O 0 6.19054034700639e-08
they O 0 3.2888191725533034e-08
are O 0 4.6153520116831714e-08
coexpressed O 0 4.145337243244285e-06
with O 0 1.5342470760515425e-07
wild O 0 3.69118720300321e-06
- O 0 6.234528700588271e-05
type O 0 0.0004789978265762329
PAX6 O 1 0.9992759823799133
. O 0 8.568770135752857e-05

We O 0 6.128281256678747e-06
found O 0 3.4337568877162994e-07
that O 0 1.9830400432852002e-08
the O 0 1.1054645199237711e-07
dominant O 0 8.133568917401135e-05
- O 0 1.3366166058403905e-06
negative O 0 9.650919707837602e-08
effects O 0 1.1576149745451403e-06
result O 0 1.807332807857165e-07
from O 0 2.6653591334024895e-08
the O 0 2.867836990105843e-08
enhanced O 0 1.7971424881579878e-07
DNA O 0 6.486851589215803e-08
binding O 0 2.6962117871676128e-08
ability O 0 4.94071983325739e-08
of O 0 1.281512709283561e-07
these O 0 2.505048826151324e-07
mutants O 0 1.9238466848037206e-05
. O 0 7.110997103154659e-06

Kinetic O 0 5.688007877324708e-05
studies O 0 1.313727466367709e-06
of O 0 3.970192494762159e-07
binding O 0 9.272118290937215e-07
and O 0 2.5752279952939716e-07
dissociation O 0 1.651963657423039e-06
revealed O 0 4.076959498888755e-07
that O 0 9.740588780005055e-09
various O 0 3.457629205172452e-08
truncation O 0 3.036281441382016e-06
mutants O 0 1.3528133422369137e-06
have O 0 4.852852697467824e-08
3 O 0 6.20446542143327e-07
- O 0 4.794449637302023e-07
5 O 0 5.060197167949809e-07
- O 0 3.4774512869262253e-07
fold O 0 2.3644786040222243e-07
higher O 0 8.735708689755484e-08
affinity O 0 1.2401763171965285e-08
to O 0 5.318662843478705e-09
various O 0 1.0883606904599219e-08
DNA O 0 3.6944477699307754e-08
- O 0 2.011036137616884e-08
binding O 0 7.0445245192729544e-09
sites O 0 8.395967476815258e-09
when O 0 5.141130632324575e-09
compared O 0 8.951261953882295e-09
with O 0 4.353585936200943e-09
the O 0 5.2399634853372845e-08
wild O 0 1.0081794243887998e-06
- O 0 5.01093882121495e-06
type O 0 2.1831645426573232e-05
PAX6 O 0 0.3258967399597168
. O 0 3.589602783904411e-05

These O 0 1.3315224123289227e-06
results O 0 1.6398474826928577e-06
provide O 0 1.287807691596754e-07
a O 0 6.725795032025417e-08
new O 0 1.1583036041429295e-07
insight O 0 3.4776635970956704e-07
into O 0 1.0262456662246677e-08
the O 0 8.774680537726454e-09
role O 0 2.817500721619126e-08
of O 0 7.641338584107871e-08
mutant O 0 4.513196472544223e-06
PAX6 O 0 0.0008661356987431645
in O 0 1.3815805459671537e-06
causing O 0 0.0001667982287472114
aniridia B-Disease 1 0.9999988079071045
. O 0 2.1170768377487548e-05
. O 0 4.110049849259667e-05

Reversal O 0 0.0002445539284963161
of O 0 0.00021701116929762065
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.9161813855171204
excellent O 1 0.8867082595825195
neuropsychologic O 0 0.2178352177143097
outcome O 0 1.630551923881285e-05
in O 0 1.628867067893225e-07
very B-Disease 0 2.063804004137637e-06
- I-Disease 0 3.364427902852185e-05
long I-Disease 0 1.7494314306532033e-05
- I-Disease 1 0.9093199372291565
chain I-Disease 1 0.5330355763435364
acyl I-Disease 1 0.9985672235488892
- I-Disease 1 0.9999997615814209
coenzyme I-Disease 1 0.9999942779541016
A I-Disease 1 0.999981164932251
dehydrogenase I-Disease 1 0.9948699474334717
deficiency I-Disease 1 0.998837411403656
. O 0 2.429342748655472e-05

Very B-Disease 0 8.129932393785566e-05
- I-Disease 0 0.002591883996501565
long I-Disease 0 3.63961880793795e-05
- I-Disease 0 0.29383739829063416
chain I-Disease 0 0.0005526732420548797
acyl I-Disease 0 0.0019716545939445496
- I-Disease 1 0.992483913898468
coenzyme I-Disease 0 0.029692262411117554
A I-Disease 0 0.00029945099959149957
dehydrogenase I-Disease 0 1.2654115380428266e-05
( I-Disease 0 4.7146295401034877e-07
VLCAD I-Disease 1 0.9993521571159363
) I-Disease 0 3.4190984479209874e-06
deficiency I-Disease 1 0.9829379916191101
is O 0 1.5204560099846276e-07
a O 0 7.704883842052368e-07
disorder O 0 0.004491853062063456
of O 0 2.6845382308238186e-06
fatty O 0 1.8841108158085262e-06
acid O 0 9.596510608389508e-07
beta O 0 8.742757131585677e-07
oxidation O 0 1.044742035105628e-07
that O 0 1.0244640691325912e-08
reportedly O 0 3.8224612808335223e-07
has O 0 3.0266022577052354e-08
high O 0 8.537031703781395e-07
rates O 0 4.964686013408937e-07
of O 0 7.680614544369746e-07
morbidity O 0 7.423661736538634e-05
and O 0 2.830033736245241e-06
mortality O 0 6.354461220325902e-05
. O 0 1.6318957932526246e-05

We O 0 1.9097701624559704e-06
describe O 0 4.6416420218520216e-07
the O 0 6.782452288689456e-08
outcome O 0 3.0278241069936485e-07
of O 0 1.1784758413568852e-07
a O 0 9.625201613516765e-08
5 O 0 6.821905458309629e-07
- O 0 5.507483251676604e-07
year O 0 5.381339818200104e-08
- O 0 5.047111812928051e-07
old O 0 1.6507179907421232e-06
girl O 0 1.796383230612264e-06
with O 0 5.020486696594162e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.0698906407924369e-05
was O 0 9.226328984368593e-06
first O 0 1.2108935720789304e-07
seen O 0 9.465192363222741e-08
at O 0 1.3693301070816233e-07
5 O 0 7.030379123307284e-08
months O 0 2.7211029873797088e-08
of O 0 2.71031872500771e-08
age O 0 5.992741307636607e-07
with O 0 4.430885951478558e-07
severe O 1 0.9999849796295166
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999998807907104
hepatomegaly B-Disease 1 1.0
, O 1 1.0
encephalopathy B-Disease 1 1.0
, O 0 0.00018650350102689117
and O 0 0.0005153241218067706
hypotonia B-Disease 1 0.9999690055847168
. O 0 0.000256699335295707

Biochemical O 0 0.0002744811063166708
studies O 0 1.9366731066838838e-05
indicated O 0 0.4954036474227905
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.2637541592121124
by O 0 3.0123345595711726e-07
a O 0 1.872727040108657e-07
stable O 0 2.2454266854765592e-06
yet O 0 5.343027851267834e-07
inactive O 0 3.901016498275567e-06
enzyme O 0 4.411097052070545e-06
. O 0 2.6247882942698197e-06

Molecular O 0 0.00011229350639041513
genetic O 0 3.799806790993898e-06
analysis O 0 1.1688726999636856e-06
of O 0 9.152008146884327e-07
her O 0 7.56562087644852e-07
VLCAD O 1 0.8172433972358704
gene O 0 5.2712975957547314e-06
revealed O 0 5.180342668609228e-06
a O 0 1.6011869092835695e-06
T1372C O 0 3.3220843761228025e-05
( O 0 1.8728122768152389e-06
F458L O 0 2.23018359974958e-05
) O 0 7.875452183725429e-07
missense O 0 2.0389457858982496e-05
mutation O 0 4.043738499603933e-06
and O 0 1.6126203945532325e-06
a O 0 7.158340395108098e-06
1668 O 0 0.0036407937295734882
ACAG O 1 0.8886794447898865
1669 O 0 0.0018527277279645205
splice O 0 0.00015894294483587146
site O 0 2.2515663658850826e-05
mutation O 0 5.8420428104000166e-05
. O 0 5.1390728913247585e-05

After O 0 1.4966229173296597e-05
initial O 0 4.475884452403989e-06
treatment O 0 3.3496021387691144e-06
with O 0 1.7788295281206956e-07
intravenous O 0 2.5224793716915883e-05
glucose O 0 0.0004402455815579742
and O 0 1.3535411653720075e-06
carnitine O 0 0.0015296151395887136
, O 0 9.834868563984855e-08
the O 0 1.2560455786569946e-07
patient O 0 1.2879415578481712e-07
has O 0 3.783256374845223e-08
thrived O 0 6.42667373540462e-07
on O 0 6.850579126194134e-08
a O 0 6.936184604455775e-08
low O 0 2.9087266284477664e-06
- O 0 7.168683623604011e-06
fat O 0 1.7510302541268175e-06
diet O 0 4.816483283320849e-07
supplemented O 0 9.147716895085978e-08
with O 0 3.1222363361393946e-08
medium O 0 4.885485031991266e-05
- O 0 7.040187483653426e-06
chain O 0 5.968757363916666e-07
triglyceride O 0 2.671910579010728e-06
oil O 0 1.5001647852841415e-06
and O 0 5.305473678163253e-07
carnitine O 0 2.7576372303883545e-05
and O 0 2.717913787364523e-07
avoidance O 0 7.687014658586122e-06
of O 0 3.7874119698244613e-06
fasting O 0 0.00010231761552859098
. O 0 1.0600208952382673e-05

Her O 0 0.0001349572412436828
ventricular O 1 0.9999768733978271
hypertrophy O 1 0.9998739957809448
resolved O 0 8.701987098902464e-05
significantly O 0 2.9053174444015895e-07
over O 0 6.765048965462483e-08
1 O 0 1.63249040951996e-07
year O 0 2.4786134034116003e-08
, O 0 2.1291233665010623e-08
and O 0 8.256648698079516e-08
cognitively O 0 0.00018294430628884584
, O 0 3.0125093530841696e-08
she O 0 8.500641079933757e-09
is O 0 7.271136581721294e-09
in O 0 8.631790393565097e-09
the O 0 4.0690892433303816e-08
superior O 0 1.2475195035221986e-05
range O 0 3.6909725622535916e-06
for O 0 6.449667466768005e-07
age O 0 1.7546230083098635e-05
. O 0 1.069258178176824e-05

Clinical O 0 8.384166721953079e-05
recognition O 0 1.347819033981068e-05
of O 1 0.9992423057556152
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.539149138807261e-06
important O 0 1.1179471925970574e-07
because O 0 6.329744728361675e-09
it O 0 1.5923775631421222e-09
is O 0 7.786160050038404e-10
one O 0 1.9201293888215787e-09
of O 0 8.279432250901664e-09
the O 0 2.550376088095163e-08
few O 0 1.296700560260433e-07
directly O 0 6.183177561069897e-07
treatable O 1 0.9999722242355347
causes O 0 3.2786141673568636e-05
of O 0 0.003384273499250412
cardiomyopathy B-Disease 1 1.0
in O 0 4.77467110613361e-05
children O 0 2.3553980099677574e-06
. O 0 1.449973296985263e-06
. O 0 1.0632365047058556e-05

Cloning O 0 1.4625775293097831e-05
of O 0 8.288013759738533e-07
a O 0 1.9819138685761573e-07
novel O 0 2.539329386763711e-07
member O 0 1.731408332261708e-07
of O 0 1.8080483243920753e-07
the O 0 2.2082473094542365e-07
low O 0 1.0000303518609144e-05
- O 0 5.016734576201998e-06
density O 0 8.580494750276557e-07
lipoprotein O 0 0.00012260396033525467
receptor O 0 2.832225800375454e-05
family O 0 2.2048877781344345e-06
. O 0 1.2859037269663531e-05

A O 0 1.4599885616917163e-05
gene O 0 1.500080429650552e-06
encoding O 0 4.203803200653056e-06
a O 0 3.7375477290879644e-07
novel O 0 1.543511871204828e-06
transmembrane O 0 1.1548469046829268e-05
protein O 0 6.477158649431658e-07
was O 0 2.73120178917452e-07
identified O 0 5.980745498845863e-08
by O 0 1.6232030830565236e-08
DNA O 0 5.4883251721093984e-08
sequence O 0 3.9144140373537084e-08
analysis O 0 4.839745315621258e-08
within O 0 9.11201922804139e-08
the O 0 2.5382956891917274e-07
insulin B-Disease 0 0.018816910684108734
- I-Disease 1 0.9826871752738953
dependent I-Disease 0 0.016344184055924416
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.256061609135941e-05
IDDM B-Disease 0 0.4673556089401245
) O 0 5.904802833356371e-07
locus O 0 5.8942364375980105e-06
IDDM4 O 0 8.385837281821296e-05
on O 0 5.744605459767627e-06
chromosome O 0 2.9565717341029085e-05
11q13 O 0 0.00011987145262537524
. O 0 2.586794835224282e-05

Based O 0 3.6952976643078728e-06
on O 0 8.111107376862492e-07
its O 0 8.596601475119314e-08
chromosomal O 0 1.4362726687977556e-06
position O 0 1.12403711227671e-06
, O 0 4.746434711933034e-08
this O 0 8.618859403952683e-09
gene O 0 3.13121795159077e-08
is O 0 8.174784404957336e-09
a O 0 2.1833006513816144e-08
candidate O 0 1.8333658147184906e-07
for O 0 1.8053346195756603e-07
conferring O 0 6.907640909048496e-06
susceptibility O 0 7.430454570567235e-05
to O 0 5.246461569186067e-06
diabetes B-Disease 1 0.9999583959579468
. O 0 0.00012859873822890222

The O 0 5.340599727787776e-06
gene O 0 2.9672644359379774e-06
, O 0 6.936277259228518e-07
termed O 0 4.043734861625126e-06
low O 0 1.5310055459849536e-05
- O 0 7.796570571372285e-06
density O 0 4.3716116238101677e-07
lipoprotein O 0 5.053434051660588e-06
receptor O 0 5.114832788422063e-07
related O 0 9.094153341493438e-08
protein O 0 6.312819067488817e-08
5 O 0 3.4291099382244283e-07
( O 0 3.710478324592259e-08
LRP5 O 0 1.1898156117240433e-05
) O 0 4.829251665228185e-08
, O 0 3.824247585271223e-08
encodes O 0 8.227973324892446e-08
a O 0 4.133569930786507e-08
protein O 0 1.1464401694638582e-07
of O 0 2.375875425286722e-07
1615 O 0 4.102880120626651e-05
amino O 0 1.5159472468440072e-06
acids O 0 2.1663146299033542e-07
that O 0 1.4640829881784612e-08
contains O 0 5.655483903410641e-08
conserved O 0 2.1771921865365584e-07
modules O 0 4.266086079951492e-07
which O 0 6.848995592889651e-09
are O 0 4.136067932591914e-09
characteristic O 0 8.501310588826527e-08
of O 0 6.087513781949383e-08
the O 0 9.159170133443695e-08
low O 0 2.648398321980494e-06
- O 0 1.835704665609228e-06
density O 0 2.0730423955228616e-07
lipoprotein O 0 1.794271156541072e-05
( O 0 3.025633361630753e-07
LDL O 0 1.623450225451961e-05
) O 0 2.8589028033820796e-07
receptor O 0 2.788801111819339e-06
family O 0 5.684141228812223e-07
. O 0 3.283991418356891e-06

These O 0 1.6426507727373973e-06
modules O 0 8.799614079180174e-06
include O 0 2.9634304610226536e-07
a O 0 2.0652618104577414e-07
putative O 0 9.300670740230998e-07
signal O 0 1.7204279174620751e-06
peptide O 0 6.031195880495943e-07
for O 0 3.7687154730292605e-08
protein O 0 1.5570321920677088e-07
export O 0 1.4022761263277062e-07
, O 0 7.616354480433074e-08
four O 0 1.6022256943415414e-07
epidermal O 0 6.619550845243793e-07
growth O 0 8.65721929699248e-08
factor O 0 1.7212700242907886e-07
( O 0 7.706177740374187e-08
EGF O 0 4.76010200145538e-06
) O 0 6.581292666396621e-08
repeats O 0 1.8853891958769964e-07
with O 0 3.82344538252255e-08
associated O 0 1.880802642517665e-07
spacer O 0 1.279133471143723e-06
domains O 0 3.850703933494515e-07
, O 0 9.437593462280347e-08
three O 0 1.649202800990679e-07
LDL O 0 1.7932319451574585e-06
- O 0 9.419417779099604e-07
receptor O 0 4.996915095034637e-07
( O 0 5.5751360861222565e-08
LDLR O 0 1.735628757160157e-05
) O 0 5.104277889245168e-08
repeats O 0 1.5185837298758997e-07
, O 0 2.075811167401298e-08
a O 0 5.9020333509351985e-08
single O 0 3.6959846738682245e-07
transmembrane O 0 7.82777806307422e-06
spanning O 0 1.6067381238826783e-06
domain O 0 3.5593700431491015e-07
, O 0 9.811110857071981e-08
and O 0 2.0033893122217705e-07
a O 0 4.468040231131454e-07
cytoplasmic O 0 9.15778673515888e-06
domain O 0 9.276025593862869e-06
. O 0 1.6022613635868765e-05

The O 0 3.997641215391923e-06
encoded O 0 1.3435460459731985e-06
protein O 0 5.464362402562983e-07
has O 0 3.136848647500301e-08
a O 0 3.030761774880375e-08
unique O 0 4.149130816699653e-08
organization O 0 3.75848614453389e-08
of O 0 2.3534283855042304e-07
EGF O 0 4.383871782920323e-05
and O 0 4.956350494467188e-07
LDLR O 0 0.0005034474306739867
repeats O 0 1.1241121455896064e-06
; O 0 4.387299057384553e-08
therefore O 0 2.461277688325936e-07
, O 0 1.5891720295257983e-07
LRP5 O 0 0.00015017167606856674
likely O 0 3.9538844021080877e-07
represents O 0 1.4425071981349902e-07
a O 0 2.8326313739057696e-08
new O 0 4.253751484384338e-08
category O 0 1.4312405482996837e-07
of O 0 1.733260290848193e-07
the O 0 1.0179398941545514e-06
LDLR O 0 0.0013173643965274096
family O 0 2.894506224038196e-06
. O 0 1.792739021766465e-05

Both O 0 8.954338227340486e-06
human O 0 2.883444267354207e-06
and O 0 1.2069903050360153e-06
mouse O 0 9.42456244956702e-06
LRP5 O 0 0.0031416157726198435
cDNAs O 0 1.8551798348198645e-05
have O 0 4.9545732849765045e-08
been O 0 6.842469701950904e-08
isolated O 0 9.723903815483936e-08
and O 0 2.8138060770288575e-08
the O 0 5.470339203839103e-08
encoded O 0 6.675058727978467e-08
mature O 0 6.058196078129185e-08
proteins O 0 3.2270706107340175e-09
are O 0 2.8844078237000303e-09
95 O 0 4.8392930551699465e-08
% O 0 7.5992288017801e-09
identical O 0 6.70562059212898e-08
, O 0 9.24411214242582e-09
indicating O 0 5.167411387674292e-08
a O 0 2.3163401863257604e-08
high O 0 3.311277794182388e-07
degree O 0 3.6743918485626637e-07
of O 0 9.256995525674938e-08
evolutionary O 0 6.680146498183603e-07
conservation O 0 1.1852157655312112e-07
. O 0 1.3852995550678315e-07
. O 0 3.0061496545386035e-06

The O 0 9.841256542131305e-06
APC B-Disease 0 3.977482992922887e-05
variants O 0 8.358775630767923e-06
I1307K O 0 2.3822720322641544e-05
and O 0 3.486277648789837e-07
E1317Q O 0 6.218603630259167e-06
are O 0 4.113506335556849e-08
associated O 0 1.5583602817059727e-06
with O 1 0.875267744064331
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.034540195018053055
but O 0 1.7629862725243584e-07
not O 0 1.6568730387689357e-08
always O 0 4.775138151558167e-08
with O 0 2.0332985073423515e-08
a O 0 1.78151182694819e-07
family O 0 1.65334128610084e-07
history O 0 2.743879122135695e-06
. O 0 1.4397654922504444e-05

Classical O 0 0.0023279108572751284
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.52638179063797
FAP B-Disease 1 0.9711589813232422
) O 0 1.4398439134311047e-06
is O 0 1.3566410927978723e-07
a O 0 2.1067042155209492e-07
high O 0 0.0002445110003463924
- O 1 0.9948915243148804
penetrance O 1 0.9999992847442627
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9998980760574341
that O 0 2.879116323128983e-08
predisposes O 0 2.204138240813336e-07
to O 0 1.725094911364522e-08
hundreds O 0 6.350013848077651e-08
or O 0 3.112425872586755e-08
thousands O 0 1.3822669586716074e-07
of O 0 0.0018009318737313151
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 1.5972971596056595e-05
that O 0 3.806701442954363e-08
results O 0 1.3906326046253525e-07
from O 0 2.379434782540102e-08
truncating O 0 6.127546043899201e-07
mutations O 0 6.904453897504936e-08
in O 0 3.357922651048284e-08
the O 0 1.9095521963663487e-07
APC B-Disease 0 4.811980033991858e-06
gene O 0 3.944441687053768e-06
. O 0 1.5677971532568336e-05

A O 0 3.74721348634921e-05
variant O 0 4.430780609254725e-05
of O 0 5.739786956837634e-06
FAP B-Disease 0 0.0002698920725379139
is O 0 2.003617964874138e-06
attenuated B-Disease 0 0.08067946135997772
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999958276748657
, O 0 2.390848067079787e-06
which O 0 1.0979542963696076e-07
results O 0 5.096092081657844e-07
from O 0 8.912152082984903e-08
germ O 0 0.0028981997165828943
- O 0 1.6882986528798938e-05
line O 0 1.2253068462086958e-06
mutations O 0 8.899140624407664e-08
in O 0 8.146114005569416e-09
the O 0 9.829238756253744e-09
5 O 0 7.483743758029959e-08
and O 0 1.0082272794420533e-08
3 O 0 9.058818761786824e-08
regions O 0 1.7928194040450762e-08
of O 0 5.807483560715809e-08
the O 0 2.843870561264339e-07
APC B-Disease 0 4.0115123738360126e-06
gene O 0 2.7630637760012178e-06
. O 0 1.0596328138490207e-05

Attenuated B-Disease 1 0.9999779462814331
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
patients O 0 2.6325435101171024e-05
have O 0 5.096184167996398e-07
" O 0 2.4884388949431013e-06
multiple O 0 0.00012962083565071225
" O 1 0.9998704195022583
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 8.778935807640664e-06
typically O 0 3.4860647701862035e-07
fewer O 0 1.2450094288851687e-07
than O 0 2.2124986287508364e-08
100 O 0 3.964531458677811e-08
) O 0 1.1353396445201724e-08
without O 0 3.466153586373366e-08
the O 0 7.828369064100116e-08
florid O 0 7.058507435431238e-06
phenotype O 0 1.320122692050063e-06
of O 0 4.6210865889406705e-07
classical O 0 1.11637937152409e-05
FAP B-Disease 0 6.686153938062489e-05
. O 0 1.093919672712218e-05

Another O 0 2.0687242795247585e-05
group O 0 1.4594013464375166e-06
of O 0 7.687686434110219e-07
patients O 0 2.98424708944367e-07
with O 0 2.2572794478037395e-07
multiple O 0 0.00033868642640300095
adenomas B-Disease 1 0.9964889287948608
has O 0 1.0487669044323411e-07
no O 0 4.338733106123982e-08
mutations O 0 4.398676978212279e-08
in O 0 6.2641438702826235e-09
the O 0 2.4540531384786846e-08
APC B-Disease 0 3.727836883626878e-07
gene O 0 4.187523572340979e-08
, O 0 1.5431711020141847e-08
and O 0 1.7749565373037512e-08
their O 0 2.726386583162821e-08
phenotype O 0 1.9522046841302654e-06
probably O 0 1.435286520745649e-07
results O 0 1.6232812072303204e-07
from O 0 2.2642621999580115e-08
variation O 0 4.632249499536556e-07
at O 0 4.828523856303946e-07
a O 0 5.079056819567995e-08
locus O 0 3.728889339527086e-07
, O 0 3.925075375832421e-08
or O 0 5.295212801570415e-08
loci O 0 7.007566864558612e-07
, O 0 9.397966493907006e-08
elsewhere O 0 2.9672256118828955e-07
in O 0 1.779632015086463e-07
the O 0 9.439084465157066e-07
genome O 0 4.28470912083867e-06
. O 0 1.3772690181212965e-05

Recently O 0 1.720467844279483e-05
, O 0 3.968644080032391e-07
however O 0 1.8619688546550606e-07
, O 0 7.884352015707918e-08
a O 0 6.47300950618046e-08
missense O 0 9.973426813303377e-07
variant O 0 1.2626766192624927e-06
of O 0 1.0697218613131554e-06
APC B-Disease 0 1.8751961761154234e-05
( O 0 6.147910198706086e-07
I1307K O 0 2.0366640455904417e-05
) O 0 1.4881241838793358e-07
was O 0 4.00596633198802e-07
described O 0 8.84082353991289e-08
that O 0 8.128544948249328e-09
confers O 0 1.0283603302241318e-07
an O 0 1.255221260265671e-08
increased O 0 1.6963045368356688e-07
risk O 0 1.0116551493410952e-05
of O 1 0.9999902248382568
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.03778509050607681
including O 0 5.342738859326346e-06
multiple O 0 0.000135715541546233
adenomas B-Disease 0 0.2751504182815552
, O 0 1.0362198281654855e-06
in O 0 1.4140362054604338e-06
Ashkenazim O 0 0.0019352516392245889
. O 0 5.329290797817521e-05

We O 0 3.8771459003328346e-06
have O 0 1.83475449944126e-07
studied O 0 6.823610192441265e-07
a O 0 6.036431443590118e-08
set O 0 5.271641256854309e-08
of O 0 6.227335802577727e-08
164 O 0 4.4098038642914617e-07
patients O 0 1.0901395341988973e-07
with O 0 2.6146747700295236e-07
multiple O 1 0.9999974966049194
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.999983549118042
/ I-Disease 1 1.0
or I-Disease 1 0.9928889274597168
carcinoma I-Disease 1 1.0
and O 0 3.2289335649693385e-06
analyzed O 0 3.4285446872672765e-06
codons O 0 6.514670985779958e-06
1263 O 0 3.0791481549385935e-05
- O 0 1.1759270819311496e-05
1377 O 0 0.0001267289335373789
( O 0 8.990069204628526e-07
exon O 0 8.552648068871349e-06
15G O 0 2.6075800633407198e-05
) O 0 7.89932883549227e-08
of O 0 1.703067056268992e-07
the O 0 3.280624980561697e-07
APC B-Disease 0 2.2739325231668772e-06
gene O 0 2.64521304416121e-07
for O 0 1.9328999201206898e-07
germ O 1 0.9871000051498413
- O 0 0.18297965824604034
line O 0 0.00032652445952408016
variants O 0 0.00027671479620039463
. O 0 3.7968351534800604e-05

Three O 0 9.399117516295519e-06
patients O 0 7.876353720348561e-07
with O 0 5.5117290287398646e-08
the O 0 1.6288950632770138e-07
I1307K O 0 2.3065938421495957e-06
allele O 0 7.578452709822159e-07
were O 0 8.889742275641765e-08
detected O 0 2.4379420437981025e-07
, O 0 5.745333808704345e-08
each O 0 4.550059173880072e-08
of O 0 4.802008675142133e-07
Ashkenazi O 0 5.95495876041241e-05
descent O 0 6.197350012371317e-05
. O 0 6.12998046563007e-05

Four O 0 5.208391303312965e-05
patients O 0 3.345212689964683e-06
had O 0 6.392967293322727e-07
a O 0 1.0221159527645796e-06
germ O 0 0.4531777501106262
- O 0 0.0007782966131344438
line O 0 5.037708979216404e-05
E1317Q O 0 9.254776523448527e-05
missense O 0 1.778745536284987e-05
variant O 0 2.8942217795702163e-06
of O 0 5.03277419738879e-07
APC O 0 1.441933932255779e-06
that O 0 1.4251979152390959e-08
was O 0 8.485515934353316e-08
not O 0 5.721186191465222e-09
present O 0 1.6837997662833004e-08
in O 0 1.0686931339876082e-08
controls O 0 1.6240554145952046e-07
; O 0 1.1904817576180449e-08
one O 0 7.46707229382082e-09
of O 0 1.3874382531753326e-08
these O 0 1.3141639776392822e-08
individuals O 0 1.5297464628361013e-08
had O 0 5.5316977665142986e-08
an O 0 1.0654935600484805e-08
unusually O 0 1.0939074712723595e-07
large O 0 3.750136912117341e-08
number O 0 5.30911812290924e-08
of O 0 6.606175020351657e-07
metaplastic B-Disease 0 0.00010263753938488662
polyps I-Disease 0 6.139044216979528e-06
of I-Disease 0 6.354399602059857e-07
the I-Disease 0 1.3383322539084475e-06
colorectum I-Disease 0 0.0002350706054130569
. O 0 2.066961496893782e-05

There O 0 1.7841382486949442e-06
is O 0 5.683762083208421e-08
increasing O 0 5.324664442696303e-08
evidence O 0 6.007154951248594e-08
that O 0 3.68462171884687e-09
there O 0 1.0195596367168491e-08
exist O 0 1.1700979030138114e-07
germ O 0 4.206702215014957e-05
- O 0 3.70743350686098e-06
line O 0 5.270495648801443e-07
variants O 0 3.0749333745916374e-07
of O 0 8.742593138322263e-08
the O 0 1.0445865683550437e-07
APC B-Disease 0 3.836807422885613e-07
gene O 0 3.0513003679288886e-08
that O 0 7.50157624906933e-09
predispose O 0 1.1474596561811268e-07
to O 0 2.081921657293151e-08
the O 0 6.821411346891182e-08
development O 0 3.6370323641676805e-07
of O 0 1.357998030471208e-06
multiple O 1 0.9999958276748657
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 5.826744654768845e-06
but O 0 7.129061430077854e-08
without O 0 1.2536915505734214e-07
the O 0 8.078562530045019e-08
florid O 0 3.521245844240184e-06
phenotype O 0 4.227255203659297e-07
of O 0 9.699731151613378e-08
classical O 0 8.87656597114983e-07
FAP B-Disease 0 7.027113952062791e-06
, O 0 3.5420491428794776e-08
and O 0 1.9072821544341423e-08
possibly O 0 1.0363645941424693e-07
with O 0 2.1963989738083e-08
importance O 0 3.845470473606838e-06
for O 1 0.9789366722106934
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.2279095244593918e-05
in O 0 2.8457526113356835e-08
the O 0 4.311279866442419e-08
general O 0 1.3859906289326318e-07
population O 0 3.211886223652982e-08
. O 0 4.0436316339764744e-07
. O 0 1.3438992937153671e-05

Genomic O 0 2.68978164967848e-05
structure O 0 8.510965017194394e-06
of O 0 4.838591394218383e-06
the O 0 4.104699473828077e-05
human O 1 0.9999715089797974
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 1.0
CLD B-Disease 1 1.0
) O 0 3.2458432542625815e-05
gene O 0 1.890725252451375e-05
. O 0 2.0424913600436412e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999998807907104
CLD B-Disease 1 1.0
) O 0 4.075453944096807e-06
is O 0 4.903168360215204e-08
caused O 0 7.009531799440083e-08
by O 0 1.0380972526036203e-08
mutations O 0 5.5935736043011275e-08
in O 0 1.0009348017092634e-08
a O 0 2.6121817597868358e-08
gene O 0 5.8531213653623126e-08
which O 0 5.408051251265533e-08
encodes O 0 1.3000526450923644e-06
an O 0 4.5623735900335305e-07
intestinal O 0 0.004205798730254173
anion O 0 0.0027624270878732204
transporter O 0 0.33393505215644836
. O 0 0.00010075838508782908

We O 0 9.54115967033431e-06
report O 0 6.227020890037238e-07
here O 0 1.607515258683634e-07
the O 0 4.6892672855847195e-08
complete O 0 1.2781369207459647e-07
genomic O 0 2.1434175323520321e-07
organization O 0 1.082607496982746e-07
of O 0 1.1268873123526646e-07
the O 0 4.13114349839816e-07
human O 0 2.2381107100954978e-06
CLD B-Disease 0 0.0016276263631880283
gene O 0 1.1210534012207063e-06
which O 0 2.759161930043774e-07
spans O 0 3.24085112879402e-06
approximately O 0 7.452646855199418e-07
39kb O 0 8.930381227401085e-06
, O 0 2.2901976137745805e-07
and O 0 5.662137709805393e-07
comprises O 0 2.3363040781987365e-06
21 O 0 1.4342194845085032e-05
exons O 0 9.989372483687475e-05
. O 0 1.9563778550946154e-05

All O 0 1.52879783854587e-05
exon O 0 9.241003135684878e-05
/ O 0 3.030567677342333e-05
intron O 0 1.54624467540998e-05
boundaries O 0 8.246794322985807e-07
conform O 0 5.375004548113793e-07
to O 0 1.3475325033596164e-07
the O 0 8.103422146632511e-07
GT O 1 0.8827269673347473
/ O 0 0.017761705443263054
AG O 1 0.954731285572052
rule O 0 3.354189175297506e-05
. O 0 3.218288111384027e-05

An O 0 8.915685612009838e-07
analysis O 0 4.836990115109074e-07
of O 0 5.698921086150222e-07
the O 0 7.589308665956196e-07
putative O 0 1.5821198758203536e-05
promoter O 0 5.373550811782479e-05
region O 0 1.2274272194190416e-06
sequence O 0 6.779281989111041e-07
shows O 0 3.3236608487641206e-07
a O 0 3.817223159785499e-07
putative O 0 1.767433604982216e-05
TATA O 0 0.008741933852434158
box O 0 3.967561497120187e-06
and O 0 6.54364214369707e-07
predicts O 0 1.9821511614281917e-06
multiple O 0 4.4631940454564756e-07
transcription O 0 9.666962341725593e-07
factor O 0 4.3972474372822035e-07
binding O 0 9.095659265767608e-07
sites O 0 1.3059602679277305e-06
. O 0 1.276920647796942e-05

The O 0 7.119519978004973e-06
genomic O 0 7.807083420630079e-06
structure O 0 5.6250992201967165e-06
was O 0 7.937862847029464e-07
determined O 0 1.6667647173562727e-07
using O 0 4.9916611288836066e-08
DNA O 0 1.1458389792551316e-07
from O 0 1.0982345699517282e-08
several O 0 1.1698006119331694e-08
sources O 0 4.326098235196696e-08
including O 0 2.7569830862717026e-08
multiple O 0 3.368257068814273e-07
large O 0 2.378700855842908e-06
- O 0 0.0005027059814892709
insert O 0 2.6211109798168764e-06
libaries O 0 1.2087622053513769e-05
and O 0 1.0707297803946858e-07
genomic O 0 4.3829246010318457e-07
DNA O 0 5.300447014633392e-07
from O 0 2.812293757870066e-07
Finnish O 0 0.002021088497713208
CLD B-Disease 1 0.9999902248382568
patients O 0 1.1487857591419015e-05
and O 0 3.236561042285757e-06
controls O 0 6.939844024600461e-05
. O 0 3.678966822917573e-05

Exon O 0 0.0004265072348061949
- O 0 1.4650052435172256e-05
specific O 0 2.4314013558068837e-07
primers O 0 3.900967840309022e-06
developed O 0 5.089933097224275e-07
in O 0 1.209321442985356e-08
this O 0 5.0354551639486544e-09
study O 0 1.4085212995951224e-08
will O 0 1.1150994794206781e-08
facilitate O 0 6.242366623609996e-08
mutation O 0 6.25378362428819e-08
screening O 0 5.994233021056061e-08
studies O 0 7.238593724423481e-08
of O 0 1.4832077965820645e-07
patients O 0 2.722749457007012e-07
with O 0 3.424296153298201e-07
the O 0 2.4003977159736678e-05
disease O 1 0.9959589838981628
. O 0 3.7688885640818626e-05

Genomic O 0 3.192842268617824e-05
sequencing O 0 8.728413376957178e-06
of O 0 2.02689579964499e-06
a O 0 5.274756858852925e-06
BAC O 1 0.9986371397972107
clone O 0 0.0004510573053266853
H O 1 1.0
_ O 0 5.2029386097274255e-06
RG364P16 O 0 1.846960913098883e-05
revealed O 0 5.677640046997112e-07
the O 0 3.183367525139147e-08
presence O 0 6.290054699320535e-08
of O 0 1.3041652380252344e-07
another O 0 1.60198126764044e-07
, O 0 1.1181028725104625e-07
highly O 0 3.160252219913673e-07
homologous O 0 1.9348308910593914e-07
gene O 0 6.196861335183712e-08
3 O 0 1.9318034105708648e-07
of O 0 1.055304394981249e-07
the O 0 3.521728899613663e-07
CLD B-Disease 0 0.020053816959261894
gene O 0 4.67604877485428e-07
, O 0 7.04536020634805e-08
with O 0 2.17810125491269e-08
a O 0 3.46893145319882e-08
similar O 0 3.857521591044133e-08
genomic O 0 3.121075735634804e-07
structure O 0 3.5128141462337226e-06
, O 0 6.378880357260641e-08
recently O 0 1.3038008717103367e-07
identified O 0 9.12643827177817e-08
as O 0 5.736956865121101e-08
the O 0 1.1332052736179321e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.0001264193415408954
( O 0 6.536383807542734e-06
PDS B-Disease 1 0.9064915180206299
) O 0 9.246968488696439e-07
. O 0 1.5219836768665118e-06
. O 0 1.6166784917004406e-05

The O 0 1.9138222342007793e-05
APCI1307K O 0 0.10164149850606918
allele O 0 9.283998952014372e-05
and O 0 3.1352512905868934e-06
cancer B-Disease 0 0.00026530795730650425
risk O 0 6.695753995700215e-07
in O 0 5.270013048175315e-08
a O 0 8.824701325238493e-08
community O 0 4.0200418993663334e-08
- O 0 2.803504912662902e-07
based O 0 4.0916589227890654e-08
study O 0 5.266947766813246e-08
of O 0 3.6463225683291967e-07
Ashkenazi O 0 2.4754377591307275e-05
Jews O 0 3.143250069115311e-05
. O 0 4.098003410035744e-05

Mutations O 0 2.4235672754002735e-05
in O 0 1.2420213124642032e-06
APC O 0 1.2295288797758985e-05
are O 0 1.9411275786751503e-07
classically O 0 3.116167863481678e-05
associated O 0 1.7835990320236306e-06
with O 0 9.394340850121807e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.99997878074646
FAP B-Disease 1 0.9999092817306519
) O 0 1.627882170396333e-06
, O 0 3.3170965707540745e-07
a O 0 1.0227946631857776e-06
highly O 0 0.010545005090534687
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9834328889846802
by O 0 5.518889338418376e-06
multiple O 1 0.7577629685401917
intestinal O 1 0.9999995231628418
polyps B-Disease 1 0.7978931069374084
and O 0 1.2931060382470605e-06
, O 0 2.7426918336459494e-07
without O 0 5.683062340722245e-07
surgical O 0 0.00016151406452991068
intervention O 0 5.926996891503222e-06
, O 0 2.692748637400655e-07
the O 0 2.1218409074208466e-07
development O 0 1.563574915053323e-05
of O 1 0.9910390973091125
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.2762831449508667
CRC B-Disease 1 0.9852069020271301
) O 0 4.688436547439778e-06
. O 0 1.6865431462065317e-05

APC B-Disease 0 0.0003405265451874584
is O 0 2.22584367293166e-06
a O 0 2.5127726530627115e-06
tumour O 1 0.9999995231628418
- O 0 3.8213438529055566e-05
suppressor O 0 1.2649421478272416e-05
gene O 0 2.4154496713890694e-07
, O 0 1.0526066773763887e-07
and O 0 3.429705088819901e-07
somatic O 0 0.00090852688299492
loss O 0 0.0003400028217583895
occurs O 0 1.576066279085353e-05
in O 0 1.0206519618805032e-05
tumours B-Disease 1 1.0
. O 0 0.0004063379019498825

The O 0 5.4417960200225934e-05
germline O 0 0.002635294571518898
T O 0 0.00017474216292612255
- O 0 5.249434707366163e-06
to O 0 1.344141509207475e-07
- O 0 1.9140222775604343e-06
A O 0 7.982409329088114e-07
transversion O 0 1.7824337191996165e-05
responsible O 0 2.969864283386414e-07
for O 0 3.75910289562853e-08
the O 0 9.230760156242468e-08
APC O 0 1.0893004400713835e-06
I1307K O 0 1.3941037195763784e-06
allele O 0 4.688972410349379e-07
converts O 0 5.14934242801246e-07
the O 0 9.109204057722309e-08
wild O 0 2.0255843935501616e-07
- O 0 1.8215565944501577e-07
type O 0 7.57773861437272e-08
sequence O 0 5.980551520679e-08
to O 0 2.047682912120763e-08
a O 0 4.3651587589010887e-07
homopolymer O 0 0.45894479751586914
tract O 0 0.00028749150806106627
( O 0 1.2695954865193926e-06
A8 O 0 0.022786680608987808
) O 0 1.1826877255316504e-07
that O 0 2.7649560863096667e-08
is O 0 1.0332657751632723e-07
genetically O 0 3.5071136608166853e-06
unstable O 0 0.00023090311151463538
and O 0 5.519015303434571e-06
prone O 0 0.0006185951642692089
to O 0 7.964060841914034e-07
somatic O 0 0.06760521978139877
mutation O 0 4.224221993354149e-05
. O 0 1.7725698853610083e-05

The O 0 2.1129826563992538e-05
I1307K O 0 9.711142047308385e-05
allele O 0 3.0181166948750615e-05
was O 0 2.3747522845951607e-06
found O 0 3.4766654266604746e-07
in O 0 3.6632656019719434e-07
6 O 0 3.0394328859983943e-05
. O 0 2.202027098974213e-05

1 O 0 1.2534776033135131e-05
% O 0 5.932754447712796e-07
of O 0 1.2201120398458443e-06
unselected O 0 0.00011300677579129115
Ashkenazi O 0 1.351157516182866e-05
Jews O 0 1.2478234339141636e-06
and O 0 1.6566556837460666e-07
higher O 0 7.37227253466699e-07
proportions O 0 1.2048569715261692e-06
of O 0 6.424670004889776e-07
Ashkenazim O 0 0.009486129507422447
with O 0 2.0557233426643506e-07
family O 0 5.075551001709755e-08
or O 0 6.828337006936636e-08
personal O 0 3.322088844015525e-07
histories O 0 6.860221901661134e-07
of O 0 1.033648459269898e-05
CRC B-Disease 1 0.9210331439971924
( O 0 3.4677586882025935e-06
ref O 0 4.7387362428708e-05
. O 0 2.6071847969433293e-07
2 O 0 3.997042767878156e-06
) O 0 1.1357769835740328e-06
. O 0 1.1356512914062478e-05

To O 0 1.1125182481919182e-06
evaluate O 0 3.4250706448801793e-06
the O 0 1.2062844234606018e-07
role O 0 1.9925266769860173e-07
of O 0 3.220401083581237e-07
I1307K O 0 1.097500808100449e-05
in O 0 1.0539707773205009e-07
cancer B-Disease 0 1.4168791722113383e-06
, O 0 1.0743096368059923e-07
we O 0 2.340997866667749e-07
genotyped O 0 5.634688477584859e-06
5 O 0 1.0813522521857521e-06
, O 0 4.4323101633381157e-07
081 O 0 3.7993995647411793e-05
Ashkenazi O 0 1.191293904412305e-05
volunteers O 0 1.0881437901844038e-06
in O 0 1.8105208710039733e-07
a O 0 6.345073870761553e-07
community O 0 1.0340124845242826e-06
survey O 0 3.6875035220873542e-06
. O 0 2.3961776605574414e-05

Risk O 0 0.00015086372150108218
of O 0 0.0005212413961999118
developing O 1 0.9999998807907104
colorectal B-Disease 1 1.0
, I-Disease 1 0.9981050491333008
breast I-Disease 1 0.9999537467956543
and I-Disease 0 3.939043381251395e-06
other I-Disease 0 3.487148774183879e-07
cancers I-Disease 1 0.8003073334693909
were O 0 2.7611702080321265e-07
compared O 0 3.91293298207529e-07
between O 0 6.604039413105056e-07
genotyped O 0 1.6597392459516414e-05
I1307K O 0 2.4024611775530502e-06
carriers O 0 6.426557064287408e-08
and O 0 8.268357731822107e-08
non O 0 6.297137247202045e-07
- O 0 3.6075863363294047e-07
carriers O 0 2.4861986247515233e-08
and O 0 1.163481133659161e-08
their O 0 1.0962380336820843e-08
first O 0 1.1722535475655604e-07
- O 0 6.5230926793447e-07
degree O 0 2.861253278751974e-06
relatives O 0 2.4547143766540103e-06
. O 0 5.511289600690361e-06

Sperm O 0 8.648792572785169e-06
DNA O 0 3.5151163046975853e-06
analysis O 0 7.810887154846569e-07
in O 0 3.999370221663412e-07
a O 0 3.5001266951439902e-06
Friedreich B-Disease 1 0.9997126460075378
ataxia I-Disease 1 0.9999998807907104
premutation O 1 0.9996814727783203
carrier O 0 1.4568243386747781e-05
suggests O 0 2.3702475573372794e-06
both O 0 6.777938210689172e-07
meiotic O 0 4.0502236515749246e-05
and O 0 4.95152676194266e-07
mitotic O 0 4.165508016740205e-06
expansion O 0 2.0747108919749735e-06
in O 0 2.6586525336824707e-07
the O 0 1.510655124548066e-06
FRDA B-Disease 0 0.0006695676711387932
gene O 0 1.8233209630125202e-05
. O 0 2.5378783902851865e-05

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 2.584720823506359e-05
usually O 0 1.7154243323602714e-06
caused O 0 7.528855689997727e-07
by O 0 2.4761657613225907e-08
an O 0 8.971635878651796e-09
expansion O 0 1.5934516284232814e-07
of O 0 3.8802761537226615e-07
a O 0 1.6631538528599776e-06
GAA O 0 0.0001079243520507589
trinucleotide O 0 8.685870125191286e-05
repeat O 0 3.0843484637443908e-06
in O 0 1.6700566618510493e-07
intron O 0 1.3814777730658534e-06
1 O 0 8.752459734751028e-07
of O 0 3.213578168015374e-07
the O 0 9.130057492257038e-07
FRDA B-Disease 0 0.0006537195877172053
gene O 0 1.5070368135639e-05
. O 0 1.6067448086687364e-05

Occasionally O 0 3.296188879176043e-05
, O 0 8.310570933645067e-07
a O 0 3.980690337357373e-07
fully O 0 8.245127105510619e-07
expanded O 0 2.1953189843770815e-07
allele O 0 6.489735255854612e-07
has O 0 2.483326611013581e-08
been O 0 2.6849882317492302e-08
found O 0 9.658226218789423e-09
to O 0 9.469341755163896e-09
arise O 0 1.6141684966441971e-07
from O 0 3.9559203912631347e-08
a O 0 9.443679260812132e-08
premutation O 0 2.49359891313361e-06
of O 0 2.1364380131672078e-07
100 O 0 4.801839281753928e-07
or O 0 4.2085903828592564e-07
less O 0 2.4387286430282984e-06
triplet O 0 0.0001234743685927242
repeats O 0 1.9378554497961886e-05
. O 0 8.49951265990967e-06

We O 0 2.934843678303878e-06
have O 0 2.648231713919813e-07
examined O 0 7.401013704111392e-07
the O 0 5.556505300319259e-08
sperm O 0 8.484236957428948e-08
DNA O 0 2.4615852112219727e-07
of O 0 3.3079291483772977e-07
a O 0 1.148928390648507e-06
premutation O 0 0.00019311757932882756
carrier O 0 5.18774104421027e-05
. O 0 8.894155325833708e-05

This O 0 6.420611043722602e-06
mans O 0 0.00016272942593786865
leucocyte O 0 4.410982728586532e-05
DNA O 0 3.8072503230068833e-06
showed O 0 4.926641850033775e-07
one O 0 7.655138745121803e-08
normal O 0 3.11720583567876e-07
allele O 0 8.241636351158377e-07
and O 0 8.367689474653162e-08
one O 0 6.197983992706213e-08
allele O 0 2.2571460078779637e-07
of O 0 1.6155776449977566e-07
approximately O 0 3.6912152268087084e-07
100 O 0 1.0222855735264602e-06
repeats O 0 6.641146683250554e-06
. O 0 5.546394277189393e-06

His O 0 5.890600732527673e-06
sperm O 0 1.7302754713455215e-06
showed O 0 4.463645097985136e-07
an O 0 4.526540564597781e-08
expanded O 0 1.6506393762938387e-07
allele O 0 1.009894162962155e-06
in O 0 5.203392561270448e-08
a O 0 1.1839008351444136e-07
tight O 0 2.555166020101751e-06
range O 0 1.2555031389638316e-05
centering O 0 5.958968358754646e-06
on O 0 2.1936571670266858e-07
a O 0 5.2996682597949984e-08
size O 0 8.489691794011378e-08
of O 0 2.419392046704161e-07
approximately O 0 2.097659717037459e-06
320 O 0 9.749206583364867e-06
trinucleotide O 0 0.000233323298743926
repeats O 0 5.066297308076173e-05
. O 0 3.124541763099842e-05

His O 0 2.6944568162434734e-05
affected O 0 2.4902765289880335e-05
son O 0 4.4981152313994244e-05
has O 0 3.5146595678270387e-07
repeat O 0 1.241508471139241e-06
sizes O 0 7.518050324506476e-07
of O 0 1.421656975253427e-06
1040 O 0 5.4651576647302136e-05
and O 0 1.915340590130654e-06
540 O 0 4.090471702511422e-05
. O 0 1.3002750165469479e-05

These O 0 7.560499284409161e-07
data O 0 4.5943605186948844e-07
suggest O 0 1.1866600857501908e-07
that O 0 6.028490151521737e-09
expansion O 0 1.7827338183451502e-07
occurs O 0 2.1825011131682004e-08
in O 0 7.311759642192328e-09
two O 0 1.4709351070507637e-08
stages O 0 1.905235649246606e-07
, O 0 8.31312174653931e-09
the O 0 8.87273010619083e-09
first O 0 2.411572985749899e-08
during O 0 4.650716789456055e-08
meiosis O 0 5.693380558113859e-07
followed O 0 8.263612727432701e-08
by O 0 3.3056359427519055e-08
a O 0 1.3759486705566815e-07
second O 0 1.566366108818329e-06
mitotic O 0 1.5160996554186568e-05
expansion O 0 2.4100381779135205e-05
. O 0 1.7990192645811476e-05

We O 0 3.725526767084375e-06
also O 0 1.4010369397965405e-07
show O 0 3.323032871094256e-08
that O 0 3.266580117511353e-09
in O 0 4.663835095897184e-09
all O 0 1.337269761592097e-08
informative O 0 1.1860920778872241e-07
carrier O 0 6.685800002514952e-08
father O 0 1.1653860809701655e-07
to O 0 4.8368104188512007e-08
affected O 0 3.1906748176879773e-07
child O 0 5.637540994030132e-07
transmissions O 0 3.5993566598335747e-06
, O 0 3.202331555485216e-08
with O 0 7.70144303885445e-09
the O 0 3.890306032872104e-08
notable O 0 6.848240730050748e-08
exception O 0 6.216975378947609e-08
of O 0 9.665158984262234e-08
the O 0 1.5062890668104956e-07
premutation O 0 1.1213026482437272e-05
carrier O 0 4.170510976564401e-07
, O 0 1.1817891021337346e-07
the O 0 2.1851465703548456e-07
expansion O 0 1.201336772282957e-06
size O 0 6.620958856728976e-07
decreases O 0 1.236240336766059e-06
. O 0 7.969790090101014e-07
. O 0 9.442070222576149e-06

The O 0 5.9391959439381026e-06
R496H O 0 2.6647430786397308e-05
mutation O 0 1.2372618130029878e-06
of O 0 8.127569230964582e-07
arylsulfatase O 0 0.00014463507977779955
A O 0 3.0082201192271896e-06
does O 0 9.048871874028919e-08
not O 0 5.591279546024452e-07
cause O 0 0.0005757281905971467
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
. O 0 0.0001914636231958866

Deficiency B-Disease 1 0.999618649482727
of I-Disease 0 0.00011053146590711549
arylsulfatase I-Disease 1 0.9738127589225769
A I-Disease 0 0.00030332195456139743
( O 0 5.060977400717093e-06
ARSA O 0 0.0027737722266465425
) O 0 4.78672404824465e-07
enzyme O 0 1.930771304614609e-06
activity O 0 3.4986248920176877e-06
causes O 0 9.823467553360388e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0003828241606242955
MLD B-Disease 1 1.0
) O 0 1.5695341062382795e-05
. O 0 4.521139999269508e-05

A O 0 5.718445208913181e-06
number O 0 6.157292773423251e-07
of O 0 1.333059799435432e-06
ARSA O 0 0.00019877066370099783
gene O 0 6.994720251896069e-07
mutations O 0 1.5385151073132874e-06
responsible O 0 1.56986391175451e-06
for O 0 1.444532472305582e-06
MLD B-Disease 1 1.0
have O 0 1.0865396689041518e-06
been O 0 8.416684522671858e-07
identified O 0 4.212728981656255e-06
. O 0 9.129986210609786e-06

Recently O 0 1.0353020115871914e-05
, O 0 4.3640471858452656e-07
the O 0 2.9833191206307674e-07
R496H O 0 3.5981552173325326e-06
mutation O 0 6.370685241563478e-07
of O 0 1.145012447523186e-06
ARSA O 0 0.06632231175899506
was O 0 1.0859532721951837e-06
proposed O 0 1.003959937406762e-07
to O 0 1.0005416051228622e-08
be O 0 2.881467509041613e-08
a O 0 5.5750831506884424e-08
cause O 0 4.3299783669681347e-07
of O 0 6.234696229512338e-06
MLD B-Disease 1 1.0
( O 0 1.9110018456558464e-06
Draghia O 0 7.289206405403093e-05
et O 0 1.286169936065562e-05
al O 0 6.556386324518826e-06
. O 0 6.562465415527186e-08
, O 0 1.4282790061770356e-07
1997 O 0 1.248023409061716e-06
) O 0 1.6627684544801014e-06
. O 0 1.6105970644275658e-05

We O 0 3.152821591356769e-06
have O 0 2.5909446321747964e-07
investigated O 0 2.0994327769585652e-06
the O 0 1.5791614771387685e-07
R496H O 0 4.68250709673157e-06
mutation O 0 4.912899953524175e-07
and O 0 5.637229349986228e-08
found O 0 4.531680630748269e-08
this O 0 1.0107805259451652e-08
mutation O 0 1.7030379240168259e-07
at O 0 2.501964218026842e-07
a O 0 2.5743631226760044e-08
relatively O 0 5.197937014145282e-08
high O 0 1.8044413252482627e-07
frequency O 0 1.9313281995891884e-07
in O 0 3.5209373194788895e-09
an O 0 2.8287101550006355e-09
African O 0 3.379524216029495e-08
American O 0 5.912801803731327e-09
population O 0 1.711522368275098e-09
( O 0 6.470142643877352e-09
f O 0 2.3103267210444756e-07
= O 0 1.5124210506201052e-07
0 O 0 1.1409430555886502e-07
. O 0 1.2452463060697028e-08
09 O 0 6.03917271746468e-07
, O 0 4.6598891856319824e-08
n O 0 6.70730912588624e-07
= O 0 1.5006698959041387e-06
61 O 0 1.169436927739298e-06
subjects O 0 3.650407506938791e-06
) O 0 1.7941557644007844e-06
. O 0 8.056609658524394e-06

The O 0 1.9690627595991828e-05
ARSA O 0 0.0008256940636783838
enzyme O 0 2.5850335987342987e-06
activity O 0 4.566430220620532e-07
in O 0 4.9732626905552024e-08
subjects O 0 3.3781233810259437e-07
with O 0 1.9949256468976273e-08
and O 0 3.478412580193435e-08
without O 0 3.6968021532857165e-08
the O 0 2.049335634524141e-08
R496H O 0 5.874466637578735e-07
mutation O 0 7.22808124464791e-08
was O 0 7.59498632874056e-08
determined O 0 1.0641414149858974e-07
and O 0 5.054799601111881e-08
found O 0 3.779823742888766e-08
to O 0 2.6846860734508482e-08
be O 0 2.062588748685812e-07
normal O 0 7.4178556133119855e-06
. O 0 9.87532712315442e-06

It O 0 1.526468054180441e-06
is O 0 1.2973065111054893e-07
therefore O 0 2.518527821848693e-07
concluded O 0 4.6151450305842445e-07
that O 0 1.2523872605640918e-08
the O 0 3.3741848426416254e-08
R496H O 0 9.840729262577952e-07
mutation O 0 3.3822689715634624e-07
of O 0 3.480537031919084e-07
ARSA O 0 0.0006288181757554412
does O 0 3.690039207526752e-08
not O 0 4.419027632707184e-08
negatively O 0 8.496365921928373e-08
influence O 0 8.52690362762587e-08
the O 0 3.7133382591036934e-08
activity O 0 1.6246565337496577e-07
of O 0 5.764993034063082e-07
ARSA O 0 0.32979267835617065
and O 0 1.71508759194694e-07
is O 0 2.4795022923740362e-08
not O 0 2.0253288823823823e-08
a O 0 1.5456919300049776e-07
cause O 0 6.774514531571185e-06
of O 0 0.0005355497705750167
MLD B-Disease 1 1.0

Down O 0 0.0001310460502281785
- O 0 2.6286925276508555e-05
regulation O 0 3.3998592243733583e-06
of O 0 2.869516947612283e-06
transmembrane O 0 0.0002635537530295551
carbonic O 1 0.8427266478538513
anhydrases O 0 0.0021247335243970156
in O 0 5.484277608047705e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 0 0.010241406969726086
lines O 0 1.6114382788146031e-06
by O 0 1.5915411211153696e-07
wild O 0 9.358146257909539e-07
- O 0 4.3992913560941815e-06
type O 0 2.231123835372273e-05
von B-Disease 1 0.9998354911804199
Hippel I-Disease 1 0.9999985694885254
- I-Disease 1 0.9999845027923584
Lindau I-Disease 1 0.9994783997535706
transgenes O 0 0.002167391823604703
. O 0 9.587468230165541e-05

To O 0 4.616585556505015e-06
discover O 0 6.052542175893905e-06
genes O 0 1.2042090702379937e-06
involved O 0 9.229472652805271e-07
in O 0 6.023757350703818e-07
von B-Disease 0 0.23712962865829468
Hippel I-Disease 1 0.9999929666519165
- I-Disease 1 0.9999955892562866
Lindau I-Disease 1 0.999998927116394
( O 0 4.035957681480795e-05
VHL B-Disease 1 0.999976634979248
) O 0 4.484904366108822e-06
- O 0 0.001326689263805747
mediated O 0 0.018392372876405716
carcinogenesis O 1 0.9891254901885986
, O 0 3.8449576322818757e-07
we O 0 3.4668750004129834e-07
used O 0 1.4414747511182213e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.993389368057251
lines O 0 3.5703746107174084e-05
stably O 0 0.00012194995360914618
transfected O 0 5.160544787941035e-06
with O 0 1.1825760282135889e-07
wild O 0 1.1942294122491148e-06
- O 0 2.6299137971363962e-05
type O 0 0.0031597097404301167
VHL O 1 0.9999997615814209
- O 1 0.9695419669151306
expressing O 0 1.2409650480549317e-05
transgenes O 0 0.0003574712318368256
. O 0 4.321719825384207e-05

Large O 0 2.278823740198277e-05
- O 0 4.772545435116626e-05
scale O 0 1.2779683856933843e-05
RNA O 0 2.323667331438628e-06
differential O 0 4.965456355421338e-06
display O 0 3.78770494080527e-07
technology O 0 4.2393182297928433e-07
applied O 0 3.167620121757864e-08
to O 0 4.1300767250618264e-09
these O 0 6.2413527679439085e-09
cell O 0 1.8390359457498562e-07
lines O 0 5.8449884932088025e-08
identified O 0 8.891166203284229e-08
several O 0 3.354126576482486e-08
differentially O 0 3.855355714676989e-07
expressed O 0 2.7095227395079746e-08
genes O 0 3.1103603248539e-08
, O 0 1.8305557958342433e-08
including O 0 2.280950539557125e-08
an O 0 5.2576634601564365e-08
alpha O 0 4.689223715104163e-06
carbonic O 0 0.00024461362045258284
anhydrase O 0 0.00020396593026816845
gene O 0 1.6763226540206233e-06
, O 0 1.0163752222069888e-06
termed O 0 1.8593991626403295e-05
CA12 O 0 0.003963957075029612
. O 0 6.86932762619108e-05

The O 0 1.0057363397208974e-05
deduced O 0 5.486636837304104e-06
protein O 0 3.565760948731622e-07
sequence O 0 2.5810135184656247e-07
was O 0 3.0241216109061497e-07
classified O 0 1.0800005867395157e-07
as O 0 2.2173441749373524e-08
a O 0 4.555026222874403e-08
one O 0 8.501196901988806e-08
- O 0 2.061486839011195e-06
pass O 0 1.3041058082308155e-06
transmembrane O 0 0.0029959536623209715
CA O 0 0.00012453288945835084
possessing O 0 4.648871617973782e-05
an O 0 1.4188896102496074e-07
apparently O 0 8.78920502600522e-07
intact O 0 2.258105041619274e-06
catalytic O 0 1.721658804854087e-06
domain O 0 4.220177913794032e-07
in O 0 5.811827108459511e-08
the O 0 2.7184037776351033e-07
extracellular O 0 9.154084182227962e-06
CA O 0 5.7676945289131254e-05
module O 0 0.00016690627671778202
. O 0 4.6550379920518026e-05

Reintroduced O 0 0.00020766894158441573
wild O 0 2.5884408387355506e-05
- O 0 4.947527122567408e-05
type O 0 3.466266571194865e-05
VHL B-Disease 1 0.8759278059005737
strongly O 0 1.5292248463083524e-06
inhibited O 0 8.87874250565801e-07
the O 0 4.662280517209183e-08
overexpression O 0 2.1305781672253943e-07
of O 0 8.733842804531378e-08
the O 0 1.150310566799817e-07
CA12 O 0 2.556870640546549e-05
gene O 0 1.0329682709198096e-07
in O 0 2.8586841338551494e-08
the O 0 1.235935656040965e-07
parental O 0 6.2964504650153685e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9998394250869751
lines O 0 0.00013705190212931484
. O 0 5.711374615202658e-05

Similar O 0 2.456109996273881e-06
results O 0 1.5289200518964208e-06
were O 0 1.8732198725501803e-07
obtained O 0 2.1006856343319669e-07
with O 0 9.811915901991597e-08
CA9 O 0 0.0023212269879877567
, O 0 3.69321554671842e-07
encoding O 0 1.73393107161246e-06
another O 0 7.365118221969169e-07
transmembrane O 0 1.5178761714196298e-05
CA O 0 2.4139214929164154e-06
with O 0 1.2167859608780418e-07
an O 0 1.575208727899735e-07
intact O 0 4.839080702367937e-06
catalytic O 0 1.8079041183227673e-05
domain O 0 1.1282738341833465e-05
. O 0 1.075588988896925e-05

Although O 0 2.1743048819189426e-06
both O 0 4.5922010372123623e-07
domains O 0 7.567344937342568e-07
of O 0 4.1738644540600944e-07
the O 0 4.5998058340046555e-07
VHL B-Disease 0 0.0002633186522871256
protein O 0 5.163244054529059e-07
contribute O 0 4.627048610927886e-08
to O 0 1.2999688436821089e-08
regulation O 0 1.5258918040217395e-07
of O 0 1.240827458559579e-07
CA12 O 0 0.0001837262389017269
expression O 0 2.6822095833267667e-07
, O 0 4.227795358247022e-08
the O 0 5.209887632418031e-08
elongin O 0 2.9554621505667455e-06
binding O 0 2.8290281761655933e-07
domain O 0 2.799444018819486e-07
alone O 0 1.0656302151801356e-07
could O 0 2.3395628545586078e-07
effectively O 0 7.38190738047706e-06
regulate O 0 8.542181603843346e-06
CA9 O 0 0.0037847759667783976
expression O 0 8.166435145540163e-05
. O 0 5.2358915127115324e-05

We O 0 2.3378765035886317e-05
mapped O 0 2.7760595912695862e-05
CA12 O 0 0.0008176857954822481
and O 0 9.5812711151666e-06
CA9 O 0 0.014312227256596088
loci O 0 1.4875970919092651e-05
to O 0 7.409021804960503e-07
chromosome O 0 5.3297312661015894e-06
bands O 0 9.217754268320277e-06
15q22 O 0 6.975339783821255e-05
and O 0 7.612630724906921e-06
17q21 O 0 0.00043017431744374335
. O 0 4.1657320252852514e-05

2 O 0 5.708134631277062e-05
respectively O 0 1.632415660424158e-05
, O 0 8.168278782250127e-07
regions O 0 1.2201271601952612e-06
prone O 0 4.053619250043994e-06
to O 0 1.2112528224861308e-07
amplification O 0 7.833543349988759e-06
in O 0 1.9171555720731703e-07
some O 0 6.436879971261078e-07
human O 0 2.2441367036662996e-05
cancers B-Disease 1 0.9799659848213196
. O 0 2.011746801144909e-05

Additional O 0 4.538636858342215e-06
experiments O 0 1.2649027212319197e-06
are O 0 2.6594177526817475e-08
needed O 0 1.0376799508549084e-07
to O 0 1.4141690485303116e-08
define O 0 1.5037055334232718e-07
the O 0 6.529466389793015e-08
role O 0 2.9216801067377673e-07
of O 0 5.827844802297477e-07
CA O 0 1.060067461366998e-05
IX O 0 0.004649011418223381
and O 0 1.42125713864516e-06
CA O 0 1.2675639482040424e-05
XII O 0 0.01735583320260048
enzymes O 0 6.741489642081433e-07
in O 0 3.714067986493319e-08
the O 0 6.235346461380686e-08
regulation O 0 2.407148258498637e-07
of O 0 1.4045608054402692e-07
pH O 0 4.98193458042806e-06
in O 0 5.765301480664675e-08
the O 0 1.4224814037788747e-07
extracellular O 0 8.54510346925963e-07
microenvironment O 0 1.954447725438513e-06
and O 0 4.740698500427243e-08
its O 0 2.5966532035681666e-08
potential O 0 2.5417330107302405e-07
impact O 0 2.6303134745830903e-06
on O 0 5.59338286620914e-06
cancer B-Disease 0 0.00011254361015744507
cell O 0 5.336792310117744e-05
growth O 0 1.1505860129545908e-05
. O 0 9.33858518692432e-06

A O 0 1.2096258615201805e-05
gene O 0 1.7232720210813568e-06
encoding O 0 3.726020850081113e-06
a O 0 1.1836891644634306e-06
transmembrane O 0 1.2150680049671791e-05
protein O 0 1.3063787491773837e-06
is O 0 4.0353597796638496e-08
mutated O 0 3.1230587183017633e-07
in O 0 4.807800380035587e-08
patients O 0 5.735501531489717e-07
with O 0 7.192361226771027e-05
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999947547912598
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 5.038040762883611e-05
. O 0 3.3785749110393226e-05

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.5195751786231995
WFS B-Disease 1 0.9999988079071045
; O 0 3.3485735912108794e-05
OMIM O 1 0.9976698756217957
222300 O 0 0.0005081950221210718
) O 0 6.389595910150092e-07
is O 0 1.5735376734937745e-07
an O 0 5.040440100856358e-07
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 1.395965682604583e-05
by O 0 6.542281312249543e-07
young O 0 4.828933742828667e-05
- O 0 0.02463933266699314
onset O 1 0.9999991655349731
non O 1 0.9999982118606567
- O 1 0.9999932050704956
immune O 1 0.9999446868896484
insulin B-Disease 1 0.9999973773956299
- I-Disease 1 0.9999971389770508
dependent I-Disease 1 0.9850183129310608
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999934434890747
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.0021682665683329105

Linkage O 0 6.652700540143996e-05
to O 0 9.57437919169024e-07
markers O 0 2.6247732876072405e-06
on O 0 1.4291634897745098e-06
chromosome O 0 8.909582902560942e-06
4p O 0 0.0012168537359684706
was O 0 7.078804628690705e-06
confirmed O 0 1.4489835393760586e-06
in O 0 2.585132392596279e-07
five O 0 1.6245957112914766e-06
families O 0 5.682873052137438e-07
. O 0 7.705244570388459e-06

On O 0 2.592447572169476e-06
the O 0 1.3808136145598837e-07
basis O 0 3.9937674500833964e-07
of O 0 7.132549626476248e-07
meiotic O 0 0.0019650859758257866
recombinants O 1 0.9746794700622559
and O 0 0.00030149176018312573
disease O 1 0.9996621608734131
- O 0 0.00021950168593320996
associated O 0 1.2837357417083695e-06
haplotypes O 0 9.581856829754543e-06
, O 0 2.6462728897058696e-07
the O 0 8.541429110664467e-07
WFS B-Disease 0 0.49656885862350464
gene O 0 7.614668220412568e-07
was O 0 4.656299950056564e-07
localized O 0 7.649357485206565e-07
to O 0 7.513807531722705e-08
a O 0 1.084866426026565e-06
BAC O 1 0.9945500493049622
/ O 0 0.015580186620354652
P1 O 0 0.0015120955649763346
contig O 0 2.182577554776799e-05
of O 0 4.4985722524870653e-07
less O 0 3.9906529991640127e-07
than O 0 3.0296004638330487e-07
250 O 0 1.8251923847856233e-06
kb O 0 0.00010829597886186093
. O 0 1.8116856153937988e-05

Mutations O 0 2.2462949345936067e-05
in O 0 3.6312169982011255e-07
a O 0 1.7273131902584282e-07
novel O 0 2.3446466457244242e-07
gene O 0 2.388511290973838e-07
( O 0 2.2528644194608205e-07
WFS1 O 0 9.717626380734146e-05
) O 0 2.5093311251112027e-07
encoding O 0 1.3894186849938706e-06
a O 0 2.5283344484705594e-07
putative O 0 2.9241964512038976e-06
transmembrane O 0 4.2213032429572195e-06
protein O 0 1.5529244024037325e-07
were O 0 4.1369538905655645e-08
found O 0 2.1181222109589726e-08
in O 0 1.7772805449567386e-08
all O 0 2.9822547986668724e-08
affected O 0 5.6975579809659394e-08
individuals O 0 1.3622517336386863e-08
in O 0 6.732199864245558e-08
six O 0 5.60075432076701e-06
WFS B-Disease 1 0.9951044321060181
families O 0 2.261983134133061e-08
, O 0 1.9993825262076825e-08
and O 0 1.0954959606124248e-08
these O 0 5.103720113197596e-09
mutations O 0 5.395285995746235e-08
were O 0 6.536332364248665e-08
associated O 0 1.936381437417367e-07
with O 0 2.749799818957399e-07
the O 0 0.0002912681084126234
disease O 1 0.9999974966049194
phenotype O 0 0.44049906730651855
. O 0 4.6751061745453626e-05

WFS1 O 0 0.004755358211696148
appears O 0 2.4589880922576413e-06
to O 0 8.325724110136434e-08
function O 0 2.436821660012356e-07
in O 0 2.1041898889961885e-08
survival O 0 5.3198169780444e-07
of O 0 1.6352764475868753e-07
islet O 0 1.5692307897552382e-06
beta O 0 2.9156003620300908e-06
- O 0 1.9114538645226276e-06
cells O 0 4.882106168224709e-07
and O 0 3.6076551168662263e-07
neurons O 0 8.983180123323109e-06
. O 0 8.701350679984898e-07
. O 0 9.118144589592703e-06

Stable O 0 0.0005876001087017357
interaction O 0 1.0782932804431766e-05
between O 0 1.122417529586528e-06
the O 0 1.2345621769327408e-07
products O 0 8.63307860754503e-08
of O 0 7.305336424678899e-08
the O 0 1.5600122083014867e-07
BRCA1 O 0 2.142611492672586e-06
and O 0 3.437383782056713e-07
BRCA2 O 0 2.360232656428707e-06
tumor B-Disease 0 1.5432379996127565e-06
suppressor O 0 2.661544613147271e-06
genes O 0 1.590227185488402e-07
in O 0 1.1768708674253503e-07
mitotic O 0 6.04010983806802e-06
and O 0 3.5066484542767284e-06
meiotic O 0 0.0004995557246729732
cells O 0 7.257614197442308e-05
. O 0 2.8411288440111093e-05

BRCA1 O 0 0.000692877103574574
and O 0 6.2940312091086525e-06
BRCA2 O 0 5.226756911724806e-05
account O 0 2.234132381317977e-07
for O 0 5.75971839111844e-08
most O 0 1.742193411757853e-08
cases O 0 2.4710514523462734e-08
of O 0 5.146146264678464e-08
familial O 0 1.499727204645751e-06
, O 0 4.1532811678735015e-07
early O 0 0.00010042993380920961
onset O 1 0.9999997615814209
breast B-Disease 1 0.9999995231628418
and I-Disease 1 0.9999407529830933
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.734392885235138e-05
encode O 0 5.182197355679818e-07
products O 0 1.6769560318152799e-07
that O 0 1.3830601552911048e-08
each O 0 2.6939499520040044e-08
interact O 0 1.3231081652520515e-07
with O 0 1.4081700783208362e-07
hRAD51 O 0 3.500452294247225e-05
. O 0 7.189949428720865e-06

Results O 0 5.560244244406931e-05
presented O 0 5.287333351589041e-06
here O 0 2.9559848258031707e-07
show O 0 7.97348675973808e-08
that O 0 3.604841225524069e-08
BRCA1 O 0 3.046694018848939e-06
and O 0 6.258580924622947e-07
BRCA2 O 0 3.417482730583288e-05
coexist O 0 3.3213650567631703e-06
in O 0 9.192299899041245e-08
a O 0 2.2766786855754617e-07
biochemical O 0 6.210424999153474e-06
complex O 0 2.790842336253263e-05
and O 0 1.6763962094046292e-06
colocalize O 0 0.00023151791538111866
in O 0 5.559918463404756e-07
subnuclear O 0 4.956263001076877e-05
foci O 0 1.9489070837153122e-05
in O 0 1.349799987337974e-07
somatic O 0 3.4257079732924467e-06
cells O 0 2.476045892763068e-07
and O 0 3.3870744431396815e-08
on O 0 6.377518246836189e-08
the O 0 2.0641051534653343e-08
axial O 0 1.6785801904006803e-07
elements O 0 3.696319765822409e-07
of O 0 2.044855136773549e-06
developing O 0 7.390224345726892e-05
synaptonemal O 0 0.0004043460066895932
complexes O 0 2.3536003936897032e-05
. O 0 1.4891598766553216e-05

Like O 0 4.398767850943841e-05
BRCA1 O 0 0.00018551420362200588
and O 0 1.0548920727160294e-05
RAD51 O 0 0.16297146677970886
, O 0 3.338656824780628e-06
BRCA2 O 0 3.252039823564701e-05
relocates O 0 5.538614004763076e-06
to O 0 4.561773039313266e-07
PCNA O 0 6.0622314776992425e-05
+ O 0 1.2981373629372683e-06
replication O 0 2.9485238428605953e-07
sites O 0 6.028238885846804e-08
following O 0 1.4829926442416763e-07
exposure O 0 5.794648245682765e-07
of O 0 3.2319388765245094e-07
S O 0 8.894726306607481e-06
phase O 0 3.506238863337785e-05
cells O 0 5.417745114755235e-07
to O 0 9.18329305932275e-08
hydroxyurea O 0 1.3070494787825737e-05
or O 0 1.5315673635996063e-06
UV O 0 0.05758665129542351
irradiation O 0 0.00011565789463929832
. O 0 1.8159304090659134e-05

Thus O 0 1.2947079994773958e-05
, O 0 1.7372630054524052e-06
BRCA1 O 0 6.936098998266971e-06
and O 0 5.420096158559318e-07
BRCA2 O 0 4.900054591416847e-06
participate O 0 2.152808349364932e-07
, O 0 6.430651922073594e-08
together O 0 3.243269830477402e-08
, O 0 1.8048279315507898e-08
in O 0 7.57740270529439e-09
a O 0 2.49512979166866e-08
pathway O 0 2.130257286125925e-07
( O 0 5.309624384608469e-08
s O 0 3.4483434774301713e-07
) O 0 2.829618139799095e-08
associated O 0 3.009368043649374e-08
with O 0 1.2785021041850086e-08
the O 0 4.1952304741244006e-08
activation O 0 2.217196595211135e-07
of O 0 2.2655329701137816e-07
double O 0 2.1429302705655573e-06
- O 0 1.913431697175838e-05
strand O 0 1.4448355614149477e-06
break O 0 1.9247524960519513e-06
repair O 0 7.270401511050295e-06
and O 0 2.3705933926976286e-06
/ O 0 0.00021622962958645076
or O 0 2.359753125347197e-06
homologous O 0 6.934987595741404e-06
recombination O 0 8.034711754589807e-06
. O 0 1.1663266377581749e-05

Dysfunction O 0 0.17768540978431702
of O 0 3.2790749173727818e-06
this O 0 1.6257693857824052e-07
pathway O 0 1.03772902093624e-06
may O 0 5.763069665931653e-08
be O 0 1.960131434941559e-08
a O 0 2.3728903286723835e-08
general O 0 7.87629588216987e-08
phenomenon O 0 1.1132256361179316e-07
in O 0 5.085112775304879e-09
the O 0 5.1473412199243285e-09
majority O 0 1.492111145751096e-08
of O 0 7.37424201702197e-08
cases O 0 9.550097246346922e-08
of O 0 3.895729605574161e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999988079071045
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005599288851954043
. O 0 9.533696720609441e-05

A O 0 3.3890752092702314e-05
novel O 0 7.869064575061202e-06
Arg362Ser O 0 6.707503052894026e-05
mutation O 0 1.1847506584672374e-06
in O 0 1.0085566515272149e-07
the O 0 1.6767050681210094e-07
sterol O 0 3.002304538313183e-06
27 O 0 5.0228954933118075e-06
- O 0 1.0510912034078501e-05
hydroxylase O 0 8.65612855704967e-06
gene O 0 5.09364326717332e-07
( O 0 2.5283924287577975e-07
CYP27 O 0 0.00030092260567471385
) O 0 9.525555810796504e-08
: O 0 2.9054579187004492e-08
its O 0 1.3179443314470518e-08
effects O 0 1.353897118860914e-07
on O 0 1.6752665032981895e-07
pre O 0 1.3989916851642192e-06
- O 0 4.133291042762721e-07
mRNA O 0 4.1741114387150446e-07
splicing O 0 6.68382313051552e-07
and O 0 1.6441869377104013e-07
enzyme O 0 9.608836535335286e-07
activity O 0 2.8140989343228284e-06
. O 0 7.054328307276592e-06

A O 0 1.994363992707804e-05
novel O 0 3.0865141980029875e-06
C O 0 8.043635716603603e-06
to O 0 6.585511158618829e-08
A O 0 3.3428483448005863e-07
mutation O 0 1.0545277717710633e-07
in O 0 2.1505137226540683e-08
the O 0 7.532317880531991e-08
sterol O 0 1.9032138425245648e-06
27 O 0 3.0958653951529413e-06
- O 0 4.6656973609060515e-06
hydroxylase O 0 7.407704742945498e-06
gene O 0 3.6283884696786117e-07
( O 0 1.6846357198119222e-07
CYP27 O 0 0.00012131644325563684
) O 0 1.313331381425087e-07
was O 0 2.861666246189998e-07
identified O 0 1.5479710668842017e-07
by O 0 6.82384495576116e-08
sequencing O 0 1.8645699810804217e-06
amplified O 0 6.654853677900974e-06
CYP27 O 0 0.0004902124055661261
gene O 0 1.2434779819159303e-06
products O 0 3.4733082543425553e-07
from O 0 1.0753305446087325e-07
a O 0 2.1351588941342925e-07
patient O 0 6.233544809219893e-07
with O 0 1.5121368051040918e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 7.488520350307226e-05
CTX B-Disease 1 0.9982085227966309
) O 0 7.3423793764959555e-06
. O 0 3.0595540010835975e-05

The O 0 7.600501248816727e-06
mutation O 0 5.97244661548757e-06
changed O 0 1.5008043874331634e-06
the O 0 7.372665891125507e-07
adrenodoxin O 0 2.7094278266304173e-05
cofactor O 0 9.2581385615631e-06
binding O 0 1.0842850315384567e-06
residue O 0 1.475075691814709e-06
362Arg O 0 4.237541361362673e-06
to O 0 2.0454545790471457e-07
362Ser O 0 2.74072681349935e-05
( O 0 1.7021495750668691e-06
CGT O 0 0.00013127554848324507
362Arg O 0 1.7168586055049673e-05
to O 0 5.139197014614183e-07
AGT O 0 0.0006753174238838255
362Ser O 0 2.2505530068883672e-05
) O 0 1.0831920604914558e-07
, O 0 5.4716849717806326e-08
and O 0 6.780692274332978e-08
was O 0 1.6668758462401456e-06
responsible O 0 3.4712065826170146e-06
for O 0 7.854779937588319e-07
deficiency O 0 0.11086931079626083
in O 0 6.500253135754974e-08
the O 0 2.2471867566764558e-07
sterol O 0 3.7539662116614636e-06
27 O 0 4.7855601224000566e-06
- O 0 6.248613317438867e-06
hydroxylase O 0 7.421988357236842e-06
activity O 0 1.2629665491203923e-07
, O 0 1.6177633455072282e-08
as O 0 1.139733196708903e-08
confirmed O 0 2.6823931520425504e-08
by O 0 5.188622420604361e-09
expression O 0 1.756206025049778e-08
of O 0 5.214440434997414e-08
mutant O 0 5.193714969209395e-07
cDNA O 0 5.20527862590825e-07
into O 0 1.7451809242174932e-07
COS O 0 1.953903483808972e-05
- O 0 6.458059033320751e-06
1 O 0 5.191117907088483e-06
cells O 0 7.726834155619144e-06
. O 0 3.808139808825217e-06

Quantitative O 0 2.9896165870013647e-05
analysis O 0 6.944630399630114e-07
showed O 0 2.586138236893021e-07
that O 0 8.060551337507604e-09
the O 0 2.4425888867085632e-08
expression O 0 4.325562130702565e-08
of O 0 1.2141209992933e-07
CYP27 O 0 1.1212833669560496e-05
gene O 0 1.1348345196893206e-07
mRNA O 0 2.6601640001899796e-07
in O 0 4.155316446485813e-08
the O 0 1.4591715569167718e-07
patient O 0 6.142788038232538e-07
represented O 0 2.1281546196405543e-06
52 O 0 2.687697451619897e-05
. O 0 2.9697683203266934e-05

5 O 0 6.060027772036847e-06
% O 0 2.371725855709883e-07
of O 0 3.5030745948461117e-07
the O 0 4.907406605525466e-07
normal O 0 3.874064077535877e-06
level O 0 5.2799445256823674e-05
. O 0 1.0229547115159221e-05

As O 0 1.7862340655483422e-06
the O 0 4.526018528849818e-07
mutation O 0 1.1637096122285584e-06
occurred O 0 2.2614065073867096e-06
at O 0 5.514777967619011e-07
the O 0 1.4821938520981348e-07
penultimate O 0 6.8924141487514134e-06
nucleotide O 0 4.140795226703631e-07
of O 0 1.5099824679509766e-07
exon O 0 1.2072883919245214e-06
6 O 0 1.717578697935096e-06
( O 0 6.955964693133865e-08
- O 0 2.1102593450450513e-07
2 O 0 3.2437651498185005e-07
position O 0 5.832259830640396e-07
of O 0 2.2228029195048293e-07
exon O 0 1.371642497360881e-06
6 O 0 1.994752437894931e-06
- O 0 7.962755148582801e-07
intron O 0 2.2641493160335813e-06
6 O 0 1.707348701529554e-06
splice O 0 1.2591833637998207e-06
site O 0 8.844990162515387e-08
) O 0 8.995385769594577e-09
of O 0 2.9328626638402966e-08
the O 0 5.7921290874674014e-08
gene O 0 1.1271345812247091e-07
, O 0 4.99670989029255e-08
we O 0 9.619860463772056e-08
hypothesized O 0 1.7984044120566978e-07
that O 0 6.754087511495754e-09
the O 0 4.8318501200128594e-08
mutation O 0 3.632505354289606e-07
may O 0 4.5910712742625037e-07
partially O 0 1.808063757380296e-06
affect O 0 1.7571149157902255e-07
the O 0 9.196701711289279e-08
normal O 0 2.1911085923420615e-07
splicing O 0 6.3548964135407e-07
efficiency O 0 2.9389227051979105e-07
in O 0 2.6820810461458677e-08
exon O 0 3.217570849756157e-07
6 O 0 1.6278498549127107e-07
and O 0 1.247028880158041e-08
cause O 0 4.169479694837719e-08
alternative O 0 1.1744154448933841e-07
splicing O 0 1.7951587949482928e-07
elsewhere O 0 3.733920905801824e-08
, O 0 6.17491346943666e-09
which O 0 2.8880027258537666e-09
resulted O 0 6.860529566665718e-08
in O 0 2.7697170779106273e-08
decreased O 0 8.472511012769246e-07
transcript O 0 1.5073969734658021e-06
in O 0 9.104896037115395e-08
the O 0 6.679222792627115e-07
patient O 0 7.580565579701215e-06
. O 0 1.8086197087541223e-05

Transfection O 0 0.0004532716702669859
of O 0 9.288658475270495e-06
constructed O 0 0.0001092501261155121
minigenes O 0 0.0002136572147719562
, O 0 1.9834435249777016e-07
with O 0 3.264557690840775e-08
or O 0 3.523424751961102e-08
without O 0 4.135249653813844e-08
the O 0 1.3791273012486727e-08
mutation O 0 2.8808411656200406e-08
, O 0 1.4444972329386019e-08
into O 0 5.1300645509400056e-08
COS O 0 8.29860073281452e-06
- O 0 7.271347044479626e-07
1 O 0 2.7941976554757275e-07
cells O 0 4.720199342500564e-08
confirmed O 0 2.009080901643756e-08
that O 0 2.479354277440393e-09
the O 0 2.3843504948217742e-08
mutant O 0 1.428964537808497e-06
minigene O 0 8.85858025867492e-06
was O 0 2.996238492869452e-07
responsible O 0 1.3870524639969517e-07
for O 0 2.4619248861768028e-08
a O 0 4.508824247295706e-08
mRNA O 0 2.2748035632957908e-07
species O 0 1.8454375805276868e-08
alternatively O 0 4.7261403324228013e-07
spliced O 0 2.7744920316763455e-06
at O 0 8.21450214516517e-07
an O 0 1.4947566739920148e-07
activated O 0 9.288605724577792e-06
cryptic O 0 5.99204304307932e-06
5 O 0 1.734126271912828e-06
splice O 0 4.284239366825204e-06
site O 0 8.891859692994331e-07
88 O 0 2.2831761725683464e-06
bp O 0 2.653497858773335e-06
upstream O 0 3.882526584675361e-07
from O 0 1.766412083270552e-08
the O 0 5.009133730027315e-08
3 O 0 5.53162806227192e-07
end O 0 9.028044019032677e-07
of O 0 6.581091156476759e-07
exon O 0 8.71809788804967e-06
6 O 0 1.2467369742807932e-05
. O 0 1.2609807527041994e-05

Our O 0 3.432634457567474e-06
data O 0 2.991068015489873e-07
suggest O 0 4.6036586098807675e-08
that O 0 5.153982129968426e-09
the O 0 1.9169869247548377e-08
C O 0 4.86636679397634e-07
to O 0 7.190620987529428e-09
A O 0 1.225807864102535e-07
mutation O 0 9.903499886831924e-08
at O 0 1.472499207011424e-07
the O 0 8.767324288783129e-08
penultimate O 0 3.499689455566113e-06
nucleotide O 0 2.1482020429175464e-07
of O 0 9.070333817362553e-08
exon O 0 5.329094392436673e-07
6 O 0 2.0917974552503438e-07
of O 0 3.962157890669005e-08
the O 0 9.23026703958385e-08
CYP27 O 0 2.9458769859047607e-05
gene O 0 1.5689329302404076e-07
not O 0 2.3851601582691728e-08
only O 0 9.845322068713358e-08
causes O 0 1.7874046989163617e-06
the O 0 1.152778622781625e-06
deficiency B-Disease 0 0.0009320536628365517
in I-Disease 0 1.138860170613043e-07
the I-Disease 0 1.9313245047669625e-07
sterol I-Disease 0 1.2390719348331913e-06
27 I-Disease 0 4.184779754723422e-06
- I-Disease 0 3.90430659535923e-06
hydroxylase I-Disease 0 2.6929487830784637e-06
activity I-Disease 0 8.176377974677962e-08
, O 0 1.4692751904021861e-08
but O 0 2.7568146876433275e-08
also O 0 2.4717113689121106e-08
partially O 0 1.3160533285372367e-07
leads O 0 3.271582471597867e-08
to O 0 7.204871366184307e-09
alternative O 0 1.9867469802647975e-07
pre O 0 8.622001814728719e-07
- O 0 1.4261392777825677e-07
mRNA O 0 1.0811402972876749e-07
splicing O 0 1.7989583511734963e-07
of O 0 7.454481476543151e-08
the O 0 2.4062072156993963e-07
gene O 0 2.708655074457056e-06
. O 0 9.021984624268953e-06

To O 0 8.206045549741248e-07
our O 0 2.6532902097642364e-07
knowledge O 0 6.390425255631271e-07
, O 0 4.16135996772482e-08
this O 0 1.0228005997703349e-08
is O 0 8.146393781771621e-09
the O 0 1.0981466402881779e-08
first O 0 4.6775472384297245e-08
report O 0 3.18516519826062e-08
regarding O 0 9.99662574940885e-08
effects O 0 3.686613752051926e-07
on O 0 1.745487310245153e-07
pre O 0 1.1943296840399853e-06
- O 0 2.2569759039470227e-07
mRNA O 0 1.10235667705183e-07
splicing O 0 1.1633062513283221e-07
of O 0 1.4933096537106394e-08
a O 0 2.3864433984499556e-08
mutation O 0 6.87808707766635e-08
at O 0 1.0333388189565085e-07
the O 0 2.6583018453152363e-08
- O 0 2.0102928033338685e-07
2 O 0 2.185686440725476e-07
position O 0 3.396643819542078e-07
of O 0 1.4869637254832924e-07
a O 0 2.3599686471698078e-07
5 O 0 1.5289026578102494e-06
splice O 0 7.734442988294177e-06
site O 0 2.99138400805532e-06
. O 0 1.3595150448963977e-05

ATM O 0 0.0007775334524922073
germline O 0 0.0004630741022992879
mutations O 0 7.139687568269437e-06
in O 0 1.3209878488851245e-06
classical O 1 0.9858055710792542
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.07111776620149612
in O 0 2.7539618940863875e-07
the O 0 4.683260783622245e-07
Dutch O 0 0.005562199745327234
population O 0 2.5224099431397917e-07
. O 0 5.603174486168427e-06

Germline O 0 0.0008535034139640629
mutations O 0 4.687175987783121e-06
in O 0 1.3120468622673798e-07
the O 0 1.379443546056791e-07
ATM O 0 4.043476110382471e-06
gene O 0 8.248463956306296e-08
are O 0 1.4300421291579823e-08
responsible O 0 2.0036893033648084e-07
for O 0 1.3012667920975218e-07
the O 0 0.00015580309263896197
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.0485303796012886e-05
. O 0 3.958705929107964e-05

In O 0 1.0732544524216792e-06
our O 0 3.407694464385713e-07
study O 0 1.0786151705133307e-07
, O 0 2.113654673507881e-08
we O 0 2.030856549595228e-08
have O 0 5.839692285292131e-09
determined O 0 8.514649607604952e-08
the O 0 4.9457828055210484e-08
ATM O 0 2.130321263393853e-06
mutation O 0 1.5736323177861777e-07
spectrum O 0 5.041040935793717e-07
in O 0 2.9415852864644876e-08
19 O 0 5.308996833264246e-07
classical O 0 1.1465180250525009e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 5.10165989453526e-07
, O 0 2.5894717481378393e-08
including O 0 6.088346715671378e-09
some O 0 2.450885050464535e-09
immigrant O 0 1.4170040252281524e-08
populations O 0 6.853543066398515e-09
, O 0 6.7877810039362885e-09
as O 0 7.551705927255625e-09
well O 0 9.088530816825369e-09
as O 0 8.424826170028155e-09
12 O 0 5.6923006752640504e-08
of O 0 5.071525777111674e-08
Dutch O 0 7.060264124447713e-06
ethnic O 0 2.523781574836903e-07
origin O 0 1.5913284414637019e-06
. O 0 1.676317333476618e-05

Both O 0 2.6715435978985624e-06
the O 0 6.750032639502024e-07
protein O 0 8.625175951237907e-07
truncation O 0 5.899967163713882e-06
test O 0 1.6479417581649614e-06
( O 0 4.3921968995164207e-07
PTT O 0 1.3364112419367302e-05
) O 0 5.782823464528519e-08
and O 0 3.679384619204029e-08
the O 0 5.036120143131484e-08
restriction O 0 1.1226075002923608e-07
endonuclease O 0 3.1985671284928685e-06
fingerprinting O 0 1.6143638958965312e-06
( O 0 3.393215024516394e-07
REF O 0 1.786402026482392e-05
) O 0 4.019543453637198e-08
method O 0 8.886384961215299e-08
were O 0 4.310260237616603e-08
used O 0 2.4598877601533786e-08
and O 0 4.742570780535971e-08
compared O 0 5.1949434975995246e-08
for O 0 6.3455556364999666e-09
their O 0 5.568236538522342e-09
detection O 0 3.232253504847904e-07
efficiency O 0 4.301115552607371e-07
, O 0 4.438100376091825e-08
identifying O 0 1.2623476663975453e-07
76 O 0 1.063058050476684e-07
% O 0 6.168062505196303e-09
and O 0 1.3441461277352573e-08
60 O 0 2.9379240373827997e-08
% O 0 6.312142364350848e-09
of O 0 3.99837034592565e-08
the O 0 1.1046635250977488e-07
mutations O 0 8.639484008199361e-07
, O 0 4.528388615199219e-07
respectively O 0 6.913875495229149e-06
. O 0 1.326855181105202e-05

Most O 0 3.6477279081736924e-06
patients O 0 7.509208330702677e-07
were O 0 2.4680491605977295e-07
found O 0 4.7324682839189336e-08
to O 0 3.875974030620455e-08
be O 0 2.38264618701578e-07
compound O 0 6.385980668710545e-06
heterozygote O 0 0.0002686269872356206
. O 0 4.4591044570552185e-05

Seventeen O 0 3.675653351820074e-05
mutations O 0 1.866220941337815e-06
were O 0 1.6931109314555215e-07
distinct O 0 9.136540057852471e-08
, O 0 2.965278689259776e-08
of O 0 3.143520999060456e-08
which O 0 1.1253124654331259e-08
10 O 0 6.859954737592489e-08
were O 0 4.977656331561775e-08
not O 0 3.6896732780178354e-08
reported O 0 6.427789571716858e-07
previously O 0 3.4752970350382384e-06
. O 0 1.4951536286389455e-05

Mutations O 0 1.3245490663393866e-05
are O 0 2.6952920961775817e-07
small O 0 3.712793841259554e-07
deletions O 0 4.20353853769484e-06
or O 0 8.875415460352087e-07
point O 0 5.391163085732842e-06
mutations O 0 5.520889772014925e-06
frequently O 0 2.4093583306239452e-06
affecting O 0 8.249883649114054e-06
splice O 0 3.380214548087679e-05
sites O 0 1.4178674064169172e-05
. O 0 5.16560539836064e-05

Moreover O 0 7.093804015312344e-05
, O 0 4.1004745980899315e-06
a O 0 4.342721695138607e-06
16 O 0 3.652657687780447e-05
. O 0 2.520796078897547e-05

7 O 0 0.00018441650900058448
- O 0 4.9277696234639734e-05
kb O 0 4.436137533048168e-05
genomic O 0 7.389546112790413e-07
deletion O 0 5.972594863123959e-07
of O 0 1.527825475022837e-07
the O 0 7.214885044959374e-08
3 O 0 5.782238190477074e-07
end O 0 1.6166303851150587e-07
of O 0 3.827071282103134e-08
the O 0 1.8261932410723603e-08
gene O 0 2.7014467107733253e-08
, O 0 1.1390117293785806e-08
most O 0 8.592055955602973e-09
likely O 0 5.240343625700916e-08
a O 0 3.400487003091257e-08
result O 0 8.217402580612543e-08
of O 0 1.1816685230314761e-07
recombination O 0 1.3799646580991975e-07
between O 0 6.632783566828948e-08
two O 0 3.514618640565459e-08
LINE O 0 2.4890084660000866e-06
elements O 0 1.000772499537561e-06
, O 0 3.0892067570675863e-07
was O 0 1.4762676983082201e-06
identified O 0 2.8422919058357365e-06
. O 0 1.3028283319727052e-05

The O 0 3.4897311707027256e-06
most O 0 2.6424848442729854e-07
frequently O 0 6.448904343869799e-08
found O 0 3.192780440031129e-08
mutation O 0 8.483201696662945e-08
, O 0 2.2894107942761366e-08
identified O 0 9.274386059132667e-08
in O 0 3.472393572678811e-08
three O 0 1.408597114505028e-07
unrelated O 0 9.972932275559288e-07
Turkish O 0 1.385439099976793e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
individuals O 0 2.1178763631723996e-07
, O 0 1.7820471498453117e-07
was O 0 6.73620661473251e-07
previously O 0 7.810590574308662e-08
described O 0 2.836702606145991e-08
to O 0 8.684073016240745e-09
be O 0 6.80239082839762e-08
a O 0 2.2683001077439258e-07
Turkish O 0 1.530669760541059e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
founder O 0 0.21144956350326538
mutation O 0 8.672264084452763e-05
. O 0 2.7760701414081268e-05

The O 0 2.3271379632205935e-06
presence O 0 1.1782469755416969e-06
of O 0 9.274037324757956e-07
a O 0 8.610825830146496e-07
founder O 0 1.0188703527092002e-05
mutation O 0 7.111934792192187e-07
among O 0 5.25795442740673e-08
relatively O 0 4.7815635895176456e-08
small O 0 1.858273179777825e-08
ethnic O 0 9.50750944639367e-09
population O 0 3.020701022649064e-09
groups O 0 3.5870002523807898e-09
in O 0 7.78608999496555e-09
Western O 0 1.711504467039049e-07
Europe O 0 3.048680241590773e-07
could O 0 4.2180811732350776e-08
indicate O 0 2.798284981508914e-08
a O 0 2.4520929287064064e-08
high O 0 1.892930896474354e-07
carrier O 0 6.604127378295743e-08
frequency O 0 3.850597352084151e-07
in O 0 2.0948313306234922e-08
such O 0 2.7781188904896226e-08
communities O 0 5.868945436304784e-07
. O 0 4.387304670672165e-06

In O 0 1.7599369357412797e-06
patients O 0 3.5654480257107934e-07
of O 0 2.755165269263671e-07
Dutch O 0 7.059919880703092e-05
ethnic O 0 5.434045391439213e-08
origin O 0 6.087536519316927e-08
, O 0 2.7729836205026004e-08
however O 0 4.9204441410211075e-08
, O 0 2.3527991999117148e-08
no O 0 2.3837683826855027e-08
significant O 0 1.0616720658163104e-07
founder O 0 1.6025129525587545e-06
effect O 0 6.56148870348261e-07
could O 0 2.873301809813711e-07
be O 0 3.7868886693104287e-07
identified O 0 6.323607976810308e-06
. O 0 1.2876279470219743e-05

The O 0 4.722774974652566e-06
observed O 0 2.6901432192971697e-06
genetic O 0 1.0595575758998166e-06
heterogeneity O 0 2.2149340566102182e-06
including O 0 1.3219099059824657e-07
the O 0 5.49947429817621e-08
relative O 0 4.6496614913849044e-07
high O 0 5.4794936659163795e-06
percentage O 0 2.5122119495790685e-07
of O 0 3.88042792565102e-07
splice O 0 4.9958794079429936e-06
- O 0 1.1088068276876584e-06
site O 0 1.5043940493342234e-07
mutations O 0 1.3063721837625053e-07
had O 0 1.0577548437140649e-07
no O 0 1.8118369382591482e-07
reflection O 0 1.4585275494027883e-06
on O 0 1.0901869700319367e-06
the O 0 2.332857548026368e-06
phenotype O 0 0.00012803907156921923
. O 0 2.0623539967346005e-05

All O 0 3.92917627323186e-06
patients O 0 7.42066163184063e-07
manifested O 0 1.7931396314452286e-06
classical O 0 8.408209396293387e-06
A B-Disease 1 0.9999712705612183
- I-Disease 1 0.9979996085166931
T I-Disease 1 0.9999971389770508
and O 0 7.921211704342568e-07
increased O 0 1.1919198641408002e-06
cellular O 0 9.282326573156752e-06
radioresistant O 0 1.0218011993856635e-05
DNA O 0 2.382683305768296e-06
synthesis O 0 7.346216989390086e-06
. O 0 4.5142642193241045e-06

Determination O 0 2.021537693508435e-05
of O 0 1.7348110077364254e-06
the O 0 3.03848622706937e-07
genomic O 0 2.7619711318038753e-07
structure O 0 2.272253709634242e-07
of O 0 8.172979448772821e-08
the O 0 1.146995742828949e-07
COL4A4 O 0 0.000121170531201642
gene O 0 2.005027539553339e-07
and O 0 9.263071376608423e-08
of O 0 6.364551836668397e-07
novel O 0 5.978914487059228e-06
mutations O 0 0.10620605200529099
causing O 1 0.9998511075973511
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999901056289673

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.015831856057047844
a O 0 0.0002941878919955343
progressive O 1 0.9999997615814209
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.13546690344810486
by O 0 9.365215191792231e-06
glomerular B-Disease 1 0.9950036406517029
basement I-Disease 1 0.9994049072265625
membrane I-Disease 1 0.8005654215812683
abnormalities I-Disease 1 0.9999599456787109
and O 0 8.014102377273957e-07
associated O 0 5.30664294728922e-07
with O 0 8.742743062839509e-08
mutations O 0 4.5249524305290834e-07
in O 0 3.6266687430952516e-08
either O 0 1.3709673396533617e-07
the O 0 2.85217652162828e-07
COL4A3 O 0 0.06661500781774521
or O 0 9.936383804642901e-08
the O 0 1.133480367343509e-07
COL4A4 O 0 1.6685757145751268e-05
gene O 0 6.81868002061492e-08
, O 0 2.4584009494788006e-08
which O 0 1.076021582946396e-08
encode O 0 8.409690366306677e-08
the O 0 9.637785325367076e-08
alpha3 O 0 7.381456725852331e-06
and O 0 4.769885890709702e-07
alpha4 O 0 4.1748346120584756e-05
type O 0 5.6294371461262926e-05
IV O 1 0.9999998807907104
collagen O 1 0.967330276966095
chains O 0 1.7317930542048998e-05
, O 0 1.7637240716794622e-06
respectively O 0 1.543513462820556e-05
. O 0 1.0945928806904703e-05

To O 0 8.29331156637636e-07
date O 0 2.7790201784227975e-06
, O 0 7.910199428806663e-08
mutation O 0 6.921185757846615e-08
screening O 0 9.720436366933427e-08
in O 0 1.0835180752621909e-08
the O 0 2.0747821238842334e-08
two O 0 1.4058320729759544e-08
genes O 0 2.957207456688593e-08
has O 0 1.0136474770661152e-08
been O 0 2.335300131051099e-08
hampered O 0 4.615413615738362e-07
by O 0 1.6201624930545222e-08
the O 0 4.5261003833729774e-08
lack O 0 2.115655775014602e-07
of O 0 2.70071609520528e-07
genomic O 0 4.2723721094262146e-07
structure O 0 3.894221663358621e-06
information O 0 1.62421781624289e-06
. O 0 9.418777153769042e-06

We O 0 9.198241968988441e-06
report O 0 1.2492403129726881e-06
here O 0 1.2759323908539955e-07
the O 0 3.4256935066423466e-08
complete O 0 1.4452831464950577e-07
characterization O 0 1.8860187367408798e-07
of O 0 7.700271709154549e-08
the O 0 9.113148280448513e-08
48 O 0 4.450018593615823e-07
exons O 0 7.94760467215383e-07
of O 0 8.441493548616563e-08
the O 0 1.0071437372971559e-07
COL4A4 O 0 5.172723103896715e-05
gene O 0 1.7082138015211967e-07
, O 0 2.827713707631574e-08
a O 0 5.6656435987179066e-08
comprehensive O 0 3.057581068333093e-07
gene O 0 8.213971369741557e-08
screen O 0 4.1308990716970584e-07
, O 0 4.25712798346467e-08
and O 0 1.9164458464615564e-08
the O 0 2.2126291909785323e-08
subsequent O 0 3.7348467429865195e-08
detection O 0 1.7949174946352286e-07
of O 0 7.186058326169587e-08
10 O 0 2.304108761563839e-07
novel O 0 1.596250029933799e-07
mutations O 0 7.842332934160368e-07
in O 0 2.0731116023853247e-07
eight O 0 1.868343497335445e-05
patients O 0 7.929857383714989e-05
diagnosed O 1 0.9998251795768738
with O 0 0.11409839242696762
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9998359680175781

Furthermore O 0 2.0657160348491743e-05
, O 0 1.3089239701002953e-06
we O 0 5.027660563428071e-07
identified O 0 4.810231644114538e-07
a O 0 1.4970120787438645e-07
glycine O 0 1.3358800288187922e-06
to O 0 7.946493241206554e-08
alanine O 0 1.5981617025317973e-06
substitution O 0 8.210092801164137e-07
in O 0 9.792415767151397e-08
the O 0 2.4607587079117366e-07
collagenous O 0 2.3005170078249648e-05
domain O 0 8.085514480171696e-08
that O 0 4.134458997384627e-09
is O 0 6.2277254464504495e-09
apparently O 0 6.420320630695642e-08
silent O 0 4.1904280578819453e-07
in O 0 1.8419665792634987e-08
the O 0 7.330069706767972e-08
heterozygous O 0 4.220137554966641e-07
carriers O 0 1.6574520600443066e-07
, O 0 1.5689644783378753e-07
in O 0 1.845902772856789e-07
11 O 0 1.2513863111962564e-05
. O 0 1.4134701814327855e-05

5 O 0 4.244793672114611e-06
% O 0 1.2291253881357989e-07
of O 0 1.0048009357888077e-07
all O 0 2.4628405981275137e-08
control O 0 1.931982041014635e-07
individuals O 0 1.2697242368631123e-08
, O 0 2.0577607173777324e-08
and O 0 1.9302651921293545e-08
in O 0 1.011708317122384e-08
one O 0 1.1835515678626507e-08
control O 0 6.990719469968099e-08
individual O 0 9.891357066749151e-09
homozygous O 0 4.848485701813843e-08
for O 0 1.4322313113268592e-08
this O 0 2.44316673558842e-08
glycine O 0 3.970460511482088e-06
substitution O 0 7.351613476203056e-06
. O 0 1.1285879736533388e-05

There O 0 2.0834290808124933e-06
has O 0 1.0216331247647759e-07
been O 0 3.669180870247146e-08
no O 0 2.292194167807793e-08
previous O 0 5.547313364218098e-08
finding O 0 9.08210537886589e-08
of O 0 6.703523069973016e-08
a O 0 5.429217964092459e-08
glycine O 0 2.456357890423533e-07
substitution O 0 1.556699658067373e-07
that O 0 5.103408806661491e-09
is O 0 4.0133594225721936e-09
not O 0 2.5891639943154132e-09
associated O 0 1.7063861434962746e-08
with O 0 4.69476901798771e-09
any O 0 3.031004425224637e-08
obvious O 0 4.2202464101137593e-07
phenotype O 0 1.6074708355517942e-06
in O 0 9.132951106494147e-08
homozygous O 0 2.153680270566838e-06
individuals O 0 4.864009497396182e-07
. O 0 6.121365004219115e-06

Founder O 0 0.004582799971103668
BRCA1 O 0 0.00027414370561018586
and O 0 4.790222192241345e-06
BRCA2 O 0 2.8678685339400545e-05
mutations O 0 1.707226601865841e-06
in O 0 2.2216288186882593e-07
French O 0 0.0607604943215847
Canadian O 1 0.9850939512252808
breast B-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.396113116759807e-05
. O 0 0.00013722268340643495

We O 0 2.0417840005393373e-06
have O 0 1.1434593005787974e-07
identified O 0 4.98578572205588e-07
four O 0 1.7842135946466442e-07
mutations O 0 2.664594660473085e-07
in O 0 2.3411917737803378e-08
each O 0 2.034144053197906e-08
of O 0 3.4378132340862066e-07
the O 0 6.923753517185105e-06
breast B-Disease 1 0.9969232678413391
cancer I-Disease 1 0.9396787285804749
- O 0 0.01591108739376068
susceptibility O 0 4.33945524491719e-06
genes O 0 3.3961612189159496e-07
, O 0 2.454763148307393e-07
BRCA1 O 0 5.0296162044105586e-06
and O 0 9.405325158695632e-07
BRCA2 O 0 2.236944237665739e-05
, O 0 1.909187830051451e-07
in O 0 8.755158376061445e-08
French O 0 0.03460567817091942
Canadian O 0 0.4080239534378052
breast B-Disease 1 0.999991774559021
cancer I-Disease 1 0.9999932050704956
and O 1 0.9999790191650391
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.6702316543160123e-06
from O 0 2.9629379696416436e-06
Quebec O 0 0.00023819692432880402
. O 0 6.170194683363661e-05

To O 0 5.5142600103863515e-06
identify O 0 1.449542924092384e-05
founder O 0 8.6683125118725e-05
effects O 0 8.918130333768204e-05
, O 0 9.842184454100789e-07
we O 0 5.972094072603795e-07
examined O 0 1.1833618600576301e-06
independently O 0 2.2542440092365723e-07
ascertained O 0 3.0606436212110566e-06
French O 0 2.8049596949131228e-05
Canadian O 0 2.4023715013754554e-05
cancer B-Disease 0 1.2448361303540878e-05
families O 0 2.645066032869181e-08
for O 0 1.5219294269286365e-08
the O 0 1.8532787748881674e-08
distribution O 0 1.6605492092480745e-08
of O 0 4.3371443325668224e-08
these O 0 5.6084445532178506e-08
eight O 0 1.2948064522788627e-06
mutations O 0 6.45042018732056e-06
. O 0 1.1613964488788042e-05

Mutations O 0 1.2972702279512305e-05
were O 0 4.6516572638211073e-07
found O 0 5.904431077397021e-08
in O 0 4.082724913700986e-08
41 O 0 5.464675609800906e-07
of O 0 6.378272132678831e-07
97 O 0 1.5913688912405632e-05
families O 0 2.429316054985975e-06
. O 0 1.9657547454698943e-05

Six O 0 1.4755491974938195e-05
of O 0 1.4991494481364498e-06
eight O 0 1.1499753327370854e-06
mutations O 0 6.964301633161085e-07
were O 0 4.642058399895177e-07
observed O 0 1.272514396077895e-06
at O 0 3.526024329403299e-06
least O 0 1.8117799527317402e-06
twice O 0 9.656415386416484e-06
. O 0 1.4988624570833053e-05

The O 0 1.8084316252497956e-05
BRCA1 O 0 4.830965190194547e-05
C4446T O 0 3.2853116863407195e-05
mutation O 0 2.3499951566918753e-06
was O 0 6.845608595540398e-07
the O 0 5.665600255611025e-08
most O 0 2.399364262828385e-08
common O 0 5.3673371525064795e-08
mutation O 0 8.025470776829025e-08
found O 0 3.523142666495005e-08
, O 0 4.0098264264543104e-08
followed O 0 1.0526989768777639e-07
by O 0 5.8460816632077695e-08
the O 0 4.687385057877691e-07
BRCA2 O 0 3.698723594425246e-05
8765delAG O 0 5.5244629038497806e-05
mutation O 0 1.9972892914665863e-05
. O 0 2.2993523089098744e-05

Together O 0 1.428059931640746e-06
, O 0 1.2295249973703903e-07
these O 0 1.4686363236648958e-08
mutations O 0 4.991870738990656e-08
were O 0 2.6215452919586824e-08
found O 0 1.263999926948145e-08
in O 0 1.0297260821801046e-08
28 O 0 2.741028595210082e-07
of O 0 1.3222314976246707e-07
41 O 0 6.485132075795264e-07
families O 0 1.3603043136356519e-08
identified O 0 9.219041885444312e-08
to O 0 3.8229639898190726e-08
have O 0 1.2216624156735634e-07
a O 0 1.1790001508416026e-06
mutation O 0 2.5627929062466137e-05
. O 0 3.833355731330812e-05

The O 0 2.6358154627814656e-06
odds O 0 4.820679350814316e-06
of O 0 1.806168086204707e-07
detection O 0 6.421312832571857e-07
of O 0 3.2311369579929305e-08
any O 0 7.62594520864468e-09
of O 0 3.199840392653641e-08
the O 0 4.523545626966552e-08
four O 0 1.5420023657952697e-07
BRCA1 O 0 1.1896723890458816e-06
mutations O 0 1.0208437970504747e-06
was O 0 2.1683310933440225e-06
18 O 0 2.2151341909193434e-05
. O 0 1.6716528989491053e-05

7x O 0 0.004083168227225542
greater O 0 5.329380655894056e-06
if O 0 4.2179888737337023e-07
one O 0 7.04525291439495e-08
or O 0 3.330634612552785e-08
more O 0 6.439413002823358e-09
cases O 0 1.7694469889306674e-08
of O 0 2.0133561520196963e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.812902261619456e-06
also O 0 5.574476702463471e-08
present O 0 3.9143245089690026e-08
in O 0 4.648960683084624e-08
the O 0 2.9557199354712793e-07
family O 0 4.510888800268731e-07
. O 0 4.914356395602226e-06

The O 0 4.786139925272437e-06
odds O 0 6.0539164223882835e-06
of O 0 2.81410734714882e-07
detection O 0 1.0314980727343936e-06
of O 0 9.403740364177793e-08
any O 0 2.718561020742527e-08
of O 0 6.539112717973694e-08
the O 0 9.00088039657021e-08
four O 0 4.3651294845403754e-07
BRCA2 O 0 3.2209832170337904e-06
mutations O 0 8.860328080118052e-07
was O 0 3.021615611942252e-06
5 O 0 1.257018720934866e-05
. O 0 1.559399242978543e-05

3x O 0 0.00018468960479367524
greater O 0 1.3246539083411335e-06
if O 0 1.116223486974377e-07
there O 0 3.808924020631821e-08
were O 0 9.012699564436844e-08
at O 0 2.0013938240026619e-07
least O 0 4.857649571476941e-08
five O 0 5.391078516936432e-08
cases O 0 4.972570266659204e-08
of O 0 1.2178718407085398e-06
breast B-Disease 1 0.5962664484977722
cancer I-Disease 0 0.00023056584177538753
in O 0 4.113730938115623e-07
the O 0 2.4859580207703402e-06
family O 0 1.7810357348935213e-06
. O 0 1.1555607670743484e-05

Interestingly O 0 3.56917007593438e-05
, O 0 4.5387176328404166e-07
the O 0 1.0653069892896383e-07
presence O 0 2.0215028939674085e-07
of O 0 2.1219573227426736e-06
a O 0 1.0021928574133199e-05
breast B-Disease 0 0.06720496714115143
cancer I-Disease 0 5.036594666307792e-05
case O 0 1.5860665598665946e-06
< O 0 4.543357135844417e-06
36 O 0 4.85028465391224e-07
years O 0 9.814255008677719e-08
of O 0 5.2394241834008426e-08
age O 0 4.562112394523865e-07
was O 0 2.6605903258314356e-07
strongly O 0 4.378512485914143e-08
predictive O 0 1.8222725373107096e-07
of O 0 1.965402596226795e-08
the O 0 8.273292273486277e-09
presence O 0 7.784174194114257e-09
of O 0 1.1757149032121106e-08
any O 0 1.4594436770209995e-08
of O 0 7.385558831174421e-08
the O 0 1.5894113403192023e-07
eight O 0 1.1855599950649776e-06
mutations O 0 2.3082266125129536e-06
screened O 0 8.084070941549726e-06
. O 0 1.0717319128161762e-05

Carriers O 0 4.7454709601879586e-06
of O 0 6.744884899489989e-07
the O 0 9.75548459791753e-08
same O 0 2.3617150901600326e-08
mutation O 0 4.751135662672823e-08
, O 0 1.0108421655274924e-08
from O 0 4.867050762413783e-09
different O 0 1.1128346244504428e-08
families O 0 8.180446542382924e-09
, O 0 1.837401519821924e-08
shared O 0 2.4614131177713716e-08
similar O 0 4.117415741689001e-08
haplotypes O 0 5.656988264490792e-07
, O 0 1.8336274720809342e-08
indicating O 0 3.8550798109326934e-08
that O 0 4.984313850542321e-09
the O 0 2.8151694309030972e-08
mutant O 0 2.5709118744998705e-07
alleles O 0 9.152395108458222e-08
were O 0 3.121533964645096e-08
likely O 0 3.000381454398848e-08
to O 0 6.874372182608113e-09
be O 0 1.3506969764875976e-08
identical O 0 5.4862837828295596e-08
by O 0 1.07617550426653e-08
descent O 0 1.3427128919829556e-07
for O 0 2.7015239822958392e-08
a O 0 4.34557421158388e-08
mutation O 0 1.7597611190467433e-07
in O 0 7.988801087321917e-08
the O 0 5.271350005386921e-07
founder O 0 3.104508141404949e-05
population O 0 8.094200438790722e-07
. O 0 1.1485907634778414e-05

The O 0 1.20167942441185e-06
identification O 0 8.818893775242032e-07
of O 0 1.6018268524931045e-06
common O 0 1.0800375093822367e-05
BRCA1 O 0 6.180447235237807e-05
and O 0 2.378787030465901e-06
BRCA2 O 0 1.3026593478571158e-05
mutations O 0 6.017664873070316e-07
will O 0 5.210165454627713e-08
facilitate O 0 1.1844869618471421e-07
carrier O 0 1.0792140869853029e-07
detection O 0 8.259403330157511e-07
in O 0 1.2331689447364624e-07
French O 0 0.14995209872722626
Canadian O 1 0.6600876450538635
breast B-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9999958276748657
and O 1 0.9999895095825195
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.2222079830244184e-05
. O 0 7.812288822606206e-05

Are O 0 4.962374532624381e-06
Dp71 O 0 0.0003690669545903802
and O 0 4.721126515505603e-06
Dp140 O 0 0.0001410672557540238
brain O 0 0.00019481127674225718
dystrophin O 0 9.124193456955254e-05
isoforms O 0 1.2453265298972838e-05
related O 0 8.173663559318811e-07
to O 0 4.29861870543391e-07
cognitive B-Disease 1 0.9991517066955566
impairment I-Disease 1 0.9999949932098389
in O 0 0.017236651852726936
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999837875366211

Molecular O 0 0.00013030986883677542
study O 0 1.4134282082522986e-06
and O 0 3.448892584856367e-07
neuropsychological O 0 1.1670676940411795e-05
analysis O 0 2.82729388345615e-07
were O 0 2.5162663064293156e-07
performed O 0 1.6722593443319056e-07
concurrently O 0 5.75442470562848e-07
on O 0 2.0843123138547526e-07
49 O 0 1.3479942708727322e-06
patients O 0 1.2438788417057367e-06
with O 0 7.425283547490835e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999996423721313
DMD B-Disease 1 1.0
) O 0 4.7252618173843075e-07
in O 0 1.3258056874576596e-08
order O 0 2.0874326267517063e-08
to O 0 4.3212389222446745e-09
find O 0 1.8955027769607113e-08
a O 0 1.707753760626929e-08
molecular O 0 1.8361758691298746e-07
explanation O 0 1.4233675926789147e-07
for O 0 4.1629558467093375e-08
the O 0 3.6410025927580136e-07
cognitive B-Disease 1 0.9956485629081726
impairment I-Disease 0 0.4227553904056549
observed O 0 1.151140622823732e-06
in O 0 2.7902592591999564e-07
most O 0 6.963697160244919e-06
DMD B-Disease 1 1.0
patients O 0 0.0001596937217982486
. O 0 4.9180885980604216e-05

Complete O 0 1.1523175999172963e-05
analysis O 0 1.3639933058584575e-06
of O 0 6.260115128498001e-07
the O 0 4.998177587367536e-07
dystrophin O 0 2.292462158948183e-05
gene O 0 5.015830879528949e-07
was O 0 3.877313190514542e-07
performed O 0 3.0080137491950154e-08
to O 0 1.0924099846931767e-08
define O 0 1.944815011256651e-07
the O 0 1.1218455142625317e-07
localization O 0 4.718921445601154e-06
of O 0 3.221805116027099e-07
deletions O 0 1.1030188034055755e-06
and O 0 1.8180247707277886e-07
duplications O 0 6.233388376131188e-06
in O 0 1.0561844732137615e-07
relation O 0 3.062416737975582e-07
to O 0 8.678380680748887e-08
the O 0 5.892921421946085e-07
different O 0 1.1122648174932692e-05
DMD B-Disease 1 1.0
promoters O 0 0.016215244308114052
. O 0 8.853495091898367e-05

Qualitative O 0 2.75435177172767e-05
analysis O 0 1.931452970893588e-06
of O 0 8.048830295592779e-07
the O 0 6.608626108572935e-07
Dp71 O 0 0.00012333516497164965
transcript O 0 2.9763050406472757e-06
and O 0 4.544941845097128e-08
testing O 0 5.030216243540053e-08
for O 0 6.337004254675094e-09
the O 0 8.461769951395581e-09
specific O 0 8.342666113492214e-09
first O 0 3.0176273924098496e-08
exon O 0 2.0399922107117163e-07
of O 0 6.881104752665124e-08
Dp140 O 0 2.5716351501614554e-06
were O 0 2.0924439070313383e-07
also O 0 1.5107920603441016e-07
carried O 0 1.536068225505005e-06
out O 0 1.8046337117993971e-06
. O 0 1.3827477232553065e-05

Neuropsychological O 0 0.0015829846961423755
analysis O 0 1.4887282304698601e-05
assessed O 0 2.6328551030019298e-05
verbal O 0 3.261008532717824e-05
and O 0 2.986523895742721e-06
visuospatial O 0 0.00035645405296236277
intelligence O 0 5.913356289966032e-06
, O 0 6.217579766598647e-07
verbal O 0 6.185164238559082e-05
memory O 1 0.9943466782569885
, O 0 4.216185516270343e-06
and O 0 5.07873573951656e-06
reading O 0 0.002662230283021927
skills O 0 0.08242173492908478
. O 0 5.259862882667221e-05

Comparison O 0 1.1640131560852751e-05
of O 0 1.78271636741556e-06
molecular O 0 1.82895855687093e-05
and O 0 4.7610009801246633e-07
psychometric O 0 2.6465595510671847e-05
findings O 0 7.045010192996415e-07
demonstrated O 0 5.848306159350614e-07
that O 0 4.119175045502743e-08
deletions O 0 7.455105901499337e-07
and O 0 1.1187983517402245e-07
duplications O 0 4.1162875277223065e-06
that O 0 2.3294322915035082e-08
were O 0 1.4698110817334964e-07
localized O 0 8.80300433436787e-07
in O 0 5.258425872511907e-08
the O 0 1.2094025692022115e-07
distal O 0 1.1417192581575364e-05
part O 0 1.293810072411361e-07
of O 0 3.5214702620578464e-07
the O 0 1.557953197561801e-07
gene O 0 1.3862867831448966e-07
seemed O 0 2.0577496684381913e-07
to O 0 2.040150981486022e-08
be O 0 6.740088309697967e-08
preferentially O 0 1.1743442200895515e-06
associated O 0 1.190806301565317e-06
with O 0 8.346429240191355e-06
cognitive B-Disease 1 0.9999994039535522
impairment I-Disease 1 0.9999963045120239
. O 0 0.00021411219495348632

Two O 0 1.3237737221061252e-05
altered O 0 1.7831715013016947e-05
Dp71 O 0 0.00012136284203734249
transcripts O 0 7.056299182295334e-06
and O 0 1.72025252709318e-07
two O 0 1.1147810141665104e-07
deleted O 0 3.681406894884276e-07
Dp140 O 0 7.410131388496666e-07
DNA O 0 1.0860552634994747e-07
sequences O 0 7.480775110479954e-08
were O 0 8.216995439624952e-08
found O 0 6.778520145189759e-08
in O 0 1.1022221713119507e-07
four O 0 2.004319185289205e-06
patients O 0 4.546395302895689e-06
with O 0 6.350831972667947e-05
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 1 0.9935552477836609

These O 0 1.7170086721307598e-06
findings O 0 8.16121655589086e-07
suggest O 0 1.309095978285768e-07
that O 0 1.0762144952991548e-08
some O 0 1.0789460880289425e-08
sequences O 0 4.229876182648695e-08
located O 0 4.0542769141893586e-08
in O 0 1.3279315425052118e-08
the O 0 6.339255520515508e-08
distal O 0 2.582424258434912e-06
part O 0 5.658699464561323e-08
of O 0 1.0509094749977521e-07
the O 0 5.3291145718503685e-08
gene O 0 6.82525111983523e-08
and O 0 5.7917201701229715e-08
, O 0 4.113255513971126e-08
in O 0 1.4930277458802266e-08
particular O 0 6.84497578617993e-08
, O 0 9.448922355659306e-08
some O 0 1.7846151934008958e-07
DMD B-Disease 1 0.9999992847442627
isoforms O 0 8.483429155603517e-06
expressed O 0 5.8850478268368533e-08
in O 0 2.451788816415501e-08
the O 0 8.372064286277237e-08
brain O 0 1.1426179298723582e-05
may O 0 6.578857636441171e-08
be O 0 3.4998549836018356e-08
related O 0 6.897609239331359e-08
to O 0 3.14778709764596e-08
the O 0 8.914291811379371e-07
cognitive B-Disease 1 0.9999943971633911
impairment I-Disease 1 0.9993023872375488
associated O 0 7.397072749881772e-06
with O 0 2.8185439077788033e-05
DMD B-Disease 1 1.0
. O 0 5.801221414003521e-05
. O 0 2.500902883184608e-05

I1307K O 0 0.0005512830102816224
APC O 0 8.97927166079171e-05
and O 0 1.8063453808281338e-06
hMLH1 O 0 1.839669312175829e-05
mutations O 0 7.732576250418788e-07
in O 0 4.0528078670831746e-08
a O 0 9.341493267811529e-08
non O 0 2.106803776769084e-06
- O 0 1.6521148609172087e-06
Jewish O 0 3.1898775887384545e-07
family O 0 6.088535542403406e-08
with O 0 2.1388008519807045e-07
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9992907047271729

We O 0 6.4793052843015175e-06
describe O 0 2.1269229364406783e-06
a O 0 5.484128564603452e-07
French O 0 1.350022830592934e-05
Canadian O 0 1.0321531590307131e-05
hereditary B-Disease 1 0.999997615814209
non I-Disease 1 0.9999998807907104
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999620914459229
HNPCC B-Disease 1 1.0
) O 0 8.282994713226799e-06
kindred O 0 6.108872912591323e-05
which O 0 2.321400671689844e-07
carries O 0 7.908884640528413e-07
a O 0 3.49688633605183e-07
novel O 0 8.559213142689259e-07
truncating O 0 1.6256222806987353e-05
mutation O 0 3.2998452752508456e-06
in O 0 1.775737473508343e-06
hMLH1 O 0 0.00020371793652884662
. O 0 4.527905548457056e-05

Interestingly O 0 2.9463970349752344e-05
, O 0 8.862008940013766e-07
the O 0 5.391278250499454e-07
I1307K O 0 1.1600448488024995e-05
APC O 0 8.400667866226286e-06
polymorphism O 0 2.6988413992512506e-06
, O 0 4.62048710403451e-08
associated O 0 2.925694175814897e-08
with O 0 6.8135812547609476e-09
an O 0 7.185232853146317e-09
increased O 0 1.3445119861899002e-07
risk O 0 3.243841274525039e-05
of O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 0.0002427567378617823
is O 0 3.159450301382094e-08
also O 0 8.148631103210846e-09
present O 0 1.4809174331276154e-08
in O 0 1.2227553192190044e-08
this O 0 4.4102534957346506e-08
family O 0 2.891543715577427e-07
. O 0 6.424549610528629e-06

The O 0 8.46938019094523e-06
I1307K O 0 6.785806908737868e-05
polymorphism O 0 6.254658728721552e-06
has O 0 5.176170958520743e-08
previously O 0 6.484402348405638e-08
only O 0 7.1952310776168815e-09
been O 0 9.934409739287275e-09
identified O 0 3.53511069306478e-08
in O 0 4.876008041776458e-09
individuals O 0 1.0531926442070016e-08
of O 0 1.8491871855985664e-07
self O 0 2.9449249268509448e-05
- O 0 0.001026543672196567
reported O 0 3.2113343877426814e-06
Ashkenazi O 0 2.4120845409925096e-05
Jewish O 0 5.653543212247314e-06
origins O 0 3.026001650141552e-05
. O 0 6.434052193071693e-05

In O 0 1.150690536633192e-06
addition O 0 3.697444128647476e-07
, O 0 4.960416433164028e-08
in O 0 1.1670728383705864e-08
this O 0 5.1487747398937245e-09
family O 0 7.202384466609146e-09
, O 0 5.686828341566752e-09
there O 0 6.591113432818929e-09
appears O 0 7.60189688975288e-09
to O 0 3.044235752369673e-09
be O 0 9.660824140667046e-09
no O 0 2.0259083299833947e-08
relationship O 0 5.8791915336087186e-08
between O 0 7.18900565743752e-08
the O 0 6.137388197657856e-08
I1307K O 0 1.186189933832793e-06
polymorphism O 0 1.37189203996968e-07
and O 0 9.847121340555987e-09
the O 0 1.2075536126587849e-08
presence O 0 3.412376869960099e-08
or O 0 1.614836691032906e-07
absence O 0 3.226495664421236e-06
of O 0 3.834403742075665e-06
cancer B-Disease 0 0.0007711194339208305
. O 0 2.8433871648303466e-06
. O 0 1.4906205251463689e-05

Identification O 0 5.62266450288007e-06
of O 0 1.1342582411089097e-06
a O 0 2.415627022855915e-07
novel O 0 1.5975142275692633e-07
mutation O 0 1.1584328518665643e-07
of O 0 1.2819748462788993e-07
the O 0 2.9993259431648767e-07
CPO O 0 1.776657154550776e-05
gene O 0 3.30244773749655e-07
in O 0 8.831082709548355e-08
a O 0 4.55157817214058e-07
Japanese O 0 4.798544250661507e-05
hereditary B-Disease 1 0.9999992847442627
coproporphyria I-Disease 1 0.9977397918701172
family O 0 1.5267522030626424e-05
. O 0 3.200524588464759e-05

Hereditary B-Disease 1 0.9999946355819702
coproporphyria I-Disease 1 0.9999904632568359
( O 0 0.0009088350925594568
HCP B-Disease 1 0.9999998807907104
) O 0 1.8071862086799229e-06
is O 0 2.527158073917235e-07
an O 0 5.17077410222555e-07
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 0.03939371556043625
by O 0 3.2472801194671774e-06
a O 0 1.8712409655563533e-05
deficiency B-Disease 1 0.9810386896133423
of I-Disease 0 0.023329751566052437
coproporphyrinogen I-Disease 1 0.9999110698699951
oxidase I-Disease 0 0.000351300579495728
( O 0 4.7592351393177523e-07
CPO O 0 1.1076748705818318e-05
) O 0 3.176998575327161e-08
caused O 0 9.683832757900745e-08
by O 0 1.2101312840684386e-08
a O 0 4.352060400947266e-08
mutation O 0 1.341434341384229e-07
in O 0 4.5198717657513043e-08
the O 0 3.9232799053934286e-07
CPO O 0 5.809232243336737e-05
gene O 0 7.018574251560494e-06
. O 0 1.0921788998530246e-05

Only O 0 1.3093884945192258e-06
11 O 0 8.090635219559772e-07
mutations O 0 8.583133137562982e-08
of O 0 4.445403334329967e-08
the O 0 2.4502179840624194e-08
gene O 0 4.629564642755213e-08
have O 0 2.3741309362890206e-08
been O 0 1.1989340009677107e-07
reported O 0 1.2761067864630604e-06
in O 0 2.544092922107666e-06
HCP B-Disease 1 0.9999997615814209
patients O 0 0.00022199282830115408
. O 0 9.459150169277564e-05

We O 0 7.2499205998610705e-06
report O 0 6.941914989511133e-07
another O 0 2.805591350352188e-07
mutation O 0 6.440208153435378e-07
in O 0 6.409540986851425e-08
a O 0 2.860552967831609e-07
Japanese O 0 7.331407232413767e-06
family O 0 5.711741323466413e-06
. O 0 2.0489527742029168e-05

Polymerase O 0 0.0003793486102949828
chain O 0 2.018261147895828e-05
reaction O 0 5.54583357370575e-06
- O 0 2.3424223400070332e-05
single O 0 6.140737696114229e-07
strand O 0 1.5018511021480663e-06
conformational O 0 6.702168207084469e-07
polymorphism O 0 4.357538614385703e-07
and O 0 2.2922726827800943e-08
direct O 0 4.4082518968480144e-08
sequence O 0 6.261470275603642e-08
analyses O 0 8.536537166037306e-08
demonstrated O 0 9.903783393383492e-08
a O 0 9.136697087797074e-08
C O 0 2.3030418105918216e-06
to O 0 3.413184046507922e-08
T O 0 6.600432129744149e-07
substitution O 0 1.3040781254858302e-07
in O 0 1.1774811348175263e-08
exon O 0 6.72160140879896e-08
1 O 0 5.605236452765894e-08
of O 0 2.3613457855731212e-08
the O 0 3.406816517781408e-08
CPO O 0 2.009987156270654e-06
gene O 0 1.1199064431366423e-07
at O 0 2.4182111246773275e-07
nucleotide O 0 2.0688553092895745e-07
position O 0 3.617404900069232e-07
85 O 0 6.122469926594931e-07
, O 0 7.66171197597032e-08
which O 0 5.649672729646227e-08
lies O 0 2.5271677372984414e-07
in O 0 2.2581378544828112e-08
the O 0 6.686106246434065e-08
putative O 0 1.755655375745846e-06
presequence O 0 6.8344488681759685e-06
for O 0 1.8977118543261895e-07
targeting O 0 2.1413918602775084e-06
to O 0 1.2373054687486729e-06
mitochondria O 0 3.848890628432855e-05
. O 0 2.0323221178841777e-05

This O 0 8.036681151679659e-07
mutation O 0 5.979069328532205e-07
changes O 0 2.3834758167140535e-07
the O 0 1.1724604576102138e-07
codon O 0 5.990129920974141e-07
for O 0 4.835869660269054e-08
glutamine O 0 3.8905588439774874e-07
to O 0 3.0634591752232154e-08
a O 0 1.498703454672068e-07
termination O 0 2.162455984944245e-06
codon O 0 9.445591786061414e-06
at O 0 3.5664313600136666e-06
amino O 0 1.3646047136717243e-06
acid O 0 1.2394169743856764e-06
position O 0 5.574174792855047e-06
29 O 0 3.575693699531257e-05
. O 0 1.4939079846953973e-05

MaeI O 0 0.0005153531092219055
restriction O 0 2.4089081307465676e-06
analysis O 0 1.1914970627913135e-06
showed O 0 7.530076118200668e-07
two O 0 9.363112951632502e-08
other O 0 2.694001288716663e-08
carriers O 0 1.5432247835178714e-07
in O 0 7.024414827583314e-08
the O 0 4.2842205516535614e-07
family O 0 1.5748452142361202e-06
. O 0 7.426023785228608e-06

The O 0 1.1688576705637388e-05
C O 0 0.3755926191806793
- O 0 0.017025651410222054
T O 0 3.8808891986263916e-05
mutation O 0 1.433565586239638e-07
is O 0 1.2606604649079145e-08
located O 0 2.7275046221575394e-08
within O 0 2.2243716202297037e-08
a O 0 3.124065273141241e-08
recently O 0 8.326392020308049e-08
proposed O 0 9.765109609816136e-08
putative O 0 3.721208656770614e-07
alternative O 0 4.140380553963041e-07
translation O 0 6.290619012361276e-07
initiation O 0 1.3566893812821945e-06
codon O 0 5.021664946980309e-06
( O 0 5.667253617502865e-07
TIC O 0 6.8424637902353425e-06
- O 0 1.080500851458055e-06
1 O 0 1.142533164966153e-06
) O 0 4.257152497189054e-08
, O 0 3.750651700329399e-08
supporting O 0 1.1426983803630719e-07
that O 0 5.221446741643376e-08
TIC O 0 3.435526195971761e-06
- O 0 1.4572163991033449e-06
1 O 0 1.0498652045498602e-06
is O 0 4.671769815445259e-08
the O 0 6.916224037922802e-08
real O 0 3.7022500691819005e-06
TIC O 0 7.036140232230537e-06
rather O 0 3.993127677404118e-07
than O 0 5.003939236303268e-07
TIC O 0 1.3786750059807673e-05
- O 0 3.0160103960952256e-06
2 O 0 3.401977210160112e-06
. O 0 1.1670215371850645e-06
. O 0 9.132007107837126e-06

Human B-Disease 0 1.0707991350500379e-05
complement I-Disease 0 3.698801083373837e-05
factor I-Disease 0 0.0009776242077350616
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 1 0.7043736577033997
with O 1 0.9999963045120239
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999990463256836

This O 0 8.363140295841731e-07
study O 0 2.7225937060393335e-07
reports O 0 1.7939112240128452e-07
on O 0 2.7659564239002066e-07
six O 0 2.6902560534836084e-07
cases O 0 1.0004579564792948e-07
of O 0 1.8257147758049541e-06
deficiency B-Disease 1 0.9920344948768616
in I-Disease 0 3.2305030117640854e-07
the I-Disease 0 3.981108136486e-07
human I-Disease 0 1.3655456143624178e-07
complement I-Disease 0 2.7275342517896206e-07
regulatory I-Disease 0 6.536980095006584e-07
protein I-Disease 0 4.104717561403959e-07
Factor I-Disease 0 8.117754646264075e-07
H I-Disease 1 0.9999734163284302
( O 0 3.577385712105752e-07
FH O 0 9.25926142372191e-05
) O 0 1.8835340398482003e-08
in O 0 4.002152831361627e-09
the O 0 9.84965708994423e-09
context O 0 3.8062154317231034e-08
of O 0 2.663024929461244e-07
an O 0 4.950510174239753e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.9997979998588562

Five O 0 4.561095920507796e-06
of O 0 4.471019678931043e-07
the O 0 1.2397960347243497e-07
cases O 0 3.663097558614936e-08
were O 0 4.655527163777151e-08
observed O 0 2.1399779370767646e-07
in O 0 3.594768926973302e-08
children O 0 7.924046485641156e-08
presenting O 0 2.4588168798800325e-06
with O 0 7.086103869369254e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.08025462925434113
. O 0 0.0003877971030306071

Two O 0 1.5573693872283911e-06
of O 0 9.851950153461075e-07
the O 0 4.4843045543530025e-07
children O 0 1.924126991070807e-07
exhibited O 0 1.970418679775321e-06
a O 0 6.014967766532209e-06
homozygous O 1 0.8295405507087708
deficiency O 1 0.9999134540557861
characterized O 0 2.5915428523148876e-06
by O 0 6.737363378306327e-08
the O 0 1.1713774483723682e-07
absence O 0 7.310591172426939e-07
of O 0 3.137629960292543e-07
the O 0 2.6812455189428874e-07
150 O 0 4.856176474277163e-07
- O 0 6.871090931781509e-07
kD O 0 1.8220029005533434e-06
form O 0 2.213853456112247e-08
of O 0 5.972731287329225e-08
Factor O 0 5.473547730616701e-07
H O 1 0.9991424083709717
and O 0 2.9056350214773374e-08
the O 0 1.1018475909452263e-08
presence O 0 2.3887567479619065e-08
, O 0 1.3471566973066729e-08
upon O 0 4.400389030934093e-08
immunoblotting O 0 8.361386107935687e-07
, O 0 1.9168151510484677e-08
of O 0 4.0468908224511324e-08
the O 0 1.1868184657259917e-07
42 O 0 7.72109558511147e-07
- O 0 1.6067780279627186e-06
kD O 0 1.0362938155594748e-05
Factor O 0 2.213489779023803e-06
H O 1 0.9617409110069275
- O 0 2.6334587346354965e-06
like O 0 6.381874584349134e-08
protein O 0 1.2913311309148412e-07
1 O 0 4.986532076145522e-07
( O 0 6.474367353348498e-08
FHL O 0 1.1126731806143653e-05
- O 0 2.744371272456192e-07
1 O 0 1.58809015715633e-07
) O 0 2.0540589673601062e-08
and O 0 2.8477128211079616e-08
other O 0 4.113255513971126e-08
FH O 0 0.0001782165636541322
- O 0 1.0003107036027359e-06
related O 0 2.1355499768560549e-07
protein O 0 3.9046688016242115e-07
( O 0 1.128861057964059e-07
FHR O 0 7.631162588950247e-05
) O 0 5.952113610874221e-07
bands O 0 1.65978981385706e-05
. O 0 1.911347317218315e-05

Southern O 0 5.6200457038357854e-05
blot O 0 3.4888744266936556e-05
and O 0 4.963639526067709e-07
PCR O 0 2.1227324396022595e-06
analysis O 0 1.467024191015298e-07
of O 0 7.983272354294968e-08
DNA O 0 2.545577615364891e-07
of O 0 1.600663352974152e-07
one O 0 1.1068063088259805e-07
patient O 0 3.8440077787527116e-07
with O 0 5.031521368437097e-07
homozygous O 1 0.5704224109649658
deficiency O 1 0.9999927282333374
ruled O 0 5.42381894774735e-05
out O 0 5.99688618763139e-08
the O 0 2.939768073417781e-08
presence O 0 3.951471327923173e-08
of O 0 8.350343705387786e-08
a O 0 4.0520969690760467e-08
large O 0 6.030919053046091e-08
deletion O 0 3.217380708520068e-07
of O 0 2.0599388506070682e-07
the O 0 7.190924975475355e-07
FH O 0 0.10390239953994751
gene O 0 3.667452972422325e-07
as O 0 1.2665707060932618e-07
the O 0 4.487731075641932e-07
underlying O 0 0.07190548628568649
defect O 0 0.004329018760472536
for O 0 1.5194692423392553e-05
the O 0 0.002858066465705633
deficiency O 1 0.9999998807907104
. O 0 0.00030593667179346085

The O 0 4.417613581608748e-06
other O 0 3.015047695953399e-07
four O 0 6.947796578060661e-07
children O 0 7.691522796449135e-08
presented O 0 4.6452026936094626e-07
with O 0 4.858548550146224e-07
heterozygous O 0 0.00038060772931203246
deficiency O 1 0.9998325109481812
and O 0 1.7802733509597601e-06
exhibited O 0 4.465469373826636e-06
a O 0 4.4427844159145025e-07
normal O 0 1.7363006463710917e-06
immunoblotting O 0 6.394926913344534e-06
pattern O 0 2.597168986540055e-07
of O 0 5.984111339785159e-08
proteins O 0 2.5073523701735212e-08
of O 0 1.9445275256657624e-07
the O 0 1.3366485518417903e-06
FH O 0 0.08468729257583618
family O 0 2.7101434625365073e-06
. O 0 1.3627992302644998e-05

Factor B-Disease 1 0.9786930084228516
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
is O 0 3.0506782877637306e-07
the O 0 2.2027954571512964e-07
only O 0 6.541127390846668e-07
complement B-Disease 1 0.9999977350234985
deficiency I-Disease 1 1.0
associated O 0 8.390987204620615e-06
with O 0 8.858140972733963e-06
HUS B-Disease 1 1.0
. O 0 0.00018286232079844922

These O 0 2.0667071112256963e-06
observations O 0 2.3010022687230958e-06
suggest O 0 4.813177270079905e-07
a O 0 1.5284885535038484e-07
role O 0 3.8623812770310906e-07
for O 0 5.246413934401062e-07
FH O 1 0.7371057868003845
and O 0 6.834722171333851e-06
/ O 0 0.07148373872041702
or O 0 5.9483445511432365e-06
FH O 0 0.0011249894741922617
receptors O 0 4.775029083248228e-07
in O 0 3.559067351943668e-08
the O 0 1.569956822322638e-07
pathogenesis O 0 0.027854179963469505
of O 0 7.4649060479714535e-06
idiopathic O 1 0.9999896287918091
HUS B-Disease 1 1.0
. O 0 7.63743810239248e-05
. O 0 8.175987750291824e-05

Further O 0 4.518752120930003e-06
evidence O 0 1.2513913816292188e-06
for O 0 7.436899807089503e-08
a O 0 8.147671337610518e-08
major O 0 2.7079116193817754e-07
ancient O 0 1.1743084087356692e-06
mutation O 0 0.00017764465883374214
underlying O 1 0.9999964237213135
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 8.612842066213489e-06
linkage O 0 0.0001802057377062738
disequilibrium O 0 0.00016100326320156455
studies O 0 2.0239122022758238e-07
in O 0 3.513499180485269e-08
the O 0 9.862068139909752e-08
Japanese O 0 7.969364332893747e-07
population O 0 1.3734013748489815e-07
. O 0 3.6775261378352297e-06

The O 1 0.9831016659736633
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999397993087769
DM B-Disease 1 1.0
) O 0 1.1654421996354358e-06
mutation O 0 4.455292526017729e-07
is O 0 3.4714336294427994e-08
an O 0 2.6853211210209338e-08
unstable O 0 1.142307428381173e-05
( O 0 1.6166362684089108e-06
CTG O 0 0.000464368611574173
) O 0 1.339514312803658e-07
n O 0 6.698800234516966e-07
repeat O 0 5.913650511502055e-07
, O 0 4.9270369117948576e-08
present O 0 3.879346976987108e-08
at O 0 1.0900043889705557e-07
a O 0 9.882400675564895e-09
copy O 0 2.013630862052196e-08
number O 0 8.826987141219433e-09
of O 0 1.689851636399453e-08
5 O 0 3.066420504183043e-07
- O 0 4.201204149012483e-07
37 O 0 3.185609500633291e-07
repeats O 0 3.2205147704189585e-07
on O 0 9.713393467336573e-08
normal O 0 5.9237201810447004e-08
chromosomes O 0 4.5245808877325544e-08
but O 0 9.042519621971223e-09
amplified O 0 6.414188646886032e-08
to O 0 8.941518636618184e-09
50 O 0 1.0951078621701527e-07
- O 0 3.207323118203931e-07
3000 O 0 8.205842050301726e-07
copies O 0 1.4409012294436252e-07
on O 0 2.152349679818144e-06
DM B-Disease 1 0.9997864365577698
chromosomes O 0 1.7071068214136176e-05
. O 0 1.1722099770850036e-05

Previous O 0 2.381420199526474e-05
findings O 0 3.924427801393904e-06
in O 0 2.019887972437573e-07
Caucasian O 0 1.3302025081429747e-06
populations O 0 1.9436097886682546e-07
of O 0 8.522543453182152e-07
a O 0 6.808603211538866e-05
DM B-Disease 1 1.0
founder O 1 0.9999725818634033
chromosome O 0 3.766869122046046e-05
raise O 0 3.062329199110536e-07
a O 0 6.590914836124284e-08
question O 0 1.6504992572663468e-07
about O 0 2.0723025073721146e-08
the O 0 3.1508562869930756e-08
molecular O 0 1.0183058520851773e-06
events O 0 1.061728767126624e-07
involved O 0 8.351139513251837e-08
in O 0 2.1368165903368208e-08
the O 0 8.553357133678219e-08
expansion O 0 2.1031562482676236e-06
mutation O 0 5.8842392718361225e-06
. O 0 8.083484317467082e-06

To O 0 2.2134834125608904e-06
investigate O 0 4.793288553628372e-06
whether O 0 4.853787913816632e-07
a O 0 8.110271778605238e-07
founder O 0 1.3819159903505351e-05
chromosome O 0 1.6631634025543462e-06
for O 0 2.1605707445360167e-07
the O 0 1.0139181085833116e-06
DM B-Disease 1 1.0
mutation O 0 6.115275255069719e-07
exists O 0 7.478563901486268e-08
in O 0 7.228946774517908e-09
the O 0 1.4966316186360018e-08
Japanese O 0 1.2507167923558882e-07
population O 0 1.1433868962740235e-08
, O 0 4.8732772484072484e-08
we O 0 1.3116053310113784e-07
genotyped O 0 3.9616666072106455e-06
families O 0 3.731492981273732e-08
using O 0 8.933016459877763e-08
polymorphic O 0 1.477998921473045e-06
markers O 0 4.1126676819658314e-07
near O 0 4.250422591667302e-07
the O 0 4.366678183487238e-07
( O 0 1.3275714536575833e-06
CTG O 0 0.0001683417212916538
) O 0 4.294398081583495e-07
n O 0 2.7955327368545113e-06
repeat O 0 3.0616886306233937e-06
region O 0 1.3153497775419964e-06
and O 0 1.4681359061796684e-06
constructed O 0 2.6384301236248575e-05
haplotypes O 0 7.255814125528559e-05
. O 0 1.4322744391392916e-05

Six O 0 1.1895637726411223e-05
different O 0 5.030441911912931e-07
haplotypes O 0 6.074481007090071e-06
were O 0 3.6619869092646695e-07
found O 0 2.0519921406503272e-07
and O 0 1.5434353599630413e-06
DM B-Disease 1 1.0
alleles O 0 9.766049515747e-06
were O 0 1.5777585531395744e-06
always O 0 1.6294027318508597e-06
haplotype O 0 1.4361219655256718e-05
A O 0 1.7973265130422078e-05
. O 0 2.5582388843758963e-05

To O 0 7.484912885047379e-07
find O 0 3.591010511172499e-07
an O 0 1.636002622262822e-08
origin O 0 4.5562252637409983e-08
of O 0 1.1616855033480533e-07
the O 0 2.7892320986211416e-07
( O 0 2.971212893498887e-07
CTG O 0 7.220199040602893e-05
) O 0 1.0447180898154329e-07
n O 0 3.120409246548661e-07
repeat O 0 2.77336511089743e-07
mutation O 0 1.1641641606274789e-07
and O 0 1.823374162768232e-08
to O 0 1.2207931554542029e-08
investigate O 0 4.018102472969076e-08
the O 0 1.544292871358266e-08
mechanism O 0 1.221390988348503e-07
of O 0 1.1599492033553815e-08
the O 0 5.847171191675216e-09
expansion O 0 2.4576273460752418e-08
mutation O 0 8.829882602867656e-09
in O 0 2.009739041852754e-09
the O 0 5.650359735653865e-09
Japanese O 0 3.995968711478781e-08
population O 0 2.2966915036448654e-09
we O 0 7.440614346876373e-09
have O 0 9.45034273058809e-09
studied O 0 3.681505233998905e-07
90 O 0 6.407096861948958e-07
Japanese O 0 8.1136058724951e-06
DM B-Disease 1 0.9999997615814209
families O 0 3.134328210308013e-07
comprising O 0 1.3730834780290024e-06
190 O 0 6.154004950076342e-07
affected O 0 2.0478202600315853e-07
and O 0 1.7963712650725938e-07
130 O 0 1.4510357004837715e-06
unaffected O 0 6.055868198018288e-06
members O 0 3.0952217002777616e-06
. O 0 1.6042933566495776e-05

The O 0 8.234069355239626e-06
results O 0 6.587674761249218e-06
suggest O 0 5.560077056543378e-07
that O 0 2.3731528742132468e-08
a O 0 3.671588899578637e-08
few O 0 3.042031693212266e-08
common O 0 7.027403370329921e-08
ancestral O 0 1.4209072674020717e-07
mutations O 0 1.2913446312268206e-07
in O 0 1.1864988991305836e-08
both O 0 3.928116498741474e-08
Caucasian O 0 1.0893679700529901e-06
and O 0 1.1375423270010288e-07
Japanese O 0 4.5268856752045394e-07
populations O 0 1.738926691530196e-08
have O 0 7.4047390441478456e-09
originated O 0 1.521389414449459e-08
by O 0 4.829359578906178e-09
expansion O 0 4.84202580253168e-08
of O 0 1.9096335179824564e-08
an O 0 1.2733378795815042e-08
ancestral O 0 8.730278722168805e-08
n O 0 2.9509234877878043e-07
= O 0 6.978382884881285e-07
5 O 0 2.863093868654687e-07
repeat O 0 1.902337771753082e-07
to O 0 2.6776339367984292e-08
n O 0 3.6212986742611974e-07
= O 0 8.447677259937336e-07
19 O 0 1.2389950825308915e-06
- O 0 6.305833153419371e-07
37 O 0 4.4611513771997124e-07
copies O 0 7.057551556499675e-07
. O 0 3.7775751025037607e-06

These O 0 8.583482440371881e-07
data O 0 7.367029297711269e-07
support O 0 1.8336507423555304e-07
multistep O 0 5.507480182131985e-06
models O 0 1.302095142818871e-06
of O 0 7.281408898052177e-07
triplet O 0 2.0591427528415807e-05
repeat O 0 7.219372264444246e-07
expansion O 0 2.484758283571864e-07
that O 0 4.331305980542766e-09
have O 0 6.2171507941855e-09
been O 0 1.6072752018203573e-08
proposed O 0 4.410892984196835e-08
for O 0 2.9253483191382657e-08
both O 0 5.327173653313366e-07
DM B-Disease 1 1.0
and O 0 8.056240403675474e-06
Friedreichs B-Disease 1 0.5857720375061035
ataxia I-Disease 1 0.9815942049026489
. O 0 5.938816684647463e-06
. O 0 2.5657958758529276e-05

The O 0 2.7780295113188913e-06
molecular O 0 5.8445984905119985e-06
basis O 0 3.842937076115049e-06
of O 0 0.002336458070203662
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.7567736538003373e-07
the O 0 6.602603974670274e-08
western O 0 4.013262184798805e-07
Cape O 0 5.947959380137036e-06
, O 0 1.5893144222900446e-07
South O 0 1.4148361060506431e-06
Africa O 0 1.0684977496566717e-05
. O 0 8.297311069327407e-06

Deficiency B-Disease 1 0.9998725652694702
of I-Disease 0 3.839791679638438e-05
the I-Disease 0 3.7712866287620272e-06
sixth I-Disease 0 3.725137503352016e-05
component I-Disease 0 1.3066479596091085e-06
of I-Disease 0 1.6254685419880843e-07
human I-Disease 0 7.306953619945489e-08
complement I-Disease 0 4.143738010498055e-07
( O 0 2.1447547737807326e-07
C6 O 1 0.9999197721481323
) O 0 6.978756061926106e-08
has O 0 1.713182307128136e-08
been O 0 2.31482530921312e-08
reported O 0 1.722885123456308e-08
in O 0 2.908101093268556e-09
a O 0 6.3803868854961365e-09
number O 0 8.188266953368384e-09
of O 0 2.7390209211830552e-08
families O 0 4.711588452721571e-09
from O 0 1.0875949918442984e-08
the O 0 3.4139002735855684e-08
western O 0 6.338832463370636e-07
Cape O 0 1.4982852917455602e-05
, O 0 3.136601094411162e-07
South O 0 4.335095582064241e-06
Africa O 0 2.5002469556056894e-05
. O 0 1.7630816728342324e-05

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9999934434890747
is O 0 7.983733780747571e-07
endemic O 0 2.4222663341788575e-07
in O 0 2.2322385717643556e-08
the O 0 1.1450863723894145e-07
Cape O 0 4.3984023250231985e-06
and O 0 3.99539743511923e-08
almost O 0 5.284617898837496e-08
all O 0 1.4185616237227805e-08
pedigrees O 0 1.3121432118623488e-07
of O 0 1.453740594570263e-07
total O 0 1.7360327547066845e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.7296029909630306e-05
C6Q0 O 1 0.9329414963722229
) O 0 4.779657558628969e-08
have O 0 1.4235109091487175e-08
been O 0 3.7614409365005486e-08
ascertained O 0 7.01604562891589e-07
because O 0 8.875070278691055e-08
of O 0 2.1840310182597023e-06
recurrent O 1 0.9890456199645996
disease O 1 0.9999725818634033
. O 0 0.0001450690469937399

We O 0 1.9213412087992765e-06
have O 0 9.214611651486848e-08
sequenced O 0 3.571294655557722e-07
the O 0 3.526779934759361e-08
expressed O 0 4.240652273779233e-08
exons O 0 8.554096666557598e-07
of O 0 1.3327264980489417e-07
the O 0 2.735090731675882e-07
C6 O 0 0.329272598028183
gene O 0 1.8630399267749453e-07
from O 0 2.129956122587373e-08
selected O 0 1.1673382260823928e-07
cases O 0 2.8925576600613567e-08
and O 0 2.4629862593883445e-08
have O 0 1.3988615599203058e-08
found O 0 4.5571638906949374e-08
three O 0 1.6753415366110858e-07
molecular O 0 0.32424935698509216
defects O 1 0.8928869962692261
leading O 0 1.9088207409367897e-05
to O 0 1.0874128975046915e-07
total O 0 2.7726036933017895e-06
deficiency O 1 0.9999963045120239
879delG O 0 0.010233623906970024
, O 0 2.158416378961192e-07
which O 0 1.4689220506625134e-08
is O 0 9.248503296532817e-09
the O 0 2.0039028214569043e-08
common O 0 2.3772466306581919e-07
defect O 0 5.461955652208417e-07
in O 0 3.2464139820831406e-08
the O 0 1.266128606403072e-07
Cape O 0 6.775605925213313e-06
and O 0 9.632510966639529e-08
hitherto O 0 5.321542744241015e-07
unreported O 0 2.7219965659242007e-07
, O 0 3.288781513788308e-08
and O 0 6.454319390059027e-08
1195delC O 0 2.303536120962235e-06
and O 0 1.7682094721749309e-07
1936delG O 0 3.5473337902658386e-06
, O 0 2.384750708017691e-08
which O 0 7.439507676565427e-09
have O 0 1.1522534038022059e-08
been O 0 5.246824130722416e-08
previously O 0 1.3937193443780416e-07
reported O 0 1.3782101859760587e-07
in O 0 9.367614239863542e-08
African O 0 1.3211176337790675e-05
- O 0 1.2617025276995264e-05
Americans O 0 2.59803096014366e-06
. O 0 1.3020644473726861e-05

We O 0 5.2004629651492e-06
also O 0 3.007319833159272e-07
show O 0 1.0695091390289235e-07
that O 0 9.136885026350683e-09
the O 0 5.281574999571603e-08
879delG O 0 3.8489929465868045e-06
and O 0 6.305779152171453e-07
1195delC O 0 0.00016532660811208189
defects O 0 0.00010528791608521715
are O 0 7.679121694081914e-08
associated O 0 4.0562656522524776e-07
with O 0 5.404204443948402e-07
characteristic O 1 0.999997615814209
C6 O 1 1.0
/ O 1 0.9999998807907104
C7 O 1 0.9999849796295166
region O 0 9.186381930703647e-07
DNA O 0 6.111345669523871e-07
marker O 0 8.576225241085922e-07
haplotypes O 0 1.1190655868631438e-06
, O 0 3.229036238394656e-08
although O 0 4.0729872807787615e-08
small O 0 4.239843676145938e-08
variations O 0 7.248755196087586e-07
were O 0 8.232335630964371e-07
observed O 0 7.098286459950032e-06
. O 0 1.6430769392172806e-05

The O 0 1.1642961908364668e-05
1936delG O 0 0.00015802070265635848
defect O 0 3.981038389611058e-05
was O 0 2.111299181706272e-06
observed O 0 2.333319599756578e-07
only O 0 2.978702084988072e-08
once O 0 4.61612650326515e-08
in O 0 1.3939980725297119e-08
the O 0 4.80588440154861e-08
Cape O 0 2.7299358862364898e-06
, O 0 2.894632800121144e-08
but O 0 2.2852399084172248e-08
its O 0 2.8095746174017222e-08
associated O 0 1.2310890440403455e-07
haplotype O 0 1.306296553593711e-06
could O 0 2.8539014351736114e-07
be O 0 5.704527552552463e-07
deduced O 0 1.366643664368894e-05
. O 0 1.160950068879174e-05

The O 0 2.3037666778691346e-06
data O 0 7.354555009442265e-07
from O 0 6.78929907849124e-08
the O 0 7.867407703088247e-08
haplotypes O 0 5.791123953713395e-07
indicate O 0 7.173937888182991e-08
that O 0 1.0475510237029084e-08
these O 0 2.7351733322689142e-08
three O 0 4.3408275018919085e-07
molecular O 0 0.11044389754533768
defects O 0 0.010839799419045448
account O 0 1.3479643712344114e-07
for O 0 1.8984556504619832e-07
the O 0 1.6447794450868969e-06
defects O 0 0.007028308697044849
in O 0 8.482521707264823e-08
all O 0 1.004036533913677e-07
the O 0 1.7906602067796484e-07
38 O 0 1.5979683212208329e-06
unrelated O 0 1.6857525224622805e-06
C6Q0 O 0 7.441800698870793e-05
individuals O 0 3.1512772835640135e-08
we O 0 6.98592117487351e-08
have O 0 1.787615744319737e-08
studied O 0 3.5618117522062676e-07
from O 0 1.1859145132575577e-07
the O 0 7.730954507678689e-07
Cape O 0 7.358565198956057e-05
. O 0 2.384974686719943e-05

We O 0 2.156874188585789e-06
have O 0 1.3012494548547693e-07
also O 0 6.999071899826959e-08
observed O 0 1.3202418358559953e-07
the O 0 8.498683712332422e-08
879delG O 0 4.955526492267381e-06
defect O 0 1.3757612578046974e-06
in O 0 1.573030488088989e-07
two O 0 9.831995839704177e-07
Dutch O 1 0.9999997615814209
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.0006811736384406686
, O 0 9.268549661101133e-08
but O 0 2.6607064995687324e-08
the O 0 4.402874154152414e-08
879delG O 0 1.970760877156863e-06
defect O 0 4.711843075710931e-07
in O 0 5.881423348341741e-08
the O 0 2.239916057078517e-07
Cape O 0 7.678471774852369e-06
probably O 0 3.449317205195257e-07
did O 0 6.718153855445053e-08
not O 0 1.7705609423046553e-08
come O 0 4.014356491666149e-08
from O 0 2.31345698153973e-08
The O 0 3.0756197588743817e-07
Netherlands O 0 1.5086917301232461e-05
. O 0 1.1496474598970963e-06
. O 0 5.771661108155968e-06

Complement B-Disease 1 0.9999997615814209
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.7580918211024255e-05
seven O 0 2.0158574898232473e-06
further O 0 6.250647288652544e-07
molecular O 0 0.0003359318361617625
defects O 0 0.00015658467600587755
and O 0 2.0454682214676723e-07
their O 0 2.180358933401294e-07
associated O 0 2.9015038762736367e-06
marker O 0 1.7812255464377813e-05
haplotypes O 0 9.504079207545146e-05
. O 0 3.931025639758445e-05

Seven O 0 1.2144527318014298e-05
further O 0 1.2475176163206925e-06
molecular O 0 4.429345153766917e-06
bases O 0 1.577202056068927e-06
of O 0 0.35477563738822937
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.4246850696508773e-05
described O 0 2.1668531189789064e-05
. O 0 1.550424894958269e-05

All O 0 1.56166765918897e-06
these O 0 2.9118609745637514e-07
new O 0 8.139677447616123e-07
molecular O 0 2.4741984816500917e-05
defects O 0 2.4595448849140666e-05
involve O 0 4.898887482340797e-07
single O 0 2.3899241341496236e-07
- O 0 2.88281739813101e-06
nucleotide O 0 3.7390807960946404e-07
events O 0 6.304648536570312e-08
, O 0 2.325623427168466e-08
deletions O 0 1.8359045839133614e-07
and O 0 4.8149495057714375e-08
substitutions O 0 4.0729955230744963e-07
, O 0 2.0645776643846148e-08
some O 0 8.070736079446306e-09
of O 0 2.7913548805713617e-08
which O 0 1.9544270202231928e-08
alter O 0 3.831118249308929e-07
splice O 0 6.930425229256798e-07
sites O 0 1.6196982244309766e-07
, O 0 1.5240709672070807e-07
and O 0 2.2606251093293395e-07
others O 0 1.3459954288919107e-06
codons O 0 4.2180545278824866e-05
. O 0 1.7430966181564145e-05

They O 0 6.846686346761999e-07
are O 0 6.010375130927059e-08
distributed O 0 7.277549940454264e-08
along O 0 5.887675058602326e-08
the O 0 1.8772115595311334e-07
C7 O 0 0.000873922894243151
gene O 0 1.5642089579159801e-07
, O 0 4.565724864846743e-08
but O 0 2.4231644246697215e-08
predominantly O 0 3.3517668640570264e-08
towards O 0 9.83494317097211e-08
the O 0 1.3581298219378368e-07
3 O 0 2.852153784260736e-06
end O 0 7.749002179480158e-06
. O 0 1.1823074601124972e-05

All O 0 2.7831044917547842e-06
were O 0 5.780501624030876e-07
found O 0 1.6434971428225253e-07
in O 0 1.7612688907320262e-07
compound O 0 3.0712865282112034e-06
heterozygous O 0 6.566492629644927e-06
individuals O 0 1.8715142005021335e-06
. O 0 2.2723068468621932e-05

The O 0 0.0002660648024175316
C6 O 1 1.0
/ O 1 0.9999665021896362
C7 O 1 0.9998657703399658
marker O 0 2.273804602737073e-05
haplotypes O 0 2.3145721570472233e-05
associated O 0 9.439687573831179e-07
with O 0 7.868837883506785e-07
most O 0 2.192190004279837e-05
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999148845672607
are O 0 1.4270497104007518e-06
tabulated O 0 1.1095218724221922e-05
. O 0 2.2938618258194765e-06
. O 0 1.5475974578293972e-05

A O 0 6.15080280113034e-05
genome O 0 8.779187737673055e-06
- O 0 4.490236733545316e-06
wide O 0 7.872966421018646e-07
search O 0 4.874853516412259e-07
for O 0 1.0409111439457774e-07
chromosomal O 0 3.3738768252078444e-05
loci O 0 5.3341671446105465e-05
linked O 0 0.00041706679621711373
to O 0 2.9190614441176876e-06
mental O 1 0.9999990463256836
health O 0 0.00023688265355303884
wellness O 0 0.00014319445472210646
in O 0 1.81822429112799e-07
relatives O 0 3.1132810818235157e-07
at O 0 1.2004572909063427e-06
high O 0 1.2436602446541656e-05
risk O 0 2.4207905880757608e-05
for O 0 0.026086876168847084
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 1.1561660357983783e-05
the O 0 2.241074980702251e-06
Old O 0 6.484085315605626e-05
Order O 0 1.1687138794513885e-05
Amish O 0 6.356612720992416e-05
. O 0 1.9316707039251924e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9994348883628845
BPAD B-Disease 1 1.0
; O 1 0.9999872446060181
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.736355625325814e-05
is O 0 6.749015568630057e-08
characterized O 0 9.778380416491927e-08
by O 0 2.8245926486647477e-08
episodes O 0 2.911827721163718e-07
of O 0 9.634924253987265e-07
mania B-Disease 0 0.00011355031165294349
and O 0 8.71553856995888e-06
/ O 1 0.9973426461219788
or O 0 9.419547131983563e-05
hypomania B-Disease 1 0.9984732270240784
interspersed O 0 2.0752434011228615e-06
with O 0 1.5839277978102473e-07
periods O 0 9.228265298588667e-06
of O 0 2.0310046238591895e-05
depression B-Disease 1 0.5976219773292542
. O 0 4.3891846871702e-05

Compelling O 0 5.1534421800170094e-05
evidence O 0 5.396317192207789e-06
supports O 0 1.0011258382291999e-06
a O 0 2.0651731347243185e-07
significant O 0 1.7400688534507935e-07
genetic O 0 3.9423366615665145e-07
component O 0 1.3731960279983468e-06
in O 0 5.761981825003204e-08
the O 0 1.4740925280420925e-07
susceptibility O 0 3.6652400012826547e-06
to O 0 4.4260204390411673e-07
develop O 0 0.00036703294608742
BPAD B-Disease 1 1.0
. O 0 0.0003445393522270024

To O 0 6.80999676205829e-07
date O 0 1.5750811144243926e-06
, O 0 7.975951632488432e-08
however O 0 4.0878678220224174e-08
, O 0 3.7609527936410814e-08
linkage O 0 2.573097219737974e-07
studies O 0 3.589671138115591e-08
have O 0 1.752027145585089e-08
attempted O 0 3.4648093105715816e-07
only O 0 1.7854620892876483e-08
to O 0 1.5041782930325098e-08
identify O 0 1.6700057869911689e-07
chromosomal O 0 3.504910182527965e-06
loci O 0 2.1871742319490295e-06
that O 0 5.432211480638216e-08
cause O 0 1.6186788798222551e-06
or O 0 1.9759389147111506e-07
increase O 0 8.250587768543483e-08
the O 0 2.3110803226700227e-07
risk O 0 1.4357809732246096e-06
of O 0 7.800206731189974e-06
developing O 1 0.837470531463623
BPAD B-Disease 1 1.0
. O 0 0.00017997788381762803

To O 0 9.771972599992296e-07
determine O 0 7.776311008456105e-07
whether O 0 2.7995454843221523e-07
there O 0 6.322579793049954e-08
could O 0 7.377744992709268e-08
be O 0 5.729641117113715e-08
protective O 0 5.084048666503804e-07
alleles O 0 2.7326893814461073e-07
that O 0 1.5265342767634138e-08
prevent O 0 1.460810352682529e-07
or O 0 6.863644586019291e-08
reduce O 0 1.0763730529106397e-07
the O 0 6.174703770511769e-08
risk O 0 1.7562136633841874e-07
of O 0 5.954725565970875e-07
developing O 0 0.41470709443092346
BPAD B-Disease 1 1.0
, O 0 4.1740868539363873e-08
similar O 0 4.815011500625133e-09
to O 0 2.673769206040788e-09
what O 0 3.3717384440024034e-09
is O 0 2.1293780072539903e-09
observed O 0 1.0637452696471428e-08
in O 0 5.5363389428464416e-09
other O 0 1.1467791694030893e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.110572043216962e-06
we O 0 4.585107262755628e-07
used O 0 2.11480960388144e-06
mental O 1 0.9998546838760376
health O 0 3.7251833418849856e-05
wellness O 0 0.0001383053750032559
( O 0 7.608282004412104e-08
absence O 0 4.1190580191141635e-07
of O 0 3.7815075870639703e-07
any O 0 2.989966560562607e-06
psychiatric B-Disease 1 0.9997051358222961
disorder I-Disease 1 0.9981948733329773
) O 0 3.971907744926284e-07
as O 0 3.368128602687648e-07
the O 0 2.7130062107971753e-07
phenotype O 0 2.6679106213123305e-06
in O 0 5.970362337848201e-08
our O 0 3.144567983781599e-07
genome O 0 3.515444007007318e-07
- O 0 3.2087320960272336e-06
wide O 0 2.7414621399657335e-06
linkage O 0 6.115255928307306e-06
scan O 0 1.2381255146465264e-05
of O 0 6.215866505954182e-07
several O 0 1.4460249531111913e-07
large O 0 3.3706027124935645e-07
multigeneration O 0 2.0403809685376473e-05
Old O 0 8.749715561862104e-06
Order O 0 1.5629146901119384e-06
Amish O 0 7.16081922291778e-06
pedigrees O 0 1.7925600559465238e-06
exhibiting O 0 8.147856078721816e-07
an O 0 1.0921500148697305e-07
extremely O 0 3.89539582101861e-06
high O 0 0.019550565630197525
incidence O 0 0.4751177132129669
of O 0 0.023715028539299965
BPAD B-Disease 1 1.0
. O 0 0.0004771549138240516

We O 0 2.9197769890743075e-06
have O 0 8.29011810310476e-08
found O 0 3.991824826243828e-08
strong O 0 5.020046955905855e-08
evidence O 0 1.7463396773109707e-07
for O 0 5.327569851942826e-08
a O 0 9.514806720289926e-08
locus O 0 7.869738851695729e-07
on O 0 9.63927163866174e-07
chromosome O 0 4.845891908189515e-06
4p O 0 0.0001285672333324328
at O 0 6.7087180468661245e-06
D4S2949 O 0 1.4775642739550676e-05
( O 0 4.22488938056631e-07
maximum O 0 5.94410903431708e-06
GENEHUNTER O 0 0.00018634067964740098
- O 0 5.51550056115957e-06
PLUS O 0 4.448093932296615e-06
nonparametric O 0 9.839107406151015e-06
linkage O 0 8.663138260089909e-07
score O 0 4.518531113717472e-07
= O 0 4.6134465492286836e-07
4 O 0 4.461866183191887e-07
. O 0 3.862867004045256e-08
05 O 0 3.4182182844233466e-06
, O 0 1.46643131415658e-07
P O 0 4.625778728950536e-06
= O 0 5.814299584017135e-07
5 O 0 9.681321699872569e-08
. O 0 7.294181258998833e-09
22 O 0 7.65493481935664e-08
x O 0 1.4089114586113283e-07
10 O 0 1.6195869534385565e-07
( O 0 3.52813245285688e-08
- O 0 9.79357324126795e-08
4 O 0 2.0239045284142776e-07
) O 0 2.5396676761602066e-08
; O 0 4.9065175034002095e-08
SIBPAL O 0 2.0792189388885163e-05
Pempirical O 0 6.757917617505882e-06
value O 0 1.3291304412632599e-07
< O 0 5.989741680423322e-07
3 O 0 1.546744812230827e-07
x O 0 1.7532917695461947e-07
10 O 0 9.795236621812364e-08
( O 0 1.4752957966379654e-08
- O 0 8.98911096669508e-08
5 O 0 6.941902341850437e-08
) O 0 1.1486942064209416e-08
) O 0 1.5939189523805908e-08
and O 0 3.743576471038068e-08
suggestive O 0 6.402930807780649e-07
evidence O 0 1.5198065739241429e-07
for O 0 5.287108351126335e-08
a O 0 1.1402196520293728e-07
locus O 0 1.334446324108285e-06
on O 0 1.2302621144044679e-06
chromosome O 0 5.825072094012285e-06
4q O 0 4.615810757968575e-05
at O 0 3.3772548704291694e-06
D4S397 O 0 9.772814337338787e-06
( O 0 2.6045580625577713e-07
maximum O 0 3.838549218926346e-06
GENEHUNTER O 0 5.696638982044533e-05
- O 0 1.9339006485097343e-06
PLUS O 0 1.2703440006589517e-06
nonparametric O 0 2.4077137368294643e-06
linkage O 0 2.8849163413724455e-07
score O 0 1.4322537822408776e-07
= O 0 1.2608580846062978e-07
3 O 0 4.52592736621682e-08
. O 0 5.154886739688891e-09
29 O 0 8.563053199850401e-08
, O 0 2.9766175302370357e-08
P O 0 8.829068178783928e-07
= O 0 2.3153381789597915e-07
2 O 0 1.2761745438183425e-07
. O 0 1.008764005661078e-08
57 O 0 9.543597201400189e-08
x O 0 9.634532460722767e-08
10 O 0 1.1932785071167018e-07
( O 0 2.7608246355725896e-08
- O 0 1.0249686965835281e-07
3 O 0 2.2753958717203204e-07
) O 0 3.1734135319538836e-08
; O 0 8.930699380016449e-08
SIBPAL O 0 1.809056084312033e-05
Pempirical O 0 8.564678864786401e-06
value O 0 1.3896820405534527e-07
< O 0 5.779845650977222e-07
1 O 0 1.8973445037318015e-07
x O 0 1.9078210300449427e-07
10 O 0 1.1377930775324785e-07
( O 0 2.906183915740712e-08
- O 0 6.771271188199535e-08
3 O 0 9.979004289561999e-08
) O 0 8.792020445014259e-09
) O 0 7.490337239346445e-09
that O 0 5.1813042745152416e-09
are O 0 4.642510020858026e-08
linked O 0 1.0858717359951697e-05
to O 0 2.358059191465145e-06
mental O 1 0.9999966621398926
health O 0 0.010877853259444237
wellness O 0 0.010258783586323261
. O 0 6.990389374550432e-05

These O 0 5.399922997639806e-07
findings O 0 3.426484909141436e-07
are O 0 1.6879702968708443e-08
consistent O 0 1.835827418972258e-07
with O 0 1.6077782660772755e-08
the O 0 3.414440641336114e-08
hypothesis O 0 5.1019419800013566e-08
that O 0 1.283324224665705e-09
certain O 0 9.39122557497285e-09
alleles O 0 1.6761167387358e-07
could O 0 8.466583523158988e-08
prevent O 0 1.6652045076170907e-07
or O 0 3.608803922361403e-08
modify O 0 9.02370871358471e-08
the O 0 2.1393489646470698e-08
clinical O 0 5.083748533252219e-07
manifestations O 0 4.0167797124013305e-06
of O 0 5.738527761423029e-06
BPAD B-Disease 1 1.0
and O 0 2.086771473841509e-06
perhaps O 0 9.632389037506073e-07
other O 0 3.8672246205351257e-07
related O 0 0.10028062760829926
affective B-Disease 1 0.9999998807907104
disorders I-Disease 1 1.0
. O 0 0.0008957423269748688

Segregation O 0 0.015903793275356293
distortion O 1 0.9998948574066162
in O 0 0.041225504130125046
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0281843151897192

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999828338623047
DM B-Disease 1 1.0
) O 0 3.6449459912546445e-06
is O 0 9.040194726139816e-08
an O 0 4.255423391441582e-08
autosomal B-Disease 1 0.9168103933334351
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9997574687004089
which O 0 1.6326211493833398e-07
, O 0 3.0983997589828505e-08
in O 0 1.1417568224203478e-08
the O 0 3.5419276400716626e-08
typical O 0 1.5599185587689135e-07
pedigree O 0 2.0250745080829802e-07
, O 0 3.177459007019934e-08
shows O 0 4.2236763420078205e-08
a O 0 7.724602113512447e-08
three O 0 1.6115707524022582e-07
generation O 0 7.965041731949896e-06
anticipation O 0 1.642801180423703e-05
cascade O 0 0.00011552231444511563
. O 0 2.959257471957244e-05

This O 0 1.3431181287160143e-06
results O 0 5.017691364628263e-06
in O 0 1.2746983202305273e-06
infertility B-Disease 1 0.9996452331542969
and O 1 0.9999514818191528
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999959468841553
CDM B-Disease 1 0.999994158744812
) O 0 1.1794124077368906e-07
with O 0 2.3605126742154425e-08
the O 0 9.850675297684575e-08
disappearance O 0 1.4358754469867563e-06
of O 0 3.375097548996564e-06
DM B-Disease 1 1.0
in O 0 6.07671950092481e-07
that O 0 1.5468435776710976e-07
pedigree O 0 8.468136002193205e-06
. O 0 8.537205758329947e-06

The O 0 1.6723913631722098e-06
concept O 0 2.408487716820673e-06
of O 0 6.409162551790359e-07
segregation O 0 1.5066071682667825e-05
distortion O 0 6.794483488192782e-05
, O 0 4.2839673142225365e-08
where O 0 2.5708596140816553e-08
there O 0 8.761402270351937e-09
is O 0 6.383770845275194e-09
preferential O 0 8.730012268642895e-08
transmission O 0 5.76231059312704e-07
of O 0 1.9972937082002318e-08
the O 0 1.7876976343700335e-08
larger O 0 4.962659616580822e-08
allele O 0 4.25533016823465e-07
at O 0 3.4757437106236466e-07
the O 0 1.1028824786762925e-07
DM B-Disease 1 1.0
locus O 0 2.281974502693629e-06
, O 0 6.148555087293062e-08
has O 0 2.1750127032760247e-08
been O 0 3.628204581218597e-08
put O 0 8.732376954867505e-08
forward O 0 5.480844720295863e-07
to O 0 4.498370742567204e-08
explain O 0 4.3326014065314666e-07
partially O 0 1.2123534816055326e-06
the O 0 1.5422303079049016e-07
maintenance O 0 1.7768689986041863e-06
of O 0 4.7918169912009034e-06
DM B-Disease 1 1.0
in O 0 8.115540595099446e-07
the O 0 6.253378046494618e-07
population O 0 2.8599637857951166e-07
. O 0 5.16699583386071e-06

In O 0 2.1241601189103676e-06
a O 0 8.736181484891858e-07
survey O 0 3.820179870217544e-07
of O 0 1.6115303651531576e-06
DM B-Disease 1 1.0
in O 0 5.063875505584292e-07
Northern O 0 1.7803021137297037e-06
Ireland O 0 2.421553517706343e-06
, O 0 3.275310405115306e-07
59 O 0 1.1605796998992446e-06
pedigrees O 0 1.5743603398732375e-06
were O 0 1.8678839524000068e-06
ascertained O 0 3.762359483516775e-05
. O 0 1.739408435241785e-05

Sibships O 0 0.0003296690119896084
where O 0 7.34213017494767e-07
the O 0 6.229296189985689e-08
status O 0 6.804959440387393e-08
of O 0 4.262335906446424e-08
all O 0 9.90948567647365e-09
the O 0 1.229678225911357e-08
members O 0 1.441546704228358e-08
had O 0 3.6452480145499067e-08
been O 0 5.317215112654594e-08
identified O 0 9.737099304629737e-08
were O 0 8.662041750540084e-08
examined O 0 1.8758012743091967e-07
to O 0 1.1492771179177907e-08
determine O 0 1.6008327463623573e-07
the O 0 7.828010240018557e-08
transmission O 0 3.6055047530680895e-05
of O 0 1.8557160501586623e-06
the O 0 1.0004509931604844e-05
DM B-Disease 1 1.0
expansion O 0 1.6592231986578554e-05
from O 0 4.653982088598241e-08
affected O 0 4.344530069033681e-08
parents O 0 9.023997549206797e-09
to O 0 1.3899890127788694e-08
their O 0 7.482744024400745e-08
offspring O 0 2.842769163180492e-06
. O 0 5.354521817935165e-06

Where O 0 4.934776825393783e-06
the O 0 1.698583673714893e-06
transmitting O 0 0.00016932756989262998
parent O 0 2.9067327886878047e-06
was O 0 3.442814204390743e-06
male O 0 2.3975380827323534e-06
, O 0 1.1871495644300012e-06
58 O 0 2.0576981114572845e-05
. O 0 2.0604549717972986e-05

3 O 0 6.004192982800305e-06
% O 0 2.1997199439738324e-07
of O 0 1.6085397192000528e-07
the O 0 5.905737765488084e-08
offspring O 0 1.0785802118107313e-07
were O 0 7.2305766707359e-08
affected O 0 8.971246501232599e-08
, O 0 3.490861288923952e-08
and O 0 2.998121573227763e-08
in O 0 1.7741442093210935e-08
the O 0 2.1811445094499504e-08
case O 0 6.579787026339545e-08
of O 0 5.985858564372393e-08
a O 0 1.5008201614818972e-07
female O 0 1.6518863503733883e-06
transmitting O 0 4.029424235341139e-05
parent O 0 2.895522129620076e-06
, O 0 2.3917532416817266e-06
68 O 0 3.5031174775213e-05
. O 0 3.266760541009717e-05

7 O 0 4.114344483241439e-05
% O 0 3.209139094906277e-06
were O 0 6.089701400924241e-06
affected O 0 1.390791203448316e-05
. O 0 2.6194386009592563e-05

Studies O 0 1.8612992789712735e-05
on O 0 6.018295607645996e-06
meiotic O 0 0.00013666209997609258
drive O 0 8.009419616428204e-06
in O 0 1.7056904653145466e-06
DM B-Disease 1 1.0
have O 0 1.5012037124506605e-07
shown O 0 4.6397659048125206e-08
increased O 0 4.494382466191382e-08
transmission O 0 3.2306013508787146e-07
of O 0 1.594703569196554e-08
the O 0 1.0852244436421188e-08
larger O 0 2.6012287435150938e-08
allele O 0 2.6698296551330714e-07
at O 0 2.799702940592397e-07
the O 0 1.950528485394898e-07
DM B-Disease 1 0.9999815225601196
locus O 0 1.6368444448744413e-06
in O 0 1.5789747465078108e-07
non O 0 3.1709278118796647e-05
- O 0 0.0019225823925808072
DM O 1 1.0
heterozygotes O 0 0.00011350193381076679
for O 0 4.643839474738343e-06
CTGn O 0 0.0006813914515078068
. O 0 2.424574995529838e-05

This O 0 6.334637987492897e-07
study O 0 2.6303109734726604e-07
provides O 0 3.70205199828888e-08
further O 0 2.4611548354869228e-08
evidence O 0 6.820214792924162e-08
that O 0 1.2712848551643674e-08
the O 0 2.5883366561174626e-07
DM B-Disease 1 1.0
expansion O 0 6.247314559004735e-06
tends O 0 5.355214511837403e-07
to O 0 7.534114132567993e-08
be O 0 2.804104042297695e-07
transmitted O 0 1.772218524820346e-06
preferentially O 0 1.8292176946488325e-06
. O 0 3.802663513852167e-06

Diagnosis O 1 0.9998865127563477
of O 1 0.9501135945320129
hemochromatosis B-Disease 1 1.0
. O 0 0.1310967653989792

If O 0 5.8204725064570084e-05
untreated O 1 0.9998337030410767
, O 0 0.0005175436963327229
hemochromatosis B-Disease 1 1.0
can O 0 0.0002050229231826961
cause O 1 0.9970512390136719
serious O 1 0.9999862909317017
illness O 1 0.5828711986541748
and O 0 1.6724267482004507e-07
early B-Disease 0 1.5382980791400769e-06
death I-Disease 0 2.018423856497975e-06
, O 0 3.952481364422056e-08
but O 0 3.190211828041356e-08
the O 0 2.9992145300639095e-07
disease O 0 8.481903932988644e-05
is O 0 4.7739906250399144e-08
still O 0 1.468987136377109e-07
substantially O 0 2.3577736101287883e-06
under O 0 1.8725120753515512e-05
- O 1 0.9940779209136963
diagnosed O 0 0.3668690621852875
. O 0 2.6004356186604127e-05

The O 0 8.819634786050301e-06
cornerstone O 0 0.00010442880011396483
of O 0 1.1004750604115543e-06
screening O 0 5.008427024222328e-07
and O 0 6.161456411746258e-08
case O 0 1.4298490214059711e-07
detection O 0 7.854525279071822e-07
is O 0 2.0776452558379788e-08
the O 0 5.748172782205074e-08
measurement O 0 1.0495068636373617e-06
of O 0 5.079672291685711e-07
serum O 0 3.232498556826613e-06
transferrin O 0 8.176023584383074e-06
saturation O 0 5.885300197405741e-06
and O 0 3.602535798563622e-07
the O 0 8.722420261619845e-07
serum O 0 8.333799087267835e-06
ferritin O 0 9.347889863420278e-05
level O 0 6.624909292440861e-05
. O 0 9.906492778100073e-06

Once O 0 1.1834343240479939e-05
the O 0 1.4878689853503602e-06
diagnosis O 0 0.00010257491521770135
is O 0 1.4071564180540008e-07
suspected O 0 5.465110007207841e-06
, O 0 6.235441674107278e-07
physicians O 0 7.568940532109991e-07
must O 0 2.759506685379165e-07
use O 0 7.863998803259165e-07
serum O 0 9.386782039655373e-06
ferritin O 0 0.0007095442852005363
levels O 0 0.00017126131569966674
and O 0 6.305704300757498e-05
hepatic O 1 0.9999998807907104
iron O 1 0.9999644756317139
stores O 0 6.4385953919554595e-06
on O 0 2.700924369491986e-06
liver O 0 5.706498086510692e-06
biopsy O 0 8.915329203773581e-07
specimens O 0 4.175074508339094e-08
to O 0 1.8858237638141873e-08
assess O 0 1.436712153690678e-07
patients O 0 2.994503844888641e-08
for O 0 1.7211544189876804e-08
the O 0 2.7752165010497265e-08
presence O 0 1.8665149070784537e-07
of O 0 5.265815616439795e-06
iron B-Disease 1 0.9999967813491821
overload I-Disease 1 0.9993977546691895
. O 0 9.085046622203663e-05

Liver O 1 0.9966112971305847
biopsy O 0 0.26580971479415894
is O 0 4.3125956494804996e-07
also O 0 4.022787791768678e-08
used O 0 8.010021979032445e-09
to O 0 9.297299818911142e-09
establish O 0 5.383012791071451e-08
the O 0 1.6302585947869375e-08
presence O 0 3.284694116700848e-08
or O 0 3.3438233515425964e-08
absence O 0 6.013035545038292e-07
of O 0 1.3285111890581902e-06
cirrhosis B-Disease 1 0.9999997615814209
, O 0 7.557176786576747e-07
which O 0 5.640682232410654e-08
can O 0 6.249992168250174e-08
affect O 0 1.285281655327708e-06
prognosis O 0 0.00015318888472393155
and O 0 4.614996214513667e-06
management O 0 0.00020983145805075765
. O 0 3.433777601458132e-05

A O 0 2.1677478798665106e-05
DNA O 0 9.545291504764464e-06
- O 0 2.701794983295258e-06
based O 0 5.6341445286989256e-08
test O 0 1.380359577751733e-07
for O 0 3.574080764678911e-08
the O 0 1.1190117987780468e-07
HFE O 0 0.00018289823492523283
gene O 0 1.683901729165882e-07
is O 0 8.413713281640867e-09
commercially O 0 2.7310967709581746e-08
available O 0 6.996933255010163e-09
, O 0 3.569317286178375e-09
but O 0 3.2717120124203802e-09
its O 0 1.967014107151499e-09
place O 0 3.3556048606442346e-08
in O 0 6.669367280665028e-09
the O 0 2.8358801529293487e-08
diagnosis O 0 1.1375969734217506e-05
of O 0 2.379685793130193e-05
hemochromatosis B-Disease 1 1.0
is O 0 3.1953018151398282e-06
still O 0 1.012858206195233e-06
being O 0 2.2516237550007645e-06
evaluated O 0 1.2887987395515665e-05
. O 0 1.1772814104915597e-05

Currently O 0 4.207919118925929e-06
, O 0 3.035497400105669e-07
the O 0 4.624340022019169e-08
most O 0 7.274132851620152e-09
useful O 0 2.8483592373618194e-08
role O 0 1.815184802467229e-08
for O 0 3.8064018603733984e-09
this O 0 1.9075356849640457e-09
test O 0 3.0286813057500694e-08
is O 0 2.75306688557464e-09
in O 0 1.9392869532453005e-09
the O 0 7.099071552829628e-09
detection O 0 4.625336771368893e-07
of O 0 3.263249254814582e-06
hemochromatosis B-Disease 1 1.0
in O 0 5.614319888991304e-07
the O 0 2.0285730784053158e-07
family O 0 2.4580304014421017e-08
members O 0 1.518669989764021e-08
of O 0 8.79432207057107e-08
patients O 0 5.265270175414116e-08
with O 0 2.3535175586175683e-08
a O 0 2.6793003371494706e-07
proven O 0 8.162962330970913e-05
case O 0 1.50898483752826e-06
of O 0 3.497407305985689e-06
the O 0 3.220234430045821e-05
disease O 1 0.9952782392501831
. O 0 6.341899279505014e-05

It O 0 1.6364448356398498e-06
is O 0 4.4592923131858697e-07
crucial O 0 2.938153556897305e-06
to O 0 1.1585957508941647e-06
diagnose O 1 0.9999961853027344
hemochromatosis B-Disease 1 1.0
before O 1 0.9999892711639404
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.3008832335472107
because O 0 3.988684966316214e-06
phlebotomy O 1 0.9622998237609863
therapy O 0 0.0461951345205307
can O 0 1.4210444305717829e-06
avert O 1 0.9973387122154236
serious O 1 1.0
chronic O 1 1.0
disease O 1 0.9999997615814209
and O 0 8.583155022279243e-07
can O 0 1.843523733668917e-08
even O 0 9.507727938284916e-09
lead O 0 4.447498014314988e-08
to O 0 1.471805166630702e-08
normal O 0 7.127123353711795e-07
life O 0 2.858324705812265e-07
expectancy O 0 3.62165081924104e-07
. O 0 1.733430394779134e-07
. O 0 3.94239577872213e-06

Prevalence O 0 3.449673022259958e-05
of O 0 1.6287750668197987e-06
the O 0 1.0258473821522784e-06
I1307K O 0 1.0456870768393856e-05
APC B-Disease 0 2.4402199869655306e-06
gene O 0 1.0536793126902921e-07
variant O 0 4.1228346958632756e-07
in O 0 1.758086298764283e-08
Israeli O 0 4.322857307670347e-07
Jews O 0 1.2537441307358677e-07
of O 0 4.116944651855192e-08
differing O 0 5.957986459748099e-08
ethnic O 0 7.829205372900105e-08
origin O 0 3.252674503073649e-07
and O 0 4.158760475547751e-06
risk O 1 0.5089111328125
for O 1 0.9999924898147583
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.7998271584510803

BACKGROUND O 0 0.00015035306569188833
& O 0 8.583113958593458e-05
AIMS O 0 1.2945130038133357e-05
Israeli O 0 2.154347839677939e-06
Jews O 0 3.0975257914178655e-07
of O 0 1.7591202094990877e-07
European O 0 5.419470880951849e-07
birth O 0 2.0824624868964747e-07
, O 0 6.03753704808696e-08
i O 0 1.1410725164751057e-07
. O 0 1.0136107952973816e-08
e O 0 4.0731269024263383e-08
. O 0 1.571612884276874e-08
, O 0 6.800275542673262e-08
Ashkenazim O 0 5.3848976676817983e-05
, O 0 1.1215053774549233e-07
have O 0 7.489140330108057e-08
the O 0 1.058244833984645e-06
highest O 1 0.9999979734420776
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 7.732390076853335e-05
of O 0 2.7805475610875874e-07
any O 0 7.465381202109711e-08
Israeli O 0 1.1295142030576244e-06
ethnic O 0 4.298856310924748e-07
group O 0 3.216682671336457e-06
. O 0 1.186470763059333e-05

The O 0 1.8407521565677598e-05
I1307K O 0 0.00015093671390786767
APC B-Disease 0 3.2271236705128103e-05
gene O 0 1.6810164424896357e-06
variant O 0 1.8678962078411132e-05
was O 0 3.7311556297936477e-06
found O 0 3.140611966045981e-07
in O 0 3.998988802322856e-07
6 O 0 6.33247836958617e-05
. O 0 2.685112485778518e-05

1 O 0 2.6823399821296334e-06
% O 0 1.1695902912833844e-07
of O 0 5.685518900122588e-08
American O 0 7.721803996219023e-08
Jews O 0 1.3361625406105304e-07
, O 0 2.98110052199263e-08
28 O 0 1.8040402949281997e-07
% O 0 1.7808163832455648e-08
of O 0 8.372575166504248e-08
their O 0 8.785920044829254e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.005755060352385044
, O 0 1.4655532254437276e-07
but O 0 3.2474421374217854e-08
not O 0 1.597013898901878e-08
in O 0 3.498499978604741e-08
non O 0 1.4258023384172702e-06
- O 0 3.7900786082900595e-06
Jews O 0 4.306941718823509e-06
. O 0 1.2677500308200251e-05

We O 0 1.4529892723658122e-05
assessed O 0 1.239138964592712e-05
the O 0 1.1982291425738367e-06
I1307K O 0 1.1915257346117869e-05
prevalence O 0 1.1560439361346653e-06
in O 0 1.917418579466812e-08
Israeli O 0 2.1256546745007654e-07
Jews O 0 6.896096493846926e-08
of O 0 2.0911466336315243e-08
differing O 0 3.62711141121963e-08
ethnic O 0 5.182928575209189e-08
origin O 0 1.4380363211330405e-07
and O 0 8.103004915938072e-07
risk O 0 0.0006648976705037057
for O 1 0.9966433048248291
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5672193169593811

METHODS O 0 1.2977874575881287e-05
DNA O 0 1.4728448149980977e-06
samples O 0 2.1883332124161825e-07
from O 0 4.788910956676773e-08
500 O 0 2.2530878140969435e-07
unrelated O 0 1.1684954870361253e-07
Jews O 0 1.584408124699621e-07
of O 0 1.1453604997768707e-07
European O 0 3.0222411169233965e-06
or O 0 2.025654026738266e-07
non O 0 3.4452511954441434e-06
- O 0 3.884078410010261e-07
European O 0 7.735483364967877e-08
origin O 0 2.9182929850435357e-08
, O 0 1.3959510880567905e-08
with O 0 6.477230751755769e-09
or O 0 2.456080672175176e-08
without O 0 4.675495546280217e-08
a O 0 2.849402669369283e-08
personal O 0 9.481526319632394e-08
and O 0 4.1731121314114716e-07
/ O 0 0.006572631653398275
or O 0 5.467449000207125e-07
family O 0 2.456877368217647e-08
history O 0 8.793534078677112e-08
of O 0 3.6317467788649083e-07
neoplasia B-Disease 1 0.9990981817245483
, O 0 9.034167760546552e-07
were O 0 4.6571167899855936e-07
examined O 0 9.202999535773415e-07
for O 0 1.1982105263541598e-07
the O 0 2.0424273827757133e-07
I1307K O 0 5.122631591802929e-06
variant O 0 1.3726081533604884e-06
by O 0 4.453227830936157e-08
the O 0 6.094972349046657e-08
allele O 0 1.210108052873693e-06
- O 0 2.2765765095300594e-07
specific O 0 7.579241412258853e-08
oligonucleotide O 0 8.753655492910184e-06
( O 0 5.733040211453044e-07
ASO O 0 0.00023169172345660627
) O 0 8.399709372497455e-07
method O 0 7.812705007381737e-06
. O 0 1.3711814972339198e-05

RESULTS O 0 6.991629197727889e-05
In O 0 1.3705363244298496e-06
persons O 0 8.872799526216113e-07
at O 0 1.9083174720435636e-06
average O 0 4.920265723740158e-07
risk O 0 5.0993089644180145e-06
for O 0 0.028137706220149994
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.211720832041465e-05
I1307K O 0 6.382567516993731e-05
was O 0 8.363491588170291e-07
found O 0 8.314965072031555e-08
in O 0 1.352014606936791e-07
5 O 0 8.733509275771212e-06
. O 0 1.216649434354622e-05

0 O 0 4.179331881459802e-06
% O 0 1.9102279225080565e-07
of O 0 1.8209505014965544e-07
120 O 0 5.576156354436534e-07
European O 0 8.17492605165171e-07
and O 0 4.920744913761155e-07
1 O 0 9.607062565919477e-06
. O 0 5.6251419664477e-06

6 O 0 1.4405249203264248e-05
% O 0 2.7817836212307157e-07
of O 0 3.403729067485983e-07
188 O 0 6.710693583045213e-07
non O 0 1.0108027481692261e-06
- O 0 4.806553874914243e-07
European O 0 3.0812387308287725e-07
Jews O 0 5.026662961427064e-07
( O 0 6.656026130258397e-08
P O 0 4.046929007017752e-06
= O 0 6.961585086173727e-07
0 O 0 3.3135174248855037e-07
. O 0 9.658248956156967e-08
08 O 0 5.567225798586151e-06
) O 0 7.072833341226215e-07
. O 0 6.691542694170494e-06

It O 0 2.825325509547838e-06
occurred O 0 1.8277552953804843e-05
in O 0 1.2276321967874537e-06
15 O 0 1.3236701306595933e-05
. O 0 1.4372550140251406e-05

4 O 0 1.1595084288273938e-05
% O 0 4.726460645088082e-07
of O 0 1.0060730346594937e-06
52 O 0 3.827841737802373e-06
Ashkenazi O 0 8.004150913620833e-06
Israelis O 0 2.1970708985463716e-06
with O 0 3.692398138355202e-07
familial O 0 1.7693777408567257e-05
cancer B-Disease 0 0.0001773775729816407
( O 0 1.0383090511822957e-06
P O 0 0.00011913441267097369
= O 0 2.0133445559622487e-06
0 O 0 2.714129436753865e-07
. O 0 2.3943673710391522e-08
02 O 0 1.236385287484154e-06
) O 0 1.523166481831595e-08
and O 0 1.5698750743808887e-08
was O 0 6.357115012178838e-08
not O 0 4.471925496574158e-09
detected O 0 2.405169752250913e-08
in O 0 1.1760737272936694e-08
51 O 0 4.2740796857287933e-07
non O 0 4.075034212291939e-06
- O 0 4.689536581281573e-06
European O 0 1.3915986301071825e-06
Jews O 0 1.2794847634722828e-06
at O 0 3.161299673593021e-06
increased O 0 1.7912936982611427e-06
cancer B-Disease 0 0.00012933980906382203
risk O 0 1.5679601347073913e-05
. O 0 1.9969596905866638e-05

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999998807907104
occurred O 0 0.427259236574173
personally O 0 5.858907115907641e-06
or O 0 1.306815846646714e-07
in O 0 2.3828590656194137e-08
the O 0 3.339470211471962e-08
families O 0 5.21368148653778e-09
of O 0 2.4809404308712146e-08
13 O 0 3.0855321142553294e-07
of O 0 2.1513551473617554e-07
20 O 0 1.1650065516732866e-06
Ashkenazi O 0 3.8749353734601755e-06
I1307K O 0 1.4472902876150329e-06
carriers O 0 4.307687717641784e-08
, O 0 3.377687818328923e-08
8 O 0 2.414224695712619e-07
of O 0 8.903741388621711e-08
whom O 0 1.981471484668873e-07
also O 0 7.193696660579008e-08
had O 0 1.364422246297181e-07
a O 0 8.823135999591614e-08
personal O 0 4.1398908479095553e-07
or O 0 3.2352446055483597e-07
family O 0 4.877750114928858e-08
history O 0 2.821680311626551e-07
of O 0 4.82986388306017e-06
noncolonic O 0 0.41851022839546204
neoplasia B-Disease 1 0.9999933242797852
. O 0 0.0005361324874684215

CONCLUSIONS O 0 0.00013566145207732916
The O 0 7.78768298914656e-06
I1307K O 0 0.00015964546764735132
APC O 0 4.610104952007532e-05
variant O 0 1.870024425443262e-05
may O 0 5.396643700805726e-07
represent O 0 1.1869736482594817e-07
a O 0 1.136621747832578e-07
susceptibility O 0 7.643414505764667e-07
gene O 0 4.992775188839005e-07
for O 0 9.661939657235052e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.3440684597298969e-05
or I-Disease 0 8.656077739033208e-07
other I-Disease 0 8.364801828975033e-08
, I-Disease 0 1.2833228879571834e-07
cancers I-Disease 0 4.431148408912122e-05
in O 0 6.781856853876889e-08
Ashkenazi O 0 1.8018488844973035e-05
Jews O 0 2.4094688342302106e-06
, O 0 8.26463519842946e-07
and O 0 1.3297534451339743e-06
partially O 0 9.047661478689406e-06
explains O 0 3.7757166637675255e-07
the O 0 2.027547907346161e-07
higher O 0 9.389110346091911e-06
incidence O 1 0.5546180605888367
of O 1 0.9999960660934448
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.2741230623068986e-06
European O 0 2.7810438041342422e-05
Israelis O 0 2.4261522412416525e-05
. O 0 6.69137671138742e-06

Systematic O 0 1.379016975988634e-05
analysis O 0 3.0836779387755087e-06
of O 0 5.132113074068911e-06
coproporphyrinogen O 0 0.0214595478028059
oxidase O 0 0.0010827822843566537
gene O 0 5.1652506954269484e-05
defects O 0 0.01649523712694645
in O 0 2.3055117708281614e-06
hereditary B-Disease 1 0.9999967813491821
coproporphyria I-Disease 1 0.9990102052688599
and O 0 1.8477659978088923e-05
mutation O 0 1.6662095731589943e-05
update O 0 4.776164496433921e-05
. O 0 2.267598574690055e-05

Hereditary B-Disease 1 0.9999723434448242
coproporphyria I-Disease 1 0.9999769926071167
( O 0 0.0002946861495729536
HC B-Disease 1 1.0
) O 0 5.1422302931314334e-06
is O 0 3.6470078157435637e-07
an O 0 6.923251589796564e-07
acute O 1 0.9999995231628418
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9891372323036194
autosomal O 1 0.9999998807907104
dominant O 1 0.9999997615814209
inheritance O 0 0.0008005606941878796
caused O 0 1.232299291586969e-05
by O 0 1.616730571640801e-07
deficient B-Disease 0 9.17504394237767e-07
activity I-Disease 0 1.580595920813721e-07
of I-Disease 0 5.845005262017366e-07
coproporphyrinogen I-Disease 0 7.448395626852289e-05
III I-Disease 1 0.999586284160614
oxidase I-Disease 0 2.5627343347878195e-05
( O 0 1.0918183761532418e-06
CPO O 0 5.645489727612585e-05
) O 0 2.1451814973261207e-06
. O 0 1.765632623573765e-05

Clinical O 0 0.004247474018484354
manifestations O 0 0.08989457786083221
of O 0 5.280568802845664e-05
the O 0 8.79158396855928e-05
disease O 1 0.9987264275550842
are O 0 2.016796685211375e-07
characterized O 0 3.014460389749729e-06
by O 0 2.5429790184716694e-07
acute O 1 0.9998751878738403
attacks O 1 0.5373043417930603
of O 1 1.0
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.2470596377388574e-05
precipitated O 0 0.00013441231567412615
by O 0 2.2495730434002326e-07
drugs O 0 1.6849407984409481e-06
, O 0 8.027320177461661e-07
fasting O 0 5.68047835258767e-05
, O 0 1.0908108833973529e-06
cyclical O 0 0.001167719135992229
hormonal O 0 0.014068678952753544
changes O 0 1.3476417734636925e-05
, O 0 2.4329550797119737e-05
or O 1 0.590424656867981
infectious B-Disease 1 0.9999998807907104
diseases I-Disease 1 0.9999967813491821
. O 0 6.167565879877657e-05

Skin O 1 1.0
photosensitivity O 1 0.9999998807907104
may O 0 0.00014361916691996157
also O 0 7.850286465327372e-07
be O 0 4.6544349174837407e-07
present O 0 1.2087781442460255e-06
. O 0 7.0156497713469435e-06

The O 0 5.118519766256213e-06
seven O 0 6.0963370742683765e-06
exons O 0 7.508860107918736e-06
, O 0 1.8805498314122815e-07
the O 0 3.043898573196202e-07
exon O 0 5.037522441853071e-06
/ O 0 5.069328835816123e-06
intron O 0 4.31339549322729e-06
boundaries O 0 2.742464175753412e-07
and O 0 5.476947251281672e-08
part O 0 5.8211572451227767e-08
of O 0 1.291396358737984e-07
3 O 0 8.922933147914591e-07
noncoding O 0 5.564092475651705e-07
sequence O 0 4.503882067297127e-08
of O 0 4.514615881134887e-08
the O 0 1.1330242699614246e-07
CPO O 0 4.9231753109779675e-06
gene O 0 2.1961753304822196e-07
were O 0 2.0826968238907284e-07
systematically O 0 1.0717917575675528e-06
analyzed O 0 2.3135459059631103e-07
by O 0 4.7967724015052227e-08
an O 0 7.872060336922004e-08
exon O 0 3.3387302664777962e-06
- O 0 2.794248075588257e-06
by O 0 4.6546037424377573e-07
- O 0 6.237466732272878e-05
exon O 0 5.474097633850761e-05
denaturing O 0 0.00025773720699362457
gradient O 0 0.00027427708846516907
gel O 0 0.00025059617473743856
electrophoresis O 0 4.927050758851692e-05
( O 0 7.972177513693168e-07
DGGE O 0 0.00025471069966442883
) O 0 1.1177723990840605e-07
strategy O 0 3.0822911867289804e-07
followed O 0 4.312455814670102e-08
by O 0 6.5234138091341265e-09
direct O 0 1.343625743999155e-08
sequencing O 0 9.744289286572894e-08
in O 0 2.6782725370821936e-08
seven O 0 3.6244423995412944e-07
unrelated O 0 1.1709322507158504e-06
heterozygous O 0 3.2215148166869767e-06
HC B-Disease 1 0.9575590491294861
patients O 0 2.701493713175296e-07
from O 0 8.391280204023133e-08
France O 0 6.274206043599406e-06
, O 0 2.6954668896905787e-07
Holland O 0 5.095939741295297e-06
, O 0 1.0502502334475139e-07
and O 0 1.2656867909299763e-07
Czech O 0 5.56306531507289e-06
Republic O 0 1.0965581168420613e-05
. O 0 1.3065932762401644e-05

Seven O 0 2.379885336267762e-05
novel O 0 2.104319946738542e-06
mutations O 0 1.553185143166047e-06
and O 0 1.431925937822598e-07
two O 0 9.368257281039405e-08
new O 0 3.420966550038429e-07
polymorphisms O 0 1.1219262887607329e-06
were O 0 1.3270499721329543e-06
detected O 0 1.2641365174204111e-05
. O 0 1.9713888832484372e-05

Among O 0 1.0830407290995936e-06
these O 0 5.999551433433226e-08
mutations O 0 1.4705149453675403e-07
two O 0 3.346490373701272e-08
are O 0 2.153210232336278e-08
missense O 0 3.095806277997326e-06
( O 0 2.5932041580745135e-07
G197W O 0 7.880938028392848e-06
, O 0 2.7556379222914984e-07
W427R O 0 5.542772669286933e-06
) O 0 4.4706570889729846e-08
, O 0 2.6679479958602315e-08
two O 0 3.443610552267273e-08
are O 0 3.225017053409829e-08
nonsense O 0 3.718275593200815e-06
( O 0 1.6565940086366027e-07
Q306X O 0 3.2928414839261677e-06
, O 0 8.046484367696394e-08
Q385X O 0 1.5386501672765007e-06
) O 0 3.901303102793463e-08
, O 0 2.931978926312695e-08
two O 0 2.3559966422226353e-08
are O 0 1.8925044642514877e-08
small O 0 8.060431611056629e-08
deletions O 0 1.60137949478667e-06
( O 0 4.872315457760124e-07
662de14bp O 0 1.0030610610556323e-05
; O 0 5.501404416463629e-07
1168del3bp O 0 2.626883542689029e-05
removing O 0 2.4298074094986077e-06
a O 0 3.6864236108158366e-07
glycine O 0 1.6212960645134444e-06
at O 0 7.322271358134458e-07
position O 0 7.824851309123915e-07
390 O 0 5.995559035909537e-07
) O 0 2.2017761835968486e-08
, O 0 2.929653319938552e-08
and O 0 3.8986105010963e-08
one O 0 3.5863521929968556e-08
is O 0 1.5418942567180238e-08
a O 0 6.136686181434925e-08
splicing O 0 5.754798166890396e-07
mutation O 0 5.405802312452579e-07
( O 0 3.858692139147024e-07
IVS1 O 0 0.00011626961349975318
- O 0 2.076108103210572e-05
15c O 0 2.3213227905216627e-05
- O 0 4.862548394157784e-06
- O 0 2.313251115992898e-06
> O 0 1.603679493200616e-06
g O 0 1.0295835863871616e-06
) O 0 4.300291323033889e-08
which O 0 1.8114183930606487e-08
creates O 0 9.598618078143772e-08
a O 0 4.316883206456623e-08
new O 0 1.3774217677564593e-07
acceptor O 0 6.237760885596799e-07
splice O 0 1.4978837498347275e-05
site O 0 5.515321845450671e-06
. O 0 1.0456422387505881e-05

The O 0 7.397355147986673e-06
pathological O 0 1.678795706538949e-05
significance O 0 1.2136827081121737e-06
of O 0 4.1595478705858113e-07
the O 0 1.603564925289902e-07
point O 0 5.372775717660261e-07
mutations O 0 4.5484236466108996e-07
G197W O 0 2.815057086991146e-06
, O 0 1.6739139141463966e-07
W427R O 0 5.269668690743856e-06
, O 0 6.365863214341516e-08
and O 0 5.4752451461581586e-08
the O 0 7.180481986779341e-08
in O 0 7.147319536215946e-08
- O 0 2.173115035475348e-06
frame O 0 5.359457645681687e-06
deletion O 0 1.6049938267315156e-06
390delGly O 0 3.5303107779327547e-06
were O 0 1.0734820676816526e-07
assessed O 0 3.6668237157755357e-07
by O 0 1.159672624595487e-08
their O 0 1.537744331869817e-08
respective O 0 1.7019047504618356e-07
expression O 0 1.0452043852637871e-07
in O 0 2.016121136705351e-08
a O 0 3.195760100993539e-08
prokaryotic O 0 1.554189736907574e-07
system O 0 9.163224490293942e-08
using O 0 7.662617917958414e-08
site O 0 4.5176480512054695e-07
- O 0 1.5458689404113102e-06
directed O 0 1.813069275158341e-06
mutagenesis O 0 0.0003198749909643084
. O 0 4.47871680080425e-05

These O 0 1.2825927342419163e-06
mutations O 0 2.361247879889561e-06
resulted O 0 9.791907586986781e-07
in O 0 5.892483301295215e-08
the O 0 8.253483940734441e-08
absence O 0 1.3943777048552874e-06
or O 0 1.193656231635032e-07
a O 0 8.193551082058548e-08
dramatic O 0 6.533166470035212e-07
decrease O 0 7.351756607931748e-07
of O 0 2.9181096579122823e-06
CPO O 0 0.0001359551533823833
activity O 0 2.2730717319063842e-05
. O 0 2.322638283658307e-05

The O 0 2.320520707144169e-06
two O 0 5.119591151014902e-07
polymorphisms O 0 1.118196109928249e-06
were O 0 2.5221646637874073e-07
localized O 0 8.029839477785572e-07
in O 0 7.832401394125554e-08
noncoding O 0 7.690055099374149e-07
part O 0 2.578899227501097e-08
of O 0 4.256503061128569e-08
the O 0 2.8762292103579057e-08
gene O 0 1.7584248723778728e-08
1 O 0 1.1938156774249364e-07
) O 0 8.81547812525696e-09
a O 0 3.583200225421024e-08
C O 0 7.280580575752538e-06
/ O 0 5.982753464195412e-06
G O 0 5.3342569117376115e-06
polymorphism O 0 4.4175530433676613e-07
in O 0 4.44045404890403e-08
the O 0 2.094250532991282e-07
promotor O 0 3.0254128432716243e-05
region O 0 9.877613820208353e-07
, O 0 6.051972150089568e-07
142 O 0 1.6578298982494744e-06
bp O 0 2.6364966743130935e-06
upstream O 0 2.463595194512891e-07
from O 0 2.439571744616842e-08
the O 0 5.128039504143089e-08
transcriptional O 0 6.843578717052878e-07
initiation O 0 8.049060511439166e-07
site O 0 3.597677675770683e-07
( O 0 1.4484886889931659e-07
- O 0 1.3083848671158194e-06
142C O 0 8.059990250330884e-06
/ O 0 8.45549857331207e-06
G O 0 1.8423290384816937e-05
) O 0 8.530027173492272e-08
, O 0 2.299059609356391e-08
and O 0 2.7034829486183298e-08
2 O 0 8.981825203591143e-07
) O 0 3.085119359980126e-08
a O 0 1.2097878254735406e-07
6 O 0 2.209135118391714e-06
bp O 0 2.261218924104469e-06
deletion O 0 7.404374287034443e-07
polymorphism O 0 3.8840229876768717e-07
in O 0 2.2641845731641297e-08
the O 0 8.020879960213279e-08
3 O 0 8.597746159466624e-07
noncoding O 0 1.440554001419514e-06
part O 0 5.931725155505774e-08
of O 0 1.627848291718692e-07
the O 0 2.6985429713022313e-07
CPO O 0 1.6176547433133237e-05
gene O 0 8.401527793466812e-07
, O 0 9.27443579712417e-07
574 O 0 1.2845028322772123e-05
bp O 0 7.174005077104084e-06
downstream O 0 7.12806865976745e-07
of O 0 2.1068930777801143e-07
the O 0 1.3059424475159176e-07
last O 0 2.4419838950962003e-07
base O 0 2.1102914615767077e-07
of O 0 1.3429178125079488e-07
the O 0 2.0544592871374334e-07
normal O 0 7.310716227948433e-07
termination O 0 1.6271666254397132e-06
codon O 0 3.543087359503261e-06
( O 0 3.2118165904648777e-07
+ O 0 3.2177656521525932e-06
574 O 0 7.396325599984266e-06
delATTCTT O 0 2.8640779419220053e-05
) O 0 1.6836910390338744e-06
. O 0 1.1329047083563637e-05

Five O 0 0.00013338947610463947
intragenic O 0 0.0014824512181803584
dimorphisms O 0 0.00035536865470930934
are O 0 2.828874414717575e-07
now O 0 2.734720396802004e-07
well O 0 8.319200617279421e-08
characterized O 0 1.5964923250066931e-07
and O 0 3.845019236337066e-08
the O 0 6.05156742494728e-08
high O 0 6.003197654536052e-07
degree O 0 6.486808388217469e-07
of O 0 2.05567047828481e-07
allelic O 0 8.695828000782058e-06
heterogeneity O 0 7.581816589663504e-06
in O 0 3.8267361901489494e-07
HC B-Disease 1 0.9999722242355347
is O 0 1.196546719484104e-07
demonstrated O 0 1.689594597564792e-07
with O 0 1.3833820311504041e-08
seven O 0 3.918657398571668e-08
new O 0 1.4695021199884195e-08
different O 0 6.179402323169825e-09
mutations O 0 3.450593055731588e-08
making O 0 1.65262488138751e-08
a O 0 1.3683583155454926e-08
total O 0 2.171095836445147e-08
of O 0 2.248541477456456e-07
nineteen O 0 2.0854682588833384e-05
CPO O 0 0.0004528967838268727
gene B-Disease 0 5.8194065786665305e-05
defects I-Disease 0 0.0020725273061543703
reported O 0 1.3977742128190584e-06
so O 0 2.691095346563088e-07
far O 0 7.589742949676292e-07
. O 0 9.705169077278697e-07
. O 0 8.106057066470385e-06

Coincidence O 0 6.549093086505309e-05
of O 0 3.454268835412222e-06
two O 0 1.036968228618207e-06
novel O 0 1.5002578948042355e-06
arylsulfatase O 0 8.200435331673361e-06
A O 0 8.570379463890276e-07
alleles O 0 8.858713727022405e-07
and O 0 1.76711026256271e-07
mutation O 0 5.524147468349838e-07
459 O 0 2.646858320076717e-06
+ O 0 4.410444944369374e-06
1G O 0 0.0002276733284816146
> O 0 5.946615146967815e-06
A O 0 8.626442422610126e-07
within O 0 2.652822388427012e-07
a O 0 1.7378235384057916e-07
family O 0 1.8482526797924947e-07
with O 0 1.1920562883460661e-06
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999998807907104
: O 0 7.148204872464703e-07
molecular O 0 2.0979678083676845e-06
basis O 0 7.139702233871503e-07
of O 0 2.018414079429931e-06
phenotypic O 0 0.0001733830285957083
heterogeneity O 0 0.00040768718463368714
. O 0 0.00010476142779225484

In O 0 2.4223941181844566e-06
a O 0 7.603072731399152e-07
family O 0 6.615335479409623e-08
with O 0 6.056370693841018e-08
three O 0 2.3313175745443004e-07
siblings O 0 5.931227065048006e-07
, O 0 3.285897420823858e-08
one O 0 2.4904986517526595e-08
developed O 0 1.5924474894291052e-07
classical O 0 1.8395988945485442e-06
late O 0 0.0003606491954997182
infantile O 1 0.999858021736145
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.8943856048281305e-05
MLD B-Disease 1 1.0
) O 0 1.1498776757434825e-06
, O 0 6.174515760903887e-07
fatal O 0 8.04933370091021e-05
at O 0 2.718784571698052e-06
age O 0 8.400390356655407e-07
5 O 0 7.466775855391461e-07
years O 0 6.103208249896852e-08
, O 0 2.133936938264469e-08
with O 0 3.214711696841732e-08
deficient O 0 3.5219177334511187e-06
arylsulfatase O 0 1.2820796655432787e-05
A O 0 3.2676093724148814e-06
( O 0 5.015988904233382e-07
ARSA O 0 0.0001369874953525141
) O 0 9.987706306446853e-08
activity O 0 2.6645108164302655e-07
and O 0 9.820303148444509e-08
increased O 0 1.2334517123235855e-06
galactosylsulfatide O 0 0.0006007928168401122
( O 0 5.239497113507241e-06
GS O 1 0.9999994039535522
) O 0 2.049576096396777e-06
excretion O 0 2.548367774579674e-05
. O 0 8.359269486390986e-06

The O 0 2.8867762011941522e-06
two O 0 4.5011515226178744e-07
other O 0 1.4261448200159066e-07
siblings O 0 1.2902357866551029e-06
, O 0 1.703340046788071e-07
apparently O 0 6.825900982221356e-07
healthy O 0 7.867584486120904e-07
at O 0 1.359879888696014e-06
12 O 0 6.961565759411315e-07
( O 0 3.637829593117203e-08
1 O 0 2.874743643133115e-07
/ O 0 2.14103550888467e-07
2 O 0 1.527076705087893e-07
) O 0 1.1649045283945725e-08
and O 0 9.445080273451367e-09
15 O 0 5.6348646637616184e-08
years O 0 3.017978400521315e-08
, O 0 1.104241853511212e-08
respectively O 0 6.773273497628907e-08
, O 0 1.014175499136627e-08
and O 0 6.467995472547727e-09
their O 0 9.436114112304494e-09
father O 0 2.2082198825046362e-07
, O 0 5.069417241543306e-08
apparently O 0 2.569267110175133e-07
healthy O 0 4.253824954503216e-07
as O 0 4.685530541337357e-08
well O 0 8.380691696174836e-08
, O 0 1.3024759937252384e-07
presented O 0 2.9902660116931656e-06
ARSA O 0 0.0009718580986373127
and O 0 1.6779925999799161e-06
GS O 1 0.9999960660934448
values O 0 2.6667888164411124e-07
within O 0 1.3800001852359856e-07
the O 0 1.0387552151769341e-07
range O 0 1.3584824500867398e-06
of O 0 6.299387223407393e-06
MLD B-Disease 1 1.0
patients O 0 3.525588181219064e-05
. O 0 3.362647112226114e-05

Mutation O 0 1.2648637493839487e-05
screening O 0 2.3086097371560754e-06
and O 0 1.3627848716168955e-07
sequence O 0 2.837931845078856e-07
analysis O 0 2.0147281531990302e-07
disclosed O 0 4.3147389305886463e-07
the O 0 6.414531128484668e-08
involvement O 0 4.212389228541724e-07
of O 0 1.4439662265886e-07
three O 0 1.4519726221351448e-07
different O 0 1.733787513558127e-07
ARSA O 0 0.0003797686949837953
mutations O 0 6.631170208493131e-07
being O 0 1.2422411543866474e-07
the O 0 2.9230449172246153e-08
molecular O 0 2.871329627396335e-07
basis O 0 2.3780266644735093e-07
of O 0 6.692069973723846e-07
intrafamilial O 0 8.852371684042737e-05
phenotypic O 0 0.0002750857674982399
heterogeneity O 0 0.0002448569575790316
. O 0 6.980796024436131e-05

The O 0 1.021777825371828e-05
late O 0 0.0069813961163163185
infantile O 1 0.9977813363075256
patient O 0 8.374350727535784e-06
inherited O 0 1.717163104331121e-05
from O 0 3.316764320970833e-07
his O 0 5.583030997513561e-07
mother O 0 1.4901605993600242e-07
the O 0 1.8732895057382848e-07
frequent O 0 1.930121982240962e-07
0 O 0 4.392801656649681e-06
- O 0 2.486647872501635e-06
type O 0 1.7660366893323953e-06
mutation O 0 1.0824088576555368e-06
459 O 0 1.6250497765213368e-06
+ O 0 1.9141536995448405e-06
1G O 0 5.3797550208400935e-05
> O 0 1.5810195463927812e-06
A O 0 2.631713584833051e-07
, O 0 2.893694528438573e-08
and O 0 2.9086017150348198e-08
from O 0 1.8948664859408382e-08
his O 0 4.902953421037637e-08
father O 0 2.0210345041959954e-07
a O 0 8.15102936257972e-08
novel O 0 1.7664565632458107e-07
, O 0 1.330520547071501e-07
single O 0 3.958608374432515e-07
basepair O 0 9.646439139032736e-06
microdeletion O 0 8.096971214399673e-06
of O 0 8.011015779629815e-07
guanine O 0 3.235817075619707e-06
at O 0 1.2982624184587621e-06
nucleotide O 0 4.633257049135864e-07
7 O 0 5.53199186015263e-07
in O 0 4.053766744505083e-08
exon O 0 6.763847864021955e-07
1 O 0 9.049922482518014e-07
( O 0 2.04844525342196e-07
7delG O 0 1.2558348316815682e-05
) O 0 1.6871822481334675e-06
. O 0 1.3401801879808772e-05

The O 0 6.053927791072056e-06
two O 0 3.521608505252516e-06
clinically O 0 0.002873881720006466
unaffected O 0 7.264801752171479e-06
siblings O 0 1.7313302578259027e-06
carried O 0 3.5225116334913764e-07
the O 0 1.810738439189663e-07
maternal O 0 9.915461305354256e-07
mutation O 0 1.3264692597658723e-06
459 O 0 5.679022251570132e-06
+ O 0 1.091102330974536e-05
1G O 0 0.00036612313124351203
> O 0 6.241395112738246e-06
A O 0 9.356843406749249e-07
and O 0 9.485958685218066e-08
, O 0 3.7442116962438377e-08
on O 0 2.8851026456777618e-08
their O 0 6.706973643133551e-09
paternal O 0 6.312000522257222e-08
allele O 0 4.094950725175295e-07
, O 0 4.527162289491571e-08
a O 0 3.754573896230795e-08
novel O 0 9.839896364383094e-08
cytosine O 0 9.54067218117416e-07
to O 0 5.828056615087007e-08
thymidine O 0 3.742630951819592e-06
transition O 0 3.324686076666694e-06
at O 0 2.4217126792791532e-06
nucleotide O 0 1.6308812291754293e-06
2435 O 0 2.2492420612252317e-05
in O 0 1.015182249375357e-07
exon O 0 9.064053188012622e-07
8 O 0 6.547187467731419e-07
, O 0 2.2912148622822315e-08
resulting O 0 8.956645558555465e-08
in O 0 2.251604946934549e-08
substitution O 0 3.7366748983913567e-07
of O 0 5.503177931132086e-07
alanine O 0 6.292062153079314e-06
464 O 0 4.884141617367277e-06
by O 0 6.040820039743267e-07
valine O 0 0.00037471376708708704
( O 0 2.253337925139931e-06
A464V O 0 7.322418241528794e-05
) O 0 3.818660843535326e-06
. O 0 2.2960830392548814e-05

The O 0 1.3054051123617683e-05
fathers O 0 1.489212445449084e-05
genotype O 0 1.3182078873796854e-05
thus O 0 3.630739456639276e-06
was O 0 1.015777434076881e-05
7delG O 0 0.00019480627088341862
/ O 0 0.00028351577930152416
A464V O 0 0.0005291230627335608
. O 0 7.913056469988078e-05

Mutation O 0 5.0678001571213827e-05
A464V O 0 7.585664570797235e-05
was O 0 1.0896942512772512e-06
not O 0 3.128221237602702e-08
found O 0 3.6761434785148595e-08
in O 0 4.189904245777143e-08
18 O 0 5.488243004947435e-06
unrelated O 0 0.0002128938358509913
MLD B-Disease 1 1.0
patients O 0 3.1757676879351493e-06
and O 0 9.516028853795433e-07
50 O 0 2.7187741125089815e-06
controls O 0 1.6152378520928323e-05
. O 0 1.897665424621664e-05

A464V O 0 0.000440680596511811
, O 0 2.1557145828410285e-06
although O 0 2.225735443062149e-06
clearly O 0 4.466303835215513e-06
modifying O 0 2.84550496871816e-05
ARSA O 0 0.0411955751478672
and O 0 1.1855276170535944e-05
GS O 1 1.0
levels O 0 1.652215541980695e-05
, O 0 1.8854557026770635e-07
apparently O 0 3.95367322880702e-07
bears O 0 4.3176163444513804e-07
little O 0 1.9845504084514687e-07
significance O 0 2.668604963673715e-07
for O 0 6.69228086280782e-08
clinical O 0 8.769403621045058e-07
manifestation O 0 6.694478543067817e-06
of O 0 9.014287570607848e-06
MLD B-Disease 1 1.0
, O 0 4.221721610520035e-06
mimicking O 0 1.2346048606559634e-05
the O 0 1.372609517602541e-06
frequent O 0 8.291221092804335e-06
ARSA O 0 0.012794987298548222
pseudodeficiency O 0 0.0015813885256648064
allele O 0 0.0004728012718260288
. O 0 9.664102253736928e-05

Our O 0 3.530502681314829e-06
results O 0 1.0438769777465495e-06
demonstrate O 0 2.3094192158623628e-07
that O 0 7.289605363780538e-09
in O 0 5.067143149517506e-09
certain O 0 3.3517668640570264e-08
genetic O 0 9.95118512037152e-07
conditions O 0 2.1721518351114355e-05
MLD B-Disease 1 1.0
- O 1 0.998401939868927
like O 0 1.3155306078260764e-05
ARSA O 1 0.9997982382774353
and O 0 6.277360171225155e-06
GS O 1 1.0
values O 0 9.593785676997868e-08
need O 0 3.148501193095399e-08
not O 0 6.841944788504861e-09
be O 0 2.03798862230542e-08
paralleled O 0 1.3931772002706566e-07
by O 0 6.294447274513004e-08
clinical O 0 0.010138371028006077
disease O 0 0.17451606690883636
, O 0 1.7097784166253405e-07
a O 0 9.944973555775505e-08
finding O 0 5.265039817459183e-07
with O 0 2.0221449403834413e-07
serious O 0 0.000810908735729754
diagnostic O 0 0.00024107666104100645
and O 0 9.189096999762114e-06
prognostic O 1 0.9116999506950378
implications O 0 0.0006229021237231791
. O 0 3.785782973864116e-05

Moreover O 0 3.160307460348122e-05
, O 0 3.1087051866052207e-06
further O 0 7.358263246715069e-06
ARSA O 0 0.001232203096151352
alleles O 0 8.082674867182504e-06
functionally O 0 2.5760043627087725e-06
similar O 0 7.374860899744817e-08
to O 0 4.948982024188808e-08
A464V O 0 1.5143144764806493e-06
might O 0 5.666638003276603e-08
exist O 0 4.0496395570244204e-08
which O 0 1.8969567250337604e-08
, O 0 1.329761545321162e-08
together O 0 7.022550096991154e-09
with O 0 9.993742722258503e-09
0 O 0 4.4570859358827875e-07
- O 0 1.7926132045431586e-07
type O 0 1.7318807010724413e-07
mutations O 0 3.001051140927302e-07
, O 0 4.665064778919259e-08
may O 0 2.785688479889359e-07
cause O 0 1.0721040780481417e-05
pathological O 0 0.05674273148179054
ARSA O 1 0.9970647692680359
and O 0 1.2358569620118942e-05
GS O 1 1.0
levels O 0 1.2550556220958242e-06
, O 0 1.066170529639976e-08
but O 0 4.521628405029787e-09
not O 0 7.935251566948409e-09
clinical O 0 4.1677273543427873e-07
outbreak O 0 1.0236792746809442e-07
of O 0 2.02130621573815e-07
the O 0 1.940022457347368e-06
disease O 0 0.0007331639644689858
. O 0 8.497304406773765e-07
. O 0 9.131771548709366e-06

Human O 1 0.9888696670532227
MLH1 O 1 1.0
deficiency O 1 0.9999998807907104
predisposes O 0 0.0004971848102286458
to O 0 4.841157078772085e-06
hematological B-Disease 1 0.9999977350234985
malignancy I-Disease 1 0.9999966621398926
and O 0 0.00010879249748541042
neurofibromatosis B-Disease 1 0.999975323677063
type I-Disease 0 0.060343753546476364
1 I-Disease 0 0.0009234911412931979
. O 0 8.072884156717919e-06

Heterozygous O 0 0.0002540248678997159
germ O 0 0.01429272536188364
- O 0 0.00026983703719452024
line O 0 9.816070814849809e-06
mutations O 0 1.402416842211096e-06
in O 0 7.050415007370248e-08
the O 0 1.390583577176585e-07
DNA O 0 3.3284393339272356e-06
mismatch O 0 0.00033319584326818585
repair O 0 6.984128049225546e-06
genes O 0 5.047015747550176e-07
lead O 0 3.0989726838015486e-06
to O 0 3.2155569442693377e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9964526891708374

The O 0 4.503179297898896e-05
disease O 0 0.020115144550800323
susceptibility O 0 1.8336491848458536e-05
of O 0 2.7101123123429716e-06
individuals O 0 2.432435621813056e-07
who O 0 4.15897261518694e-07
constitutionally O 0 1.3558873206420685e-06
lack O 0 1.7750279539541225e-06
both O 0 8.997943155009125e-07
wild O 0 3.174120820403914e-06
- O 0 5.006334049539873e-06
type O 0 1.8628904854267603e-06
alleles O 0 1.6352528291463386e-06
is O 0 1.2911083047129068e-07
unknown O 0 4.618144430423854e-06
. O 0 8.077566235442646e-06

We O 0 2.313412096555112e-06
have O 0 1.100251978414235e-07
identified O 0 3.17276629857588e-07
three O 0 3.866146869313525e-08
offspring O 0 6.762675042182309e-08
in O 0 2.548406996538688e-08
a O 0 8.084325600066222e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.733344369218685e-05
who O 0 3.888395440299064e-06
developed O 0 0.03240136057138443
hematological B-Disease 1 0.9999997615814209
malignancy I-Disease 1 0.9999964237213135
at O 0 4.849571269005537e-05
a O 0 7.123298217948104e-08
very O 0 1.765829260591545e-08
early O 0 9.512991994142794e-08
age O 0 1.5516482676503074e-07
, O 0 1.1655556519940546e-08
and O 0 1.2540844807062967e-08
at O 0 7.965096671114225e-08
least O 0 4.7857486862312726e-09
two O 0 3.276895643722355e-09
of O 0 8.771602111323773e-09
them O 0 1.1947560274450097e-08
displayed O 0 2.053530749890342e-07
signs O 0 1.235495460605307e-06
of O 0 2.2195563360583037e-06
neurofibromatosis B-Disease 1 0.7018308043479919
type I-Disease 0 3.250343434046954e-05
1 I-Disease 0 3.541044134180993e-05
( O 0 8.005898735063965e-07
NF1 B-Disease 0 0.00018619716865941882
) O 0 1.2225708587720874e-06
. O 0 7.703994924668223e-06

DNA O 0 1.2700915249297395e-05
sequence O 0 1.6034455256885849e-06
analysis O 0 6.576266855518043e-07
and O 0 2.750528835804289e-07
allele O 0 4.385543434182182e-06
- O 0 1.095757170332945e-06
specific O 0 7.270751467558512e-08
amplification O 0 1.4934998944227118e-06
in O 0 7.588209882669616e-08
two O 0 2.385267521276546e-07
siblings O 0 1.550333422528638e-06
revealed O 0 1.534564603389299e-06
a O 0 8.435673066742311e-07
homozygous O 0 8.510835868946742e-06
MLH1 O 0 0.0009614431764930487
mutation O 0 4.901755801256513e-06
( O 0 1.5159226904870593e-06
C676T O 0 6.56793054076843e-05
- O 0 7.991071470314637e-05
- O 0 3.658266723505221e-05
> O 0 5.213053009356372e-05
Arg226Stop O 0 0.0011765003437176347
) O 0 3.497870920909918e-06
. O 0 1.4726476365467533e-05

Thus O 0 1.3197777661844157e-05
, O 0 1.0723664445322356e-06
a O 0 1.1825021601907793e-06
homozygous O 0 9.710014637676068e-06
germ O 0 0.10538271814584732
- O 0 0.0017943376442417502
line O 0 0.0001527560962131247
MLH1 O 1 0.9999334812164307
mutation O 0 4.1068920836551115e-05
and O 0 3.6577046103047905e-06
consequent O 1 0.9996297359466553
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 0.10296856611967087
in O 0 9.623693131288746e-07
a O 0 6.152078185550636e-06
mutator O 1 0.9354460835456848
phenotype O 0 6.782611308153719e-05
characterized O 0 4.4624107431445736e-07
by O 0 1.7464930124333478e-07
leukemia B-Disease 1 0.9999927282333374
and O 1 0.6044099926948547
/ O 1 1.0
or O 1 0.9999986886978149
lymphoma B-Disease 1 1.0
associated O 0 0.1572633534669876
with O 0 7.011884918028954e-06
neurofibromatosis B-Disease 1 0.9999977350234985
type I-Disease 0 0.00995589978992939
1 I-Disease 0 8.590638026362285e-05
. O 0 5.17495209351182e-07
. O 0 3.180065277774702e-06

Missense O 0 0.0005329664563760161
mutations O 0 1.2687370144703891e-05
in O 0 3.8129442714307515e-07
the O 0 1.4978617457472865e-07
most O 0 3.0903553493999425e-08
ancient O 0 1.0084854551450917e-07
residues O 0 2.392412170593161e-07
of O 0 2.273510943950896e-07
the O 0 6.384893822541926e-07
PAX6 O 0 0.29459619522094727
paired O 0 7.934488166938536e-06
domain O 0 1.7208266172019648e-06
underlie O 0 1.2434456039045472e-05
a O 0 5.578560831054347e-07
spectrum O 0 0.000154230379848741
of O 0 0.00971501599997282
human O 1 1.0
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.8676626086235046

Mutations O 0 1.2473743481677957e-05
of O 0 2.1108078271936392e-06
the O 0 1.2480674058679142e-06
human O 0 1.999155301746214e-06
PAX6 O 0 0.0031303048599511385
gene O 0 2.446258076815866e-05
underlie O 1 0.9998866319656372
aniridia B-Disease 1 1.0
( O 1 0.9999676942825317
congenital B-Disease 1 1.0
absence I-Disease 0 0.2839001417160034
of I-Disease 0 0.0011818902567029
the I-Disease 0 4.3479783926159143e-05
iris I-Disease 1 0.5832774639129639
) O 0 3.242336390485434e-07
, O 0 1.5095289995770145e-07
a O 0 3.523842337926908e-07
rare O 0 5.39851316716522e-05
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 0.718981921672821
the I-Disease 0 0.3101990520954132
eye I-Disease 1 0.9998911619186401
. O 0 0.00013349586515687406

The O 0 6.532595307362499e-06
spectrum O 0 2.275926453876309e-05
of O 0 2.756231879175175e-06
PAX6 O 0 0.48499026894569397
mutations O 0 1.903873635455966e-05
in O 0 9.746750038175378e-07
aniridia B-Disease 1 1.0
patients O 0 5.562744718190515e-07
is O 0 1.0810100370406417e-08
highly O 0 5.7864866676027304e-08
biased O 0 1.3815895272273337e-07
, O 0 9.339085060844354e-09
with O 0 4.696945499205185e-09
92 O 0 2.071801219472036e-07
% O 0 1.2109395264303657e-08
of O 0 4.368552453115626e-08
all O 0 5.301437866478409e-08
reported O 0 8.019334529763e-08
mutations O 0 1.2707955932000914e-07
leading O 0 2.5867427666526055e-07
to O 0 2.7806422053799906e-08
premature O 0 6.831202199464315e-07
truncation O 0 2.385493417023099e-06
of O 0 4.351803681856836e-07
the O 0 2.8702018539661367e-07
protein O 0 6.503017857539817e-07
( O 0 6.180783174158933e-08
nonsense O 0 9.676518857304472e-07
, O 0 3.934339787292629e-08
splicing O 0 2.5139112835859123e-07
, O 0 4.261571717734114e-08
insertions O 0 2.776784526759002e-07
and O 0 6.859849577267596e-08
deletions O 0 3.0295080932774e-07
) O 0 5.397951952090807e-08
and O 0 3.454596964047596e-08
just O 0 8.145341467979961e-08
2 O 0 2.7186291617908864e-07
% O 0 2.386830288969577e-08
leading O 0 1.240016018755341e-07
to O 0 8.79515660301422e-09
substitution O 0 1.786868182307444e-07
of O 0 1.7091980453187716e-07
one O 0 1.1579954417584304e-07
amino O 0 1.9313650057029008e-07
acid O 0 1.1302237368226997e-07
by O 0 2.3902106960349556e-08
another O 0 2.0227815866746823e-07
( O 0 2.5861012886707613e-07
missense O 0 2.0179148123133928e-05
) O 0 1.899185122056224e-06
. O 0 1.6865962606971152e-05

The O 0 6.185800430102972e-06
extraordinary O 0 4.53563825431047e-06
conservation O 0 3.5972865930489206e-07
of O 0 1.2959810646862024e-07
the O 0 2.2505537344841287e-07
PAX6 O 0 0.00012783423881046474
protein O 0 1.5138438129724818e-06
at O 0 6.994740147092671e-07
the O 0 1.3742661053584015e-07
amino O 0 6.486529855465051e-07
acid O 0 1.4533776493408368e-06
level O 0 3.283758633187972e-05
amongst O 0 5.378084551921347e-06
vertebrates O 0 5.358782800612971e-06
predicts O 0 4.7242028244909307e-07
that O 0 1.4840447093433795e-08
pathological O 0 1.1644078767858446e-06
missense O 0 3.3884623462654417e-06
mutations O 0 5.651094738823303e-07
should O 0 6.122749596215726e-08
in O 0 1.3048750524546904e-08
fact O 0 2.28771259713767e-08
be O 0 1.5216622628599907e-08
common O 0 2.1388430582192086e-08
even O 0 5.89445914300768e-09
though O 0 6.34421182255096e-09
they O 0 6.843210886842144e-09
are O 0 2.203750781859526e-08
hardly O 0 6.60678608710441e-07
ever O 0 1.1196912055311259e-06
seen O 0 2.860642325686058e-06
in O 0 1.7603128981136251e-06
aniridia B-Disease 1 0.999997615814209
patients O 0 3.48532666976098e-05
. O 0 3.162432767567225e-05

This O 0 2.465336876866786e-07
indicates O 0 1.903332247366052e-07
that O 0 1.03668247319888e-08
there O 0 1.900088975048675e-08
is O 0 5.985730577862114e-09
a O 0 3.180672791813777e-08
heavy O 0 9.513455552223604e-06
ascertainment O 0 0.09824931621551514
bias O 0 8.511606210959144e-06
in O 0 8.378853522117424e-08
the O 0 6.286288822821007e-08
selection O 0 3.2957083817564126e-07
of O 0 1.7288870424181368e-07
patients O 0 1.0434634134526277e-07
for O 0 1.174024646388716e-07
PAX6 O 0 6.378618854796514e-05
mutation O 0 1.6575882000324782e-07
analysis O 0 6.082662196149613e-08
and O 0 2.4485268923513104e-08
that O 0 1.3475421667408227e-08
the O 0 1.2655034709041502e-07
missing O 0 6.86321300236159e-06
PAX6 O 0 0.19550614058971405
missense O 0 0.00019887871167156845
mutations O 0 2.1216668756096624e-05
frequently O 0 1.1512217952258652e-06
may O 0 2.232510496469331e-06
underlie O 0 0.0002487840538378805
phenotypes O 0 9.063387551577762e-05
distinct O 0 2.3524685275333468e-06
from O 0 2.755043851720984e-06
textbook O 0 0.0006568690296262503
aniridia B-Disease 1 0.9999983310699463
. O 0 0.00010404828935861588

Here O 0 7.742782145214733e-06
we O 0 5.454433562590566e-07
present O 0 2.2952966105549422e-07
four O 0 2.900110303016845e-07
novel O 0 6.440048991862568e-07
PAX6 O 0 0.00018825707957148552
missense O 0 2.5271698177675717e-05
mutations O 0 3.7641827930201543e-06
, O 0 2.83522666677527e-07
two O 0 3.169360809351929e-07
in O 0 1.8053620465252607e-07
association O 0 9.634749176257174e-07
with O 0 4.2136750266763556e-07
atypical O 0 0.0012625247472897172
phenotypes O 0 0.46738871932029724
ectopia B-Disease 1 0.9380529522895813
pupillae I-Disease 0 0.016648659482598305
( O 0 6.475169698205718e-07
displaced B-Disease 0 1.1005569149347139e-06
pupils I-Disease 0 4.500148406805238e-06
) O 0 1.1025581443391275e-06
and O 0 0.00013114129251334816
congenital B-Disease 1 1.0
nystagmus I-Disease 1 1.0
( O 0 5.8658229136199225e-06
searching B-Disease 0 4.269628789188573e-06
gaze I-Disease 0 4.972430178895593e-05
) O 0 1.6333173391558375e-07
, O 0 8.311951660289196e-08
and O 0 1.6467541286147025e-07
two O 0 3.986940271261119e-07
in O 0 2.030531760510712e-07
association O 0 2.0396204547523666e-07
with O 0 9.744104545461596e-08
more O 0 3.4671890603021893e-07
recognizable O 0 0.0001609596802154556
aniridia B-Disease 1 0.9999953508377075
phenotypes O 0 0.000567360024433583
. O 0 1.9556931874831207e-05

Strikingly O 0 7.344502955675125e-05
, O 0 6.747483780600305e-07
all O 0 1.15553099533372e-07
four O 0 7.35704617227384e-08
mutations O 0 3.594837494347303e-08
are O 0 5.9352531778245066e-09
located O 0 5.121939850027957e-08
within O 0 9.692998759192051e-08
the O 0 3.0247215931922256e-07
PAX6 O 0 0.0006651541334576905
paired O 0 3.4038366720778868e-06
domain O 0 6.875541771478311e-07
and O 0 1.6935501889747684e-07
affect O 0 4.193246354589064e-07
amino O 0 2.9082059427310014e-07
acids O 0 6.482559911091812e-08
which O 0 1.1964069734915483e-08
are O 0 6.061985580174678e-09
highly O 0 5.874987607512594e-08
conserved O 0 8.43610123979488e-08
in O 0 1.2909550761719402e-08
all O 0 3.7725271795352455e-08
known O 0 7.791545186819349e-08
paired O 0 7.491547080462624e-07
domain O 0 8.060767413553549e-07
proteins O 0 7.680299631829257e-07
. O 0 3.109452336502727e-06

Our O 0 2.729706693571643e-06
results O 0 1.5545543874395662e-06
support O 0 1.5889658300238807e-07
the O 0 9.744086071350466e-08
hypothesis O 0 1.0314503384734053e-07
that O 0 2.1338057987208003e-09
the O 0 5.560488514078088e-09
under O 0 5.828490046155821e-08
- O 0 9.929070898806458e-08
representation O 0 7.917746813745907e-08
of O 0 2.0262181976704596e-07
missense O 0 1.4677908438898157e-05
mutations O 0 2.0888082872261293e-06
is O 0 7.677247282344979e-08
caused O 0 4.156427166890353e-07
by O 0 2.0860483118667617e-07
ascertainment O 0 0.05270276218652725
bias O 0 2.721414784900844e-05
and O 0 2.096138871365838e-07
suggest O 0 9.410612733518064e-08
that O 0 1.4509669910012235e-08
a O 0 4.1844739229190964e-08
substantial O 0 3.317061612051475e-07
burden O 0 1.9464864635665435e-06
of O 0 6.009221760905348e-05
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
related I-Disease 1 0.8676894307136536
disease I-Disease 0 0.20971883833408356
remains O 0 4.287048795958981e-07
to O 0 1.6784769130140376e-08
be O 0 8.821570673944734e-08
uncovered O 0 2.374193172727246e-06
. O 0 6.490545843007567e-07
. O 0 9.917439456330612e-06

The O 0 4.181532403890742e-06
chromosomal O 0 9.678996320872102e-06
order O 0 6.296128276517265e-07
of O 0 6.090278361625678e-07
genes O 0 4.565881681628525e-07
controlling O 0 6.825765922258142e-06
the O 0 1.3109428209645557e-06
major O 0 0.0002214689739048481
histocompatibility O 1 0.9999961853027344
complex O 0 0.00023757887538522482
, O 0 2.375098517859442e-07
properdin O 0 3.89903789255186e-06
factor O 0 3.900514968790958e-07
B O 0 1.309101571678184e-05
, O 0 1.5357753113676154e-07
and O 0 5.968165623926325e-07
deficiency B-Disease 0 0.00023558014072477818
of I-Disease 0 1.029038685373962e-06
the I-Disease 0 3.10271445869148e-07
second I-Disease 0 1.0317509122614865e-06
component I-Disease 0 7.835648716536525e-07
of I-Disease 0 7.026920343378151e-07
complement I-Disease 0 6.649505394307198e-06
. O 0 1.2315827007114422e-05

The O 0 2.2353076474246336e-06
relationship O 0 3.2136915706360014e-07
of O 0 2.366197406900028e-07
the O 0 1.0241616621442517e-07
genes O 0 8.407493368167707e-08
coding O 0 2.3610220978298457e-07
for O 0 5.207671804896563e-08
HLA O 0 8.564504128116823e-07
to O 0 1.926381187900006e-08
those O 0 2.9078028873641415e-08
coding O 0 2.588958807336894e-07
for O 0 2.6128942565151192e-08
properdin O 0 1.3289497928781202e-06
Factor O 0 3.8224033005462843e-07
B O 0 3.3137841910502175e-06
allotypes O 0 3.1488491458731005e-06
and O 0 4.4382019837030384e-08
for O 0 1.0738364153439761e-07
deficiency B-Disease 0 8.323386282427236e-06
of I-Disease 0 9.051478855326422e-08
the I-Disease 0 3.5674677434371915e-08
second I-Disease 0 7.017224135097422e-08
component I-Disease 0 7.042458349815206e-08
of I-Disease 0 4.6102840656203625e-08
complement I-Disease 0 5.218709020482493e-07
( O 0 1.897869310596434e-07
C2 O 0 0.039549827575683594
) O 0 4.6689368815577836e-08
was O 0 1.2941086424689274e-07
studied O 0 1.8163403581183957e-07
in O 0 1.1719826886746887e-08
families O 0 8.113458349612301e-09
of O 0 1.584444362379145e-07
patients O 0 3.3917926884896588e-06
with O 0 0.005742501467466354
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.9983590245246887

Patients O 0 8.248042831837665e-06
were O 0 3.477265693163645e-07
selected O 0 1.310266242171565e-07
because O 0 1.2681607763909142e-08
they O 0 1.1653400910915934e-08
were O 0 5.851592632666325e-08
heterozygous O 0 3.416669471789646e-07
or O 0 3.336319309710234e-07
homozygous O 0 1.918591806315817e-05
for O 0 0.00033140211598947644
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0069142552092671394

12 O 0 2.117656185873784e-05
families O 0 2.3240188795625727e-07
with O 0 2.0443702908323758e-07
15 O 0 3.0560554478142876e-06
matings O 0 4.2520277929725125e-05
informative O 0 6.689100700896233e-05
for O 0 9.944978228304535e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.3639200005854946e-05
found O 0 2.8321371701167664e-06
. O 0 1.0996694072673563e-05

Of O 0 1.8346043361816555e-05
57 O 0 3.047109021281358e-05
informative O 0 2.2368076315615326e-05
meioses O 0 2.9030816222075373e-05
, O 0 3.997646444986458e-07
two O 0 1.5537926856268314e-07
crossovers O 0 9.4698299335505e-07
were O 0 2.7898173016183136e-07
noted O 0 4.425362192250759e-07
between O 0 2.0554757611535024e-06
the O 0 0.00011493470083223656
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 8.413105661020381e-07
and O 0 1.902221811178606e-07
the O 0 4.4895162432112556e-07
HLA O 0 1.1079823707405012e-05
- O 0 1.2970334637429914e-06
B O 0 9.597397365723737e-07
gene O 0 2.9533238077306123e-08
, O 0 9.785317445221153e-09
with O 0 8.946704710410813e-09
a O 0 3.9003506202561766e-08
recombinant O 0 1.3475607829604996e-07
fraction O 0 8.575557330914307e-08
of O 0 3.188180528468365e-07
0 O 0 5.52839219380985e-06
. O 0 6.043993835191941e-06

035 O 0 0.07888742536306381
. O 0 0.0006619663909077644

A O 0 2.2978681954555213e-05
lod O 0 7.239449041662738e-05
score O 0 2.074610165436752e-06
of O 0 4.37508191453162e-07
13 O 0 9.741304438648513e-07
was O 0 2.6570353384158807e-07
calculated O 0 1.0968323493898424e-07
for O 0 8.159584297118272e-08
linkage O 0 1.5343086488428526e-05
between O 0 0.31843841075897217
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 4.102852471987717e-05
HLA O 0 0.0005327300168573856
- O 0 2.5120586997218197e-06
B O 0 1.399560233039665e-06
at O 0 5.5190298553497996e-08
a O 0 3.463481945686908e-09
maximum O 0 2.5834136607727487e-08
likelihood O 0 1.4738276377102011e-08
value O 0 6.964312682100626e-09
of O 0 1.2655415382312185e-08
the O 0 1.581276798390263e-08
recombinant O 0 3.909534385115876e-08
fraction O 0 1.6585108397748627e-08
of O 0 8.566124876097092e-08
0 O 0 3.2830644158821087e-06
. O 0 4.641041414288338e-06

04 O 0 0.02415749803185463
. O 0 0.0007751494995318353

18 O 0 2.5920424377545714e-05
families O 0 5.429962470770988e-07
with O 0 1.4081014398925618e-07
21 O 0 1.506175522081321e-06
informative O 0 1.1884885680046864e-06
matings O 0 7.674310609218082e-07
for O 0 3.9200028112418295e-08
both O 0 6.792173934400125e-08
properdin O 0 4.088339210284175e-06
Factor O 0 6.876249472043128e-07
B O 0 3.1276119898393517e-06
allotype O 0 5.117075488669798e-06
and O 0 2.0845467929575534e-07
HLA O 0 1.2838293514505494e-05
- O 0 1.8832072328223148e-06
B O 0 2.9465154511854053e-06
were O 0 3.314067384962982e-07
found O 0 6.199799145178986e-07
. O 0 6.5402623476984445e-06

Of O 0 1.6408972442150116e-05
72 O 0 3.622498843469657e-05
informative O 0 2.0304660210967995e-05
meioses O 0 3.3412943594157696e-05
, O 0 3.014630749476055e-07
three O 0 2.3454873598893755e-07
recombinants O 0 7.054644356685458e-06
were O 0 1.2166628948762082e-07
found O 0 4.596919822574819e-08
, O 0 6.961632692537023e-08
giving O 0 8.231458537011349e-08
a O 0 7.582625016766542e-08
recombinant O 0 2.3687442762820865e-07
fraction O 0 1.2469759269606584e-07
of O 0 3.9935235918164835e-07
0 O 0 9.380822120874655e-06
. O 0 7.684639967919793e-06

042 O 0 0.011979867704212666
. O 0 0.0007038865587674081

A O 0 2.43433823925443e-05
lod O 0 6.811786442995071e-05
score O 0 2.352957608309225e-06
of O 0 8.259009405264806e-07
16 O 0 4.009813892480452e-06
between O 0 1.7555482827447122e-06
HLA O 0 1.9594343029893935e-05
- O 0 6.323833758870023e-07
B O 0 9.536242941976525e-07
and O 0 2.8479300695494203e-08
Factor O 0 2.355175041657276e-07
B O 0 2.367220758969779e-06
allotypes O 0 4.751815140480176e-06
was O 0 1.32500986183004e-07
calculated O 0 1.1105958463986099e-07
at O 0 1.0346759182766618e-07
a O 0 1.3880867122395557e-08
maximum O 0 9.767606456989597e-08
likelihood O 0 4.8616723091754466e-08
value O 0 1.4118674229735007e-08
of O 0 1.9502042647445705e-08
the O 0 1.3826355171886462e-08
recombinant O 0 3.737854115115624e-08
fraction O 0 2.9262132272833696e-08
of O 0 8.528644457328483e-08
0 O 0 3.979779194196453e-06
. O 0 6.2630983848066535e-06

04 O 0 0.020837105810642242
. O 0 0.0009739714441820979

A O 0 5.480696017912123e-06
crossover O 0 3.134796543236007e-06
was O 0 5.430335363598715e-07
shown O 0 2.9650694344240947e-08
to O 0 1.4228241695946053e-08
have O 0 1.7585659151109212e-08
occurred O 0 3.0528264005624806e-07
between O 0 3.701239847941906e-08
genes O 0 6.503834359961047e-09
for O 0 4.131936126583469e-09
Factor O 0 6.029768684356895e-08
B O 0 4.096841053069511e-07
and O 0 8.604622081520574e-08
HLA O 0 2.330375764358905e-06
- O 0 8.798278940957971e-07
D O 0 1.4709695506098797e-06
, O 0 4.1130906680564294e-08
in O 0 3.6570657613310686e-08
which O 0 1.2018875850117183e-07
HLA O 0 8.405683729506563e-06
- O 0 2.9976010864629643e-06
D O 0 9.94285710476106e-06
segregared O 0 1.8589682440506294e-05
with O 0 5.862970056114136e-07
HLA O 0 0.0003477381251286715
- O 0 7.479157375200884e-06
A O 0 1.2344272590780747e-06
and O 0 6.631859719163913e-07
B O 0 7.663095311727375e-05
. O 0 6.250234491744777e-06

These O 0 5.888842906642822e-07
studies O 0 1.5035936939966632e-07
suggest O 0 3.261147085709126e-08
that O 0 5.025955651660752e-09
the O 0 1.307141861417449e-08
genes O 0 1.1261369614601335e-08
for O 0 9.936456990544684e-09
Factor O 0 6.413980599973002e-07
B O 0 0.0017836748156696558
and O 0 0.030796704813838005
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.443741730142392e-08
located O 0 2.1753072232399973e-08
outside O 0 1.7434899746149313e-08
those O 0 6.188248580230038e-09
for O 0 2.043784874672383e-08
HLA O 0 1.0538999504206004e-06
, O 0 6.9596648444303355e-09
that O 0 1.9658552563583953e-09
the O 0 4.083969162849144e-09
order O 0 3.0122965455348094e-08
of O 0 8.201149626074766e-08
genese O 0 7.378416285064304e-06
is O 0 2.0378590193104174e-07
HLA O 0 4.23323581344448e-06
- O 0 5.409288519331312e-07
A O 0 2.899532489664125e-07
, O 0 1.02526399814451e-07
- O 0 3.8749365671719715e-07
B O 0 1.2629343473236077e-06
, O 0 4.25712798346467e-08
- O 0 2.2766982965549687e-07
D O 0 4.505248512032267e-07
, O 0 2.334903648204545e-08
Factor O 0 2.826684522005962e-07
B O 0 1.2712524039670825e-05
allotype O 0 0.00025622890098020434
, O 0 5.292931018630043e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.6892136396081696e-08
that O 0 6.913939198938124e-09
the O 0 1.5068861713984916e-08
genes O 0 9.879765627829329e-08
coding O 0 1.7273804360229406e-06
for O 0 3.6819583328906447e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.386319752327836e-07
Factor O 0 3.5577005519371596e-07
B O 0 1.218759621224308e-06
allotypes O 0 8.536721907148603e-07
are O 0 3.2030138541472297e-09
approximately O 0 1.5473535341925526e-08
3 O 0 5.369159694623704e-08
- O 0 6.138278507705763e-08
- O 0 5.419585491495127e-08
5 O 0 8.109237370490519e-08
centimorgans O 0 5.26357894159446e-07
from O 0 1.751967104723917e-08
the O 0 8.956457264730489e-08
HLA O 0 5.993734703224618e-06
- O 0 7.620146220688184e-07
A O 0 4.102600428268488e-07
and O 0 3.4035795692943793e-07
HLA O 0 2.1701287550968118e-05
- O 0 1.0565274806140224e-06
B O 0 1.0365598654971109e-06
loci O 0 1.3645302487930167e-07
, O 0 7.784589861614677e-09
and O 0 4.133544173612336e-09
that O 0 1.0061637079061825e-09
the O 0 5.266894920197274e-09
apparent O 0 8.848735433275579e-08
lack O 0 1.9391517014355486e-07
of O 0 4.1680573303892743e-07
recombinants O 0 5.9947983572783414e-06
between O 0 8.577241317198059e-08
the O 0 3.0368376258138596e-08
Factor O 0 1.860958747101904e-07
B O 0 2.8822978492826223e-06
gene O 0 1.2415831633916241e-06
and O 0 7.787132926750928e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.2663237448105065e-07
suggests O 0 2.4607230031392646e-08
that O 0 1.9769703651917325e-09
these O 0 4.302873612971325e-09
two O 0 1.1415411727000446e-08
genes O 0 1.9147687879694786e-08
lie O 0 1.155570714672649e-07
in O 0 1.8393931711102596e-08
close O 0 3.0186987487468286e-07
proximity O 0 3.8536390434273926e-07
to O 0 8.47380619006799e-08
one O 0 4.462576725927647e-07
another O 0 2.899634182540467e-06
. O 0 1.150191110355081e-05

Distribution O 0 3.921034476661589e-06
of O 0 2.7949940886173863e-06
emerin O 0 0.00022819532023277134
and O 0 1.0211153949057916e-06
lamins O 0 0.0003343987336847931
in O 0 1.629285009130399e-07
the O 0 2.7852422590513015e-07
heart O 0 4.863262802246027e-06
and O 0 4.806251467925904e-07
implications O 0 1.3020035112276673e-05
for O 0 1.7827708234108286e-06
Emery B-Disease 1 0.9998138546943665
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.1339791715145111

Emerin O 0 0.006550668738782406
is O 0 1.387069914926542e-06
a O 0 4.360361458566331e-07
nuclear O 0 2.415717744952417e-06
membrane O 0 9.269519409826898e-07
protein O 0 1.3124348186011048e-07
which O 0 7.54588835860659e-09
is O 0 1.04416386648154e-08
missing O 0 1.817783896740366e-07
or O 0 1.3852573488293274e-07
defective O 0 8.225852070609108e-06
in O 0 8.876634183252463e-07
Emery B-Disease 1 0.9996298551559448
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9695298671722412
EDMD B-Disease 1 1.0
) O 0 2.7497324481373653e-05
. O 0 3.0232440622057766e-05

It O 0 6.127143024059478e-07
is O 0 8.963635167447137e-08
one O 0 3.583104302151696e-08
member O 0 9.166632963797383e-08
of O 0 1.1924593934509176e-07
a O 0 1.5097320726908947e-07
family O 0 4.124883190570472e-08
of O 0 4.0352875885218964e-07
lamina O 1 0.8555877208709717
- O 0 0.08348270505666733
associated O 0 5.001811587135307e-07
proteins O 0 9.145449553216167e-08
which O 0 6.746107317212591e-08
includes O 0 1.9752492619318218e-07
LAP1 O 0 0.00020549556938931346
, O 0 8.435295626441075e-07
LAP2 O 0 0.00010494630259927362
and O 0 1.7317595393251395e-06
lamin O 0 3.1583127565681934e-05
B O 0 1.3070731256448198e-05
receptor O 0 4.5353481255006045e-06
( O 0 5.85481302550761e-07
LBR O 0 4.356628414825536e-05
) O 0 1.714513359729608e-06
. O 0 2.2793150492361747e-05

A O 0 5.1193950639571995e-05
panel O 0 1.8087577700498514e-05
of O 0 9.445342357139452e-07
16 O 0 2.198158654209692e-06
monoclonal O 0 4.4495897100205184e-07
antibodies O 0 2.6415929710310593e-07
( O 0 1.7145953279396053e-07
mAbs O 0 8.119791345961858e-06
) O 0 9.073344386933968e-08
has O 0 4.2217514817366464e-08
been O 0 3.7636656458062134e-08
mapped O 0 4.220962424028585e-08
to O 0 9.374456766408912e-09
six O 0 5.589137330730409e-08
specific O 0 7.812300140130901e-09
sites O 0 2.49238052418832e-08
throughout O 0 3.899227607462308e-08
the O 0 6.68995809860462e-08
emerin O 0 2.8599058623512974e-06
molecule O 0 2.1143326023320697e-07
using O 0 1.0410104067659631e-07
phage O 0 2.6824702672456624e-06
- O 0 3.6879885101370746e-07
displayed O 0 1.3475889204528357e-07
peptide O 0 1.4520141178309132e-07
libraries O 0 5.1351744190242243e-08
and O 0 2.0162209679597254e-08
has O 0 6.322022461091592e-09
been O 0 5.608313369265261e-09
used O 0 8.403497453457476e-09
to O 0 3.97940311813727e-08
localize O 0 5.624718141916674e-06
emerin O 0 0.00011858086509164423
in O 0 4.461015237211541e-07
human O 0 3.145742766719195e-06
and O 0 5.525440428755246e-06
rabbit O 0 1.4202708371158224e-05
heart O 0 0.00018425268353894353
. O 0 5.681887341779657e-05

Several O 0 8.58766998135252e-06
mAbs O 0 7.303233724087477e-05
against O 0 4.087652996531688e-06
different O 0 1.4837045227977796e-06
emerin O 0 4.4782809709431604e-05
epitopes O 0 1.2088567018508911e-05
did O 0 1.9339213963576185e-07
not O 0 4.3085421452815353e-08
recognize O 0 2.9747226903964474e-07
intercalated O 0 9.437370863452088e-06
discs O 0 4.67872132503544e-06
in O 0 9.036350689939354e-08
the O 0 1.4249349078454543e-07
heart O 0 1.7566468386576162e-06
, O 0 3.696661110552668e-08
though O 0 1.6427756932557713e-08
they O 0 1.4885181975898831e-08
recognized O 0 6.875266933548119e-08
cardiomyocyte O 0 2.6383002023067093e-06
nuclei O 0 2.761499217740493e-06
strongly O 0 5.535776494980382e-07
, O 0 1.9408794571518229e-07
both O 0 2.3576222929477808e-07
at O 0 5.584332029684447e-06
the O 0 3.660045706510573e-07
rim O 0 4.030075160699198e-06
and O 0 1.1060845395149954e-07
in O 0 1.380459622168928e-07
intranuclear O 0 5.587085979641415e-06
spots O 0 1.9177825834049145e-06
or O 0 4.820518029191589e-07
channels O 0 3.322692464280408e-06
. O 0 4.059960247104755e-06

A O 0 0.0002410725282970816
polyclonal O 0 0.0009822521824389696
rabbit O 0 5.234862692304887e-05
antiserum O 0 0.00010499225027160719
against O 0 1.1006525710399728e-05
emerin O 0 6.425591709557921e-05
did O 0 3.4761251299642026e-07
recognize O 0 1.8801517853717087e-07
both O 0 8.088399283678882e-08
nuclear O 0 1.7952204416360473e-06
membrane O 0 1.0938987315967097e-06
and O 0 1.27349863987547e-07
intercalated O 0 3.007044142577797e-06
discs O 0 5.016869408791536e-07
but O 0 2.95561175533976e-08
, O 0 1.5132226138803162e-08
after O 0 3.672149162525784e-08
affinity O 0 5.39741691341078e-08
purification O 0 2.3376938429464644e-07
against O 0 2.2647941477771383e-07
a O 0 1.4252229618705314e-07
pure O 0 1.88031788184162e-06
- O 0 3.2328189263353124e-06
emerin O 0 8.704880201548804e-06
band O 0 3.8163713611538697e-07
on O 0 1.475237354497949e-07
a O 0 5.6258009806242626e-08
western O 0 1.9882975266227731e-07
blot O 0 2.9625875868077856e-06
, O 0 1.3659507658303482e-07
it O 0 5.119693469168851e-08
stained O 0 6.067429694667226e-06
only O 0 1.128562914232134e-07
the O 0 2.637683564898907e-07
nuclear O 0 1.3593620678875595e-05
membrane O 0 3.886118793161586e-05
. O 0 1.144033194577787e-05

These O 0 9.01405599051941e-07
results O 0 1.114077917918621e-06
would O 0 3.646200497087193e-08
not O 0 7.425175585495936e-09
be O 0 1.3859756009537705e-08
expected O 0 5.8164186356179925e-08
if O 0 6.147769227027311e-08
immunostaining O 0 5.353153483156348e-06
at O 0 8.73719784522109e-07
intercalated O 0 4.425701717991615e-06
discs O 0 2.1080418264318723e-06
were O 0 1.0744203393642238e-07
due O 0 8.04215787297835e-08
to O 0 1.1768726437821897e-08
a O 0 1.4081720678404963e-08
product O 0 1.4167689244004578e-08
of O 0 3.578241702939522e-08
the O 0 5.5410428245750154e-08
emerin O 0 2.3933300781209255e-06
gene O 0 4.765566430364743e-08
and O 0 2.420485323284538e-08
, O 0 1.7946806707413998e-08
therefore O 0 5.608380604371632e-08
, O 0 1.4291913430497516e-08
cast O 0 2.873690441163035e-08
some O 0 7.566614002030292e-09
doubt O 0 9.297941971908585e-08
upon O 0 4.1419355056859786e-08
the O 0 4.2597839922109415e-08
hypothesis O 0 9.464819754612108e-07
that O 0 1.652215786407396e-07
cardiac B-Disease 1 0.9913948178291321
defects I-Disease 1 0.9159938097000122
in O 0 2.1091069356771186e-05
EDMD B-Disease 1 1.0
are O 0 8.569807050662348e-07
caused O 0 2.625554316182388e-06
by O 0 1.0804085803783892e-07
absence O 0 2.4936987301771296e-06
of O 0 3.373540039319778e-06
emerin O 0 0.0001982709509320557
from O 0 1.3513433714251732e-06
intercalated O 0 0.00010749316425062716
discs O 0 0.00018932257080450654
. O 0 2.2382117094821297e-05

Although O 0 1.3379734809859656e-05
emerin O 0 0.000238644759519957
was O 0 2.797234174067853e-06
abundant O 0 5.481664970830025e-07
in O 0 4.035259948409475e-08
the O 0 4.3036962438236515e-08
membranes O 0 1.9685769814259402e-07
of O 0 8.570210496827713e-08
cardiomyocyte O 0 4.146827905060491e-06
nuclei O 0 3.605334086387302e-06
, O 0 1.200508421561608e-07
it O 0 9.188966032525059e-09
was O 0 1.1564283397547115e-07
absent O 0 1.49656671055709e-07
from O 0 1.063096188858026e-08
many O 0 3.1446603543372476e-08
non O 0 3.9621390897082165e-06
- O 0 8.358360901183914e-06
myocyte O 0 4.300235741538927e-05
cells O 0 8.293959581351373e-07
in O 0 1.39504521712297e-07
the O 0 6.545208179886686e-07
heart O 0 4.746836930280551e-05
. O 0 2.3789323677192442e-05

This O 0 9.374850833410164e-07
distribution O 0 9.876248441287316e-07
of O 0 6.639656362494861e-07
emerin O 0 7.431495760101825e-05
was O 0 3.4313899277549353e-07
similar O 0 1.3207853477581466e-08
to O 0 4.823762278505228e-09
that O 0 4.144754761625791e-09
of O 0 1.0940243555523921e-07
lamin O 0 2.7746673367801122e-05
A O 0 6.804517624914297e-07
, O 0 4.6014992705067925e-08
a O 0 4.5655159652824295e-08
candidate O 0 1.0593257115942833e-07
gene O 0 6.842965660780465e-08
for O 0 2.601337634189349e-08
an O 0 2.574343405115087e-08
autosomal O 0 1.0854665788428974e-06
form O 0 4.480428287934046e-06
of O 0 0.07472275197505951
EDMD B-Disease 1 1.0
. O 0 0.003088813740760088

In O 0 3.048507551284274e-06
contrast O 0 5.032557055528741e-06
, O 0 4.04645061280462e-06
lamin O 0 0.0003889989457093179
B1 O 0 0.011581630446016788
was O 0 4.449468178790994e-06
absent O 0 2.376741804255289e-06
from O 0 1.8370096199760155e-07
cardiomyocyte O 0 7.2820594141376205e-06
nuclei O 0 9.273725481762085e-06
, O 0 5.235648359303013e-07
showing O 0 8.799092370281869e-07
that O 0 1.7843173338860652e-07
lamin O 0 8.721126505406573e-05
B1 O 0 0.00022026689839549363
is O 0 7.185523287489559e-08
not O 0 1.761486423390579e-08
essential O 0 1.2547046424060682e-07
for O 0 7.149486691560014e-08
localization O 0 7.482495675503742e-06
of O 0 5.739407811233832e-07
emerin O 0 1.5490888472413644e-05
to O 0 1.890412448801726e-07
the O 0 9.782667120816768e-07
nuclear O 0 0.00012453288945835084
lamina O 1 0.9537490010261536
. O 0 0.00012817882816307247

Lamin O 1 0.9961023330688477
B1 O 1 0.9998134970664978
is O 0 1.3073845366307069e-06
also O 0 1.6483159015479032e-07
almost O 0 2.5491610244898766e-07
completely O 0 1.0365776006437954e-06
absent O 0 4.021375389129389e-06
from O 0 1.0955575362459058e-06
skeletal O 0 0.004123870749026537
muscle O 0 0.00034449881059117615
nuclei O 0 0.3730414807796478
. O 0 0.00018232938600704074

In O 0 1.3563188986154273e-05
EDMD B-Disease 1 0.9999998807907104
, O 0 7.730105835435097e-07
the O 0 1.1609810002255472e-07
additional O 0 1.0676707518086914e-07
absence O 0 3.523519751524873e-07
of O 0 1.0035910236183554e-06
lamin O 0 0.0007769775693304837
B1 O 1 0.5295120477676392
from O 0 1.1283632375125308e-06
heart O 0 0.0013872971758246422
and O 0 0.00011622969759628177
skeletal O 1 0.9999927282333374
muscle O 0 0.04528354853391647
nuclei O 1 0.8516175150871277
which O 0 9.219057233167405e-07
already O 0 5.324928338268364e-07
lack O 0 5.491504907695344e-06
emerin O 0 0.00022886077931616455
may O 0 1.0932858884871166e-07
offer O 0 3.444313634304308e-08
an O 0 5.911099165700762e-09
alternative O 0 9.461528094334426e-08
explanation O 0 8.248117211451245e-08
of O 0 4.967953159962235e-08
why O 0 5.072725173249637e-08
these O 0 2.7063720153819304e-08
tissues O 0 5.478409548231866e-07
are O 0 3.5173414403288916e-08
particularly O 0 4.204125616524834e-07
affected O 0 3.2240518521575723e-07
. O 0 3.389990013147326e-07
. O 0 3.839153578155674e-06

Genetic O 0 1.488813359173946e-05
mapping O 0 4.774592071044026e-06
of O 0 2.615929133753525e-06
the O 0 4.05348373533343e-06
copper B-Disease 0 0.08040125668048859
toxicosis I-Disease 1 0.9996113181114197
locus O 0 6.53315510135144e-05
in O 0 3.3817152598203393e-06
Bedlington O 0 0.0019695539958775043
terriers O 0 4.994332994101569e-05
to O 0 3.6433365835364384e-07
dog O 0 8.43276154682826e-07
chromosome O 0 1.0463169246577309e-06
10 O 0 4.0927173472482536e-07
, O 0 5.576678674401592e-08
in O 0 1.8911151755673927e-08
a O 0 5.945884495872633e-08
region O 0 5.687443263013847e-07
syntenic O 0 1.5154982065723743e-05
to O 0 2.452502769756393e-07
human O 0 1.1700248023771564e-06
chromosome O 0 5.681476068275515e-06
region O 0 2.8043655220244545e-06
2p13 O 0 0.00017337988538201898
- O 0 0.00016124571266118437
p16 O 0 0.00015549630916211754
. O 0 3.3682252251310274e-05

Abnormal O 1 0.9999556541442871
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9955381751060486
accumulation I-Disease 0 0.00863159354776144
is O 0 2.0151681212610129e-07
recognized O 0 1.0953606022212625e-07
as O 0 1.0428406937990076e-07
an O 0 2.25081763005619e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.00044357473962008953
man O 1 0.9986802935600281
, O 0 3.1696006772108376e-05
mouse O 0 0.000165844481671229
, O 0 9.262606909032911e-06
rat O 0 7.265078602358699e-05
and O 0 6.6913189584738575e-06
dog O 0 6.78904980304651e-05
. O 0 6.552422564709559e-05

The O 0 8.498750503349584e-06
major O 0 7.88893157732673e-06
cause O 0 1.497733683208935e-05
of O 0 0.0003027551283594221
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9994747042655945
accumulation I-Disease 1 0.6090186238288879
in O 0 3.859100615954958e-06
man O 0 0.0001252887595910579
is O 0 7.104329569074253e-08
a O 0 1.6066999819486227e-07
dysfunctional O 0 1.496728032179817e-06
ATP7B O 0 0.0020710318349301815
gene O 0 2.0892982774967095e-06
, O 0 6.313402991509065e-07
causing O 0 0.00023606105241924524
Wilson B-Disease 0 0.026503516361117363
disease I-Disease 1 0.9987836480140686
( O 0 2.1615283912979066e-05
WD B-Disease 1 0.9961764812469482
) O 0 1.383568269375246e-05
. O 0 4.534564504865557e-05

Mutations O 0 2.141784534614999e-05
in O 0 3.685471199332824e-07
the O 0 4.5386528313429153e-07
ATP7B O 0 0.00011722612543962896
genes O 0 7.759304310184234e-08
have O 0 1.3726348946363487e-08
also O 0 2.3403924132026077e-08
been O 0 5.7193446423298155e-08
demonstrated O 0 6.922095963091124e-07
in O 0 4.117699177186296e-07
mouse O 0 1.1722770068445243e-05
and O 0 6.029324595147045e-06
rat O 0 8.887321746442467e-05
. O 0 1.1858498510264326e-05

The O 0 1.3307315384736285e-05
ATP7B O 0 0.0017706064973026514
gene O 0 1.2449266932890168e-06
has O 0 8.899904457848606e-08
been O 0 8.140324325722759e-08
excluded O 0 2.729792925038055e-07
in O 0 1.5198407865568697e-08
the O 0 2.9795089062645275e-08
much O 0 2.914694903211057e-07
rarer O 0 0.0006239402573555708
human O 0 5.021938341087662e-05
copper B-Disease 1 0.999859094619751
overload I-Disease 1 0.9999973773956299
disease O 1 0.9999958276748657
non B-Disease 1 0.8065849542617798
- I-Disease 0 0.0023772448766976595
Indian I-Disease 0 6.935384249118215e-07
childhood I-Disease 0 4.433652065927163e-06
cirrhosis I-Disease 1 0.7799899578094482
, O 0 5.025340215070173e-07
indicating O 0 1.9112844711344223e-06
genetic O 0 1.028066617436707e-05
heterogeneity O 0 0.00010610834578983486
. O 0 2.6805095330928452e-05

By O 0 6.158652468002401e-06
investigating O 0 1.48165918290033e-05
the O 0 1.244802092514874e-06
common O 0 8.962146239355206e-05
autosomal O 1 0.9999724626541138
recessive O 1 0.9999903440475464
copper B-Disease 1 0.9999990463256836
toxicosis I-Disease 1 1.0
( O 0 0.00014016128261573613
CT B-Disease 1 0.999993085861206
) O 0 3.603927609674429e-07
in O 0 2.651805459663592e-07
Bedlington O 0 0.0020376930478960276
terriers O 0 1.8837745301425457e-05
, O 0 3.7526412199895276e-08
we O 0 2.5740391151884978e-08
have O 0 4.773733408569569e-09
identified O 0 2.9728898454095543e-08
a O 0 1.2468934329490367e-08
new O 0 4.205797665690625e-08
locus O 0 1.1204484735571896e-06
involved O 0 7.49171192637732e-07
in O 0 6.17295927440864e-06
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.6968172788619995

We O 0 7.32782291379408e-06
examined O 0 2.0151251192146447e-06
whether O 0 1.7125934448358748e-07
the O 0 2.3576154717375175e-07
WD B-Disease 0 7.37430018489249e-05
gene O 0 2.8393335469445447e-06
ATP7B O 0 0.032057203352451324
was O 0 1.801253574740258e-06
also O 0 1.0075548573240667e-07
causative O 0 5.256080157778342e-07
for O 0 1.0556627927371665e-07
CT B-Disease 0 0.0006464804173447192
by O 0 1.5625330718194164e-07
investigating O 0 8.089824632406817e-07
the O 0 2.746196230418718e-07
chromosomal O 0 3.445307083893567e-05
co O 0 6.510325329145417e-05
- O 0 9.844481974141672e-05
localization O 0 0.00022605103731621057
of O 0 1.0725732863647863e-05
ATP7B O 1 0.6667842864990234
and O 0 1.0346270755690057e-06
C04107 O 0 3.6702733723359415e-06
, O 0 3.67986210392246e-08
using O 0 3.7755004456130337e-08
fluorescence O 0 3.4834127404792525e-07
in O 0 4.361534067243156e-08
situ O 0 1.8403200101602124e-06
hybridization O 0 8.973811418400146e-07
( O 0 3.9811840224501793e-07
FISH O 0 6.995113380980911e-06
) O 0 2.3915115434647305e-06
. O 0 1.637255263631232e-05

C04107 O 0 0.0005315858870744705
is O 0 1.2123396118113305e-06
an O 0 3.8647800693070167e-07
anonymous O 0 2.215519316450809e-06
microsatellite O 0 7.823933265171945e-05
marker O 0 3.384824231034145e-05
closely O 0 7.60820284995134e-06
linked O 0 3.202010702807456e-05
to O 0 9.309099368692841e-06
CT B-Disease 1 0.9999610185623169
. O 0 0.00030230660922825336

However O 0 1.4986367204983253e-05
, O 0 7.389190614048857e-06
BAC O 0 0.0015833321958780289
clones O 0 9.91823344520526e-06
containing O 0 3.1238259907695465e-06
ATP7B O 0 0.0005906136357225478
and O 0 1.4338215805764776e-06
C04107 O 0 1.3441966984828468e-05
mapped O 0 9.144505384028889e-07
to O 0 8.236107618131427e-08
the O 0 3.662423750938615e-07
canine O 0 6.4965124693117104e-06
chromosome O 0 2.4850619411154184e-06
regions O 0 8.518310323779588e-07
CFA22q11 O 0 0.00019531698490027338
and O 0 6.873705729049107e-07
CFA10q26 O 0 0.000468820973765105
, O 0 1.266939193556027e-07
respectively O 0 3.103253050085186e-07
, O 0 3.1902967378982794e-08
demonstrating O 0 1.4440020379424823e-07
that O 0 1.8046007355110305e-08
WD B-Disease 0 4.438842552190181e-06
cannot O 0 1.806900229439634e-07
be O 0 1.1746909933663119e-07
homologous O 0 1.3161678680262412e-06
to O 0 7.279756459865894e-07
CT B-Disease 0 0.024731779471039772
. O 0 3.998651300207712e-05

The O 0 2.3212078303913586e-05
copper O 0 6.239208596525714e-05
transport O 0 1.0837437002919614e-05
genes O 0 1.5052651178848464e-06
CTR1 O 0 0.0002384748513577506
and O 0 9.308674862040789e-07
CTR2 O 0 0.2875211536884308
were O 0 4.375674507173244e-07
also O 0 3.486443134192996e-08
excluded O 0 1.2263420501312794e-07
as O 0 9.376870835353657e-09
candidate O 0 1.952444783626106e-08
genes O 0 1.03664685724425e-08
for O 0 1.9412418339470605e-08
CT B-Disease 0 0.00016308359045069665
since O 0 1.1492249996081227e-07
they O 0 1.330256171883093e-08
both O 0 3.5529698294567424e-08
mapped O 0 2.527223443848925e-07
to O 0 1.378486160774628e-07
canine O 0 1.4984209883550648e-05
chromosome O 0 1.8623541109263897e-05
region O 0 2.0882047465420328e-05
CFA11q22 O 0 0.025086283683776855
. O 0 8.326441457029432e-05

2 O 0 0.00022777471167501062
- O 0 0.0001866557722678408
22 O 0 5.194874756853096e-05
. O 0 3.3431144402129576e-05

5 O 0 0.0008258813177235425
. O 0 0.0002956398529931903

A O 0 1.6455091099487618e-05
transcribed O 0 2.2610679479839746e-06
sequence O 0 3.444609717462299e-07
identified O 0 2.8407589525158983e-07
from O 0 6.759592707794582e-08
the O 0 1.9772771508996811e-07
C04107 O 0 1.34698384499643e-05
- O 0 4.887304839940043e-06
containing O 0 8.125376211864932e-07
BAC O 1 0.9628860950469971
was O 0 4.245783884471166e-07
found O 0 1.1699524016250962e-08
to O 0 5.779413392303923e-09
be O 0 1.3491932904230453e-08
homologous O 0 2.6647338557950206e-08
to O 0 4.132677311474708e-09
a O 0 2.0778434972612558e-08
gene O 0 4.85139040051763e-08
expressed O 0 3.7569954258742655e-08
from O 0 5.109167489081301e-08
human O 0 3.088093194492103e-07
chromosome O 0 1.5361077885245322e-06
2p13 O 0 8.989753041532822e-06
- O 0 8.264388270617928e-06
p16 O 0 3.359167067173985e-06
, O 0 1.1840035796240045e-07
a O 0 1.4522662183935608e-07
region O 0 3.5519812513484794e-07
devoid O 0 3.0939793305151397e-06
of O 0 8.563412734474696e-08
any O 0 8.158697539784043e-08
positional O 0 1.1885556887136772e-05
candidate O 0 5.890724423807114e-06
genes O 0 1.369506207993254e-05
. O 0 3.0524402973242104e-05

Molecular O 0 2.500156369933393e-05
analysis O 0 1.7034502661772422e-06
of O 0 7.832459232304245e-07
the O 0 7.338783802879334e-07
APC B-Disease 0 2.7857388431584695e-06
gene O 0 1.6173413541764603e-07
in O 0 4.715726831250322e-08
205 O 0 4.750519622120919e-07
families O 0 2.3006387905866177e-08
: O 0 7.848851879543872e-08
extended O 0 7.023081707302481e-07
genotype O 0 1.4722882042406127e-05
- O 0 9.226857400790323e-06
phenotype O 0 2.1623156953864964e-06
correlations O 0 9.185961857838265e-07
in O 0 5.415359183302826e-08
FAP B-Disease 0 1.8388902844890254e-06
and O 0 3.331003028961277e-08
evidence O 0 9.424156388604388e-08
for O 0 1.3125107223288524e-08
the O 0 1.7433169574587737e-08
role O 0 1.2964557072336902e-07
of O 0 4.4287821765465196e-07
APC B-Disease 0 6.922743523318786e-06
amino O 0 2.6683862870413577e-06
acid O 0 3.1228728403220885e-06
changes O 0 2.9776720111840405e-05
in O 1 0.997500479221344
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999462366104126
. O 0 0.0004045551468152553

BACKGROUND O 0 0.0004939095233567059
/ O 0 0.004580412060022354
AIMS O 0 9.59635799517855e-05
The O 0 1.8809832909028046e-06
development O 0 1.6551819498999976e-05
of O 1 0.9763516187667847
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4520655895466916e-06
a O 0 1.3567976964168338e-07
variable O 0 2.4101663598230516e-07
range O 0 2.6775632022690843e-07
of O 0 1.6705202199318592e-07
extracolonic O 0 1.590015563124325e-05
manifestations O 0 3.7128807889530435e-05
in O 0 6.717756377838668e-07
familial B-Disease 1 0.9999963045120239
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.008268481120467186
FAP B-Disease 0 0.05877969413995743
) O 0 3.5380051599531726e-07
is O 0 4.5946933369123144e-08
the O 0 2.6907043704227362e-08
result O 0 1.0382818516063708e-07
of O 0 2.5840009243438544e-07
the O 0 2.9165829573685187e-07
dominant O 0 0.0003082263865508139
inheritance O 0 7.757372259220574e-06
of O 0 0.00016899159527383745
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999997615814209
( O 0 4.279213317204267e-05
APC B-Disease 0 0.00010093704622704536
) O 0 1.5159589565882925e-06
gene O 0 5.334592970029917e-06
mutations O 0 5.280573896015994e-05
. O 0 7.001311314525083e-05

In O 0 7.225488616313669e-07
this O 0 3.918627200505398e-08
study O 0 3.799940628823606e-08
, O 0 8.008570695494655e-09
direct O 0 1.9330578027165757e-08
mutation O 0 2.950801381018664e-08
analysis O 0 1.9325932854030725e-08
of O 0 3.192098674276167e-08
the O 0 6.133795693585853e-08
APC B-Disease 0 6.839696311544685e-07
gene O 0 1.3396201836712862e-07
was O 0 1.96828608522992e-07
performed O 0 2.7641544164680454e-08
to O 0 2.445749736068592e-08
determine O 0 7.027147717053595e-07
genotype O 0 2.1795138309244066e-05
- O 0 5.0297403504373506e-05
phenotype O 0 8.165628969436511e-06
correlations O 0 6.086838766350411e-06
for O 0 9.254961810256646e-07
nine O 0 1.2474492905312218e-05
extracolonic O 0 0.00015510492085013539
manifestations O 0 6.335401849355549e-05
and O 0 1.8576199067865673e-07
to O 0 5.875985209513601e-08
investigate O 0 3.7521979834309604e-07
the O 0 8.142699670088405e-08
incidence O 0 1.1848377425849321e-06
of O 0 5.471126200973231e-07
APC B-Disease 0 4.3058084884251e-06
mutations O 0 1.649076807552774e-06
in O 0 1.072769350685121e-06
non O 1 0.9999746084213257
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.01737755350768566

METHODS O 0 6.187311373651028e-05
The O 0 7.751005796308164e-06
APC B-Disease 0 1.8270999134983867e-05
gene O 0 1.4997142443462508e-06
was O 0 1.4046506748854881e-06
analysed O 0 2.1622784061037237e-06
in O 0 1.1116406284372715e-07
190 O 0 1.4596616892958991e-06
unrelated O 0 2.4830837901390623e-06
FAP B-Disease 0 1.2825895282730926e-05
and O 0 7.275168627529638e-07
15 O 0 3.2611140341032296e-05
non O 1 0.9994915723800659
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.4201715354574844e-06
using O 0 1.2617052789209993e-06
denaturing O 0 8.615414117230102e-05
gradient O 0 2.7278872948954813e-05
gel O 0 1.3017490346101113e-05
electrophoresis O 0 2.2092276594776195e-06
, O 0 9.31713302065873e-08
the O 0 5.508596956360634e-08
protein O 0 1.663809143792605e-07
truncation O 0 1.9779722606472205e-06
test O 0 5.06934043187357e-07
, O 0 9.72006546362536e-08
and O 0 1.1852802117573447e-07
direct O 0 6.215083772076468e-07
sequencing O 0 5.0079675020242576e-06
. O 0 6.284446044446668e-06

RESULTS O 0 0.0005689277313649654
Chain O 0 3.643980744527653e-05
terminating O 0 9.874339411908295e-06
signals O 0 1.7573103150425595e-06
were O 0 1.7850747724423854e-07
only O 0 3.448119301197039e-08
identified O 0 1.1624722873193605e-07
in O 0 3.082590183112188e-08
patients O 0 3.130130821205057e-08
belonging O 0 1.261957578435613e-07
to O 0 3.094909217793429e-08
the O 0 1.6922940915264917e-07
FAP B-Disease 0 2.048767237283755e-05
group O 0 6.796359457439394e-07
( O 0 3.9005820440252137e-07
105 O 0 3.3644219001871534e-06
patients O 0 5.738384061260149e-07
) O 0 7.667836712244025e-07
. O 0 1.071138285624329e-05

Amino O 0 3.361938797752373e-05
acid O 0 2.968880608023028e-06
changes O 0 4.5822136485185183e-07
were O 0 2.046000844302398e-07
identified O 0 1.5299205813334993e-07
in O 0 2.3943309557239445e-08
four O 0 9.971754622029039e-08
patients O 0 3.054765329579823e-08
, O 0 1.946009398068327e-08
three O 0 2.583142943990424e-08
of O 0 5.080529774659226e-08
whom O 0 1.957796769147535e-07
belonged O 0 3.4312984098505694e-07
to O 0 3.4826943107191255e-08
the O 0 2.424598335437622e-07
non O 0 0.0013415584107860923
- O 0 0.14705635607242584
FAP O 0 0.0012670874129980803
group O 0 8.639939915155992e-05
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8428962230682373
. O 0 0.00012181768397567794

Genotype O 0 0.003920806106179953
- O 0 0.0016017364105209708
phenotype O 0 4.582316614687443e-05
correlations O 0 8.802661795925815e-06
identified O 0 5.649456511491735e-07
significant O 0 2.1483413092937553e-07
differences O 0 1.268837763745978e-06
in O 0 9.834530345642634e-08
the O 0 1.419123805135314e-07
nature O 0 1.4512346524497843e-07
of O 0 1.3755523298186745e-07
certain O 0 3.529610239638714e-07
extracolonic O 0 7.629118044860661e-05
manifestations O 0 0.00016558296920266002
in O 0 4.3693361817531695e-07
FAP B-Disease 0 1.1467716831248254e-05
patients O 0 1.434227527852272e-07
belonging O 0 1.6746595576933032e-07
to O 0 6.794675044830001e-08
three O 0 9.06244508769305e-07
mutation O 0 1.0681616004148964e-05
subgroups O 0 4.103892933926545e-05
. O 0 4.262473521521315e-05

CONCLUSIONS O 0 0.00012781207624357194
Extended O 0 2.9996377634233795e-05
genotype O 0 0.00012153805437264964
- O 0 4.7972680476959795e-05
phenotype O 0 7.175688097049715e-06
correlations O 0 2.343949518035515e-06
made O 0 1.374954479160806e-07
in O 0 1.8198093698629236e-08
this O 0 4.853016655204101e-09
study O 0 7.990032635518673e-09
may O 0 1.1097738727983142e-08
have O 0 4.790872587534523e-09
the O 0 6.522157480759461e-09
potential O 0 1.75435133087376e-08
to O 0 3.3943032828887e-09
determine O 0 2.803295906517178e-08
the O 0 1.4769569567363305e-08
most O 0 5.691016546904848e-09
appropriate O 0 2.750527983153006e-08
surveillance O 0 2.2128324417280965e-07
and O 0 1.4117682667347253e-07
prophylactic O 0 0.00012115679419366643
treatment O 0 5.250285994407022e-06
regimens O 0 4.800786427949788e-06
for O 0 9.636112707767097e-08
those O 0 3.452127117498094e-08
patients O 0 1.9909951021190864e-08
with O 0 9.552917568100838e-09
mutations O 0 3.7094139315740904e-07
associated O 0 1.7041118383076537e-07
with O 0 1.2817621097838128e-07
life O 0 2.9557411380665144e-06
threatening O 0 6.13898882875219e-05
conditions O 0 0.0003536221047397703
. O 0 3.378661858732812e-05

This O 0 8.512017188877508e-07
study O 0 4.087689262632921e-07
also O 0 3.103675894067237e-08
provided O 0 5.0256129924264314e-08
evidence O 0 1.3720465119604341e-07
for O 0 3.828684924656045e-08
the O 0 9.85766774874719e-08
pathological O 0 2.725479589571478e-06
nature O 0 2.7402865043768543e-07
of O 0 5.208938773648697e-07
amino O 0 7.458689879058511e-07
acid O 0 3.016028244928748e-07
changes O 0 3.079640862324595e-07
in O 0 8.986059896187726e-08
APC O 0 2.0594334273482673e-06
associated O 0 1.3305051993484085e-07
with O 0 3.725440933521895e-08
both O 0 1.631348141017952e-07
FAP B-Disease 0 1.760017403285019e-05
and O 0 2.319569148312439e-06
non O 1 0.9999850988388062
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.492619963362813e-05
. O 0 2.810368187056156e-06
. O 0 1.3663542631547898e-05

Inherited B-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9923020601272583
cancer B-Disease 1 0.9997194409370422
risk O 0 1.5813990103197284e-05
of O 0 1.2223177691339515e-05
the O 0 1.473305110266665e-05
APC O 0 0.00014667905634269118
I1307K O 0 0.00026219431310892105
polymorphism O 0 0.00011331700079608709
. O 0 4.03556514356751e-05

Germ O 1 0.999543309211731
- O 0 0.08405653387308121
line O 0 3.375183587195352e-05
and O 0 5.878966931049945e-07
somatic O 0 8.029088348848745e-06
truncating O 0 2.5286844902439043e-06
mutations O 0 8.524887107341783e-08
of O 0 7.934361434536186e-08
the O 0 9.095453634699879e-08
APC B-Disease 0 7.44496048810106e-07
gene O 0 7.420322134521484e-08
are O 0 1.6490101728550144e-08
thought O 0 1.593193275084559e-07
to O 0 1.2947012351105514e-07
initiate O 0 3.607406324590556e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.06677722185850143
formation O 0 0.0017682791221886873
in O 0 4.294089012546465e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999686479568481
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.0006616112659685314
respectively O 0 0.0004471135907806456
. O 0 5.828425855725072e-05

Recently O 0 2.5672792617115192e-05
, O 0 1.18939453841449e-06
an O 0 7.144619758037152e-07
isoleucine O 0 0.002118215663358569
- O 0 0.07222220301628113
- O 0 0.16259883344173431
> O 0 0.0005270075635053217
lysine O 0 9.207032417180017e-05
polymorphism O 0 3.100853064097464e-06
at O 0 9.285498094868672e-07
codon O 0 3.84830309485551e-06
1307 O 0 4.9394566303817555e-05
( O 0 2.606662690141093e-07
I1307K O 0 3.1728616249893093e-06
) O 0 4.849956525276866e-08
of O 0 6.218457571094405e-08
the O 0 1.2382338354655076e-07
APC B-Disease 0 1.1092976137661026e-06
gene O 0 1.3547897026455757e-07
has O 0 1.7302058452628444e-08
been O 0 2.4549567712028875e-08
identified O 0 2.4929605046963843e-08
in O 0 1.1779708763981489e-08
6 O 0 3.478897383502044e-07
% O 0 3.301703799252209e-08
- O 0 2.186155541039625e-07
7 O 0 2.567968806488352e-07
% O 0 9.683663648729635e-09
of O 0 5.265370717211226e-08
the O 0 1.1136567934499908e-07
Ashkenazi O 0 1.5519267435593065e-06
Jewish O 0 4.0314296256838134e-07
population O 0 2.503983580481872e-07
. O 0 5.189415333006764e-06

To O 0 3.6880803691019537e-06
assess O 0 7.517794983868953e-06
the O 0 2.4100884843392123e-07
risk O 0 2.1734436472797825e-07
of O 0 9.559629177147144e-08
this O 0 3.459430075736236e-08
common O 0 7.72875694110553e-07
APC B-Disease 0 1.1486948096717242e-05
allelic O 0 0.00017571139323990792
variant O 0 0.018068483099341393
in O 0 1.2204985068819951e-05
colorectal O 1 1.0
carcinogenesis O 1 0.9999992847442627
, O 0 7.266563670782489e-07
we O 0 1.4655084612513747e-07
have O 0 2.30721273197787e-08
analyzed O 0 1.2373344304705824e-07
a O 0 2.4551910726700044e-08
large O 0 5.660674773366736e-08
cohort O 0 8.062443725975754e-07
of O 0 5.37298035396816e-07
unselected O 0 0.00020516588119789958
Ashkenazi O 0 3.6865007132291794e-05
Jewish O 0 1.89744537237857e-06
subjects O 0 8.133027222356759e-06
with O 0 6.437537081183109e-07
adenomatous B-Disease 0 0.008954362943768501
polyps I-Disease 0 0.0001749784278217703
and O 0 1.6693543329893146e-06
. O 0 5.637919002765557e-06
or O 1 0.999998927116394
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.5072236237756442e-05
for O 0 4.1747881596165826e-07
the O 0 1.238659592672775e-06
APC O 0 2.111129288095981e-05
I1307K O 0 5.862619218532927e-05
polymorphism O 0 4.468917177291587e-05
. O 0 2.7271718863630667e-05

The O 0 1.8264416212332435e-05
APC O 0 6.732194015057757e-05
I1307K O 0 5.3806583309778944e-05
allele O 0 1.0344740076106973e-05
was O 0 1.3218535741543747e-06
identified O 0 2.867496107228362e-07
in O 0 4.1329787592303546e-08
48 O 0 4.235031099142361e-07
( O 0 3.3146012157203586e-08
10 O 0 4.8825626208781614e-08
. O 0 5.806328751134515e-09
1 O 0 6.50742322250153e-08
% O 0 1.442198538370576e-08
) O 0 2.6475293068983774e-08
of O 0 2.7669827318277385e-07
476 O 0 1.1402068594179582e-05
patients O 0 4.779585196956759e-06
. O 0 1.6848245650180615e-05

Compared O 0 2.6800926207215525e-06
with O 0 5.220958954055277e-08
the O 0 6.606119029584079e-08
frequency O 0 3.975762012942141e-07
in O 0 9.819793866938653e-09
two O 0 7.52879536491946e-09
separate O 0 3.632496081706904e-09
population O 0 7.804790702614639e-10
control O 0 1.744391298075243e-08
groups O 0 9.030040715174437e-09
, O 0 2.4426775269148493e-08
the O 0 1.1890719520124549e-07
APC O 0 1.5894978560027084e-06
I1307K O 0 3.1245619993569562e-06
allele O 0 1.6277067516057286e-06
is O 0 3.5302527123803884e-08
associated O 0 7.466476859008253e-08
with O 0 1.827677742483047e-08
an O 0 1.5876111092438805e-08
estimated O 0 2.4164076961596948e-08
relative O 0 2.76904444262982e-07
risk O 0 6.572875008714618e-07
of O 0 2.3978511762834387e-06
1 O 0 0.0001353246479993686
. O 0 1.682607216935139e-05

5 O 0 0.0001353046391159296
- O 0 9.124384814640507e-05
1 O 0 3.467149508651346e-05
. O 0 2.432514156680554e-05

7 O 0 0.00019537679327186197
for O 0 4.141415047342889e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999955892562866
( O 0 2.8409695005393587e-06
both O 0 1.2077030078216922e-06
P O 0 0.00023780255287420005
= O 0 6.381085768225603e-06
. O 0 4.804102218258777e-07
01 O 0 2.3096461518434808e-05
) O 0 7.621003987878794e-07
. O 0 5.066728590463754e-06

Furthermore O 0 3.764692519325763e-05
, O 0 1.3697001577384071e-06
compared O 0 1.1772463039960712e-06
with O 0 2.641570233663515e-07
noncarriers O 0 4.304847971070558e-05
, O 0 4.888246962764242e-07
APC O 0 3.380390126039856e-06
I1307K O 0 3.827192358585307e-06
carriers O 0 1.0962467911213025e-07
had O 0 3.803936365898153e-08
increased O 0 3.898231426546772e-08
numbers O 0 3.381045843298125e-08
of O 0 4.360523462310084e-07
adenomas B-Disease 1 0.999213457107544
and O 0 0.21609213948249817
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
per O 0 2.370772108406527e-06
patient O 0 4.801354407391045e-07
( O 0 1.1136079081097705e-07
P O 0 1.820664147089701e-05
= O 0 9.686323210189585e-07
. O 0 2.9699087633616728e-08
03 O 0 1.6392126553910202e-06
) O 0 2.9058623951527807e-08
, O 0 1.50664760667496e-08
as O 0 1.992317066878968e-08
well O 0 2.8094943260725813e-08
as O 0 4.0596471961862335e-08
a O 0 6.665796803417834e-08
younger O 0 3.2456205190101173e-06
age O 0 9.472320925851818e-06
at O 0 2.715335358516313e-05
diagnosis O 0 0.00021082695457153022
. O 0 1.5025407265056856e-05

We O 0 6.842933544248808e-06
conclude O 0 5.6623443924763706e-06
that O 0 6.96715858339303e-08
the O 0 2.7950957814937283e-07
APC O 0 6.649016995652346e-06
I1307K O 0 1.0178254342463333e-05
variant O 0 8.406252163695171e-06
leads O 0 4.3398011939643766e-07
to O 0 1.0728046362373789e-07
increased O 0 7.123887826310238e-06
adenoma B-Disease 1 1.0
formation O 0 0.00015709616127423942
and O 0 3.458328876604355e-07
directly O 0 4.394350483494236e-08
contributes O 0 5.561995308767109e-09
to O 0 2.8733655454971085e-09
3 O 0 4.204410330999053e-08
% O 0 4.810733589266647e-09
- O 0 2.9581270766243506e-08
4 O 0 4.1730761068947686e-08
% O 0 4.1626124769322814e-09
of O 0 2.3683325522938503e-08
all O 0 8.73742536100508e-08
Ashkenazi O 0 4.6460791054414585e-05
Jewish O 0 0.06222829222679138
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004123092512600124

The O 0 2.559089807618875e-06
estimated O 0 5.283076234263717e-07
relative O 0 1.322176444773504e-06
risk O 0 9.13261715140834e-07
for O 0 1.325739162894024e-07
carriers O 0 1.5428952337970259e-07
may O 0 2.0033874648106575e-07
justify O 0 1.809802654406667e-07
specific O 0 1.9014848362530756e-08
clinical O 0 1.1843762592889107e-07
screening O 0 2.1140376560424556e-08
for O 0 9.583102311694347e-09
the O 0 3.3610366045877527e-08
360 O 0 4.204286199183116e-07
, O 0 5.2537540540242844e-08
000 O 0 1.847447208547237e-07
Americans O 0 2.8006876817698867e-08
expected O 0 7.398361390187347e-08
to O 0 2.2228235252441664e-08
harbor O 0 3.351556472352968e-07
this O 0 2.4905556728072042e-08
allele O 0 1.1370611900929362e-06
, O 0 6.34296881685259e-08
and O 0 4.680706666704282e-08
genetic O 0 6.566121157902671e-08
testing O 0 8.029957143662614e-08
in O 0 6.779978800608433e-09
the O 0 1.4968371431223204e-08
setting O 0 2.030146504239383e-07
of O 0 6.443482192253214e-08
long O 0 1.5817238363524666e-07
- O 0 7.20366415407625e-07
term O 0 4.737336212201626e-07
- O 0 6.986267067077279e-07
outcome O 0 6.147441240500484e-07
studies O 0 7.627593134884592e-08
may O 0 7.416516467628753e-08
impact O 0 9.384350505570183e-07
significantly O 0 7.1121098699222784e-06
on O 1 0.9967836141586304
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.014117993414402008
in O 0 5.857610929638213e-08
this O 0 2.499960061186357e-08
population O 0 8.56377226909899e-08
. O 0 3.257199068684713e-06

Localization O 0 0.0002904074208345264
of O 0 5.550675268750638e-06
human O 0 1.627576352802862e-06
BRCA1 O 0 3.462814675003756e-06
and O 0 1.324179805806125e-07
its O 0 6.074337477457448e-08
loss O 0 3.875970378430793e-06
in O 0 2.3206700916489353e-07
high O 0 0.0001253457594430074
- O 0 8.866379357641563e-05
grade O 0 0.031037025153636932
, O 0 7.218653991003521e-06
non B-Disease 1 0.9997052550315857
- I-Disease 1 0.9999837875366211
inherited I-Disease 1 0.9999972581863403
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.1340661197900772

Although O 0 4.867554707743693e-06
the O 0 6.697439971503627e-07
link O 0 1.4713189102621982e-06
between O 0 4.0086794683702465e-07
the O 0 5.099154805066064e-07
BRCA1 O 0 3.2818956242408603e-05
tumour B-Disease 1 0.9999998807907104
- O 0 0.00010084748646477237
suppressor O 0 1.726176924421452e-05
gene O 0 7.561653205812036e-07
and O 0 2.2520296170114307e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 3.6392359561432386e-06
established O 0 2.133060661435593e-07
, O 0 1.5184847157456716e-08
the O 0 1.7449071521014048e-08
role O 0 5.411043701997187e-08
, O 0 1.2085466849498516e-08
if O 0 7.194023599055299e-09
any O 0 1.664036908266553e-08
, O 0 3.6261294411588096e-08
of O 0 2.0604871053819807e-07
BRCA1 O 0 4.744380021293182e-06
in O 0 6.718242957504117e-07
non B-Disease 1 0.6883435845375061
- I-Disease 1 0.9984436631202698
familial I-Disease 1 0.914173424243927
cancers I-Disease 1 0.9999991655349731
is O 0 3.166323494951939e-06
unclear O 0 1.9575369151425548e-05
. O 0 3.491200914140791e-05

BRCA1 O 0 0.00013397930888459086
mutations O 0 8.007388714759145e-06
are O 0 1.5039522338611278e-07
rare O 0 4.866222980126622e-07
in O 0 1.484209519730939e-07
sporadic B-Disease 0 0.00015335020725615323
cancers I-Disease 1 0.9999794960021973
, O 0 4.585750446040038e-07
but O 0 9.593456695711211e-08
loss O 0 4.4118960431660526e-06
of O 0 1.8800094494508812e-06
BRCA1 O 0 5.282086476654513e-06
resulting O 0 3.1476852768719255e-07
from O 0 5.3723866244581586e-08
reduced O 0 9.312989845966513e-07
expression O 0 1.7811331076700299e-07
or O 0 7.786999134395955e-08
incorrect O 0 2.725303147599334e-07
subcellular O 0 3.15606143885816e-06
localization O 0 5.082806183054345e-06
is O 0 3.717618568543912e-08
postulated O 0 2.183563481139572e-07
to O 0 9.58149382057627e-09
be O 0 2.272266108604981e-08
important O 0 7.198116236395435e-08
in O 0 8.23796071358629e-08
non B-Disease 0 0.0003514298878144473
- I-Disease 1 0.8269581198692322
familial I-Disease 1 0.9997108578681946
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9999897480010986

Epigenetic O 0 0.0007681125425733626
loss O 0 0.00026550228358246386
, O 0 9.174440833703557e-07
however O 0 2.7579542916100763e-07
, O 0 4.461474389927389e-08
has O 0 4.674610920574196e-09
not O 0 4.337242121010831e-09
received O 0 1.7533878349240695e-08
general O 0 5.917734924310025e-08
acceptance O 0 1.2108671398891602e-07
due O 0 1.629193349117486e-07
to O 0 4.111169360498934e-08
controversy O 0 4.084338058873982e-07
regarding O 0 3.575288474166882e-07
the O 0 2.5516223445265496e-07
subcellular O 0 1.3321904589247424e-05
localization O 0 9.291909918829333e-06
of O 0 5.099821009935113e-07
BRCA1 O 0 1.685488882685604e-06
proteins O 0 6.274166253206204e-08
, O 0 2.8649504102418177e-08
reports O 0 2.934602960635857e-08
of O 0 5.2578940312741906e-08
which O 0 1.9077223356589457e-08
have O 0 2.816807587180392e-08
ranged O 0 9.345197327093047e-07
from O 0 2.2371828833911422e-08
exclusively O 0 5.732417562853698e-08
nuclear O 0 4.3378315695008496e-07
, O 0 2.4747683013970345e-08
to O 0 1.2865844389864378e-08
conditionally O 0 6.718998974974966e-07
nuclear O 0 4.2764077079482377e-07
, O 0 2.1833754360045532e-08
to O 0 1.5201770509065682e-08
the O 0 2.6959554588756873e-07
ER O 0 5.159180363989435e-05
/ O 0 1.2829589650209527e-05
golgi O 0 1.009840070764767e-05
, O 0 8.108479931934198e-08
to O 0 2.8664151940915872e-08
cytoplasmic O 0 2.9935217753518373e-06
invaginations O 0 6.053200195310637e-06
into O 0 2.2806727884017164e-07
the O 0 4.5862884689995553e-07
nucleus O 0 2.5626170099712908e-05
. O 0 1.1992501640634146e-05

In O 0 1.3637825304613216e-06
an O 0 1.7459133516695147e-07
attempt O 0 5.377224852054496e-07
to O 0 6.333695523608185e-08
resolve O 0 1.3779580285699922e-06
this O 0 4.8599847701780163e-08
issue O 0 1.4215659405181214e-07
, O 0 6.108356132017434e-08
we O 0 8.302587417574614e-08
have O 0 9.544779544512494e-08
comprehensively O 0 2.1475974790519103e-05
characterized O 0 1.4099655345489737e-06
19 O 0 1.426006383553613e-05
anti O 0 0.0005989233031868935
- O 0 0.03814093768596649
BRCA1 O 0 6.154675065772608e-05
antibodies O 0 8.038136911636684e-06
. O 0 1.869560765044298e-05

These O 0 5.1621004786284175e-06
reagents O 0 1.5898336641839705e-05
detect O 0 1.295619676966453e-05
a O 0 2.2964620711718453e-06
220 O 0 7.071902018651599e-06
- O 0 2.172402491851244e-05
kD O 0 4.3681600800482556e-05
protein O 0 4.831020419260312e-07
localized O 0 8.848447237141954e-07
in O 0 3.3633707374747246e-08
discrete O 0 3.866265672058944e-07
nuclear O 0 8.59587714785448e-07
foci O 0 2.784023081403575e-06
in O 0 1.7115397099587426e-08
all O 0 2.6412799059016834e-08
epithelial O 0 1.2255381989234593e-06
cell O 0 1.923835043271538e-06
lines O 0 2.7528642476681853e-07
, O 0 4.356279248440842e-08
including O 0 4.6482870885711236e-08
those O 0 4.23195842813584e-08
derived O 0 3.9305527366195747e-07
from O 0 2.4304470116476296e-06
breast B-Disease 0 0.05315876007080078
malignancies I-Disease 0 0.15922251343727112
. O 0 0.00011230208474444225

Immunohistochemical O 0 0.005247185006737709
staining O 0 0.0029424699023365974
of O 0 0.00034207466524094343
human O 0 0.00014385272515937686
breast O 0 0.00013098058116156608
specimens O 0 1.458772317164403e-06
also O 0 2.961272400625603e-07
revealed O 0 3.5134974041284295e-06
BRCA1 O 0 1.0595196727081202e-05
nuclear O 0 3.0539373256033286e-05
foci O 0 0.0029858879279345274
in O 0 3.850149369100109e-06
benign O 1 0.9999963045120239
breast O 1 0.9999990463256836
, O 0 0.05583779513835907
invasive B-Disease 1 0.9999994039535522
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
and O 0 0.000616700854152441
low B-Disease 1 0.9999967813491821
- I-Disease 1 0.999997615814209
grade I-Disease 1 0.9999970197677612
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00046295716310851276

Conversely O 0 0.00010587002907413989
, O 0 6.4066166487464216e-06
BRCA1 O 0 1.0770876542665064e-05
expression O 0 6.204335250004078e-07
was O 0 3.152026124553231e-07
reduced O 0 1.8876453111715819e-07
or O 0 2.9272126056412162e-08
undetectable O 0 4.0929631950348266e-07
in O 0 2.826800793442885e-09
the O 0 7.527589218625508e-09
majority O 0 1.1793353849043342e-08
of O 0 6.748938830014595e-08
high O 0 1.6480580597999506e-05
- O 0 1.4341237147164065e-05
grade O 0 0.0018360958201810718
, O 0 1.4777926480746828e-05
ductal B-Disease 1 0.9999997615814209
carcinomas I-Disease 1 1.0
, O 0 3.761653033507173e-07
suggesting O 0 1.0938573780094885e-07
that O 0 7.327046969152207e-09
absence O 0 4.634869981146039e-07
of O 0 6.292875127655861e-07
BRCA1 O 0 9.951470929081552e-06
may O 0 1.842430918941318e-07
contribute O 0 5.169994565790148e-08
to O 0 2.2171072089349764e-08
the O 0 4.706184242309064e-08
pathogenesis O 0 6.984265928622335e-05
of O 0 6.794208218252606e-08
a O 0 2.4825025590757832e-08
significant O 0 5.6615387933334205e-08
percentage O 0 1.994034164454206e-07
of O 0 5.62270543014165e-07
sporadic B-Disease 1 0.5445870161056519
breast I-Disease 1 0.9999808073043823
cancers I-Disease 1 0.999834418296814
. O 0 8.62606793816667e-06
. O 0 3.07006121147424e-05

